<SEC-DOCUMENT>0001493152-22-023497.txt : 20220819
<SEC-HEADER>0001493152-22-023497.hdr.sgml : 20220819
<ACCEPTANCE-DATETIME>20220818190200
ACCESSION NUMBER:		0001493152-22-023497
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		23
FILED AS OF DATE:		20220819
DATE AS OF CHANGE:		20220818

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Shuttle Pharmaceuticals Holdings, Inc.
		CENTRAL INDEX KEY:			0001757499
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-265429
		FILM NUMBER:		221178528

	BUSINESS ADDRESS:	
		STREET 1:		ONE RESEARCH COURT
		STREET 2:		SUITE 450
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		2404034212

	MAIL ADDRESS:	
		STREET 1:		ONE RESEARCH COURT
		STREET 2:		SUITE 450
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>forms-1a.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
filed with the Securities and Exchange Commission on August 18, 2022</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
No. 333-265429</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AMENDMENT NO. 3 </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TO</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
S-1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTRATION
STATEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
SECURITIES ACT OF 1933</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SHUTTLE
PHARMACEUTICALS HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2834</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>82-5089826</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(State
    or other jurisdiction of<BR>
    incorporation or organization)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Primary
    Standard Industrial<BR>
    Classification Code Number)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(I.R.S.
    Employer<BR>
    Identification No.)</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>One
Research Court, Suite 450</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rockville,
Maryland 20850</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(240)
403-4212</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Address,
including zip code, and telephone number, including<BR>
area code, of registrant&rsquo;s principal executive office)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anatoly
Dritschilo, M.D.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chief
Executive Officer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Shuttle Pharmaceuticals Holdings, Inc.</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>One
Research Court, Suite 450</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rockville,
Maryland 20850</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(240)
403-4212</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Name,
address, including zip code, and telephone number,<BR>
including area code, of agent for service)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Copies
to:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 49%"><P STYLE="margin-right: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Megan
                                            J. Penick, Esq.</B></FONT></P>
    <P STYLE="margin-right: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; width: 49%"><P STYLE="margin-right: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Spencer
                                            G. Feldman, Esq.</B></FONT></P>
    <P STYLE="margin-right: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><P STYLE="margin-right: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stephen
                                   A. Weiss, Esq.</B></FONT></P>
    <P STYLE="margin-right: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><P STYLE="margin-right: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Olshan
                                   Frome Wolosky LLP</B></FONT></P>
    <P STYLE="margin-right: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><P STYLE="margin-right: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Michelman
                                   &amp; Robinson LLP</B></FONT></P>
    <P STYLE="margin-right: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1325
    Avenue of the Americas,</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><P STYLE="margin-right: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>800
                                   Third Avenue, 24<SUP>th</SUP> Floor</B></FONT></P>
    <P STYLE="margin-right: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><P STYLE="margin-right: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15<SUP>th
                                   </SUP>Floor</B></FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><P STYLE="margin-right: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>New
                                   York, NY 10020</B></FONT></P>
    <P STYLE="margin-right: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><P STYLE="margin-right: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>New
                                   York, NY 10019</B></FONT></P>
    <P STYLE="margin-right: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(212)
    730-7700</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(212)
    451-2300</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximate
date of commencement of proposed sale to the public: As soon as practicable after the effective date of this Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act, check the following box. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of <B>&ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo;
&ldquo;smaller reporting company,&rdquo;</B> and <B>&ldquo;emerging growth company&rdquo;</B> in Rule 12b-2 of the Exchange Act. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer &#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer &#9744;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
    filer &#9746;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company &#9746;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    Growth Company &#9746;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective
on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXPLANATORY
NOTE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Registration Statement contains two prospectuses, as set forth below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    Offering Prospectus. A prospectus to be used for the public offering of up to 1,660,000<SUP>(1)</SUP> units, with each unit consisting
    of (i) one share of common stock and (ii) a warrant to purchase one share of common stock of the Registrant (the &ldquo;Public
    Offering Prospectus&rdquo;), with such units to be sold in an underwritten offering through the underwriter named on the cover
    page of the Public Offering Prospectus.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resale
    Prospectus. A prospectus to be used for the resale by the selling stockholders set forth therein of (i) 196,667 shares of common
    stock and warrants to purchase 196,667 shares of common stock, which shares and warrants will be issuable upon conversion of
    convertible notes (the &ldquo;Convertible Notes&rdquo;), and which Convertible Notes will automatically convert into common
    stock and warrants upon the effectiveness of this Registration Statement, and (ii) 520,000 shares of common stock issuable
    upon exercise of warrants held by certain warrant holders, as set forth in the resale prospectus set forth herein (the &ldquo;Resale
    Prospectus&rdquo;).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Resale Prospectus is substantively identical to the Public Offering Prospectus, except for the following principal points:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">they
    contain different outside and inside front covers and back covers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">they
    contain different Offering sections in the Prospectus Summary section beginning on page 1;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">they
    contain different Use of Proceeds sections on page 40;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    Selling Stockholder section is included in the Resale Prospectus; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            Selling Stockholder Plan of Distribution is included in the Resale Prospectus; and</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">the Legal Matters section in the Resale Prospectus on
    page Alt-13 deletes the reference to counsel for the underwriter.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Registrant has included in this Registration Statement a set of alternate pages after the back cover page of the Public Offering Prospectus
(the &ldquo;Alternate Pages&rdquo;) to reflect the foregoing differences in the Resale Prospectus as compared to the Public Offering
Prospectus. The Public Offering Prospectus will exclude the Alternate Pages and will be used for the public offering by the Registrant.
The Resale Prospectus will be substantively identical to the Public Offering Prospectus except for the addition or substitution of the
Alternate Pages and will be used for the resale offering by the selling stockholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
Assumes the underwriter&rsquo;s over-allotment option has not been exercised.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B><I>The
information in this preliminary prospectus is not complete and may be changed. We may not sell these securities nor may we accept offers
to buy these securities until the registration statement filed with the Securities and Exchange Commission becomes effective. This preliminary
prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where
the offer or sale is not permitted.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>PRELIMINARY
    PROSPECTUS</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>SUBJECT
    TO COMPLETION, DATED AUGUST 18, 2022</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$9,960,000</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="text-align: center; margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0"><B></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="formdrs_007.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SHUTTLE
PHARMACEUTICALS HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <B>1,660,000 Units</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <B>Each Unit Consisting of One Share of Common
Stock and </B> </P>

<P STYLE="text-align: center; margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0"> <B>One Warrant to Purchase
One Share</B> <B> of Common Stock</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> This is an initial public offering of Shuttle
Pharmaceuticals Holdings, Inc. We are offering a total of 1,660,000 units of securities, with each unit consisting of one share of
our common stock, par value $0.00001 per share (&ldquo;common stock&rdquo;), and a warrant to purchase one share of our common stock.
The units are being offered at an assumed combined public offering price of $6.00 per share of common stock and accompanying
warrants. Each of the warrants is immediately exercisable for one share of common stock at an exercise price of $0.01 per share and
will expire five years from the date of issuance. In addition, the selling shareholders (as defined herein) are offering 984,334
shares of common stock to be sold pursuant to a separate resale prospectus. We will not receive any proceeds from the sale of the
common stock to be sold by the selling stockholders. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0; font: 10pt Times New Roman, Times, Serif">Prior to this offering, no public market has existed
for our common stock. No stockholder affiliated with management is selling shares in this offering. <FONT STYLE="letter-spacing: 0.15pt">We
have applied to list our common stock included in the units and our common stock issuable upon exercise of the warrants for trading on
the Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;) under the symbol &ldquo;SHPH&rdquo;. We do not intend to apply for listing of the warrants
on Nasdaq or on any other national securities exchange or trading system. Without an active trading market, the liquidity of the warrants
will be limited.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>An
investment in our common stock involves significant risks. You should carefully consider the risk factors beginning on page 13 of this
prospectus before you make your decision to invest in our common stock.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Per Share</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; text-align: justify">Offering price</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right"> 6.00 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right"> 9,960,000 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting discounts and commissions <SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> 0.42 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> 697,200 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Proceeds, before expenses, to us</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> 5.58 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> 9,262,800 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have also agreed to pay a non-accountable expense allowance and reimburse the underwriter for certain expenses
    incurred in connection with this offering. See &ldquo;<A HREF="#poa_002">Underwriting</A>&rdquo; on page 92 for a description
    of compensation payable to the underwriter. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have granted a 45-day option to the underwriter
to purchase up to 249,000 additional units solely to cover over-allotments, if any.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are an &ldquo;emerging growth company&rdquo;
as defined in Section 2(a) of the Securities Act of 1933, as amended, and we have elected to comply with certain reduced public company
reporting requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriter expects to deliver the shares of common stock against payment as set forth under &ldquo;Underwriting&rdquo; on or
about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt"><B>Boustead
Securities, LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this prospectus is ____________, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_001">PUBLIC
    OFFERING PROSPECTUS SUMMARY</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_003">RISK FACTORS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_004">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_005">USE OF PROCEEDS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_006">DIVIDEND POLICY</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_007">CAPITALIZATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_008">DILUTION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_009">MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_010">BUSINESS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pri_001">MANAGEMENT</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pri_002">EXECUTIVE COMPENSATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pri_003">PRINCIPAL
     STOCKHOLDERS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pri_004">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">87</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pri_005">DESCRIPTION OF CAPITAL STOCK</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pri_006">SHARES ELIGIBLE FOR FUTURE SALE</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">91</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#poa_002">UNDERWRITING</A></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">92</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pri_007">LEGAL MATTERS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pri_008">EXPERTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">97</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pri_009">WHERE YOU CAN FIND MORE INFORMATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">97</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pri_010">DISCLOSURE OF SEC POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pri_011">INDEX TO FINANCIAL STATEMENTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABOUT
THIS PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not, and the underwriter has not, authorized anyone to provide you with any information or to make any representation other
than that contained in this prospectus, any amendment or supplement to this prospectus or in any free writing prospectus prepared we
may authorize to be delivered or made available to you. We do not, and the underwriter does not, take any responsibility for,
and can provide no assurance as to the reliability of, any information that others may provide to you. We are offering to sell, and seeking
offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The information in this prospectus
is accurate only as of the date on the front cover of this prospectus, regardless of the time of delivery of this prospectus or any sale
of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date.
You should also read and consider the information in the documents to which we have referred you under the caption &ldquo;Where You Can
Find More Information&rdquo; in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
investors outside the United States: Neither we nor the underwriter have done anything that would permit a
public offering of the securities or possession or distribution of this prospectus in any jurisdiction where action for that purpose
is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform
themselves about, and observe any restrictions relating to, the offering of the securities and the distribution of this prospectus outside
of the United States. You are required to inform yourselves about and to observe any restrictions relating to this offering and the distribution
of this prospectus outside of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should rely only on the information contained in this prospectus. Neither we nor the underwriter have authorized
any dealer, salesperson or other person to provide you with information concerning us, except for the information contained in this prospectus. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, information contained in this prospectus concerning our industry and the markets in which we operate or plan to
operate, including our general expectations and market position, market opportunity and market share, is based on information from our
own management estimates and research, as well as from industry and general publications and research, surveys and studies conducted
by third parties. Management estimates are derived from publicly available information, our knowledge of our industry, and assumptions
based on such information and knowledge which we believe to be reasonable. Our management estimates have not been verified by any independent
source, and we have not independently verified any third-party information. In addition, assumptions and estimates of our company&rsquo;s
and our industry&rsquo;s future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of
factors, including those described in the section entitled &ldquo;Risk Factors&rdquo; beginning on page 13. These and other factors
could cause our future performance to differ materially from our assumptions and estimates. See &ldquo;Special Note Regarding Forward-Looking
Statements&rdquo; on page 39 below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PUBLIC OFFERING</B><B> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_001"></A>PROSPECTUS
SUMMARY</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following summary provides an overview of all material information contained in this prospectus. It does not contain all of the information
you should consider before making a decision to purchase our shares of common stock in the offering. Prior to investing in our
common stock, you should carefully and thoroughly read the more detailed information in this prospectus and review our financial statements
and all other information that is included in this prospectus, including the section entitled &ldquo;Risk Factors&rdquo; beginning at
page 13.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the context otherwise requires, references in this prospectus to &ldquo;Shuttle Pharma,&rdquo; &ldquo;Shuttle Pharmaceuticals,&rdquo;
&ldquo;the Company,&rdquo; &ldquo;we,&rdquo; &ldquo;our&rdquo; and &ldquo;us&rdquo; refers to Shuttle Pharmaceuticals Holdings, Inc.
and its subsidiary, Shuttle Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="text-align: center; margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0"><B>Our Company</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Founded
in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharmaceuticals is a discovery and development stage
specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT). Our mission
is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting
the late effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers,
we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment, or in combination
with surgery, chemotherapy and immunotherapy. We currently have no FDA approved products and we have not yet applied for a new drug application.
To date, we have been funded by investments from private investors and government contracts obtained from the National Institutes of
Health (NIH) for performing research. We have no product revenue and our independent auditors, in their report dated June 3, 2022,
expressed doubt about our ability to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Historically, the major advances in radiation oncology
have focused on improving technology to increase the amount of radiation that can be administered to a tumor without damaging adjacent,
normal tissues. Examples of other such technologies include intensity modulated radiation therapy (IMRT), stereotactic body radiation
therapy (SBRT), stereotactic radiosurgery (SRS) and proton therapy &ndash; the backbones of state-of-the-art RT. All offer improvements
in physical radiation dose shaping. The basic principle underlying the effectiveness of RT for curing cancers lies in the differential
cancer cell kill achieved in tumors, as compared to the effects of RT on the normal surrounding tissues, which is achieved by delivery
of highly conformal RT doses &ndash; in other words, delivery of high-dose to volumes that are shaped to conform to the target
cancers while minimizing the dose to surrounding normal tissues. The treated volumes frequently include sensitive
normal tissues, thereby limiting the magnitudes of the prescribed RT doses. We suggest that technological innovations to define tumor
volumes and shape radiation delivery have reached an effectiveness plateau and that further improvements in RT outcomes will require
pharmacological and immunological approaches to sensitize cancers, protect normal tissues and engage the immune system.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At present, the drugs being used for sensitizing
cancers to RT are chemotherapeutic agents possessing radiation sensitizing properties as secondary effects. With the exception of
Cituximab, a growth factor targeting monoclonal antibody biologic, all other drugs used as radiation sensitizers are used &ldquo;off-label&rdquo;
to address the clinical need for radiation sensitizers. For example, certain chemotherapeutic agents, such as 5-fluorouracil,
capecitabine and cis-platinum, are approved as single agents for cancer treatment, but are used &ldquo;off-label&rdquo; as radiation
sensitizers in combination with RT. Treatments with such agents are associated with inherent toxicities associated with the drug&rsquo;s
primary, single-agent mechanisms of action.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shuttle Pharma&rsquo;s platform of sensitizers offers
a pipeline of product candidates designed to address the urgent clinical need and the current limitations of using &ldquo;off-label&rdquo;
drugs with potential new sensitizer agents. Our pipeline includes Ropidoxuridine, our lead clinical sensitizer drug candidate, to sensitize
rapidly growing cancer cells and selective histone deacetylase (HDAC) inhibitors to sensitize cancer cells and stimulate the immune system.
Our novel technologies will be tested in combinations with radiation therapies (conventional X-ray and proton radiation therapies) and
in combinations with immune-therapies. To date, Ropidoxuridine has completed a Phase I clinical trial. Our HDAC inhibitor platform drug
candidates have been tested in preclinical models of solid tumor cancers. Ropidoxuridine and the selective HDAC6 inhibitor
SP-2-225 are the clinical and preclinical candidate drug products we propose to develop using funding from this offering.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our intellectual property for Ropidoxuridine
includes novel formulations that show improved drug bioavailability (in a preclinical animal model) and for
sensitizing cancers to proton and to conventional radiation therapies. Our HDAC inhibitor intellectual property includes new patent
applications and granted patents for composition of matter and methods of use for treating cancers with HDAC inhibitors in
combinations with radiation therapy.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To date, we have obtained funding for our research
from private investors and Small Business Innovation Research (&ldquo;SBIR&rdquo;) contracts obtained through the National Institutes
of Health (&ldquo;NIH&rdquo;) to support the development of the radiation sensitizer Ropidoxuridine in a Phase I clinical trial. We have
also received awards for Phase I and II SBIR contracts for development of human cell cultures for health disparities studies and predictive
biomarkers of radiation late effects through the NIH&rsquo;s National Cancer Institute. The completed Phase I and II funded discovery
work performed to establish &ldquo;Cell-based Models for Prostate Cancer Health Disparity Research&rdquo; and to develop &ldquo;Predictive
Biomarkers of Prostate Cancer Sensitivity for Radiation Late Effects&rdquo; enables Shuttle Pharma to apply for NIH SBIR Phase II
funding to develop these products for advancing basic science and clinical research.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Product Candidates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. Food and Drug Administration (the &ldquo;FDA&rdquo;) considers new molecular entities as drugs that use new and unique
mechanisms of action for treating medical conditions. Our clinical stage agent, Ropidoxuridine (IPdR), increases DNA double
strand breaks following radiation exposure and our inhibitors of histone deacetylases (HDACs) stimulate the immune system to produce
T-lymphocytes targeting cancer cells.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
objective is to improve the outcomes of cancer treatment through RT while reducing its side effects by:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sensitizing
    growing cancer cells to render them more susceptible to the effects of RT;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Activating
    the DNA damage response pathway to protect normal cells located near cancers; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Activating
    the immune response to antigens present on irradiated and un-irradiated cancer cells.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To our knowledge, no drug utilizing the mechanisms
of our candidate small molecule drugs has received FDA approval as a radiation sensitizer. We have developed, to clinical stage,
the small molecule strategies to sensitize growing cancer cells in tumors to conventional RT and to large fraction radiation therapy.
The pre-clinical technology, HDAC inhibitor platform, is designed to target cancer cells while protecting healthy tissue/normal
cells, thus enhancing the candidate radiation sensitizer product pipeline. The selective HDAC6 inhibitor (SP-2-225), discovered
and developed by our scientists, has inhibited the growth of melanoma tumors and breast cancers in animal models by an
immune stimulating mechanism.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are focused on developing a clinical stage product
candidate (Ropidoxuridine) and a pre-clinical product candidate, selective HDAC6 inhibitor (SP-2-225). We propose to develop these
drug candidates as illustrated below:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0"><B>Overview of Radiation
Sensitizer Development</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-1_009.jpg" ALT="" STYLE="height: 256px; width: 650px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Ropidoxuridine, the clinical stage molecule, sensitizes
rapidly growing cancers to radiation therapy by increasing reactive free radicals that increase DNA strand breaks. Ropidoxuridine development
for treating glioblastoma will require Phase II clinical testing for use in treating brain tumors. The selective HDAC6
inhibitor, SP-2-225, a pre-clinical stage molecule, activates the innate immune system to target irradiated tumor cells
by immune mechanisms.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ropidoxuridine
(IPdR)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Ropidoxuridine (IPdR) is an orally available halogenated
pyrimidine (5-iodo-2-pyrimidinone-2-deoxyribose) with strong cancer radiation sensitizing properties. As a prodrug that does not
become an active drug until after it is metabolized, IPdR is absorbed and metabolized to IUdR by enzymes in the liver and
in cancer cells. IUdR, a halogenated pyrimidine, is incorporated into DNA by rapidly growing cancer cells. Cells that incorporate
IUdR into their DNA then become more sensitive to the effects of RT. The Phase I clinical trial of Ropidoxuridine and RT, supported by
an NIH SBIR contract to Shuttle Pharma, was sub-contracted to the Brown University Oncology Group (BrUOG) at the LifeSpan/Rhode
Island Hospital. This Phase I clinical trial has been completed and the results were initially reported by the sub-contractor
at the 30th EORTC-NCI-AACR Symposium in November 2018 and published in the medical journal Clinical Cancer Research in 2019. A maximum
tolerated dose (MTD) of 1200 mg/day for 28 days was established for use in combination with radiation therapy to achieve therapeutic
blood levels of IUdR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The reported Phase I clinical trial of Ropidoxuridine
in combination with RT provides the foundation for proposed Phase II clinical trials to establish the data necessary for the FDA to determine
efficacy in treating brain tumors, sarcomas and pancreatic cancers, diseases that offer potential for orphan designations. The FDA granted
approval of our application for orphan-drug designation for IPdR for the treatment of glioblastoma. Orphan designation protects the marketing
position of Ropidoxuridine for up to seven years after marketing approval is received from the FDA. This approval integrates well
into the overall intellectual property strategy for Ropidoxuridine which includes filed patent applications for &ldquo;Method and Compositions
for Cancer Therapies that Include Delivery of Halogenated Thymidines and Thymidine Phosphorylase Inhibitors in Combination with Radiation.&rdquo;
We believe that we are positioned to initiate Phase II clinical studies with Ropidoxuridine and RT in 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Extended Bio-availability Ropidoxuridine (IPdR/TPI)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Ropidoxuridine and Tipiracil (IPdR/TPI) is a new
combination drug formulation designed to increase the bio-availability and incorporation of IUdR into DNA. Shuttle Pharma&rsquo;s
preclinical studies of the combination of IPdR/TPI have shown up to 10-fold greater bioavailability of the active metabolite (IUdR)
as compared to IPdR administered alone in controls. We have filed an application under the Patent Cooperation Treaty (or PCT) for the
intellectual property. This new formulation will be tested in a Phase I clinical trial as a sensitizer of rectal cancers. Another nucleoside
analogue, Trifluridine has been formulated in combination with Tipiracil (TAS-102) to enhance drug uptake by colon cancer cells to prolong
survival in patients treated for metastatic colorectal cancers, as has been reported in the New England Journal of Medicine (N Engl J
Med. 2015; 372:1909-1919). We anticipate testing for uptake of IPdR by colorectal cancer cells following administration of the IPdR/TPI
drug formulation.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Proton radiation therapy is an advanced form of radiation
therapy using charged proton particles (p+). Proton RT differs from conventional RT in that the radiation is delivered by a beam of protons
to precisely target tumors and, due to the favorable physics of energy deposition by proton particles, there is no exit beam, resulting
in less radiation to surrounding healthy tissues. The use of Proton RT is expanding rapidly in the U.S. and worldwide. According
to the National Association of Proton Therapy, more than 30 facilities are currently in operation in the U.S. and an additional 30
facilities are planned for installation over the next five years. (<I>See </I>www.proton-therapy.org.) Much attention has been paid to
proton therapy in the popular press, promoting its advantages, as well as addressing the increased health care costs. The role of a sensitizer
that offers proton radiation sensitization presents an opportunity to enhance the value of proton radiation therapy as a cancer treatment
modality. We believe the development of a proton therapy targeted radiation sensitizer, such as IPdR/TPI, is timely and consistent with
current market needs to advance protons as a therapeutic modality.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to perform clinical studies to support the development of the IPdR/TPI combination to advance this drug candidate with proton RT. The addressable market includes diseases such as brain tumors, cancers of the head
and neck, GI cancers and lung cancers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Selective
HDAC Inhibitors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The roles of acetylation in the epigenetic regulation
of chromatin structure and gene expression rests on the balance of activities of histone acetyltransferases (HATs) and histone deacetylases
(HDACs). Increased acetylation of histones leads to changes in chromatin structure and accessibility for key cellular proteins to specific
target sites. Acetylations of non-histone proteins also modulates their enzymatic activities. We have discovered novel HDAC inhibitor
molecules and testing in preclinical models has shown cancer radiation sensitizing properties, normal tissue protective properties
and selective HDAC6 inhibitory properties. Our HDAC inhibitor platform, described below, will be evaluated in pre-clinical studies of
radiation sensitization of solid tumors and activation of the immune response to irradiated cancer cells.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="width: 0.5in">&#9679;</TD>
  <TD STYLE="text-align: justify">SP-1-161 is our candidate lead pre-clinical, pan-HDAC inhibitor that initiates the mutated in
  ataxia-telangiectasia (ATM) response pathway. ATM is activated by ionizing radiation induced DNA damage. Activated ATM phosphorylates
  critical factors involved in DNA repair, apoptosis, and cell cycle checkpoint. Phosphorylation of the molecules in these pathways,
  in turn, activates the cellular functions. ATM also can be activated by HDAC inhibitors and imparts radiation protective properties.
  Using rational drug design, we discovered HDAC inhibitors and ATM activators capable of radiation sensitizing cancer cells and protecting
  normal cells. SP-1-161 is our lead candidate radiation sensitizing pan-HDAC inhibitor.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&#9679;</TD>
  <TD STYLE="text-align: justify">SP-2-225 is our candidate lead selective histone deacetylase inhibitor of HDAC6. HDAC6 is a member
  of the Class IIb HDAC family. Selective HDAC6 inhibitors are an emerging class of pharmaceuticals due to effects on neurodegenerative
  diseases, cancers and immunology. Specifically, the potential to affect regulation of the immune system and enhance the immune
  response to cancers is of significant interest as an adjuvant treatment in combination with radiation therapy. We propose to test our
  HDAC6 inhibitors for a role in enhancing post-RT immune responses to antigens produced in irradiated cancers for their effects on
  control of local and metastatic disease.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&#9679;</TD>
  <TD STYLE="text-align: justify">SP-1-303 is a selective Class I HDAC inhibitor that preferentially affects histone deacetylases HDAC1
  and HDAC3 and shows direct and selective cytotoxicity for ER positive and Her2 negative breast cancer cells. </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Drug Development Projects</B><B> for Radiation
Treatment of Cancers</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To advance research that is complementary to our
radiation sensitizer discovery and development projects, the NIH has awarded  SBIR contracts to us to develop reagents for
health disparities research and to develop biomarkers of radiation sensitivity for patients treated with radiation therapy.
Our scientists have been engaged in developing model human cell systems for testing radiation sensitizers in tissue cultures.
This project provides an efficient and low-cost screening technology to provide data for the FDA&rsquo;s determination of
drug efficacy and to identify candidate lead molecules for treating prostate cancers in African-Americans. First developed at
Georgetown University, the conditional cellular reprogramming (CRC) technology offers the ability to establish new cell lines from
biopsies of cancers. We have obtained a sub-license from Propagenix, Inc. to establish 100 normal and cancer cell lines from
prostate biopsy samples for use in screening drug candidates and for health disparities research. A more detailed description of
the Propagenix license is set forth on page 60 below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, to identify patients who may be more
sensitive to radiation therapy and are at a higher risk to suffer treatment-related complications, collaborative research with Georgetown
University has led to discovery of metabolite biomarkers, which are predictive of patient responses to radiation therapy. A patent for
the intellectual property has been submitted by Georgetown University with Shuttle Pharma scientist (Scott Grindrod, PhD) as co-inventor.
Developmental work in health disparities and predictive biomarker development has been supported by NIH SBIR contracts to
Shuttle Pharmaceuticals for the following areas:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Develop
    prostate cancer cell lines from African-American men with the goal of advancing research to address prostate cancer health disparities
    (designated SBIR &ldquo;Topic 352: Cell-Based Models for Prostate Cancer Health Disparity Research- Moonshot Project (Phase
    II)&rdquo;); and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Develop
    predictive biomarkers of prostate patient outcomes following treatment with SBRT (designated SBIR &ldquo;Topic 345:
    Predictive Biomarkers for Prostate Cancer Sensitivity for Radiation Late Effects (Phase I and II).&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NIH&rsquo;s SBIR program is designed to encourage small businesses to engage in Federal Research/Research and Development (&ldquo;R/R&amp;D&rdquo;)
that has the potential for commercialization. Shuttle Pharma will apply for additional NIH SBIR grants and contracts to fund advancement
of these projects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Market
Opportunity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The American Cancer Society (Cancer Facts &amp; Figures
2020) estimates 1,806,590 new cancer cases and 606,520 cancer deaths each year in the United States and, according to the American Society
for Radiation Oncology, more than 50% of patients undergo RT at some point in the treatment of their diseases. RT is used to treat cancers
of the lung, breast, brain, esophagus, pancreas, rectum, head and neck, uterus, lymphomas and sarcomas. At present, we are developing
drug candidates to address brain, pancreas, rectum, sarcomas and lymphomas, although we may test and seek approval for our drug candidates
to treat other cancers in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Currently,
                                            there is only one drug (the monoclonal antibody, Cetuximab) that has received FDA approval
                                            for the radiation sensitizer indication. Cetuximab is a recombinant monoclonal antibody
                                            that binds to epidermal growth factor receptor (EGFR) and inhibits the binding of epidermal
                                            growth factor (EGF). Cetuximab is administered via intravenous infusion and is used as monotherapy
                                            or in combination with other chemotherapies or radiation therapy. In clinical trials, cetuximab
                                            was associated with serious and fatal infusion reactions, cardiopulmonary arrest or sudden
                                            death, and serious dermatologic toxicities, toxicities that have created deterrents to its
                                            use as a radiation sensitizer. Present treatment utilizes &ldquo;off-label&rdquo; small
                                            molecule drugs, which are cytotoxic chemotherapy agents that also sensitize, but
                                            do not have radiation sensitization as an FDA approved indication. Moreover, since &ldquo;off-label&rdquo;
                                            drugs are cytotoxic, they are often associated with intrinsic acute and chronic side effects.
                                            Nevertheless, these drugs have shown clinically significant improvements in disease control
                                            and survival and are typically included in standard-of-care treatment recommendations for
                                            patients with cancers of the head and neck, brain, lung, esophagus, stomach, pancreas, liver,
                                            bladder, lymphomas and sarcomas. As a result, we believe that there is a significant market
                                            opportunity for our product candidates. Based on cancer incidence data published by the American
                                            Cancer Society, we have estimated the numbers of patients presenting with local/regional
                                            disease, suitable for treatment with RT.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-bottom: 0pt"><B>Estimated RT Cases by
Disease Site</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: normal; text-align: center">Cancer Type</TD><TD STYLE="font-weight: bold; font-style: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: normal; text-align: center">Cases Diagnosed
    Annually</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-style: normal">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: normal; text-align: center">Estimated
    RT Cases</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-style: normal">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 32%; font-weight: 400; font-style: normal; text-align: center; padding-bottom: 1.5pt">Brain</TD><TD STYLE="width: 2%; font-weight: 400; font-style: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%; font-weight: 400; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; width: 30%; font-weight: 400; font-style: normal; text-align: center">23,890</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-weight: 400; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-weight: 400; font-style: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%; font-weight: 400; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; width: 30%; font-weight: 400; font-style: normal; text-align: center">21,979</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-weight: 400; font-style: normal; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: 400; font-style: normal; text-align: center; padding-bottom: 1.5pt">Pancreas</TD><TD STYLE="font-weight: 400; font-style: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: 400; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: 400; font-style: normal; text-align: center">57,600</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: 400; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: 400; font-style: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: 400; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: 400; font-style: normal; text-align: center">32,832</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: 400; font-style: normal; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: 400; font-style: normal; text-align: center; padding-bottom: 1.5pt">Sarcomas</TD><TD STYLE="font-weight: 400; font-style: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: 400; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: 400; font-style: normal; text-align: center">13,130</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: 400; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: 400; font-style: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: 400; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: 400; font-style: normal; text-align: center">4,000</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: 400; font-style: normal; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: 400; font-style: normal; text-align: center; padding-bottom: 1.5pt">Rectum</TD><TD STYLE="font-weight: 400; font-style: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: 400; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: 400; font-style: normal; text-align: center">43,340</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: 400; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: 400; font-style: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: 400; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: 400; font-style: normal; text-align: center">26,437</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: 400; font-style: normal; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Annual cancer cases for each disease site
are estimated from American Cancer Society Facts &amp; Figures 2020 publication. The fraction of patients optimally receiving
RT for each disease site were obtained from published estimates of Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy
in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer. 2005 Sep 15;104(6):1129-37.
doi: 10.1002/cncr.21324. The Estimated RT cases were obtained by multiplying Cases Diagnosed Annually by the fraction receiving RT
for optimal utilization.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Development Strategy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our
                                            goal is to maintain and build upon our leadership position in radiation sensitization. We
                                            plan to develop Ropidoxuridine and the HDAC6 inhibitor (SP-2-225) and, if approved
                                            by the FDA, to commercialize our product candidates for the treatment of cancers. While
                                            this process may require years to complete, we believe achieving this goal could result
                                            in radiation sensitizer and immunotherapy products for cancer treatment. Key elements
                                            of our strategy include:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Capitalize on Ropidoxuridine as an orally available, small molecule
    radiation sensitizer</B>. To date, there is one drug (Cetuximab) approved by the FDA specifically as a radiation sensitizer.
    If we are successful in developing Ropidoxuridine to obtain FDA approval, a small moleculesensitizer will be enabled
    for clinical applications  for radiation sensitization.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Expand our leadership position within radiation sensitizers</B>.
    In addition to our traditional radiation sensitizers, we plan to advance our near-term pipeline to include radiation sensitizers
    for proton therapy. Proton Therapy is growing worldwide as a form of radiation therapy due to its unique beam shaping characteristics.
    As a result, this new technology offers a major opportunity for Shuttle Pharma to strive to develop a sensitizer drug for
    proton therapy sensitization applications.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Execute a disciplined business development strategy to strengthen
    our portfolio of product candidates</B>. We have built our current product pipeline through in-house development, partnerships with
    leading academic institutions and through successful in-licensing deals. We will continue to evaluate new in-licensing opportunities
    and collaboration agreements with leading academic institutions and other biotechnology companies around programs that seek to address
    areas of high unmet need and for which we believe there is a high probability of clinical success, including programs beyond our
    target franchise areas and current technology footprint.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Invest in our HDAC platform technology to maximize its utility
    across cancer therapies</B>. We are initially applying the platform to develop drugs for cancer radiation sensitization and normal
    tissue radiation protection. In addition, these drugs also affect immune regulatory properties. We intend to invest to investigate
    other properties of our platform technology.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Enter into collaborations to realize the full potential of our platform.
    </B>The breadth of our HDAC technology platform enables other therapeutic applications, in addition to radiation sensitization
    and immune therapy. We intend to seek collaborations centered on our platform to maximize applications for our HDAC inhibitor technology.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We propose the following clinical development plan
to identify, develop and commercialize drugs for use in cancer treatments in combination with RT:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Develop
Ropidoxuridine (IPdR) for Orphan disease indications to take to market</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacture
    24 kg of Ropidoxuridine and formulate for use in  clinical trials.</FONT></TD></TR>



<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct
    a Phase II clinical trial of Ropidoxuridine, Temodar and RT in glioblastoma.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct
    a Phase III clinical trial in glioblastoma to secure FDA approval to market Ropidoxuridine for the glioblastoma indication
    using orphan disease designation for marketing protection.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Develop
Ropidoxuridine and tipiracil (IPdR/TPI) for colorectal cancer indications to take to market</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Formulate
    5 kg of IPdR/TPI for use in pre-clinical efficacy studies, IND-enabling studies and a Phase I clinical trial.</FONT></TD></TR>

  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct
    IND-enabling studies;  obtain IND for IPdR/TPI with RT.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct
    a Phase I clinical trial of IPdR/TPI with RT in rectal cancers to establish the MTD.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct
    a Phase II clinical trial of IPdR/TPI with RT in rectal cancer.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Develop
HDAC Inhibitors for use in breast cancer for immune activation after RT</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complete
    pre-clinical  studies of HDAC inhibitors in human xenograft tumor models.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 96px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px">&#9675;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-1-161
    with RT in breast cancers.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9675;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-1-303
    with RT in ER+, Her2- breast cancers.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9675;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-2-225
    with immune checkpoint inhibitors in lung cancers.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advance
    the lead HDAC6 inhibitor, SP-2-225, for IND-enabling.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct
    Phase I clinical trials to determine  MTD.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct
    Phase II clinical trials for proof-of-concept efficacy evaluation in lung cancers.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Management
Team</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management team has significant experience in radiation oncology and in progressing products from early-stage research through clinical
trials. Our CEO, Anatoly Dritschilo, M.D., is an experienced clinician and researcher who has held senior academic and management
positions including serving as Department Chairman, Hospital Medical Director and Cancer Center Director at Georgetown University Medical
Center. Prior to co-founding our company, Dr. Dritschilo was a co-founder of Oncomed, Inc., a company that became
public as NeoPharm, Inc. (Nasdaq: NEOL). He has experience in providing care for patients undergoing treatment for cancers of the prostate,
breast, brain, lung, sarcomas and GI systems. Dr. Dritschilo has directed basic science research supported by grants from the National
Cancer Institute (&ldquo;NCI&rdquo;) and performed clinical trials using drugs and radiation therapy. In addition, Dr. Dritschilo served
as the principal investigator of pharmaceutical industry sponsored clinical evaluations of human interferon alpha-2 (Bristol-Myers) with
radiation therapy and antisense raf oligonucleotides, LErafAON (NeoPharm) with radiation therapy. He serves as a Radiation Biology and
Radiation Oncology expert on committees of the NIH to review Program Project (P01) grant applications, Specialized Program of
Research Excellence (SPORE) grant applications and investigator-initiated research project (R01) applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Dritschilo is supported in our clinical development effort by Tyvin Rich, MD, our Chief Clinical Officer and Medical Director.
Dr. Rich is the former Professor and Chairman of the Department of Therapeutic Radiology and Oncology at the University of Virginia Health
Sciences Center and proton radiation therapy specialist at the Hampton Proton Therapy Center in Hampton, Virginia. Dr. Rich has served
as principal investigator on multi-modality clinical trials for the treatment of gastrointestinal (GI) cancers and helped to develop
treatment with 5-fluorouracil (5-FU) as a radiation sensitizer for use with RT in the treatment of GI cancers. He has extensive cancer
clinical trial experience in developing radiation sensitizer applications through his participation in the Radiation Therapy Oncology
Group (RTOG). Dr. Rich is a co-inventor with scientists at the University of Virginia of the Proton Activated Atomic Medicine
technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our administrative services are provided by Peter
Dritschilo, MBA, who has served as our President and COO since 2012. Mr. Dritschilo&rsquo;s experience in hospital administration
and management of medical oncology clinical services and radiation therapy facilities, including management of day-to-day operations,
human resources and financial oversight. Peter Dritschilo is the son of our Chairman and CEO, Dr. Anatoly Dritschilo. The addition of
Michael Vander Hoek as our CFO and Vice President for Operations and Regulatory expands our capability to provide the level
of management needed for the proposed expansion of clinical trials. Mr. Vander Hoek has served as administrative director of the
Lombardi Comprehensive Cancer Center (LCC) for the past 12 years and has extensive experience in negotiations, management and supervision
of Contract Research Organizations (CROs) and research contracts in general. As the administrative director of the Lombardi Comprehensive
Cancer Center, Mr. Vander Hoek also served as the chief financial officer. Taken together, we believe our leadership team of
highly qualified specialists will help us achieve the proposed milestones for the development of radiation sensitizer products.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pre-IPO Bridge Financing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2021, we completed a $500,000
note offering pursuant to which we sold to two accredited investors (the &ldquo;Investors&rdquo;) units consisting of (i) a $250,000
promissory note bearing 10% interest, repayable at the time of this offering (the &ldquo;Note&rdquo;) and (ii) a warrant
to purchase 250,000 shares (the &ldquo;Warrant Shares&rdquo;) of our common stock at an exercise price of $1.00 per share (the
&ldquo;Warrant&rdquo;). <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immediately before closing on the
Offering, the Notes will be repaid and cancelled in exchange for the exercise of the Warrants and issuance of the 500,000 Warrant Shares
to the Investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> In February and March 2022, we sold a total
of $365,000 and $225,000, respectively, in convertible notes (&ldquo;Convertible Notes&rdquo;) to certain accredited investors, which
notes will automatically convert into units, with each unit consisting of one share of common stock and a warrant to purchase one
share of common stock, upon effectiveness of this offering at a conversion price of $3.00 per unit (the &ldquo;Conversion
Units&rdquo;). In addition, each of the Convertible Note holders will be entitled to demand registration rights, and we are required
to register the Conversion Units within 180 days of the closing of this offering. We are using the net proceeds from the Convertible
Notes offering to expand our current operations, including our technology and intellectual property portfolio, and to fund the costs
of this offering. Any funds remaining will be used for working capital and other general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> In August 2022, we completed a $125,000 note offering
pursuant to which we sold to three accredited investors (the &ldquo;Investors&rdquo;) units consisting of (i) a total of $125,000 in
10% promissory notes bearing 10% interest, repayable at the time of this offering (the &ldquo;August Note&rdquo;) and (ii) warrants to
purchase a total of 50,000 shares of common stock exercisable at $2.50 per share. We
anticipate that the notes will be repaid upon closing of the Offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Boustead Securities LLC (&ldquo;Boustead&rdquo;)
acted as placement agent in both the Note and Warrant offering and the Convertible Notes offering, pursuant to which Boustead waived
its cash compensation related to the Note and Warrant offerings and received cash compensation of $36,500 and $22,250 in each
of the February and March 2022 closings, respectively, and also received warrants to purchase 10% of the total number of Conversion Shares,
exercisable at the conversion price of the Convertible Notes. For the August 2022 offering, Boustead received a warrant to purchase
5,000 shares of common stock and is entitled to receive $12,500 in cash compensation, which cash compensation has been deferred. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Resale Offering</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
of our shareholders will be selling through a separate prospectus (the &ldquo;Resale Prospectus&rdquo;) (i) 196,667 shares of common
stock and warrants to purchase 196,667 shares of common stock, which shares and warrants will be issuable upon conversion of convertible
notes, which convertible notes will automatically convert into common stock and warrants upon the effectiveness of this offering and
the date of this prospectus, and (ii) 520,000 shares of common stock issuable upon exercise of warrants held by certain warrant holders,
as set forth in the Resale Prospectus. We will not receive any proceeds from the sales by the selling stockholders of the securities
set forth in thee Resale Prospectus.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Resale Prospectus is substantively identical to this Prospectus, except for the following principal points:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">they
    contain different outside and inside front covers and back covers;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">they
    contain different Offering sections in the Prospectus Summary section beginning on page 1;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">they
    contain different Use of Proceeds sections on page 40;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    Selling Stockholder section is included in the Resale Prospectus; </FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    Selling Stockholder Plan of Distribution is included in the Resale Prospectus; and</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Legal Matters section in the Resale Prospectus deletes the reference to counsel for the underwriter.</FONT> </TD></TR>
  </TABLE>
<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
Risk Factors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to a number of risks you should be aware of before making an investment decision. These risks are discussed more
fully in the &ldquo;Risk Factors&rdquo; section of this prospectus at page 13 immediately following this prospectus summary. These risks
include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    success is primarily dependent on achieving the development, regulatory approval and commercialization of our product
    candidates, both of which are in the early stages of development.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    approach to the discovery and development of innovative radiation oncology drugs based on our HDAC small molecule delivery platform,
    which is novel, unproven and may not result in marketable products.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have no product revenue, have incurred significant losses since inception, may never become profitable and may incur substantial
    and increasing net losses for the foreseeable future as we continue the development of, and seek regulatory approvals for our product
    candidates.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    clinical trials of our product candidates fail to demonstrate safety and efficacy, which are ongoing determinations that are
    solely within the authority of the FDA, we may be unable to obtain regulatory approvals to commercialize our product
    candidates.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">We have
                                            not generated any revenue and have incurred losses in each year since our founding in December
                                            2012. Our net loss for the year ended December 31, 2021 and the six months
                                            ended June 30, 2022 was $1,152,134 and $1,279,114 respectively. As of
                                            June 30, 2022, we had an accumulated deficit of $7,126,082 and received a &ldquo;going
                                            concern&rdquo; opinion from our independent auditors for the fiscal year ended December 31,
                                            2021. As a clinical stage pharmaceutical company, we expect to continue to incur significant
                                            losses for the foreseeable future. Even if we achieve profitability in the future, we may
                                            not be able to sustain profitability in subsequent periods.</P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are subject to regulatory approval processes that are lengthy, time-consuming and unpredictable. We may not obtain approval for any
    of our product candidates from the FDA or foreign regulatory authorities.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if we obtain regulatory approval, the market may not be receptive to our product candidates.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may not be able to establish  collaborative partnerships with other pharmaceutical companies, through which we expect to complete
    development of, obtain marketing approval for and, if approved, manufacture and market our product candidates.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may encounter difficulties satisfying the requirements of clinical trial protocols, including patient enrollment.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may face competition from other companies in our field or claims from third parties alleging infringement of their intellectual property.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be unable to recruit or retain key employees, including our senior management team.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will need to obtain significant additional funding on acceptable terms to continue operations following this offering.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are a Phase I clinical stage pharmaceutical company with a limited operating history upon which you can evaluate our business and
    prospects. Specialty pharmaceutical product development is a highly speculative undertaking and involves a substantial degree of
    risk. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">We do not currently have any product candidates in advanced
    clinical trials or approved for sale, and we continue to incur significant research and development and general and administrative
    expenses in relation to our operations. In addition, we have  not yet demonstrated an ability to successfully
    overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly
    in the specialty pharmaceutical industry.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">have not submitted an application or received
    marketing approval for any of our product candidates. Regulatory approval of our product candidates is not guaranteed, and the approval
    process is expensive and may take several years.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
    is difficult and costly to protect our intellectual property rights.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">The offering price of the primary offering and resale
    offering could differ.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">The resale by the Selling Stockholders whose shares
    are being registered in our resale offering may cause the market price of our common stock to decline.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Implications
of Being an Emerging Growth Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&#9679;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    a smaller reporting company, and as a</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> company
    with less than $1.0 billion in revenue during our last fiscal year, we qualify as an &ldquo;emerging growth company&rdquo; as defined
    in the JOBS Act. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from specified
    disclosure and other requirements that are applicable to other public companies that are not emerging growth companies. These exemptions
    include:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">being
    permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements,
    with correspondingly reduced &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;
    disclosure;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    being required to comply with any mandatory audit firm rotation or a supplement to the auditor&rsquo;s report providing additional
    information about the audit and the financial statements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
    disclosure obligations regarding executive compensation; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemptions
    from the requirements of holding a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute
    payments not previously approved.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may take advantage of the above provisions for up to five years or until such earlier time that we are no longer an emerging growth company.
We would cease to be an emerging growth company if we have more than $1.0 billion in annual revenues, have more than $700 million in
market value of our capital stock held by non-affiliates or issue more than $1.0 billion of non-convertible debt over a three-year period.
We may also choose to take advantage of some, but not all, of the available exemptions. We have taken advantage of some reduced reporting
requirements in this prospectus. Accordingly, the information contained in this prospectus may be different than the information
you receive from other public companies in which you hold stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with
new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of some accounting standards
until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended
transition period for adopting new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting
standards as other public companies that are not emerging growth companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was formed as a limited liability company in the state of Maryland in December 2012 and was converted to a C corporation, Shuttle
Pharmaceuticals, Inc. (&ldquo;Shuttle&rdquo;), in August of 2016.  In June 2018, Shuttle completed a share exchange with Shuttle Pharma Acquisition Corp. Inc. (&ldquo;Acquisition Corp.&rdquo;),
pursuant to which Shuttle Pharmaceuticals, Inc. became a subsidiary of Acquisition Corp. and we subsequently changed the name of Acquisition
Corp. to Shuttle Pharmaceuticals Holdings, Inc. Our executive offices are located at 1 Research Court, Suite 450, Rockville, Maryland
20850 and our telephone number is (240) 403-4212. Our corporate website is www.shuttlepharma.com. Information appearing on our corporate
website is not incorporated as part of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
    </FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">offered by us:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 49%"><P STYLE="margin-top: 0; margin-bottom: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,660,000 units, with each unit comprised of (i) one share of common stock and (ii) a warrant to purchase one share of common stock. The units will not be certificated, and the common stock and the warrants comprising each unit are immediately separable and will be issued separately in this offering.</FONT> </P>
                                                                                          <P STYLE="margin-top: 0; margin-bottom: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This prospectus also relates to the offering of shares of common stock and warrants included in the units.</FONT> </P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> Warrants </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> Each warrant entitles the holder thereof to purchase
    one share of common stock at a price of $0.01 per share. Only whole warrants are exercisable. The warrants are exercisable at any
    time for period of five years from the date on which such warrants were issued. The warrants and the shares of common stock will
    be purchased together in this offering. The exercise price and the number of shares into which the warrant may be exercised are subject
    to adjustments in certain circumstances. See &ldquo;Description of Capital Stock&mdash;Warrants&rdquo; for a discussion of the terms
    of the Warrants. </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock outstanding before this offering:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,312,991
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares<SUP>(1)</SUP></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock outstanding immediately after this offering:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,123,629
    </FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares (and 14,417,629 shares if the
    underwriter exercises its over-allotment option in full) <SUP>(2)</SUP></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriter&rsquo;s
    over-allotment</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> option:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have granted the underwriter a 45-day option, exercisable one or more times in whole or in part, to purchase up to an additional
    294,000 units, with each unit comprised of (i) one share of common stock and (ii) one warrant to purchase a share of common
    stock. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    policy:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have never paid cash dividends on our common stock and we do not anticipate paying any cash dividends in the foreseeable future.
    See the section entitled &ldquo;Dividend Policy.&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
    of proceeds:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            net proceeds from this offering, after deducting underwriting discounts and commissions and
                                            estimated offering expenses payable by us at closing of approximately $1,296,736, will
                                            be approximately $8,663,264. </FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    intend to use the net proceeds from this offering to fund Phase II clinical trials of product candidates, including radiation
    sensitizer Ropidoxuridine and the HDAC inhibitor small molecule technology platform, potential acquisition or in-licensing activities
    and working capital and general corporate purposes. We anticipate that the funds raised from this Offering will allow us to complete
    Phase II clinical trials, although there is no guarantee that we will not require additional funds. See &ldquo;Risk Factors&rdquo;
    beginning on page 13 below.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposed
    Nasdaq symbol:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;SHPH&rdquo;.
    <FONT STYLE="letter-spacing: 0.15pt">We do not intend to apply for listing of the warrants on Nasdaq or on any other national securities
    exchange or trading system. Without an active trading market, the liquidity of the warrants will be limited.</FONT></FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    Factors:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
    should carefully read and consider the information set forth under &ldquo;Risk Factors&rdquo; beginning on page 13 below and
    all other information included in this prospectus for a discussion of factors that you should consider before deciding to invest
    in shares of our common stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    number of shares of our common stock outstanding excludes:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
    3,000,000 shares of our common stock reserved for issuance under our 2018 Equity Incentive Plan, of which 384,167 restricted
    stock units have been issued, of which 353,390 RSUs are fully vested and 30,777 remain subject to vesting; (ii) 500,000 shares of
    our common stock issuable upon exercise of warrants held by certain selling stockholders, which warrants will be exercised and sold
    in this offering; (iii) 269,444 shares of our common stock issuable upon conversion of 1,212.5 shares of Series A convertible preferred
    stock and 269,444 shares of common stock issuable upon exercise of outstanding warrants to purchase common stock, which will be convertible
    or exercised upon completion of this offering (which conversion amounts do not include an 8.5% cumulative dividend payable, which
    dividend may be paid in either cash or common stock as determined by the Company); (iv) 196,667 shares of common stock and warrants
    to purchase 196,667 shares of common stock issuable upon conversion of the outstanding convertible notes, which will be convertible
    and issued upon effectiveness of this offering; and (v) 50,000 shares of common stock issuable upon exercise of warrants to purchase
    common stock. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> 232,400 shares of common stock issuable upon exercise
    of the underwriter warrants, which underwriter warrants are expected to be issued in this offering.</TD></TR>

  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.25in">(2)</TD>
  <TD STYLE="text-align: justify">This number assumes (i) all warrants to purchase 1,660,000 shares of common stock issued in this
  offering have been exercised, (ii) 269,444 shares of our common stock issuable upon conversion of 1,212.5 shares of Series A
  convertible preferred stock and 269,444 shares of common stock issuable upon exercise of outstanding warrants to purchase common
  stock, which will be issued upon completion of this offering (which conversion amounts do not include an 8.5% cumulative dividend
  payable, which dividend may be paid in either cash or common stock as determined by the Company), (iii) 500,000 shares of our
  common stock issuable upon exercise of warrants held by certain selling stockholders whose shares will be exercised in full at the
  time of this offering; (iv) 196,667 shares of common stock and warrants to purchase 196,667 shares of common stock issuable upon conversion of outstanding convertible notes, which
  will be convertible and issued upon completion of this offering and (v) the exercise of 50,000 shares of our common stock
  issuable upon exercise of warrants to purchase common stock. </TD></TR>

</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Reverse Stock Split</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective April 1, 2022, we effected a 2-for-1
reverse stock split of our issued and outstanding common stock (the &ldquo;Reverse Stock Split&rdquo;). All references to shares of our
common stock in this prospectus refers to the number of shares of common stock after giving effect to the Reverse Stock
Split (unless otherwise indicated).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_002"></A>SUMMARY
FINANCIAL INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary financial data should be read in conjunction with &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition
and Results of Operations,&rdquo; and the Financial Statements and notes thereto, included elsewhere in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Statements
of Operations Data:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">For the Years Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">For the Six Months Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> June 30, </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(As Restated)</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; text-align: left">Operating expenses</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">1,742,992</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">509,522</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right"> 992,022 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right"> 512,377 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,742,992</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(509,522</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> (992,002 </TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> (512,337 </TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other income (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">590,858</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(296,210</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> (287,092 </TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> 36,212 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,152,134</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(805,732</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> (1,279,114 </TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> (476,125 </TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Weighted average common shares outstanding - basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,301,750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 9,291,526 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 9,312,583 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,291,526</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss per share - basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.12</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.09</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> (0.14 </TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> (0.05 </TD><TD STYLE="text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Balance
Sheet Data:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> As of June 30, 2022 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Actual </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Pro Forma </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Pro Forma as Adjusted for Conversions
    and this Offering </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%"> Cash </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 14%; text-align: right"> 50,437 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 14%; text-align: right"> 10,846,965 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 14%; text-align: right"> 10,923,974 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Total current assets </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 63,952 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 10,860,480 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 10,937,489 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Total assets </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 173,480 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 10,970,008 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 11,047,017 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Total current liabilities </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,453,951 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,453,951 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,851,326 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Total liabilities </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,479,553 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,479,553 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,876,928 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Accumulated deficit </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (7,126,082 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (7,126,082 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (7,126,082 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Total stockholders&rsquo; equity (deficit) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> (2,306,073 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 8,490,455 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 9,170,089 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of shares of common stock issued and
outstanding actual, pro forma (reflecting the conversions of Series A preferred stock and convertible notes) and pro forma as adjusted
in the table above excludes 3,000,000 shares reserved for issuance under our 2018 Equity Incentive Plan, of which 384,167 shares
(on a post-reverse split basis) have been granted to date in the form of restricted stock units, some of which remain subject to certain
vesting conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_003"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>An
investment in our common stock involves a high degree of risk. You should carefully consider the following risk factors and all the other
information in this prospectus before you decide to buy our common stock. If any of the following risks related to our business actually
occurs, our business, financial condition, operating results, and prospects would be adversely affected. The market price of our common
stock could decline due to any of these risks and uncertainties related to our business, or related to an investment in our common stock,
and you may lose part or all of your investment.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Business</B></FONT><B>, Financial Condition and Capital Requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our funds are limited and our independent
auditing firm issued a going concern opinion related to our audit for the year ended December 31, 2021.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, we have been funded by investments from
private investors and government contracts obtained from the National Institutes of Health (NIH) for performing research. While this
has allowed us to complete a Phase I clinical trial for Ropidoxuridine and a pre-clinical trial for our HDAC inhibitor platform, we have
not yet completed our clinical trials, will require additional funds to reach such milestone, and do not know if any of our products
will ever achieve commercial viability. As such, to date we have no product revenue and our independent auditors, in their report dated
June 3, 2022, have expressed doubt about our ability to continue as a going concern.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
success is primarily dependent on the successful development, regulatory approval and commercialization of our product candidates, all
of which are in the early stages of development.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have one clinical stage product candidate in the early stages of development. Ropidoxuridine has undergone an
SBIR funded Phase 1 clinical trial at Lifespan/Rhode Island Hospital. We also have an HDAC inhibitor small molecule platform. The three
lead drug candidate molecules are in preclinical phases of development. none of our product candidates have gained marketing approval
for sale in the United States or any other country, and we cannot guarantee that we will ever have marketable products. To date, we have
invested substantially all of our efforts and financial resources in the research and development and commercial planning for our current
product candidate and our HDAC small molecule delivery platform. Our near-term prospects, including our ability to finance our Company
and generate revenue, as well as our future growth, will depend heavily on the development, marketing approval and commercialization
of our product candidates. The clinical and commercial success of product candidates will depend on a number of factors, including the
following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    favorable results from our Phase 1 clinical trial for IPdR and proceeding to Phase II and Phase III clinical trials,
    which may be slower or cost more than we currently anticipate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to demonstrate safety and efficacy of our product candidates, which are ongoing determinations that are solely within the
    authority of the FDA;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">even
    if our clinical trials are completed, there can be no assurance that the FDA will agree that we have satisfactorily demonstrated
    safety or efficacy or that the FDA will not raise new issues regarding the design of our clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    we are required by the FDA to conduct additional clinical trials to support the approval of our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    acceptance by the FDA of our proposed parameters for regulatory approval, including our proposed indication, endpoints and endpoint
    measurement tools relating to our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    incidence, duration and severity of adverse side effects;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timely receipt of necessary marketing approvals from the FDA;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    we are able to secure collaborations for completing the development and, if approved, commercialization of our product candidates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effectiveness of our and our potential collaborators&rsquo; marketing, sales and distribution strategy and operations of product
    candidates that are approved;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    success in educating physicians and patients about the benefits, administration and use of our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability of our third-party manufacturers and potential collaborators to manufacture clinical trial and commercial supplies of our
    product candidates to remain in good standing with regulatory bodies, and to develop, validate and maintain commercially viable manufacturing
    processes that are compliant with current Good Manufacturing Practices (&ldquo;cGMP&rdquo;) regulations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to commercialize our product candidates, if approved for marketing;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to enforce our intellectual property rights;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to avoid third-party patent interference or patent infringement claims;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
    of our product candidates as safe and effective by patients and the medical community; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    continued acceptable quality profile of our product candidates following approval.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Many
of the above-listed factors are beyond our control. Accordingly, we cannot assure you that we will ever be able to generate revenue through
the sale of our product candidates. Any one of these factors or other factors discussed in this prospectus could affect our ability to
commercialize product candidates, which could impact our ability to earn sufficient revenues to transition from a developmental stage
company and continue our business. If we do not obtain marketing approval of and commercialization of our product candidates,
or are significantly delayed in doing so, our business will be materially harmed. We have a limited operating history and have incurred
significant losses since our inception, and we anticipate that we will continue to incur losses for the foreseeable future and may never
achieve or maintain profitability.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a Phase I clinical stage pharmaceutical company with a limited operating history upon which you can evaluate our business and prospects.
Specialty pharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We do not
currently have any product candidates in advanced clinical trials or approved for sale, and we continue to incur significant research
and development and general and administrative expenses related to our operations. In addition, we have limited experience and have not
yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and
rapidly evolving fields, particularly in the specialty pharmaceutical industry. We have not generated any revenue and have incurred losses
in each year since our founding in December 2012. Our accumulated deficit as of June 30, 2022 was $7,126,082. We expect
to continue to incur significant losses for the foreseeable future. Even if we achieve profitability in the future, we may not be able
to sustain profitability in subsequent periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
currently have no source of product sales revenue.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not generated any revenues from commercial sales of our product candidates. Our ability to generate product revenue depends upon
our ability to develop and commercialize products, including any of our current product candidates or other product candidates
that we may develop, in-license or acquire in the future. We do not anticipate generating revenue from the sale of products for the foreseeable
future. Our ability to generate future product revenue from our current or future product candidates also depends on a number of additional
factors, including our ability to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">complete
    research and clinical development of current and future product candidates, either directly or through collaborative relationships;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    and maintain supply and manufacturing relationships with third parties, and ensure adequate and legally compliant manufacturing of
    bulk drug substances and drug products to maintain that supply;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    regulatory approval from relevant regulatory authorities in jurisdictions where we intend to market our product candidates, either
    directly or through collaborative relationships;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">launch
    and commercialize future product candidates for which we obtain marketing approval, if any, through collaborative partners;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    coverage and adequate product reimbursement from third-party payors, including government payors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieve
    market acceptance for our products, if any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish,
    maintain and protect our intellectual property rights; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract,
    hire and retain qualified personnel.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, because of the numerous risks and uncertainties associated with clinical product development, including that our product candidates
may not advance through development or achieve the endpoints of applicable clinical trials, we are unable to predict the timing or amount
of any potential future product sales revenues. Our expenses also could increase beyond expectations if we decide to or are required
by the FDA, or comparable foreign regulatory authorities, to perform studies or trials in addition to those that we currently anticipate.
Even if we complete the development and regulatory processes described above, we anticipate incurring significant costs associated with
launching and commercializing these products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
market may not be receptive to our product candidates based on our novel therapeutic modality, and we may not generate any future revenue
from the sale or licensing of product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if approval is obtained for a product candidate, we may not generate or sustain revenue from sales of the product due to factors such
as whether the product can be sold at a competitive cost and otherwise accepted in the market. The product candidates that we are developing
are based on new delivery platform therapeutic approaches (there currently is no drug which has FDA approval for indications of radiation
sensitization). Market participants with significant influence over acceptance of new treatments, such as physicians and third-party
payors, may not accept our delivery platform, and we may not be able to convince the medical community and third-party payors to accept
and use, or to provide favorable reimbursement for, any product candidates developed by us. Market acceptance of our product candidates
will depend on, among other factors:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">timing
    of our receipt of any marketing and commercialization approvals;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">terms
    of any approvals and the countries in which approvals are obtained;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">safety
    and efficacy of our product candidates, which are determinations solely within the authority of the FDA;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prevalence
    and severity of any adverse side effects associated with our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">warnings
    contained in any labeling approved by the FDA or other regulatory authority;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">convenience
    and ease of administration of our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">success
    of our physician education programs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability
    of adequate government and third-party payor reimbursement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pricing
    of our products, particularly as compared to alternative treatments; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability
    of alternative effective products for indications our product candidates are intended to treat.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will require substantial additional financing in order to obtain marketing approval of our product candidates and commercialize our product
candidates; a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce
or terminate our product development, other operations or commercialization efforts.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, substantially all of our resources have been dedicated to the preclinical and clinical development of our HDAC small molecule
delivery platform and our initial product candidate, Ropidoxuridine. Our capital needs to date have been met by contributions from existing
shareholders, as well as through private offerings of our securities and our SBIR contracts. We believe that we will continue to expend
substantial resources for the foreseeable future on the completion of clinical development and regulatory preparedness of our product
candidates, preparations for a commercial launch of our product candidates, if approved, and development of any other current or future
product candidates we may choose to further develop. These expenditures will include costs associated with research and development,
conducting preclinical studies and clinical trials, obtaining marketing approvals, and, if we are not able to enter into planned collaborations,
manufacturing and supply as well as marketing and selling any products approved for sale. In addition, other unanticipated costs may
arise. Because the outcome of any drug development process is highly uncertain, we cannot reasonably estimate the actual amounts necessary
to complete the development and commercialization of our current product candidates, if approved, or future product candidates,
if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate that our net proceeds from this Offering will be approximately $8,663,264, if all 1,660,000 units, with each unit
consisting of (i) one share of common stock and (ii) a warrant to purchase one share of common stock, offered hereby, are offered
and sold, less offering expenses payable by us. We believe that such proceeds together with our existing capital resources, will be sufficient
to fund our operations through 2024. However, our operating plan may change as a result of factors currently unknown to us, and we may
need to seek additional funds sooner than planned, through public or private equity or debt financings or other sources, such as strategic
collaborations. Such financing may result in dilution to shareholders, imposition of debt covenants and repayment obligations, or other
restrictions that may adversely affect our business. In addition, we may seek additional capital due to favorable market conditions or
strategic considerations even if we believe we have sufficient funds for our current or future operating plans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements depend on many factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, progress, results and costs of researching and developing our current product candidates, future product candidates and conducting
    preclinical and clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of commercialization activities if our current product candidates and future product candidates are approved for sale, including
    securing collaborative ventures for completing development of, securing marketing approval for and ultimately marketing, selling
    and distributing our product candidates, if approved or building a corporate infrastructure if we have to undertake these activities
    directly;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number and characteristics of any additional product candidates we may develop or acquire;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    product liability or other lawsuits related to our products or commenced against us;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    expenses needed to attract and retain skilled personnel;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs associated with being a public company;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs
    and the outcome of such litigation; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing, receipt and amount of sales of, or royalties on, any future approved products, if any.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
funds may not be available when we need them, on terms that are acceptable to us, or at all. If adequate funds are not available to us
on a timely basis, we may be required to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay,
    limit, reduce or terminate preclinical studies, clinical trials or other development activities for our current product candidates
    or future product candidates, if any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay,
    limit, reduce or terminate our research and development activities; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay,
    limit, reduce or terminate our establishment of sales and marketing capabilities or other activities that may be necessary to commercialize
    our current or future product candidates.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Raising
additional capital may cause dilution to our existing shareholders, restrict our operations or require us to relinquish rights to our
technologies or product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek additional capital through a combination of public and private equity offerings, debt financings, strategic collaborations and
alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities,
your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights
as a shareholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive
covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual
property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional
funds through strategic collaborations and alliances and licensing arrangements with third parties, we may have to relinquish valuable
rights to our technologies or product candidates or grant licenses on terms unfavorable to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Unstable market and economic conditions
caused by the ongoing conflict between the Ukraine and Russia, as well as the ongoing COVID-19 pandemic, may have serious adverse consequences
on our business, financial condition and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The global economy, including credit and financial
markets, has experienced extreme volatility and disruptions as a result of the ongoing conflict between the Ukraine and Russia, as well
as challenges arising from the ongoing COVID-19 pandemic, including severely diminished liquidity and credit availability, declines in
consumer confidence, declines in economic growth, increases in unemployment rates, increases in inflation rates and uncertainty about
economic stability. Any such volatility and disruptions may have adverse consequences on us or the third parties upon whom we rely.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
product candidates are in the early stages of development and may fail in development or suffer delays that materially adversely affect
their commercial viability.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no products on the market and all of our product candidates are in the early stages of development. Our ability to achieve and sustain
profitability depends on obtaining regulatory approvals, including institutional review board (&ldquo;IRB&rdquo;) approval, for and commercializing
our product candidates, either alone or with third parties. Before obtaining regulatory approval for the commercial distribution of our
product candidates, we or one of our collaborators must conduct extensive preclinical tests and clinical trials to demonstrate the safety
and efficacy in humans of our product candidates, the final determination of which rests solely in the authority of the FDA. Preclinical
testing and clinical trials are expensive, difficult to design and implement, can take many years to complete and are uncertain as to
outcome. The start or end of a clinical study is often delayed or halted due to changing regulatory requirements, manufacturing challenges,
required clinical trial administrative actions, slower than anticipated patient enrollment, changing standards of care, availability
or prevalence of use of a comparative drug or required prior therapy, clinical outcomes or financial constraints. For instance, delays
or difficulties in patient enrollment or difficulties in retaining trial participants can result in increased costs, longer development
times or termination of a clinical trial. Clinical trials of a new product candidate require the enrollment of a sufficient number of
patients, including patients who are suffering from the disease the product candidate is intended to treat and who meet other eligibility
criteria. Rates of patient enrollment are affected by many factors, including the size of the patient population, the eligibility criteria
for the clinical trial, the age and condition of the patients, the stage and severity of disease, the nature of the protocol, the proximity
of patients to clinical sites and the availability of effective treatments for the relevant disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
product candidate can unexpectedly fail at any stage of preclinical and clinical development. The historical failure rate for product
candidates is high due to scientific feasibility, lack of quality and effectiveness, changing standards of medical care and other
variables. The results from preclinical testing or early clinical trials of a product candidate may not predict the results that will
be obtained in later phase clinical trials of the product candidate. We, the FDA or other applicable regulatory authorities may suspend
clinical trials of a product candidate at any time for various reasons, including a belief that subjects participating in such trials
are being exposed to unacceptable health risks or adverse side effects. We may not have the financial resources to continue development
of, or to enter into collaborations for, a product candidate if we experience any problems or other unforeseen events that delay or prevent
regulatory approval of, or our ability to commercialize, product candidates, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative
    or inconclusive results from our clinical trials or the clinical trials of others for product candidates similar to ours, leading
    to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">serious
    and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar
    to our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in submitting an Investigational New Drug application (&ldquo;IND&rdquo;) or delays or failure in obtaining the necessary approvals
    from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions
    imposed by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in enrolling research subjects in clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">high
    drop-out rates of research subjects;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">greater
    than anticipated clinical trial costs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">poor
    effectiveness of our product candidates during clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable
    FDA or other regulatory agency inspection and review of a clinical trial site;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations
    in a timely manner, or at all;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around
    clinical testing generally or with respect to our technology in particular; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">varying
    interpretations of data by the FDA and similar foreign regulatory agencies.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
third parties on which we depend to conduct our preclinical studies, or any future clinical trials, do not perform as contractually required,
fail to satisfy regulatory or legal requirements or miss expected deadlines, our development program could be delayed with materially
adverse effects on our business, financial condition, results of operations and prospects.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are relying on third party collaborators to conduct our efficacy clinical trials for Ropidoxuridine and plan to rely on third party clinical
investigators, contract research organizations (&ldquo;CROs&rdquo;), clinical data management organizations and consultants to design,
conduct, supervise and monitor preclinical studies of our product candidates and will do the same for any clinical trials. Because we
plan to largely rely on third parties and do not have the ability to conduct preclinical studies or clinical trials independently, we
have less control over the timing, quality and other aspects of preclinical studies and clinical trials than we would if we conducted
them on our own. These investigators, CROs, and consultants are not our employees and we have limited control over the amount
of time and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities,
some of which may be our competitors, which may draw time and resources from our programs. The third parties with whom we contract might
not be diligent, careful or timely in conducting our preclinical studies or clinical trials, resulting in the preclinical studies or
clinical trials being delayed or unsuccessful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry
out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or
meet expected deadlines, our clinical development programs could be delayed and otherwise adversely affected. In all events, we are responsible
for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the general investigational plan
and protocols for the trial. The FDA requires clinical trials to be conducted in accordance with good clinical practices, including for
conducting, recording and reporting the results of preclinical studies and clinical trials to assure that data and reported results are
credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. Our reliance on
third parties that we do not control does not relieve us of these responsibilities and requirements. Any such event could have a material
adverse effect on our business, financial condition, results of operations and/or prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Because
we rely on third party manufacturing and supply partners, our supply of research and development, preclinical and clinical development
materials may become limited or interrupted or may not be of satisfactory quantity or quality.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on third party supply and manufacturing partners to supply the materials and components for, and manufacture, our research and development,
preclinical and clinical trial drug supplies. We do not own manufacturing facilities or supply sources for such components and materials.
There can be no assurance that our supply of research and development, preclinical and clinical development drugs and other materials
will not be limited, interrupted, restricted in certain geographic regions or of satisfactory quality or continue to be available at
acceptable prices. In particular, any replacement of any drug product formulation manufacturer we may use could require significant effort
and expertise in the event there are a limited number of qualified replacements for a particular product candidate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacturing process for a product candidate is subject to FDA and foreign regulatory authority review. Suppliers and manufacturers
must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities
in order to comply with regulatory standards, such as Current Good Manufacturing Practice (or CGMP). In the event that any of our suppliers
or manufacturers fail to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise,
or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the
materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third
party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture
our product candidates may be unique or proprietary to the original manufacturer, and we may have difficulty, or there may be
contractual restrictions prohibiting us from, transferring such skills or technology to another third party and a feasible alternative
may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer
in order to have another third party manufacture our product candidates. If we are required to change manufacturers for any reason, we
will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with
all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect
our ability to develop product candidates in a timely manner or within budget.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to rely on third party manufacturers if we receive regulatory approval for any product candidate. To the extent that
we have existing or future manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations
in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance.
If we are unable to obtain or maintain third-party manufacturing for product candidates, or to do so on commercially reasonable terms,
we may not be able to fully develop and commercialize our product candidates. Our or a third party&rsquo;s failure
to execute on our manufacturing requirements could adversely affect our business in a number of ways, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    inability to initiate or continue clinical trials of product candidates under development;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    in submitting regulatory applications, or receiving regulatory approvals, for product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
    of the cooperation of a collaborator;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subjecting
    our product candidates to additional inspections by regulatory authorities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements
    to cease distribution or to recall batches of our product candidates; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be unsuccessful in engaging in strategic transactions which could adversely affect our ability to develop and commercialize product
candidates, impact our cash position, increase our expense and present significant distractions to our management.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may consider strategic transactions, such as collaborations, acquisitions of companies, asset purchases and out- or
in- licensing of product candidates or technologies. In particular, we will evaluate and, if strategically attractive, seek to enter
into additional collaborations, including with major biotechnology or pharmaceutical companies to complete development and marketing
of our product candidates, if approved. The competition for collaborators is intense, and the negotiation process is time-consuming and
complex. Any proposed collaboration may be on terms that are not optimal for us, and we may not be able to maintain any new or existing
collaboration if, for example, development or approval of a product candidate is delayed, sales of an approved product candidate do not
meet expectations or the collaborator terminates the collaboration. Any such collaboration, or other strategic transaction, may require
us to incur non-recurring or other charges, increase our near- and long-term expenditures and pose significant integration or implementation
challenges or disrupt our management or business. These transactions would entail numerous operational and financial risks, including
exposure to unknown liabilities, disruption of our business and diversion of our management&rsquo;s time and attention in order to manage
a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances
of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs,
write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration
or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or
customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired
business. Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature
described above, any transactions that we do complete may be subject to the foregoing or other risks and have a material adverse effect
on our business, results of operations, financial condition and prospects. Conversely, any failure to enter into any collaboration or
other strategic transaction that would be beneficial to us could delay the development and potential commercialization of our product
candidates and have a negative impact on the competitiveness of any product candidate that reaches market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
face competition from entities that have developed or may develop product candidates for our target disease indications, including companies
developing novel treatments and technology platforms based on modalities and technology similar to ours. If these companies develop technologies
or product candidates more rapidly than we do or their technologies, including delivery technologies, are more effective, our ability
to develop and commercialize product candidates may be adversely affected.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development and commercialization of drugs is highly competitive. We compete with a variety of multinational pharmaceutical companies
and specialized biotechnology companies, as well as with universities and other research institutions which are developing new technology.
Our competitors have developed, are developing or will develop product candidates and processes competitive with our product candidates.
Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments
that enter the market. We believe that a significant number of products are currently under development, and may become commercially
available in the future, for the treatment of conditions for which we may try to develop product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience
than we have. If we obtain approval for any product candidate, we will face competition based on many different factors, including the
quality and effectiveness of our products, the ease with which our products can be administered and the extent to which patients
accept relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and
cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could
present superior treatment alternatives, including by being more effective, safer, less expensive or marketed and sold more effectively
than any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover
the expense of developing and commercializing our product candidates. Such competitors could also recruit our employees, which could
negatively impact our level of expertise and our ability to execute our business plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Any
inability to attract and retain qualified key management and technical personnel would impair our ability to implement our business plan.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our success largely depends on the continued
service of certain key management and other specialized personnel, including Anatoly Dritschilo, M.D., our Chief Executive Officer, Mira
Jung, Ph.D., our Chief Scientific Officer for Biology, Michael Vander Hoek, our Chief Financial Officer and Vice President Operations
and Regulatory, and Peter Dritschilo, our President and Chief Operating Officer. The loss of one or more members of our management team
or other key employees or advisors could delay our research and development programs and materially harm our business, financial condition,
results of operations and prospects. The relationships that our key managers have cultivated within our industry make us particularly
dependent upon their continued employment with us. We are dependent on the continued service of our technical personnel because of the
highly technical nature of our product candidates and technologies and the specialized nature of the regulatory approval process. Because
our management team and key employees are not obligated to provide us with continued service, they could terminate their employment with
us at any time without penalty. We do not maintain key person life insurance policies on any of our management team members or key employees.
Our future success will depend in large part on our continued ability to attract and retain other highly qualified scientific, technical
and management personnel, as well as personnel with expertise in clinical testing, manufacturing, governmental regulation and commercialization.
We face competition for personnel from other companies, universities, public and private research institutions, government entities and
other organizations.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
our product candidates advance into Phase II and Phase III clinical trials, we may experience difficulties in managing our growth and
expanding our operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have limited experience in drug development and have not begun clinical trials for any of our product candidates, other than a Phase
1 clinical trial for Ropidoxuridine. As our product candidates enter and advance through preclinical studies and any clinical trials,
we will need to expand our development, regulatory and manufacturing capabilities or contract with other organizations to provide these
capabilities for us. In the future, we expect to have to manage additional relationships with collaborators or partners, suppliers and
other organizations. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial
and management controls, reporting systems and procedures. We may not be able to implement improvements to our management information
and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
any of our product candidates are approved for marketing and commercialization and we are unable to develop sales, marketing and distribution
capabilities on our own or enter into agreements with third parties to perform these functions on acceptable terms, we will be unable
to commercialize any such future products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have no sales, marketing or distribution capabilities or experience. If any of our product candidates is approved, we plan
to enter into collaborations with third parties to sell, market and distribute our products. In the alternative, we would have to develop
internal sales, marketing and distribution capabilities to commercialize any approved product, which would be expensive and time-consuming,
or, as is more likely, enter into collaborations with third parties to perform these services. If we rely on third parties with sales,
marketing and distribution capabilities to market our products or decide to co-promote products with collaborators, we will need to establish
and maintain marketing and distribution arrangements with third parties, and there can be no assurance that we will be able to enter
into such arrangements on acceptable terms, if, at all. In entering into third-party marketing or distribution arrangements, any revenue
we receive will depend upon the efforts of the third parties and there can be no assurance that such third parties will establish adequate
sales and distribution capabilities or be successful in gaining market acceptance of any approved product. If we decide to market our
products directly, we will need to commit significant financial and managerial resources to develop a marketing and sales force with
technical expertise and supporting distribution, administration and compliance capabilities. If we are not able to commercialize
any product approved in the future, either on our own or through third parties, our business, financial condition, results of operations
and prospects could be materially adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to comply with U.S. and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization
approvals we may receive and subject us to other penalties that could materially harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we receive marketing and commercialization approval of a product candidate, there can be no assurance we will not be subject to future
or continuing regulatory review, including in relation to adverse patient experiences with the product and clinical results that are
reported after a product is made commercially available, both in the U.S. and any foreign jurisdiction in which we seek regulatory approval.
The FDA has significant post-market authority, including the authority to require labeling changes based on new safety information and
to require post-market studies or clinical trials to evaluate safety risks related to the use of a product or to require withdrawal of
the product from the market. The FDA also has the authority to require a risk evaluation and mitigation strategies (&ldquo;REMS&rdquo;)
plan after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug. The manufacturer
and manufacturing facilities we use to make a future product, if any, will also be subject to periodic review and inspection by the FDA
and other regulatory agencies, including for continued compliance with CGMP requirements. The discovery of any new or previously unknown
problems with our third-party manufacturers, manufacturing processes or facilities may result in restrictions on the product, manufacturer
or facility, including withdrawal of the product from the market. If we rely on third-party manufacturers, we will not have control over
compliance with applicable rules and regulations by such manufacturers. Any product promotion and advertising will also be subject to
regulatory requirements and continuing regulatory review. If we or our collaborators, manufacturers or service providers fail to comply
with applicable continuing regulatory requirements in the U.S. or foreign jurisdictions in which we seek to market our products, we or
they may be subject to, among other things, fines, warning letters, holds on clinical trials, refusal by the FDA to approve pending applications
or supplements to approved applications, suspension or withdrawal of regulatory approval, product recalls and seizures, refusal to permit
the import or export of products, operating restrictions, injunction, civil penalties and criminal prosecution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
business entails a significant risk of product liability and our ability to obtain sufficient insurance coverage could have a material
effect on our business, financial condition, results of operations or prospects.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic
treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products,
such claims could result in an FDA investigation of the quality and effectiveness of our products, our manufacturing processes
and facilities or our marketing programs and potentially a recall of our products or more serious enforcement action, limitations on
the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome,
liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation,
a diversion of management&rsquo;s time and our resources, substantial monetary awards to trial participants or patients and a decline
in our stock price. We currently have product liability insurance that we believe is appropriate for our stage of development and may
need to obtain higher levels prior to marketing any of our product candidates. Any insurance we have or may obtain may not provide sufficient
coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive.
As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability
claims that could have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with
FDA regulations, provide accurate information to the FDA, comply with manufacturing standards we may establish, comply with federal and
state healthcare fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities
to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations,
kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting,
marketing and promotion, sales commission, customer incentive programs and other business arrangements. While we make an effort to maintain
strict employee work processes and oversight, employee misconduct could expose us to liability through the improper use of information
obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. Furthermore,
it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity
may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other
actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against
us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business,
including the imposition of significant fines or other sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could
result in a material disruption of our product development programs.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the implementation of cyber security measures, our internal computer systems and those of our CROs and other contractors and consultants
are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical
failures. Such events could cause interruptions of our operations. For example, the loss of preclinical data or data from any future
clinical trial involving our product candidates could result in delays in our development and regulatory filing efforts and significantly
increase our costs. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data, or inappropriate
disclosure of confidential or proprietary information, we could incur liability and the development of our product candidates could be
delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
proprietary information, or that of our customers, suppliers and business partners, may be lost or we may suffer security breaches.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of our business, we collect and store sensitive data, including intellectual property, clinical trial data, our proprietary
business information and that of our customers, suppliers and business partners, and personally identifiable information of our customers,
clinical trial subjects and employees, in our data centers and on our networks. The secure processing, maintenance and transmission of
this information is critical to our operations. Despite our security measures, our information technology and infrastructure may be vulnerable
to attacks by hackers or breached due to employee error, malfeasance or other disruptions. Although to our knowledge we have not experienced
any such material security breach to date, any such breach could compromise our network, or the networks of our CROs or other third party
service providers, and the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure
or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information,
regulatory penalties, disrupt our operations, damage our reputation, and cause a loss of confidence in our products and our ability to
conduct clinical trials, which could adversely affect our business and reputation and lead to delays in gaining regulatory approvals
for our drugs. Although we maintain business interruption insurance coverage, our insurance might not cover all losses from any future
breaches of our systems.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Failure
of our information technology systems could significantly disrupt the operation of our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business increasingly depends on the use of information technologies, which means that certain key areas such as research and development,
production and sales are to a large extent dependent on our information systems or those of third-party providers. Our ability to execute
our business plan and to comply with regulatory requirements with respect to data control and data integrity, depends, in part, on the
continued and uninterrupted performance of our information technology systems, or IT systems and the IT systems supplied by third-party
service providers. These systems are vulnerable to damage from a variety of sources, including telecommunications or network failures,
malicious human acts and natural disasters. Moreover, despite network security and backup measures, some of our servers are potentially
vulnerable to physical or electronic break-ins, computer viruses and similar disruptive problems. Despite the precautionary measures
we and our third-party service providers have taken to prevent unanticipated problems that could affect our IT systems, sustained or
repeated system failures or problems arising during the upgrade of any of our IT systems that interrupt our ability to generate and maintain
data, and in particular to operate our proprietary technology platform, could adversely affect our ability to operate our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely
affected.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research, development and manufacturing involve the use of hazardous materials and various chemicals. We maintain quantities of various
flammable and toxic chemicals in our facilities in Gaithersburg, Maryland that are required for our research, development and manufacturing
activities. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal
of these hazardous materials. We believe our procedures for storing, handling and disposing these materials in our Gaithersburg facilities
comply with the relevant guidelines of Gaithersburg, the State of Maryland and the Occupational Safety and Health Administration of the
U.S. Department of Labor. Although we believe that our safety procedures for handling and disposing of these materials comply with the
standards mandated by applicable regulations, the risk of accidental contamination or injury from these materials cannot be eliminated.
If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental,
health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens
and the handling of animals and biohazardous materials. Although we maintain workers&rsquo; compensation insurance to cover us for costs
and expenses, we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not
provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims
that may be asserted against us in connection with our storage or disposal of biological or hazardous materials. Additional federal,
state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply
with, and substantial fines or penalties if we violate any of these laws or regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
information technology systems could face serious disruptions that could adversely affect our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
information technology and other internal infrastructure systems, including corporate firewalls, servers, leased lines and connection
to the Internet, face the risk of systemic failure that could disrupt our operations. A significant disruption in the availability of
our information technology and other internal infrastructure systems could cause interruptions in our collaborations with our partners
and delays in our research and development work.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes
in accounting rules and regulations, or interpretations thereof, could result in unfavorable accounting charges or require us to change
our compensation policies.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting
methods and policies for pharmaceutical companies, including policies governing revenue recognition, research and development and related
expenses and accounting for stock-based compensation are subject to review, interpretation and guidance from relevant accounting authorities,
including the SEC. Changes to accounting methods or policies, or interpretations thereof, may require us to reclassify, restate or otherwise
change or revise our financial statements, including those contained in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Intellectual Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are not able to obtain and enforce patent protection for our technologies or product candidates, development and commercialization
of our product candidates may be adversely affected.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends in part on our ability to obtain and maintain patents and other forms of intellectual property rights, including in-licenses
of intellectual property rights of others, for our product candidates, methods used to manufacture our product candidates and methods
for treating patients using our product candidates, as well as our ability to preserve our trade secrets, to prevent third parties from
infringing upon our proprietary rights and to operate without infringing upon the proprietary rights of others. As of the date of this
prospectus, we have filed five patent applications with the U.S. Patent and Trademark Office (the &ldquo;USPTO&rdquo;) with respect to
various aspects of our HDAC inhibitor small molecule delivery platform and Ropidoxuridine, our lead product candidate. However, we may
not be able to apply for patents on certain aspects of our product candidates or delivery technologies in a timely fashion or at all.
To date, four US patents and two European patents have been granted. There is no guarantee that any of our pending patent applications
will result in issued or granted patents, that any of our issued, granted or licensed patents will not later be found to be invalid or
unenforceable or that any issued, granted or licensed patents will include claims that are sufficiently broad to cover our product candidates
or delivery technologies or to provide meaningful protection from our competitors. Moreover, the patent position of specialty pharmaceutical
companies can be highly uncertain because it involves complex legal and factual questions. We will be able to protect our proprietary
rights from unauthorized use by third parties only to the extent that our current and future proprietary technology and product candidates
are covered by valid and enforceable patents or are effectively maintained as trade secrets. If third parties disclose or misappropriate
our proprietary rights, it may materially and adversely impact our position in the market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other
requirements during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or
patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors
might be able to enter the market earlier than would otherwise have been the case. The standards applied by the USPTO and foreign patent
offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding
patentable subject matter or the scope of claims allowable in pharmaceutical patents. As such, we do not know the degree of future protection
that we will have on our proprietary products and technology. While we will endeavor to try to protect our product candidates with intellectual
property rights such as patents, as appropriate, the process of obtaining patents is time-consuming, expensive and sometimes unpredictable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may decide for business reasons to no longer pursue or to abandon certain intellectual property rights in the US or elsewhere, including
due to non-cooperation of inventors or owners of such intellectual property, prior art, or scope of protection, or for other reasons.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
granted, patents may remain open to opposition, interference, re-examination, post-grant review, inter partes review, nullification or
derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which
time third parties can raise objections against such initial grant. In the course of such proceedings, which may continue for a protracted
period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked, or may lose the
allowed or granted claims altogether. In addition, there can be no assurance that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
    will not or may not be able to make, use or sell compounds that are the same as or similar to our product candidates but that are
    not covered by the claims of the patents that we own or license;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    or our licensors, collaborators or any future collaborators are the first to make the inventions covered by each of our issued patents
    and pending patent applications that we own or license;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    or our licensors, collaborators or any future collaborators are the first to file patent applications covering certain aspects of
    our inventions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
    will not independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual
    property rights;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    third party may not challenge our patents and, if challenged, a court may not hold that our patents are valid, enforceable and infringed;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    issued patents that we own or have licensed will provide us with any competitive advantages, or will not be challenged by third parties;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may develop additional proprietary technologies that are patentable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    patents of others will not have an adverse effect on our business; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    competitors do not conduct research and development activities in countries where we do not have enforceable patent rights and then
    use the information learned from such activities to develop competitive products for sale in our major commercial markets.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
intend to license patent rights from third-party owners or licensees. If such owners or licensees do not properly or successfully obtain,
maintain or enforce the patents underlying such licenses, or if they retain or license to others any competing rights, our competitive
position and business prospects may be adversely affected. We may not be able to protect our intellectual property rights throughout
the world.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
a valid and enforceable issued or granted patent covering our technology in the U.S. and worldwide can be extremely costly. In jurisdictions
where we have not obtained patent protection, competitors may use our technology to develop their own products and further, may export
otherwise infringing products to territories where we have patent protection, but where it is more difficult to enforce a patent as compared
to the U.S. Competitor products may compete with our future products in jurisdictions where we do not have issued or granted patents
or where our issued or granted patent claims or other intellectual property rights are not sufficient to prevent competitor activities
in these jurisdictions. The legal systems of certain countries, particularly certain developing countries, make it difficult to enforce
patents and such countries may not recognize other types of intellectual property protection, particularly that relating to biopharmaceuticals.
This could make it difficult for us to prevent the infringement of patents or marketing of competing products in violation of our proprietary
rights generally in certain jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial
cost and divert our efforts and attention from other aspects of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
generally file a provisional patent application first (a priority filing) at the USPTO. A U.S. utility application and international
application under the Patent Cooperation Treaty (PCT) are usually filed within twelve months after the priority filing. Based on the
PCT filing, national and regional patent applications may be filed in the European Union, Japan, Australia and Canada and other countries.
We have so far not filed for patent protection in all national and regional jurisdictions where such protection may be available.
In addition, we may decide to abandon national and regional patent applications before grant. Finally, the grant proceeding of each national
or regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused
by the relevant registration authorities, while granted by others. It is also quite common that depending on the country, various scopes
of patent protection may be granted on the same product candidate or technology. The laws of some jurisdictions do not protect intellectual
property rights to the same extent as the laws in the U.S., and many companies have encountered significant difficulties in protecting
and defending such rights in such jurisdictions. If we or our licensors encounter difficulties in protecting, or are otherwise precluded
from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights
may be diminished, and we may face additional competition from others in those jurisdictions. Many countries have compulsory licensing
laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability
of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which
could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties with
respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business
and results of operations may be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
or our licensors, or any future collaborators or a strategic partners may become subject to third party claims or litigation alleging
infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights, and we may need to
resort to litigation to protect or enforce our patents or other proprietary rights, all of which could be costly, time consuming, delay
or prevent the development and commercialization of our product candidates, or put our patents and other proprietary rights at risk.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
or our licensors, or any future collaborators or strategic partners may be subject to third-party claims for infringement or misappropriation
of patent or other proprietary rights. We are generally obligated under our license or collaboration agreements to indemnify and hold
harmless our licensors or collaborator for damages arising from intellectual property infringement by us. If we or our licensors, or
any future collaborators or strategic partners are found to infringe a third-party patent or other intellectual property rights,
we could be required to pay damages, potentially including treble damages, if we are found to have willfully infringed. In addition,
we or our licensors, collaborators or any future strategic partners may choose to seek, or be required to seek, a license from a third
party, which may not be available on acceptable terms, if at all. Even if a license can be obtained on acceptable terms, the rights may
be non-exclusive, which could give our competitors access to the same technology or intellectual property rights licensed to us. If we
fail to obtain a required license, we or our collaborator, or any future collaborator, may be unable to effectively market product candidates
based on our technology, which could limit our ability to generate revenue or achieve profitability and possibly prevent us from generating
revenue sufficient to sustain our operations. In addition, we may find it necessary to pursue claims or initiate lawsuits to protect
or enforce our patent or other intellectual property rights. The cost to us in defending or initiating any litigation or other proceeding
relating to patent or other proprietary rights, even if resolved in our favor, could be substantial, and litigation would divert our
management&rsquo;s attention. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively
than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent
litigation or other proceedings could delay our research and development efforts and limit our ability to continue our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we were to initiate legal proceedings against a third party to enforce a patent covering one of our products or our technology, the defendant
could counterclaim that our patent is invalid or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity
or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements,
for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone
connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution.
The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to
the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner
were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose
at least part, and perhaps all, of the patent protection on one or more of our products or certain aspects of our platform technology.
Such a loss of patent protection could have a material adverse impact on our business. Patents and other intellectual property rights
also will not protect our technology if competitors design around our protected technology without legally infringing our patents or
other intellectual property rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Intellectual
property rights of third parties could adversely affect our ability to commercialize our product candidates, and we might be required
to litigate or obtain licenses from third parties in order to develop or market our product candidates. Such litigation or licenses could
be costly or not available on commercially reasonable terms.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
competitive position may suffer if patents issued to third parties or other third-party intellectual property rights cover our
products or elements thereof, or our manufacture or uses relevant to our development plans. In such cases, we may not be in a position
to develop or commercialize products or product candidates unless we successfully pursue litigation to nullify or invalidate the third-party
intellectual property right concerned, or enter into a license agreement with the intellectual property right holder, if available
on commercially reasonable terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
party intellectual property right holders may also actively bring infringement claims against us. We cannot guarantee that we will be
able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully settle future claims on terms
acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming litigation and may be prevented
from or experience substantial delays in marketing our products. If we fail in any such dispute, in addition to being forced to pay damages,
we may be temporarily or permanently prohibited from commercializing any of our product candidates that are held to be infringing. We
might, if possible, also be forced to redesign product candidates so that we no longer infringe the third-party intellectual property
rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources
that we would otherwise be able to devote to our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could
lose intellectual property rights that are necessary for developing and protecting our product candidates and delivery technologies or
we could lose certain rights to grant sublicenses.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current licenses impose, and any future licenses we enter into are likely to impose, various development, commercialization, funding,
milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement, and other obligations on us. If we breach
any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages
and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture and sell
products that are covered by the licensed technology or enable a competitor to gain access to the licensed technology. Moreover, our
licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless
of their merit, that we are infringing or otherwise violating the licensor&rsquo;s rights. In addition, while we cannot currently determine
the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant.
The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we aim
to develop and commercialize, if any. Therefore, even if we are able to develop and commercialize products, we may be unable
to achieve or maintain profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to seeking patent protection for certain aspects of our product candidates and delivery technologies, we also consider trade
secrets, including confidential and unpatented know-how important to the maintenance of our competitive position. We protect trade secrets
and confidential and unpatented know-how, in part, by entering into non-disclosure and confidentiality agreements with parties who have
access to such knowledge, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers,
consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with
our employees and consultants that obligate them to maintain confidentiality and assign their inventions to us. Despite these efforts,
any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not
be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade
secret is difficult, expensive and time- consuming, and the outcome is unpredictable. In addition, some courts in the U.S. and certain
foreign jurisdictions are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained
or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete
with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would
be harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets of our employees&rsquo;
or consultants&rsquo; former employers or their clients. These claims may be costly to defend and if we do not successfully do so, we
may be required to pay monetary damages and may lose valuable intellectual property rights or personnel.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our employees were previously employed at universities or biotechnology or pharmaceutical companies, including our competitors or
potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have
inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may
be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose
valuable intellectual property rights or personnel. A loss of key research personnel or their work product could hamper our ability to
commercialize, or prevent us from commercializing, our product candidates, which could severely harm our business. Even if we are successful
in defending against these claims, litigation could result in substantial costs and be a distraction to management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest
and our business may be adversely affected.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks.
We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need
for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based
on our trademarks and trade names, we may not be able to effectively compete  and our business may be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Government Regulation and Product Approvals</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be unable to obtain U.S. or foreign regulatory approval and, as a result, unable to commercialize our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates are subject to extensive governmental regulations relating to, among other things, research, testing, development,
manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing,
marketing and distribution of drugs. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process are
required to be completed in the U.S. and in many foreign jurisdictions before a new drug can be marketed. Satisfaction of
these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. It is possible that
none of the product candidates we may develop will obtain the regulatory approvals necessary for us or our collaborators to begin selling
them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have very limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval
by the FDA. The time required to obtain FDA and other approvals is unpredictable but typically takes many years following the commencement
of clinical trials, depending upon the type, complexity and novelty of the product candidate. The standards that the FDA and its foreign
counterparts use when regulating us are not always applied predictably or uniformly and can change. Any analysis we perform of data from
preclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit
or prevent regulatory approval. We may also encounter unexpected delays or increased costs due to new government regulations, for example,
from future legislation or administrative action, or from changes in FDA policy during the period of product development, clinical trials
and FDA regulatory review. It is impossible to predict whether legislative changes will be enacted, or whether FDA or foreign regulations,
guidance or interpretations will be changed, or what the impact of such changes, if any, may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
delay or failure in obtaining required approvals could have a material adverse effect on our ability to generate revenues from the particular
product candidate for which we are seeking approval. Furthermore, any regulatory approval to market a product may be subject to limitations
on the approved uses for which we may market the product or the labeling or other restrictions. In addition, the FDA has the authority
to require a Risk Evaluation and Mitigation Strategy (REMS) plan as part of an NDA or biologics license application (BLA) or after approval,
which may impose further requirements or restrictions on the distribution or use of an approved drug or biologic, such as limiting prescribing
to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use
criteria and requiring treated patients to enroll in a registry. These limitations and restrictions may limit the size of the market
for the product and affect reimbursement by third-party payors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we or our collaborators, manufacturers or service providers fail to comply with healthcare laws and regulations, we or they could be
subject to enforcement actions, which could affect our ability to develop, market and sell our products and may harm our reputation.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and our collaborators are subject to federal, state, and foreign healthcare laws and regulations pertaining to fraud and abuse and patients&rsquo;
rights. These laws and regulations include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    U.S. federal healthcare program anti-kickback law, which prohibits, among other things, persons from soliciting, receiving or providing
    remuneration, directly or indirectly, to induce either the referral of an individual for a healthcare item or service, or the purchasing
    or ordering of an item or service, for which payment may be made under a federal healthcare program such as Medicare or Medicaid;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    U.S. federal false claims law, which prohibits, among other things, individuals or entities from knowingly presenting or causing
    to be presented, claims for payment by government funded programs such as Medicare or Medicaid that are false or fraudulent, and
    which may apply to us by virtue of statements and representations made to customers or third parties;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    U.S. federal Health Insurance Portability and Accountability Act (HIPAA) and Health Information Technology for Economic and Clinical
    Health (HITECH) Act, which prohibit executing a scheme to defraud healthcare programs, impose requirements relating to the privacy,
    security, and transmission of individually identifiable health information, and require notification to affected individuals and
    regulatory authorities of certain breaches of security of individually identifiable health information;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Open Payments regulations under the National Physician Payment Transparency Program have been issued under the Patient Protection
    and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, and will require that manufacturers
    of pharmaceutical and biological drugs covered by Medicare, Medicaid, and Children&rsquo;s Health Insurance Programs report all consulting
    fees, travel reimbursements, research grants, and other payments or gifts with values over $10 made to physicians and teaching hospitals;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    laws comparable to each of the above federal laws, such as, for example, anti-kickback and false claims laws applicable to commercial
    insurers and other non-federal payors, requirements for mandatory corporate regulatory compliance programs, and laws relating to
    patient data privacy and security.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our operations are found to be in violation of any such requirements, we may be subject to penalties, including civil or criminal penalties,
monetary damages, the curtailment or restructuring of our operations, loss of eligibility to obtain approvals from the FDA, or exclusion
from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid,
any of which could adversely our financial results. Although effective compliance programs can mitigate the risk of investigation and
prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected
violation could cause us to incur significant legal expenses and could divert our management&rsquo;s attention from the operation of
our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations
may be costly to us in terms of money, time and resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we or our collaborators, manufacturers or service providers fail to comply with applicable federal, state or foreign laws or regulations,
we could be subject to enforcement actions, which could affect our ability to develop, market and sell our products successfully and
could harm our reputation and lead to reduced acceptance of our products by the market. These enforcement actions include, among others:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    regulatory inspection findings;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning
    letters;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">voluntary
    or mandatory product recalls or public notification or medical product safety alerts to healthcare professionals;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on, or prohibitions against, marketing our products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on, or prohibitions against, importation or exportation of our products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    of review or refusal to approve pending applications or supplements to approved applications;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exclusion
    from participation in government-funded healthcare programs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exclusion
    from eligibility for the award of government contracts for our products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    or withdrawal of product approvals;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    seizures;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">civil
    and criminal penalties and fines.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Any
drugs we develop may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives,
thereby harming our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
regulations that govern marketing approvals, pricing and reimbursement for new drugs vary widely from country to country. Some countries
require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing
or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing
governmental control even after initial approval is granted. Although we intend to monitor these regulations, our programs are currently
in the early stages of development and we will not be able to assess the impact of price regulations for a number of years. As a result,
we might obtain regulatory approval for a product in a particular country, but then be subject to price regulations that delay our commercial
launch of the product and negatively impact the revenues we are able to generate from the sale of the product in that country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to commercialize any products also will depend in part on the extent to which reimbursement for these products and
related treatments will be available from government health administration authorities, private health insurers and other organizations.
Even if we succeed in bringing one or more products to the market, these products may not be considered cost-effective, and the amount
reimbursed for any products may be insufficient to allow us to sell our products on a competitive basis. Because our programs are in
the early stages of development, we are unable at this time to determine their cost effectiveness or the likely level or method of reimbursement.
Increasingly, the third-party payors who reimburse patients or healthcare providers, such as government and private insurance plans,
are requiring that drug companies provide them with predetermined discounts from list prices and are seeking to reduce the prices charged
or the amounts reimbursed for pharmaceutical products. If the price we are able to charge for any products we develop, or the reimbursement
provided for such products, is inadequate in light of our development and other costs, our return on investment could be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current product candidates will need to be administered under the supervision of a physician on an outpatient basis. Under currently
applicable U.S. law, certain drugs that are not usually self-administered (including injectable drugs) may be eligible for coverage under
the Medicare Part B program if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">they
    are incident to a physician&rsquo;s services;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">they
    are reasonable and necessary for the diagnosis or treatment of the illness or injury for which they are administered according to
    accepted standards of medical practice; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">they
    have been approved by the FDA and meet other requirements of the statute.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
may be significant delays in obtaining coverage for newly-approved drugs, and coverage may be more limited than the purposes for which
the drug is approved by the FDA. Moreover, eligibility for coverage does not imply that any drug will be reimbursed in all cases or at
a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim payments for new drugs, if
applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement may be based on payments allowed
for lower- cost drugs that are already reimbursed, may be incorporated into existing payments for other services and may reflect budgetary
constraints or imperfections in Medicare data. Net prices for drugs may be reduced by mandatory discounts or rebates required by government
healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where
they may be sold at lower prices than in the U.S. Third-party payors often rely upon Medicare coverage policy and payment limitations
in setting their own reimbursement rates. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded
and private payors for new drugs that we develop and for which we obtain regulatory approval could have a material adverse effect on
our operating results, our ability to raise capital needed to commercialize products and our financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the efforts of governments and third-party payors to contain or reduce the cost of healthcare and legislative and regulatory
proposals to broaden the availability of healthcare will continue to affect the business and financial condition of pharmaceutical and
biopharmaceutical companies. A number of legislative and regulatory changes in the healthcare system in the U.S. and other major healthcare
markets have been proposed in recent years, and such efforts have expanded substantially in recent years. These developments have included
prescription drug benefit legislation that was enacted and took effect in January 2006, healthcare reform legislation enacted by certain
states, and Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act
(the &ldquo;ACA&rdquo;), a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare
spending and enhance remedies against fraud and abuse. The ACA also contains provisions that will affect companies in the pharmaceutical
industry and other healthcare related industries by imposing additional costs and changes to business practices. Provisions affecting
pharmaceutical companies include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mandatory
    rebates for drugs sold into the Medicaid program have been increased, and the rebate requirement has been extended to drugs used
    in risk-based Medicaid managed care plans;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    340B Drug Pricing Program under the Public Health Services Act has been extended to require mandatory discounts for drug products
    sold to certain critical access hospitals, cancer hospitals and other covered entities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pharmaceutical
    companies are required to offer discounts on brand-name drugs to patients who fall within the Medicare Part D coverage gap, commonly
    referred to as the &ldquo;Donut Hole&rdquo;; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pharmaceutical
    companies are required to pay an annual non-tax deductible fee to the federal government based on each company&rsquo;s market share
    of prior year total sales of branded products to certain federal healthcare programs, such as Medicare, Medicaid, Department of Veterans
    Affairs and Department of Defense. Since we expect our branded pharmaceutical sales to constitute a small portion of the total federal
    health program pharmaceutical market, we do not expect this annual assessment to have a material impact on our financial condition.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
we cannot predict what healthcare reform initiatives may be adopted in the future. Further federal and state legislative and regulatory
developments are likely, and we expect ongoing initiatives in the U.S. to increase pressure on drug pricing. Such reforms could have
an adverse effect on anticipated revenues from product candidates that we may develop and for which we may obtain regulatory
approval and may affect our overall financial condition and ability to develop product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
ability to obtain services, reimbursement or funding from the federal government may be impacted by possible reductions in federal spending.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
federal government agencies currently face potentially significant spending reductions. Under the Budget Control Act of 2011, the failure
of Congress to enact deficit reduction measures of at least $1.2 trillion for the years 2013 through 2021 triggered automatic cuts to
most federal programs. These cuts would include aggregate reductions to Medicare payments to providers of up to two percent per fiscal
year, starting in 2013. Under the American Taxpayer Relief Act of 2012, which was enacted on January 1, 2013, the imposition of these
automatic cuts was delayed until March 1, 2013. Certain of these automatic cuts have been implemented. The full impact on our business
of these automatic cuts is uncertain. If federal spending is reduced, anticipated budgetary shortfalls may also impact the ability of
relevant agencies, such as the FDA or the National Institutes of Health to continue to function at current levels. Amounts allocated
to federal grants and contracts may be reduced or eliminated. These reductions may also impact the ability of relevant agencies to timely
review and approve drug research and development, manufacturing, and marketing activities, which may delay our ability to develop, market
and sell any products we may develop.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
any of our product candidates receives marketing approval and we or others later identify undesirable side effects caused by the product
candidate, our ability to market and derive revenue from the product candidates could be compromised.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that any of our product candidates receive regulatory approval and we or others identify undesirable side effects caused by
one of our products, any of the following adverse events could occur, which could result in the loss of significant revenue to us and
materially and adversely affect our results of operations and business:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may withdraw their approval of the product or seize the product;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to recall the product or change the way the product is administered to patients;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional
    restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component
    thereof;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be subject to fines, injunctions or the imposition of civil or criminal penalties;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may require the addition of labeling statements, such as a &ldquo;black box&rdquo; warning or a contraindication;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to create a Medication Guide outlining the risks of such side effects for distribution to patients;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    could be sued and held liable for harm caused to patients;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product may become less competitive; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reputation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to our Common Stock and this Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
internal controls may be inadequate, which could cause our financial reporting to be unreliable and lead to misinformation being disseminated
to the public.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting. As defined in Rule 13a-15(f)
under the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), internal control over financial reporting is
a process designed by, or under the supervision of, the principal executive and principal financial officer and effected by the board
of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those
policies and procedures that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pertain
    to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our
    assets;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with
    generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with
    authorizations of management and/or directors of the Company; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&rsquo;s
    assets that could have a material effect on the financial statements.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will be required to include a report of management on the effectiveness of our internal control over financial reporting. We expect to
incur additional expenses and diversion of management&rsquo;s time as a result of performing the system and process evaluation, testing
and remediation required in order to comply with the management certification requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have a sufficient number of employees to segregate responsibilities and may be unable to afford increasing our staff or engaging
outside consultants or professionals to overcome our lack of employees. During the course of our testing, we may identify other deficiencies
that we may not be able to timely remediate. Moreover, effective internal controls, particularly those related to revenue recognition,
are necessary for us to produce reliable financial reports and are important to help prevent financial fraud. If we cannot provide reliable
financial reports or prevent fraud, our business and operating results could be harmed, investors could lose confidence in our reported
financial information, and the trading price of our common stock, if a market ever develops, could drop significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
Jobs Act has reduced the information that we are required to disclose.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Jobs Act, the information that we  will be required to disclose has been reduced in a number of ways.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a company that had gross revenues of less than
$1.0 billion during the Company&rsquo;s last fiscal year, the Company is an &ldquo;emerging growth company,&rdquo; as defined in the
Jobs Act (an &ldquo;EGC&rdquo;). We will retain that status until the earliest of (a) the last day of the fiscal year which we
have total annual gross revenues of $1,000,000,000 (as indexed for inflation in the manner set forth in the Jobs Act) or more; (b)
the last day of the fiscal year of following the fifth anniversary of the date of the first sale of the common stock pursuant to an effective
registration statement under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;); (c) the date on which
we have, during the previous three year period, issued more than $1,000,000,000 in non-convertible debt; or (d) the date on which
we are deemed to be a &ldquo;large accelerated filer,&rdquo; as defined in Rule 12b-2 under the Exchange Act or any successor
thereto. As an EGC, the Company is relieved from the following:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company is excluded from Section 404(b) of Sarbanes-Oxley Act (&ldquo;Sarbanes-Oxley&rdquo;), which otherwise would have required
    the Company&rsquo;s auditors to attest to and report on the Company&rsquo;s internal control over financial reporting. The JOBS Act
    also amended Section 103(a)(3) of Sarbanes-Oxley to provide that (i) any new rules adopted by the PCAOB requiring mandatory audit
    firm rotation or changes to the auditor&rsquo;s report to include auditor discussion and analysis (in the event the PCAOB adopts
    an auditor rotation requirement) will not apply to an audit of an EGC; and (ii) any other future rules adopted by the PCAOB
    will not apply to the Company&rsquo;s audits unless the SEC determines otherwise.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Jobs Act amended Section 7(a) of the Securities Act  to provide that the Company
    need not present more than two years of audited financial statements in an initial public offering registration statement and in
    any other registration statement, need not present selected financial data pursuant to Item 301 of Regulation S-K for any period
    prior to the earliest audited period presented in connection with such initial public offering. In addition, the Company is not required
    to comply with any new or revised financial accounting standard until such date as a private company (i.e., a company that is not
    an &ldquo;issuer&rdquo; as defined by Section 2(a) of Sarbanes-Oxley) is required to comply with such new or revised accounting standard.
    Corresponding changes have been made to the Exchange Act, which relates to periodic reporting requirements, which would be applicable
    if the Company were required to comply with them.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    long as we are an EGC, we may comply with Item 402 of Regulation S-K, which requires extensive quantitative and qualitative
    disclosure regarding executive compensation, by disclosing the more limited information required of a &ldquo;smaller reporting company.&rdquo;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jobs Act will also exempt us from the
    following additional compensation-related disclosure provisions that were imposed on U.S. public companies pursuant to the Dodd-Frank
    Act: (i) the advisory vote on executive compensation required by Section 14A(a) of the Exchange Act; (ii) the requirements of Section
    14A(b) of the Exchange Act relating to shareholder advisory votes on &ldquo;golden parachute&rdquo; compensation; (iii) the requirements
    of Section 14(i) of the Exchange Act as to disclosure relating to the relationship between executive compensation and our financial
    performance; and (iv) the requirement of Section 953(b)(1)of the Dodd-Frank Act, which requires disclosure as to the relationship
    between the compensation of our chief executive officer and median employee pay.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
stock price may be volatile, and purchasers of our common stock could incur substantial losses.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
stock price is likely to be volatile. As a result of this volatility, investors may not be able to sell their common stock at or above
the initial public offering price. The market price for our common stock may be influenced by many factors, including the other risks
described in this section of the prospectus entitled &ldquo;Risk Factors&rdquo; and the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    success of competitive products or technologies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">results
    of preclinical and clinical studies of our product candidates, or those of our competitors, our existing collaborator or any future
    collaborators;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    or legal developments in the U.S. and other countries, especially changes in laws or regulations applicable to our products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">introductions
    and announcements of new products by us, our commercialization partners, or our competitors, and the timing of these introductions
    or announcements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actions
    taken by regulatory agencies with respect to our products, clinical studies, manufacturing process or sales and marketing terms;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated variations in our financial results or those of companies that are perceived to be similar to us;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    success of our efforts to acquire or in-license additional technologies, products or product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    concerning our collaborations, including but not limited to those with our sources of manufacturing supply and our commercialization
    partners;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent
    protection for our products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability or inability to raise additional capital and the terms on which we raise it;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    recruitment or departure of key personnel;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the structure of healthcare payment systems;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">market
    conditions in the pharmaceutical and biotechnology sectors;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding our common stock, other
    comparable companies or our industry generally;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    failure or the failure of our competitors to meet analysts&rsquo; projections or guidance that we or our competitors may give to
    the market;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fluctuations
    in the valuation of companies perceived by investors to be comparable to us;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcement
    and expectation of additional financing efforts;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">speculation
    in the press or investment community;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">trading
    volume of our common stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
    of our common stock by us or our shareholders;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    concentrated ownership of our common stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">terrorist
    acts, acts of war or periods of widespread civil unrest;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">natural
    disasters and other calamities; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    economic, industry and market conditions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the stock markets in general, and the markets for pharmaceutical stocks, in particular, have experienced extreme volatility
that has been often unrelated to the operating performance of the issuer. These broad market and industry factors may seriously harm
the market price of our common stock, regardless of our operating performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>You
will experience immediate and substantial dilution as a result of this offering and may experience additional dilution in the
future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you purchase common stock in this offering, you will incur immediate and substantial dilution of $5.36 per share, representing
the difference between the assumed initial public offering price of $6.00 per share and our pro forma net tangible book value
per share after giving effect to this offering. In addition, we can offer no assurance that you will not experience substantial dilution
in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
future issuance of equity or of debt securities that are convertible into common stock will dilute our share capital.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may choose to raise additional capital in
the future, depending on market conditions, strategic considerations and operational requirements. To the extent that additional capital
is raised through the issuance of shares or other securities convertible into shares of our common stock, our stockholders will
be diluted. Future issuances of our common stock or other equity securities, or the perception that such sales may occur, could adversely
affect the trading price of our common stock and impair our ability to raise capital through future offerings of shares or equity
securities. No prediction can be made as to the effect, if any, that future sales of common stock or the availability of common
stock for future sales will have on the trading price of our common stock.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Holders
of 1% or more of our common stock prior to this offering will be subject to a six month lock-up agreement, and all directors, officers
and 10% shareholders will be subject to a one year lock-up. Nonetheless, at such time as such stock becomes available for sale, it is
possible</I></B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I> a significant number of our
shares may cause the market price of our common stock to drop significantly.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
six months after the date of this prospectus, the &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of our common stock outstanding as of the date of this prospectus, will be eligible for sale in the public market from time to
time thereafter pursuant to Rule 144 under the Securities Act, and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares
of our common stock will be eligible for resale following a one-year lock-up period; some of such shares may be subject to the volume
and other restrictions of Rule 144. Further, we have 3,000,000 shares reserved for issuance under our 2018 Equity Incentive Plan, which
shares may be issued from time to time by our management and which will be subject to vesting and other requirements. At such time
as the lock-up periods end, it is possible that a significant number of such shares will be sold into the market. At such time, the
sale of a significant number of shares of our common stock in the public market or the perception that such sales may occur could
significantly reduce the market price of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
offering price of the shares and the other terms of this Offering have been arbitrarily determined by the Company.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
offering price of the shares and other terms of this offering have been arbitrarily determined by us and bear no relationship
to our assets, book value, potential earnings or any other recognized criterion of value. In addition, no investment banker, appraiser,
or other independent third party has been consulted concerning the offering price for the shares or the fairness of the offering price
used for the shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B><I>The offering price of the primary
offering and resale offering could differ.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">The offering price of shares
of our common stock in the initial public offering has been determined by negotiations between the Company and the underwriter. The offering
price in the initial public bears no relationship to our assets, earnings or book value, or any other objective standard of value. The
selling shareholders may sell the resale shares at prevailing market prices or privately negotiated prices after close of the offering
and listing of our common stock on Nasdaq. Therefore, the offering prices of the initial public and resale offering could differ. As
a result, the purchasers in the resale offering could pay more or less than the offering price in the primary offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B><I>The Resale by the Selling Stockholders
in our Resale Offering may cause the market price of our Common Stock to decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">The resale of shares of our common stock by the
selling stockholders in the Resale Offering, as well as the issuance of common stock in this Offering, could result in resales of our
common stock by our current stockholders concerned about the potential dilution of their holdings. In addition, the resale by other unregistered
stockholders after expiration of the lock-up&nbsp;period could have the effect of depressing the market price for our common stock.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>An
active trading market for our common stock may not develop.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to this offering, there has been no public market for our common stock. We intend to apply to have the shares of common stock listed
on Nasdaq, subject to our sale of a sufficient number of shares in the offering to meet the listing requirements of Nasdaq. There can
be no assurance that an application for listing the shares on Nasdaq or on any other market will be approved. Accordingly, an active
trading market for our shares may never develop or be sustained following this offering. If an active market for our common stock does
not develop, it may be difficult for you to sell shares you purchase in this offering without depressing the market price for the shares
or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to meet or maintain applicable listing requirements, Nasdaq may delist our common stock from trading, in which case the liquidity
and market price of our common stock could decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
our common stock is listed on Nasdaq, we cannot assure you that we will be able to meet the continued listing standards of Nasdaq in
the future. If we fail to comply with the applicable listing standards and Nasdaq delists our common stock, we and our stockholders could
face significant material adverse consequences, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    limited availability of market quotations for shares of our common stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
    liquidity for our common stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    determination that our common stock is &ldquo;penny stock,&rdquo; which would require brokers trading in our common stock to adhere
    to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for shares of
    our common stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    limited amount of news about us and analyst coverage of us; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    decreased ability for us to issue additional equity securities or obtain additional equity or debt financing in the future.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
National Securities Markets Improvement Act&nbsp;of&nbsp;1996, which is a federal statute, prevents or preempts the states from regulating
the sale of certain securities, which are referred to as &ldquo;covered securities.&rdquo; Because we expect that our common stock will
be listed on Nasdaq, such securities will be deemed covered securities. Although the states will be preempted from regulating the sale
of our securities, the federal statute does allow states to investigate companies if there is a suspicion of fraud and, if there is a
finding of fraudulent activity, then the states can regulate or bar the sale of covered securities in a particular case. Further, if
we were no longer listed on Nasdaq, our securities would not be covered securities and we would be subject to regulations in each state
in which we offer our securities.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Because
our management will have broad discretion over the use of the net proceeds from this Offering, you may not agree with how we use them
and the proceeds may not be invested successfully.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to use the net proceeds to us from this offering to fund offering to fund preclinical and clinical trials of product candidates,
Ropidoxuridine and new formulations of Ropidoxuridine with Tipiracil, O-18 containing molecules for proton radiation sensitization, continued
HDAC technology platform development, working capital and general corporate purposes, including the costs of operating as a public company,
as well as potential acquisition or in-licensing activities. Therefore, our management will have broad discretion as to the use of the
offering proceeds. Accordingly, you will be relying on the judgment of our management with regard to the use of these net proceeds,
and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately.
It is possible that the proceeds will be invested in a way that does not yield a favorable, or any, return for our Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion
regarding our stock, our stock price and trading volume could decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about
us or our business. We do not currently have and may never obtain research coverage by securities and industry analysts. If no or few
securities or industry analysts commence coverage of us, the trading price for our stock would be negatively impacted. In the event we
obtain securities or industry analyst coverage, if any of the analysts who cover us issue an adverse or misleading opinion regarding
us, our business model, our intellectual property or our stock performance, or if our target studies and operating results fail to meet
the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to
publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading
volume to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
board of directors has the authority, without shareholder approval, to issue preferred stock with terms that may not be beneficial to
holders of our common stock and such issuance could potentially affect adversely shareholder voting power and perpetuate their control
over us.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation, as amended to date, allows us to issue shares of preferred stock without any vote or further action
by our shareholders. Our board of directors has the authority to fix and determine the relative rights and preferences of any preferred
stock. As a result, our board of directors could authorize the issuance of a series of preferred stock that would grant to holders the
preferred right to our assets upon liquidation, the right to receive dividend payments before dividends are distributed to the holders
of common stock and the right to the redemption of the shares, together with a premium, prior to the redemption of shares of our common
stock. These rights and preferences could negatively affect the holders of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
ability of our executive officers and directors, who are our principal stockholders, to control our business may limit or eliminate
the ability of minority shareholders to influence corporate affairs.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
executive officers and directors, who are our principal stockholders, own approximately 73% of our issued and outstanding
common stock and, following this offering, will own approximately 63% of our issued and outstanding
common stock. Accordingly, they will be able to effectively control the election of directors, as well as all other matters requiring
shareholder approval. The interests of our principal stockholders may differ from the interests of other shareholders with respect
to the issuance of shares, business transactions with or sales to other companies, selection of other directors and other business decisions.
The minority shareholders have no way of overriding decisions made by our principal stockholders. This level of control may also
have an adverse impact on the market value of our shares because our principal stockholders may institute or undertake transactions,
policies or programs that result in losses and may not take any steps to increase our visibility in the financial community and/or may
sell sufficient numbers of shares to significantly decrease our price per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
Certificate of Incorporation and Bylaws, each as amended to date, provide for indemnification of officers and directors at the
expense of the Company and limit their liability that may result in a major cost to us and hurt the interests of our shareholders because
corporate resources may be expended for the benefit of officers and/or directors.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation and Bylaws, each as amended to date, provide for the indemnification of our officers and directors.
We have been advised that, in the opinion of the SEC, indemnification for liabilities arising under federal securities laws is against
public policy as expressed in the Securities Act and is therefore, unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our Certificate of Incorporation, as amended
to date, provides that disputes must be resolved in the Court of Chancery of the State of Delaware, except for cases brought under the
Securities Act or Exchange Act. </I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Certificate of Incorporation, as amended to
date, provides that the Court of Chancery in the State of Delaware will be the exclusive forum for dispute resolution for certain enumerated
actions, excluding any actions brought under the Securities Act or Exchange Act, or unless the Company consents in writing to an alternative
jurisdiction. This exclusive forum selection clause may cause inconvenience of our shareholders or other stakeholders, should they need
to bring suit against the Company for an action other than one arising under the Securities Act or Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
do not expect to pay cash dividends in the foreseeable future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never paid cash dividends on our common stock. We do not expect to pay cash dividends on our common stock at any time in the foreseeable
future. The future payment of dividends directly depends upon our future earnings, capital requirements, financial requirements and other
factors that our board of directors will consider. Since we do not anticipate paying cash dividends on our common stock, return on your
investment, if any, will depend solely on an increase, if any, in the market value of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Provisions
in our amended and restated certificate of incorporation, as amended, and bylaws, as amended, as well as Delaware law,
might discourage, delay or prevent a change of control of our company or changes in our management and, therefore, depress the market
price of our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Certificate of Incorporation and Bylaws, each
as amended to date, and bylaws contain provisions that could depress the market price of our common stock by acting to discourage,
delay, or prevent a change in control of our company or changes in our management that the stockholders of our company may deem advantageous.
These provisions, among other things:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">permit
    the board of directors to establish the number of directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    that directors may only be removed &ldquo;for cause&rdquo; and only with the approval of 66 2/3 percent of our stockholders;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
    super-majority voting to amend some provisions in our Certificate of Incorporation and Bylaws;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorize
    the issuance of &ldquo;blank check&rdquo; preferred stock that our board could use to implement a stockholder rights plan (also known
    as a &ldquo;poison pill&rdquo;);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">eliminate
    the ability of our stockholders to call special meetings of stockholders;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prohibit
    stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    that the board of directors is expressly authorized to make, alter or repeal our bylaws; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders
    at annual stockholder meetings.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, Section 203 of the Delaware General Corporation Law may discourage, delay or prevent a change in control of our company. Section
203 imposes certain restrictions on merger, business combinations and other transactions between us and holders of 15% or more of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_004"></A>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus contains forward-looking statements that involve risks and uncertainties. All statements other than statements of historical
facts contained in this prospectus are forward-looking statements. In some cases, you can identify forward-looking statements by terminology
such as &ldquo;may,&rdquo; &ldquo;could,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; &ldquo;should,&rdquo; &ldquo;expect,&rdquo;
&ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;intend,&rdquo; &ldquo;predict,&rdquo;
&ldquo;seek,&rdquo; &ldquo;contemplate,&rdquo; &ldquo;project,&rdquo; &ldquo;continue,&rdquo; &ldquo;potential,&rdquo; &ldquo;ongoing&rdquo;
or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements
about:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    initiation, timing, progress and results of our research and development programs, preclinical studies, any clinical trials and INDs,
    NDAs other regulatory submissions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    expected dependence on third party collaborators for developing, obtaining regulatory approval for and commercializing product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    receipt and timing of any milestone payments or royalties under any research collaboration and license agreement we enter into;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to identify and develop product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    or a collaborator&rsquo;s ability to obtain and maintain regulatory approval of any of our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    rate and degree of market acceptance of any approved products candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    commercialization of any approved product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish and maintain additional collaborations and retain commercial rights for our product candidates subject to collaborations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    implementation of our business model and strategic plans for our business, technologies and product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    estimates of our expenses, ongoing losses, future revenue and capital requirements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain additional funds for our operations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain and maintain intellectual property protection for our technologies and product candidates and our ability to operate
    our business without infringing the intellectual property rights of others;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reliance on third parties to conduct our preclinical studies or any future clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reliance on third party supply and manufacturing partners to supply the materials and components for, and manufacture, our research
    and development, preclinical and clinical trial drug supplies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to attract and retain qualified key management and technical personnel;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    use of net proceeds to us from this offering;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    expectations regarding the time during which we will be an emerging growth company under the JOBS Act;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    financial performance; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    relating to our competitors or our industry.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other
factors that may cause our actual results, performance or achievements to be materially different from any future results, performance
or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially
from current expectations include, among other things, those described in the section entitled &ldquo;Risk Factors&rdquo; and elsewhere
in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
forward-looking statement in this prospectus reflects our current view with respect to future events and is subject to these and
other risks, uncertainties and assumptions relating to our operations, results of operations, industry and future growth. Given
these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by U.S. federal
securities law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new
information becomes available in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_005"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We estimate that the net proceeds from this offering
will be approximately $8,663,264, after deducting underwriting discounts and commissions and estimated offering expenses payable
by us. If the underwriter exercises its over-allotment option to purchase additional shares in full, we estimate that our net proceeds
will be approximately $10,157,264, after deducting underwriting discounts and commissions and estimated offering expenses payable
by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to use the net proceeds from this offering
to fund Phase II clinical trials and IND-enabling studies of our product candidates, including radiation sensitizer Ropidoxuridine
and the HDAC inhibitor small molecule technology platform, potential acquisition or in-licensing activities, and working capital and
general corporate purposes. We anticipate that the funds raised from this offering will allow us to complete Phase II clinical trial
of 30 patients for Ropidoxuridine and complete IND-enabling studies to file for IND in preparation for a Phase I clinical trial
for our selective HDAC6 inhibitor. The funds are expected to be used as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">approximately
                                            $8.5 million will be used for product development and operational costs, including
                                            the drug manufacturing costs and the costs related to performing the Phase II clinical trials
                                            of Ropidoxuridine, as well as covering our IPO-related expenses; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">approximately
                                            $1.5 million will be used to fund drug manufacturing and perform pre-IND testing and
                                            obtain IND in preparation for initiating Phase I clinicals trials of our
                                            selective HDAC6 inhibitor.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The above estimates include the working capital
necessary to fund each of the above listed projects; any additional funds raised in this offering will be used toward additional
working capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding our planned use of funds, there
is no guarantee that we will not require additional funds to complete the above clinical trials. In addition, following our completion
of the above-listed clinical trials, we believe we will need approximately $22 million in additional funding to complete Phase
III clinical trials for Ropidoxuridine and approximately $30 million in additional funding to complete Phase I through III clinical
trials for our selective HDAC6 inhibitor. If such additional funds are required, we will have to secure additional funding from investors
or through a joint development partner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the net proceeds from this offering, together with our existing cash on hand, cash equivalents and investments, will enable
us to fund our operations and continued growth and development through at least the next 12 months. We have based
this estimate on assumptions that may prove to be wrong and we may end up using our available capital resources more quickly than
currently anticipated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions,
which could change in the future as our plans and business conditions evolve. The amounts and timing of our actual expenditures depend
on numerous factors, including the progress of our preclinical development efforts, the results of any clinical trials and other studies
and any unforeseen cash needs. All of our research and development programs are at an early stage and development of product
candidates from these programs is highly uncertain and may not result in approved products. Completion dates and completion costs can
vary significantly for each product candidate and are difficult to predict. Accordingly, we will have broad discretion in the use
of the net proceeds from this offering and could spend the proceeds in ways that do not improve our results of operations or enhance
the value of our stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may seek additional financing to support the
intended use of proceeds discussed above. If we secure additional equity funding, investors in this offering would be diluted. In all
events, there can be no assurance that additional financing would be available when needed and, if available, on terms acceptable to
us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pending the use of the proceeds from this offering,
we intend to invest the net proceeds in short-term, interest-bearing, investment-grade securities, certificates of deposit or government
securities.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_006"></A>DIVIDEND
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not paid any dividends on our common stock since inception and we currently expect that, in the foreseeable future, all earnings
(if any) will be retained for the development of our business and no dividends will be declared or paid. Any future dividends will be
subject to the discretion of our board of directors and will depend upon, among other things, our earnings (if any), operating results,
financial condition and capital requirements, general business conditions and other pertinent facts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_007"></A>CAPITALIZATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth our cash and cash equivalents and capitalization as of June 30, 2022:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">on an actual basis; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">on a pro forma basis to reflect the sale of
    1,660,000 units, with the units consisting of a total of 1,660,000 shares of common stock and warrants to purchase 1,660,000 shares
    of common stock at an exercise price of $0.01 per share, at an initial public offering price of $6.00 per unit, after deducting estimated
    underwriting discounts and commissions and offering expenses payable by us; and </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">on a pro forma as adjusted basis to reflect the (a) Pre-IPO Bridge
    Financings, (b) sale of 1,660,000 units, with the units consisting of a total of 1,660,000 shares of common stock and warrants
    to purchase 1,660,000 shares of common stock at an exercise price of $0.01 per share, at an initial public offering price of $6.00
    per unit, after deducting estimated underwriting discounts and commissions and offering expenses payable by us, and (c)
    the conversion of the Series A convertible preferred stock, convertible notes and the exercise of certain warrants
    upon effectiveness of this offering.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this table in conjunction with our financial statements and related notes and the sections titled &ldquo;Use of Proceeds,&rdquo;
&ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations,&rdquo; and &ldquo;Description of
Capital Stock&rdquo; appearing elsewhere in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Actual </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Pro forma </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Pro form <BR> As Adjusted </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; padding-bottom: 2.5pt"> Cash and cash equivalents </TD><TD STYLE="width: 2%; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="width: 12%; border-bottom: Black 2.5pt double; text-align: right"> 50,437 </TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="width: 12%; border-bottom: Black 2.5pt double; text-align: right"> 10,846,965 </TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="width: 12%; border-bottom: Black 2.5pt double; text-align: right"> 10,923,974 </TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Capitalization: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Notes payable </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1,261,097 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1,261,097 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 671,097 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Stockholders&rsquo; equity (deficit): </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Series A convertible preferred stock, $0.00001 par value; $1,000 per share liquidation value or
    aggregate of $1,212,500; 20,000,000 shares authorized; 1,213 shares issued and outstanding actual, 0 shares pro forma, and 0 shares
    pro forma as adjusted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Common stock, $0.00001 par value; 100,000,000 shares authorized; 9,312,991 shares issued and outstanding at June 30, 2022
    actual, 13,671,879 shares pro forma, and 14,123,629 shares pro forma as adjusted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 93 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 137 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 141 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Additional paid-in capital </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 4,819,916 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 15,616,400 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 16,296,030 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Accumulated deficit </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (7,126,082 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (7,126,082 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (7,126,082 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Total stockholders&rsquo; equity (deficit) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (2,306,073 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 8,490,455 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 9,170,089 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"> Total capitalization </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (1,044,976 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 9,751,552 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 9,841,186 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of common stock issued and outstanding actual, pro forma and pro forma as adjusted in the table above excludes 2,615,883
shares reserved for issuance under our 2018 Equity Incentive Plan. To date, we have issued grants of  384,167
shares (on a post-reverse split basis), which were issued  in the form of restricted stock units, some of which remain
subject to certain vesting conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_008"></A>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you invest in our common stock, your interest will be diluted to the extent of the difference between the public offering price per share
of our common stock that you pay and the pro forma as adjusted net tangible book value per share of our common stock after this Offering,
which includes the conversion of 1,212.5 shares of Series A convertible preferred stock (which will convert into approximately
269,444 shares of common stock upon completion of this offering, not including the 8.5% cumulative dividend, which is payable at the
time of conversion in either cash or common stock at the Company&rsquo;s determination), the exercise of approximately 269,444 shares
of common stock issuable to the Series A convertible preferred stockholders upon exercise of warrants (which warrants will be issuable
to the Series A convertible preferred stockholders upon completion of this offering, and which share calculation does not including the
8.5% cumulative dividend payable at the time of conversion in either cash or common stock at the Company&rsquo;s determination), the
exercise of 500,000 warrants into 500,000 shares of common stock (which shares are being registered in the Resale Offering), and the
conversion of $590,000 of convertible notes and accrued interest of $12,625 (which will convert into units consisting of a
total of 200,875 shares of common stock and warrants to purchase 200,875 shares of common stock (the &ldquo;Conversion Units&rdquo;)
upon completion of this Offering and which Conversion Units are being registered in the Resale Offering). Net tangible book
value per share is determined by dividing our total tangible assets less our total liabilities by the number of shares of common stock
outstanding. Our historical net tangible book value as of June 30, 2022 was $(2,393,456) or $(0.26) per share, based
on 9,312,991 shares of common stock, 500,000 warrants to purchase common stock, and 1,212.5 shares of Series A preferred stock
and related warrants outstanding as of June 30, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net tangible book value dilution per
share represents the difference between the amount per share paid by new investors who purchase shares from us in this offering and
the pro forma net tangible book value per share of common stock immediately after completion of this Offering. As of June 30,
2022, after giving effect to our sale of 1,660,000&nbsp;units, with each unit consisting of one share of common stock and one
warrant to purchase one share of common stock, in this Offering at an initial offering price of $6.00 per unit,
the exercise of warrants to purchase 500,000 shares of common stock and the sale of such common stock by certain selling
stockholders in the Resale Offering, the automatic conversion of our Series A convertible preferred stock into 538,888 shares
of common stock and the automatic conversion of our convertible notes into the equivalent of 401,750 shares of common stock,
after deducting estimated Offering expenses that we must pay, our pro forma as adjusted net tangible book value would have been $9,082,706,
or $0.64 per share. This represents an immediate increase in pro forma net tangible book value of $0.90 per share to
existing shareholders, and an immediate dilution in pro forma net tangible book value of $5.36 per share to new investors
purchasing shares in this Offering. The table below illustrates this per share dilution as of June 30, 2022.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"> Pro forma, </TD><TD STYLE="font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> <B>Before</B> </TD><TD> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"> as adjusted </TD><TD STYLE="font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Offering </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> after offering </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%"> Assumed initial offering price per common share </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 14%; text-align: right"> &nbsp; </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 14%; text-align: right"> 6.00 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt"> Net tangible book value per share as of June 30, 2022 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> (0.26 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"> Increase in pro forma net tangible book value per share attributable to new investors participating
    in this Offering and conversion of the Convertible Notes </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.90 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"> Pro forma as adjusted net tangible book value per share after this Offering
    and conversion of the Convertible Notes </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 0.64 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"> Dilution of pro forma net tangible book value per share to new investors </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 5.36 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth, on a pro forma as adjusted basis as of June 30, 2022, the number of shares of common stock purchased
or to be purchased from us, the total consideration paid or to be paid and the average price per share paid or to be paid by existing
holders of common stock and by new investors, at a public offering price of $6.00 per share, before deducting estimated Offering
expenses that we must pay.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> Average </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> Shares Purchased </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> Total Consideration </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: center"> Price Per </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"> Number </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"> Percent </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"> Amount </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"> Percent </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"> Share </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 32%; text-align: left"> Existing stockholders </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 9,312,991 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 74 </TD><TD STYLE="width: 1%; text-align: left"> % </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 4,820,000 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 33 </TD><TD STYLE="width: 1%; text-align: left"> % </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 12%; text-align: right"> 0.52 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> New investors </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 3,320,000 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 26 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> % </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 9,976,600 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 67 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> % </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 3.01 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt"> Total </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 12,632,991 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 100 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> % </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 14,796,600 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 100 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> % </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 1.17 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> *reflects both shares of common stock and
warrants issued in this unit offering, and assumes the new investors&rsquo; exercise of warrants to purchase 1,660,000 shares of common
stock. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing discussion and tables are based
on the number of shares of common stock outstanding as of June 30, 2022 but excluding 2,615,883 shares of common stock reserved
for issuance under our 2018 Equity Incentive Plan. To date, 384,167 shares have been granted in the form of restricted stock units (&ldquo;RSUs&rdquo;),
of which 357,390 RSUs have vested and 30,777 RSUs remain subject to vesting.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_009"></A>MANAGEMENT&rsquo;S
DISCUSSION AND ANALYSIS OF<BR>
FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following Management&rsquo;s Discussion and Analysis should be read in conjunction with our financial statements and the related notes
thereto included elsewhere in this prospectus. The Management&rsquo;s Discussion and Analysis contains forward-looking statements that
involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. Any statements that are not
statements of historical fact are forward-looking statements. When used, the words &ldquo;believe,&rdquo; &ldquo;plan,&rdquo; &ldquo;intend,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;target,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; and the like, and/or future-tense or conditional
constructions (&ldquo;will,&rdquo; &ldquo;may,&rdquo; &ldquo;could,&rdquo; &ldquo;should,&rdquo; etc.), or similar expressions, identify
certain of these forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause
actual results or events to differ materially from those expressed or implied by the forward-looking statements in this form. Our actual
results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several
factors including, but not limited to, those noted under &ldquo;Risk Factors&rdquo; in this prospectus. In addition, any compensation
disclosure contained in this prospectus regarding our officers and directors is likely to increase in the near term following completion
of the offering, and therefore all such disclosures made within this prospectus reflect historical facts and will not reflect forward
looking or anticipated compensation going forward. See the section entitled &ldquo;Executive Compensation&rdquo; below for a more detailed
discussion.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>We
do not undertake any obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this
prospectus, except as required by U.S. federal securities laws.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Founded by Georgetown University Medical School
faculty members, we are a discovery and development stage pharmaceutical company leveraging our proprietary technology to develop novel
therapies that are designed to cure cancer. Originally formed as Shuttle Pharmaceuticals, LLC in 2012, our goal is to extend the benefits
of cancer treatments by leveraging insights into cancer therapy with surgery, radiation therapy, chemotherapy and immunotherapy. While
there are several therapies being developed with the goal of curing cancer, one of the most effective and proven approaches to this is
radiation therapy (RT). We are developing a pipeline of products designed to address the limitations of this current standard of cancer
therapies. We believe that our product candidates will enable us to deliver cancer treatments that are safer, more reliable and at a
greater scale than that of the current standard of care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operations to date have focused on continuing our
research and development efforts to advance Ropidoxuridine clinical testing and improved drug formulation, to advance HDAC6 inhibitor
(SP-2-225) preclinical development, and complete SBIR contract work on predictive biomarkers of radiation response, as well as prostate
cell lines for health disparities research. We have received SBIR contract funding from the NIH for the aforementioned projects. The
clinical development of Ropidoxuridine has shown drug bioavailability and a maximum tolerated dose has been established for use in Phase
II clinical trials. The radiation biomarker project and the health disparities project have been completed. Changes in operational,
administrative, legal and professional expenses related to our operations are set forth in more detail in the discussion below.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results
of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Comparison
of the three months ended June 30, 2022 and 2021</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the results of our operations:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="text-align: center"> Three Months Ended </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; text-align: center"> June 30, </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; text-align: center"> Change </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"> 2022 </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"> 2021 </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"> $ </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"> % </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt"> Revenue </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Operating expenses: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left"> Research and development, net of contract expense reimbursements </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 11%; text-align: right"> 83,868 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 11%; text-align: right"> 286,730 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 11%; text-align: right"> (202,862 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 11%; text-align: right"> (71 </TD><TD STYLE="width: 1%; text-align: left"> )% </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> General and administrative </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 9,078 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 7,213 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,865 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 26 </TD><TD STYLE="text-align: left"> % </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Legal and professional </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 260,680 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 42,308 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 218,372 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 516 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> % </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Total operating expenses </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 353,626 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 336,251 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 17,375 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 5 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> % </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Other (income) expense: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Interest expense - related party </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 14,836 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 10,547 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 4,289 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 41 </TD><TD STYLE="text-align: left"> % </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Interest expense </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 170,391 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 120 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 170,271 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> (Gain) Loss on change in fair value of warrant liability </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 58,422 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (117 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 58,539 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</FONT> </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Total other expense </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 243,649 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 10,550 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 233,099 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 2209 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> % </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"> Net loss </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 597,275 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 346,801 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 250,474 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 72 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> % </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Research
and Development-Net of contract expense reimbursements. </I>Research and development-net of contract expense reimbursements
(&ldquo;R&amp;D&rdquo;) was $83,368 for the three months ended June 30, 2022, as compared to $286,730 for three months ended June
30, 2021. For the three months ended June 30, 2022, the Company received $211,455 in reimbursement from the NIH contracts and
incurred $295,323 in R&amp;D expenses. For the three months ended June 30, 2021, reimbursement from the NIH totaled $0 and total
expenses related to R&amp;D was $286,731. Quarterly expenses increased by $8,592, or 3%, in the second quarter of 2022 as Topic 345
work was completed. Expenses were offset by a final payment of $211,455 received in April 2022 following the Company&rsquo;s
submission of a final report to the NIH for the period of performance ending March 15, 2022.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> R&amp;D expense reimbursements
reflect the final payment of $211,455 received in April 2022 after the final report was filed with the NIH and reviewed. NIH requires
that milestones included in the fixed price contract be met, therefore, compensation related expenses continued in 2022 under the no
cost extension from the NIH. Compensation related expenses were $225,597 in the three months ended June 30,2021 as compared to $270,164
in the three months ended June 30, 2022. Compensation related expenses increased from 79% of total R&amp;D in the three months ened June
30, 2021 to 91% for the three months ended June 30, 2022. Subcontract work made up 13% of total R&amp;D expense in the three months ended
June 30, 2021 and there were no subcontractor expenses during the three months ended June 30, 2022. All other R &amp; D expenses were
inconsequential. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is a breakdown of the actual costs and reimbursements received by the company for the three months ended June 30, 2022 and 2021, and
a breakdown of how such cost and reimbursements were distributed across research projects.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended June 30, 2022, total research and development costs were $295,323 for which all costs were funded by the Shuttle.
For the three months ended June 30, 2021, total R &amp; D costs were $286,730 for which 21.3% of the costs were allocated to the NIH
funded project (Topic 345) and Shuttle funded the remaining costs of $225,597, or 78.7% of the total costs. For the three months ended
June 30, 2022, total R&amp;D costs were $295,323 for which $211, 455 was reimbursed by NIH and the remaining costs were funded by the
Shuttle for a net R&amp;D loss of $83,868. Company funded R&amp;D activities increased in 2021 and decreased in 2022 due to NIH no cost
extensions required to complete contracted work and file the final reports before receiving payment from the NIH.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Key
Research and Development Projects </B></FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-left: 10pt; text-align: justify; text-indent: -10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>R
    &amp; D, Net of Contract Expense Reimbursements </B></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-left: 10pt; text-align: justify; text-indent: -10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3
    Months</B></FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3
Month Periods ending June 30, 2021 and 2022 (Q2)</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid"> Research &amp; Development </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> NIH&nbsp;Topic&nbsp;345 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> NIH Topic 352* </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Shuttle Funded </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Total </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid"> Revenue and Expenses </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2021 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2022 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2021 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2022 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2021 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2022 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2021 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2022 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; text-align: left"> NIH Reimbursement </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 5%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 5%; text-align: right"> 211,455 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 5%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 5%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 5%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 5%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 5%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 5%; text-align: right"> 211,455.00 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> Compensation </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 225,596.59 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 270,164.09 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 225,596.59 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 270,164.09 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Subcontracts </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 36,927.56 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 36,927.56 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> Supplies </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 7,143.63 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 619.36 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 7,143.63 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 619.36 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Other, Lab </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 17,062.90 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 24,539.10 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 17,062.90 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 24,539.10 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"> Expense total </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"> 61,134.09 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"> 225,596.59 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"> 295,322.55 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"> 286,730.68 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"> 295,322.55 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt"> Research and Development, Net of Contracts </TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"> (61,134.09 </TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> ) </TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"> 211,455 </TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"> - </TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"> - </TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"> (225,596.59 </TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> ) </TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"> (295,322.55 </TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> ) </TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"> (286,730.68 </TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> ) </TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"> (83,867.55 </TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD STYLE="font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: bold; text-align: right"> 21.3 </TD><TD STYLE="font-weight: bold; text-align: left"> % </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD STYLE="font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: bold; text-align: right"> 0.0 </TD><TD STYLE="font-weight: bold; text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD STYLE="font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: bold; text-align: right"> 78.7 </TD><TD STYLE="font-weight: bold; text-align: left"> % </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD STYLE="font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: bold; text-align: right"> 100.0 </TD><TD STYLE="font-weight: bold; text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Note:</I></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Project
    352 reimbursements were not received in 2021 and research costs were Company funded through an NIH extension without cost Project
    345 reimbursement for the period of performance ending March 15, 2022, which reimbursement was received in April 2022</I></FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the CEO and CMO are actively involved in the research and development activities, but neither receives a salary from the Company.
As such, research and development expenses are lower than might be incurred in the future.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
allocation of costs to each research project for the three months ended June 30, 2021 and 2022 are as follows:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Cost
Allocation for the 3-month Period Ending June 30, 2021</U></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation
    </B>- $225,597, making up 79% of total R &amp; D, with all research cost allocated to Shuttle.</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subcontracts
    - </B>$36,928, making up 13% of total R&amp;D, with 100% of costs allocated to Topic 345.</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Supplies
    and Other Lab expenses - </B>$24,207, making up 8% of total R&amp;D, with all costs allocated to Topic 345.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General
and Administrative Expenses. </I>General and Administrative expenses in the three months ended June 30, 2022 increased by $1,865, from
$7,213 in 2021 to $9,078 in 2022.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Legal
and Professional Expenses</I>. During the three months ended June 30, 2022, legal and professional expenses
increased by $260,680 or 497%. This increase in legal and professional fees was primarily due to increases in our expenses related to
obtaining pre-IPO financing and other expenses related to preparation for the IPO.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other
(Income) Expense</I>. Other expense was $243,649 for the three months ended June 30, 2022, which consisted
of $170,394 in interest expense on convertible loans, $14,836 in interest expense on related party loans, and a loss on change in warrant
liability of $58,422. Other income was $10,550 for the three months ended June 30, 2021, which consisted of $120 in interest expense,
$10,547 in interest expense on related party loans and a gain on change in warrant liability of $117.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Comparison
of the six months ended June 30, 2022 and 2021</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the results of our operations:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Six
    Months Ended</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    30,</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    expenses:</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development, net of contract expense reimbursements</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">379,783</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">392,726</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12,943</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,847</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,461</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,386</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
    and professional</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">589,392</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">106,150</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">483,242</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">455</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    operating expenses</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">992,022</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">512,337</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">479,685</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    (income) expense:</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expense - related party</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,383</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,094</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,289</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expense</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">315,944</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">350</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">315,594</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Gain)
    Loss on change in fair value of warrant liability</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,772</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(57,656</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">76,428</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain
    on forgiveness of Paycheck Protection Program note payable</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(73,007</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(73,007</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    other (income) expense</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">287,092</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(36,212</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">323,304</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,279,114</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">476,125</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">802,989</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">169</FONT> </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT> </TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Research
and Development-Net of contract expense reimbursements. </I>Research and development-net of contract expense reimbursements (&ldquo;R&amp;D&rdquo;)
was $379,783 for the six months ended June 30, 2022, as compared to $392,726 for six months ended June 30, 2021. For six months ended
June 30, 2022, the Company received $211,455 in reimbursement from the NIH contracts and incurred $591,237 in R&amp;D expenses. For the
six months ended June 30, 2021, reimbursement from NIH totaled $211,455 and total expenses related to R&amp;D were $604,181. The decrease
of $12,945, or 2%, is primarily related to the Company reducing R&amp;D spending as a result of NIH contracts ending and new contract proposals
being prepared but not yet started. The no cost extension from the NIH ended on March 15, 2022, and the final
report to the NIH was filed and accepted, resulting in a payment of $211,455 during the six months ended June 30, 2022.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> R&amp;D expense reimbursements
were the same during the six months ended June 30, 2021 and June 30, 2022. NIH requires that milestones included in the fixed price contract
be met, therefore, compensation related expenses continued in 2022 under the no cost extension from the NIH. Compensation related expenses
were $447,222 in the six months ended June 30, 2021 as compared to $532,961 in the six months ended June 30, 2022. Compensation related
expenses increased from 74% of total R&amp;D in the six months ended June 30, 2021 as compared to 90.1% in the six months ended June
30, 2022. Subcontract work made up 17% of total R&amp;D expense in the six months ended June 30, 2021 and there were no subcontractor
expenses during the six months ended June 30, 2022. All other R&amp;D expenses were inconsequential. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is a breakdown of the actual costs and reimbursements received by the Company for the six months ended June 30, 2022 and 2021, and a
breakdown of how such cost and reimbursements were distributed across research projects.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> For the six months ended
June 30, 2022, total research and development costs were $591,236 for which $211,455 was paid by reimbursements received from the NIH,
leaving a net of $392,726. For the six months ended June 30, 2021, total R&amp;D costs were $604,181 for which $211,455 was paid by reimbursements
received from the NIH, leaving a net of $379,783. Company funded R&amp;D activities increased in the six months ended June 30, 2021 and
remained relatively consistent during the six months ended June 30, 2022 due to the NIH no cost extensions required for the Company to
complete contracted work and file the final reports. A summary of the breakdown of costs is listed below. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Key
Research and Development Projects</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; width: 60%"> <B>Research and Development, Net of Contract Expense Reimbursements</B> </TD>
  <TD STYLE="text-align: justify; width: 40%"> <B>6 Months</B><BR> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6
Month Periods ending June 30, 2021 and 2022 (Q2)</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
    &amp;&nbsp;Development</B></FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NIH&nbsp;Topic&nbsp;345</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NIH&nbsp;Topic&nbsp;352*</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuttle
    Funded</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
    and Expenses</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NIH
    Reimbursement</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">211,455</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"> -<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">211,455.00</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">211,455.00</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">447,222.22</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">532,961.32</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">447,222.22</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">532,961.32</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subcontracts</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">102,855.59</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> -<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">102,855.59</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplies</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,522.47</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> -<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,198.70</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,522.47</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,198.70</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other,
    Lab</FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,581.15</FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> -<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56,076.87</FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,581.15</FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56,076.87</FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expense
    total</FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">156,959.21</FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">447,222.22</FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">591,236.89</FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">604,181.43</FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">591,236.89</FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and Development, Net of Contracts</FONT> </TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(156,959.21</FONT> </TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">211,455</FONT> </TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</FONT> </TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;-</FONT> </TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(447,222.22</FONT> </TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(591,236.89</FONT> </TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(392,726.43</FONT> </TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(379,781.89</FONT> </TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD></TR>
  </TABLE>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Note:</I></FONT> </TD>
  <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Project 352 reimbursements
  were not received in 2021 and research costs were Company funded through an NIH extension without cost</I></FONT> </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the CEO and CMO are actively involved in the research and development activities, but neither receives a salary from the Company.
As such, research and development expenses are lower than might be incurred in the future.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
allocation of costs to each research project for the six months ended June 30, 2021 and 2022 are as follows:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Cost
Allocation for the six-month Period Ending June 30, 2022</U></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation
    </B>- $270,164, making up 91% of total R&amp;D expenses, with all costs allocated to Shuttle. </FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Remaining
    costs </B>of $25,158 were all allocated to Shuttle, with supplies and other lab expenses making up 9%of total R&amp;D costs.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General
and Administrative Expenses. </I>General and Administrative expenses increased by $9,386, from $13,461 in
the six months ending June 30, 2021 to $22,847 in the six months ended June 30, 2022. Processing fees related to filing accounted for
an increase of $6,215 and are related to pre-IPO activities. Website expenses during the six moths ended June 30, 2022 increased by $1,424
in order to maintain and update the company&rsquo;s profile and prepare for the Company&rsquo;s IPO.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Legal
and Professional Expenses</I>. Legal and professional expenses increased by $475,242, or 448%, primarily
due to increases in fees related to obtaining pre-IPO financing and expenses incurred related to preparing for the IPO.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other
(Income) Expense</I>. Other expense was $221,516 for the six months ended June 30, 2022, which consisted
of $315,944 in interest expense on convertible loans, $25,383 in interest expense on related party loans, a gain on change in warrant
liability of $46,804 and a $73,007 gain on the forgiveness of the Company&rsquo;s Paycheck Protection Program loan. Other income was $36,212
for the six months ended June 30, 2021, which consisted of $350 in interest expense, $21,094 in interest expense on related party loans
and a gain on change in warrant liability of $57,656.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Comparison
of the Years ended December 31, 2021 (Restated) and 2020</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the results of our operations for the years ended December 31, 2021 (Restated) and 2020:</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">Years Ended</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Change</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Revenue</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; width: 40%; text-align: left">Research and development, net of contract expense reimbursements</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,021,808</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">161,772</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">860,036</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">532</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">85,927</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(49,427</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(58</TD><TD STYLE="text-align: left">%)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Legal and professional</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">684,684</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">261,823</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">422,861</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">162</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,742,992</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">509,522</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,233,470</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">242</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Interest expense - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(46,947</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(36,771</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,176</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,841</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,859</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(982</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Change in fair value of warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">579,146</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(256,580</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">835,726</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">326</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Gain on disposal of loan</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">62,500</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">62,500</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">100</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total other income (expense)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">590,858</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(296,210</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">887,068</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">299</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,152,134</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(805,732</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(346,402</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">43</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Research
and Development-Net of contract expense reimbursements. </I>Research and development-net of contract expense reimbursements was $1,021,808
for the year ended December 31, 2021, as compared to $161,772 for the year ended December 31, 2020. For the year ended December 31, 2021,
the Company received $505,377 in reimbursement from NIH contracts and incurred $1,527,185 in research and development expenses. For the
year ended December 31, 2020, reimbursement from the NIH totaled $1,258,141 and total expenses related to research and development
was $1,419,913. The increase of $860,036 or 532% is primarily related to the Company receiving $752,764 less in contract reimbursements
in 2021 as compared to 2020. The lower contract reimbursements are due to the completion of Topic 345-Predictive-Biomakers and Phase
1 of Topic 352-Prostate Health Disparity contracts in 2020. In 2021, the Company received $82,467 for Topic 352 Prostate Health Disparity
Phase 2 and $422,910 Topic 345-Predictive-Biomakers and Phase 2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
research and development expenses with the largest variances included compensation of $885,349, subcontractor expenses of $539,043, and
lab supply costs of $30,181 for the year end December 31, 2021, as compared to compensation of $888,001, subcontractor expenses of $403,409,
and lab supply costs of $57,355 for the year end December 31, 2020. Subcontractor expenses increased by $135,634, or 33.62%, between
2020 and 2021. These expenses increased as more subcontractor&nbsp;services were needed due to the Phase 2 NIH contracts and pending
additional financing. All other research and development expense variances between 2020 and 2021 are immaterial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Below is a breakdown of the actual costs and
reimbursements received by the company for the years ended December 31, 2021 and 2020, and a breakdown of how such cost and reimbursements
were distributed across research projects.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Key
Research and Development Projects </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and Development, Net of Contract Expense Reimbursements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Periods
ending December 31, 2020 and 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Research &amp; Development Revenue and</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">NIH Topic 345</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">NIH Topic 352*</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shuttle Funded</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold">Expenses</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2020</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2021</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2020</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2021</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2020</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2021</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2020</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2021</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; text-align: left">NIH Reimbursement</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">845,820</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">422,910</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">412,321</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">82,467</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">1,258,141</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">505,377</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">183,183</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">198,426</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">174,026</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">530,791</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">686,923</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">888,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">885,349</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Subcontracts</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">236,633</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">539,043</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">163,979</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,797</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">403,409</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">539,043</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Supplies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,670</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,181</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,655</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57,355</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,181</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other, Lab</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">36,969</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">72,611</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">34,179</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">71,148</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">72,611</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Expense total</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">481,485</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">840,261</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">404,840</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">533,588</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">686,923</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,419,913</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,527,185</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Research and Development, Net of Contracts</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">364,336</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(417,351</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">7,481</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">82,467</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(533,588</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(686,923</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(161,772</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(1,021,808</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Note:
The Project 352 final reimbursement was received in 2021 and research costs were company funded through an NIH extension
without cost</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our CEO and CMO are actively involved in the research and development activities, but neither receives a salary from
the Company. As such, research and development expenses are lower than might be incurred in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>General and Administrative Expenses.</I> General
and Administrative expenses decreased by $49,427, from $85,927 for the year ended December 31, 2020, to $36,500 for the year ended December
31, 2021. There were two changes that account for the decrease in expenses: (1) directors and officers insurance decreased by $34,322
from $45,629 in 2020 to $$11,308 in 2021; and (2) a decrease in travel and conference expenses by $16,686 from $16,887 in 2020 to $202
in 2021. The decrease in costs for insurance was due to a negotiated reduction in premiums for 2021 and the reduction in the number of
members serving on our board of directors from seven directors in 2020 to five directors in 2021. Travel and conference fees decreased
from 2020 to 2021 due to a shift to virtual investment conferences related to the ongoing Covid-19 pandemic and a change in company strategy
from contacting investors through conferences in 2020 to contacting investors through introductions made through an agreement with Boustead
Securities.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Legal and Professional Expenses</I>. The 162%
increase in legal and professional fees was primarily due to a non-cash payment of $420,000 for business consulting services resulting
from the transfer of 210,000 shares (105,000 shares on a post-split basis) of common stock from a major shareholder, who is also the
wife our Chairman and CEO, to a business consultant, and increases in accounting and consulting fees of $684,684 for the year ended
December 31, 2021 as compared to $261,823 for the year ended December 31, 2020.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Other Income (Expense).</I> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Other
income was $590,858 for the year ended December 31, 2021, which consisted of $3,841 for interest expense on convertible loans, $46,947
interest expense on a loan-related party, gain on change in warrant liability of $579,146 and $62,500 gain on the forgiveness of the
PPP loan. Other expense was $296,210 for the year ended December 31, 2020, which consisted of $2,859 for interest expense on convertible
loans, $36,771 interest expense on a loan-related party and loss on change in warrant liability of $256,580.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
and Capital Resources</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
capital needs to date have been met by contributions from existing shareholders, as well as through private offerings of our securities,
SBIR contracts and other grants. In the six months ended June 30, 2022, we raised a total of $525,715 through the sale of convertible
notes and warrants. In the year ended December 31, 2021, we raised a total of $687,932 through the sale of convertible notes and warrants
and PPP loans. In addition, since inception, we have received a total of $5,531,722 in SBIR contracts and other grants received primarily
through the National Institutes of Health.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that we will continue to expend substantial resources for the foreseeable future on the completion of clinical development and
regulatory preparedness of our product candidates, preparations for a commercial launch of our product candidates, if approved, and development
of any other current or future product candidates we may choose to further develop. These expenditures will include costs associated
with research and development, conducting preclinical studies and clinical trials, obtaining marketing approvals, and, if we are not
able to enter into planned collaborations, manufacturing and supply as well as marketing and selling any products approved for sale.
In addition, other unanticipated costs may arise. Because the outcome of any drug development process is highly uncertain, we cannot
reasonably estimate the actual amounts necessary to complete the development and commercialization of our current product candidates,
if approved, or future product candidates, if any.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that additional financing will be available to us when needed, on favorable terms or otherwise. Moreover, any such
additional financing may dilute the interests of existing shareholders. The absence of additional financing, when needed, could cause
us to delay implementation of its business plan in whole or in part, curtail its business activities and seriously harm us and our prospects.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Balance
Sheet Data:</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> June 30, </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> December 31, </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> 2022 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> 2021 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> Change </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> % </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left"> Current assets </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 11%; text-align: right"> 63,952 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 11%; text-align: right"> 509,615 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 11%; text-align: right"> (445,663 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 11%; text-align: right"> (87 </TD><TD STYLE="width: 1%; text-align: left"> )% </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Current liabilities </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 2,453,951 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 2,217,331 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 236,620 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 11 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> % </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"> Working capital deficiency </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (2,389,999 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (1,707,716 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (682,283 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 40 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> % </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2022, total current assets were $63,952. Total current liabilities as of June 30, 2022, were $2,453,951, resulting in a working
capital deficiency of $2,389,999. As of December 31, 2021, total current assets were $509,615. Total current liabilities as of December
31, 2021, were $2,217,331, resulting in a working capital deficiency of $1,707,716. The current assets primarily resulted from $525,715
cash received from notes payable issued. The increase in current liabilities is due to the increase in notes payable issued, forgiveness
of the PPP loan and payments on trades payable.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> </P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cash
Flows from Operating Activities</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="text-align: center"> Six Months Ended </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> June 30, </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> 2022 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> 2021 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> Change </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> % </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left"> Cash used in operating activities </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 11%; text-align: right"> (980,027 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 11%; text-align: right"> (147,641 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 11%; text-align: right"> (832,386 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 11%; text-align: right"> 564 </TD><TD STYLE="width: 1%; text-align: left"> % </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Cash used in investing activities </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> % </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Cash provided by financing activities </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 525,715 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 73,007 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 452,708 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 620 </TD><TD STYLE="text-align: left"> % </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Cash on hand </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 50,437 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 42,519 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 7,918 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 19 </TD><TD STYLE="text-align: left"> % </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not generated positive cash flows from operating activities. For the six months ended June 30, 2022, net cash flows used in operating
activities was $980,027, consisting of a net loss of $1,279,114, reduced by depreciation expense of $2,899, loss on change in warranty
liability of $18,772 amortization of right of use assets of $29,599, amortization of debt discount of $278,531, stock-based compensation
of $333,066, gain on forgiveness of the PPP of loan of $73,007 and a net change in working capital of $290,773. For the six months ended
June 30, 2021, net cash flows used in operating activities was $147,641, consisting of a net loss of $476,125, adjusted for depreciation
expense of $2,700, change in warranty liability of $57,656, amortization of right of use assets of $26,582, stock-based compensation
of $245,034, and a net change in working capital of $111,824.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cash
Flows from Investing Activities</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the six months ended June 30, 2022 and 2021, we had no investing activities.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cash
Flows from Financing Activities</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the six months ended June 30, 2022, we received $525,715 from the issuance of convertible notes. For the six months ended June 30, 2021,
we received, $73,007 from the Paycheck Protection Program.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Going
Concern</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation
of the Company as a going concern. The Company&rsquo;s only revenue source since inception from 2014 through present has been awards
from government contracts totaling $5,531,722, and the Company has incurred losses since inception, having accumulated a deficit of $7,126,082
as of June 30, 2022. We currently have limited liquidity and have not completed our efforts to establish a stabilized source of revenues
sufficient to cover operating costs over an extended period. These factors, among others, raise substantial doubt about our ability to
continue as a going concern.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will need to raise capital to fund its operations. To address its financing requirements, the Company intends to seek financing through
debt or equity financings with an aim to continue progress toward commercial viability of its products. We continue to submit Federal
grant and contract applications which have historically been the primary source of revenue. The financial statements do not include any
adjustments that might result from the outcome of the uncertainty of raising additional capital.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Off-Balance
Sheet Arrangements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial
condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources
that are material to investors.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Critical
Accounting Policies and Significant Judgments and Estimates</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared
in accordance with generally accepted accounting principles in the United States (&ldquo;GAAP&rdquo;). The preparation of these financial
statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure
of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting
periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances,
the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent
from other sources. Actual results may differ from these estimates under different assumptions or conditions. While our significant accounting
policies are described in more detail in the notes to our financial statements included elsewhere in this registration statement, we
believe that the following accounting policies are critical to understanding our historical and future performance, as these policies
relate to the more significant areas involving management&rsquo;s judgments and estimates.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
most critical accounting policies and estimates relate to the following:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and Development Expenses</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    Lease Accounting</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative
    Financial Instruments</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
    Taxes</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Research
and Development</I></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and Development expenses are offset by contract receivable payments from an NIH SBIR contract that supports this scientific research.
This is stated in the financials as research and development-net of contract expense reimbursements.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Operating
Lease Right-of-use Assets and Operating Lease Liability</I></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease right-of-use assets and liabilities are recognized at the present value of the future lease payments at the lease commencement
date. The interest rate used to determine the present value is our incremental borrowing rate, estimated to be 10%, as the interest rate
implicit in most of our leases is not readily determinable. Operating lease expense is recognized on a straight-line basis over the lease
term.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Derivative
Financial Instruments</I></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
evaluate all of our agreements to determine if such instruments have derivatives or contain features that qualify as embedded derivatives.
For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair
value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based
derivative financial instruments, we use a Binomial Simulation model to value the derivative instruments at inception and on subsequent
valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or
as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as
current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of
the balance sheet date. As of June 30, 2022, our only derivative financial instrument was an embedded warrant feature associated with
warrants issuable to our Series A convertible preferred stockholders upon completion of our initial public offering or public listing
due to certain provisions that allow for a change in the warrant value based on fluctuations of our fair value of common stock at the
date of issuance of the warrant based on certain contingent call features.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_010"></A>BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers.
Our goal is to extend the benefits of cancer treatments with surgery, radiation therapy,
chemotherapy and immunotherapy. Radiation therapy (RT) is one of the most effective modalities for treating cancers. We are developing
a pipeline of products designed to address limitations of the current cancer therapies as well as to extend to the new applications of
radiation therapy. We believe that our product candidates will enable us to deliver cancer treatments that are safer, more reliable and
at a greater scale than that of the current standard of care.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates include Ropidoxuridine, Extended Bio-availability Ropidoxuridine (IPdR/TPI), and a platform of HDAC inhibitors
(SP-1-161, SP-2-225 and SP-1-303). We have advanced Ropidoxuridine through a Phase I clinical trial using non-dilutive NIH SBIR contracts
and are currently preparing a Phase II study that we intend to commence in 2022. We also plan to submit investigational new drug
applications (INDs) for the extended Bio-availability Ropidoxuridine with the goals of initiating Phase I clinical trials in 2023, leveraging
the outcomes of the Phase I clinical study results of Ropidoxuridine. We have applied for and received FDA approval of Orphan designation
for Ropidoxuridine and RT for treating brain cancer (glioblastoma). In addition, we plan to continue to develop our pre-clinical products
SP-1-161, SP-2-225 and SP-1-303 with the goal of submitting INDs in 2023 and 2024. We believe our management team&rsquo;s
expertise in radiation therapy, combined modality cancer treatment and immuno-oncology will help drive the development and, if
approved, the commercialization of these potentially curative therapies for patients with aggressive cancers.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radiation
Oncology has gone through transformative technological innovation over the last several years to better define tumors, allow improved
shaping of radiation delivery and support dose escalation with shorter courses of treatment. Furthermore, achieving higher dose distributions
within tumor volumes has reached a practical plateau, since cancers are frequently integrated with or surrounded by more sensitive normal
tissues and further dose increases risk of tissue necrosis. To increase cancer cures at maximally tolerated radiation doses, pharmacological
and biological modifications of cells are needed to sensitize cancers, protect normal tissues, and stimulate the immune system to react
against antigens produced by irradiated, damaged cancer cells. Drugs that show sensitizing properties, or the ability to make cancer
cells more sensitive to radiation, offer a solution to this problem. Currently, such drugs are used off-label, and many have inherent
toxicities since they were designed for direct cancer treatments and not for sensitization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing our</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> products with the goal of
addressing the unmet need in cancer treatment for a commercially marketable radiation response modifier solution that leads to greater
sensitivity of cancer cells to ionizing radiation therapy. The goal of our products is to increase the therapeutic index for patients
receiving radiation and to decrease radiation-related toxicities in patients with solid tumors. Our products operate across three areas
related to the treatment of cancer with RT:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sensitization
    of growing cancer cells, rendering them more susceptible to the effects of radiation therapy.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Activation
    of the DNA damage response pathway to kill cancer cells and protect adjacent normal cells.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Activation
    of the immune system to kill any remaining cells after RT.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
platform technology allows for the creation of an inventory of products for radiation sensitizing, immune modulation, and protection
of healthy tissue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Pipeline</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are currently developing a pipeline of small
molecule radiation sensitizers and immune response regulating drugs. Our most advanced product candidate is Ropidoxuridine, an orally
available halogenated pyrimidine with strong cancer radiation sensitizing properties in preclinical studies. In addition to our
clinical study-ready candidate, we have a pipeline of complimentary product candidates that we are developing to address a host of solid
tumor cancer indications. Our pipeline is represented in the diagram below:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="formdrs_008.jpg" ALT="" STYLE="height: 316px; width: 670px">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Timeline for clinical phase (Ropidoxuridine)
and pre-clinical phase (HDAC inhibitors) pipeline. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
lead product candidates include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Ropidoxuridine
    (IPdR)</U></B> is our lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma)
    and sarcomas. Phase I clinical trial results supported by Shuttle Pharma and the NCI (CTEP) were reported at the 30th EORTC-NCI-AACR
    Symposium in November 2018 and in a full report in the medical journal, Clinical Cancer Research, in July 2019, by our SBIR subcontractor.
    Eighteen patients completed dose escalations to 1,800 mg/day for 30 days, establishing the maximum tolerated dose (MTD) of 1,200
    mg/day in combination with RT. Four partial responses, nine stable disease and one progressive disease in target lesions were reported.
    Four patients did not have measurable disease and, as a result, were not evaluable. These Phase I trial results demonstrate
    oral bioavailability and an MTD of 1,200 mg per day for 28 days for use in combination with radiation for Phase II clinical
    trials in brain tumors and Phase II clinical trials in sarcomas and/or unresectable pancreatic cancers. These disease sites are eligible
    for orphan disease designations.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Ropidoxuridine
    and Tipracil (IPdR/TPI)</U></B> is a new combination formulation demonstrating extended bioavailability after oral administration
    in an animal model system. The IPdR/TPI formulation will be developed for use as a radiation sensitizer of stage II and stage III
    rectal cancers with an endpoint of pathologic complete response rate (pCR) of greater than 40% as the therapeutic target. The pCR
    is recognized as a surrogate of survival in patients with solid tumors. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SP-1-161
    </U></B>is Shuttle Pharma&rsquo;s pre-clinical candidate lead HDAC inhibitor product. This pan HDAC inhibitor initiates the mutated
    in ataxia-telangiectasia (ATM) response pathway. Using rational drug design, we discovered HDAC inhibitors and ATM activators capable
    of radiation sensitizing cancer cells and protecting normal cells. These candidate drugs may serve as direct chemotherapeutic agents
    or as radiation sensitizers for treating cancers.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SP-2-225
    </U></B>is Shuttle Pharma&rsquo;s pre-clinical class IIb selective HDAC inhibitor that affects histone deacetylase HDAC6.
    SP-2-225 has effects on the regulation of the immune system. The interactions of RT with the immune response to cancers are of great
    current interest, offering insight into potential mechanisms for primary site and metastatic cancer treatment. With the introduction
    of check-point inhibitors, CAR-T therapies and personalized medicine in cancer, regulation of the immune response following RT is
    of significant clinical and commercial interest.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SP-1-303
    </U></B>is Shuttle Pharma&rsquo;s pre-clinical selective Class I HDAC inhibitor that preferentially affects histone deacetylases
    HDAC1 and HDAC3 and is a member of the class I HDAC family. SP-1-303 data show direct cellular toxicity in ER positive breast
    cancer cells. Furthermore, SP-1-303 increases  PD-L1 expression.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Approach</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that we have established a leadership position in radiation sensitizer discovery and development. Over approximately
six years of research, we have identified two clinical phase product candidates and discovered new pre-clinical molecules using our proprietary
platform technologies to increase the therapeutic index for patients receiving radiation for treatment of solid tumors. Our development
strategy has four key pillars: (1) to improve the efficacy of RT by demonstrating improved disease-free survival rates in patients who
undergo radiation therapy, (2) reduce the amount of radiation needed for a favorable tumor response, thereby limiting the potential for
radiation related toxicities to healthy cells, (3) decrease the extent of surgery needed to remove cancers and improve quality of life,
and (4) leverage our next generation technologies to create drugs that regulate the immune response assisting immune checkpoint and CAR-T
therapies and other personalized medicines targeting cancers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
propose to perform Phase I and Phase II clinical trials to advance our clinical product candidates. In addition, candidate HDAC
inhibitor molecules will be tested, and IND-enabling studies will be performed to prepare for Phase I clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> have been awarded three SBIR contracts
from the NIH to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Develop IPdR as a radiation sensitizer for the treatment of gastro-intestinal
    cancers, in combination with radiation therapy. This funding provided partial support for the Phase I clinical trial of Ropidoxuridine
    and RT.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Develop prostate cancer cell cultures from African-American
    men, with donor matched normal prostate cells, with the goal of establishing 50 pairs for accelerating research to reduce
    prostate cancer health disparities in African-American men. This project was funded under &ldquo;Moonshot&rdquo; designation and
    Shuttle Pharma is eligible to submit an application for additional SBIR (Phase IIb) funding to establish the infrastructure
    required to expand and distribute cells for research purposes. Cells from African-American patients are distributed
    to investigators who are conducting health disparities research.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Develop predictive biomarkers for determining outcomes for prostate
    cancer patients following treatment with SBRT. This SBIR-funded project was completed on March 15, 2022 and Shuttle Pharma is
    eligible to apply for additional funding through the SBIR (Phase IIb) mechanism to de-risk clinical validation to
    develop the predictive biomarkers.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All three SBIR funded projects have been completed.
The Company is eligible to apply for SBIR Phase IIb funding to &ldquo;bridge&rdquo; the funding gap should Shuttle Pharma elect to advance
the &ldquo;Moon shot&rdquo; health disparities or the predictive biomarker project. The NIH SBIR program is designed to encourage
small businesses to engage in Federal Research/Research and Development (&ldquo;R/R&amp;D&rdquo;) that has the potential for commercialization.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our
Strategy</B>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our
                                            goal is to maintain and build upon our leadership position in radiation sensitization. We
                                            plan to develop Ropidoxuridine and the HDAC6 inhibitor (SP-2-225) and, if approved by the
                                            FDA, commercialize our product candidates for the treatment of cancers. While this process
                                            may require years to complete, we believe achieving this goal could result in new
                                            radiation sensitizer and immunotherapy products. Key elements of our strategy include:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Capitalize
    on Ropidoxuridine as an orally available, small molecule radiation sensitizer. </B>To date, there is one drug (Cetuximab,
    a monoclonal antibody) approved by the FDA specifically as a radiation sensitizer. If we are successful in developing Ropidoxuridine
    and obtaining FDA approval, a small molecule sensitizer would then be enabled for clinical applications
    for radiation sensitization.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expand
    our leadership position within radiation sensitizers</B>. In addition to our traditional radiation sensitizers, we plan to advance
    our near-term pipeline to include radiation sensitizers for proton therapy. Proton Therapy is growing worldwide as a form of radiation
    therapy due to its unique beam shaping characteristics. As a result, this new technology offers a major opportunity for Shuttle Pharma
    to strive to develop an innovative and well-tolerated  drug for proton therapy sensitization.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Execute
    a disciplined business development strategy to strengthen our portfolio of product candidates</B>. We have built our current product
    pipeline through in-house development, partnerships with leading academic institutions and through successful in-licensing deals.
    We will continue to evaluate new in-licensing opportunities and collaboration agreements with leading academic institutions and other
    biotechnology companies around programs that seek to address areas of high unmet need and for which we believe there is a high probability
    of clinical success, including programs beyond our target franchise areas and current technology footprint.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Invest in our HDAC platform technology and maximize its utility
    across cancer therapies</B>. We are initially applying the platform to develop drugs for cancer radiation sensitization and normal
    tissue radiation protection. In addition, based on the data we have obtained thus far, these drugs are immune
    regulatory. We intend to invest to develop other properties of our platform technology, as well.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Enter into collaborations to realize the full potential of our platform</B>.
    The breadth of our HDAC technology platform enables other therapeutic applications, including radiation sensitization
    and immune therapy. We intend to seek collaborations centered on our platform to maximize applications for cancer
    treatment.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Radiation
Therapy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radiation
    Oncologists use Radiation Therapy (RT) to treat cancers that cannot be completely removed by surgery but have not yet spread to distant
    sites within the body. RT has been a mainstay for the treatment of cancer malignancies for more than half a century. The combination
    treatment of radiation therapy and chemotherapy has involved the use of cytotoxic drugs, targeted biologic agents and targeted external
    beam radiation to increase the destruction of tumor cells and cure or delay cancer progression. The low number of drugs and biologic
    agents under investigation as radiation sensitizing agents highlights an unmet need for new approaches and agents that provide greater
    effectiveness, increased quality and better tolerability for patients.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
    &ldquo;chemo-radiation&rdquo; treatments are established in cancers of the head and neck, esophagus, lung, stomach, breast,
    brain, pancreas, rectum and uterine cervix. The ideal radiation sensitizer would reach the tumor in adequate concentrations and act
    selectively in the tumor, as compared to surrounding normal tissues. It would have predictable pharmacokinetics for timing with radiation
    therapy and could be administered with every radiation treatment approach. The ideal radiation sensitizer would have minimal toxicity
    or manageable enhancement of radiation toxicity.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    U.S. market for radiation sensitizing agents is experiencing dynamic growth through development of new radiation technology, the
    introduction of new agents, growth in the number of diagnosed patients in a variety of cancers and changes in treatment patterns.
    New agents have been introduced, including bevacizumab (Avastin&reg;, Roche), panitumumab (Vectibix&reg;, Amgen), temozolomide (Temodar&reg;,
    Merck) and cetuximab (Erbitux&reg;, Eli Lilly/Imclone), with potential as radiation sensitizing agents (though all but cetuximab
    are used off label); and all are recommended by the NCCN&reg; (National Comprehensive Cancer Network) in clinical practice guidelines
    for use in combination with established therapies such as FOLFOX (leucovorin, 5-FU, oxaliplatin), CapeOX (capecitabine, oxaliplatin)
    and FOLFIRI (leucovorin, 5-FU, irinotecan).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
growth in the number of patients with cancers is being driven by an aging population and improved diagnostic tools. According to the
National Cancer Institute (NCI), more than half (~50 - 60%) of all cancer patients undergo some type of radiotherapy during the course
of their treatment. Confirming the patient estimate from the NCI, the American Society for Therapeutic Radiology and Oncology (ASTRO)
factsheet states approximately 67% of approximately 1.25 million cancer patients are treated with radiation therapy annually, either
one or more times during the course of treatment. In addition, in a study published by the Journal of Clinical Oncology in 2016, it is
estimated that the number of cancer patients needing radiation therapy will increase by 22% in the next 10 years. (<I>See &ldquo;The
Future of Radiation Oncology in the United States From 2010 to 2020: Will Supply Keep Pace With Demand?&rdquo; Benjamin D. Smith, Bruce
G. Haffty, Lynn D. Wilson, Grace L. Smith, Akshar N. Patel, and Thomas A. Buchholz Journal of Clinical Oncology 2010 28:35, 5160-5165).</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    American Society of Clinical Oncology (ASCO) estimates more than 80% of cancers in the U.S. occur in people in the age group of 50
    and above with over 60% of cancers occurring in those 65 and over. (<I>See</I>, 2018 Clinical Cancer Advances Report, American
    College of Clinical Oncology, 2018). For example, according to the American Cancer Society (ACS), more than 90% of colorectal
    cancer patients are individuals aged 50 years and older, with approximately 40% of all cases occur in patients aged 75 years and
    over. The Colon Cancer Alliance estimates that 90% of new cases and 95% of deaths from colorectal cancers occur in people aged 50
    or older. Also, the U.S. Census estimates that the age group of 65-84 will grow by 23% within the next five years, indicating
    a likely increase in the overall number of cancer patients in the U.S.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below details the number and rate of cancers occurring in the United States in 2018:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Estimated
New Cancer Cases in the US</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Male</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="9" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Female</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 25%">Prostate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">174,650</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">26</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 26%">Breast</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">268,600</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">38</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Lung &amp; bronchus</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">116,440</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Lung &amp; bronchus</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">111,710</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Colon &amp; rectum</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Colon &amp; rectum</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">67,100</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Urinary bladder</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61,700</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Uterine corpus</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61,880</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Melanoma of the skin</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57,220</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Melanoma of the skin</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39,260</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Kidney &amp; renal pelvis</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,120</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD>Thyroid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,810</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Non-Hodgkin lymphoma</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41,090</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Non-Hodgkin lymphoma</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,110</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Oral cavity &amp; pharynx</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,140</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Kidney &amp; renal pelvis</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,700</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Leukemia</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,920</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD>Pancreas</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,830</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Pancreas</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,940</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD>Leukemia</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,860</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">All sites</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">677,720</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">All sites</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">701,860</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018
Clinical Cancer Advances Report, American College of Clinical Oncology, 2018</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Colon
Cancer Alliance. Colorectal Cancer Survival Rates from Facts and Figures, 2017. Chicago, IL; 2017</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    U.S. 2019 estimated incidence, deaths and five-year survival rate of cancer patients responsive to radiation therapy is significant
    (ACS Facts &amp; Figures, 2019). The top cancers responsive to radiation are shown, based on the number of newly diagnosed patients.
    The incidence rates for some cancers are increasing by approximately 1-2% per year in the U.S. The number of newly diagnosed patients
    is significant and growing due to the aging of the population and improved diagnostic techniques.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    of the listed cancers illustrate the opportunity presented for radiation sensitizers. Of note is the low five-year survival of pancreas,
    brain, lung and esophagus cancers&mdash;all are candidates for Shuttle&rsquo;s pipeline of radiation sensitizing compounds. Cancers
    with low survival rates are of interest since they show a high unmet need for new therapeutics and an opportunity for Shuttle to
    gain significant uptake of their pipeline compounds.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Factors
    that are challenges and may restrict growth in the radiation sensitizer market include the safety and tolerability of many of the
    newer agents with radiation sensitizing properties; a regulatory environment that engenders greater levels of scrutiny of clinical
    practice issues; the high cost of newer agents; and the changing (and more restrictive) reimbursement environment in radiation
    oncology through CMS (Center for Medicare and Medicaid Services) and private payors. These factors may negatively impact the potential
    for growth in the US market.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
    of the drugs used &ldquo;off-label&rdquo; as radiation sensitizers currently require close scrutiny of their potential for side effects
    that can affect the safety and tolerability of their use with patients. All of the current agents carry significant potential for
    side effects that can affect patients&rsquo; therapies and quality of life. Radiation sensitizing agents can cause both acute and
    chronic side effects in patients. Side effects can vary from person to person depending on age, sex, type of cancer, dose given per
    day, total dose given, and the patient&rsquo;s general medical condition. Some common side effects of currently used radiation sensitizers
    include leukopenia, skin damage, hair loss, fatigue, bladder problems, nausea, fibrosis, memory loss, infertility, and enhanced risk
    of developing a second cancer, which may arise as a result of the patient&rsquo;s weakened immune system due to cytotoxic drugs used
    in treatment or when newer biologic agents cause the over-production of specific cytokines or proteins, which can lead to developing
    secondary cancers.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over
    the past five years, the FDA has taken an increasingly conservative approach to the approval of new agents for oncology treatment.
    There is greater scrutiny of results from clinical trials regarding progression free survival, overall survival, and safety
    and tolerability of new agents. Restrictions such as black box warnings and REMS (Risk Evaluation and Migration Strategies) are being
    applied to more new products over the past five years compared to the previous five years. These restrictions require physicians
    to be more careful in evaluating the use of newer agents and newer diagnostic tools to select the most appropriate patients for newer
    approved agents.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
    of the new agents are molecularly targeted therapies that are biologic in their development and manufacturing. The cost of the newer
    agents can be significant. For example, the cost for Avastin for one treatment course as a radiation sensitizer is estimated at $9,000-12,000
    according to one Key Opinion Leader in the U.S. (Carl Schmidt, Consultant, Shuttle Pharmaceuticals Holdings, Inc., Business Plan
    2018). Recently, a CAR-T gene therapy from Novartis was launched with a yearly cost of $475,000. Further, as many private
    payors scrutinize the cost and appropriate use of newer drugs, they require physicians to provide justification for
    use of newer agents through prior authorization requests, use of step therapy and to follow guidelines that delay treatment, increase
    administrative costs and limit the therapeutic choices for physicians and hospitals.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    payors for radiation oncology therapies such as CMS have instituted reimbursement reductions that potentially affect the overall
    cost of therapy and can limit the acceptance of newer agents. With CMS announced reductions in reimbursement for radiation oncology,
    there is increased pressure to find a more potent radiation sensitizer agent with reduced side effects, and greater cost-effectiveness.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Escalating
    healthcare spending is adding pressure on government and commercial payors to contain drug costs. While the oncology space
    is arguably not as tightly managed by payors as other therapeutic areas, utilization management of costly cancer therapeutics
    has become an increasing priority for US payors, especially with the advent of biologics. Payors (and market access
    agencies in the EU) will most often restrict high-cost drugs, drugs with limited or no survival benefits, and drugs deemed to be
    at high risk for widespread off-label use.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
    efforts at cost containment by insurers (which often require patients to first be prescribed lower cost drugs in order to determine
    effectiveness prior to allowing for reimbursements for more expensive (or less cost effective) drugs), payors are also looking
    toward implementing clinical pathways as a way to maintain or improve health outcomes while lowering costs. Clinical pathways are
    designed to address the limitations of prior authorization and of reduced fee schedules, offering more durable cost containment to
    payors. These pathways may lead to cost savings by encouraging the use of generics, streamlining treatment choices, and reducing
    side effects while maintaining outcomes.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Engineered
Radiation Sensitizers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market for radiation sensitizers in selected cancer types is defined by the need to improve local-regional tumor control. Treatment regimens
have been developed to address patient needs for tumor control and quality of life. Since the initial applications of Ropidoxuridine
and selective HDAC inhibitors are as adjuncts to the standard of care for the treatment of radiation responsive cancers, the unmet needs
of the market lie in the potential for the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Improvement in efficacy of radiation treatments as determined by
    overall survival, progression free survival and response rates in comparison to currently used &ldquo;off-label&rdquo;
    sensitizer drugs.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Reduction in radiation doses needed to affect a positive clinical
    response for the patient.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Reduction in the surgical extent that is needed to remove residual cancer.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Improvement in</FONT><FONT STYLE="font-size: 10pt"> quality
    of life outcomes.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Various sources have estimated that more
than 800,000 patients in the US are treated with radiation therapy for their cancers. According to the American Cancer Society about
50% are treated for curative purposes and the balance for palliative care. The market opportunity for radiation sensitizers lies with
the 400,000 patients treated for curative purposes. The number of patients being treated with RT is expected to grow by more than 22%
over the next five years. Based on a rough estimate of a course of radiation sensitizing brand drug therapy (off label at this time)
of $12,000 per patient&mdash;the market size would be in excess of $4.0 billion. This would represent about 4% of the annual cost of
cancer care in the US.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past two decades, developments in the field of oncology have resulted in an increase in the number of clinical trials
of marketed products that exhibit radiation sensitizing properties. The following are a few examples of recently approved products that
exhibit radiation sensitizing properties: topotecan (Hycamtin&reg;) was approved for ovarian and small-cell lung cancer and also in cervical
cancer when used in combination with cisplatin. Irinotecan (Camptosar&reg;) is used for metastatic colorectal carcinoma, trastuzumab
(Hercepetin&reg;) for breast cancer, and gefitinib (Iressa&reg;) for locally advanced non-small-cell lung cancer. However, the claims
on radiation sensitization are anecdotal in the scientific literature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, clinical trials are in progress to develop novel molecules (such as poly (ADP-ribose) polymerase (PARP), histone deacetylase
(HDAC) inhibitors (such Zolinza&reg; (vorinostat) and heat-shock protein 90 (hsp90) inhibitors with potential to increase the therapeutic
use of compounds with radiation sensitizing properties for other cancers.<SUP></SUP> Several drugs with radiation sensitizing properties
are currently in Phase III clinical trials, such as nimorazole (for head and neck cancer), motexafin gadolinium (for brain metastases),
and cisplatin (for cervical cancer); though none are likely to apply for a radiosensitizing claim with the FDA since the radiosensitizing
element in their clinical trials are not primary endpoints. While additional drugs with radiation sensitizing properties are expected
to be launched in the future, thereby driving the radiation sensitizers market further, to date, there is no indication that any drug
in development is expected to be approved specifically as a radiation sensitizer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
competitive environment for &ldquo;off-label&rdquo; radiation sensitizers for solid tumor cancers is anticipated to become predominantly
generic. Avastin, Erbitux, Camptosar and Xeloda have or will lose patent protection in the next three years. Newer products under investigation
or approved, such as Vectibix&reg; (panitumumab) from Amgen will be promoted as having radiation sensitizing properties, along with indications
for treatment for specific cancers. The high cost of these new therapies coupled with limited efficacy compared to current standard of
care will be constrained by both public and private payors. Other new agents are in development but will face similar challenges.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We anticipate that new products launching into the
cancer market with anecdotal claims for use as radiation sensitizers with improved effectiveness, quality and tolerability will
initially be limited in their growth until they have been added to established clinical pathways and guidelines. If their effectiveness,
quality and tolerability are demonstrated clinically, as determined by the FDA, it is anticipated the National Comprehensive
Cancer Network (NCCN), the leading authority in oncology drug evaluation for treatment guidelines, would issue a recommendation and addition
to standard of care within approximately six to twelve months after launch. An NCCN recommendation would positively impact the growth
potential for a new product entering the market. Also, payors, both public and private, would add the new product to their approved drug
lists and provide reimbursement giving providers incentive to use the product as neoadjuvant and adjuvant therapy to standard of care.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
with many cancer therapies, side effects can often have a distinct impact on quality of life and influence the potential for market growth.
Patients increasingly have a stronger voice in the decision-making process for the appropriate therapies and costs to treat their cancers.
As payors are increasingly placing more of the financial burden of the cost of therapy directly on patients, patients are voicing
their opinions to their physicians and payors which have a direct effect on which products are selected. Many of the current therapies
have significant side effects:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private
insurers are expected to have more restrictive formularies and medical benefits in which patients will be expected to carry more of the
burden of the cost of drugs. Also, it is anticipated that increased application of third party developed treatment guidelines, such as
those from the NCCN (National Comprehensive Cancer Network), are expected to be used by private payors to limit the access to
products for specific conditions through prior authorizations and implementation of step therapy or increased out of pocket cost approaches.
As many of the current drugs used as radiation sensitizers are expensive and not approved for use as radiation sensitizers (thus, such
treatment is &ldquo;off label&rdquo;), and as many of the products in clinical trials are expected to be at the current or higher price
levels, new products that may be specifically approved for an indication as the only approved product as a radiation sensitizer will
have increased consideration for reimbursement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CMS
is increasingly moving many patients to private insurance through Medicare Advantage and ACOs. Medicare Advantage plans are capitation
HMO and PPO plans offered through private insurers to Medicare patients. ACOs are being developed to increase quality of care for their
patients. Most of the new ACOs are initially positioned for Medicare patients with over 400 approved by CMS. Several studies from the
Center for Health Strategies, 2017, Journal of American Medical Association, 2018 and the Brookings Institute, 2015 estimated that almost
1000 ACOs for Medicare and non-Medicare patient populations would be approved by CMS or developed by a variety of healthcare entities
to begin operating under the ACA in 2017. We expect the growth in ACOs to continue, regardless of any changes that may be made to the
ACA going forward. In early 2017, Health Affairs, a magazine tracking ACOs, estimated that over 22 million patients are enrolled in Medicare
and private ACOs. To address the quality of care measures designated by CMS and to gain additional incentives, use of clinical pathways
or treatment guidelines is anticipated to be increasingly instituted to manage patient care. The impact on the uptake of new products
in this environment can be profound if the new product is first in class and is included in national guidelines from organizations such
as the NCCN and/or approval by the regional CMS contracting groups.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>ROPIDOXURIDINE</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The halogenated thymidine (TdR) analogs, bromodeoxyuridine
(BUdR) and iododeoxyuridine (IUdR), are a class of pyrimidine analogs that have been recognized as potent radiosensitizing agents since
the early 1960s. (<I>See</I> Kinsella TJ. An Approach to the Radiosensitization of Human Tumors. <I>Cancer J Sci Am.</I> Jul-Aug 1996:2(4);
184-193). Their cellular uptake and metabolism are dependent on the TdR salvage pathway where they are initially phosphorylated to the
monophosphate derivative by the rate-limiting enzyme, thymidine kinase (TK). (<I>See</I> Shewach DS, Lawrence TS. Antimetabolite radiosensitizers.
<I>J Clin Oncol, </I>Sep 10 2007; 25(26):4043-4050). After sequential phosphorylation to triphosphates, they are then used in DNA replication,
in competition with deoxythymidine triphosphate (dTTP), by DNA polymerase. DNA incorporation is a prerequisite for radiosensitization
of human tumors by the halogenated TdR analogs, and the extent of radiosensitization correlates directly with the percentage TdR replacement
in DNA. (<I>See </I>Lawrence TS, Davis MA, Maybaum J, Stetson PL, Ensminger WD. The Dependence of Halogenated Pyrimidine Incorporation
and Radiosensitization on the Duration of Drug Exposure. <I>International Journal of radiation oncology, biology, physics.</I> Jun 1990;
18(6);1393-1398). The molecular mechanisms of radiosensitization are most likely the result of increased susceptibility of TdR
analog-substituted DNA to the generation of highly reactive uracil free radicals by ionizing radiation (IR), which may also damage unsubstituted
complementary-strand DNA. Repair of IR damage may also be reduced by pre-IR exposure to these analogs.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rationale for using Ropidoxuridine as a radiation sensitizer is based on prior clinical studies with the active metabolite IUdR; identified
in NIH laboratories as a potent radiation sensitizer. Ropidoxuridine is an orally available prodrug of IUdR. In the body, Ropidoxuridine
is metabolized in the liver into IUdR. IUdR is incorporated into the DNA of actively growing cells and when cells are exposed to ionizing
radiation, DNA strand breaks are generated, resulting in more cell death and radiation sensitization. (<I>See</I> Gurkan E, Schupp
JE, Aziz MA, Kinsella TJ, Loparo KA. Probabilistic modeling of DNA mismatch repair effects on cell cycle dynamics and iododeoxyuridine-DNA
incorporation. Cancer Res. Nov 15 2007; 67(22):10993-11000).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
of the clinical efficacy data were obtained from NIH supported studies performed with IUdR, the active metabolite of Ropidoxuridine.
However, IUdR requires constant infusion over six weeks of therapy which creates a significant compliance issue for patients. Ropidoxuridine
can be given as a capsule for oral administration, resulting in greater ease of medication delivery and potentially improved compliance
and fewer complications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Over
                                            the last 20 years, there has been renewed interest in these halogenated TdR analogs as experimental
                                            radiation sensitizers in selected cancer patient groups. These analogs are rapidly metabolized
                                            in both rodents and humans, principally with cleavage of deoxyribose and subsequent dehalogenation
                                            by hepatic and extrahepatic metabolism, when given as a bolus infusion with a plasma half-life
                                            of &lt;5 min. Consequently, prolonged continuous or repeated intermittent drug infusions
                                            over several weeks before and during irradiation are necessary, based on in vivo human tumor
                                            kinetics, to maximize the proportion of tumor cells that incorporate these analogs into DNA
                                            during the S phase of the cell cycle. (<I>See</I> Fowler JF, Kinsella TJ. The Limiting Radiosensitization
                                            of Tumors by S-phase Sensitizers. <I>Br J Cancer</I>. 1996;74 (Suppl)(27):294-296). Phase
                                            I and Phase II trials using prolonged continuous or repeated intermittent intravenous infusions
                                            of BUdR or IUdR before and during radiation therapy (RT) have focused principally on patients
                                            with high-grade brain tumors. These clinically radiation resistant tumors can have a rapid
                                            proliferation rate (potential tumor doubling times of 5&ndash;15 days) and are surrounded
                                            by non-proliferating normal brain tissues that show little to no DNA incorporation of the
                                            TdR analogs. As such, high-grade brain tumors are ideal targets for this approach to radiation
                                            sensitization. In Phase I/Phase II clinical trials, prolonged survival outcomes
                                            were observed compared to RT alone in patients with anaplastic astrocytomas and in patients
                                            with glioblastoma multiforme IUdR continuous IV infusion (1000 mg/m<SUP>2</SUP>/ day/ 14
                                            days), Total 39 patients (F. Sullivan, et al. Int J Radiat Oncol Biol Phys. 1994; 30(3):583-90.)
                                            A therapeutic gain in clinical radiation sensitization using these halogenated TdR analogs
                                            was proposed for other types of clinically poorly radiation responsive (radiation
                                            resistant) cancers, including locally advanced cervical cancer, head and neck cancers, unresectable
                                            hepatic metastases from colorectal cancers, and locally advanced sarcomas, based on the results
                                            of other Phase I/Phase II clinical trials.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Target
Indication: Glioblastoma, Sarcomas and Rectal Cancers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After completion of the Phase I clinical trial of
Ropidoxuridine and RT in advanced GI cancers, we proposed to perform Phase II efficacy clinical trials in brain tumors (glioblastoma),
soft tissue sarcomas, and rectal cancers. Glioblastoma multiforme is a deadly malignancy of the brain with no known cure. Radiation therapy
provides delay of disease progression and is standard of care following surgical resection or biopsy. Radiation therapy is combined with
Temodar, a drug that has shown activity (~ four months survival benefit) in treating brain tumors. Preliminary data using radiation
therapy in combination with IUdR resulted in a delay of disease progression of up to six months. We propose to test
IPdR in combination with radiation therapy in the Phase II clinical trial. Similarly, delay in disease progression has been observed
following treatment of sarcomas by the combination of IUdR and RT. Based on the Phase I data of our clinical trial we know that therapeutic
levels of IUdR are reached by administering the orally available prodrug, IPdR.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Clinical
Data</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The
                                            Phase I results of the clinical trial supported by an SBIR contract to Shuttle Pharma
                                            and a sub-contract to the Brown University Oncology Group (BrUOG) at the LifeSpan/Rhode
                                            Island Hospital were reported by the subcontractor at the 30th EORTC-NCI-AACR Symposium in
                                            November 2018 and in the medical journal, Clinical Cancer Research, in 2019. Eighteen patients
                                            completed dose escalation to 1800 mg/day for 30 days, establishing the maximum tolerated
                                            dose (MTD) of 1,200 mg/day in combination with RT. Therapeutic blood levels of IUdR were
                                            achieved. Four patients were scored as partial responses, nine patients had stable disease
                                            and one patient progressed in the target lesions. These data support advancing IPdR and
                                            RT to clinical trials for the FDA to determine efficacy.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Development
Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A key to driving the Ropidoxuridine product forward,
the new formulation of IPdR/TPI, is the development of a clinical plan with aggressive timelines and support within the radiation oncology
community to participate in clinical trials with the appropriate patients to ensure a comprehensive NDA dossier for each product. Initially,
the plan is focused on the Phase I and Phase II clinical trials. Upon completion of these studies, we will determine whether to extend
the Phase II study to a randomized Phase II, or to perform a randomized Phase III clinical trial. Such determination will be based,
in part, on results of the initial clinical trials and the end of a Phase II meeting with the FDA. Shuttle Pharmaceuticals
requested and received FDA orphan drug status for Ropidoxuridine as a clinical radiation sensitizer for treatment of glioblastoma
and pre-operative treatment of soft tissue sarcomas. As a result, the application for &ldquo;orphan&rdquo; designation for Ropidoxuridine
with RT for glioblastoma has been approved. The application for sarcomas, however, was not approved and will require addressing
certain FDA comments and resubmission. The IPdR/TPI formulation clinical plan will focus on resectable stage II and III rectal
cancer patients.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our clinical plan for Ropidoxuridine development
includes:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GMP
    manufacture and formulation of 24 kg of Ropidoxuridine for use in clinical trials.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion
    of pre-clinical Ropidoxuridine and Temodar drug-drug interaction safety study.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submission
    of an IND for a Phase II clinical trial of Ropidoxuridine, Temodar and RT in glioblastoma.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Negotiations
    for CRO contracts to perform the Phase II clinical trial.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion
    of the Phase II clinical trial in glioblastomas to determine appropriate dosing, quality, effectiveness and
    tolerability.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We
                                            believe the data obtained from the NIH/NCI SBIR funded Phase I clinical trial supports efforts
                                            to raise additional capital to enable performing the Phase II clinical trials of Ropidoxuridine.
                                            We aim to conduct and complete the Phase II clinical trial so that we may present data to
                                            the FDA for its determination of efficacy. We believe this will support our efforts to raise
                                            the additional required capital to fund Phase III clinical trials and seek FDA approval
                                            of an NDA with &ldquo;orphan&rdquo; designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The clinical plan for the IPdR/TPI formulation will
focus on resectable Stage II and Stage III rectal cancer patients. Nonetheless, we cannot guarantee the successful completion of any
of these trials. Our inability to meet any of the aforementioned milestones in the Phase II or Phase III clinical trials will cause us
to be unable to proceed with our present efforts and will likely cause us to be unable to raise additional funds.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
HDAC Small Molecule Delivery Platform</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>General</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the founding of Shuttle Pharma, our discovery research and development efforts have been focused on our small molecule technology
delivery platform which uses HDAC inhibitors, designed to target cancer cells, while protecting healthy tissue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HDACs
are a class of enzymes that regulate gene expression through chemical modification of histones and non-histone proteins. Increased HDAC
activity leads to a more condensed chromatin (which is a protein complex consisting of DNA and other proteins), decreased gene
expression and loss of key gene products, including tumor suppressor gene function. Inhibition of HDAC activity leads to a more open
chromatin and increased expression of the key gene products. This chromatin modification underlies the epigenetic cellular regulatory
system and is an area of intense investigation. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development efforts to date have focused on the discovery of novel, dual functional molecules for potential use in cancer
treatment as radiation sensitizers of cancers, protectors of normal tissues, and activators of the immune responses to antigens expressed
by irradiated cancer cells. To date, we have produced three candidate molecules:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-1-161,
    a candidate lead of compounds demonstrating activation of the &ldquo;ATM&rdquo; gene product (mutated in Ataxia-Telangiectasia).
    Ataxia-Telangiectasia is a human genetic disease characterized by neurological, immunological and radiobiological clinical features.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-2-225,
    a candidate lead of compounds demonstrating Class II (HDAC6) selective inhibition. HDAC6 is a molecule integral to the presentation
    of antigens by macrophages to T-lymphocytes.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-1-303
    is a candidate Class I HDAC inhibitor with preferential efficacy against ER positive cancers.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SP-1-161</U>
- A Dual Functional Agent</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SP-1-161 is an HDAC inhibitor of the hydroxamate
chemical class of compounds and an ATM activator of the indole chemical class. HDACs modify histones and non-histone proteins, which
are key components of the chromatin structure, gene expression regulation, and cell growth. HDAC inhibitors inhibit cell proliferation,
angiogenesis and immunity. Eighteen human HDACs have been identified, subdivided into four classes based on sequence and functional homology.
In cancer cells, HDAC activity silences tumor suppressor genes important for cell growth regulation and to chromosomal instability.
Abnormal HDAC activity is also associated with tumor cell growth, invasion, metastasis and resistance to therapy. Therefore, inhibitors
of HDACs have emerged as anti-cancer agents for cancer therapy. Vorinostat and romidepsin have been approved by the FDA for treatment
of patients with relapsed or refractory T-cell lymphomas. In addition, panobinostat received FDA approval for treatment of recurrent
multiple myeloma in combination with bortezomib and dexamethasone.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preclinical studies, SP-1-161 inhibited the activity of pan-HDACs and activated the ATM gene product. ATM is a critical protein for
the activation of the cell stress response for cellular recovery from radiation exposure in normal cells, but not in cancer cells. ATM
activates the P53 protein, referred to as the &ldquo;guardian of the genome,&rdquo; and serves as a tumor suppressor critical for normal
cell function and activation of programmed cell death in cancer cells.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In preclinical studies, SP-1-161 protected
normal breast epithelial cells (184A1) following exposure to ionizing radiation while increasing sensitivity of breast cancer cells (MCF7).
SP-1-161 provides this dual function in a single molecule and this molecule is differentiated from other HDAC inhibitors
by treatment of cancers while protecting normal cells.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SP-2-225</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">SP-2-225 is a selective HDAC inhibitor that affects
histone deacetylase (HDAC6) and is a member of the class IIb HDAC family. Class II HDACs play important roles in cancer motility, invasion,
neurological diseases, and immune checkpoint. HDAC6 inhibition has been most extensively studied for its role in the treatment of hematological
cancers. HDAC6 is unique among HDAC enzymes in having two active catalytic domains and a unique physiological function. In addition to
the modification of histones, HDAC6 targets specific substrates including &alpha;-tubulin and HSP90, and are involved in protein trafficking
and degradation, cell shape and migration. Selective HDAC6 inhibitors are an emerging class of pharmaceuticals due to the involvement
of HDAC6 in pathways related to neurodegenerative diseases, cancer and immunology. Specifically, its potential to affect regulation of
the immune system and enhance the immune response in cancer is of great interest. With the introduction of check-point inhibitors, CAR-T
therapies and personalized medicine in cancer, regulation of the immune response to this therapy is of significant clinical and commercial
interest. (<I>See</I> Grindrod S, Brown M, Jung M. &ldquo;Development of dual Function Small Molecules as Therapeutic Agents for Cancer
Research,&rdquo; Poster presentation #A178, American Association of Cancer Research Oct 2017).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Selective inhibition of HCAC6 reduces dose
limiting side effects associated with non-selective HDAC inhibitors. Selective HDAC6 inhibitors may be combined with other
cytotoxic agents. Shuttle&rsquo;s discovery of selective HDAC inhibitors has yielded several HDAC6 selective candidate molecules including
SP-2-225. HDAC6 inhibitors are under investigation for roles in the treatment of diseases such as multiple myeloma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B><U>SP-1-303</U> - Target Indication: Breast Cancer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Histone deacetylase inhibitors sensitize
cancers to the effects of radiation, protecte normal tissues from radiation injury and activate the immune system. SP-1-303
is a selective Class I HDAC inhibitor that inhibits HDAC1, 3 and 6 and has direct cellular toxicity in ER positive breast cancer cells.
Furthermore, SP-1-303 increases the PD-L1 expression level in a time-dependent manner, support combination of SP-1-303 with an
immune checkpoint blocker to enhance the therapeutic benefits. We are currently conducting preclinical efficacy studies of these
molecules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>Development Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The HDAC inhibitor platform of candidate molecules
will require pre-clinical evaluation, completion of IND-enabling studies and the lead drug candidates will be tested in Phase I clinical
trials for pharmacokinetics and MTD determination. We have three lead candidates for potential development for the treatment of solid
tumors, including breast cancer, lung cancer and multiple myeloma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The results of Phase I and Phase II clinical
trials will determine further drug development and Shuttle will seek to establish collaborative partnerships with other pharmaceutical
companies to complete pre-clinical and clinical development, drug manufacturing and marketing of our product candidates. In the event
we are unsuccessful in completing our clinical trials at any stage, or in the event we obtain negative results, we will likely
be unable to raise additional funding related to our HDAC studies or will have to change direction of our research efforts regarding
the HDAC inhibitor platform of candidate molecules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>Our Manufacturing Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We have no manufacturing facilities that are company
owned or operated. We have performed laboratory scale synthesis and testing in our research laboratories in Gaithersburg, Maryland.
GMP synthesis of API, drug formulation and human dosage preparation will be performed under contracts with third-party manufacturers.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Strategic
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have developed important strategic agreements
with academic institutions for access to resources such as intellectual property, core facilities and contracting relationships. In addition,
we have established an agreement with Propagenix for intellectual property in-licensing. Our current and ongoing relationships
include:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Georgetown
    University</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9675;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sub-contractor
    for the SBIR supported African-American prostate cancer patient health disparities project (completed). The conditional reprogramming
    of cells (CRC) technology was invented at Georgetown University and Georgetown University owns the intellectual property. Propagenix
    holds the license for the intellectual property for the CRC technology from Georgetown University. The intellectual property for
    cells derived from African-American patients under the Georgetown University subcontract belong to Shuttle Pharmaceuticals, Inc.
    based on our sub-licensing agreement with Propagenix.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9675;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sub-contractor
    for the SBIR supported metabolomic predictive biomarker project (completed). The metabolomic biomarker intellectual property belongs
    to Georgetown University </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brown
    University</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9675;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sub-contractor
    of the SBIR supported Phase I clinical trial of IPdR and RT (completed).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">University
    of Virginia</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    collaboration to develop heavy oxygen molecules for proton radiation sensitizer applications.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
    Washington University</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material
    transfer agreement for testing HDAC inhibitor effects in immune model systems</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9675;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    material transfer agreement that protects our HDAC inhibitor intellectual property is with George Washington University,
    transferring drugs for research purposes and sharing authorship on publications. There is no transfer of funds related to such activities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Propagenix,
    Inc.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">License
    agreement for &ldquo;conditional re-programmed cell&rdquo; (CRC) technology. The cells established by Shuttle Pharma scientists
    at Georgetown University belong to us, based on the sublicense from Propagenix, Inc. An up-front licensing fee of $25,000 was paid
    to Propagenix. No other future milestone or royalty payments owed related to the Propagenix agreement. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U></U></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U></U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Competition
&ldquo;Off-Label&rdquo; Use</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="formdrs_003.jpg" ALT="" STYLE="height: 301px; width: 604px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Drugs with radiation sensitizing properties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Product Candidates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are advancing a clinical stage product
candidate, Ropidoxuridine, that we believe will target cancer cells while protecting healthy tissue when used in conjunction with RT.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Ropidoxuridine</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ropidoxuridine, an orally available halogenated pyrimidine
with strong cancer radiation sensitizing properties, is our lead &ldquo;clinical phase&rdquo; product candidate. Halogenated pyrimidines
are incorporated into DNA by rapidly growing cancer cells and become more sensitive to the effects of RT. We have received an SBIR contract
from the NIH to fund a Phase I clinical trial in collaboration with Brown University at the Lifespan/Rhode Island Hospital to determine
the maximum tolerated dose in patients with advanced gastrointestinal cancers. In connection with the trial, NCI has approved the Phase
I clinical protocol and provided drug and clinical data management support to Rhode Island Hospital. The Phase I clinical trial has been
completed and the results support advancing Ropidoxuridine to Phase II clinical trials of brain tumors, sarcomas and other tumors through
contracted research organizations (or CROs).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables provide data from reported clinical trials of Iododeoxyuridine and RT therapy in brain cancers (glioblastoma multiforme)
and high-grade sarcomas. Our primary strategy for Ropidoxuridine and RT therapy is to provide oral drug delivery to effect
radiation sensitization of cancers and validate effectiveness in glioblastoma and sarcoma, potential &ldquo;Orphan&rdquo; indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>
 Brain Cancer Treatment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Efficacy compared to historical
RT-alone controls for treatment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>of high-grade primary
brain tumors (RTOG*, NCI** trials)</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="formdrs_004.jpg" ALT="" STYLE="height: 201px; width: 623px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IUdR
    continuous IV infusion (1000 mg/m2/ day/ 14 days), Total of 39 patients (F. Sullivan, et al. Int J Radiat Oncol Biol Phys.
    1994; 30(3):583-90)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IUdR
    continuous IV infusion (2000 mg/m2/ 4 day infusion/ 6 week treatment), Total of 21 patients (R. Urtasun, et al. Int J Radiat
    Oncol Biol Phys. 1996;36(5):1163-7.)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>
 Sarcoma Treatment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Efficacy compared to historical
RT-alone controls for treatment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>of high-grade sarcomas
(University of Michigan*** trials)</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="formdrs_005.jpg" ALT="" STYLE="height: 200px; width: 621px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16
    patients were treated with continuous infusion (1000-1600 mg/m2/day) plus RT (J.M. Robertson, et al. Int J Radiat Oncol Biol
    Phys. 1995; 31(1):87-92).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to our primary product candidate, we are developing and planning to develop other cancer radiation sensitizers and radiation
protectors, which target protecting normal tissue during the administration of RT, and other products utilizing our HDAC
small molecule technology platform.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SBIR
Contracts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
SBIR Program</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Small Business Innovation Research program, as developed by Congress under the Small Business Innovation Development Act of 1982,
is designed to encourage domestic small businesses to engage in Federal Research/Research and Development (&ldquo;R/R&amp;D&rdquo;)
that has the potential for commercialization. Through a competitive awards-based program, SBIR enables small businesses to explore their
technological potential and provides the incentive to profit from its commercialization. Some of the SBIR&rsquo;s program goals include
stimulating technological innovation, meeting Federal research and development needs and encouraging participation in innovation and
entrepreneurship.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SBIR program is a three-phase program. Phase
1 is to establish the technical merit and commercial potential of the proposed R/R&amp;D efforts. Phase 2 is to continue the R/R&amp;D
efforts initiated in Phase 1 and funding is based on the results achieved in Phase 1. Phase 3 allows for the small business to pursue
commercialization objectives resulting from the Phase 1 and 2 R/R&amp;D activities. In addition, companies that have successfully
completed Phases I and II are also eligible to apply for Phase IIb funding.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the SBIR contract to fund our Phase I clinical study on Ropidoxuridine in combination with RT for treatment of advanced gastrointestinal
cancers, we have also received awards of SBIR contracts from the NIH to address prostate cancer health disparities and prostate
cancer radiation biomarker development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">As of the date of this prospectus, all SBIR contracts received by the Company have been completed. The Company submitted <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
final report for SBIR contract # 75N81018C00031 on March 28, 2022. The following summary of terms for the three Phase II SBIR contracts
is provided below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Summary
of SBIR Contracts</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SBIR
    contract #261201400013C: Phase I ($191,971) and Phase II ($1,428,117) for Clinical Development of IPdR for Radiosensitization, dates
    September 19, 2014 through August 3, 2017, Subcontract to Brown University/LifeSpan Rhode Island Hospital. No related intellectual
    property.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SBIR
    contracts # HHSN261201600038C; Phase I ($224,687) and #261201800016C: Cell-Based Models for Prostate Cancer Health Disparity Research
    - Moonshot Project (Phase II), award amount $1,484,350, dates September 19, 2016 through September 16, 2021, Subcontract to Georgetown
    University, Intellectual property consists of cell cultures and is property of Shuttle Pharmaceuticals, Inc. via licensing agreement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">SBIR contracts #HHSN261201600027C ($299,502) and #75N81018C00031:
    Predictive Biomarkers of Prostate Cancer Patient Sensitivity for Radiation Late Effects, award amount $1,903,015, dates September
    16, 2019 through March 15, 2022. Subcontract to Georgetown University, Intellectual property is owned by subcontractor Georgetown
    University with option to license to Shuttle Pharmaceuticals, Inc.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Prostate
Cancer Studies to Address Health Disparities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prostate
cancer health disparities studies have shown that African-American men are at higher risk for developing prostate cancer, as well as
at higher risk of cancer specific death rates as compared to Caucasian American men. The causes of disparities have been attributed to
socioeconomic differences, environmental exposures and biological factors. Most disparities studies have been population based, in part,
due to the lack of relevant in vitro and in vivo models to support biological studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuttle
Pharma has been awarded Phase I and II SBIR contracts entitled &ldquo;Cell-based models for prostate cancer health disparity research&rdquo;
to develop African-American prostate cancer cell lines with donor matched normal prostate epithelial cell lines from African American
men.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The commercialization of the prostate cells will
require additional support through the SBIR funding mechanism. Companies that have completed Phase I and II SBIR awards are eligible
to apply for Phase IIb SBIR funding. These awards are intended to de-risk a project by providing up to $4 million of matching funding
for product development to commercialization. We intend to apply for such government funding to advance laboratory facilities and to
expand the availability of the cell cultures. We are not raising capital through this IPO for the health disparities project. Should
we not be successful for SBIR IIb funding, we will pause and may have to terminate this project.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Prostate
Cancer Biomarker Development</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
treated for prostate cancer may experience treatment related late effects that adversely affect quality of life and may prove life-threatening.
Shuttle has been awarded a Phase I SBIR contract entitled &ldquo;Predictive biomarkers for prostate cancer patient sensitivity
for radiation late effects&rdquo; to determine the technical and commercial feasibility of a biomarker panel predictive of radiation
mediated late effects in patients treated for prostate cancer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
collaboration with Georgetown University, patients treated with SBRT for prostate cancers will be analyzed for urinary and rectal symptoms
and their blood will be analyzed by mass spectroscopy for predictive biomarkers. The discovery and validation of metabolite panels to
serve as a predictive biomarker of patient outcomes following radiation therapy will support future development and commercialization
of a diagnostic product through a Phase 2 SBIR effort.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The development to commercialization of the metabolite
predictive biomarker panel will require additional support through the SBIR funding mechanism. We will be eligible to apply for Phase
IIb SBIR funding the next round of solicitation. A Phase IIb will help de-risk the project by providing up to $4 million of matching
funds for performing the clinical validation trial for product development to commercialization. We intend to apply for such government
funding to advance this project. We do not intend to use the funds raised through this IPO for the health disparities project. Should
we not be successful for SBIR IIb funding, we will terminate this project.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Collaborative
Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we intend to enter into collaborative arrangements to further develop our drug candidates in the future, at present we have not entered
into any collaborative arrangements with third parties to develop our drug candidates as we are still completing clinical trials and,
as a result,</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> there can be no assurance that we will
be able to do so on commercially reasonable terms or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intellectual
Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> We invest significant amounts in research
and development. Our research and development expenses before contract reimbursements were $591,237 and $604,181 for the six months ended
June 30, 2022 and 2021 respectively. After reimbursements for contracts of $211,455 for the six months ended June 30, 2022 and 2021,
net research and development expenses were $379,783 and $392,726, respectively. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are seeking multifaceted protection for our intellectual property that includes licenses, confidentiality and non-disclosure agreements,
copyrights, patents, trademarks and common law rights, such as trade secrets. We enter into confidentiality and proprietary rights agreements
with our employees, consultants, collaborators, subcontractors and other third parties and generally control access to our documentation
and proprietary information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, we have filed four patent applications with the USPTO with respect to various aspects of our HDAC small
molecule delivery platform and Ropidoxuridine, our lead product candidate. The following is the status of the patent applications Shuttle
has filed to date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
of Shuttle Pharma&rsquo;s Intellectual Property Portfolio</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>USPTO
    number</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date
    Filed</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date
    Granted</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anticipated
    Expiration Date**</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
    Application No.: 16/475,999</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods
    and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination
    with radiation</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/3/2019&#9;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
    Application No.: 17/484,876</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dual
    function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/24/2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
    Application No.: 17/315,567</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selective
    histone deacetylase inhibitors for the treatment of human disease</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/10/2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
                                            Application No.:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/959,570</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selective
    histone deacetylase inhibitors for the treatment of human disease</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/01/2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
    Patent No.: 9,809,539</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dual
    function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/3/2015</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/7/2017</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/3/2035</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
    Patent No.: 11,034,667</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selective
    histone deacetylase inhibitors for the treatment of human disease</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/3/2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/15/2021
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/9/2038</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
    Patent No.: 10,730,834 </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selective
    histone deacetylase inhibitors for the treatment of human disease</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/4
    /2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/4/2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/3/2035</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
    Patent No.: 10,745,352 </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selective
    histone deacetylase inhibitors for the treatment of human disease</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/18/2020
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/18/2020
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/3/2035</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Morgan, Lewis &amp; Bockius LLP prepared patent
applications related to Ropidoxuridine (IpdR) and HDAC inhibitors, and, in the fourth quarter of 2018, found no freedom to operate
(FTO) issue for Ropidoxuridine used as radiosensitizer and used with tipiracil, and HDAC inhibitors SP-1-161 and SP-2-225.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
strategy around protection of our proprietary technology, including any innovations and improvements, is to obtain worldwide patent coverage
with a focus on jurisdictions that represent significant global pharmaceutical markets. Generally, patents have a term of twenty years
from the earliest priority date, assuming that all maintenance fees are paid, no portion of the patent has been terminally disclaimed
and the patent has not been invalidated. In certain jurisdictions, and in certain circumstances, patent terms can be extended or shortened.
We are obtaining worldwide patent protection for at least novel molecules, composition of matter, pharmaceutical formulations, methods
of use, including treatment of disease, methods of manufacture and other novel uses for the inventive molecules originating from our
research and development efforts. We continuously assess whether it is strategically more favorable to maintain confidentiality for the
&ldquo;know-how&rdquo; regarding a novel invention rather than pursue patent protection. For each patent application that is filed we
strategically tailor our claims in accordance with the existing patent landscape around a particular technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that an issued patent will remain valid and enforceable in a court of law through the entire patent term. Should
the validity of a patent be challenged, the legal process associated with defending the patent can be costly and time consuming. Issued
patents can be subject to oppositions, interferences and other third-party challenges that can result in the revocation of the
patent limit patent claims such that patent coverage lacks sufficient breadth to protect subject matter that is commercially relevant.
Competitors may be able to circumvent our patents. Development and commercialization of pharmaceutical products can be subject to substantial
delays and it is possible that at the time of commercialization any patent covering the product has expired or will be in force for only
a short period of time following commercialization. We cannot predict with any certainty if any third-party U.S. or foreign patent
rights or other proprietary rights will be deemed infringed by the use of our technology. Nor can we predict with certainty which, if
any, of these rights will or may be asserted against us by third parties. Should we need to defend ourselves and our partners against
any such claims, substantial costs may be incurred. Furthermore, parties making such claims may be able to obtain injunctive or other
equitable relief, which could effectively block our ability to develop or commercialize some or all of our products in the U.S. and abroad,
and could result in the award of substantial damages. In the event of a claim of infringement, we or our partners may be required to
obtain one or more licenses from a third party. There can be no assurance that we can obtain a license on a reasonable basis should we
deem it necessary to obtain rights to an alternative technology that meets our needs. The failure to obtain a license may have a material
adverse effect on our business, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also rely on trade secret protection for our confidential and proprietary information. No assurance can be given that we can meaningfully
protect our trade secrets on a continuing basis. Others may independently develop substantially equivalent confidential and proprietary
information or otherwise gain access to our trade secrets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is our policy to require our employees and consultants, outside scientific collaborators, sponsored researchers and other advisors who
receive confidential information from us to execute confidentiality agreements upon the commencement of employment or consulting relationships.
These agreements provide that all confidential information developed or made known to these individuals during the course of the individual&rsquo;s
relationship with the company is to be kept confidential and is not to be disclosed to third parties except in specific circumstances.
The agreements provide that all inventions conceived by an employee will be the property of our company. There can be no
assurance, however, that these agreements will provide meaningful protection or adequate remedies for our trade secrets in the event
of unauthorized use or disclosure of such information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will depend in part on our ability to obtain and maintain patent protection, preserve trade secrets, prevent third parties from
infringing upon our proprietary rights and operate without infringing upon the proprietary rights of others, both in the U.S. and other
territories worldwide.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Manufacturing
and Supply</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently own or operate manufacturing facilities for the production of preclinical, clinical or commercial quantities of any
of our product candidates. We currently use a number of our suppliers for the raw materials and formulation to meet the preclinical and
any clinical requirements of our product candidates. We do not have a long-term agreement with any of these parties and we believe
alternative sources of supply exist. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to enter into collaborations for the manufacture of our product candidates, with our collaborators assuming responsibility for
such manufacturing. Manufacturing is subject to extensive regulations that impose various procedural and documentation requirements,
which govern record keeping, manufacturing processes and controls, personnel, quality control and quality assurance, among others. Any
collaborator or third-party contract manufacturer we use would need to be compliant with cGMP. cGMP is a regulatory standard for
the production of pharmaceuticals that will be used in humans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Competition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development and commercialization of drugs is highly competitive. We compete with a variety of multinational pharmaceutical companies
and specialized biotechnology companies, as well as technology being developed at universities and other research institutions. Our competitors
have developed, are developing or will develop product candidates and processes competitive with our product candidates. Competitive
therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments that
enter the market. We believe that a significant number of products are currently under development, and may become commercially available
in the future, for the treatment of conditions for which we may try to develop product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience
than we have. If we are able to obtain approval for any product candidate, we will face competition based on many different factors,
including the quality and effectiveness of our products, the ease with which our products can be administered and the extent to
which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability
and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could
present superior treatment alternatives, including by being more effective, safer, and less expensive or marketed and sold more effectively
than any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover
the expense of developing and commercializing our product candidates. Such competitors could also recruit our employees, which could
negatively impact our level of expertise and our ability to execute our business plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following figure provides summary information about cytotoxic drugs that may be used with radiation therapy for their sensitizing properties
that currently comprise the competition for Shuttle&rsquo;s agents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="formdrs_006.jpg" ALT="" STYLE="height: 413px; width: 584px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Fluorouracil</U>
(5-FU) is an anti-metabolite used to treat cancer, by injection, for colon cancer, esophageal cancer, stomach cancer, pancreatic
cancer, breast cancer, and cervical cancer. Fluorouracil was patented in 1956 and is an effective and safe drug with radiation sensitizing
properties. Capecitabine, an orally available formulation of 5-FU and was patented in 1992. It is used for the treatment of gastric,
esophageal and other cancers for sensitization to radiation therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Cetuximab</U> is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of metastatic colorectal, lung cancer and head and
neck cancers. This monoclonal antibody is administered by intravenous infusion and improves the 5-year survival of patients when used
in combination with radiation therapy, compared with radiotherapy alone.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Platinum</U>
based compounds (cis-platin, carbo-platin and oxaloplatin) also exhibit radiation sensitizing properties. Platinum and radiation are
used together for the treatment of locally advanced cervical cancer and for head and neck cancers. Cisplatin is believed to augment
the effects of radiation by inhibiting the repair of radiation-induced sub-lethal damage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Bevacizumab</U>
works as an anti-angiogenic agent. It was approved for medical use in the United States in 2004. The addition of bevacizumab to
standard treatment can prolong the lives of breast and lung cancer patients by several months and may be used with radiation
therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Irinotecan</U> is given by injection and is used to treat colon cancer and small cell lung cancer and can be combined with radiation therapy. For
colon cancer it is used either alone or with fluorouracil.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Government
Regulation and Product Approval</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governmental
authorities in the U.S., at the federal, state and local level, and other countries extensively regulate, among other things, the research,
development, testing, manufacture, labeling, packaging, promotion, storage, advertising, distribution, marketing and export and import
of products such as those we are developing. Our product candidates must be approved by the FDA through the NDA process before they may
be legally marketed in the U.S. and will be subject to similar requirements in other countries prior to marketing in those countries.
The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes
and regulations require the expenditure of substantial time and financial resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>U.S.
government regulation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>NDA
approval processes</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the U.S., the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (the &ldquo;FDCA&rdquo;) and implementing regulations.
Failure to comply with the applicable U.S. requirements at any time during the product development or approval process, or after approval,
may subject an applicant to administrative or judicial sanctions, any of which could have a material adverse effect on us. These sanctions
could include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    to approve pending applications;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
    of an approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposition
    of a clinical hold;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning
    letters;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    seizures;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">total
    or partial suspension of production or distribution; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions,
    fines, disgorgement, or civil or criminal penalties.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process required by the FDA before a drug may be marketed in the U.S. generally involves the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
    of nonclinical laboratory tests, animal studies and formulation studies conducted according to GLPs or other applicable regulations;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an IND, which must become effective before human clinical trials may begin;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    of adequate and well-controlled human clinical trials according to GCPs to produce data that the FDA may review to determine  safety and efficacy of the product candidate for its intended use;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an NDA;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA inspection of the manufacturing facility or facilities at which the product candidate is produced to assess
    compliance with cGMPs to assure that the facilities, methods and controls are adequate to preserve the product candidate&rsquo;s
    identity, strength, quality and purity; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    review and approval of the NDA.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
a pharmaceutical candidate is identified for development, it enters the preclinical or nonclinical testing stage. Nonclinical tests include
laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. An IND sponsor must submit the results
of the nonclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND. Some nonclinical
testing may continue even after the IND is submitted. In addition to including the results of the nonclinical studies, the IND will also
include a protocol detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring quality
and the effectiveness criteria to be evaluated if the first phase lends itself to an efficacy determination. The IND automatically
becomes effective thirty (30) days after receipt by the FDA, unless the FDA, within the thirty (30) day time period, places the IND on
clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin. A
clinical hold may occur at any time during the life of an IND and may affect one or more specific studies or all studies conducted under
the IND.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with GCPs. They must be
conducted under protocols detailing the objectives of the trial, dosing procedures, research subject selection and exclusion criteria
and the quality and effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND, and
progress reports detailing the status of the clinical trials must be submitted to the FDA annually. Sponsors also must timely report
to FDA serious and unexpected adverse reactions, any clinically important increase in the rate of a serious suspected adverse reaction
over that listed in the protocol or investigation brochure or any findings from other studies or animal or in vitro testing that suggest
a significant risk in humans exposed to the drug. An institutional review board (IRB) at each institution participating in the clinical
trial must review and approve the protocol before a clinical trial commences at that institution and must also approve the information
regarding the trial and the consent form that must be provided to each research subject or the subject&rsquo;s legal representative,
monitor the study until completed and otherwise comply with IRB regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
clinical trials are typically conducted in three sequential phases that may overlap or be combined.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase
    I</B>&mdash;The product candidate is initially introduced into healthy human subjects and tested for quality, dosage tolerance,
    absorption, metabolism, distribution and elimination. In the case of some product candidates for severe or life-threatening diseases,
    such as cancer, especially when the product candidate may be inherently too toxic to ethically administer to healthy volunteers,
    the initial human testing is often conducted in patients.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase
    II</B>&mdash;Clinical trials are performed on a limited patient population intended to identify possible adverse effects and safety
    risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and
    optimal dosage.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase
    III</B>&mdash;Clinical trials are undertaken to further evaluate dosage and produce data that the FDA may determine to establish
    clinical efficacy and safety in an expanded patient population at geographically dispersed clinical study sites. These studies
    are intended to establish the overall risk-benefit ratio of the product and provide an adequate basis for product labeling.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
clinical trials are inherently uncertain and Phase I, Phase II and Phase III testing may not achieve desired results or otherwise
be completed. The FDA or the sponsor may suspend a clinical trial at any time for a variety of reasons, including a finding that
the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval
of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&rsquo;s requirements or
if the product candidate has been associated with unexpected serious harm to patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the development of a new product candidate, sponsors are given opportunities to meet with the FDA at certain points. These points may
be prior to the submission of an IND, at the end of Phase II and before an NDA is submitted. Meetings at other times may be requested.
These meetings can provide an opportunity for the sponsor to share information about the data gathered to date and for the FDA to provide
advice on the next phase of development. Sponsors typically use the meeting at the end of Phase II to discuss their Phase II clinical
results and present their plans for the pivotal Phase III clinical trial that they believe will support the approval of the new drug.
If a Phase II clinical trial is the subject of discussion at the end of Phase II meeting with the FDA, a sponsor may be able to request
a Special Protocol Assessment (&ldquo;SPA&rdquo;), the purpose of which is to reach agreement with the FDA on the Phase III clinical
trial protocol design and analysis that will form the primary basis of an efficacy claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to published guidance on the SPA process, a sponsor which meets the prerequisites may make a specific request for a SPA and provide information
regarding the design and size of the proposed clinical trial. The FDA is supposed to evaluate the protocol within forty-five (45) days
of the request to assess whether the proposed trial is adequate, which evaluation may result in discussions and a request for additional
information. An SPA request must be made before the proposed trial begins, and all open issues must be resolved before the trial begins.
If a written agreement is reached, it will be documented and made part of the record. The agreement will be binding on the FDA and may
not be changed by the sponsor or the FDA after the trial begins except with the written agreement of the sponsor and the FDA or if the
FDA determines that a substantial scientific issue essential to determining the safety or efficacy of the product candidate was identified
after the testing began.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent
with clinical trials, sponsors usually complete additional animal safety studies and also develop additional information about the chemistry
and physical characteristics of the product candidate and finalize a process for manufacturing commercial quantities of the product candidate
in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product
candidate and the manufacturer must develop methods for testing the quality, purity and potency of the product candidate. Additionally,
appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does
not undergo unacceptable deterioration over its proposed shelf-life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of product development, nonclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical
tests and other control mechanisms, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting
approval to market the product. The submission of an NDA is subject to the payment of user fees, but a waiver of such fees may be obtained
under specified circumstances. The FDA reviews all NDAs submitted to ensure that they are sufficiently complete for substantive review
before it accepts them for filing. It may request additional information rather than accept an NDA for filing. In this event, the NDA
must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it
for filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
the submission is accepted for filing, the FDA begins an in-depth review. NDAs receive either standard or priority review. A drug representing
a significant improvement in treatment, prevention or diagnosis of disease may receive priority review. The FDA may refuse to approve
an NDA if the applicable regulatory criteria are not satisfied or may require additional clinical or other data. Even if such data are
submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. The FDA reviews an NDA to determine,
among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant. The
FDA may refer the NDA to an advisory committee for review and recommendation as to whether the application should be approved and under
what conditions. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations.
Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured and tested.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Expedited
review and approval</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has various programs, including Fast Track, priority review and accelerated approval, which are intended to expedite or simplify
the process for reviewing product candidates, or provide for the approval of a product candidate on the basis of a surrogate endpoint.
Even if a product candidate qualifies for one or more of these programs, the FDA may later decide that the product candidate no longer
meets the conditions for qualification or that the time period for FDA review or approval will be shortened. Generally, product candidates
that are eligible for these programs are those for serious or life-threatening conditions, those with the potential to address unmet
medical needs and those that offer meaningful benefits over existing treatments. For example, Fast Track is a process designed to facilitate
the development and expedite the review of product candidates to treat serious or life-threatening diseases or conditions and fill unmet
medical needs. Priority review is designed to give product candidates that offer major advances in treatment or provide a treatment where
no adequate therapy exists an initial review within six months as compared to a standard review time of ten (10) months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
Fast Track and priority review do not affect the standards for approval, the FDA will attempt to facilitate early and frequent meetings
with a sponsor of a Fast Track designated product candidate and expedite review of the application for a product candidate designated
for priority review. Accelerated approval, which is described in Subpart H of 21 CFR Part 314, provides for an earlier approval for a
new product candidate that is intended to treat a serious or life-threatening disease or condition and that fills an unmet medical need
based on a surrogate endpoint. A surrogate endpoint is a laboratory measurement or physical sign used as an indirect or substitute measurement
representing a clinically meaningful outcome. As a condition of approval, the FDA may require that a sponsor of a product candidate receiving
accelerated approval perform post-marketing clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the Food and Drug Administration Safety and Innovation Act (&ldquo;FDASIA&rdquo;), the U.S. Congress encouraged the FDA to utilize innovative
and flexible approaches to the assessment of product candidates under accelerated approval. The law required the FDA to issue related
draft guidance within a year after the law&rsquo;s enactment and also promulgate confirming regulatory changes. In June 2013, the FDA
published a draft Guidance for Industry titled &ldquo;Expedited Programs for Serious Conditions&mdash;Drugs and Biologics,&rdquo; which
provides guidance on FDA programs that are intended to facilitate and expedite development and review of new product candidates as well
as threshold criteria generally applicable to concluding that a product candidate is a candidate for these expedited development and
review programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the Fast Track, accelerated approval and priority review programs discussed above, the FDA also provided guidance on a new
program for Breakthrough Therapy designation. The FDA defines a Breakthrough Therapy as a drug that is intended, alone or in combination
with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates
that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as
substantial treatment effects observed early in clinical development. A drug designated as a Breakthrough Therapy is eligible for accelerated
approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development
and review of an application for approval of a Breakthrough Therapy. Even if a product qualifies for one or more of these programs, the
FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review
or approval will not be shortened. A request for Breakthrough Therapy designation should be submitted concurrently with, or as an amendment
to an IND. FDA has already granted this designation to approximately thirty (30) new product candidates and has begun approving Breakthrough
Therapy designated drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Patent
term restoration and marketing exclusivity</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depending
upon the timing, duration and specifics of FDA approval of the use of our product candidates, some of our U.S. patents may be eligible
for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-
Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years as compensation for patent term lost during product
development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond
a total of fourteen (14) years from the product candidate&rsquo;s approval date. The patent term restoration period is generally one
half of the time between the effective date of an IND and the submission date of an NDA, plus the time between the submission date of
an NDA and the approval of that application. Only one patent applicable to an approved product candidate is eligible for the extension
and the application for extension must be made prior to expiration of the patent. The USPTO, in consultation with the FDA, reviews and
approves the application for any patent term extension or restoration. In the future, we intend to apply for restorations of patent term
for some of our currently owned or licensed patents to add patent life beyond their current expiration date, depending on the expected
length of clinical trials and other factors involved in the submission of the relevant NDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year
period of non-patent marketing exclusivity within the U.S. to the first applicant to gain approval of an NDA for a new chemical entity.
A product candidate is a new chemical entity if the FDA has not previously approved any other new product candidate containing the same
active moiety, which is the molecule or ion responsible for the action of the product candidate substance. During the exclusivity period,
the FDA may not accept for review an abbreviated new drug application (&ldquo;ANDA&rdquo;) or a 505(b)(2) NDA submitted by another company
for another version of such product candidate where the applicant does not own or have a legal right of reference to all the data required
for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement.
The FDCA also provides three years of marketing exclusivity for an NDA, 505(b) (2) NDA, or supplement to an approved NDA if new clinical
investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential
to the approval of the application, for example, for new indications, dosages or strengths of an existing product candidate. This three-year
exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs
for product candidates containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval
of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the
preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate quality and effectiveness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Orphan
drug designation</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Orphan Drug Act, the FDA may grant orphan drug designation to product candidates intended to treat a rare disease or condition, which
is generally a disease or condition that affects fewer than 200,000 individuals in the U.S. or more than 200,000 individuals in the U.S.
and for which there is no reasonable expectation that the cost of developing and making available in the U.S. a product candidate for
this type of disease or condition will be recovered from sales in the U.S. for that product candidate. Orphan drug designation must be
requested before submitting an NDA. After the FDA grants orphan drug designation, the FDA publicly discloses the identity of the therapeutic
agent and its potential orphan use. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory
review and approval process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a product candidate that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such
designation, the product candidate is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications
to market the same product candidate for the same indication, except in very limited circumstances, for seven  years. Orphan drug
exclusivity, however, could also block the approval of one of our product candidates for seven years if a competitor obtains approval
of the same product candidate as defined by the FDA or if our product candidate is determined to be contained within the competitor&rsquo;s
product candidate for the same indication or disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Pediatric
exclusivity and pediatric use</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Best Pharmaceuticals for Children Act (&ldquo;BPCA&rdquo;), certain product candidates may obtain an additional six  months
of exclusivity if the sponsor submits information requested in writing by the FDA (a &ldquo;Written Request&rdquo;) relating to the use
of the active moiety of the product candidate in children. The FDA may not issue a Written Request for studies on unapproved or approved
indications or where it determines that information relating to the use of a product candidate in a pediatric population, or part of
the pediatric population, may not produce health benefits in that population.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Pediatric Research Equity Act
(&ldquo;PREA&rdquo;) requires a sponsor to conduct pediatric studies for most product candidates and biologics, for a new active ingredient,
new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs, biologics license application
and supplements thereto must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment
must assess the quality and effectiveness of the product candidate for the claimed indications in all relevant pediatric subpopulations
and support dosing and administration for each pediatric subpopulation for which the product candidate is safe and effective. The sponsor
or FDA may request a deferral of pediatric studies for some or all of the pediatric subpopulations. A deferral may be granted for several
reasons, including a finding that the product candidate or biologic is ready for approval for use in adults before pediatric studies
are complete, or that additional quality or effectiveness data needs to be collected before the pediatric studies begin. After
April 2013, the FDA must send a noncompliance letter to any sponsor that fails to: submit the required assessment, keep a deferral current,
or submit a request for approval of a pediatric formulation.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Post-approval
requirements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements is not maintained or if problems
occur after the product candidate reaches the market. Later discovery of previously unknown problems with a product candidate may result
in restrictions on the product candidate or even complete withdrawal of the product candidate from the market. After approval, some types
of changes to the approved product candidate, such as adding new indications, manufacturing changes and additional labeling claims, are
subject to further FDA review and approval. In addition, the FDA may require testing and surveillance programs to monitor the effect
of approved product candidates that have been commercialized, and the FDA has the power to prevent or limit further marketing of a product
candidate based on the results of these post-marketing programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
product candidates manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including,
among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">record-keeping
    requirements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reporting
    of adverse experiences with the product candidate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">providing
    the FDA with updated data for the FDA&rsquo;s continuing safety and efficacy determination;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">drug
    sampling and distribution requirements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">notifying
    the FDA and gaining its approval of specified manufacturing or labeling changes; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">complying
    with FDA promotion and advertising requirements.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug
manufacturers and other entities involved in the manufacture and distribution of approved product candidates are required to register
their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and some
state agencies for compliance with cGMP and other laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Regulation
outside of the U.S.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to regulations in the U.S., we will be subject to regulations of other countries governing any clinical trials and commercial
sales and distribution of our product candidates. Whether or not we obtain FDA approval for a product, we must obtain approval by the
comparable regulatory authorities of countries outside of the U.S. before we can commence clinical trials in such countries and approval
of the regulators of such countries or economic areas, such as the European Union, before we may market products in those countries or
areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary
greatly from place to place, and the time may be longer or shorter than that required for FDA approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
European Union regulatory systems, a company may submit marketing authorization applications either under a centralized or decentralized
procedure. The centralized procedure, which is compulsory for medicines produced by biotechnology or those medicines intended to treat
AIDS, cancer, neurodegenerative disorders or diabetes and is optional for those medicines which are highly innovative, provides for the
grant of a single marketing authorization that is valid for all European Union member states. The decentralized procedure provides for
mutual recognition of national approval decisions. Under this procedure, the holder of a national marketing authorization may submit
an application to the remaining member states. Within 90 days of receiving the applications and assessments report, each member
state must decide whether to recognize approval. If a member state does not recognize the marketing authorization, the disputed points
are eventually referred to the European Commission, whose decision is binding on all member states.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
in the U.S., we may apply for designation of a product candidate as an orphan drug for the treatment of a specific indication in the
European Union before the application for marketing authorization is made. Orphan drugs in Europe enjoy economic and marketing benefits,
including up to ten years of market exclusivity for the approved indication unless another applicant can show that its product is safer,
more effective or otherwise clinically superior to the orphan-designated product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Reimbursement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of our products will depend, in part, on the extent to which the costs of our products will be covered by third-party payors, such as
government health programs, commercial insurance and managed healthcare organizations. These third-party payors are increasingly challenging
the prices charged for medical products and services. Additionally, the containment of healthcare costs has become a priority of federal
and state governments and the prices of drugs have been a focus in this effort. The U.S. government, state legislatures and foreign governments
have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and
requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive
policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. If these third-party
payors do not consider our products to be cost-effective compared to other therapies, they may not cover our products after approved
as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable
basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (&ldquo;MMA&rdquo;) imposed new requirements for the distribution
and pricing of prescription drugs for Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription drug plans
offered by private entities which will provide coverage of outpatient prescription drugs. Part D plans include both stand-alone prescription
drug benefit plans and prescription drug coverage as a supplement to Medicare Advantage plans. Unlike Medicare Part A and B, Part D coverage
is not standardized. Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan
can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription
drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the
drugs in each category or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and
therapeutics committee. Government payment for some of the costs of prescription drugs may increase demand for our products for which
we receive marketing approval. However, any negotiated prices for our products covered by a Part D prescription drug plan will likely
be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries,
private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment
that results from the MMA may result in a similar reduction in payments from non-governmental payors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
American Recovery and Reinvestment Act of 2009 provides funding for the federal government to compare the effectiveness of different
treatments for the same illness. A plan for the research will be developed by the Department of Health and Human Services, the Agency
for Healthcare Research and Quality and the National Institutes for Health, and periodic reports on the status of the research and related
expenditures will be made to the U.S. Congress. Although the results of the comparative effectiveness studies are not intended to mandate
coverage policies for public or private payors, it is not clear what effect, if any, the research will have on the sales of any product,
if any such product or the condition that it is intended to treat is the subject of a study. It is also possible that comparative effectiveness
research demonstrating benefits in a competitor&rsquo;s product could adversely affect the sales of our product candidates. If third-party
payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our products as a
benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable
basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act of 2010, collectively
referred to as the &ldquo;ACA,&rdquo; enacted in March 2010, had a significant impact on the health care industry by expanding coverage
for the uninsured. With regard to pharmaceutical products, among other things, ACA is expanded and increased industry rebates for drugs
covered under Medicaid programs and made changes to the coverage requirements under the Medicare Part D program. The administration and
Congress which will take office in January 2017, has pledged to repeal and replace the ACA, largely because of significantly increasing
health insurance premiums and decreasing participation by members of the insurance companies. We cannot predict the impact of any repeal,
replacement or modifications which may be enacted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in some non-U.S. jurisdictions, the proposed pricing for a product candidate must be approved before it may be lawfully marketed.
The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its
member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and
to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it
may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market.
There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow
favorable reimbursement and pricing arrangements for any of our product candidates. Historically, product candidates launched in the
European Union do not follow price structures of the U.S. and generally tend to be significantly lower.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Environment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
third-party manufacturers are subject to inspections by the FDA for compliance with cGMP and other U.S. regulatory requirements, including
U.S. federal, state and local regulations regarding environmental protection and hazardous and controlled substance controls, among others.
Environmental laws and regulations are complex, change frequently and have tended to become more stringent over time. We have incurred,
and may continue to incur, significant expenditures to ensure we are in compliance with these laws and regulations. We would be subject
to significant penalties for failure to comply with these laws and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sales
and Marketing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current focus is on the development of our existing portfolio, the completion of clinical trials and, if and where appropriate, the registration
of our product candidates. We currently do not have marketing, sales and distribution capabilities. If we receive marketing and commercialization
approval for any of our product candidates, we intend to market the product either directly or through collaborations, strategic alliances
and distribution agreements with third parties. The ultimate implementation of our strategy for realizing the financial value of our
product candidates is dependent on the results of clinical trials for our product candidates, the availability of funds and the ability
to negotiate acceptable commercial terms with third parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, we have five employees, including our three executive officers, one  engaged in research
and development and one in administration. We consider our relationship with our employees to be good.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Facilities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate headquarters are located in Rockville, Maryland, where we lease shared access to office space and reception services. Our
research and development activities are performed in approximately 1,727 square feet of laboratory and office space located in Gaithersburg,
Maryland. All of such space is leased from a non-affiliated third party, pursuant to leases expiring in 2023, which provide for an aggregate
monthly rental of $5,757.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our existing facilities are adequate for our current needs and have sufficient laboratory space to house additional scientists
as we grow. When our lease expires, we may exercise our renewal options or look for additional or alternate space for our operations.
We believe that suitable additional or alternative space will be available in the future on commercially reasonable terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Legal
Proceedings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there are no legal proceedings pending or threatened
against us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="pri_001"></A>MANAGEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Directors
and Executive Officers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors and executive officers and their respective ages and titles are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 58%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position(s)
    and Office(s) Held</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anatoly
    Dritschilo, M.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board and Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Vander Hoek</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer, VP for  Operations and Regulatory</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter
    Dritschilo</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Operating Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mira
    Jung, Ph.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Scientific Officer for Biology </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tyvin
    Rich, M.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Clinical Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joshua
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schafer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven
    Richards</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milton
    Brown, M.D., Ph.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director and Chief Scientific Officer for Chemistry</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">William
    H. Adkins</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chris
    Senanayake, Ph.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below is a  description of the background and business experience of our directors and executive officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anatoly
Dritschilo, M.D.</B> is a co-founder of the Company and has served as Chairman of the Board and Chief Executive Officer since the Company&rsquo;s
formation in December 2012. Dr. Dritschilo is a radiation oncologist by training and has held multiple leadership positions in health
care. At Georgetown University Medical School in Washington, D.C., he served principally as Department Chair from 1980 to 2018; Chief
of Radiation Oncology at MedStar-Georgetown University Hospital from 2005 to 2016; Medical Director of Georgetown University Hospital
from 1994 to 1997; and Interim Director of the NCI-funded Lombardi Comprehensive Cancer Center from 2005 to 2007. He has also served
on the Boards of Directors of MedStar-Georgetown University Hospital, the National Capital Rehabilitation Hospital and the MedStar Health
Research Institute. His experience with Pharma includes Board of Directors membership of NeoPharm, Inc, and he was a founding director
of Oncomed (Neopharm). His 200+ scientific publications and 12 issued patents have earned him election as a Fellow of the National Academy
of Inventors. Dr. Dritschilo holds a Bachelor of Science degree in Chemical Engineering from the University of Pennsylvania, his medical
degree from the College of Medicine of New Jersey and residency training from the Harvard, Joint Center for Radiation Therapy. His qualifications
support his service as our Chairman of the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Michael
P. Vander Hoek</B> serves as the Company&rsquo;s Chief Financial Officer, a position he was appointed to in August 2019, and Vice President,
Operations and Regulatory, a position he has held since 2019. From November 2019 until April 2021, Mr. Vander Hoek served as Director,
Finance and Business Development at Georgetown Lombardi Comprehensive Cancer Center (&ldquo;LCCC&rdquo;), where he directed a new five-year
$221.9 million institutional commitment for cancer center research under a new NCI-approved cancer consortium arrangement and recruited
scientists to fulfill strategic objectives with senior leaders to improve cancer research and treatment. From 2007 until November 2019,
Mr. Vander Hoek served as Associate Director, Administration, at Georgetown&rsquo;s LCCC, where he was responsible for direct administrative
operations for more than 400 faculty and staff in the department of oncology, radiation medicine, pathology and biostatistics, bioinformatics
and biomathematics, including managing $216.9 million in institutional commitments to LCCC from Medstar Health, John Theurer Cancer Center
(&ldquo;JTCC&rdquo;), and Georgetown University. and implementing an enterprise-wide clinical trial management system for Georgetown
University and Medstar Health. From 2004 until 2007, Mr. Vander Hoek served as Chief Financial Officer at Georgetown&rsquo;s LCCC. During
his time at Georgetown, Mr. Vander Hoek negotiated a series of 12 research integration agreements between LCCC and the JTCC that resulted
in the approval of an NCI recognized Consortium in 2019. From 2001 until 2004, Mr. Vander Hoek served as Vice-Chair, Planning and Administration,
at MedStar Georgetown University Hospital, where he was responsible for managing administrative and financial operations for some 440
staff, physicians, residents and fellows in the departments of Medicine and Neurology. From 1996 until 2001, Mr. Vander Hoek served as
Senior Associate Administrator, Finance and Information Systems, for the Department of Medicine, Georgetown University Medical Center,
where he designed and managed the faculty compensation system, while managing the finances and information systems for the department.
His financial management experience in publicly held companies includes Director of Managed Care Reimbursement for Critical Care America
from 1990 to 1993 and Regional Controller for Laboratory Corporation of America (LabCorp) from 1993 to 1996. His responsibilities at
both companies included extensive financial management related to mergers, acquisitions, and start-up operations. Mr. Vander Hoek holds
a Master&rsquo;s in Health Services Administration from The George Washington University and a Bachelor of Arts in Biology and Psychology
from Hope College.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Peter
Dritschilo </B> has served as our President and Chief Operating Officer since Shuttle was formed in December 2012. He also served as
our Chief Financial Officer from December 2012 until August 2019. Mr. Dritschilo has over 20 years of business management experience
in medical services and cancer treatment. He has held administrative positions with Medstar-Rad America from 2001 to 2005, Georgetown
University 2005 to 2006, Prince William Hospital and the Fauquier Hospital Cancer Center 2006 to 2011 and Inova Health System&rsquo;s
Schar Cancer Institute from 2011 to 2018. In 2014, Mr. Dritschilo filed for Chapter 7 bankruptcy protection due to the failure of a personal
business venture. Mr. Dritschilo graduated from Georgetown University and received his MBA from the George Washington University.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mira Jung, Ph.D.</B>, a co-founder of our company,
presently serves as our Chief Scientific Officer for Biology and was a member of our board of directors from our formation
in December 2012 until 2019. Since 2005, Dr. Jung has served as Professor of Radiation Medicine and Microbiology at Georgetown University
Medical School, with over 20 years of experience in molecular radiation biology research. She is an expert in mechanisms of radiation
resistance and on the roles of HDAC inhibitors in modifying the radiation response. Dr. Jung&rsquo;s research has been funded by NIH
and the DOD leading to 100 publications and six issued patents, including the first reports of HDAC inhibitor drug classes modifying
cancer cell radiation resistance and protecting normal tissues from radiation damage. Dr. Jung holds an MA degree and a PhD in Microbiology
and Molecular Virology from the University of Kansas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Tyvin A. Rich, M.D.</B> serves as our company&rsquo;s
Chief Medical Officer and is responsible for the clinical development of novel radiation sensitizers. Since 2010, Dr. Rich has served
as a Staff Radiation Oncologist at the Hampton University Proton Therapy Institute in Hampton Virginia and Professor Emeritus at University
of Virginia Health Sciences Center, Department of Radiation Oncology. From 1995 until 2010, Dr. Rich was a Professor and Chairman of
the Department of Therapeutic Radiology and Oncology at the University of Virginia Health Sciences Center. And prior to that, from 1984
through 1995, Dr. Rich was a Professor of Radiotherapy and Director of Clinics in the Department of Radiotherapy of the University of
Texas M. D. Anderson Cancer Center. He has served as the protocol chair for RTOG clinical trials that advanced the use of chemoradiation
for the treatment of rectal and pancreatic cancers. He is an expert in the applications of infusional 5-Fluorouracil for chemoradiation
therapy of gastro-intestinal cancers and has authored more than 200 scientific articles, reviews and book chapters. Dr. Rich received
his undergraduate degree at Rutgers University, his medical degree at the University of Virginia, and completed residencies in internal
medicine at Georgetown University Medical Center and radiation therapy at Massachusetts General, Harvard Medical School.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Joshua Schafer </B>was appointed to be a member
of our company&rsquo;s board of directors in 2019. Since 2015, he has served as Senior Vice President and Head of Corporate Strategy
and Business Development for Mallinckrodt Pharmaceuticals Incorporated. From 2009 until 2015, he served as Vice President and Oncology
Therapeutic Area Head at Astellas Pharmaceuticals Incorporated, where he was responsible for building the company&rsquo;s global oncology
franchise. From 2000 until 2009, Mr. Schafer served in positions of increasing seniority at Takeda Pharmaceuticals North America, including
Manager and Senior Manager, New Product and New Business Development; Senior Product Manager, Gastrointestinal Marketing; and Director,
Oncology and Renal Marketing and Commercial Development. He began working in the healthcare and pharmaceutical industry in 1998, and
has served in various positions including management consulting at Accenture (formerly Anderson Consulting), G.D. Searle &amp; Co. (later
acquired by Pfizer) and Cognia Corporation. He received his Bachelor of Arts in Biology and German at the University of Notre Dame, his
MS in Biotechnology from Northwestern University and his MBA from Northwestern University. We believe Mr. Schafer&rsquo;s extensive experience
in pharmaceutical strategy, marketing and business development will assist our board&rsquo;s oversight role as we build and develop our
Company.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Steven Richards </B>was appointed to be a member
of our company&rsquo;s board of directors in 2019. He is CEO and Founder of Endurance Media, a media finance company based in
Santa Monica, California, that launched in 2014 with a strategic alliance with eOne Entertainment and a mandate to produce and finance
commercially driven feature films. From 2006 to 2014, Mr. Richards served as Co-President and Chief Operating Officer of Silver Pictures
where he oversaw all business activities and managed a team of more than 20 people responsible for film development, production and financial
information. From 2000 to 2006, he served as Chief Financial Officer at Silver Pictures and from 1995 to 2000 as Vice President, Finance,
at Silver Pictures. Mr. Richards holds an MBA in Finance from UCLA, a BBA in accounting from Temple University, and holds his CPA license.
We believe his experience as a chief financial officer and in accounting will assist in providing our board guidance and oversight as
we grow our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Milton Brown, M.D., Ph.D.</B> is a co-founder
of our company and has served as our Chief Scientific Officer for Chemistry and as a member of our board of directors since we were formed
in December 2012. Since August 2022, Dr. Brown has also served as Vice Dean of Research at Eastern Virginia Medical School. Dr.
Brown was a founder in 2004 of Rivanna Pharmaceuticals, a Virginia-based biopharmaceutical company engaged in the discovery and development
of novel small molecule therapeutics for the treatment of neurological diseases and cancer. Since 2012, Dr. Brown has served as Director
of the Drug Discovery Center at Georgetown University Medical School and since 2010, he has been the principal investigator of the NIH/NCI
funded Chemical Diversity Center. He brings to Shuttle 15 years of experience in drug discovery with over 80 publications and eight issued
patents, including discovery of novel HDAC inhibitors and has two drugs currently in clinical trials. He has served on government committees
including the NIH Experimental Therapeutics Study Section, the NIH Drug Discovery and Molecular Pharmacology Study Section and was a
scientific counselor to the U.S. Secretary of Health. Dr. Brown holds a Ph.D. in synthetic chemistry from University of Alabama, and
an MD from the University of Virginia. His extensive experience and expertise in drug discovery makes him uniquely qualified to
direct the company&rsquo;s drug discovery program and serve as our director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William H. Adkins </B>was appointed to be a
member of our company&rsquo;s board of directors in 2019. From 2018 to present, Mr. Adkins has worked as a consultant to businesses,
working with business owners to develop strategy, planning and problem solving, especially as concerns developing strategic goals, performance
plans and marketing strategies. From 2017 until present, Mr. Adkins has served as the President and General Manager at Gen&rsquo;R LLC,
a business consulting firm. From 2014 until 2017 Mr. Adkins served as a Strategic Business Development Manager at automotiveMastermind
Inc., where he was responsible for training dealer candidates and general management, including consulting with dealers and interviewing
applicants for management instructor positions. While at automotiveMastermind Inc., he partnered with the company&rsquo;s founders to
develop automotiveMastermind Inc. into a major company that eventually merged with IHS Markit Ltd. From 2004 to 2014, Mr. Adkins was
a management instructor for the National Automobile Dealers Association, where he trained managers and dealer successors how to effectively
operate a retail automobile dealership with knowledge of the various departments in a traditional dealership (e.g. sales, service, parts,
and accounting). From 1985 until 2003, Mr. Adkins was President and General Manager at Chevrolet dealerships in Ohio, California and
New York, including Adkins Chevrolet Buick Oldsmobile, Bayview Lincoln Mercury and Palanker Chevrolet. Mr. Adkins attended the University
of Maryland where he studied marketing and business management. Mr. Adkins studied marketing at the University of Cincinnati and law
at Bryant and Stranton Business College. Mr. Adkins&rsquo; substantial business and marketing experience will help us as we develop the
Company&rsquo;s products and business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Chris Senanayake, Ph.D. </B>was appointed to be
a member of the Company&rsquo;s board of directors in 2021. He is CEO and Founder of TCG GreenChem, Inc., a US subsidiary of TCG Lifesciences
Pvt. Ltd., a leading global Contract Research and Manufacturing Services (CRAMS) company in the area of drug discovery, development and
commercialization. Dr. Senanayake has more than 30 years of pharmaceutical industry experience, making him an invaluable asset to Shuttle
Pharma&rsquo;s mission as the Company advances its pharmaceutical candidates in clinical trials. He is the Founder and Chief Executive
Officer (CEO) of TCG GreenChem Inc. and Chief Scientific Officer of TCG Lifesciences, Pvt. Ltd. He has held positions of Senior Scientist
at Dow Chemical, and Research Fellow at Merck &amp; Co, Inc. Director and Executive Director of Process Research at Sepracor, Inc. (1996
to 2002), Director of Chemical Development and Vice President of Chemical Development for Boehringer Ingelheim Pharmaceuticals, Inc. In
2018, he was appointed as the CEO of Asta GreenChem, Inc in Richmond VA and Astatech (Chengdu) Biopharmaceuticals Corp. in China. He has
a record of leading and delivering on high complexity APIs for manufacturing. Dr. Senanayake participated in development activities of
many drugs, including multi-billion-dollar blockbuster drugs, such as Crixivan, Lunesta, Jardiance, Formotorol, Desvenlafaxine and other
drug candidates. He is co-author of 425 scientific publications and is co-inventor of more than 150 patents. We believe he will provide
value to us by introducing potential joint venture partners, as well as enhancing our oversight through his in-depth understanding of
and experience in the pharmaceuticals industry.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Scientific
Advisory Committee</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Theodore
                                            L. Phillips, M.D.</B> has served as the Chair of our Scientific Advisory Committee
                                            since 2018. He held the position of Chief Medical Officer and Clinical Director at
                                            Shuttle Pharmaceuticals from 2014 until 2018. Dr. Phillips&rsquo; distinguished career has
                                            included positions of Chair of the Department of Radiation Oncology (from1978 to 1998) and
                                            Associate Director (from 1996 to 1999) of the UCSF Cancer Center at the University of California
                                            at San Francisco. He is highly experienced in radiation oncology clinical trials of hypoxic
                                            radiation sensitizers. Dr. Phillips served as the principal investigator of the SBIR contract
                                            for the Phase I clinical trial of Ropidoxuridine. He previously served as Associate Director
                                            of the Northern California Oncology Group from 1983-1990, president of the American Society
                                            of Therapeutic Radiation Oncologists from 1984 to 1985, and is an elected member of the Institute
                                            of Medicine of the National Academy of Science. Dr. Phillips holds a BS degree from Dickinson
                                            College in Carlisle, Pennsylvania and a MD from the University of Pennsylvania. He provides
                                            advice to the leadership team to help design and implement clinical trials of radiation therapy
                                            and radiation response modifying drugs.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ralph R. Weichselbaum, M.D. </B>has served
as Scientific Advisor to Shuttle Pharmaceuticals for translational research for the discovery and development of radiation response modifiers
since 2013. Dr. Weichselbaum is the Daniel K. Ludwig Professor and Chairman of the Department of Radiation and Cellular Oncology, the
University of Chicago, a position he has held since 1985. He is also an elected member of the Institute of Medicine, National Academy
of Sciences. He has devoted his career to translational research in cancer with combined radiotherapy and chemotherapy. Dr. Weichselbaum
and his colleagues conceived &ldquo;genetic radiotherapy&rdquo; and developed viral constructs for use in clinical tumor radiation sensitization.
These were commercialized as TNFerade (GenVec, Inc.) and tested in a Phase I clinical trial in prostate cancer and a Phase
III clinical trial for pancreatic cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>J. Martin Brown, Ph.D.</B> has served as a Scientific
Advisor to Shuttle Pharmaceuticals for translational research for the development of hypoxic radiation sensitizers since 2017. Dr. Brown
received his Ph.D.in Cancer Biology from Oxford University in 1968 and was Director of the Division of Radiation and Cancer Biology at
Stanford University from 1984 to 2004. He is an expert in the radiation biology of hypoxia in cancers and has more than 300 peer-reviewed
published articles. He has received awards in recognition of his work, including the Gold Medal, American Society for Therapeutic
Radiology and Oncology (1999, the Failla Memorial Award, Radiation Research Society (2000), the Weiss Medal, Association for Radiation
Research (2001) and the Henry S. Kaplan Distinguished Scientist Award, International Association for Radiation Research (2007). He developed
etanidazole, a hypoxic radiation sensitizer, and tirapazamine, a hypoxic cytotoxic drug, from bench to clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Alejandro Villagra, Ph.D.</B> has served as a Scientific
Advisor to Shuttle Pharmaceuticals with expertise in cellular signaling pathways, epigenetics and immunology since 2017. Dr. Villagra
received his Ph.D. in Molecular Biology from the University of Concepcion, in Chile in 2004 and completed post-graduate training at the
H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida in Molecular Immunology in 2009, in the Laboratory of Eduardo Sotomayor,
MD. He joined the faculty of the Moffitt Cancer Center and Research Institute, as a research scientist from 2009 through 2015 and advanced
to Assistant Professor of Oncologic Sciences. He became an Assistant Professor in the Department of Biochemistry and Molecular Medicine
at the George Washington University (GWU) School of Medicine and Health Sciences in 2015, as a member of the GWU Cancer Center. His research
is focused on molecular and cellular roles of histone deacetylases (HDACs) in tumor immunology and as adjuvants for immunotherapy of cancers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Joseph Armstrong, III, Ph.D.</B> joined as a Scientific
Advisor to Shuttle Pharmaceuticals in 2021, He received his Ph.D. from the University of Colorado in 1988, completed his post-doctoral
work at the University of Virginia at Charlottesville and holds the position of Chief Operating Officer at and Global Head of Business
Development TCG GreenChem, Inc. He provides industry experience in chemistry, drug development and process research, having previously
held positions at Merck &amp; Co. Inc. in Rahway, N.J and in the U.K. for two pharmaceutical companies in the areas of Pharmaceutical
Research and Development. His primary areas of focus have been in the design and implementation of efficient synthesis of drug candidates
amenable to large scale production. Dr. Armstrong led the development team that designed, developed and implemented the manufacturing
process for the new treatment for Type II diabetes, Januvia TM. His team was awarded the Solvias Prize in 2004 (Basel, Switzerland),
the IChemE Aztra-Zeneca Award for Green Chemistry and Engineering in 2005 (London, England), Dr. Armstrong has more than 40 publications
and holds 10 patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Family
Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Anatoly Dritschilo and Peter Dritschilo are father and son. There are no other family relationships among our directors and executive
officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors is responsible for overseeing the Company&rsquo;s business consistent with its fiduciary duty to the stockholders.
This significant responsibility requires highly skilled individuals with various qualities, attributes and professional experience. There
are general requirements for service on the board that are applicable to directors and there are other skills and experience that should
be represented on the board as a whole but not necessarily by each director. Our Corporate Governance and Nominating Committee, detailed
below, considers the qualifications of director candidates individually and in the broader context of the board&rsquo;s overall composition
and the Company&rsquo;s current and future needs.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Terms
of Office</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors were initially appointed for staggered two and three-year terms as initial appointments. The Chairman of the
Board is also the CEO and was appointed for an initial three-year term. Following this offering, we intend that all of
our directors will be elected to one-year terms to hold office until the next annual meeting of our stockholders and until a
successor is appointed and qualified, or until their removal, resignation, or death. Executive officers serve at the pleasure of the
board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director
Independence</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to qualify to list our shares of common stock for trading on Nasdaq, our board of directors must consist of a majority of &ldquo;independent&rdquo;
directors, as defined under Nasdaq listing standards and Rule 10A-3(b)(1) under the Exchange Act. At present, four of the six
directors serving on our board of directors qualify as &ldquo;independent.&rdquo; Our independent directors consist of Messrs. Adkins,
Richards and Schafer and Dr. Senanayake.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Board
Committees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>General</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">board of directors has established three
committees consisting of an audit committee, a compensation committee, and a nominating and corporate governance committee. The members
of each committee qualify as &ldquo;independent&rdquo; as defined under Nasdaq listing standards and Rule 10A-3(b)(1). Moreover,
at least one member of the audit committee qualifies as an &ldquo;audit committee financial expert&rdquo; as the term is defined
under Nasdaq listing standards and applicable rules and regulations of the SEC, based on their respective business professional experience
in the financial and accounting fields.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Audit
Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee, which consists of Steve Richards, MBA, CPA (Chair), William Adkins and Chris Senanayake, MD, assists our board
of directors in its oversight of the Company&rsquo;s accounting and financial reporting processes and the audits of the Company&rsquo;s
financial statements, including (a) the quality and integrity of the Company&rsquo;s financial statements (b) the Company&rsquo;s
compliance with legal and regulatory requirements, (c) the independent auditors&rsquo; qualifications and independence and (d) the
performance of the Company&rsquo;s internal audit functions and independent auditors, as well as other matters which may come before
it as directed by the board of directors. Further, the audit committee, to the extent it deems necessary or appropriate, among its several
other responsibilities, will:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    responsible for the appointment, compensation, retention, termination and oversight of the work of any independent auditor engaged
    for the purpose of preparing or issuing an audit report or performing other audit, review or attest services for the Company;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">discuss
    the annual audited financial statements and the quarterly unaudited financial statements with management and the independent auditor
    prior to their filing with the SEC in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    with the Company&rsquo;s management on a periodic basis (i) issues regarding accounting principles and financial statement presentations,
    including any significant changes in our company&rsquo;s selection or application of accounting principles; and (ii) the effect of
    any regulatory and accounting initiatives, as well as off-balance sheet structures, on the financial statements of the company;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitor
    the Company&rsquo;s policies for compliance with federal, state, local and foreign laws and regulations and the Company&rsquo;s policies
    on corporate conduct;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain
    open, continuing and direct communication between the board of directors, the audit committee and our independent auditors; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitor
    our compliance with legal and regulatory requirements and will have the authority to initiate any special investigations of
    conflicts of interest, and compliance with federal, state and local laws and regulations, including the Foreign Corrupt Practices
    Act, as may be warranted.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Compensation
Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation committee, which consists of Steve Richards (Chair) and Joshua Schafer, aids our board of directors in meeting its
responsibilities relating to the compensation of the Company&rsquo;s executive officers and to administer all incentive compensation
plans and equity-based plans of the Company, including the plans under which Company securities may be acquired by directors, executive
officers, employees and consultants. Further, the compensation committee, to the extent it deems necessary or appropriate, among its
several other responsibilities, will:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    periodically our Company&rsquo;s philosophy regarding executive compensation to (i) ensure the attraction and retention of corporate
    officers; (ii) ensure the motivation of corporate officers to achieve the Company&rsquo;s business objectives; and (iii) align the
    interests of key management with the long-term interests of the Company&rsquo;s shareholders;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    and approve corporate goals and objectives relating to chief executive officer compensation and other executive officers of Shuttle;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    recommendations to the board of directors regarding compensation for non-employee directors, and review periodically non- employee
    director compensation in relation to other comparable companies and in light of such factors as the compensation committee may deem
    appropriate; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    periodically reports from management regarding funding the Company&rsquo;s pension, retirement, long-term disability and other management
    welfare and benefit plans.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Nominating
and Corporate Governance Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
nominating and corporate governance committee, which consists of Joshua Schafer (Chair) and Steve Richards, recommends to the
board of directors individuals qualified to serve as directors and on committees of the board of directors to advise the board of directors
with respect to the board of directors composition, procedures and committees to develop and recommend to the board of directors a set
of corporate governance principles applicable to the Company, and to oversee the evaluation of the board of directors and Shuttle&rsquo;s
management. In addition, the nominating and corporate governance committee will consider diversity of background including diversity
of race, ethnicity, international background, gender and age when evaluating candidates for board membership.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the nominating and corporate governance committee, to the extent it deems necessary or appropriate, among its several other responsibilities
will:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommend
    to the board of directors and for approval by a majority of independent directors for election by shareholders or appointment by
    the board of directors as the case may be, pursuant to our bylaws and consistent with the board of director&rsquo;s evidence for
    selecting new directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    the suitability for continued service as a director of each member of the board of directors when his or her term expires or when
    he or she has a significant change in status;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    annually the composition of the board of directors and to review periodically the size of the board of directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    recommendations on the frequency and structure of board of directors meetings or any other aspect of procedures of the board of directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    recommendations regarding the chairmanship and composition of standing committees and monitor their functions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    annually committee assignments and chairmanships;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommend
    the establishment of special committees as may be necessary or desirable from time to time; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop
    and periodically review corporate governance procedures and consider any other corporate governance issue.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Code
of Ethics</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a code of ethics that applies to all of our executive officers, directors and employees. The code of ethics codifies the
business and ethical principles that govern all aspects of our business. This document will be made available in print, free of charge,
to any shareholder requesting a copy in writing from our Secretary at our executive offices in Rockville, Maryland. A copy of our code
of ethics is available on our website at www.shuttlepharma.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Board
of Directors Role in Risk Oversight</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Members
of the board of directors have periodic meetings with management and the Company&rsquo;s independent auditors to perform risk oversight
with respect to the Company&rsquo;s internal control processes. The Company believes that the board&rsquo;s role in risk oversight does
not materially affect the leadership structure of the Company. The Company believes that its founders, leadership team and members of
the board of directors exemplify diversity and inclusivity with respect to race, sex and ethnic origin. The board of directors presently
has two diverse directors and is in the process of reviewing and vetting a female candidate to serve as a director. As such, the Company
anticipates being in full compliance with Nasdaq&rsquo;s newly adopted diversity requirements by the end of its first year of listing.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="pri_002"></A>EXECUTIVE
COMPENSATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
Compensation Table</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes all compensation awarded to, earned by, or paid to our Chief Executive Officer and Chief Financial Officer and
certain of our other executive officers for 2021 and 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUMMARY
COMPENSATION TABLE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold">Name and principal position</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Salary ($)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Bonus<BR> ($)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Stock Awards ($)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option Awards ($)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Non-Equity Incentive Plan Compensation ($)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nonqualified Deferred Compensation Earnings<BR> ($)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">All Other Compensation ($)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total<BR> ($)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; text-align: left">Anatoly Dritschilo M.D., CEO</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">2021</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">18,829</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">18,829</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2020</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,144</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,144</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Michael Vander Hoek, CFO, VP</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2021</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,338</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,138</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2020</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,484</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,484</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Peter Dritschilo, President and COO</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2021</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,534</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,534</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2020</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,970</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,970</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employment
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of our executive officers has entered into an employment agreement with us. The employees each will receive compensation on an
annual basis in cash, payable in monthly installments commencing at the completion of this offering, as well as restricted stock units
subject to achieving certain key performance indicators. </FONT>Certain of our executive officers are entitled to various target bonuses,
upon achievement of certain milestones. The terms of the employment agreements are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Employment Agreement
with Anatoly Dritschilo, MD</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 28, 2019, we entered into an employment
agreement with our Chief Executive Officer and Chairman of the Board, Anatoly Dritschilo, M.D. Under Dr. Dritschilo&rsquo;s employment
agreement, Dr. Dritschilo will receive base compensation of $274,000 per year. Dr. Dritschilo also received an initial restricted stock
unit grant of 45,495 restricted stock units (&ldquo;RSUs&rdquo;) (22,747 on a post-reverse split basis) issuable under the Company&rsquo;s
2018 Equity Incentive Plan, which RSUs vest over three years in substantially equal one-third installments on each one year anniversary
of the agreement. Under his employment agreement, if Dr. Dritschilo terminates his employment for &ldquo;Good Reason,&rdquo; as defined
in the agreement, Dr. Dritschilo will be entitled to his then applicable base salary for period of 12 months, subject to his continued
compliance with certain requirements of his employment agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Employment Agreement with Michael Vander
Hoek</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 1, 2019, we entered into an amended
employment agreement with our Chief Financial Officer and Vice President for Operations and Regulatory, Michael
Vander Hoek. Under Mr. Vander Hoek&rsquo;s employment agreement, he will receive base compensation of $227,000 and is entitled to a target
bonus of $72,000 upon achievement of certain milestones. Mr. Vander Hoek also received an initial restricted stock unit grant of 6,096
RSUs (on a post-reverse split basis) issuable under the Company&rsquo;s 2018 Equity Incentive Plan, which RSUs vest over three
years in substantially equal installments on each one year anniversary of the agreement. Under Mr. Vander Hoek&rsquo;s employment agreement,
if he terminates his employment for &ldquo;Good Reason,&rdquo; as defined in the agreement, he will be entitled to his then applicable
base salary for period of 12 months, subject to his continued compliance with certain requirements of his employment agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>Employment Agreement with Peter Dritschilo</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On May 30, 2019, we entered into an employment
agreement with our President and Chief Operating Officer, Peter Dritschilo. Under Mr. Dritschilo&rsquo;s employment agreement, Mr. Dritschilo
will receive base compensation of $236,000 and is entitled to a target bonus of $72,000 upon achievement of certain milestones. Mr. Dritschilo
also received an initial restricted stock unit grant of 20,760 RSUs (10,380 on a post-reverse split basis) issuable under the Company&rsquo;s
2018 Equity Incentive Plan, which RSUs vest over three years in substantially equal installments on each one year anniversary of the
agreement. Under Mr. Dritschilo&rsquo;s employment agreement, if Mr. Dritschilo terminates his employment for &ldquo;Good Reason,&rdquo;
as defined in the agreement, he will be entitled to his then applicable base salary for period of 12 months, subject to his continued
compliance with certain requirements of his employment agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Employment Agreement
with Tyvin Rich, MD</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 31, 2019, we entered
into an employment agreement with our Chief Clinical Officer, Tyvin Rich, M.D. Under Dr. Rich&rsquo;s employment agreement, Dr. Rich
receives base compensation of $218,000 per year and is entitled to a target bonus of $43,000 upon achievement of certain milestones.
Dr. Rich also received an initial restricted stock unit grant of 3,843 RSUs (on a post-reverse split basis) issuable under
the Company&rsquo;s 2018 Equity Incentive Plan, which RSUs vest over three years in substantially equal installments on each one year
anniversary of the agreement. Under Dr. Rich&rsquo;s employment agreement, if Dr. Rich terminates his employment for &ldquo;Good Reason,&rdquo;
as defined in the agreement, he is entitled to his then applicable base salary for period of 12 months, subject to his continued compliance
with certain provisions of his employment agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Employment Agreement
with Mira Jung, Ph.D.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 30, 2019, we entered
into an employment agreement with our Chief Scientific Officer for Biology, Mira Jung, Ph.D. Under Dr. Jung&rsquo;s employment agreement,
Dr. Jung receives base compensation of $46,800 and is entitled to a target bonus of $14,200 upon achievement of certain milestones. Dr.
Jung also received an initial restricted stock unit grant of 892 RSUs (on a post-reverse split basis) issuable under the
Company&rsquo;s 2018 Equity Incentive Plan, which RSUs vest over three years in substantially equal installments on each one year anniversary
of the agreement. Under Dr. Jung&rsquo;s employment agreement, if Dr. Jung terminates her employment for &ldquo;Good Reason,&rdquo; as
defined in the agreement, Dr. Jung is then entitled to her then applicable base salary for period of 12 months, subject to her continued
compliance with certain requirements of her employment agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outstanding
Equity Awards at Fiscal Year-End</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On a post-reverse split basis, a total
of 384,167 RSUs have been granted to our executive officers under our 2018 Equity Incentive Plan (the &ldquo;Plan&rdquo;), of
which 357,390 have vested to date yet remain unissued. After completion of this public offering, it is our intent to file a registration
statement on Form S-8 to register the shares granted under our 2018 Equity Incentive Plan, at which time we will issue all such vested
shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2018 Equity Incentive Stock Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our 2018 Equity Incentive Plan provides for equity
incentives to be granted to our employees, executive officers or directors and to key advisers and consultants. Equity incentives may
be in the form of stock options with an exercise price of not less than the fair market value of the underlying shares as determined
pursuant to the 2018 Equity Incentive Plan, restricted stock awards, other stock- based awards, or any combination of the foregoing.
The 2018 Equity Incentive Plan is administered by the Company&rsquo;s compensation committee or, alternatively, if there is no compensation
committee, the Company&rsquo;s board of directors. We have reserved 3,000,000 shares of our common stock for issuance under the 2018
Equity Incentive Plan (the &ldquo;Plan&rdquo;), of which 384,167 shares have been granted under the Plan as of the date of this
prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director
Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each of our non-employee directors, who were elected
in 2019, receives compensation on an annual basis consisting of $25,000 in cash, payable in quarterly installments commencing 90
days after completion of the offering, and 2,702 restricted stock units. Pursuant to director offer letters entered into between
each director and our company (the &ldquo;Director Agreements&rdquo;), the RSUs vest over a two-year period in one third increments,
with one-third vesting immediately upon signing and then one-third vesting on each of the first and second anniversary of election.
In addition, non-employee directors will also be reimbursed for out-of-pocket costs incurred in connection with attending meetings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="pri_003"></A>PRINCIPAL
STOCKHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth, as of the date of this prospectus, the beneficial ownership of our common stock by each director and executive
officer, by each person known by us to beneficially own 5% or more of our common stock and by directors and executive officers as a group. Unless otherwise stated, the address of the persons set forth in the table is c/o Shuttle Pharmaceuticals
Holdings, Inc., One Research Court, Suite 450, Rockville, Maryland 20850.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with SEC rules and generally includes voting or investment power with respect to securities. Unless
otherwise indicated, the stockholders listed in the table below have sole voting and investment power with respect to the shares indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
share ownership figures include shares of our commons stock issuable upon securities convertible or exchangeable into shares of our common
stock, whether or not convertible or exchangeable within 60 days of the effective date of this registration statement. Such shares
are deemed outstanding and beneficially owned by such person only for purposes of computing his or her percentage ownership, but not
for purposes of computing the percentage ownership for any other person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of August 15, 2022, there were issued and outstanding 9,312,991 shares of common stock, 269,444 shares of common stock
issuable upon conversion of 1,212.5 shares of Series A convertible preferred stock, warrants to purchase up to 269,444 common
stock issuable to the Series A convertible preferred stockholders upon completion of this initial public offering, 196,667 shares
of common stock and warrants to purchase 196,667 shares of common stock issuable upon conversion of convertible notes, which
conversion will occur immediately following completion of this initial public officer, and warrants to purchase 550,000 shares of
common stock issuable upon exercise of such warrants. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Names and addresses</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of shares of common stock beneficially owned (#)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Percentage
    of shares of common stock beneficially owned before offering (%)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of shares of common stock
    beneficially owned after the Offering</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percentage
    of shares of common stock beneficially owned after offering (%) <SUP>(1)</SUP></B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 36%; text-align: left">Directors and Named Executive Officers:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Anatoly Dritschilo, M.D.<SUP>(2)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,557,979</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 48.9 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,557,979</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"> 32.3 </P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Milton Brown, M.D., Ph.D.<SUP>(3)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,073,826</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 11.5 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,073,826</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"> 7.6 </P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Mira Jung, Ph.D.<SUP>(4)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,071,716</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 11.5 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,071,716</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"> 7.5 </P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Michael
    Vander Hoek<SUP>(5)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,095</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,095</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">-</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(5)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,380</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,380</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">-</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Tyvin A.
    Rich, M.D. <SUP>(5)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,843</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,843</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">-</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Steve Richards<SUP>(6)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,702</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,702</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">-</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Joshua Schafer<SUP>(6)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,702</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,702</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">-</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chris Senanayake<SUP>(6)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,843</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,843</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">-</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">William
    H. Adkins<SUP>(6)(7)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">224,298</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2.4</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">224,298</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 1.6 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">All directors and officers as a group (eleven persons)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,957,384</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 74.4 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">6,957,384</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"> 49.0 </P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Other 5%  beneficial owners:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Amir F.
    Heshmatpour<SUP>(8)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,569,518</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">16.9</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1,569,581</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"> 11.1 </P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denotes
    the holder owns less than one percent of the outstanding common stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&plusmn;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    persons named above have full voting and investment power with respect to the shares indicated. Under the rules of the SEC, a person
    (or group of persons) is deemed to be a &ldquo;<B>beneficial owner</B>&rdquo; of a security if he or she, directly or indirectly,
    has or shares the power to vote or to direct the voting of such security, or the power to dispose of or to direct the disposition
    of such security. Accordingly, more than one person may be deemed to be a beneficial owner of the same security.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumes
    the Series A convertible preferred shares will convert at 90% of the IPO per share price, in accordance with the Series A
    convertible preferred stock certificate of designation, as amended. Upon conversion, each holder of Series A convertible
    preferred stock will consist of 50% common stock and 50% warrants to purchase common stock, which warrants will be exercisable
    at the per share price of this offering.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gives
    pro forma effect to the sale of (i) 1,660,000 units, with each unit consisting of (i) one share of common stock and (ii) a
    warrant to purchase one share of common stock, offered hereby, (ii) 269,444 shares of common stock issuable upon conversion
    of Series A preferred stock and the issuance of 269,444 shares of common stock issuable upon exercise of warrants held by the Series
    A preferred stockholders, which warrants are issuable upon completion of the IPO, (iii) 500,000 shares of common stock issuable upon
    the exercise of warrants, which warrants will be exercised upon completion of the IPO, (iv) 196,667 shares and warrants to purchase
    196,667 shares of common stock issuable upon conversion of convertible notes outstanding, which conversion will occur upon
    completion of the IPO, and (v) the exercise of warrants to purchase 50,000 shares of common stock. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of 1,070,824 shares of common stock held of record by Dr. Anatoly Dritschilo, 22,748 restricted stock units which have
    been granted to Dr. Dritschilo, two-thirds of which have fully vested but none of which has yet been issued, and 3,464,407
    shares of common stock held of record by Joy Dritschilo, his spouse.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">(3)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Consists of 1,070,824 shares of our common stock
    held by Dr. Milton Brown and 2,702 restricted stock units which have been granted to Dr. Brown, all of which
    have fully vested but none of which have been issued.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Consists of 1,070,824 shares of our common stock held
    by Dr. Mira Jung and 892 restricted stock units which have been granted to Dr. Jung, two-thirds of which have vested and one-third
    of which remain subject to vesting.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of a grant of restricted stock units, two-thirds of which is fully vested and one-third of which remains subject to
    vesting.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    of our  directors have been granted restricted stock units (&ldquo;RSUs&rdquo;) pursuant to their letter agreements with
    the Company, all of which have fully vested as of the date of this prospectus, aside from the RSUs held by Dr. Senanayake, of which
    two-thirds have fully vested and one-third remains subject to vesting.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    the following shares held by the William Henry Adkins &amp; Pauline Adkins 1993 Revocable Trust (i) 111,112 shares of common
    stock issuable upon conversion of Series A Convertible preferred stock, (ii) 111,112 shares of common stock issuable
    upon exercise of warrants to purchase common stock, and 2,702 restricted stock units, all of which have vested but have yet to be
    issued.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    (i) 1,119,581 shares of our common stock held of record by AFH Holding &amp; Advisory, LLC, of which Mr. Heshmatpour is the sole
    member and over which he has sole voting and investment control; (ii) 300,000 shares of our common stock held of record by KIG LLC
    of which Mr. Heshmatpour&rsquo;s spouse, Kathy Heshmatpour, exercises sole voting and investment control; and (iii) 150,000
    shares held by Angelina Heshmatpour, the minor daughter of Mr. Heshmatpour.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>&nbsp;</P>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="pri_004"></A>CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Related
Party Transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><BR>
Unless described below, during the last two fiscal years, there were no transactions or series of similar transactions to which we
were a party or will be a party, in which:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    amounts involved exceed or will exceed $120,000; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    of our directors, executive officers or holders of more than 5% of our capital stock, or any member of the immediate family of any
    of the foregoing had, or will have, a direct or indirect material interest.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 25, 2018, Shuttle entered into a loan from Joy Dritschilo, the wife of our Chief Executive Officer, Anatoly Dritschilo, in
the amount of $300,000 (the &ldquo;January 2018 Loan&rdquo;). The January 2018 Loan bears an interest rate of 7.5% per annum. The
loan plus accrued interest was payable in full on January 25, 2019. On January 25, 2019, the Company amended the terms to extend the
maturity date from January 25, 2019 to October 25, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 4, 2018, Shuttle entered into a loan from Mrs. Dritschilo in the amount of $50,000 (the &ldquo;April 2018 Loan&rdquo;).
The April 2018 Loan bears an interest rate of 7.5% per annum. The loan plus accrued interest were payable in full on September 4, 2018.
On October 31, 2018, the Company amended the terms to extend the maturity date of the April 2018 Loan from September 4, 2018 to April
4, 2019. On April 4, 2019, the Company amended the terms to extend the maturity date from April 4, 2019 to October 25, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 5, 2018, our predecessor in interest, Shuttle Pharma Acquisition Corp. Inc. (&ldquo;Acquisition Corp.&rdquo;), issued 3,600,000
shares to its founders, AFH Holding &amp; Advisory, LLC and its affiliates (together, &ldquo;AFH&rdquo;). Such shares were issued at
par value. AFH has also served as an advisor and consultant to the Company, and its owner, Amir Heshmatpour, has also served as a board
member to our Company, a position he relinquished in advance of our commencement of the IPO process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 31, 2018, the Company entered into a loan with our Chief Executive Officer in the amount of $25,000 (the &ldquo;May 2018 Loan&rdquo;).
The May 2018 Loan bears interest at the rate of 7.5% per annum. The loan plus accrued interest were payable in full on July 15, 2018.
On October 31, 2018, the Company amended the terms to extend the maturity date from July 15, 2018 to November 30, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 29, 2018, the Company entered into a loan with our Chief Executive Officer in the amount of $25,000. The loan bears an interest
rate of 7.5% per annum. The loan plus accrued interest were payable in full on August 15, 2018. On December 6, 2018, the Company amended
the terms to extend the maturity date from August 15, 2018 to February 15, 2019. On February 19, 2019, the Company paid off this note
in full. The interest expense incurred on this loan was $1,223 for the year ended December 31, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 24, 2019, the Company entered into a loan from Mrs. Dritschilo in the amount of $70,000. The loan bears an interest rate
of 7.5% per annum. The loans plus accrued interest are payable in full on June 23, 2020. This loan has since been satisfied in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the fall of 2018 through to June 2019, we paid a total of $500,000 in cash to pay for a deposit on Acquisition Corp. in order to facilitate
the process of taking the Company public.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 15, 2019, the Company issued 639,161 RSUs to our then consultant, AFH, to satisfy certain compensation owed to the consultant
in relation to certain advisory services provided during 2018 and 2019. Such shares were issued pursuant to the Company&rsquo;s 2018
Equity Incentive Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 24, 2019, the Company entered into a loan with our Chief Executive Officer in the amount of $70,000. The loan bears interest
at the rate of 7.5% per annum. The loan plus accrued interest is due and payable in full on August 24, 2020. This loan has since been
satisfied in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 23, 2019, the Company entered into a loan with our Chief Executive Officer in the amount of $100,000 (the &ldquo;September
2019 Loan&rdquo;). The September 2019 Loan bear interest at the rate of 7.5% per annum and the loan plus accrued interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 1, 2020, the Company consolidated the January 2018 Loan and the April 2018 Loan into a single loan between Mrs. Dritschilo and
the Company (the &ldquo;2018 Consolidated Loan&rdquo;) such that, with accrued interest, the 2018 Consolidated Loan had a principal balance
of $424,005.65, bears interest at a rate of 7.5% per annum, and has a maturity date of December 31, 2021. The 2018 Consolidated Loan
was extended until June 30, 2022, pursuant to an amendment to the 2018 Consolidated Loan agreement dated January 24, 2022. On July
29, 2022, the Company and Mrs. Dritschilo entered into an amendment to the 2018 Consolidated Loan, pursuant to which repayment was extended
through June 30, 2023. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 1, 2020, the Company consolidated the May 2018 Loan and the September 2019 Loan with our Chief Executive Officer (the &ldquo;2019
Consolidated Loan&rdquo;), such that, with accrued interest, the 2019 Consolidated Loan had a principal balance of $138,448.20, bears
interest at the rate of 7.5% per annum, and has a maturity date of December 31, 2021. The 2019 Consolidated Loan was extended until June
30, 2022, pursuant to an amendment to the 2019 Consolidated Loan agreement dated January 24, 2022. On July 29, 2022, the Company and
our Chief Executive Officer entered into an amendment to the 2019 Consolidated Loan, pursuant to which repayment was extended through
June 30, 2023. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 21, 2021, the Company entered into a loan
agreement with Mrs. Dritschilo in the amount of $120,000 (principal), bearing interest at the rate of 7.5% per annum, with a single balloon
payment due at maturity on June 21, 2022 (the &ldquo;June 2021 Loan Agreement&rdquo;). On July 29, 2022, the Company and Mrs. Dritschilo
entered into an amendment to the June 2021 Loan Agreement, pursuant to which repayment was extended through June 30, 2023. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 22, 2021, Mrs. Dritschilo, who is one
of our major shareholders, transferred 210,000 shares (105,000 shares post-split) of common stock of the Company in a private transaction
to Steven Bayern, who had also been engaged by the Company to perform certain consulting services for the Company. Such shares, which
represent approximately three percent of her total share ownership, were sold at par value pursuant to an exemption from registration
under Section 4(a)(7) of the Securities Act. As a result of the transfer, the Company recognized $420,000 in non-cash stock compensation
in legal and professional fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> On August 1, 2022, in conjunction with our private
placement of $125,000 of units consisting of 10% notes and warrants to purchase common stock, which were sold to three accredited investors
in total, Mrs. Dritschilo purchased a $50,000 note and received warrants to purchase 20,000 shares of common stock at $2.50 per share.
The notes and warrants were sold pursuant to an exemption from registration pursuant to Rule 506(b) of Regulation D of the Securities
Act. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Review,
Approval and Ratification of Related Party Transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
related party transactions are subject to the review, approval, or ratification of our board of directors or an appropriate committee
thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="pri_005"></A>DESCRIPTION
OF CAPITAL STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Capital
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
authorized capital stock consists of 100,000,000 shares of common stock, par value $0.00001 per share, and 20,000,000 shares of preferred
stock, par value $0.00001 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, we had 9,312,991 shares of common stock issued and outstanding. In addition, 500,000
shares of common stock will be issuable upon exercise of certain warrants at the effectiveness of this  offering, and 236,000 shares will be issuable upon conversion of notes upon effectiveness of this offering. The
shares of common stock and preferred stock presently outstanding are, and the shares of common stock in this offering, when issued
and paid for as contemplated in this prospectus, will be, fully paid and non-assessable. Each holder of common stock is entitled to
one vote for each share owned on all matters voted upon by shareholders, and a majority vote is required for all actions to be taken
by shareholders. In the event we liquidate, dissolve or wind-up our operations, the holders of the common stock are entitled to
share equally and ratably in our assets, if any, remaining after the payment of all our debts and liabilities and the liquidation
preference of any shares of preferred stock that may then be outstanding. The common stock has no preemptive rights, no cumulative
voting rights, and no redemption, sinking fund, or conversion provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of common stock are entitled to receive dividends, if and when declared by the board of directors, out of funds legally available for
such purpose, subject to the dividend and liquidation rights of any preferred stock that may then be outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B>Warrants</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>General</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> The following is a summary of the material terms
and provisions of the Warrants that are being offered hereby. This summary is subject to and qualified in its entirety by the form of
warrant, which has been filed as an exhibit to the registration statement of which this prospectus is a part. Prospective investors should
carefully review the terms and provisions of the form of warrant for a complete description of the terms and conditions of the Warrants. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>Duration and Exercise Price</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Each Unit offered in this offering consists of
one ordinary share and one Warrant. Each whole warrant shall be exercisable into one share of common stock at an exercise price equal
to $0.01 per share. The Warrants will be immediately exercisable and will be exercisable for a five-year period after the date of issuance.
The exercise price and numbers of shares of common stock issuable upon exercise are subject to appropriate adjustment in the event of
stock dividends, stock splits, reorganizations or similar events affecting our ordinary shares. The Warrants will be issued in certificated
form only. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>Exercisability</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> The Warrants will be exercisable, at the option
of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number
of our shares of common stock purchased upon such exercise. A holder (together with its affiliates) may not exercise any portion of such
holder&rsquo;s Warrants to the extent that the holder would own more than 4.99% of our outstanding shares of common stock immediately
after exercise. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>Transferability</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> A Warrant may be transferred at the option of
the holder upon surrender of the Warrant to us together with the appropriate instruments of transfer. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>Fractional Shares</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> No fractional shares of common stock will be issued
upon the exercise of the Warrants. Rather, the number of shares of common stock to be issued will, at our election, either be rounded
up to the nearest whole number or we will pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the exercise price. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>Trading Market</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> There is no established trading market for any
of the Warrants. Without an active trading market, the liquidity of the Warrants will be limited. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>Rights as a Shareholder</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Except as otherwise provided in the Warrants or
by virtue of the holders&rsquo; ownership of our ordinary shares, the holders of Warrants do not have the rights or privileges of holders
of our ordinary shares, including any voting rights, until such warrant holders exercise their Warrants. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>Fundamental Transaction</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> In the event of a fundamental transaction, as
described in the Warrants and generally including any reorganization, recapitalization or reclassification of our shares of common stock,
the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or
into another person, the acquisition of more than 50% of our outstanding ordinary shares, or any person or group becoming the beneficial
owner of 50% of the voting power represented by our outstanding ordinary shares, the holders of the Warrants will be entitled to receive
upon exercise of the Warrants the kind and amount of securities, cash or other property that the holders would have received had they
exercised the Warrants immediately prior to such fundamental transaction. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>Waivers and Amendments</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> No term of the Warrants may be amended or waived
without the written consent of the holder of such Warrant. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <I>Exclusive Forum</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> We have agreed that any action, proceeding or
claim against us arising out of or relating in any way to the Warrants will be brought and enforced in the courts of the State of New
York sitting in the City and County of New York or the United States District Court for the Southern District of New York, and we irrevocably
submit to such jurisdiction, which jurisdiction will be the exclusive forum for any such action, proceeding or claim. See &ldquo;Risk
Factors&rdquo;. This exclusive forum provision shall not apply to suits brought to enforce a duty or liability created by the Exchange
Act, any other claim for which the federal courts have exclusive jurisdiction or any complaint asserting a cause of action arising under
the Securities Act against us or any of our directors, officers, other employees or agents. Section 27 of the Exchange Act creates exclusive
federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations
thereunder.<B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has the authority, without further action by the shareholders, to issue shares of preferred stock in one or more series
and to fix the rights, preferences and the number of shares constituting any series or the designation of such series. While our Certificate
of Incorporation and Bylaws, each as amended to date, do not contain any provisions that may delay, defer or prevent a change in control, the issuance
of preferred stock may have the effect of delaying or preventing a change in control or make removal of our management more difficult.
At present, our board of directors has authorized the issuance of up to 10,000 shares of Series A preferred stock, of which 1,212.5 shares
are issued and outstanding as of the date of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Series
A Convertible Preferred Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has designated and authorized the issuance of up to 10,000 shares of Series A Convertible Preferred Stock, par value
$0.00001 per share (the &ldquo;Series A Convertible Preferred Stock&rdquo;), of which there are presently 1,212.5 shares outstanding.
A total of $1,212,500 was raised during 2018 and 2019 from the sale of our Series A Convertible Preferred Stock. The Series A
Convertible Preferred Stock has a stated value of $1,000 per share, is entitled to receive a dividend at the rate of 8.5% per annum,
which dividend is cumulative and will be payable at our option in shares of common stock or cash upon the
date of conversion or redemption, as so determined by the Company. The Series A Convertible Preferred Stock will be automatically
convertible upon the earlier of (a) the closing of the sale of shares of common stock to the public at an offering price of at
least $5.00 per share in a firm commitment underwritten public offering pursuant to an effective registration statement under
the Securities Act, resulting in gross proceeds to us (before underwriter&rsquo;s discounts, commissions and expenses) of an amount
of at least $10 million (a &ldquo;Qualified IPO&rdquo;), or (b) listing of the common stock on the NYSE or Nasdaq
(a &ldquo;Qualified Listing&rdquo;). All shares of Series A Convertible Preferred Stock will be convertible at either (i)
90% of the gross public offering price per share of the Qualified IPO (before deducting underwriter&rsquo;s discounts, commissions and
expenses) or (ii) in the case of (b) above, $5.00 per share. Until such time as the Series A Convertible Preferred Stock has been
converted into our common stock, the Series A Convertible Preferred stockholders have no voting rights other than to rights to
vote on matters concerning the Series A Convertible Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conjunction with our sale of Series A Convertible Preferred Stock, our board of directors authorized the issuance of warrants to
purchase up to approximately 269,444 shares of common stock (the &ldquo;Warrants&rdquo;) to the holders of
Series A Preferred Stock. The Warrants are issuable upon the earlier of the closing of a Qualified IPO or Qualified Listing,
will have an exercise price per share equal to the IPO&rsquo;s initial per share offering price and shall be exercisable
at any time on or before expiration on the three-year anniversary following their issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
and Warrants</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2021, we completed a private placement offering (the &ldquo;Note and Warrant Offering&rdquo;) pursuant to which we sold
to two accredited investors (the &ldquo;Note and Warrant holders&rdquo;) an aggregate of $500,000 of our 10% promissory notes, which
are due upon completion of this Offering, and warrants to purchase $500,000 shares of common stock, at an exercise price of $1.00 per
share. Such issuance was completed pursuant to an exemption from registration under Rule 506(b) of Regulation D of the Securities Act.
Boustead Securities, LLC acted as placement agent in the Note and Warrant offering but waived its compensation in relation to such offering.
Upon completion of this Offering, the notes will be repaid and the warrants will be exercised simultaneously, such that the Note and
Warrant holders will have been repaid in full through their receipt of 500,000 shares of common stock, all of which shares will then
be registered for resale in the resale offering accompanying this Offering. </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2022, we completed a private placement offering (the &ldquo;2022 Note and Warrant Offering&rdquo;) pursuant to which we
sold to three accredited investors (the &ldquo;Note and Warrant holders&rdquo;) an aggregate of $125,000 of our 10% promissory
notes, which are due upon completion of this Offering, and warrants to purchase 50,000 shares of common stock, at an exercise price
of $2.50 per share. Such issuance was completed pursuant to an exemption from registration under Rule 506(b) of Regulation D of the
Securities Act. Boustead Securities, LLC acted as placement agent in the Note and Warrant offering but deferred its cash compensation
in relation to such offering.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6%
Convertible Notes</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2022 and March 11, 2022, we completed private placement offerings pursuant to which we sold to several accredited
investors an aggregate of $365,000 and $225,000, respectively, of our 6% convertible notes due three years from the date of issuance
(the &ldquo;Convertible Notes&rdquo;), pursuant to an exemption from registration under Rule 506(b) of Regulation D of the Securities
Act. Boustead Securities, LLC acted as placement agent in the Convertible Note and Warrant offering and received commissions and non-accountable
reimbursements of 10% of the gross proceeds received and warrants to purchase 10% of the common stock.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon completion of this Offering, the Convertible
Notes will automatically convert into units, comparable to those issued in this Offering, at a conversion price equal to 50%
of the per share price in our initial public offering. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this Convertible Note offering, each purchaser of Convertible Notes entered into an investor rights and lock-up agreement
(the &ldquo;Investor Rights and Lock-up Agreement&rdquo;) pursuant to which the Company has agreed, upon conversion of the Convertible
Notes, to register the shares of common stock underlying the Convertible Notes and the Convertible Note holders have each agreed not
to sell their shares of common stock for a period of 180 days following completion of this offering.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are party to a registration rights agreement with the holders of Series A Convertible Preferred Stock pursuant to which
we are obligated to register the shares of common stock underlying the Series A Convertible Preferred Stock and Warrants. The registration
of these shares of common stock would enable the holders to sell their shares without restriction under the Securities Act when the registration
statement is declared effective. We will pay for the registration expenses, other than underwriting discounts and commissions, of any
shares subject to registration rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Generally, in an underwritten offering, the managing
underwriter, if any, has the right, subject to specific conditions, to limit the number of shares such holders may include. As a result
of the underwriter objecting to the registration of the common stock underlying the Series A Convertible Preferred shares in this
offering, we will be required to file a resale registration statement registering the shares, with an obligation of having such registration
statement declared effective within 180 days of the initial filing of such resale registration statement.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anti-Takeover
Effects of Provisions of our Certificate of Incorporation, our Bylaws and Delaware Law</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
provisions of Delaware law, our certificate of incorporation and our bylaws contain provisions that could make the following transactions
more difficult: acquisition of us by means of a tender offer; acquisition of us by means of a proxy contest or otherwise; or removal
of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter
transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions that
might result in a premium over the market price for our shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are
also designed to encourage persons seeking to acquire control of us to first negotiate with our Board of Directors. We believe that the
benefits of increased protection of our potential ability to negotiate with the proponent of a non-friendly or unsolicited proposal to
acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result
in an improvement of their terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Delaware
Anti-Takeover Statute</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, Delaware corporations are subject to Section 203 of the DGCL, which prohibits a Delaware corporation from engaging in any business
combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder,
with the following exceptions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">before
    such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in
    the stockholder becoming an interested holder;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned
    at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining
    the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (i) by
    persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to
    determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting
    of the stockholders, and not by written consent, by the affirmative vote of at least 66<SUP>2</SUP>/<SUB>3</SUB>% of the outstanding
    voting stock that is not owned by the interested stockholder; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    corporation does not have a class of voting stock that is: (i) listed on a national securities exchange; or (ii) held of record by
    more than 2,000 stockholders, unless any of the foregoing results from action taken, directly or indirectly, by an interested stockholder
    or from a transaction in which a person becomes an interested stockholder</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, Section 203 defines business combination to include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    merger or consolidation involving the corporation and the interested stockholder;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    sale, transfer, pledge, or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
    to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation
    to the interested stockholder;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series
    of the corporation beneficially owned by the interested stockholder; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges or other financial benefits by or
    through the corporation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
203 defines interested stockholder as an entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation
or any entity or person affiliated with or controlling or controlled by such entity or person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we are currently not subject to the restrictions contained in Section 203, we will become subject to these restrictions if our common
stock is listed on a national securities exchange or we have more than 2,000 stockholders of record of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nasdaq
Listing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have applied to list our shares of common
stock on The Nasdaq Capital Market <FONT STYLE="letter-spacing: 0.15pt">(&ldquo;Nasdaq&rdquo;) under the symbol &ldquo;SHPH&rdquo;.
</FONT> There can be no assurance that our application for listing will be approved. <FONT STYLE="letter-spacing: 0.15pt">We do
not intend to apply for listing of the warrants included in the Units on Nasdaq or on any other national securities exchange or trading
system. Without an active trading market, the liquidity of the warrants will be limited.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
Agent</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">transfer agent and registrar of our common stock
is VStock Transfer, LLC, of Woodmere, New York. Our transfer agent&rsquo;s telephone number is (212) 828-8436.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="pri_006"></A>SHARES
ELIGIBLE FOR FUTURE SALE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to this offering, there has been no public market for our common stock, and we cannot assure you that a liquid trading market for our
common stock will develop or be sustained after this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
90 days after the date of this prospectus, subject to lock-up agreements of 365 days for directors, officer and affiliates and 180
days for holders of 1% or more of our comment stock (excluding the non-affiliate stockholders whose shares are being registered
in the resale offering), the 9,312,991 shares of our common stock outstanding as of the date of this prospectus will be eligible
for sale in the public market from time to time thereafter pursuant to Rule 144 under the Securities Act, and in some cases, subject
to the volume and other restrictions of Rule 144. In addition, we have 1,212.5 share of Series A convertible preferred common stock,
which shares will be convertible into approximately 269,444 shares of common stock upon the earlier of completion of the offering or
the Company&rsquo;s listing on a national securities exchange, as well as warrants to purchase up to 269,444 shares of common stock,
which will be issuable upon closing of this offering. We also have 3,000,000 shares of common stock reserved for issuance under our
2018 Equity Incentive Plan, of which 384,167 shares have been granted to date. The sale of a significant number of shares of our
common stock in the public market or the perception that such sales may occur could significantly reduce the market price of our
common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule
144</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, under Rule 144 under the Securities Act, beginning 90 days after the effective date of the registration statement of
which this prospectus is a part, a person (or persons whose shares are aggregated) who is not deemed to have been an affiliate of ours
at any time during the three months preceding a sale, and who has beneficially owned restricted securities within the meaning of Rule
144 for at least six  months (including any period of consecutive ownership of preceding non-affiliated holders) would be entitled
to sell those shares, subject only to the availability of current public information about us. A non-affiliated person who has beneficially
owned restricted securities within the meaning of Rule 144 for at least one year would be entitled to sell those shares without regard
to the provisions of Rule 144.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
person (or persons whose shares are aggregated) who is deemed to be an affiliate of ours and who has beneficially owned restricted securities
within the meaning of Rule 144 for at least six  months would be entitled to sell within any three-month period a number of shares
that does not exceed the greater of one percent of the then outstanding shares of our common stock or the average weekly trading volume
of our common stock reported through Nasdaq or such other market on which our shares of common stock are listed for trading during the
four calendar weeks preceding such sale. Such sales are also subject to certain manner of sale provisions, notice requirements and the
availability of current public information about us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2018
Equity Incentive Plan Form S-8 Registration Statement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to file with the SEC a registration statement on Form S-8 under the Securities Act covering the shares of common stock that we
may issue upon exercise of awards which may be granted under our 2018 Equity Incentive Plan. Such registration statement is expected
to be filed and become effective as soon as practicable after the effectiveness of this registration statement. Accordingly, shares registered
under such registration statement will be available for sale in the open market following its effective date, subject to Rule 144 volume
and manner of sale limitations, if applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Selling Stockholder Resale Prospectus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;As described in the Explanatory Note to
the registration statement of which this prospectus forms a part, the registration statement also contains the Resale Prospectus to be
used in connection with the potential resale by certain selling stockholders of our common stock. These shares of common stock have been
registered to permit public resale of such shares, and the selling stockholders may offer the shares for resale from time to time pursuant
to the Resale Prospectus. The selling stockholders may also sell, transfer or otherwise dispose of all or a portion of their shares in
transactions exempt from the registration requirements of the Securities Act or pursuant to another effective registration statement
covering those shares. Any shares sold by the selling stockholders until our common stock is listed or quoted on an established public
trading market will take place at $4.00 per share, which is the low end of the public offering price range of the shares of common stock
we are selling in our initial public offering. Thereafter, any sales will occur at prevailing market prices or in privately negotiated
prices.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="poa_002"></A>UNDERWRITING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with this offering, we will enter into
an underwriting agreement with Boustead Securities, LLC to serve as lead book-running manager of the offering and as representative of
the several underwriters (if any) named below. Subject to the terms and conditions of the underwriting agreement, each underwriter will
severally agree to purchase from us the number of shares of common stock set forth opposite its name below, at the public offering price,
less the underwriting discount set forth on the cover page of this prospectus.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><B>Underwriters</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of Units </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boustead
    Securities, LLC</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,660,000</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,660,000</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> *Each unit consists of one share of common stock
and one warrant to purchase one share of common stock, exercisable at $0.01 per share. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subject to the terms and conditions set forth in
the underwriting agreement, the underwriter has agreed to purchase the 1,660,000 units offered by this prospectus (other
than those covered by the over-allotment option described below, if any are purchased).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriter is offering the shares of common stock subject to various conditions and may reject all or part of any order. The underwriter
has advised us that the underwriter proposes initially to offer the shares of common stock to the public at the public offering price
set forth on the cover page of this prospectus and to dealers at a price less a concession not in excess of $0.42 per share of
common stock to brokers and dealers. After the shares of common stock are released for sale to the public, the underwriter may change
the offering price, the concession and other selling terms at various times.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below provides information regarding the amount of the discounts and commissions to be paid to the underwriters by us, before
estimated expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Over-Allotment
Option</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have granted the underwriter an over-allotment
option. This option, which is exercisable for up to 45 days after the date of this prospectus, permits the underwriter to purchase a
maximum of 249,000 additional units from us to cover over-allotments. If the underwriter exercises all or part of this
option, it will purchase shares covered by the option at the initial public offering price that appears on the cover page of this prospectus,
less the underwriting discount. If this option is exercised in full, the total proceeds to us will be $11,454,000 before deduction
of underwriting discounts and estimated offering expenses. The underwriters have agreed that, to the extent the over-allotment option
is exercised, they will purchase a number of additional shares proportionate to the underwriter&rsquo;s initial amount reflected in the
foregoing table.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underwriting
Discount</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> The following table summarizes the compensation
and estimated expenses we will pay. The information assumes either no exercise or full exercise by the underwriter of the over-allotment
option. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"> Per Share </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"> &nbsp; </TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"> Total </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Without<BR>
                                            Over-allotment</B></FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; text-align: center"> &nbsp; </TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"> <FONT STYLE="font-size: 10pt"><B>With<BR>
                                            Over-allotment</B></FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; text-align: center"> &nbsp; </TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Without<BR>
                                            Over-allotment</B></FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; text-align: center"> &nbsp; </TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"> <FONT STYLE="font-size: 10pt"><B>With<BR>
                                            Over-allotment</B></FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font-size: 10pt; text-align: left"> Underwriting discount payable by us </TD><TD STYLE="width: 2%; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"> $ </TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right"> 0.42 </TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"> $ </TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right"> 0.42 </TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"> $ </TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right"> 697,000 </TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"> $ </TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right"> 801,780 </TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"> Non-accountable and accountable expenses payable by us </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> $ </TD><TD STYLE="font-size: 10pt; text-align: right"> 0.06 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> $ </TD><TD STYLE="font-size: 10pt; text-align: right"> 0.06 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> $ </TD><TD STYLE="font-size: 10pt; text-align: right"> 99,600 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> $ </TD><TD STYLE="font-size: 10pt; text-align: right"> 114,500 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have agreed to pay a non-accountable expense
allowance to the underwriter equal to 1.0% of the gross proceeds (including proceeds subject to the over-allotment option, if and to
the extent it is exercised) for expenses in connection with this offering. We have also agreed to pay the underwriter an accountable
expense reimbursement of up to $255,000 for out-of-pocket expenses incurred by it with respect to this offering. We estimate that our
total expenses of the offering, excluding the underwriting discounts and commissions, will be approximately $499,936. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have also agreed to issue to the underwriter
a warrant to purchase a number of shares of common stock equal to an aggregate of 7% of the aggregate number of the units
sold in this offering. The warrant will be exercisable on a cashless basis at an exercise price equal to 140% of the offering
price of the shares sold in this offering. The warrants are exercisable commencing six months after the date of effectiveness of the
registration statement of which this prospectus forms a part, and will be exercisable for a period of five years from the effective
date of the registration statement of which this prospectus forms a part. We have agreed to a one-time demand registration of the
shares of common stock underlying the underwriter&rsquo;s warrants for a period of five years from the effective date of the
registration statement. The underwriter&rsquo;s warrants also provide for immediate &ldquo;piggyback&rdquo; registration rights with
respect to the underlying shares of common stock during the three-year period commencing from the effective date of the registration
statement related to this offering. The warrants are not redeemable by us. The warrants and the shares of common stock issuable
upon exercise of the warrants have been included on the registration statement of which this prospectus forms a part. Pursuant to
applicable FINRA rules, and in particular Rule 5110, the warrants (and underlying shares) issued to the underwriter may not be sold,
transferred, assigned, pledged, or hypothecated, or the subject of any hedging, short sale, derivative, put or call transaction that
would result in the effective disposition of the securities by any person for a period of 180 days after the effective date of the
registration statement related to this offering; provided, however, the warrants (and underlying shares) may be transferred to the
underwriter&rsquo;s officers, partners, registered persons or affiliates as long as the warrants (and underlying shares) remain
subject to the lock-up.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
 have agreed to indemnify the underwriter against certain liabilities, including liabilities under
the Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the underwriting agreement, we will provide the underwriter the right of first refusal for two years from the date of commencement
of sales of this offering to act as financial advisor or to act as joint financial advisor on at least equal economic terms on any public
or private financing (debt or equity), merger, business combination, recapitalization or sale of some or all of the equity or assets
of our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have agreed to a six-month &ldquo;lock-up&rdquo;
from the closing of this offering, during which, without the prior written consent of the underwriter, we will not issue,
sell or register with the SEC (other than on Form S-8 or on any successor form) with respect to any of our equity securities (or any
securities convertible into, exercisable for or exchangeable for any of our equity securities), except for (i) the issuance of the shares
of common stock offered pursuant to this prospectus; and (ii) the issuance of shares of common stock pursuant to our existing stock option
or bonus plan as described in the registration statement of which this prospectus forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our executive officers, directors and certain of
our significant stockholders have also agreed to a 12-month &ldquo;lock-up&rdquo; period, and any stockholders who own in excess
of 1% of the outstanding shares of our common stock will be subject to a six-month lock-up period, during which time, without
the prior written consent of the underwriter, they will not, directly or indirectly, (i) offer, pledge, assign, encumber,
announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell,
grant any option, right or warrant to purchase, or otherwise transfer or dispose of, any shares of common stock or any securities convertible
into or exercisable or exchangeable for common stock, owned either of record or beneficially (as defined in the Securities Exchange Act
of 1934, as amended (the &ldquo;Exchange Act&rdquo;) by any signatory of the lock-up agreement on the date of the prospectus or thereafter
acquired; (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership
of the common stock or any securities convertible into or exercisable or exchangeable for common stock, whether any such transaction
described in clauses (i) or (ii) above is to be settled by delivery of common stock or such other securities, in cash or otherwise, or
publicly announce an intention to do any of the foregoing; and (iii) make any demand for or exercise any right with respect to, the registration
of any shares of common stock or any security convertible into or exercisable or exchangeable for common stock. The foregoing will
not apply to (i) common stock to be transferred as a gift or gifts (<I>provided</I>, that (a) any donee will execute and deliver
to the underwriter, not later than one business day prior to such transfer, a lock-up agreement to the underwriter and (b) if
the lock-up signatory is required to file a report under Section 16(a) of the Exchange Act, reporting a reduction in beneficial ownership
of shares of common stock or beneficially owned shares or any securities convertible into or exercisable or exchangeable for common stock
or beneficially owned shares during the six-month &ldquo;lock-up,&rdquo; the lock-up signatory will include a statement in such
report to the effect that such transfer is being made as a gift), and (ii) the sale of the shares of common stock to be sold pursuant
to this prospectus<I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rules
of the SEC may limit the ability of the underwriter to bid for or purchase shares before the distribution of the shares is completed.
However, the underwriter may engage in the following activities in accordance with the rules:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stabilizing
    transactions &mdash; The representative may make bids or purchases for the purpose of pegging, fixing or maintaining the price of
    the shares, so long as stabilizing bids do not exceed a specified maximum.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over-allotments
    and syndicate covering transactions &mdash; The underwriter may sell more shares of common stock in connection with this offering
    than the number of shares that they have committed to purchase. This over-allotment creates a short position for the underwriter.
    This short sales position may involve either &ldquo;covered&rdquo; short sales or &ldquo;naked&rdquo; short sales. Covered short
    sales are short sales made in an amount not greater than the underwriter&rsquo;s over-allotment option to purchase additional
    shares in this offering described above. The underwriters may close out any covered short position either by exercising their over-allotment
    option or by purchasing shares in the open market. To determine how they will close the covered short position, the underwriter will
    consider, among other things, the price of shares available for purchase in the open market, as compared to the price at which they
    may purchase shares through the over-allotment option. Naked short sales are short sales in excess of the over-allotment option.
    The underwriter must close out any naked short position by purchasing shares in the open market. A naked short position is more likely
    to be created if the underwriter is concerned that, in the open market after pricing, there may be downward pressure on the
    price of the shares that could adversely affect investors who purchase shares in this offering.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Penalty
    bids &mdash; If the representative purchases the shares in the open market in a stabilizing transaction or syndicate covering transaction,
    it may reclaim a selling concession from the underwriter and selling group members who sold those shares as part of this offering.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Passive
    market making &mdash; Market makers in the shares who are underwriters or prospective underwriters may make bids for or purchase
    the shares, subject to limitations, until the time, if ever, at which a stabilizing bid is made.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similar
to other purchase transactions, the underwriter&rsquo;s purchases to cover the syndicate short sales or to stabilize the market
price of our common stock may have the effect of raising or maintaining the market price of our common stock or preventing or mitigating
a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might
otherwise exist in the open market. The imposition of a penalty bid might also have an effect on the price of the common stock if it
discourages resales of our shares of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
we nor the underwriters make any representation or prediction as to the effect that the transactions described above may have on the
price of our common stock. These transactions may occur on the Nasdaq Capital Market or otherwise. If such transactions are commenced,
they may be discontinued without notice at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2021, we completed a $500,000 unit offering private placement offering to two investors, which units consisted of a total of
$500,000 of 10% promissory notes and warrants to purchase 500,000 shares of common stock, exercisable at a purchase price of $1.00 per
share, which private placement was completed pursuant to an exemption from registration under Rule 506(b) of the Securities Act. Boustead
acted as placement agent in the private placement, however, Boustead agreed to waive its placement agent fees and expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February and March 2022, we completed a $365,000
and a $225,000 convertible note offering, respectively, to certain accredited investors, which notes are convertible into shares of units,
consisting of one share of common stock and a warrant to purchase one share of common stock, (the &ldquo;Conversion Units&rdquo;)
at a conversion price of $3.00 per unit upon effectiveness of this offering. The convertible note offering was completed
pursuant to an exemption from registration under Rule 506(b) of the Securities Act. Boustead acted as placement agent in each of the
February and March 2022 private placements and received $36,500 and $22,250 cash compensation, respectively, and five-year warrants to
purchase shares of common stock equal to 10% of the number of Conversion Shares, which warrants will be exercisable at the conversion
price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> In August 2022, we completed a $125,000 unit offering
private placement offering to two investors, which units consisted of a total of $125,000 of 10% promissory notes and warrants to purchase
50,000 shares of common stock, exercisable at a purchase price of $2.50 per share, which private placement was completed pursuant to
an exemption from registration under Rule 506(b) of the Securities Act. Boustead acted as placement agent in the private placement and
received a placement agent warrant to purchase 5,000 shares of our common stock, exercisable at $2.50 per share, however, Boustead agreed to waive its cash fees and
expenses related to the private placement. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> The warrants received in connection with the
February, March 2022 and August 2022 private placements (the &ldquo;Private Placement Warrants&rdquo;) will not be exercisable or convertible
more than five years from the commencement of this public offering. Pursuant to applicable FINRA rules and, in particular, Rule 5110(e)(1),
the Private Placement Warrants may not be sold, transferred, assigned, pledged or hypothecated, or be the subject of any hedging, short
sale, derivative, put or call transaction that would result in the effective economic disposition of the securities for a period of 180
days beginning on the date of commencement of sales of this public offering; provided, however, the Private Placement Warrants may be
transferred to the underwriter&rsquo;s officers, partners, registered persons or affiliates as long as the warrants remain subject to
the lock-up restriction <FONT STYLE="letter-spacing: -0.1pt">above.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.1pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A prospectus in electronic format may be delivered
to potential investors by one or more of the underwriters participating in this offering. The prospectus in electronic format will be
identical to the paper version of such preliminary prospectus. Other than the prospectus in electronic format, the information on any
underwriter&rsquo;s website and any information contained in any other website maintained by an underwriter is not part of the prospectus
or the registration statement of which this prospectus forms a part.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
Agent and Registrar</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for shares of our common stock and preferred stock is VStock Transfer, LLC, Woodmere, New York. Our transfer
agent&rsquo;s telephone number is (212) 828-8436.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notice
to Non-US Investors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Canada</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal who are &ldquo;accredited
investors,&rdquo; as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario),
and are &ldquo;permitted clients&rdquo;, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant
Obligations. Any resale of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the
prospectus requirements of applicable securities laws. Securities legislation in certain provinces or territories of Canada may provide
a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation,
provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities
legislation of the purchaser&rsquo;s province or territory. The purchaser should refer to any applicable provisions of the securities
legislation of the purchaser&rsquo;s province or territory for particulars of these rights or consult with a legal advisor. Pursuant
to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the
disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>European
Economic Area</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
relation to each Member State of the European Economic Area which has implemented the Prospectus Directive, each, a Relevant Member State,
with effect from and including the date on which the European Union Prospectus Directive, or the EU Prospectus Directive, was implemented
in that Relevant Member State, or the Relevant Implementation Date, no offer of securities may be made to the public in that Relevant
Member State other than:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    any legal entity which is a qualified investor as defined under the EU Prospectus Directive;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    fewer than 150 natural or legal persons (other than qualified investors as defined in the EU Prospectus Directive), subject to obtaining
    the prior consent of the representatives; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    any other circumstances falling within Article 3(2) of the EU Prospectus Directive;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided
that no such offer of securities shall require the Company or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus
Directive and each person who initially acquires any securities or to whom any offer is made will be deemed to have represented, acknowledged
and agreed to and with each of the underwriters and the Company that it is a &ldquo;qualified investor&rdquo; within the meaning of the
law in that Relevant Member State implementing Article 2(1)(e) of the Prospectus Directive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the case of any securities being offered to a financial intermediary as that term is used in Article 3(2) of the Prospectus Directive,
each such financial intermediary will be deemed to have represented, acknowledged and agreed that the securities acquired by it in the
offer have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale
to, persons in circumstances which may give rise to an offer of any securities to the public other than their offer or resale in a Relevant
Member State to qualified investors as so defined or in circumstances in which the prior consent of the representatives has been obtained
to each such proposed offer or resale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purposes of this provision, the expression an &ldquo;offer of securities to the public&rdquo; in relation to any securities in any
Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the
securities to be offered so as to enable an investor to decide to purchase or subscribe for the securities, as the same may be varied
in that Member State by any measure implementing the EU Prospectus Directive in that Member State. The expression &ldquo;EU Prospectus
Directive&rdquo; means Directive 2003/71/EC (and any amendments thereto, including the 2010 PD Amending Directive, to the extent implemented
in the Relevant Member State) and includes any relevant implementing measure in each Relevant Member State, and the expression &ldquo;2010
PD Amending Directive&rdquo; means Directive 2010/73/EU.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>United
Kingdom</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may only be
directed at persons who are &ldquo;qualified investors&rdquo; (as defined in the Prospectus Directive) (i) who have professional experience
in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion)
Order 2005, as amended, or the Order, and/or (ii) who are high net worth companies (or persons to whom it may otherwise be lawfully communicated)
falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as &ldquo;relevant persons&rdquo;) or
otherwise in circumstances which have not resulted and will not result in an offer to the public of the securities in the United Kingdom.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
person in the United Kingdom who is not a relevant person should not act or rely on the information included in this document
or use it as basis for taking any action. In the United Kingdom, any investment or investment activity that this document relates to
may be made or taken exclusively by relevant persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="pri_007"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the common stock being offered hereby has been passed upon by Michelman &amp; Robinson, LLP, California and New York. The underwriter has been represented
in connection with this offering by Olshan Frome Wolosky LLP, New York, New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="pri_008"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of Shuttle Pharmaceuticals Holdings, Inc. appearing in this prospectus and related registration statement
for the years ended December 31, 2021 and 2020 have been audited by BF Borgers CPA PC, an independent registered
public accounting firm, as set forth in their report thereon and are included in reliance upon such report given on the authority of
BF Borgers CPA PC as experts in accounting and auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="pri_009"></A>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed a registration statement on Form S-1 under the Securities Act with the SEC with respect to the shares of our common stock
offered through this prospectus. This prospectus is filed as a part of that registration statement, but does not contain all of the information
contained in the registration statement and exhibits. Statements made in the registration statement are summaries of the material terms
of the referenced contracts, agreements or documents of the company. We refer you to our registration statement and each exhibit attached
to it for a more detailed description of matters involving the company. You may inspect the registration statement, exhibits and schedules
filed with the SEC at the SEC&rsquo;s principal office in Washington, D.C. Copies of all or any part of the registration statement may
be obtained from the Public Reference Section of the SEC, 100 F Street, N.E. Washington, D.C. 20549. Please Call the Commission at 1-800-SEC-0330
for further information on the operation of the public reference rooms. The SEC also maintains a web site at http://www.sec.gov that
contains reports, proxy Statements and information regarding registrants that files electronically with the SEC. Our registration statement
and the referenced exhibits can also be found on this site.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="pri_010"></A>DISCLOSURE
OF SEC POSITION ON INDEMNIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR SECURITIES ACT LIABILITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the provisions in our Certificate
of Incorporation, as amended, we will indemnify an officer, director, or former officer or director, to the full extent permitted
by law.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons
pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against
public policy as expressed in the Securities Act and is, therefore, unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="pri_011"></A>SHUTTLE
PHARMACEUTICALS HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 0.5in; text-align: center"><FONT STYLE="font-size: 10pt">Page</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#fina_001">Condensed Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021 (unaudited)</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">F-2 </FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#fina_002">Consolidated Statements of Operations for the three and six months ended June 30, 2022 and 2021 (unaudited)</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">F-3 </FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#fina_003">Condensed consolidated Statements of Changes in Stockholders&rsquo; Deficit for the three and six months ended June 30, 2022 and 2021 (unaudited)</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">F-4</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#fina_005">Condensed Consolidated Statements of Cash Flows
    for the three and six months ended June 30, 2022 and 2021 (unaudited)</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">F-6</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#fina_006">Notes to Consolidated Financial Statements (unaudited)</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">F-7</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#vba_001">Report of Independent Registered Public Accounting Firm</A> (PCAOB ID: 5081)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-16    </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#vba_002">Consolidated
    Balance Sheets as of December 31 2021, and 2020</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-17
    </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#vba_003">Consolidated
    Statements of Operations for the Years Ended December 31, 2021 and 2020</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-18
    </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#vba_004">Consolidated
    Statements of Changes in Stockholders&rsquo; Deficit for the Years Ended December 31, 2021 and 2020</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-19</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#vba_005">Consolidated
    Statements of Cash Flows for the Years Ended December 31, 2021 and 2020</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-20</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#vba_006">Notes
    to Consolidated Financial Statements</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-21</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 104; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shuttle
Pharmaceuticals Holdings, Inc.</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="fina_001"></A>Condensed
Consolidated Balance Sheets</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Unaudited)</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold"> June 30, </TD><TD STYLE="font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold"> December 31, </TD><TD STYLE="font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> 2022 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> 2021 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; font-weight: bold"> Assets </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Current assets </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; width: 60%"> Cash </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 16%; text-align: right"> 50,437 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 16%; text-align: right"> 504,749 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; padding-bottom: 1.5pt; text-align: left"> Prepaid expenses </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 13,515 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 4,866 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Total current assets </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 63,952 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 509,615 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"> Property and equipment, net </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 15,665 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 18,564 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"> Other assets </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 6,480 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 6,480 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"> Operating lease right-of-use asset </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 87,383 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 116,982 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> Total Assets </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 173,480 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 651,641 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center"> Liabilities and Stockholders&rsquo; Deficit </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Current Liabilities </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"> Accounts payable and accrued expenses </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 515,786 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 828,313 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"> Accrued interest payable </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 37,828 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 552 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"> Accrued interest payable - related parties </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 72,330 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 46,947 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"> Dividends Payable </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 382,595 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 331,059 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"> Notes payable to related parties </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 685,473 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 685,473 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"> Notes payable </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 575,624 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 91,021 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"> Paycheck Protection Program note payable </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 73,007 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"> Derivative liability </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 112,797 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 94,025 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"> Operating lease liability current portion </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 71,518 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 66,934 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0pt; text-align: left"> Total Current Liabilities </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,453,951 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,217,331 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"> Operating lease liability non-current </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 25,602 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 62,442 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"> Total Liabilities </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 2,479,553 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 2,279,773 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Stockholders&rsquo; Deficit </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"> Series A convertible preferred stock, $0.00001 par value; $1,000 per share liquidation
    value or aggregate of $1,212,500; 20,000,000 shares authorized; 1,213 shares issued and outstanding at June 30, 2022 and December
    31, 2021 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"> Common stock, $0.00001 par value; 100,000,000 shares authorized; 9,312,991 and
    9,312,152 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 93 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 93 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Additional paid in capital </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 4,819,916 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 4,150,867 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Common stock to be issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 16,340 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"> Accumulated deficit </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (7,126,082 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (5,795,432 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"> Total Stockholders&rsquo; Deficit </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (2,306,073 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (1,628,132 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> Total Liabilities and Stockholders&rsquo; Deficit </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 173,480 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 651,641 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shuttle
Pharmaceuticals Holdings, Inc.</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="fina_002"></A>Condensed
Consolidated Statements of Operations</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Unaudited)</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center"> Three Months Ended </TD><TD STYLE="font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center"> Six Months Ended </TD><TD STYLE="font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> June 30, </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> June 30, </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2022 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2021 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2022 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2021 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"> Revenue </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"> Operating expenses </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 40%; text-align: left"> Research and development, net of contract expense reimbursements </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 11%; text-align: right"> 83,868 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 11%; text-align: right"> 286,730 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 11%; text-align: right"> 379,783 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 11%; text-align: right"> 392,726 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"> General and administrative </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 9,078 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 7,213 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 22,847 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 13,461 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"> Legal and professional </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 260,680 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 42,308 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 589,392 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 106,150 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt"> Total operating expenses </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 353,626 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 336,251 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 992,022 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 512,337 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Net loss from operations </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (353,626 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (336,251 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (992,022 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (512,337 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"> Other income (expense) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"> Interest expense - related parties </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (14,836 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (10,547 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (25,383 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (21,094 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"> Interest expense </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (170,391 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (120 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (315,944 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (350 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"> Change in fair value of derivative liability </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (58,422 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 117 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (18,772 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 57,656 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"> Gain on forgiveness of Paycheck Protection Program note
    payable </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 73,007 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt"> Total other income (expense) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (243,649 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (10,550 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (287,092 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 36,212 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"> Income (loss) before income taxes </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (597,275 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (346,801 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (1,279,114 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (476,125 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"> Provision for income taxes </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt"> Net income (loss) </TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"> (597,275 </TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> ) </TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"> (346,801 </TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> ) </TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"> (1,279,114 </TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> ) </TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"> (476,125 </TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"> Dividend on Series A Preferred Stock </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (25,768 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (25,768 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (51,536 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (51,536 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt"> Net loss attributable to common stockholders </TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"> (623,043 </TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> ) </TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"> (372,569 </TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> ) </TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"> (1,330,650 </TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> ) </TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"> (527,661 </TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"> Weighted average common shares outstanding - basic and diluted </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 9,312,991 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 9,291,526 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 9,312,583 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 9,291,526 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"> Net loss per shares - basic and diluted </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (0.06 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (0.04 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (0.14 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (0.05 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shuttle
Pharmaceuticals Holdings, Inc.</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="fina_003"></A><B>Condensed
Consolidated Statements of Changes in Stockholders&rsquo; Deficit</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Unaudited)</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"> Series
                                            A </P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"> Preferred
                                            Stock </P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Common Stock </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"> Additional </P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"> Paid in </P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"> Common </P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"> Stock </P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"> to be </P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"> Accumulated </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"> Total </P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"> Stockholders&rsquo; </P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Shares </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Amount </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Shares </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Amount </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Capital </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Issued </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Deficit </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Deficit </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%; font-weight: bold"> Balance - December 31, 2021 </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 5%; text-align: right"> 1,213 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 5%; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 5%; text-align: right"> 9,312,152 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 5%; text-align: right"> &nbsp;&nbsp;&nbsp;93 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 5%; text-align: right"> &nbsp;&nbsp;4,150,867 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 5%; text-align: right"> 16,340 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 5%; text-align: right"> (5,795,432 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 5%; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;(1,628,132 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"> Warrants issued for financing costs </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 319,643 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 319,643 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"> Common stock issued for conversion of convertible debt and accrued interest </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 839 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 16,340 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (16,340 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"> Common stock issued for restricted stock units </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 166,533 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 166,533 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"> Dividends on Series A preferred stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (25,768 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (25,768 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"> Net loss (Unaudited) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (681,839 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (681,839 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold"> Balance - March 31, 2022 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,213 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 9,312,991 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 93 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 4,653,383 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> (6,503,039 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> (1,849,563 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"> Warrants issued for financing costs </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"> Common stock issued for restricted stock units </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 166,533 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 166,533 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"> Dividends on Series A preferred stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (25,768 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (25,768 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"> Net loss (Unaudited) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (597,275 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (597,275 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt"> Balance - June 30, 2022 (Unaudited) </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 1,213 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> - </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 9,312,991 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 93 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 4,819,916 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> - </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (7,126,082 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (2,306,073 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shuttle
Pharmaceuticals Holdings, Inc.</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <A NAME="fina_004"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Statements of Changes in Stockholders&rsquo; Deficit</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Unaudited)</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"> Series
                                            A </P>
                                                                                                    <P STYLE="margin-top: 0; margin-bottom: 0"> Convertible </P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"> Preferred
                                            Stock </P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Common Stock </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"> Additional </P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"> Paid-in </P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"> Common </P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"> Stock </P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"> to be </P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"> Accumulated </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"> Total </P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"> Stockholders&rsquo; </P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Shares </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Amount </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Shares </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Amount </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Capital </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Issued </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Deficit </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Deficit </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%; font-weight: bold"> Balance, December 31, 2020 </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 5%; text-align: right"> 1,213 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 5%; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 5%; text-align: right"> 9,291,526 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 5%; text-align: right"> &nbsp;&nbsp;&nbsp;93 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 5%; text-align: right"> &nbsp;&nbsp;2,833,507 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 5%; text-align: right"> 16,340 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 5%; text-align: right"> (4,540,236 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 5%; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1,690,296 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Warrants issued for financing costs </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Common stock issued for restricted stock units </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 122,517 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 122,517 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Dividends on Series A preferred stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (25,768 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (25,768 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Net loss </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (129,324 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (129,324 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"> Balance, March 31, 2021 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,213 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 9,291,526 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 93 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2,956,024 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 16,340 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> (4,695,328 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> (1,722,871 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Warrants issued for financing costs </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Common stock issued for restricted stock units </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 7,738 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 122,517 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 122,517 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Dividends on Series A preferred stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (25,768 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (25,768 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Net loss </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (346,801 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (346,801 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt"> Balance, June 30, 2021 </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 1,213 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> - </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 9,299,264 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 93 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 3,078,541 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 16,340 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (5,067,897 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (1,972,923 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shuttle
Pharmaceuticals Holdings, Inc.</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="fina_005"></A>Consolidated
Statements of Cash Flows</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Unaudited)</B></FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="text-align: center; font-weight: bold"> Six Months Ended </TD><TD STYLE="font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> June 30, </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> 2022 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> 2021 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"> CASH FLOWS FROM OPERATING ACTIVITIES: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 60%; text-align: left"> Net income (loss) </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 16%; text-align: right"> (1,279,114 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 16%; text-align: right"> (476,125 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left"> Adjustments to reconcile net income (loss) to net cash used in operating activities: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt"> Depreciation </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,899 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,700 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left"> Change in fair value of derivative liability </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 18,772 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (57,656 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left"> Amortization of right-of-use asset </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 29,599 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 26,582 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left"> Amortization of debt discount </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 278,531 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left"> Gain on forgiveness of Paycheck Protection Program note payable </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (73,007 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left"> Stock-based compensation </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 333,066 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 245,034 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left"> Changes in operating assets and liabilities: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 30pt; text-align: left"> Contracts receivable </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 211,455 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 30pt; text-align: left"> Prepaid expenses </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (8,649 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 7,450 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 30pt; text-align: left"> Accounts payable and accrued expenses </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (312,527 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (100,241 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 30pt; text-align: left"> Accrued interest payable </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 37,276 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 210 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 30pt; text-align: left"> Accrued interest payable - related parties </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 25,383 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 21,094 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 30pt; text-align: left"> Operating lease liability </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (32,256 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (28,144 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"> Net Cash used in Operating Activities </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (980,027 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (147,641 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"> CASH FLOWS FROM INVESTING ACTIVITIES: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left"> Purchase of property and equipment </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"> Net Cash used in Investing Activities </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"> CASH FLOWS FROM FINANCING ACTIVITIES: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left"> Proceeds from PPP note payable </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 73,007 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left"> Proceeds from notes payable </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 525,715 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"> Net Cash provided by Financing Activities </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 525,715 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 73,007 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Net change in cash </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (454,312 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (74,634 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt"> Cash, beginning of period </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 504,749 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 117,153 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt"> Cash, end of period </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 50,437 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 42,519 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Cash paid for: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 10pt"> Interest </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> - </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> - </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"> Income taxes </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> - </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> - </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Supplemental non-cash financing activities: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"> Shares issued for conversion of accrued interest </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 16,340 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> - </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>


<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="fina_006"></A><B>Shuttle
Pharmaceuticals Holdings, Inc.</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Condensed Consolidated Financial Statements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
the Six Months Ended June 30, 2022 and 2021</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Unaudited)</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
1 &ndash; Organization and Going Concern</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Organization
and Line of Business</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was formed as Shuttle Pharmaceuticals, LLC, in the State of Maryland on December 18, 2012. On August 12, 2016, the Company filed
articles of conversion with the state of Maryland to convert from an LLC to a corporation and the Company changed its name to Shuttle
Pharmaceuticals, Inc. (&ldquo;Shuttle&rdquo;). In connection with the conversion the Company issued 45,000,000 shares of common stock
in exchange for 100% of the outstanding membership interests prior to conversion. On June 4, 2018, Shuttle completed a reverse merger
with Shuttle Pharmaceuticals Holdings, Inc. (then known as Shuttle Pharma Acquisition Corp.), a Delaware corporation (the &ldquo;Company&rdquo;),
pursuant to which Shuttle, our operating entity, became a wholly owned subsidiary of the Company.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s primary purpose is to develop and commercialize unique drugs for the sensitization of cancers and protection of normal
tissues, with the goal of improving outcomes for cancer patients receiving radiation therapy. Shuttle has deployed its proprietary technology
to develop novel cancer immunotherapies which has produced a pipeline of selective HDAC inhibitors for cancer and immunotherapy applications.
The Company&rsquo;s HDAC platform is designed to target candidate molecules with potential roles in therapeutics beyond cancer, including
autoimmune, inflammatory, metabolic, neurological and infectious diseases. The Company&rsquo;s Ropidoxuridine product, which is used
with radiation therapy to sensitize cancer cells, was funded by a Small Business Innovation Research (SBIR) contract provided by the
National Cancer Institute (NCI), a unit of the National Institutes of Health (NIH). Ropidoxuridine has been further developed though
the Company&rsquo;s collaborations with the University of Virginia for use in combination with proton therapy to improve patient survival.
The Company is working on developing products through NIH grants, including a product to predict late effects of radiation with metabolite
biomarkers and develop prostate cancer cell lines in health disparities research.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
production and marketing of the Company&rsquo;s products and its ongoing research and development activities will be subject to extensive
regulation by numerous governmental authorities in the United States. Prior to marketing in the United States, any combination product
developed by the Company must undergo rigorous preclinical (animal) and clinical (human) testing and an extensive regulatory approval
process implemented by the Food and Drug Administration (&ldquo;FDA&rdquo;) under the Food, Drug and Cosmetic Act. There can be no assurance
that the Company will not encounter problems in clinical trials that will cause the Company or the FDA to delay or suspend clinical trials.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s success will depend in part on its ability to obtain patents and product license rights, maintain trade secrets, and
operate without infringing on the proprietary rights of others, both in the United States and other countries. There can be no assurance
that patents issued to or licensed by the Company will not be challenged, invalidated or circumvented, or that the rights granted thereunder
will provide proprietary protection or competitive advantages to the Company now or in the future.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Reverse
Stock Split</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
April 1, 2022, we effected a 2-for-1 reverse stock split of our issued and outstanding common stock (the &ldquo;Reverse Stock Split&rdquo;).
All references to shares of our common stock in this report refers to the number of shares of common stock after giving effect to the
Reverse Stock Split (unless otherwise indicated).</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Going
Concern</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation
of the Company as a going concern. The Company&rsquo;s only revenue source since inception has been government awarded contracts totaling
$5,531,722, and the Company has incurred losses since inception, having accumulated a deficit of $7,126,082 as of June 30, 2022. The
Company currently has limited liquidity and has not completed its efforts to establish a stabilized source of revenues sufficient to
cover operating costs over an extended period. These factors, among others, raise substantial doubt about the Company&rsquo;s ability
to continue as a going concern.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will need to raise capital to fund its operations. To address its financing requirements, the Company intends to seek financing
through debt or equity financings with an aim to continue progress toward commercial viability of its products. The Company continues
to submit Federal grant and contract applications which have historically been the primary source of revenue. The financial statements
do not include any adjustments that might result from the outcome of the uncertainty of raising additional capital.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
2 &ndash; Summary of Significant Accounting Policies</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Basis
of Presentation</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange
Commission (&ldquo;SEC&rdquo;). The financial statements have been prepared using the accrual basis of accounting in accordance with
Generally Accepted Accounting Principles of the United States (&ldquo;GAAP&rdquo;).</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Basis
of Consolidation</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements have been prepared on a consolidated basis with those of the Company&rsquo;s wholly-owned subsidiary, Shuttle Pharmaceuticals,
Inc. All intercompany transactions and balances have been eliminated.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Use
of Estimates</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and
assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that
it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results
experienced by the Company may differ materially and adversely from the Company&rsquo;s estimates. To the extent there are material differences
between the estimates and the actual results, future results of operations will be affected. Significant estimates in the accompanying
financial statements include useful lives of property and equipment, valuation of derivatives, and the valuation allowance on deferred
tax assets.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Property
and Equipment</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and
betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation
are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided
using the straight-line method for substantially all assets with estimated lives as follows:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5
    years</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers
    and equipment</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5
    years</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    Equipment</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10
    years</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development Expenses</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to expense as incurred. Research and development expenses include, but are not limited to, product
development, clinical and regulatory expenses, payroll and other personnel expenses, materials, supplies, related subcontract expenses,
and consulting costs. The expenses assigned to NIH SBIR sponsored research are related to: (1) &ldquo;Topic 352: Cell-Based Models for
Prostate Cancer Health Disparity Research &ndash; Moonshot Project&rdquo; and (2) &ldquo;Topic 345: Predictive Biomarkers of Prostate
Cancer Patient Sensitivity for Radiation Late Effects.&rdquo;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
research expenses are assigned to the research projects to demonstrate proof of principle in patients with prostate cancer that may support
development and commercialization of biomarker products and to gather prostate cancer cell lines in African American men to serve as
the product for use in health disparities research. Costs that are not covered by the SBIR contract for performing the Phase I contract
to determine commercialization feasibility included partial salary support of personnel and a consultant to develop a commercialization
plan. Costs that are not covered in the Phase II contract include business development and partial salary support.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
expenses related to new drug discovery include partial support of personnel, space, supplies, and legal costs.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
fiscal year 2022, the Company completed two SBIR contracts from the NIH to support research projects with potential for commercialization.
The SBIR contract awards are fixed payments made by the NIH in response to quarterly Shuttle invoices and provide non-dilutive funds
that do not include a repayment obligation. Details on the three contracts follow:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
Contract #HHSN261201600027C/75N91018C00016 supported &ldquo;Topic 345: Predictive Biomarkers of Prostate Cancer Patient Sensitivity
for Radiation Late Effects.&rdquo; This $299,502 Phase I award includes funded research from 9/19/2016 through 9/18/2017 and was
advanced to Phase II of the awards with funding of $1,903,095 with a fixed price contract period of 9/17/2018 through 9/16/2020 and
subsequent no cost extensions through 9/15/2021 and then 3/15/2022 (Reference 75N91019C00031). The Company received quarterly
payments of $211,455 for a total of $845,820 in 2020; and 2 quarterly payments related to Topic 345 for a total of $422,910 in 2021.
On April 6, 2022, the Company submitted the final invoice for &ldquo;Topic 345: Predictive Biomarkers of Prostate Cancer Patient
Sensitivity for Radiation Late Effects,&rdquo; for $211,455, following the completion of the Final Quarterly Progress Report to NIH
covering the performance period of 9/16/2019-3/15/2022. The invoice was paid in full on April 27, 2022. In Phase II of the SBIR
effort, the Company will license the metabolite signatures (intellectual property) from Georgetown University, manufacture 500
&ldquo;kits,&rdquo; test and validate the metabolic kit performance and develop a multi-institutional clinical trial to be
implemented in the Phase III effort. This contract includes a subcontract to Georgetown University (&ldquo;Georgetown&rdquo;) for
use of Mass Spectrometry core facilities to analyze clinical samples. The contract was extended to complete the milestones which
were delayed due to the impact of COVID-19.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 6, 2019, the Company engaged Georgetown to perform the $795,248 subcontract of its Phase II contract #HHSN75N91019C00031.
The Company agreed to reimburse Georgetown for its allowable costs not to exceed the ceiling amount of $795,248. Georgetown invoiced
the Company for a total of $791,017.12 as of June 30, 2022, leaving a balance of $4,230.88. Depending on the resources it uses,
Georgetown may or may not invoice for the total subcontract amount. In the event Georgetown does not invoice for the total allowable
amount, the Company is not obligated to pay the ceiling amount. As of April 2022, cumulative payments of $791,017.12
were made to Georgetown, including an additional invoice for $282,643 which was received but not paid until the second quarter of
2022. All invoices have now been paid.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
The Phase II contract #HHSN261201800016C supports the discovery work following a Phase I contract # HHSN261600038C &ldquo;Topic 352 &ndash;
SBIR Phase II Cell-based Models for Prostate Cancer Health Disparity Research&rdquo; and was awarded to provide $1,484,350 to fund research
from 9/17/2018 through 9/16/2020 and was extended without cost through 11/16/2021 due to delays caused by the impact of COVID-19. For
the entire contract period, the Company invoiced and received a total of $1,411,883. The final draft report was filed with the NIH along
with the final invoice for $10,000, which payment was made on December 3, 2021, and no additional payments are expected. The Phase II contract also includes a subcontract to Georgetown
University for $742,002 to establish prostate cancer cell lines from African American patients undergoing prostate surgery for cancers.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 5, 2018, the Company engaged Georgetown University to perform the $742,002 subcontract of its Phase II contract #HHSN261201800016C.
Depending on the resources it uses, Georgetown may or may not invoice for the total subcontract amount. In the event Georgetown does
not invoice for the total allowable amount, the Company is not obligated to pay the ceiling amount. The Company has been invoiced by
Georgetown and has paid Georgetown a total of $305,866.35 as of June 30, 2022.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the amounts received from the contract at fair value when there is reasonable assurance that the contract amount
will be received, and it is probable that all attaching conditions will be complied with. The Company recognizes the amounts
received in accordance with the contract as a reduction of research and development expenses over the periods necessary to match the
contract on a systematic basis to the costs that it is intended to compensate. The Company records reimbursements on the balance
sheet as contract receivables upon meeting the criteria discussed above until cash is received. During the quarter ended June 30,
2022, the Company recorded a net deficit of $83,868 with the Company funding the NIH no-cost extension along with other R&amp;D
activities. The NIH made the final payment of $211,455 in April 2022 for Topic 345.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regarding
the accounting treatment for reimbursements, GAAP provides limited guidance on the accounting for government grants received by for-profit
companies. We understand there is more than one acceptable alternative for the accounting treatment &ndash; a reduction of costs, a deferred
credit to be amortized, revenue, or other income. Due to the terms of the contracts, we have entered into the Company concluded that
the reimbursements were more akin to a reduction of costs rather than any of the other alternatives that would match the contract reimbursements
on a systematic basis to the costs that the contract is intended to compensate.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Derivative
Financial Instruments</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations.
For stock-based derivative financial instruments, the Company uses a Binomial Simulation model to value the derivative instruments at
inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should
be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified
in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required
within 12 months of the balance sheet date. As of June 30, 2022, the Company&rsquo;s only derivative financial instrument was an embedded
warrant feature associated with Series A Convertible Preferred Stock due to certain provisions that allow for a change in the warrant
value based on fluctuations of the Company&rsquo;s fair value of common stock at the date of issuance of the warrant based on certain
contingent call features.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Fair
Value of Financial Instruments</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
certain of the Company&rsquo;s financial instruments, including cash, accounts receivable, accounts payable, accrued liabilities and
short-term debt, the carrying amounts approximate their fair values due to their short maturities.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB
ASC Topic 820, <I>Fair Value Measurements and Disclosures</I>, requires disclosure of the fair value of financial instruments held by
the Company. FASB ASC Topic 825, <I>Financial Instruments</I>, defines fair value, and establishes a three-level valuation hierarchy
for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported
in the consolidated balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable
estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization
and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for
    identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly,
    for substantially the full term of the financial instrument.</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the fair value measurement.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, <I>Distinguishing Liabilities
from Equity</I>, and FASB ASC Topic 815, <I>Derivatives and Hedging</I>.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
certain financial instruments, the carrying amounts reported in the balance sheets for cash and current liabilities, including convertible
notes payable, each qualify as a financial instrument, and are a reasonable estimate of their fair values because of the short period
of time between the origination of such instruments and their expected realization and their current market rate of interest.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
established trading market for the Company&rsquo;s common stock does not exist. The fair value of the shares was determined based on
the then most recent price per share at which we sold preferred stock to unrelated parties in a private placement during the six months
then ended.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2020, the Company utilized $25.22 (post-share exchange) per share as the fair value of its common stock for
accounting purposes based on preferred share transactions with investors from August 2018 through December 2019, with no transactions
occurring in 2020 and $5.00 in 2021, $4.00 through March 31, 2022 and $6.00 through June 30, 2022.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2022, the Company identified the following liabilities that are required to be presented on the balance sheet at fair value:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold"> June 30, 2022 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> Level 1 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> Level 2 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> Level 3 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> Total </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"> Liabilities </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; text-align: left"> Derivative Liabilities </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 11%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 11%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 11%; text-align: right"> 112,797 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 11%; text-align: right"> 112,797 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2021, the Company identified the following liabilities that are required to be presented on the balance sheet at fair value:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold"> December 31, 2021 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> Level 1 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> Level 2 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> Level 3 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> Total </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"> Liabilities </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; text-align: left"> Derivative Liabilities </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 11%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 11%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 11%; text-align: right"> 94,025 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 11%; text-align: right"> 94,025 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Revenue
Recognition</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from providing research and development is recognized under <I>Topic 606</I> in a manner that reasonably reflects the delivery of its
services to customers in return for expected consideration and includes the following elements:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">executed
    contracts with the Company&rsquo;s customers that it believes are legally enforceable;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identification
    of performance obligations in the respective contract;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">determination
    of the transaction price for each performance obligation in the respective contract;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocation
    the transaction price to each performance obligation; and</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognition
    of revenue only when the Company satisfies each performance obligation.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
satisfy these five elements, the Company records revenue for research and development services on a quarterly basis as services are provided.
Revenue received from National Institutes of Health contracts is received in accordance with Federal grants and contracts policies. Research
and development expenses are posted against revenue and recorded on the statement of operations as &ldquo;Research and development, net
of contract expense reimbursements.&rdquo;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Basic
and Diluted Earnings Per Share</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings per share (&ldquo;EPS&rdquo;) is computed based on the weighted average number of shares of common stock outstanding during
the period. Diluted EPS is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential
common shares outstanding during the period using the treasury stock method and as if converted method. Dilutive potential common shares
include outstanding warrants and Series A preferred stock.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the six months ended June 30, 2022 and year ended December 31, 2021, the following common stock equivalents were excluded from the computation
of diluted net loss per share as the result of the computation was anti-dilutive.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> <B>&nbsp;</B> </TD><TD> <B>&nbsp;</B> </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> <B>June 30,</B> </TD><TD> <B>&nbsp;</B> </TD><TD> <B>&nbsp;</B> </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> <B>December 31,</B> </TD><TD> <B>&nbsp;</B> </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> 2022 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> 2021 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left"> Series A preferred stock </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 16%; text-align: right"> 97,062 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 16%; text-align: right"> 97,062 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt"> Warrants </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 48,531 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 48,531 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 145,593 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 145,593 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Recent
Accounting Pronouncements</I></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU 2020-06, ASC Subtopic 470-20 &ldquo;Debt&mdash;Debt with &ldquo;Conversion and Other Options&rdquo;
and ASC subtopic 815-40 &ldquo;Hedging&mdash;Contracts in Entity&rsquo;s Own Equity.&rdquo; The standard reduced the number of accounting
models for convertible debt instruments and convertible preferred stock. Convertible instruments that continue to be subject to separation
models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition
of a derivative, and that do not qualify for a scope exception from derivative accounting; and (2) convertible debt instruments issued
with substantial premiums for which the premiums are recorded as paid-in capital. The amendments in this update are effective for fiscal
years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company
adopted this standard on January 1, 2021.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying
financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
3 &ndash; Property and Equipment, Net</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consisted of the following:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> June 30, </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> December 31, </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> 2022 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> 2021 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left"> Office Furniture and equipment </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 16%; text-align: right"> 8,861 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 16%; text-align: right"> 8,861 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Laboratory equipment </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 118,605 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 118,605 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 127,466 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 127,466 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Less accumulated depreciation </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (111,801 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (108,902 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"> Property and equipment, net </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 15,665 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 18,564 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense for the six months ended June 30, 2022 and 2021, were $2,899 and $2,700 respectively.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
4 &ndash; Operating Lease Right-of-use Asset and Operating Lease Liability</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease right-of-use assets and liabilities are recognized at the present value of the future lease payments at the lease commencement
date. The interest rate used to determine the present value is our incremental borrowing rate, estimated to be 10%, as the interest rate
implicit in most of our leases is not readily determinable. Operating lease expense is recognized on a straight-line basis over the lease
term. During the six months ended June 30 2022, and 2021, the Company recorded $35,088 and $35,088, respectively, as operating lease
expense.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently has a lease agreement which allows for the use of a laboratory facility for a monthly payment of $6,107, which monthly
lease payment increases by 3% every year. The laboratory lease commenced October 1, 2018, with the first payment due January 1, 2019,
and expires on October 31, 2023. A security deposit of $6,480 is being held for the duration of the lease term.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
adopting ASC Topic 842, Leases (Topic 842), the Company has elected the &lsquo;package of practical expedients,&rsquo; which permits
the Company to avoid reassessing its prior conclusions about lease identification, lease classification and initial direct costs under
the new standard. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements, as the latter
is not applicable to the Company. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12
month or less. On January 1, 2019, upon adoption of ASC Topic 842, the Company recorded a right-of-use asset.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Right-of-use assets are summarized below:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> June 30, </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> December 31, </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> 2022 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> 2021 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left"> Office Lease </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 16%; text-align: right"> 265,207 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 16%; text-align: right"> 265,207 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Less accumulated amortization </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (177,824 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (148,225 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"> Right-of-use, net </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 87,383 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 116,982 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
on the right-of -use asset is included in rent expense on the statements of operations.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease liabilities are summarized below:</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> June 30, </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> 2022 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 80%; text-align: left"> Office Lease </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 16%; text-align: right"> 97,120 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Less: current portion </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (71,518 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"> Long term portion </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 25,602 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Maturities of lease liabilities are summarized below:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> As of </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> June 30, </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> 2022 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 80%; text-align: right"> 2022 </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 16%; text-align: right"> 38,502 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: right; padding-bottom: 1.5pt"> 2023 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 64,800 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"> Total future minimum lease payments </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 103,302 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Less imputed interest </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (6,182 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; padding-bottom: 2.5pt"> PV of Payments </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 97,120 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
5 &ndash; Notes Payable-Related Party</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 1, 2020, the Company consolidated all of the outstanding loans owed to an officer of the Company and to his spouse, resulting
in the following two loans: (i) a single loan from the spouse of an officer of the Company, dated December 1, 2020, with a principal
balance of $426,243, bearing interest at the rate of 7.5% per annum, with a maturity date of December 31, 2021; and (ii) a single loan
owed to an officer of the company in the principal amount of $139,229, bearing interest at the rate of 7.5% per annum, with a maturity
date of December 31, 2021. In December of 2021 the maturity dates of these loans were extended to June 30, 2022. As of June 30, 2022,
the accrued interest was $47,575 and $15,533, and the total balances with accrued interest of $473,818 and $154,762 respectively. Subsequent
to the date of this report, in July of 2022 the notes were extended to June 30, 2023 (Note 8).</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 21, 2021, the Company entered into a loan from the spouse of an officer of the Company in the amount of $120,000 (principal) with
an interest rate of 7.5% per annum due June 21, 2022, due at maturity. As of June 30, 2022, the accrued interest was $9,222 and the total
balances with accrued interest of $129,222. Subsequent to the date of this report, in July of 2022 the notes were extended to June 30,
2023 (Note 8).</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
6 - Notes Payable</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 9, 2021, the Company obtained a $73,007 term note issued under the Coronavirus Aid, Relief, and Economic Security Act&rsquo;s Paycheck
Protection Program (the &ldquo;PPP&rdquo;). The note bears an interest rate of 1% per annum, has a six-month deferral period with payments
beginning the seventh month and all outstanding principal and interest is due within two years from the note&rsquo;s inception date.
All or a portion of the note may be forgiven in accordance with PPP requirements. No more than 25% of the amount forgiven can be attributable
to non-payroll costs. As of December 31, 2021, a &ldquo;Loan Forgiveness Application&rdquo; was submitted to PNC Bank along with the
requested documentation and during the quarter ended March 31, 2022 the note liability was reduced in its entirety.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 15, 2020, the Company obtained a $62,500 term note issued under the Coronavirus Aid, Relief, and Economic Security Act&rsquo;s Paycheck
Protection Program (the &ldquo;PPP&rdquo;). The note bears an interest rate of 1% per annum, has a six-month deferral period with payments
beginning the seventh month and all outstanding principal and interest is due within two years from the note&rsquo;s inception date.
All or a portion of the note may be forgiven in accordance with PPP requirements. No more than 25% of the amount forgiven can be attributable
to non-payroll costs. A &ldquo;Loan Forgiveness Application&rdquo; was submitted to PNC Bank along with the requested documentation and
the note liability was reduced in its entirety during the year ended December 31, 2021.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> June 30, </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> December 31, </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt"></TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> 2022 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> 2021 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> PPP Note payable </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 60%"> PPP Note May 15, 2020 </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 16%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 16%; text-align: right"> 62,500 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> PPP Note March 9, 2021 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 73,007 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 73,007 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Loan Forgiveness </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (73,007 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (62,500 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> - </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 73,007 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2021, the Company issued $500,000 note units, consisting of two $250,000 notes, for a total of $500,000 10% unsecured promissory
notes with a maturity date of December 28, 2022, and 500,000 warrants exercisable at $1.00 per share with an expiry date of December
28, 2026, and fees of $5,075. The value of the warrants was determined using a computed volatility of 85.5%, 0% dividend rate, and a
risk free interest rate of 1.27% and was applied as a discount on the notes payable.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> On February 8, 2022,
and March 11, 2022, the Company sold $365,000 and $224,985, respectively, in 6% convertible notes (the &ldquo;Notes&rdquo;), which bear
6% interest, are repayable three years from the date of issuance, and will convert automatically into units, with each unit consisting
of one share of common stock and a warrant to purchase one share of commons stock (the &ldquo;Conversion Units&rdquo;) at a conversion
price equal to 50% of the per unit offering price upon closing of this offering. Boustead Securities LLC acted as placement agent for
this offering and received compensation of $36,500 and $22,250, respectively, and warrants to purchase shares of common stock equal to
10% of the Conversion Shares, exercisable at the conversion price of the Convertible Notes. The value of the warrants was determined
using computed volatility of 83.4%, 0% dividend rate, and a risk free interest rate of 1.27%, and computed volatility of 85.5% %, 0%
dividend rate, and a risk free interest rate of 1.96%, and was applied as a discount on the notes payable. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> June 30, </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> December 31, </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> 2022 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> 2021 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left"> Promissory note issued on December 28, 2021 </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 16%; text-align: right"> 500,000 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 16%; text-align: right"> 500,000 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Promissory note issued on February 8, 2022 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 365,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Promissory note issued on March 11, 2022 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 225,000 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,090,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 500,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Less discount on notes payable </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (514,376 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (408,979 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 575,624 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 91,021 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
7 &ndash; Stockholders&rsquo; Equity</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Company&rsquo;s amended and restated articles of incorporation, the Company is authorized to issue 100,000,000 shares of common
stock, with a par value of $0.00001 per share, and 20,000,000 shares of preferred stock, with a par value of $0.00001 per share.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Series
A Preferred Shares</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A Preferred Stock, in accordance with its terms, is automatically convertible into a number of shares of the Company&rsquo;s common
stock upon the closing of the sale of shares of common stock to the public in a qualified offering (as set forth in the Series A certificate
of designation) or upon listing of the Company&rsquo;s common stock on a national securities exchange.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2022, and December 31, 2021, the Company had 1,213 shares of Series A Preferred Stock issued and outstanding.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2022, and December 31, 2021, the Company accrued $51,536 for the 8.5% cumulative dividends on the Series A Preferred stock
for the six months ended June 30, 2022 and $103,062 for the year ended December 31, 2021, for a total of $382,595 and $331,059 respectively.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Common
Stock</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2022 and December 31, 2021, the Company had 9,312,991 and 9,312,152 shares of common stock issued and outstanding, respectively.
The balance includes 20,626 and 21,530 shares of restricted stock issued in 2021 and 2020 respectively and 839 common shares issued to
settle common stock to be issued.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Common
Stock to be Issued</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 4, 2018, $120,250 outstanding convertible notes were converted to 6,182 shares of common stock of the Company at a price of $19.44
per share. The Company recorded $16,340 of common stock to be issued for the accrued interest. As of June 30, 2022, 839 common shares
were issued to settle the $16,340 of common stock to be issued.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Warrants</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A Preferred Stock sold in the private placement offerings, included warrants to be issued upon the earlier of a closing of the
sale of shares of common stock to the public at a prices per share of at least $13.88 or in a firm commitment underwritten public offering
pursuant to an effective registration statement resulting in gross proceeds of at least $15,000,000. The warrants shall be exercisable
for a period of three years after the date of issuance. The warrant exercise price is contingent on the terms of the public offering.
If an initial public offering occurs at a price at or above $13.88 per share, then the exercise price shall be set to the issuance price
of the common stock with the number of warrants determined based on a 10% discount to the per share common stock issuance price. In the
scenario where the common stock is listed with the common stock issuance price below $13.88, the exercise price will be set to $20.82
with the number of warrants based on a fixed conversion price of $12.49, which represents a 10.0% discount to the $13.88 threshold. The
warrants also have contingent call features based on the terms of the public offering. If an initial public offering occurs at a price
at or above $13.88, then the warrants are callable if the 20-day VWAP of the common stock in at or above 150% of the variable exercise
price. In the scenario where the common stock is listed with a common stock issuance price below $13.88, then the warrants are callable
if the 20-day VWAP of the common stock is at or above the $20.82 exercise price. The detachable warrants contained terms and features
that gave rise to derivative liability classification.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
accounting principles that are provided in ASC 815 - Derivatives and Hedging require derivative financial instruments to be classified
in liabilities and carried at fair value with changes recorded in income. The Company has selected the Binomial Option Pricing valuation
technique to fair value the compound embedded derivative. Inherent in a binomial options pricing model are assumptions related to expected
stock-price volatility, expected life, risk-free interest rate, and dividend yield. The Company estimates the volatility of its ordinary
shares based on historical volatility of comparable companies that matches the expected remaining life of the warrants. The risk-free
interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining
life of the warrants.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
derivative liability linked to the Series A Preferred Stock as of June 30, 2022, and December 31, 2021 was $47,221 and $94,025, respectively.
For the period ended June 30, 2022 and 2021, the change in fair value of warrant liability was a gain of $46,804 and a gain of $57,656,
respectively.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair values of the liability measured on a recurring basis are as follows:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"> June 30, </TD><TD STYLE="font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"> December&nbsp;31, </TD><TD STYLE="font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"> June 30, </TD><TD STYLE="font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt"> % </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2022 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2021 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2021 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%"> Expected average volatility </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 14%; text-align: right"> 87.4 </TD><TD STYLE="width: 1%; text-align: left"> % </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 14%; text-align: right"> 85.5 </TD><TD STYLE="width: 1%; text-align: left"> % </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 14%; text-align: right"> 86 </TD><TD STYLE="width: 1%; text-align: left"> % </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Dividend yield </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 8.5 </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 8.5 </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 8.5 </TD><TD STYLE="text-align: left"> % </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Expected life </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.84
                                            Years</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.33
                                            Years</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.84
                                            Years</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Risk-free interest rate </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 2.92 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> % </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 0.73 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> % </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 0.25 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> % </TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
continuity schedule of the Series A Preferred Stock warrants is set forth below:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> Number of Warrants </TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> Weighted Average Exercise Price </TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> Weighted Average Life (years) </TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; padding-left: 5.4pt"> Outstanding, December 31, 2020 </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 14%; text-align: right"> 48,532 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 14%; text-align: right"> 24.98 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 14%; text-align: right"> 3.33 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt"> Forfeited </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 5.4pt"> Exercised </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt"> Outstanding and Exercisable, December 31, 2021 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 48,532 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 24.98 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt"> Forfeited </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 5.4pt"> Exercised </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 5.4pt"> Outstanding and Exercisable, June 30, 2022 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 48,532 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 24.98 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 1.83 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Equity
Incentive Plan</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
2018 Equity Incentive Plan provides for equity incentives to be granted to our employees, executive officers or directors and to key
advisers and consultants. Equity incentives may be in the form of stock options with an exercise price of not less than the fair market
value of the underlying shares as determined pursuant to the 2018 Equity Incentive Plan, restricted stock awards, other stock-based awards,
or any combination of the foregoing. The 2018 Equity Incentive Plan is administered by the Company&rsquo;s compensation committee or,
alternatively, if there is no compensation committee, the Company&rsquo;s board of directors. We have reserved 3,000,000 shares of our
common stock for issuance under the 2018 Equity Incentive Plan. As of June 30, 2022, 384,167 shares have been granted under the 2018
Equity Incentive Plan.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Restricted
Stock Units</I>. We may grant restricted stock units under our 2018 Plan. Restricted stock units are bookkeeping entries representing
an amount equal to the fair market value of one share of our common stock. Subject to the provisions of our 2018 Plan, the administrator
determines the terms and conditions of restricted stock units, including the vesting criteria and the form and timing of payment. The
administrator, in its sole discretion, may pay earned restricted stock units in the form of cash, in shares or in some combination thereof.
Notwithstanding the foregoing, the administrator, in its sole discretion, may accelerate the time at which any restrictions will lapse
or be removed.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 16, 2019, five individuals were appointed to the Board of Directors of the Company to serve as directors. Each individual entered
into an agreement pursuant to which they will serve as a director and pursuant to which they would each receive a grant of $75,000 worth
of Restricted Stock Units (&ldquo;RSUs&rdquo;) issuable under the Company&rsquo;s 2018 Equity Incentive Plan (the &ldquo;2018 Plan&rdquo;).
The RSUs vest annually in one third increments from the date of appointment. Under the terms of the director agreements, the Company
has also agreed to pay each director $25,000 per annum, payable in equal quarterly installments commencing 90 days following the Company
becoming a publicly reporting company under the Securities Exchange Act of 1934, as amended.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the six months ended June 30, 2022 and 2021, pursuant to the agreements with directors and officers compensation expense for the RSUs
of $333,066 and $245,034 was included in wages, respectively.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2022, there was $32,001 of total unrecognized compensation cost related to non-vested share-based compensation arrangements
which is expected to be recognized within the current year.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
continuity schedule of the Restricted Stock Units (RSU) follows:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Number of RSU </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Weighted Average Exercise Price </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Weighted Average Life (years) </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; text-align: justify"> Outstanding, December 31, 2020 </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 14%; text-align: right"> 61,884 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 14%; text-align: right"> 23.76 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 14%; text-align: right"> 4.33 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"> Forfeited </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (2,702 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 27.76 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"> Exercised </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"> Outstanding, December 31, 2021 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 59,182 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 23.57 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 3.33 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"> Forfeited </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"> Exercised </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"> Outstanding, June 30, 2022 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 59,182 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 23.57 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 2.84 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"> Exercisable, June 30, 2022 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 57,768 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 23.74 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 2.84 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
8 &ndash; Subsequent Events</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
evaluated all additional events subsequent to the balance sheet date through August 12, 2022, the date the financial statements were
available to be issued, and determined the following items:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July of 2022, the Company signed extension agreements for the related party notes of $138,449, $424,036 and $120,000 that were due during
June of 2022. The extensions updated the maturity date for the three notes to June 30, 2023.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August of 2022, the Company closed on a bridge financing arrangement or $125,000 of 10% notes and warrants to purchase 50,000 shares of common stock exercisable at $2.50
per share. The notes are due 12 months from the date of execution or upon
closing the initial public offering (&ldquo;IPO&rdquo;) and warrants are exercisable  for five years.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>























<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="vba_001"></A>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the shareholders and the board of directors
of Shuttle Pharmaceuticals Holdings, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Opinion on the Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of Shuttle Pharmaceuticals Holdings, Inc. (the &ldquo;Company&rdquo;) as of December 31, 2021 and 2020, the related statements
of operations, stockholders&rsquo; equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred
to as the &ldquo;financial statements&rdquo;). In our opinion, the financial statements present fairly, in all material respects, the financial
position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended,
in conformity with accounting principles generally accepted in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Restatement of December 31, 2021 Financial
Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As discussed in Note 9 to the financial statements,
the financial statements have been restated to correct certain misstatements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Substantial Doubt about the Company&rsquo;s
Ability to Continue as a Going Concern</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have been
prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company&rsquo;s
significant operating losses raise substantial doubt about its ability to continue as a going concern. The financial statements do not
include any adjustments that might result from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Basis for Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements are the responsibility
of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s financial statements based on our audit. We
are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&ldquo;PCAOB&rdquo;) and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audit in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audit included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial
statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as
evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">/s/ BF Borgers CPA PC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>BF Borgers CPA PC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Served as Auditor since 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lakewood, CO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">June 3, 2022, except for the effects of the
restatement disclosed in Note 9, as to which the date is June 23, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


<!-- Field: Page; Sequence: 119; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shuttle
Pharmaceuticals Holdings, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="vba_002"></A>Consolidated
Balance Sheets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center"></TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="text-align: center; margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0">(As Restated)</P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Current Assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%">Cash</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">504,749</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">117,153</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,866</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,579</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Contracts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">211,455</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">509,615</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">341,187</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,564</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,782</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,480</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,480</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating lease right-of-use asset</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">116,982</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">171,598</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Total assets</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">651,641</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">544,047</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center">LIABILITIES AND STOCKHOLDERS&rsquo; DEFICIT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Current Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">828,313</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">516,966</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accrued interest payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">552</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">392</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued interest payable - related parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,947</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Dividends Payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">331,059</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">227,997</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Notes payable - related parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">685,473</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">565,473</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">91,021</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Paycheck Protection Program note payable, current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,007</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">62,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Derivative liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">94,025</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">673,171</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating lease liability current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">66,934</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">58,468</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,217,331</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,104,967</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating lease liability non-current</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">62,442</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">129,376</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,279,773</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,234,343</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Stockholders&rsquo; Deficit:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Series A convertible preferred stock, $0.00001 par value; $1,000 per share liquidation value or aggregate
    of $1,212,500; 20,000,000 shares authorized; 1,213 shares issued and outstanding at December 31, 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Common stock, $0.00001 par value; 100,000,000 shares authorized; 9,312,152 and 9,291,526 shares issued
    and outstanding at December 31, 2021 and 2020, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">93</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">93</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Additional paid in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,150,867</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,833,507</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Common stock to be issued</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,340</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,340</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accumulated deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,795,432</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,540,236</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total stockholders&rsquo; deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,628,132</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,690,296</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Total liabilities and stockholders&rsquo;
    deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">651,641</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">544,047</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><BR STYLE="clear: both">
Shuttle Pharmaceuticals Holdings, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="vba_003"></A><B>Consolidated
Statements of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">Year Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(As Restated)</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">Revenue</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 60%; text-align: left">Research and development, net of contract expense reimbursements</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">1,021,808</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">161,772</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">85,927</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Legal and professional</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">684,684</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">261,823</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,742,992</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">509,522</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,742,992</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(509,522</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Loss on write off of deposit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Interest expense - related parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(46,947</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(36,771</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,841</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,859</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Change in fair value of warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">579,146</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(256,580</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Gain on forgiveness of Paycheck Protection Program note
    payable</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">62,500</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total other income (expense)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">590,858</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(296,210</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Loss before income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,152,134</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(805,732</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Income tax provision</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,152,134</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(805,732</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Dividend on Series A preferred stock</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(103,062</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(103,062</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss attributable to common stockholders</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,255,196</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(908,794</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Weighted average common shares outstanding - basic and
    diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9,301,750</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9,291,526</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-weight: bold; padding-bottom: 2.5pt">Diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9,306,610</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">18,575,143</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss per shares - basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.12</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.09</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 121; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shuttle
Pharmaceuticals Holdings, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="vba_004"></A>Consolidated
Statements of Changes in Stockholders&rsquo; Deficit</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">Series A Convertible</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Additional</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Common</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Total</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Preferred Stock</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Paid-in</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Stock to</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Accumulated</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Stockholders&rsquo;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">be&nbsp;Issued</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; font-weight: bold">Balance, December 31, 2019</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">1,213</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">9,269,996</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;93</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">2,373,918</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">&nbsp;&nbsp;16,340</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">(3,631,442</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;(1,241,091</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Common stock issued for restricted stock units</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,530</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">459,589</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">459,589</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Dividends on Series A preferred stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(103,062</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(103,062</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(805,732</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(805,732</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Balance, December 31, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,213</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,291,526</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">93</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,833,507</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">16,340</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(4,540,236</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,690,296</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Stock based compensation (As Restated)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">420,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">420,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Warrants issued for financing costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">407,293</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">407,293</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Common stock issued for restricted stock units</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,626</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">490,067</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">490,067</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Dividends on Series A preferred stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(103,062</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(103,062</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,152,134</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,152,134</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Balance, December 31, 2021 (As Restated)</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,213</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9,312,152</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">93</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,150,867</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">16,340</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(5,795,432</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,628,132</TD><TD STYLE="text-align: left">)</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shuttle
Pharmaceuticals Holdings, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="vba_005"></A>Consolidated
Statements of Cash Flows</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">Year Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">(As Restated)</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash Flows From Operating Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: left">Net loss</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">(1,152,134</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">(805,732</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,218</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,782</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Change in fair value of warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(579,146</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">256,580</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Amortization of right-of-use asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54,616</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,169</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Amortization of debt discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,389</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Gain on forgiveness of Paycheck Protection Program note payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(62,500</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">490,067</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">459,589</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Contracts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">211,455</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">164,927</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,713</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(586</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">311,347</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(51,127</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued interest payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">160</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">392</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accrued interest payable - related parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,947</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(54,959</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating lease liability</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(58,468</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(50,866</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net cash used in operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(300,336</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(26,831</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash Flows From Investing Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Purchase of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(10,818</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net cash used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(10,818</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash Flows From Financing Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Proceeds from notes payable-related parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,573</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Proceeds from PPP note payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,007</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">62,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Proceeds from notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">494,925</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net cash provided by financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">687,932</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">70,073</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Net change in cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">387,596</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,424</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Cash, beginning of period</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">117,153</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">84,729</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Cash, end of period</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">504,749</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">117,153</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash paid for:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Interest</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">293</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,886</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 123; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shuttle
Pharmaceuticals Holdings, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="vba_006"></A>Notes
to Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year
Ended December 31, 2020 and 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
1 &ndash; Organization and Going Concern</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Organization
and Line of Business</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was formed as Shuttle Pharmaceuticals, LLC, in the State of Maryland on December 18, 2012. On August 12, 2016, the Company filed
articles of conversion with the state of Maryland to convert from an LLC to a corporation and the Company changed its name to Shuttle
Pharmaceuticals, Inc. (&ldquo;Shuttle&rdquo;). In connection with the conversion the Company issued 45,000,000 shares of common stock
in exchange for 100% of the outstanding membership interests prior to conversion. On June 4, 2018, Shuttle completed a reverse merger
with Shuttle Pharmaceuticals Holdings, Inc. (then known as Shuttle Pharma Acquisition Corp.), a Delaware corporation (the &ldquo;Company&rdquo;),
pursuant to which Shuttle, our operating entity, became a wholly owned subsidiary of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s primary purpose is to develop and commercialize unique drugs for the sensitization of cancers and protection of normal
tissues, with the goal of improving outcomes for cancer patients receiving radiation therapy. Shuttle has deployed its proprietary technology
to develop novel cancer immunotherapies which has produced a pipeline of selective HDAC inhibitors for cancer and immunotherapy applications.
The Company&rsquo;s HDAC platform is designed to target candidate molecules with potential roles in therapeutics beyond cancer, including
autoimmune, inflammatory, metabolic, neurological and infectious diseases. The Company&rsquo;s Ropidoxuridine product, which is used
with radiation therapy to sensitize cancer cells, was funded by a Small Business Innovation Research (SBIR) contract provided by the
National Cancer Institute (NCI), a unit of the National Institutes of Health (NIH). Ropidoxuridine has been further developed though
the Company&rsquo;s collaborations with the University of Virginia for use in combination with proton therapy to improve patient survival.
The Company is working on developing products through NIH grants, including a product to predict late effects of radiation with metabolite
biomarkers and develop prostate cancer cell lines in health disparities research.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The production and marketing
of the Company&rsquo;s products and its ongoing research and development activities will be subject to extensive regulation by numerous
governmental authorities in the United States. Prior to marketing in the United States, any combination product developed by the Company
must undergo rigorous preclinical (animal) and clinical (human) testing and an extensive regulatory approval process implemented by the
Food and Drug Administration (&ldquo;FDA&rdquo;) under the Food, Drug and Cosmetic Act. There can be no assurance that the Company will
not encounter problems in clinical trials that will cause the Company or the FDA to delay or suspend clinical trials.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s success will depend in part on its ability to obtain patents and product license rights, maintain trade secrets, and
operate without infringing on the proprietary rights of others, both in the United States and other countries. There can be no assurance
that patents issued to or licensed by the Company will not be challenged, invalidated or circumvented, or that the rights granted thereunder
will provide proprietary protection or competitive advantages to the Company now or in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Reverse
Stock Split</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Effective April 1, 2022,
we effected a 2-for-1 reverse stock split of our issued and outstanding common stock (the &ldquo;Reverse Stock Split&rdquo;). All references
to shares of our common stock in this registration statement on Form S-1 refers to the number of shares of common stock after giving effect to
the Reverse Stock Split (unless otherwise indicated).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Going
Concern</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation
of the Company as a going concern. The Company&rsquo;s only revenue source since inception has been government awarded contracts totaling
$5,531,722, and the Company has incurred losses since inception, having accumulated a deficit of $5,795,432 as of December 31,
2021. The Company currently has limited liquidity and has not completed its efforts to establish a stabilized source of revenues sufficient
to cover operating costs over an extended period. These factors, among others, raise substantial doubt about the Company&rsquo;s ability
to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will need to raise capital to fund its operations. To address its financing requirements, the Company intends to seek financing
through debt or equity financings with an aim to continue progress toward commercial viability of its products. The Company continues
to submit Federal grant and contract applications which have historically been the primary source of revenue. The financial statements
do not include any adjustments that might result from the outcome of the uncertainty of raising additional capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
2 &ndash; Summary of Significant Accounting Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Basis
of Presentation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statements and related disclosures
have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&ldquo;SEC&rdquo;). The financial
statements have been prepared using the accrual basis of accounting in accordance with Generally Accepted Accounting Principles of the
United States (&ldquo;GAAP&rdquo;).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Basis
of Consolidation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements have been prepared on a consolidated basis with those of the Company&rsquo;s wholly-owned subsidiary, Shuttle Pharmaceuticals,
Inc. All intercompany transactions and balances have been eliminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Use
of Estimates</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and
assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that
it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results
experienced by the Company may differ materially and adversely from the Company&rsquo;s estimates. To the extent there are material differences
between the estimates and the actual results, future results of operations will be affected. Significant estimates in the accompanying
financial statements include useful lives of property and equipment, valuation of derivatives, and the valuation allowance on deferred
tax assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Accounts
Receivable</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s accounts receivable consists of amounts due from the National Institutes of Health (&ldquo;NIH&rdquo;), a government
agency under the Department of Health and Human Services. The Company submits quarterly reports of progress for tasks performed on
research and development contracts it is awarded. The contracts are typically reimbursed on a fixed fee cost reimbursement basis and
payments from the contracts are generally collected within 30 days of the Company&rsquo;s submission for reimbursement. The Company
currently does not provide an allowance for doubtful collections, which is based upon a review of outstanding receivables,
historical collection information, and existing economic conditions. Normal receivable terms vary from 7-30 days after the issuance
of the invoice and typically would be considered past due when the term expires. The Company&rsquo;s allowance for doubtful accounts
was $0 at December 31, 2020 and 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Property
and Equipment</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and
betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation
are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided
using the straight-line method for substantially all assets with estimated lives as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5
    years</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers
    and equipment</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5
    years</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    Equipment</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10
    years</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 125; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to expense as incurred. Research and development expenses include, but are not limited to, product
development, clinical and regulatory expenses, payroll and other personnel expenses, materials, supplies, related subcontract expenses,
and consulting costs. The expenses assigned to NIH SBIR sponsored research are related to: (1) &ldquo;Topic 352: Cell-Based Models for
Prostate Cancer Health Disparity Research &ndash; Moonshot Project&rdquo; and (2) &ldquo;Topic 345: Predictive Biomarkers of Prostate
Cancer Patient Sensitivity for Radiation Late Effects.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
research expenses are assigned to the research projects to demonstrate proof of principle in patients with prostate cancer that may support
development and commercialization of biomarker products and to gather prostate cancer cell lines in African American men to serve as
the product for use in health disparities research. Costs that are not covered by the SBIR contract for performing the Phase I contract
to determine commercialization feasibility included partial salary support of personnel and a consultant to develop a commercialization
plan. Costs that are not covered in the Phase II contract include business development and partial salary support.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
expenses related to new drug discovery include partial support of personnel, space, supplies, and legal costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
fiscal year 2021, the Company has made progress on completing two SBIR contracts from the NIH to support research projects with potential
for commercialization. The SBIR contract awards are fixed payments made by the NIH in response to quarterly Shuttle invoices and provide
non-dilutive funds that do not include a repayment obligation. Details on the three contracts follow:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
Contract #HHSN261201600027C/75N91018C00016 supported &ldquo;Topic 345: Predictive Biomarkers of Prostate Cancer Patient Sensitivity for
Radiation Late Effects.&rdquo; This $299,502 Phase I award includes funded research from 9/19/2016 through 9/18/2017 and was advanced
to Phase II of the awards with funding of $1,903,095 with a fixed price contract period of 9/17/2018 through 9/16/2020 and subsequent
no cost extensions through 9/15/2021 and then 3/15/2022 (Reference 75N91019C00031). The Company received quarterly payments of $211,455
for a total of $845,820 in 2020; and 2 quarterly payments related to Topic 345 for a total of $422,910 in 2021. In Phase II of the SBIR
effort, the Company will license the metabolite signatures (intellectual property) from Georgetown University, manufacture 500 &ldquo;kits,&rdquo;
test and validate the metabolic kit performance and develop a multi-institutional clinical trial to be implemented in the Phase III effort.
This contract includes a subcontract to Georgetown University for use of Mass Spectrometry core facilities to analyze clinical samples.
The contract was extended to complete the milestones which were delayed due to the impact of COVID-19.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 6, 2019, the Company engaged Georgetown University to perform the $795,248 subcontract of its Phase II contract #HHSN75N91019C00031.
The Company will reimburse Georgetown for its allowable costs not to exceed the ceiling amount of $795,248. Depending on the resources
it uses, Georgetown may or may not invoice for the total subcontract amount. In the event Georgetown does not invoice for the total allowable
amount, the Company is not obligated to pay the ceiling amount. As of December 31, 2021, payments of $354,829 were made to Georgetown,
and additional invoices for $436,188 were received but not yet paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
The Phase II contract #HHSN261201800016C supports the discovery work following a Phase I contract # HHSN261600038C &ldquo;Topic 352 &ndash;
SBIR Phase II Cell-based Models for Prostate Cancer Health Disparity Research&rdquo; and was awarded to provide $1,484,350 to fund research
from 9/17/2018 through 9/16/2020 and was extended without cost through 11/16/2021 due to delays caused by the impact of COVID-19. For
2020, the Company received 2.5 quarterly payments for a total of $412,321 and $82,467 in 2021. The Phase II contract also includes a
subcontract to Georgetown University for $742,002 to establish prostate cancer cell lines from African American patients undergoing prostate
surgery for cancers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 5, 2018, the Company engaged Georgetown University to perform the $742,002 subcontract of its Phase II contract #HHSN261201800016C.
Depending on the resources it uses, Georgetown may or may not invoice for the total subcontract amount. In the event Georgetown does
not invoice for the total allowable amount, the Company is not obligated to pay the ceiling amount. The Company has been invoiced by
Georgetown and has paid Georgetown a total of $292,252 as of December 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 126; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the amounts received from the contract at fair value when there is reasonable assurance that the contract amount will
be received, and it is probable that all attaching conditions will be complied with. The Company recognizes the amounts received in accordance
with the contract as a reduction of research and development expenses over the periods necessary to match the contract on a systematic
basis to the costs that it is intended to compensate. The Company records reimbursements on the balance sheet as contract receivables
upon meeting the criteria discussed above until cash is received. During the 12 months ended December 31, 2021, the Company recorded
a net deficit of $1,021,808 from these two SBIR contracts which is the result of recording $1,527,185 in SBIR contract related expenses
on revenues of $505,377.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regarding
the accounting treatment for reimbursements, GAAP provides limited guidance on the accounting for government grants received by for-profit
companies. We understand there is more than one acceptable alternative for the accounting treatment &ndash; a reduction of costs, a deferred
credit to be amortized, revenue, or other income. Due to the terms of the contracts, we have entered into the Company concluded that
the reimbursements were more akin to a reduction of costs rather than any of the other alternatives that would match the contract reimbursements
on a systematic basis to the costs that the contract is intended to compensate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Derivative
Financial Instruments</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations.
For stock-based derivative financial instruments, the Company uses a Binomial Simulation model to value the derivative instruments at
inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should
be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified
in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required
within 12 months of the balance sheet date. As of December 31, 2021, the Company&rsquo;s only derivative financial instrument was an
embedded warrant feature associated with Series A Convertible Preferred Stock due to certain provisions that allow for a change in the
warrant value based on fluctuations of the Company&rsquo;s fair value of common stock at the date of issuance of the warrant based on
certain contingent call features.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Fair
Value of Financial Instruments</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
certain of the Company&rsquo;s financial instruments, including cash, accounts receivable, accounts payable, accrued liabilities and
short-term debt, the carrying amounts approximate their fair values due to their short maturities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB
ASC Topic 820, <I>Fair Value Measurements and Disclosures</I>, requires disclosure of the fair value of financial instruments held by
the Company. FASB ASC Topic 825, <I>Financial Instruments</I>, defines fair value, and establishes a three-level valuation hierarchy
for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported
in the consolidated balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable
estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization
and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for
    identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly,
    for substantially the full term of the financial instrument.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 inputs to the valuation methodology us one or more unobservable inputs which are significant to the fair value measurement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 127; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, <I>Distinguishing Liabilities
from Equity</I>, and FASB ASC Topic 815, <I>Derivatives and Hedging</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
certain financial instruments, the carrying amounts reported in the balance sheets for cash and current liabilities, including convertible
notes payable, each qualify as a financial instrument, and are a reasonable estimate of their fair values because of the short period
of time between the origination of such instruments and their expected realization and their current market rate of interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
established trading market for the Company&rsquo;s common stock does not exist. The fair value of the shares was determined based on
the then most recent price per share at which we sold preferred stock to unrelated parties in a private placement during the six months
then ended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2020, the Company utilized $25.22 (post-share exchange) per share as the fair value of its common stock for
accounting purposes based on preferred share transactions with investors from August 2018 through December 2019, with no transactions
occurring in 2020 and $5.00 in 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2021, the Company identified the following liabilities that are required to be presented on the balance sheet at fair value:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid">Description</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center">Level 1</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center">Level 2</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center">Level 3</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Warrant Liability</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">94,025</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2020, the Company identified the
following liabilities that are required to be presented on the balance sheet at fair value:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">Description</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Level 1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Level 2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Level 3</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 52%"><FONT STYLE="font-size: 10pt">Warrant Liability</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">673,171</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Revenue
Recognition</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from providing research and development is recognized under <I>Topic 606</I> in a manner that reasonably reflects the delivery of its
services to customers in return for expected consideration and includes the following elements:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">executed
    contracts with the Company&rsquo;s customers that it believes are legally enforceable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identification
    of performance obligations in the respective contract;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">determination
    of the transaction price for each performance obligation in the respective contract;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocation
    the transaction price to each performance obligation; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognition
    of revenue only when the Company satisfies each performance obligation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To satisfy these five elements, the Company records
revenue for research and development services on a quarterly basis as services are provided. Revenue received from National Institutes
of Health contracts is received in accordance with Federal grants and contracts policies. Research and development expenses are posted
against revenue and recorded on the statement of operations as &ldquo;Research and development, net of contract expense reimbursements.&rdquo;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Impairment
of Long-Lived Assets</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying
amount of the asset may not be fully recoverable. Recoverability of assets is measured by a comparison of the carrying amount of an asset
to the estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount of the asset exceeds its estimated
future cash flows, an impairment charge will be recognized in the amount by which the carrying amount of the asset exceeds the fair value
of the asset. There were no impairments of long-lived assets during the periods presented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 128; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Income
Taxes</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes in accordance with ASC Topic 740, <I>Income Taxes</I>. ASC 740 requires a company to use the asset
and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences,
and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the
reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the
opinion of management, the Company does not foresee generating taxable income in the near future and utilizing its deferred tax asset,
therefore, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets
and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ASC 740, a tax position is recognized as a benefit only if it is &ldquo;more likely than not&rdquo; that the tax position would be sustained
in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that
is greater than 50% likely of being realized on examination. For tax positions not meeting the &ldquo;more likely than not&rdquo; test,
no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Basic
and Diluted Earnings Per Share</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings per share (&ldquo;EPS&rdquo;) is computed based on the weighted average number of shares of common stock outstanding during
the period. Diluted EPS is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential
common shares outstanding during the period using the treasury stock method and as if converted method. Dilutive potential common shares
include outstanding warrants and Series A preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2021, and 2020, the following common stock equivalents were excluded from the computation of diluted net
loss per share as the result of the computation was anti-dilutive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">December 31,</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">December 31,</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center">2021</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center">2020</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left">Series A preferred stock</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">97,062</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">97,062</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">48,532</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">48,532</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Total</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">145,594</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">145,594</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Recent
Accounting Pronouncements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU 2020-06, ASC Subtopic 470-20 &ldquo;Debt&mdash;Debt with &ldquo;Conversion and Other Options&rdquo;
and ASC subtopic 815-40 &ldquo;Hedging&mdash;Contracts in Entity&rsquo;s Own Equity.&rdquo; The standard reduced the number of accounting
models for convertible debt instruments and convertible preferred stock. Convertible instruments that continue to be subject to separation
models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition
of a derivative, and that do not qualify for a scope exception from derivative accounting; and (2) convertible debt instruments issued
with substantial premiums for which the premiums are recorded as paid-in capital. The amendments in this update are effective for fiscal
years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company
has adopted this standard on January 1, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying
financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 129; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
3 &ndash; Property and Equipment, Net</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consisted of the following as of December 31, 2021, and 2020:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">December 31,</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">December 31,</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center">2021</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center">2020</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left">Office Furniture and equipment</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">8,861</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">8,861</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Laboratory equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">118,605</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">118,605</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">127,466</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">127,466</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Less accumulated depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(108,902</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(102,684</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">18,564</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">24,782</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense for the twelve months ended December 31, 2021, and 2020 were $6,218 and $5,782 respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
4 &ndash; Operating Lease Right-of-use Asset and Operating Lease Liability</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease right-of-use assets and liabilities are recognized at the present value of the future lease payments at the lease commencement
date. The interest rate used to determine the present value is our incremental borrowing rate, estimated to be 10%, as the interest rate
implicit in most of our leases is not readily determinable. Operating lease expense is recognized on a straight-line basis over the lease
term. During the twelve months ended December 31, 2021, and the year ended December 31, 2020, the Company recorded $74,028 and $71,872,
respectively, as operating lease expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently has a lease agreement which allows for the use of a laboratory facility for a monthly payment of $6,107, which monthly
lease payment increases by 3% every year. The laboratory lease commenced October 1, 2018, with the first payment due January 1, 2019,
and expires on October 31, 2023. A security deposit of $6,480 is being held for the duration of the lease term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
adopting ASC Topic 842, Leases (Topic 842), the Company has elected the &lsquo;package of practical expedients,&rsquo; which permits
the Company to avoid reassessing its prior conclusions about lease identification, lease classification and initial direct costs under
the new standard. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements, as the latter
is not applicable to the Company. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12
month or less. On January 1, 2019, upon adoption of ASC Topic 842, the Company recorded a right-of-use asset.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 130; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">December 31,</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">December 31,</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center">2021</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center">2020</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left">Office Lease</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">265,207</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">265,207</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Less accumulated amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(148,225</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(93,609</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Right-of-use, net</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">116,982</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">171,598</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Right-of-use assets are summarized below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
on the right-of -use asset is included in rent expense on the statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease liabilities are summarized below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">December 31,</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center">2021</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Office Lease</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 22%; text-align: right">129,376</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Less: current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(66,934</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Long term portion</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">62,442</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Maturities of lease liabilities are summarized below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">As of</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">December 31,</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center">2021</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">2022</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 22%; text-align: right">76,248</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2023</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">64,800</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total future minimum lease payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">141,048</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Less imputed interest</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(11,672</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>PV of Payments</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">129,376</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
5 &ndash; Notes Payable-Related Party</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 25, 2018, the Company entered into a loan from the spouse of an officer of the Company in the amount of $300,000. The loan bears
interest at the rate of 7.5% per annum. The loan plus accrued interest was payable in full on January 25, 2019. On January 25, 2019,
the Company amended the loan for purposes of extending the maturity date from January 25, 2019, to October 25, 2020. On December 1, 2020,
the Company again amended the terms and extended the maturity date to December 31, 2021, bringing the total amount owed under the loan,
together with accrued interest of $64,084, to a total of $364,084. This note was rolled into the note referenced below with a principal amount of $424,056.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 4, 2018, the Company entered into a loan from the spouse of an officer of the Company in the amount of $50,000. The loan bears
an interest rate of 7.5% per annum. The loan plus accrued interest was payable in full on September 4, 2018. On October 31, 2018, the
Company amended the terms to extend the maturity date from September 4, 2018, to April 4, 2019. On April 4, 2019, the Company amended
the terms to extend the maturity date from April 4, 2019, to October 25, 2020. On December 1, 2020, the Company again amended the terms
and extended the maturity date to December 31, 2021, bringing the total amount owed under the loan, together with accrued interest of
$9,972, to a total of $59,972. This note was rolled into the note referenced below with a principal amount of $424,056.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 30, 2018, the Company entered into a loan with an officer of the Company in the amount of $25,000. The loan bears an interest rate
of 7.5% per annum. The loan plus accrued interest was payable in full on July 15, 2018. On October 31, 2018, the Company amended the
terms to extend the maturity date from July 15, 2018, to November 30, 2020. On December 1, 2020, the Company again amended the terms
and extended the maturity date to December 31, 2021, bringing the total amount owed under the loan, together with accrued interest of
$4,698, to a total of $29,698. This note was rolled into the note reference below with a principal amount of $138,448.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 131; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 24, 2019, the Company entered into a loan from the spouse of an officer of the Company in the amount of $70,000. The loan bore interest
rate of 7.5% per annum and required monthly payments of $6,073. The loan plus accrued interest was paid in full on June 30, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 24, 2019, the Company entered into a loan from the spouse of an officer of the Company in the amount of $70,000. The loan bore
an interest rate of 7.5% per annum and required monthly payments of $6,073. The loan plus accrued interest was paid in full on August
23, 2020. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 23, 2019, the Company entered into a loan from the spouse of an officer of the Company in the amount of $100,000. The loan
bore an interest rate of 7.5% per annum and became payable in full on September 22, 2020. This note was rolled into the note reference below with a principal amount of $138,448.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 1, 2020, the Company consolidated all of the outstanding loans owed to an officer of the Company and to his spouse, resulting
in the following two loans: (i) a single loan from the spouse of an officer of the Company, dated December 1, 2020, with a principal
balance of $424,056, bearing interest at the rate of 7.5% per annum, with a maturity date of December 31, 2021; and (ii) a single loan
owed to an officer of the company in the principal amount of $138,449, bearing interest at the rate of 7.5% per annum, with a maturity
date of December 31, 2021. In December of 2021 the maturity dates of these loans were extended to June 30, 2022. As of December 31, 2021,
the accrued interest was $31,804 and $10,384, and the total balances with accrued interest of $458,047 and $149,613 respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 21, 2021, the Company entered into a loan
from the spouse of an officer of the Company in the amount of $120,000 (principal) with an interest rate of 7.5% per annum due June 21,
2022, due at maturity. As of December 31, 2021, the accrued interest was $4,759 and the total balances with accrued interest of $124,759.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
6 - Notes Payable</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 9, 2021, the Company obtained a $73,007 term note issued under the Coronavirus Aid, Relief, and Economic Security Act&rsquo;s Paycheck
Protection Program (the &ldquo;PPP&rdquo;). The note bears an interest rate of 1% per annum, has a six-month deferral period with payments
beginning the seventh month and all outstanding principal and interest is due within two years from the note&rsquo;s inception date.
All or a portion of the note may be forgiven in accordance with PPP requirements. No more than 25% of the amount forgiven can be attributable
to non-payroll costs. As of December 31, 2021, a &ldquo;Loan Forgiveness Application&rdquo; was submitted to PNC Bank along with the
requested documentation and subsequent to the close of the December 31, 2021, reporting period the note liability was reduced in its
entirety.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 15, 2020, the Company obtained a $62,500 term note issued under the Coronavirus Aid, Relief, and Economic Security Act&rsquo;s Paycheck
Protection Program (the &ldquo;PPP&rdquo;). The note bears an interest rate of 1% per annum, has a six-month deferral period with payments
beginning the seventh month and all outstanding principal and interest is due within two years from the note&rsquo;s inception date.
All or a portion of the note may be forgiven in accordance with PPP requirements. No more than 25% of the amount forgiven can be attributable
to non-payroll costs. A &ldquo;Loan Forgiveness Application&rdquo; was submitted to PNC Bank along with the requested documentation and
the note liability was reduced in its entirety during the year ended December 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">December 31,</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">December 31,</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center">2021</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center">2020</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%">PPP Note May 15, 2020</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 24%; text-align: right">62,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 24%; text-align: right">62,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>PPP Note March 9, 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,007</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loan Forgiveness</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(62,500</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Total</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">73,007</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">62,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 132; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2021, the Company issued $500,000 note units, consisting of two $250,000 notes, for a total of $500,000 10% unsecured
promissory notes with a maturity date of December 28, 2022, and 500,000 warrants exercisable at $1.00 per share with an expiry date
of December 28, 2026, and fees of $5,075. The value of the warrants was determined using a computed volatility of 85.5%, 0% dividend
rate, and a risk free interest rate of 1.27% and was applied as a discount on the notes payable as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">December 31,</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center">2021</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Promissory notes issued on December 28, 2021</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 22%; text-align: right">500,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Less unamortized discount on notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(408,979</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Total</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">91,021</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
7 &ndash; Stockholders&rsquo; Equity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Company&rsquo;s amended and restated articles of incorporation, the Company is authorized to issue 100,000,000 shares of common
stock, with a par value of $0.00001 per share, and 20,000,000 shares of preferred stock, with a par value of $0.00001 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Series
A Preferred Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A Preferred Stock, in accordance with its terms, is automatically convertible into a number of shares of the Company&rsquo;s common
stock upon the closing of the sale of shares of common stock to the public in a qualified offering (as set forth in the Series A certificate
of designation) or upon listing of the Company&rsquo;s common stock on a national securities exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, and 2020, the Company had 1,213 shares of Series A Preferred Stock issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As of December 31, 2021,
and 2020, the Company had accrued the 8.5% cumulative dividends on the Series A Preferred stock of $331,059 and $227,997 respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Common
Stock</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, and 2020, the Company had 9,312,152 and 9,291,526 shares of common stock issued and outstanding, respectively. The balance includes 20,626 and 21,530 shares of restricted stock issued in 2021 and 2020 respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Common
Stock to be Issued</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 4, 2018, $120,250 outstanding convertible notes were converted to 6,182 shares of common stock of the Company at a price of
$19.44 per share. The Company has recorded $16,340 of common stock to be issued for the accrued interest. As of December 31, 2020
and 2021, the common stock has not been issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Warrants</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A Preferred Stock sold in the private placement offerings, included warrants to be issued upon the earlier of a closing of the
sale of shares of common stock to the public at a prices per share of at least $13.88 or in a firm commitment underwritten public offering
pursuant to an effective registration statement resulting in gross proceeds of at least $15,000,000. The warrants shall be exercisable
for a period of three years after the date of issuance. The warrant exercise price is contingent on the terms of the public offering.
If an initial public offering occurs at a price at or above $13.88 per share, then the exercise price shall be set to the issuance price
of the common stock with the number of warrants determined based on a 10% discount to the per share common stock issuance price. In the
scenario where the common stock is listed with the common stock issuance price below $13.88, the exercise price will be set to $20.82
with the number of warrants based on a fixed conversion price of $12.49, which represents a 10.0% discount to the $13.88 threshold. The
warrants also have contingent call features based on the terms of the public offering. If an initial public offering occurs at a price
at or above $13.88, then the warrants are callable if the 20-day VWAP of the common stock in at or above 150% of the variable exercise
price. In the scenario where the common stock is listed with a common stock issuance price below $13.88, then the warrants are callable
if the 20-day VWAP of the common stock is at or above the $20.82 exercise price. The detachable warrants contained terms and features
that gave rise to derivative liability classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 133; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
accounting principles that are provided in ASC 815 - Derivatives and Hedging require derivative financial instruments to be classified
in liabilities and carried at fair value with changes recorded in income. The Company has selected the Binomial Option Pricing valuation
technique to fair value the compound embedded derivative. Inherent in a binomial options pricing model are assumptions related to expected
stock-price volatility, expected life, risk-free interest rate, and dividend yield. The Company estimates the volatility of its ordinary
shares based on historical volatility of comparable companies that matches the expected remaining life of the warrants. The risk-free
interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining
life of the warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
derivative liability linked to the Series A Preferred Stock as of December 31, 2021 and 2021 was $94,025 and $673,171, respectively.
The change in fair value of warrant liability was a gain of $579,146 as of December 31, 2021 and a loss of $256,580 as of December 31,
2020.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2021, and 2020, the estimated fair values of the liability measured on a recurring basis are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    average volatility</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">85.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">69.8</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    yield</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8.5</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8.5</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    life</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.33
                                            Years</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.33
                                            Years</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.73</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.17</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
continuity schedule of the Series A Preferred Stock warrants is set forth below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Life (years)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Intrinsic Value</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: justify">Outstanding, December 31, 2019</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">48,532</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">24.98</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">4.33</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Forfeited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Outstanding, December 31, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,532</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"></TD><TD STYLE="text-align: right">24.98</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.33</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Forfeited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Outstanding and Exercisable, December 31, 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">48,532</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">24.98</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.33</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 134; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Equity
Incentive Plan</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
2018 Equity Incentive Plan provides for equity incentives to be granted to our employees, executive officers or directors and to key
advisers and consultants. Equity incentives may be in the form of stock options with an exercise price of not less than the fair market
value of the underlying shares as determined pursuant to the 2018 Equity Incentive Plan, restricted stock awards, other stock-based awards,
or any combination of the foregoing. The 2018 Equity Incentive Plan is administered by the Company&rsquo;s compensation committee or,
alternatively, if there is no compensation committee, the Company&rsquo;s board of directors. We have reserved 3,000,000 shares of our
common stock for issuance under the 2018 Equity Incentive Plan. As of December 31, 2021, 384,167 shares have been granted under the 2018
Equity Incentive Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Restricted
Stock Units</I>. We may grant restricted stock units under our 2018 Plan. Restricted stock units are bookkeeping entries representing
an amount equal to the fair market value of one share of our common stock. Subject to the provisions of our 2018 Plan, the administrator
determines the terms and conditions of restricted stock units, including the vesting criteria and the form and timing of payment. The
administrator, in its sole discretion, may pay earned restricted stock units in the form of cash, in shares or in some combination thereof.
Notwithstanding the foregoing, the administrator, in its sole discretion, may accelerate the time at which any restrictions will lapse
or be removed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 16, 2019, five individuals were appointed to the Board of Directors
of the Company to serve as directors. Each individual entered into an agreement pursuant to which they will serve as a director and pursuant
to which they would each receive a grant of $75,000 worth of Restricted Stock Units (&ldquo;RSUs&rdquo;) issuable under the Company&rsquo;s
2018 Equity Incentive Plan (the &ldquo;2018 Plan&rdquo;). The RSUs vest annually in one third increments from the date of appointment.
Under the terms of the director agreements, the Company has also agreed to pay each director $25,000 per annum, payable in equal quarterly
installments commencing 90 days following the Company becoming a publicly reporting company under the Securities Exchange Act of 1934,
as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2021 and 2020, pursuant to the agreements with directors and officers 20,626 and 21,530 RSUs were
issued with a value of $490,067 and $459,589 included in wages, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, there was $390,067 of total unrecognized compensation cost related to non-vested share-based compensation arrangements
which is expected to be recognized within the next two years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
continuity schedule of the Restricted Stock Units (RSU) follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSU</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Life (years)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; text-align: justify">Outstanding, December 31, 2019</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">60,169</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">24.02</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,417</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22.64</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Forfeited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,702</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27.76</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Outstanding, December 31, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61,884</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"></TD><TD STYLE="text-align: right">23.76</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.33</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Forfeited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,702</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27.76</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Outstanding, December 31, 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">59,182</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">23.57</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3.33</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Exercisable, December 31, 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">43,056</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">23.93</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3.33</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
8 &ndash; Income Taxes (Restated)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not made provision for income taxes for the years ended December 31, 2021, since the Company has the benefit of net operating
losses in these periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 135; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reconciliation of income tax benefit at the U.S. statutory rate of 21% to the Company&rsquo;s tax expense is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">December 31,</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">December 31,</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(Restated)</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left">Federal tax benefit at statutory rate</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">(241,948</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">(21,111</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">State income tax benefit, net of federal tax effect</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(95,051</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,293</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Permanent differences</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,381</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,381</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">317,618</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,023</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal components of deferred tax assets consist of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">December 31,</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">December 31,</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="text-align: center; margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0">(Restated)</P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Deferred income tax asset:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 64%; text-align: left">Net operation loss carry forwards</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">890,970</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">587,699</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Fixed assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,479</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,110</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Intangibles</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,788</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,788</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,574</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,596</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">R&amp;D tax credits</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">87,801</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">87,801</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left">Total deferred income tax asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,039,612</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">721,994</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,039,612</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(721,994</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total deferred income tax asset</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has approximately $3,000,000 of net operating losses (&ldquo;NOL&rdquo;) carried forward to offset taxable income, if
any, in future. In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some
portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation
of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled
reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on
the assessment, management has established a full valuation allowance against all of the deferred tax asset relating to NOLs for every
period because it is more likely than not that all of the deferred tax asset will not be realized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 136; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
9 &ndash; Restatement of Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s financial statements as of and for the year ended December 31, 2021, contained an understatement of legal and
professional expenses of $420,000 for the valuation of a total of 210,000 shares (105,000 shares on a post-split basis) of incentive
stock transferred from a significant shareholder of the Company , who is also the wife of our Chairman and CEO, to a consultant for
the Company in a private transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Originally</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Reported
                                            <BR> ($)</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Restatement Adjustment<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">As</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Restated</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">($)</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Stockholders&rsquo; Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 52%; text-align: left">Additional paid-in capital</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">3,730,867</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">420,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">4,150,867</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accumulated deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,375,432</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(420,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,795,432</TD><TD STYLE="text-align: left">)</TD></TR>
  </TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year
Ended December 31, 2021</B></FONT></P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Originally Reported <BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Restatement Adjustment<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As Restated ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">OPERATING EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 52%; text-align: left">Legal and professional</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">264,684</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">420,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">684,684</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Total operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,322,992</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">420,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,742,992</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,322,992</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(420,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,742,992</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">Loss before Income Taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(732,134</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(420,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,152,134</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(732,134</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(420,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,152,134</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Net loss attributable to common stockholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(835,196</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(420,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,255,196</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Net loss per shares - basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.08</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.04</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.12</TD><TD STYLE="text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Originally Reported <BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Restatement Adjustment<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">As
                                            Restated</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">($)</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash Flows From Operating Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 52%; text-align: left">Net loss</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">(732,134</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">(420,000</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">(1,152,134</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">490,067</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">420,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">910,067</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
10 &ndash; Subsequent Events</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
evaluated all additional events subsequent to the balance sheet date through June 3, 2022, the date the financial statements were
available to be issued, and determined the following items:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 22, 2022, the Company received notice of forgiveness for the PPP loan entered into on March 9, 2021 for $73,007 and $641 in interest
that reduced the note liability in its entirety.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2022, and March 11, 2022, the Company sold $365,000 and $224,985, respectively, in 6% convertible notes (the &ldquo;Notes&rdquo;),
which bear 6% interest, are repayable three years from the date of issuance, and will convert automatically into shares of common stock
(the &ldquo;Conversion Shares&rdquo;) at a conversion price of $2.50 per share upon closing of this offering. Boustead Securities LLC
acted as placement agent for this offering and received compensation of $36,500 and $22,250, respectively, and warrants to purchase shares
of common stock equal to 10% of the Conversion Shares, exercisable at the conversion price of the Convertible Notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective March 30, 2022, the Company issued
1,678 shares (839 shares post-reverse split) of common stock to correct an issuance error on completion of the 2018 share exchange which
is valued at $16,340 common stock to be issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective April 1, 2022, pursuant to the consent of the Company&rsquo;s board of directors
and a majority of its common stockholders, the Company effectuated a two-for-one reverse split, pursuant to which each stockholder received
one share of common stock for every two shares held.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 6, 2022, the Company submitted the final invoice for &ldquo;Topic 345: Predictive Biomarkers of Prostate Cancer Patient Sensitivity
for Radiation Late Effects,&rdquo; for $211,455, following the completion of the Final Quarterly Progress Report to NIH covering the
performance period of 9/16/2019-3/15/2022. The invoice was paid in full on April 27, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 137; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

























<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <B>1,660,000 Units</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <B>Each Unit Consisting of One Share of Common
Stock and </B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <B>One Warrant to Purchase One Share of Common
Stock</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>SHUTTLE PHARMACEUTICALS HOLDINGS, INC.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="coverlogo.jpg" ALT="" STYLE="height: 194px; width: 280px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">_______________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PROSPECTUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">______________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt">Boustead Securities,
LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">______________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">_______, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Through
and including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022 (the
25</FONT><FONT STYLE="font-size: 12pt"><SUP>th</SUP></FONT><FONT STYLE="font-size: 10pt">&nbsp;day after the date of this prospectus),
all dealers effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus.
This is in addition to a dealer&rsquo;s obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold
allotment or subscription.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 138 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement
filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell and is not soliciting an offer
to buy these securities in any jurisdiction where the offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: red"><B>SUBJECT
TO COMPLETION, </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRELIMINARY PROSPECTUS DATED AUGUST
18, 2022</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 143px; width: 245px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SHUTTLE
PHARMACEUTICALS HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>913,334
</B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>shares of common stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus relates to the resale of 913,334 shares of common stock, par value $0.00001 per share of the Company, which includes
(i) 196,667 shares of common stock and warrants to purchase 197,667 shares of common stock issuable upon conversion of
certain convertible notes and (ii) exercise of warrants to purchase shares of common stock held by the selling stockholder named
in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to this offering, there has been no public market for our common stock. We have reserved the symbol &ldquo;SHPH&rdquo; for purposes of
listing our Common Stock on The Nasdaq Capital Market and have applied to list our shares on Nasdaq. There is no guarantee or assurance
that our shares of common stock will be approved for listing on Nasdaq. We will not receive any proceeds from the sale of shares by the
selling stockholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any shares sold by the selling
stockholders until our common stock is listed or quoted on an established public trading market will take place at $6.00, which
is the per share public offering price we are selling in our initial public offering. Thereafter, any sales will occur at prevailing
market prices or in privately negotiated prices. The distribution of securities offered hereby may be effected in one or more transactions
that may take place in ordinary brokers&rsquo; transactions, privately negotiated transactions or through sales to one or more dealers
for resale of such securities as principals. Usual and customary or specifically negotiated brokerage fees or commissions may be paid
by the selling shareholders. No sales of the shares covered by this prospectus shall occur until the common stock sold in our initial
public offering begins trading on Nasdaq.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
______, 2022, a registration statement under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) with respect to
our initial public offering of shares of our common stock was declared effective by the U.S. Securities and Exchange Commission. We received
approximately $___ million in net proceeds from the offering (assuming no exercise of the underwriters&rsquo; over-allotment option)
after payment of underwriting discounts and commissions and estimated expenses of the offering.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our common stock involves a high degree of risk, including the risk of losing your entire investment. See &ldquo;Risk
Factors&rdquo; beginning on page 13 of the primary offering prospectus contained in this Registration Statement to read about
factors you should consider before buying our common stock.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission nor any other regulatory body has approved or disapproved
of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 139 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RESALE
PROSPECTUS SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following summary provides an overview of all material information contained in this prospectus. It does not contain all of the information
you should consider before making a decision to purchase our shares of common stock in the offering. Prior to investing in our common
stock, you should carefully and thoroughly read the more detailed information in this prospectus and review our financial statements
and all other information that is included in this prospectus, including the section entitled &ldquo;Risk Factors&rdquo; beginning at
page 13.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the context otherwise requires, references in this prospectus to &ldquo;Shuttle Pharma,&rdquo; &ldquo;Shuttle Pharmaceuticals,&rdquo;
&ldquo;the Company,&rdquo; &ldquo;we,&rdquo; &ldquo;our&rdquo; and &ldquo;us&rdquo; refers to Shuttle Pharmaceuticals Holdings, Inc.
and its subsidiary, Shuttle Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Founded
in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharmaceuticals is a discovery and development stage
specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT). Our mission
is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting
the late effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers,
we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment, or in combination
with surgery, chemotherapy and immunotherapy. We currently have no FDA approved products and we have not yet applied for a new drug application.
To date, we have been funded by investments from private investors and government contracts obtained from the National Institutes of
Health (NIH) for performing research. We have no product revenue and our independent auditors, in their report dated June 3, 2022, expressed
doubt about our ability to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
the major advances in radiation oncology have focused on improving technology to increase the amount of radiation that can be administered
to a tumor without damaging adjacent, normal tissues. Examples of other such technologies include intensity modulated radiation therapy
(IMRT), stereotactic body radiation therapy (SBRT), stereotactic radiosurgery (SRS) and proton therapy &ndash; the backbones of state-of-the-art
RT. All offer improvements in physical radiation dose shaping. The basic principle underlying the effectiveness of RT for curing cancers
lies in the differential cancer cell kill achieved in tumors, as compared to the effects of RT on the normal surrounding tissues, which
is achieved by delivery of highly conformal RT doses &ndash; in other words, delivery of high-dose to volumes that are shaped to conform
to the target cancers while minimizing the dose to surrounding normal tissues. The treated volumes frequently include sensitive normal
tissues, thereby limiting the magnitudes of the prescribed RT doses. We suggest that technological innovations to define tumor volumes
and shape radiation delivery have reached an effectiveness plateau and that further improvements in RT outcomes will require pharmacological
and immunological approaches to sensitize cancers, protect normal tissues and engage the immune system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
present, the drugs being used for sensitizing cancers to RT are chemotherapeutic agents possessing radiation sensitizing properties as
secondary effects. With the exception of Cituximab, a growth factor targeting monoclonal antibody biologic, all other drugs used as radiation
sensitizers are used &ldquo;off-label&rdquo; to address the clinical need for radiation sensitizers. For example, certain chemotherapeutic
agents, such as 5-fluorouracil, capecitabine and cis-platinum, are approved as single agents for cancer treatment, but are used &ldquo;off-label&rdquo;
as radiation sensitizers in combination with RT. Treatments with such agents are associated with inherent toxicities associated with
the drug&rsquo;s primary, single-agent mechanisms of action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuttle
Pharma&rsquo;s platform of sensitizers offers a pipeline of product candidates designed to address the urgent clinical need and the current
limitations of using &ldquo;off-label&rdquo; drugs with potential new sensitizer agents. Our pipeline includes Ropidoxuridine, our lead
clinical sensitizer drug candidate, to sensitize rapidly growing cancer cells and selective histone deacetylase (HDAC) inhibitors to
sensitize cancer cells and stimulate the immune system. Our novel technologies will be tested in combinations with radiation therapies
(conventional X-ray and proton radiation therapies) and in combinations with immune-therapies. To date, Ropidoxuridine has completed
a Phase I clinical trial. Our HDAC inhibitor platform drug candidates have been tested in preclinical models of solid tumor cancers.
Ropidoxuridine and the selective HDAC6 inhibitor SP-2-225 are the clinical and preclinical candidate drug products we propose to develop
using funding from this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
intellectual property for Ropidoxuridine includes novel formulations that show improved drug bioavailability (in a preclinical animal
model) and for sensitizing cancers to proton and to conventional radiation therapies. Our HDAC inhibitor intellectual property includes
new patent applications and granted patents for composition of matter and methods of use for treating cancers with HDAC inhibitors in
combinations with radiation therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 140; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Alt-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have obtained funding for our research from private investors and Small Business Innovation Research (&ldquo;SBIR&rdquo;) contracts
obtained through the National Institutes of Health (&ldquo;NIH&rdquo;) to support the development of the radiation sensitizer Ropidoxuridine
in a Phase I clinical trial. We have also received awards for Phase I and II SBIR contracts for development of human cell cultures for
health disparities studies and predictive biomarkers of radiation late effects through the NIH&rsquo;s National Cancer Institute. The
completed Phase I and II funded discovery work performed to establish &ldquo;Cell-based Models for Prostate Cancer Health Disparity Research&rdquo;
and to develop &ldquo;Predictive Biomarkers of Prostate Cancer Sensitivity for Radiation Late Effects&rdquo; enables Shuttle Pharma to
apply for NIH SBIR Phase IIb funding to develop these products for advancing basic science and clinical research.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Product Candidates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. Food and Drug Administration (the &ldquo;FDA&rdquo;) considers new molecular entities as drugs that use new and unique mechanisms
of action for treating medical conditions. Our clinical stage agent, Ropidoxuridine (IPdR), increases DNA double strand breaks following
radiation exposure and our inhibitors of histone deacetylases (HDACs) stimulate the immune system to produce T-lymphocytes targeting
cancer cells.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
objective is to improve the outcomes of cancer treatment through RT while reducing its side effects by:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sensitizing
    growing cancer cells to render them more susceptible to the effects of RT;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Activating
    the DNA damage response pathway to protect normal cells located near cancers; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Activating
    the immune response to antigens present on irradiated and un-irradiated cancer cells.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
our knowledge, no drug utilizing the mechanisms of our candidate small molecule drugs has received FDA approval as a radiation sensitizer.
We have developed, to clinical stage, the small molecule strategies to sensitize growing cancer cells in tumors to conventional RT and
to large fraction radiation therapy. The pre-clinical technology, HDAC inhibitor platform, is designed to target cancer cells while protecting
healthy tissue/normal cells, thus enhancing the candidate radiation sensitizer product pipeline. The selective HDAC6 inhibitor (SP-2-225),
discovered and developed by our scientists, has inhibited the growth of melanoma tumors and breast cancers in animal models by an immune
stimulating mechanism.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are focused on developing a clinical stage product candidate (Ropidoxuridine) and a pre-clinical product candidate, selective HDAC6 inhibitor
(SP-2-225). We propose to develop these drug candidates as illustrated below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview
of Radiation Sensitizer Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="image_003.jpg" ALT="" STYLE="height: 211px; width: 550px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ropidoxuridine,
the clinical stage molecule, sensitizes rapidly growing cancers to radiation therapy by increasing reactive free radicals that increase
DNA strand breaks. Ropidoxuridine development for treating glioblastoma will require Phase II clinical testing for use in treating brain
tumors. The selective HDAC6 inhibitor, SP-2-225, a pre-clinical stage molecule, activates the innate immune system to target irradiated
tumor cells by immune mechanisms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 141 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Alt-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ropidoxuridine
(IPdR)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ropidoxuridine
(IPdR) is an orally available halogenated pyrimidine (5-iodo-2-pyrimidinone-2-deoxyribose) with strong cancer radiation sensitizing properties.
As a prodrug that does not become an active drug until after it is metabolized, IPdR is absorbed and metabolized to IUdR by enzymes in
the liver and in cancer cells. IUdR, a halogenated pyrimidine, is incorporated into DNA by rapidly growing cancer cells. Cells that incorporate
IUdR into their DNA then become more sensitive to the effects of RT. The Phase I clinical trial of Ropidoxuridine and RT, supported by
an NIH SBIR contract to Shuttle Pharma, was sub-contracted to the Brown University Oncology Group (BrUOG) at the LifeSpan/Rhode Island
Hospital. This Phase I clinical trial has been completed and the results were initially reported by the sub-contractor at the 30th EORTC-NCI-AACR
Symposium in November 2018 and published in the medical journal Clinical Cancer Research in 2019. A maximum tolerated dose (MTD) of 1200
mg/day for 28 days was established for use in combination with radiation therapy to achieve therapeutic blood levels of IUdR.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reported Phase I clinical trial of Ropidoxuridine in combination with RT provides the foundation for proposed Phase II clinical trials
to establish the data necessary for the FDA to determine efficacy in treating brain tumors, sarcomas and pancreatic cancers, diseases
that offer potential for orphan designations. The FDA granted approval of our application for orphan-drug designation for IPdR for the
treatment of glioblastoma. Orphan designation protects the marketing position of Ropidoxuridine for up to seven years after marketing
approval is received from the FDA. This approval integrates well into the overall intellectual property strategy for Ropidoxuridine which
includes filed patent applications for &ldquo;Method and Compositions for Cancer Therapies that Include Delivery of Halogenated Thymidines
and Thymidine Phosphorylase Inhibitors in Combination with Radiation.&rdquo; We believe that we are positioned to initiate Phase II clinical
studies with Ropidoxuridine and RT in 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Extended
Bio-availability Ropidoxuridine (IPdR/TPI)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ropidoxuridine
and Tipiracil (IPdR/TPI) is a new combination drug formulation designed to increase the bio-availability and incorporation of IUdR into
DNA. Shuttle Pharma&rsquo;s preclinical studies of the combination of IPdR/TPI have shown up to 10-fold greater bioavailability of the
active metabolite (IUdR) as compared to IPdR administered alone in controls. We have filed an application under the Patent Cooperation
Treaty (or PCT) for the intellectual property. This new formulation will be tested in a Phase I clinical trial as a sensitizer of rectal
cancers. Another nucleoside analogue, Trifluridine has been formulated in combination with Tipiracil (TAS-102) to enhance drug uptake
by colon cancer cells to prolong survival in patients treated for metastatic colorectal cancers, as has been reported in the New England
Journal of Medicine (N Engl J Med. 2015; 372:1909-1919). We anticipate testing for uptake of IPdR by colorectal cancer cells following
administration of the IPdR/TPI drug formulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proton
radiation therapy is an advanced form of radiation therapy using charged proton particles (p+). Proton RT differs from conventional RT
in that the radiation is delivered by a beam of protons to precisely target tumors and, due to the favorable physics of energy deposition
by proton particles, there is no exit beam, resulting in less radiation to surrounding healthy tissues. The use of Proton RT is expanding
rapidly in the U.S. and worldwide. According to the National Association of Proton Therapy, more than 30 facilities are currently in
operation in the U.S. and an additional 30 facilities are planned for installation over the next five years. (<I>See </I>www.proton-therapy.org.)
Much attention has been paid to proton therapy in the popular press, promoting its advantages, as well as addressing the increased health
care costs. The role of a sensitizer that offers proton radiation sensitization presents an opportunity to enhance the value of proton
radiation therapy as a cancer treatment modality. We believe the development of a proton therapy targeted radiation sensitizer, such
as IPdR/TPI, is timely and consistent with current market needs to advance protons as a therapeutic modality.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to perform clinical studies to support the development of the IPdR/TPI combination to advance this drug candidate with proton
RT. The addressable market includes diseases such as brain tumors, cancers of the head and neck, GI cancers and lung cancers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Selective
HDAC Inhibitors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
roles of acetylation in the epigenetic regulation of chromatin structure and gene expression rests on the balance of activities of histone
acetyltransferases (HATs) and histone deacetylases (HDACs). Increased acetylation of histones leads to changes in chromatin structure
and accessibility for key cellular proteins to specific target sites. Acetylations of non-histone proteins also modulates their enzymatic
activities. We have discovered novel HDAC inhibitor molecules and testing in preclinical models has shown cancer radiation sensitizing
properties, normal tissue protective properties and selective HDAC6 inhibitory properties. Our HDAC inhibitor platform, described below,
will be evaluated in pre-clinical studies of radiation sensitization of solid tumors and activation of the immune response to irradiated
cancer cells.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 142 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Alt-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-1-161
    is our candidate lead pre-clinical, pan-HDAC inhibitor that initiates the mutated in ataxia-telangiectasia (ATM) response pathway.
    ATM is activated by ionizing radiation induced DNA damage. Activated ATM phosphorylates critical factors involved in DNA repair,
    apoptosis, and cell cycle checkpoint. Phosphorylation of the molecules in these pathways, in turn, activates the cellular functions.
    ATM also can be activated by HDAC inhibitors and imparts radiation protective properties. Using rational drug design, we discovered
    HDAC inhibitors and ATM activators capable of radiation sensitizing cancer cells and protecting normal cells. SP-1-161 is our lead
    candidate radiation sensitizing pan-HDAC inhibitor.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-2-225
    is our candidate lead selective histone deacetylase inhibitor of HDAC6. HDAC6 is a member of the Class IIb HDAC family. Selective
    HDAC6 inhibitors are an emerging class of pharmaceuticals due to effects on neurodegenerative diseases, cancers and immunology. Specifically,
    the potential to affect regulation of the immune system and enhance the immune response to cancers is of significant interest as
    an adjuvant treatment in combination with radiation therapy. We propose to test our HDAC6 inhibitors for a role in enhancing post-RT
    immune responses to antigens produced in irradiated cancers for their effects on control of local and metastatic disease.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-1-303
    is a selective Class I HDAC inhibitor that preferentially affects histone deacetylases HDAC1 and HDAC3 and shows direct and selective
    cytotoxicity for ER positive and Her2 negative breast cancer cells. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Drug
Development Projects for Radiation Treatment of Cancers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
advance research that is complementary to our radiation sensitizer discovery and development projects, the NIH has awarded SBIR contracts
to us to develop reagents for health disparities research and to develop biomarkers of radiation sensitivity for patients treated with
radiation therapy. Our scientists have been engaged in developing model human cell systems for testing radiation sensitizers in tissue
cultures. This project provides an efficient and low-cost screening technology to provide data for the FDA&rsquo;s determination of drug
efficacy and to identify candidate lead molecules for treating prostate cancers in African-Americans. First developed at Georgetown University,
the conditional cellular reprogramming (CRC) technology offers the ability to establish new cell lines from biopsies of cancers. We have
obtained a sub-license from Propagenix, Inc. to establish 100 normal and cancer cell lines from prostate biopsy samples for use in screening
drug candidates and for health disparities research. A more detailed description of the Propagenix license is set forth on page 60 below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, to identify patients who may be more sensitive to radiation therapy and are at a higher risk to suffer treatment-related complications,
collaborative research with Georgetown University has led to discovery of metabolite biomarkers, which are predictive of patient responses
to radiation therapy. A patent for the intellectual property has been submitted by Georgetown University with Shuttle Pharma scientist
(Scott Grindrod, PhD) as co-inventor. Developmental work in health disparities and predictive biomarker development has been supported
by NIH SBIR contracts to Shuttle Pharmaceuticals for the following areas:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Develop
    prostate cancer cell lines from African-American men with the goal of advancing research to address prostate cancer health disparities
    (designated SBIR &ldquo;Topic 352: Cell-Based Models for Prostate Cancer Health Disparity Research- Moonshot Project (Phase II)&rdquo;);
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Develop
    predictive biomarkers of prostate patient outcomes following treatment with SBRT (designated SBIR &ldquo;Topic 345: Predictive Biomarkers
    for Prostate Cancer Sensitivity for Radiation Late Effects (Phase I and II).&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 143 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Alt-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NIH&rsquo;s SBIR program is designed to encourage small businesses to engage in Federal Research/Research and Development (&ldquo;R/R&amp;D&rdquo;)
that has the potential for commercialization. Shuttle Pharma will apply for additional NIH SBIR grants and contracts to fund advancement
of these projects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Market
Opportunity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
American Cancer Society (Cancer Facts &amp; Figures 2020) estimates 1,806,590 new cancer cases and 606,520 cancer deaths each year in
the United States and, according to the American Society for Radiation Oncology, more than 50% of patients undergo RT at some point in
the treatment of their diseases. RT is used to treat cancers of the lung, breast, brain, esophagus, pancreas, rectum, head and neck,
uterus, lymphomas and sarcomas. At present, we are developing drug candidates to address brain, pancreas, rectum, sarcomas and lymphomas,
although we may test and seek approval for our drug candidates to treat other cancers in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
there is only one drug (the monoclonal antibody, Cetuximab) that has received FDA approval for the radiation sensitizer indication. Cetuximab
is a recombinant monoclonal antibody that binds to epidermal growth factor receptor (EGFR) and inhibits the binding of epidermal growth
factor (EGF). Cetuximab is administered via intravenous infusion and is used as monotherapy or in combination with other chemotherapies
or radiation therapy. In clinical trials, cetuximab was associated with serious and fatal infusion reactions, cardiopulmonary arrest
or sudden death, and serious dermatologic toxicities, toxicities that have created deterrents to its use as a radiation sensitizer. Present
treatment utilizes &ldquo;off-label&rdquo; small molecule drugs, which are cytotoxic chemotherapy agents that also sensitize, but do
not have radiation sensitization as an FDA approved indication. Moreover, since &ldquo;off-label&rdquo; drugs are cytotoxic, they are
often associated with intrinsic acute and chronic side effects. Nevertheless, these drugs have shown clinically significant improvements
in disease control and survival and are typically included in standard-of-care treatment recommendations for patients with cancers of
the head and neck, brain, lung, esophagus, stomach, pancreas, liver, bladder, lymphomas and sarcomas. As a result, we believe that there
is a significant market opportunity for our product candidates. Based on cancer incidence data published by the American Cancer Society,
we have estimated the numbers of patients presenting with local/regional disease, suitable for treatment with RT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Estimated
RT Cases by Disease Site</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cancer Type</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cases Diagnosed Annually</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Estimated RT Cases</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 30%; text-align: center">Brain</TD><TD STYLE="text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 32%; text-align: center">23,890</TD><TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 30%; text-align: center">21,979</TD><TD STYLE="width: 1%; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">Pancreas</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">57,600</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">32,832</TD><TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">Sarcomas</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">13,130</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">4,000</TD><TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">Rectum</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">43,340</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">26,437</TD><TD STYLE="text-align: center">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
cancer cases for each disease site are estimated from American Cancer Society Facts &amp; Figures 2020 publication. The fraction of patients
optimally receiving RT for each disease site were obtained from published estimates of Delaney G, Jacob S, Featherstone C, Barton M.
The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer.
2005 Sep 15;104(6):1129-37. doi: 10.1002/cncr.21324. The Estimated RT cases were obtained by multiplying Cases Diagnosed Annually by
the fraction receiving RT for optimal utilization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Development Strategy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
goal is to maintain and build upon our leadership position in radiation sensitization. We plan to develop Ropidoxuridine and the HDAC6
inhibitor (SP-2-225) and, if approved by the FDA, to commercialize our product candidates for the treatment of cancers. While this process
may require years to complete, we believe achieving this goal could result in radiation sensitizer and immunotherapy products for cancer
treatment. Key elements of our strategy include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Capitalize
    on Ropidoxuridine as an orally available, small molecule radiation sensitizer</B>. To date, there is one drug (Cetuximab) approved
    by the FDA specifically as a radiation sensitizer. If we are successful in developing Ropidoxuridine to obtain FDA approval, a small
    moleculesensitizer will be enabled for clinical applications for radiation sensitization.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expand
    our leadership position within radiation sensitizers</B>. In addition to our traditional radiation sensitizers, we plan to advance
    our near-term pipeline to include radiation sensitizers for proton therapy. Proton Therapy is growing worldwide as a form of radiation
    therapy due to its unique beam shaping characteristics. As a result, this new technology offers a major opportunity for Shuttle Pharma
    to strive to develop a sensitizer drug for proton therapy sensitization applications.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Execute
    a disciplined business development strategy to strengthen our portfolio of product candidates</B>. We have built our current product
    pipeline through in-house development, partnerships with leading academic institutions and through successful in-licensing deals.
    We will continue to evaluate new in-licensing opportunities and collaboration agreements with leading academic institutions and other
    biotechnology companies around programs that seek to address areas of high unmet need and for which we believe there is a high probability
    of clinical success, including programs beyond our target franchise areas and current technology footprint.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 144 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Alt-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Invest
    in our HDAC platform technology to maximize its utility across cancer therapies</B>. We are initially applying the platform to develop
    drugs for cancer radiation sensitization and normal tissue radiation protection. In addition, these drugs also affect immune regulatory
    properties. We intend to invest to investigate other properties of our platform technology.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enter
    into collaborations to realize the full potential of our platform. </B>The breadth of our HDAC technology platform enables other
    therapeutic applications, in addition to radiation sensitization and immune therapy. We intend to seek collaborations centered on
    our platform to maximize applications for our HDAC inhibitor technology.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
propose the following clinical development plan to identify, develop and commercialize drugs for use in cancer treatments in combination
with RT:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Develop
Ropidoxuridine (IPdR) for Orphan disease indications to take to market</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacture
    24 kg of Ropidoxuridine and formulate for use in clinical trials.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct
    a Phase II clinical trial of Ropidoxuridine, Temodar and RT in glioblastoma.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct
    a Phase III clinical trial in glioblastoma to secure FDA approval to market Ropidoxuridine for the glioblastoma indication using
    orphan disease designation for marketing protection.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Develop
Ropidoxuridine and tipiracil (IPdR/TPI) for colorectal cancer indications to take to market</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Formulate
    5 kg of IPdR/TPI for use in pre-clinical efficacy studies, IND-enabling studies and a Phase I clinical trial.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct
    IND-enabling studies; obtain IND for IPdR/TPI with RT.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct
    a Phase I clinical trial of IPdR/TPI with RT in rectal cancers to establish the MTD.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct
    a Phase II clinical trial of IPdR/TPI with RT in rectal cancer.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Develop
HDAC Inhibitors for use in breast cancer for immune activation after RT</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complete
    pre-clinical studies of HDAC inhibitors in human xenograft tumor models.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&cir;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-1-161
    with RT in breast cancers.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&cir;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-1-303
    with RT in ER+, Her2- breast cancers.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&cir;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-2-225
    with immune checkpoint inhibitors in lung cancers.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advance
    the lead HDAC6 inhibitor, SP-2-225, for IND-enabling.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct
    Phase I clinical trials to determine MTD.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct
    Phase II clinical trials for proof-of-concept efficacy evaluation in lung cancers.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 145 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Alt-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Management
Team</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management team has significant experience in radiation oncology and in progressing products from early-stage research through clinical
trials. Our CEO, Anatoly Dritschilo, M.D., is an experienced clinician and researcher who has held senior academic and management positions
including serving as Department Chairman, Hospital Medical Director and Cancer Center Director at Georgetown University Medical Center.
Prior to co-founding our company, Dr. Dritschilo was a co-founder of Oncomed, Inc., a company that became public as NeoPharm, Inc. (Nasdaq:
NEOL). He has experience in providing care for patients undergoing treatment for cancers of the prostate, breast, brain, lung, sarcomas
and GI systems. Dr. Dritschilo has directed basic science research supported by grants from the National Cancer Institute (&ldquo;NCI&rdquo;)
and performed clinical trials using drugs and radiation therapy. In addition, Dr. Dritschilo served as the principal investigator of
pharmaceutical industry sponsored clinical evaluations of human interferon alpha-2 (Bristol-Myers) with radiation therapy and antisense
raf oligonucleotides, LErafAON (NeoPharm) with radiation therapy. He serves as a Radiation Biology and Radiation Oncology expert on committees
of the NIH to review Program Project (P01) grant applications, Specialized Program of Research Excellence (SPORE) grant applications
and investigator-initiated research project (R01) applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Dritschilo is supported in our clinical development effort by Tyvin Rich, MD, our Chief Clinical Officer and Medical Director. Dr. Rich
is the former Professor and Chairman of the Department of Therapeutic Radiology and Oncology at the University of Virginia Health Sciences
Center and proton radiation therapy specialist at the Hampton Proton Therapy Center in Hampton, Virginia. Dr. Rich has served as principal
investigator on multi-modality clinical trials for the treatment of gastrointestinal (GI) cancers and helped to develop treatment with
5-fluorouracil (5-FU) as a radiation sensitizer for use with RT in the treatment of GI cancers. He has extensive cancer clinical trial
experience in developing radiation sensitizer applications through his participation in the Radiation Therapy Oncology Group (RTOG).
Dr. Rich is a co-inventor with scientists at the University of Virginia of the Proton Activated Atomic Medicine technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
administrative services are provided by Peter Dritschilo, MBA, who has served as our President and COO since 2012. Mr. Dritschilo&rsquo;s
experience in hospital administration and management of medical oncology clinical services and radiation therapy facilities, including
management of day-to-day operations, human resources and financial oversight. Peter Dritschilo is the son of our Chairman and CEO, Dr.
Anatoly Dritschilo. The addition of Michael Vander Hoek as our CFO and Vice President for Operations and Regulatory expands our capability
to provide the level of management needed for the proposed expansion of clinical trials. Mr. Vander Hoek has served as administrative
director of the Lombardi Comprehensive Cancer Center (LCC) for the past 12 years and has extensive experience in negotiations, management
and supervision of Contract Research Organizations (CROs) and research contracts in general. As the administrative director of the Lombardi
Comprehensive Cancer Center, Mr. Vander Hoek also served as the chief financial officer. Taken together, we believe our leadership team
of highly qualified specialists will help us achieve the proposed milestones for the development of radiation sensitizer products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pre-IPO
Bridge Financing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2021, we completed a $500,000 note offering pursuant to which we sold to two accredited investors (the &ldquo;Investors&rdquo;)
units consisting of (i) a $250,000 promissory note bearing 10% interest, repayable at the time of this offering (the &ldquo;Note&rdquo;)
and (ii) a warrant to purchase 250,000 shares (the &ldquo;Warrant Shares&rdquo;) of our common stock at an exercise price of $1.00 per
share (the &ldquo;Warrant&rdquo;). Immediately before closing on the Offering, the Notes will be repaid and cancelled in exchange for
the exercise of the Warrants and issuance of the 500,000 Warrant Shares to the Investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> February and March 2022, we sold a total of $365,000
and $225,000, respectively, in convertible notes (&ldquo;Convertible Notes&rdquo;) to certain accredited investors, which notes will
automatically convert upon effectiveness of this offering at a conversion price of 50% of the per unit offering price (the &ldquo;Conversion
Units&rdquo;). In addition, each of the Convertible Note holders will be entitled to demand registration rights, and we are required
to register the shares underlying the Convertible Notes within 180 days of the closing of this offering. We are using the net proceeds from the Convertible
Notes offering to expand our current operations, including our technology and intellectual property portfolio, and to fund the costs
of this offering. Any funds remaining will be used for working capital and other general corporate purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2022, we completed a $125,000 note and warrant offering pursuant to which we sold to three accredited investors (the &ldquo;Investors&rdquo;)
units consisting in total of (i) $125,000 in promissory notes bearing 10% interest, repayable at the time of this offering (the &ldquo;Note&rdquo;)
and (ii) warrant to purchase a total of 50,000 shares (the &ldquo;Warrant Shares&rdquo;) of our common stock at an exercise price of
$2.50 per share (the &ldquo;Warrants&rdquo;).</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boustead
Securities LLC (&ldquo;Boustead&rdquo;) acted as placement agent in both the Note and Warrant offering and the Convertible Notes offering,
pursuant to which Boustead waived its cash compensation related to the Note and Warrant offering and received cash compensation of $36,500
and $22,250 in each of the February and March 2022 closings, respectively, and also received (i) warrants to purchase 5,000 shares
of common stock, exercisable at $2.50 per share, and (ii) warrants to purchase 10% of the total number of Conversion Shares, exercisable
at the conversion price of the Convertible Notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
Risk Factors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to a number of risks you should be aware of before making an investment decision. These risks are discussed more
fully in the &ldquo;Risk Factors&rdquo; section of this prospectus at page 13 immediately following this prospectus summary. These risks
include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    success is primarily dependent on achieving the development, regulatory approval and commercialization of our product candidates,
    both of which are in the early stages of development.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    approach to the discovery and development of innovative radiation oncology drugs based on our HDAC small molecule delivery platform,
    which is novel, unproven and may not result in marketable products.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have no product revenue, have incurred significant losses since inception, may never become profitable and may incur substantial
    and increasing net losses for the foreseeable future as we continue the development of, and seek regulatory approvals for our product
    candidates.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 146 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Alt-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    clinical trials of our product candidates fail to demonstrate safety and efficacy, which are ongoing determinations that are solely
    within the authority of the FDA, we may be unable to obtain regulatory approvals to commercialize our product candidates.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have not generated any revenue and have incurred losses in each year since our founding in December 2012. Our net loss for the year
    end December 31, 2021 and the six months ended June 30, 2022 was $1,152, 134 and $1,279,114, respectively. As
    of June 30, 2022, we had an accumulated deficit of $7,126,082 and received a &ldquo;going concern&rdquo; opinion from
    our independent auditors for the fiscal year ended December 31, 2021. As a clinical stage pharmaceutical company, we expect to continue
    to incur significant losses for the foreseeable future. Even if we achieve profitability in the future, we may not be able to sustain
    profitability in subsequent periods.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are subject to regulatory approval processes that are lengthy, time-consuming and unpredictable. We may not obtain approval for any
    of our product candidates from the FDA or foreign regulatory authorities.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if we obtain regulatory approval, the market may not be receptive to our product candidates.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may not be able to establish collaborative partnerships with other pharmaceutical companies, through which we expect to complete
    development of, obtain marketing approval for and, if approved, manufacture and market our product candidates.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may encounter difficulties satisfying the requirements of clinical trial protocols, including patient enrollment.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may face competition from other companies in our field or claims from third parties alleging infringement of their intellectual property.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be unable to recruit or retain key employees, including our senior management team.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will need to obtain significant additional funding on acceptable terms to continue operations following this offering.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are a Phase I clinical stage pharmaceutical company with a limited operating history upon which you can evaluate our business and
    prospects. Specialty pharmaceutical product development is a highly speculative undertaking and involves a substantial degree of
    risk. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    do not currently have any product candidates in advanced clinical trials or approved for sale, and we continue to incur significant
    research and development and general and administrative expenses in relation to our operations. In addition, we have not yet demonstrated
    an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving
    fields, particularly in the specialty pharmaceutical industry.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have not submitted an application or received marketing approval for any of our product candidates. Regulatory approval of our product
    candidates is not guaranteed, and the approval process is expensive and may take several years.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
    is difficult and costly to protect our intellectual property rights.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    offering price of the primary offering and resale offering could differ.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Resale by the Selling Stockholders may cause the market price of our common stock to decline.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 147 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Alt-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Implications
of Being an Emerging Growth Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    a smaller reporting company, and as a company with less than $1.0 billion in revenue during our last fiscal year, we qualify as an
    &ldquo;emerging growth company&rdquo; as defined in the JOBS Act. For so long as we remain an emerging growth company, we are permitted
    and intend to rely on exemptions from specified disclosure and other requirements that are applicable to other public companies that
    are not emerging growth companies. These exemptions include:</FONT></TD>
    </TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">being
    permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements,
    with correspondingly reduced &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;
    disclosure;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    being required to comply with any mandatory audit firm rotation or a supplement to the auditor&rsquo;s report providing additional
    information about the audit and the financial statements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
    disclosure obligations regarding executive compensation; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemptions
    from the requirements of holding a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute
    payments not previously approved.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may take advantage of the above provisions for up to five years or until such earlier time that we are no longer an emerging growth company.
We would cease to be an emerging growth company if we have more than $1.0 billion in annual revenues, have more than $700 million in
market value of our capital stock held by non-affiliates or issue more than $1.0 billion of non-convertible debt over a three-year period.
We may also choose to take advantage of some, but not all, of the available exemptions. We have taken advantage of some reduced reporting
requirements in this prospectus. Accordingly, the information contained in this prospectus may be different than the information you
receive from other public companies in which you hold stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with
new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of some accounting standards
until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended
transition period for adopting new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting
standards as other public companies that are not emerging growth companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was formed as a limited liability company in the state of Maryland in December 2012 and was converted to a C corporation, Shuttle
Pharmaceuticals, Inc. (&ldquo;Shuttle&rdquo;), in August of 2016. In June 2018, Shuttle completed a share exchange with Shuttle Pharma
Acquisition Corp. Inc. (&ldquo;Acquisition Corp.&rdquo;), pursuant to which Shuttle Pharmaceuticals, Inc. became a subsidiary of Acquisition
Corp. and we subsequently changed the name of Acquisition Corp. to Shuttle Pharmaceuticals Holdings, Inc. Our executive offices are located
at 1 Research Court, Suite 450, Rockville, Maryland 20850 and our telephone number is (240) 403-4212. Our corporate website is www.shuttlepharma.com.
Information appearing on our corporate website is not incorporated as part of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 148 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Alt-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
RESALE OFFERING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 38%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock we are offering</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">913,334
    </FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    of Common Stock outstanding before this offering </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,312,991
    shares of common stock </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    of Common Stock outstanding after this offering </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up
    to 14,123,629 shares of common stock (1)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
    of proceeds</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will not receive any proceeds from the sale of common stock held by the selling stockholder being registered in this prospectus.
    </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposed
    Nasdaq Symbol</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SHPH</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    factors</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An investment in our securities involves a high degree of risk. See &ldquo;Risk
Factors&rdquo; beginning on page 39 of the primary offering prospectus contained in this Registration Statement and other information
included in this prospectus and the Registration Statement for a discussion of factors you should carefully consider before deciding to
invest in our common stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumes
    the issuance and sale by us of 1,660,000 units, with each unit consisting of (i) one share of commons stock and (ii) a warrant to
    purchase one share of our common stock, pursuant to the Public Offering Prospectus filed contemporaneously herewith and
    assumes the 249,000 over-allotment options available for sale to the underwriters in the Public Offering Prospectus have not
    been exercised. In addition, assumes (i) 269,444 shares of our common stock issuable upon conversion of 1,212.5 shares of Series
    A convertible preferred stock and 269,444 shares of common stock issuable upon exercise of outstanding warrants to purchase common
    stock, which will be issued upon completion of this offering (which conversion amounts do not include an 8.5% cumulative dividend
    payable, which dividend may be paid in either cash or common stock as determined by the Company), (ii) 500,000 shares of our common
    stock issuable upon exercise of warrants held by certain selling stockholders whose shares will be exercised in full at the time of
    this offering, (iii) 196,667 shares of common stock and warrants to purchase 196,667 shares of common stock issuable upon conversion
    of outstanding convertible notes, which will be convertible and issued upon completion of this offering, and (iv) the exercise of
    50,000 shares of common stock issuable upon exercise of warrants to purchase common stock. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will not receive any of the proceeds from the sale of the common stock held by the selling stockholders named in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 149 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Alt-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SELLING
STOCKHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information with respect to the selling stockholders&rsquo; beneficial ownership of shares of common
stock as of the date of this prospectus. Although there was no agreement between the Company and the stockholders to register these shares,
the Company believes the registration of these shares is beneficial to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percentage
of beneficial ownership before this offering is based on 9,313,334 shares of our common stock outstanding as of August 15,
2022. We have determined beneficial ownership in accordance with the rules of the SEC. Beneficial ownership is based on information
furnished by the selling stockholder. Unless otherwise indicated, the selling stockholder named in the following table has, to our knowledge,
sole voting and investment power with respect to the shares it beneficially owns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selling stockholders may offer for sale from time to time any or all of the shares. The table below assumes that the selling stockholders will sell all of the shares offered
for sale hereby. The selling stockholders, however, are under no obligation to sell any shares pursuant to this
prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>Names and addresses</B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of shares of common stock beneficially owned before the Offering(#)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of shares being registered in the Offering</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Number of shares of common stock beneficially owned after Offering</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percentage of class of common stock beneficially owned after Offering(*)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left">Steven Bayern</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right"> 355,000 </TD><TD STYLE="width: 1%; text-align: left"> (1) </TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right"> 250,000 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">105,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Rui Wu</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 250,000 </TD><TD STYLE="text-align: left"> (2) </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 250,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> BaseStones, Inc. </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 20,000 </TD><TD STYLE="text-align: left"> (3) </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 20,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Chris Etherington</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 16,667 </TD><TD STYLE="text-align: left"> (4) </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 16,667 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Mel Feldman</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 16,667 </TD><TD STYLE="text-align: left"> (4) </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 16,667 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Robert Frome (5) </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 16,667 </TD><TD STYLE="text-align: left"> (4) </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 16,667 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Robert Gutman</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 26,666 </TD><TD STYLE="text-align: left"> (4) </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 26,666 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">One10 Food Sciences Pte. Ltd.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 66,667 </TD><TD STYLE="text-align: left"> (4) </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 66,667 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Jerry Katzman</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 16,666 </TD><TD STYLE="text-align: left"> (4) </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 16,666 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">John &amp; Mary Lynch</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 16,666 </TD><TD STYLE="text-align: left"> (4) </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 16,666 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Lawrence Shields</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 50,000 </TD><TD STYLE="text-align: left"> (4) </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 50,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Kenneth Zuckerbrot</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 16,667 </TD><TD STYLE="text-align: left"> (4) </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 16,667 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Dan Montzka</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 66,666 </TD><TD STYLE="text-align: left"> (4) </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 66,666 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Daniel Hutt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 16,667 </TD><TD STYLE="text-align: left"> (4) </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 16,667 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Frank Bucciero</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 16,667 </TD><TD STYLE="text-align: left"> (4) </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 16,667 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Tanya White</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 16,667 </TD><TD STYLE="text-align: left"> (4) </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 16,667 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Lanier W. Moore II</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 16,667 </TD><TD STYLE="text-align: left"> (4) </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 16,667 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Varkes Churukian</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 16,667 </TD><TD STYLE="text-align: left"> (4) </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 16,667 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denotes
    the holder owns less than one percent of the outstanding common stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&plusmn;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
    ownership is determined in accordance with the rules and regulations of the SEC. In computing the number of shares beneficially owned
    by a person and the percentage ownership of that person, securities that are currently convertible or exercisable into shares of
    common stock, or convertible or exercisable into shares of our common stock within 60 days of the date hereof are deemed outstanding.
    Such shares, however, are not deemed outstanding for the purposes of computing the percentage ownership of any other person. Except
    as indicated in the footnotes to the following table, each stockholder named in the table has sole voting and investment power with
    respect to the shares set forth opposite such stockholder&rsquo;s name.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gives
    pro forma effect to the sale of 1,660,000 units, with each unit consisting of (i) one share of common stock and (ii) one
    warrant to purchase common stock, being sold in our initial public offering (&ldquo;IPO&rdquo;).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    registered broker-dealers or associates of such broker-dealers are participating in this resale offering.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of (i) 250,000 shares of common stock issuable upon exercise of warrants to purchase common stock and (ii) 105,000 shares of common
    stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of 250,000 shares of common stock issuable upon exercise of warrants to purchase common stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of shares of common stock issuable upon exercise of warrants to purchase common stock. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> (4) </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> Consists of shares of common stock and common stock
    underlying warrants issuable upon conversion of a 6% convertible note, which note automatically converts at conversion price of $2.50
    per share upon completion of the IPO. </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT> </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Frome is of counsel to the law firm Olshan Frome Wolosky LLP, which is acting as counsel to the underwriter in the Company&rsquo;s
    IPO.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 150 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Alt-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR STYLE="clear: both"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SELLING
STOCKHOLDER <FONT STYLE="text-transform: uppercase">PLAN OF DISTRIBUTION</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
there is currently no public market established for our securities, the selling stockholders have represented to the Company that they
will not offer or sell shares prior to the closing of the primary offering and listing of our common stock on the Nasdaq Capital Market
(&ldquo;Nasdaq&rdquo;). After the primary offering closes, our common stock is listed on Nasdaq and there is an established market for
these resale shares, the selling stockholder may sell the resale shares from time to time at the market price prevailing on the Nasdaq
Capital Market at the time of offer and sale, or at prices related to such prevailing market prices or in negotiated transactions or
a combination of such methods of sale directly or through brokers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selling stockholders may use any one or more of the following methods when disposing of shares or interests therein:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary
    brokerage transactions and transactions in which the broker-dealer solicits purchasers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">block
    trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block as
    principal to facilitate the transaction; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases
    by a broker-dealer as principal and resale by the broker-dealer for its account; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    exchange distribution in accordance with the rules of the applicable exchange; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">privately
    negotiated transactions; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    cover short sales made after the date the registration statement of which this Resale Prospectus is a part is declared effective by
    the SEC;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through
    the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">broker-dealers
    may agree with the selling shareholder to sell a specified number of such shares at a stipulated price per share; and </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    combination of any such methods of sale.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selling stockholder may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by
them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares
of common stock from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other applicable
provision of the Securities Act amending the list of selling stockholder to include the pledgee, transferee or other successors in interest
as selling stockholder under this prospectus. The selling stockholder also may transfer the securities in other circumstances, in which
case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the sale of our common stock or interests therein, the selling stockholder may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of the common stock and deliver these securities to close out
their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling stockholder
may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative
securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which
shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect
such transaction).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 151 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Alt-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate proceeds to the selling stockholder from the sale of the common stock offered by them will be the purchase price of the common
stock less discounts or commissions, if any. The selling stockholder reserves the right to accept and, together with their agents from
time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through agents. We will not
receive any of the proceeds from this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broker-dealers
engaged by the selling stockholders may arrange for other broker-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the selling stockholders (or, if any broker-dealer acts as agent for the purchase of shares, from the purchaser) in
amounts to be negotiated. The selling stockholders do not expect these commissions and discounts to exceed what is customary in the types
of transactions involved, and in no case will the maximum compensation received by any broker-dealer exceed seven percent (7%).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selling stockholders also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities
Act, provided that they meet the criteria and conform to the requirements of that rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
underwriters, agents, or broker-dealers, and any selling stockholders who are affiliates of broker-dealers, that participate in the sale
of the Common Stock or interests therein may be &ldquo;underwriters&rdquo; within the meaning of Section 2(11) of the Securities Act.
Any discounts, commissions, concessions or profit they earn on any resale of the shares may be underwriting discounts and commissions
under the Securities Act. The selling stockholders who are &ldquo;underwriters&rdquo; within the meaning of Section 2(11) of the Securities
Act will be subject to the prospectus delivery requirements of the Securities Act. We know of no existing arrangements between any of
the selling stockholder and any other stockholder, broker, dealer, underwriter, or agent relating to the sale or distribution of the
shares, nor can we presently estimate the amount, if any, of such compensation. See &ldquo;Selling Stockholder&rdquo; for description
of any material relationship that a shareholder has with us and the description of such relationship.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent required, shares of our common stock to be sold, the name of the selling stockholder, the respective purchase prices and public
offering prices, the names of any agents, dealer or underwriter, any applicable commissions or discounts with respect to a particular
offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement
that includes this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to comply with the securities laws of some states, if applicable, the shares of common stock may be sold in these jurisdictions
only through registered or licensed brokers or dealers. In addition, in some states the shares of common stock may not be sold unless
it has been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied
with.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have advised the selling stockholder that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares
in the market and to the activities of the selling stockholder and its affiliates. In addition, we will make copies of this prospectus
(as it may be supplemented or amended from time to time) available to the selling stockholder for the purpose of satisfying the prospectus
delivery requirements of the Securities Act. The selling stockholder may indemnify any broker-dealer that participates in transactions
involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
legal matters in connection with this offering with respect to the United States federal securities law and New York law will be passed
upon for us by Michelman &amp; Robinson LLP, Los Angeles, California and New York, New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 152 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Alt-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">943,333
</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="image_004.jpg" ALT="" STYLE="height: 143px; width: 245px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SHUTTLE
PHARMACEUTICALS HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RESALE
PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 30%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>You
should rely only on the information contained in this Resale Prospectus. No dealer, salesperson or other person is authorized to give
information that is not contained in this Resale Prospectus. This Resale Prospectus is not an offer to sell nor is it seeking an offer
to buy these securities in any jurisdiction where the offer or sale is not permitted. The information contained in this Resale Prospectus
is correct only as of the date of this prospectus, regardless of the time of the delivery of this prospectus or the sale of these securities.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
date of this Resale Prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 153 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
NOT REQUIRED IN THE PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ITEM
    13.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OTHER
    EXPENSES OF ISSUANCE AND DISTRIBUTION</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 82%">Financial Printing Fees</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">$</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 14%">5,000</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">SEC Filing Fees</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">$</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,711</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Nasdaq Application Fees</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">$</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">75,000</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">FINRA Expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">$</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,225</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Transfer Agent Fees</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">$</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 21,000 </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Accounting Fees and Expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">$</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">45,000</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Legal Fees and Expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">$</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">350,000</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Miscellaneous Fees and Expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">$</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Total</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">$</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 499,936 </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
amounts are estimates other than the Nasdaq Application Fees and the SEC&rsquo;s and FINRA&rsquo;s registration fees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ITEM
    14.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INDEMNIFICATION
    OF DIRECTORS AND OFFICERS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145 of the Delaware General Corporation Law, as amended, authorizes us to indemnify any director or officer under certain prescribed
circumstances and subject to certain limitations against certain costs and expenses, including attorney&rsquo;s fees actually and reasonably
incurred in connection with any action, suit or proceeding, whether civil, criminal, administrative or investigative, to which a person
is party by reason of being one of our directors or officers if it is determined that such person acted in accordance with the applicable
standard of conduct set forth in such statutory provisions. Our certificate of incorporation contains provisions relating to the indemnification
of directors and officers and our by-laws extend such indemnities to the full extent permitted by Delaware law. We currently maintain
insurance for the benefit of any director or officer which cover claims for which we could not indemnify such persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us
pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC, such indemnification is against
public policy as expressed in the Securities Act and is, therefore, unenforceable.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ITEM
    15.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RECENT
    SALES OF UNREGISTERED SECURITIES </B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the past three years, we effected the following transactions in reliance upon exemptions from registration under the Securities Act,
as amended:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period commencing October 29, 2018 through February 11, 2019, we issued 1,215.5 units (the &ldquo;Units&rdquo;), at a purchase price
of $1,000 per Unit, which Units consist of a total of (i) 1,215.5 shares of Series A convertible preferred stock, par value $0.001 per
share, which shares will convert into approximately 269,444 shares of common stock, and (ii) warrants to purchase up to
269,444 shares of common stock, which warrants will be issuable upon completion of the Company&rsquo;s initial public offering
(&ldquo;IPO&rdquo;). The Units were sold to a total of 21 accredited investors pursuant to an exemption from registration under Rule
506(b) of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 15, 2019, the Company issued to AFH Holding &amp; Advisory, LLC, as consultant (&ldquo;AFH&rdquo;), 639,161 restricted stock units
(319,580 shares post-reverse split) under the Company&rsquo;s 2018 Equity Incentive Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2021, in conjunction with entering into two loan agreements for a total of $500,000, which are repayable at the time of
our IPO, we issued warrants to purchase a total of 500,000 shares of our common stock, exercisable at $1.00 per share.
Such warrants were sold to two accredited investors pursuant to an exemption from registration under Rule 506(b) of the Securities Act.
Boustead Securities LLC acted as placement agent, but waived its cash compensation related to such offering and, to date, has received
no warrant compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above disclosures do not include 768,334 shares (384,167 shares on a post-reverse split basis) granted pursuant to the
Shuttle Pharmaceuticals Holdings, Inc. 2018 Equity Incentive Plan, which were issued to certain employees, directors and consultants,
and vest on a periodic basis in accordance with the grant agreements between such individuals and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 8, 2022 and March
11, 2022, the Company sold to certain accredited investors $365,000 and $224,985, respectively, in 6% convertible notes (the &ldquo;Notes&rdquo;),
which bear 6% interest, are repayable three years from the date of issuance, and will convert automatically into shares of common stock
or, in the event that units are sold in the offering, units, at a conversion price of $3.00 per share or unit upon
closing of this offering. Such notes were sold to accredited investors pursuant to an exemption from registration under Rule 506(b) of
the Securities Act. Boustead Securities LLC acted as placement agent and received compensation of (i) $36,500 in cash and warrants to
purchase 10% of the total number of shares issuable upon conversion of the Convertible Notes, exercisable at the conversion price of
the Convertible Notes for the February offering and (ii) $22,750 in cash and warrants to purchase 10% of the total number of shares issuable
upon conversion of the Convertible Notes, exercisable at the conversion price of the Convertible Notes for the March offering.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective March 30, 2022,
the Company issued a total of 1,678 shares (839 shares on a post-reverse split basis) of common stock (the &ldquo;Issuance&rdquo;) to
some 23 existing shareholders in satisfaction of certain interest that had accrued as the result of an inaccurate conversion of convertible
notes in our 2018 share exchange. The Issuance satisfied in full all interest owed or otherwise accruing as the result of the inaccurate
conversion. Such issuance was made in accordance with Rule 506(b) of the Securities Act.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> On August, 1 2022, in conjunction
with entering into three loan agreements for a total of $125,000, which are repayable at the time of our IPO, we issued warrants to purchase
a total of 50,000 shares of our common stock, exercisable at $2.50 per share. Such warrants were sold to three accredited investors pursuant
to an exemption from registration under Rule 506(b) of the Securities Act. Boustead Securities LLC acted as placement agent, and received
warrants to purchase 5,000 shares of common stock exercisable at $2.50 per share, equal to 10% of the value of the note offering. To
date, Boustead has deferred its cash compensation. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 154; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ITEM
    16.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBITS
    </B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Exhibit</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Number</B></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Description
    </B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">1.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="ex1-1.htm"><FONT STYLE="font-size: 10pt">Form of Underwriting Agreement*</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex3-1.htm" STYLE="-sec-extract: exhibit">Amended and Restated Certificate of Incorporation</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">3.2</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex3-2.htm" STYLE="-sec-extract: exhibit">Certificate of Amendment to Amended and Restated Certificate of Incorporation, effective March 30, 2022</A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">3.3</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex3-3.htm" STYLE="-sec-extract: exhibit">Amended and Restated By-Laws</A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3.4</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex3-4.htm" STYLE="-sec-extract: exhibit">Amended and Restated Certificate of Designation for Series A Convertible Preferred Stock, effective April 6, 2022</A></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">3.5</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex3-5.htm" STYLE="-sec-extract: exhibit">Certificate of Amendment to Amended and Restated Certificate of Incorporation, effective June 22, 2022.</A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">4.1</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex4-1.htm" STYLE="-sec-extract: exhibit">Form of Convertible Note, dated February 2022</A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> 4.2 </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="ex4-2.htm"> Form of 10% Promissory Note, dated August 2022 </A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> 4.3 </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="ex4-3.htm"> Form of Warrant, dated August 2022 </A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> 4.4 </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <A HREF="ex4-4.htm">Form of Public Offering Warrant</A> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex4-2.htm" STYLE="-sec-extract: exhibit">Form of Underwriting Warrant issuable to Boustead Securities LLC</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex5-1.htm">Opinion of Michelman &amp; Robinson, LLP*</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">5.2</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex5-2.htm" STYLE="-sec-extract: exhibit">Intellectual Property Opinion (Morgan Lewis)</A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-1.htm" STYLE="-sec-extract: exhibit">Form of Subscription Agreement for Series A Convertible Preferred Stock</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-2.htm" STYLE="-sec-extract: exhibit">2018 Equity Incentive Plan</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">10.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-3.htm" STYLE="-sec-extract: exhibit">Code of Business Conduct and Ethics</A></FONT></TD></TR>


<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">10.4</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex10-4.htm" STYLE="-sec-extract: exhibit">Employment Agreement, dated July 30, 2014, between Shuttle Pharmaceuticals Holdings, Inc. and Tyvin Rich</A></TD></TR>



<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">10.5</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex10-5.htm" STYLE="-sec-extract: exhibit">SBIR Contract #HHSN261201400013C, dated September 19, 2014, between Shuttle Pharmaceuticals, LLC and National Institute of Health National Cancer Institute</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">10.6</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex10-6.htm" STYLE="-sec-extract: exhibit">SBIR Contract #HHSN261201400013C Amendment of Solicitation/Modification of Contract, dated August 3, 2015, between Shuttle Pharmaceuticals, LLC and National Institute of Health National Cancer Institute (Radiosensitizer Option Phase II)</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">10.7</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex10-7.htm" STYLE="-sec-extract: exhibit">SBIR Contract #HHSN261201600027C, dated September 19, 2016, between Shuttle Pharmaceuticals, LLC and National Institute of Health National Cancer Institute</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">10.8</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex10-8.htm" STYLE="-sec-extract: exhibit">SBIR Contract #HHSN261600038C dated September 19, 2016 between Shuttle Pharmaceuticals, LLC. and National Institute of Health National Cancer Institute</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">10.9</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex10-9.htm" STYLE="-sec-extract: exhibit">Material Transfer Agreement, dated April 25, 2017, between Shuttle Pharmaceuticals, Inc. and George Washington University</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">10.10</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-10.htm" STYLE="-sec-extract: exhibit">Employment Agreement, dated May 30, 2019, between Shuttle Pharmaceuticals Holdings, Inc. and Peter Dritschilo</A></FONT></TD></TR>

  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">10.11</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-11.htm" STYLE="-sec-extract: exhibit">Employment Agreement, dated May 30, 2019, between Shuttle Pharmaceuticals Holdings, Inc. and Mira Jung</A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">10.12</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex10-12.htm" STYLE="-sec-extract: exhibit">Employment Agreement, dated June 28, 2019, between Shuttle Pharmaceuticals Holdings, Inc. and Anatoly. Dritschilo</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">10.13</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-13.htm" STYLE="-sec-extract: exhibit">Amended and Restated Employment Agreement, dated September 1, 2019, between Shuttle Pharmaceuticals Holdings, Inc. and Michael Vander Hoek</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">10.14</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-14.htm" STYLE="-sec-extract: exhibit">Form of Letter Agreement with Director</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">10.15</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex10-15.htm" STYLE="-sec-extract: exhibit">Subaward Agreement dated October 28, 2014 between Shuttle Pharmaceuticals, LLC and LifeSpan/Rhode Island Hospital</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">10.16</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex10-16.htm" STYLE="-sec-extract: exhibit">Sublicense Agreement, dated February 15, 2019, between Shuttle Pharmaceuticals Inc. and Propagenix, Inc.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">10.17</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex10-17.htm" STYLE="-sec-extract: exhibit">SBIR Contract #HHSN261201800016C/75N91018C00016 Agreement between Shuttle Pharmaceuticals, LLC and National Institute of Health National Cancer Institute.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">10.18</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-18.htm" STYLE="-sec-extract: exhibit">Promissory Note, dated as of August 24, 2019, between Shuttle Pharmaceuticals Holdings, Inc. and Anatoly Dritschilo.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">10.19</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-19.htm" STYLE="-sec-extract: exhibit">SBIR Phase II Contract #75N9101C00031, dated September 6, 2019, between Shuttle Pharmaceuticals, Inc. and National Institute of Health National Cancer Institute</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">10.20</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-20.htm" STYLE="-sec-extract: exhibit">Director Offer Letter, dated December 2, 2020, between Chris Senanayake and Shuttle Pharmaceuticals Holdings, Inc.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">10.21</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-21.htm" STYLE="-sec-extract: exhibit">Promissory Note, dated December 1, 2020, between Shuttle Pharmaceuticals Holdings, Inc. and Joy Dritschilo.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">10.22</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-22.htm" STYLE="-sec-extract: exhibit">Promissory Note, dated December 1, 2020, between Shuttle Pharmaceuticals Holdings, Inc. and Anatoly Dritschilo.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">10.23</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-23.htm" STYLE="-sec-extract: exhibit">Non-Disclosure, Evaluation and Option Agreement, dated May 30, 2019, between Shuttle Pharmaceuticals, Inc. and University of Virginia Licensing &amp; Ventures Group</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">10.24</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-24.htm" STYLE="-sec-extract: exhibit">First Amendment to Non-Disclosure, Evaluation and Option Agreement, dated November 30, 2019, between Shuttle Pharmaceutical, Inc. and University of Virginia Licensing &amp; Ventures Group</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">10.25</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-25.htm" STYLE="-sec-extract: exhibit">Form of Note and Warrant Subscription Agreement, dated December 28, 2021</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">10.26</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-26.htm" STYLE="-sec-extract: exhibit">Form of Note, dated December 28, 2021</A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">10.27</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-27.htm" STYLE="-sec-extract: exhibit">Form of Common Stock Purchase Warrant, dated December 28, 2021</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">10.28</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-28.htm" STYLE="-sec-extract: exhibit">Consulting Agreement, dated January 1, 2022, between Shuttle Pharmaceuticals Holdings, Inc. and Steven Bayern</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">10.29</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-29.htm" STYLE="-sec-extract: exhibit">Amendment to Promissory Note, dated January 25, 2022, between Shuttle Pharmaceuticals Holdings, Inc. and Joy Dritschilo.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10.30</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-30.htm" STYLE="-sec-extract: exhibit">Amendment to Promissory Note, dated January 25, 2022, between Shuttle Pharmaceuticals Holdings, Inc. and Anatoly Dritschilo.</A></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">10.31</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-31.htm" STYLE="-sec-extract: exhibit">Form of Convertible Note Subscription Agreement and Investor Rights Agreement</A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> 10.32 </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="ex10-32.htm"> Amendment No. 1 to Promissory Note, dated July 29, 2022, between Shuttle Pharmaceuticals Holdings, Inc. and Joy Dritschilo* </A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> 10.33 </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="ex10-33.htm"> Amendment No. 2 to Promissory Note, dated July 29, 2022, between Shuttle Pharmaceuticals holdings, Inc. and Joy Dritschilo* </A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> 10.34 </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="ex10-34.htm"> Amendment No. 2 to Promissory Note, dated July 29, 2022, between Shuttle Pharmaceuticals Holdings, inc. and Anatoly Dritschilo* </A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">15.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex15-1.htm" STYLE="-sec-extract: exhibit">List of Subsidiaries</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">23.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="ex23-1.htm">Consent of BF Borgers CPA PC*</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">23.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="ex5-1.htm">Consent of Michelman &amp; Robinson, LLP (included in Exhibit 5.1)</A><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/forms-1.htm#poa_001" STYLE="-sec-extract: exhibit">Consent of Morgan Lewis (included in Exhibit 5.2)</A></FONT></TD></TR>
                      <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">24.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#poa_001"><FONT STYLE="font-size: 10pt">Power of Attorney (included in the signature page to this registration statement)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">107</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A HREF="ex107.htm">Filing Fee Table*</A></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Unless otherwise indicated, all exhibits previously
    filed.</TD></TR>

  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Filed herewith.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 155; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ITEM
17. UNDERTAKINGS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned registrant hereby undertakes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high and of the estimated maximum offering range
may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume
and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration
Fee&rdquo; table in the effective registration statement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
To include any material information with respect to the plan of distribution not previously disclosed in this registration statement
or any material change to such information in this registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time to be
deemed the initial bona fide offering thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser each prospectus filed pursuant to Rule
424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other
than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the
date it is first used after effectiveness. <I>Provided, however,</I> that no statement made in a registration statement or prospectus
that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration
statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such
first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration
statement or made in any such document immediately prior to such date of first use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.8pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling
persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of
the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is
asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless
in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication
of such issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.8pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 156; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that
it meets all of the requirements for filing this registration statement on Form S-1 to be signed on its behalf by the undersigned, in
Rockville, Maryland, on August 18, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SHUTTLE
    PHARMACEUTICALS, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><I>/s/ Anatoly Dritschilo</I></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anatoly
                                            Dritschilo, M.D.,</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="poa_001"></A>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>Signatures</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>Title(s)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 34%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><I>/s/ Anatoly Dritschilo</I></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chairman of the Board and </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-size: 10pt">August 18,</FONT> <FONT STYLE="font-size: 10pt">
    2022</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Anatoly Dritschilo, M.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chief Executive Officer (Principal Executive Officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><I>/s/ Michael Vander Hoek</I></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-size: 10pt">August 18,
    </FONT> <FONT STYLE="font-size: 10pt">2022</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Michael Vander Hoek</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><I>/s/ Chris Senanayake*</I></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Director </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-size: 10pt">August 18,</FONT> <FONT STYLE="font-size: 10pt">
    2022</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Chris Senanayake, Ph.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><I>/s/ Steven Richards*</I></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-size: 10pt">August 18,</FONT> <FONT STYLE="font-size: 10pt">
    2022</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Steven Richards</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><I>/s/ Josh Schafer*</I></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-size: 10pt">August 18,
    2022</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Josh Schafer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><I>/s/ Milton Brown*</I></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-size: 10pt">August 18,
    2022</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Milton Brown, M.D., Ph.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><I>/s/ William Adkins*</I></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-size: 10pt">August 18,
    2022</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">William H. Adkins</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Anatoly Dritschilo</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 66%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anatoly
    Dritschilo</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Attorney-in-Fact</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 157; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ex1-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
1.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDERWRITING
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________,
2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boustead
Securities, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6
Venture, Suite 265</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Irvine,
CA 92618</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>As
Representative of the several Underwriters</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>named
on Schedule 1 attached hereto</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), hereby confirms its agreement
(this &ldquo;<B>Agreement</B>&rdquo;) with Boustead Securities, LLC (hereinafter referred to as &ldquo;you&rdquo; (including its correlatives)
or the &ldquo;<B>Representative</B>&rdquo;) and with the other underwriters named on <U>Schedule 1</U> hereto for which the Representative
is acting as representative (the Representative and such other underwriters being collectively called the &ldquo;<B>Underwriters</B>&rdquo;
or, individually, an &ldquo;<B>Underwriter</B>&rdquo;) as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Purchase and Sale of Units. </U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1
<I><U>Firm Units. </U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1.1.
<U>Nature and Purchase of Firm Units. </U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"> (i) On the basis of the representations
and warranties herein contained, but subject to the terms and conditions herein set forth, the Company agrees to sell in the aggregate
1,660,000 units (the &ldquo;<B>Units</B>&rdquo;), with each of the Units consisting of (i) one share of common stock of the Company,
par value $0.00001 per share (the &ldquo;<B>Common Stock</B>&rdquo;), and (ii) one warrant (&ldquo;<B>Warrant</B>&rdquo;) to purchase
one share of Common Stock, and each Underwriter agrees to purchase, severally and not jointly, at the Closing, an aggregate of 1,660,000
Units (&ldquo;<B>Firm Units&rdquo;). The shares of Common Stock and the shares of Common Stock underlying each Warrant, together comprising
the Firm Units, are called the &ldquo;Shares&rdquo;. The offering and sale of the Units is herein referred to as the &ldquo;Offering.&rdquo;</B> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"> (ii) The Firm Units are to
be offered together to the public at the offering price per one Firm Unit as set forth on <U>Schedule 2-A</U> hereto (the &ldquo;<B>Purchase
Price</B>&rdquo;). The Underwriters, severally and not jointly, agree to purchase from the Company the number of Firm Units set forth
opposite their respective names on <U>Schedule 1</U> attached hereto and made a part hereof at the purchase price for one Firm Unit of
$___ (or 93% of the Purchase Price). </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1.2.
<U>Firm Units Payment and Delivery</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Delivery and payment for the Firm Units shall be made at 10:00 a.m., Eastern time, on the second (2<SUP>nd</SUP>) Business Day
following the effective date (the &ldquo;<B>Effective Date</B>&rdquo;) of the Registration Statement (as defined in <U>Section 2.1.1
</U>below) (or the third (3<SUP>rd</SUP>) Business Day following the Effective Date if the Registration Statement is declared effective
after 4:01 p.m., Eastern time) or at such earlier time as shall be agreed upon by the Representative and the Company, at the offices
of Olshan Frome Wolosky LLP, 1325 Avenue of the Americas, 15<SUP>th</SUP> Floor, New York, New York 10019 (&ldquo;<B>Representative&rsquo;s
Counsel</B>&rdquo;), or at such other place (or remotely by facsimile or other electronic transmission) as shall be agreed upon by the
Representative and the Company. The hour and date of delivery and payment for the Firm Units is called the &ldquo;<B>Closing Date</B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Payment for the Firm Units shall be made on the Closing Date by wire transfer in Federal (same day) funds, payable to the order
of the Company upon delivery of the certificates (in form and substance satisfactory to the Underwriters) representing the Firm Units
(or through the facilities of the Depository Trust Company (&ldquo;<B>DTC</B>&rdquo;)) for the account of the Underwriters. The Firm
Units shall be registered in such name or names and in such authorized denominations as the Representative may request in writing
prior to the Closing Date. The Company shall not be obligated to sell or deliver the Firm Units except upon tender of payment
by the Representative for all of the Firm Units. The term &ldquo;<B>Business Day</B>&rdquo; means any day other than a Saturday,
a Sunday or a legal holiday or a day on which banking institutions are authorized or obligated by law to close in New York, New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2
<I><U>Over-allotment Option</U></I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">1.2.1. <U>Option Units. </U>
For the purposes of covering any over-allotments in connection with the distribution and sale of the Firm Units, the Company
hereby grants to the Underwriters an option to purchase up to 249,000 additional Units, representing fifteen percent (15%)
of the Firm Units sold in the offering, from the Company (the &ldquo;<B>Over-allotment Option</B>&rdquo;). Such 249,000
additional Units, the net proceeds of which will be deposited with the Company&rsquo;s account, are hereinafter referred to as
&ldquo;<B>Option Units.&rdquo; </B> The purchase price to be paid per Option Unit shall be equal to the price per
Firm Unit set forth in Section 1.1.1 hereof.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">1.2.2. <U>Exercise of Option</U>.
The Over-allotment Option granted pursuant to Section 1.2.1 hereof may be exercised by the Representative as to all (at any time) or
any part (from time to time) of the Option Units within 45 days after the Effective Date. The purchase price to be paid per Option
Unit shall be equal to the Firm Unit purchase price. The Underwriters shall not be under any obligation to purchase any Option Units
prior to the exercise of the Over-allotment Option. The Over-allotment Option granted hereby may be exercised by the giving of oral
notice to the Company from the Representative, which must be confirmed in writing by overnight mail or facsimile or other electronic
transmission setting forth the number of Option Units to be purchased and the date and time for delivery of and payment for the
Option Units (the &ldquo;<B>Option Closing Date</B>&rdquo;), which shall not be later than five (5) full Business Days after the
date of the notice or such other time as shall be agreed upon by the Company and the Representative, at the offices of Representative
Counsel at such other place (including remotely by facsimile or other electronic transmission) as shall be agreed upon by the Company
and the Representative. If such delivery and payment for the Option Units does not occur on the Closing Date, the Option Closing
Date will be as set forth in the notice. Upon exercise of the Over-allotment Option with respect to all or any portion of the Option
Units, subject to the terms and conditions set forth herein, (i) the Company shall become obligated to sell to the Underwriters the number
of Option Units specified in such notice and (ii) each of the Underwriters, acting severally and not jointly, shall purchase that
portion of the total number of Option Units then being purchased that the number of Firm Units as set forth on Schedule
1 opposite the name of such Underwriter bears to the total number of Firm Units (except as otherwise agreed to by the Underwriters).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 63pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">1.2.3. <U>Option Units Payment
and Delivery</U>. Payment for the Option Units shall be made on the Option Closing Date by wire transfer in Federal (same day)
funds, payable to the order of the Company upon delivery to you of certificates (in form and substance satisfactory to the Underwriters)
representing the Option Units (or through the facilities of DTC) for the account of the Underwriters. The Option Units
shall be registered in such name or names and in such authorized denominations as the Representative may request in writing at least
two (2) full Business Days prior to the Option Closing Date. The Company shall not be obligated to sell or deliver the Option Units
except upon tender of payment by the Representative for applicable Option Units. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3
<I><U>Representative&rsquo;s Warrants</U></I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3.1.
<U>Purchase Warrants</U>. The Company hereby agrees to issue and sell to the Representative (and/or its designees) on the Closing Date,
or Option Closing Date, as applicable (&ldquo;<B>Representative&rsquo;s Warrants</B>&rdquo;), five-year warrants for the purchase of
a number of shares of Common Stock equal to 7.0% of the number of the Firm Units issued in the Offering, pursuant to a
warrant in the form attached hereto as <B><U>Exhibit A</U></B>, at an initial exercise price of $___ (or 140% of the public offering
price per Firm Unit). The Representative&rsquo;s Warrants and the shares of Common Stock issuable upon exercise thereof
are hereinafter referred to together as the &ldquo;<B>Representative&rsquo;s Securities</B>.&rdquo; The Representative understands and
agrees that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Representative&rsquo;s Warrants and
the underlying shares of Common Stock during the one hundred eighty (180) days after the Effective Date and by its acceptance
thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Representative&rsquo;s Warrants, or any portion
thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic
disposition of such securities for a period of one hundred eighty (180) days following the Effective Date to anyone other than (i) an
Underwriter or a selected dealer in connection with the Offering, or (ii) an officer, partner, registered person or affiliate of the
Representative or of any such Underwriter or selected dealer; and only if any such transferee agrees to the foregoing lock-up restrictions.
The Representative understands and agrees that the Representative&rsquo;s Warrants are exercisable or convertible commencing six months
after the Effective Date of the Registration Statement (as defined in Section 2.1.1 below) and will not be exercisable or convertible
for more than five years from the commencement of sales of the Offering. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 63pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3.2.
<U>Delivery</U>. Delivery of the Representative&rsquo;s Warrants shall be made on the Closing Date and shall be issued in the name or
names and in such authorized denominations as the Representative may request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 63pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Representations and Warranties of the Company</U>. The Company represents and warrants to the Underwriters as of the Applicable Time
(as defined below), as of the Closing Date and as of the Option Closing Date, if any, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.1.
<U>Filing of Registration Statement</U>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.1.
<U>Pursuant to the Securities Act</U>. The Company has filed with the U.S. Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;)
a registration statement, and an amendment or amendments thereto, on Form S-1 (File No. 333-265429), including any related prospectus
or prospectuses, for the registration of the Units and the Representative&rsquo;s Securities under the Securities Act of 1933,
as amended (the &ldquo;<B>Securities Act</B>&rdquo;), which registration statement and amendment or amendments have been prepared by
the Company in all material respects in conformity with the requirements of the Securities Act and the rules and regulations of the Commission
under the Securities Act (the &ldquo;<B>Securities Act Regulations</B>&rdquo;) and will contain all material statements that are required
to be stated therein in accordance with the Securities Act and the Securities Act Regulations. Except as the context may otherwise require,
such registration statement, as amended, on file with the Commission at the time the registration statement became effective (including
the Preliminary Prospectus (as hereinafter defined) included in the registration statement, financial statements, schedules, exhibits
and all other documents filed as a part thereof and all information deemed to be a part thereof as of the Effective Date pursuant to
paragraph (b) of Rule 430A of the Securities Act Regulations (the &ldquo;<B>Rule 430A Information</B>&rdquo;)), is referred to herein
as the &ldquo;<B>Registration Statement</B>.&rdquo; If the Company files any registration statement pursuant to Rule 462(b) of the Securities
Act Regulations, then after such filing, the term &ldquo;<B>Registration Statement</B>&rdquo; shall include such registration statement
filed pursuant to Rule 462(b). The Registration Statement has been declared effective by the Commission on the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
prospectus used prior to the effectiveness of the Registration Statement, and each prospectus that omitted the Rule 430A Information
that was used after such effectiveness and prior to the execution and delivery of this Agreement, is herein called a &ldquo;<B>Preliminary
Prospectus</B>.&rdquo; The Preliminary Prospectus, subject to completion, dated __________, 2022, that was included in the Registration
Statement immediately prior to the Applicable Time is hereinafter called the &ldquo;<B>Pricing Prospectus</B>.&rdquo; The final prospectus
in the form first furnished to the Underwriters for use in the Offering is hereinafter called the &ldquo;<B>Prospectus</B>.&rdquo; Any
reference to the &ldquo;<B>most recent Preliminary Prospectus</B>&rdquo; shall be deemed to refer to the latest Preliminary Prospectus
included in the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 49.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Applicable
Time</B>&rdquo; means 4:00 p.m., Eastern time, on the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 49.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Issuer
Free Writing Prospectus</B>&rdquo; means any &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433 of the Securities Act
Regulations (&ldquo;<B>Rule 433</B>&rdquo;), including without limitation any &ldquo;free writing prospectus&rdquo; (as defined in Rule
405 of the Securities Act Regulations) relating to the Units that is (i) required to be filed with the Commission by the Company,
(ii) a &ldquo;road show that is a written communication&rdquo; within the meaning of Rule 433(d)(8)(i), whether or not required to be
filed with the Commission, or (iii) exempt from filing with the Commission pursuant to Rule 433(d)(5)(i) because it contains a description
of the Units or of the Offering that does not reflect the final terms, in each case in the form filed or required to be filed
with the Commission or, if not required to be filed, in the form retained in the Company&rsquo;s records pursuant to Rule 433(g).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 49.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Issuer
General Use Free Writing Prospectus</B>&rdquo; means any Issuer Free Writing Prospectus that is intended for general distribution to
prospective investors (other than a &ldquo;<I>bona fide</I> electronic road show,&rdquo; as defined in Rule 433 (the &ldquo;<B>Bona Fide
Electronic Road Show</B>&rdquo;)), as evidenced by its being specified in <U>Schedule 2-B</U> hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 49.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Issuer
Limited Use Free Writing Prospectus</B>&rdquo; means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing
Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 49.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Pricing
Disclosure Package</B>&rdquo; means any Issuer General Use Free Writing Prospectus issued at or prior to the Applicable Time, the Pricing
Prospectus and the information included on <U>Schedule 2-A</U> hereto, all considered together.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 49.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.2.
<U>Pursuant to the Exchange Act</U>. The Company has filed with the Commission a Form 8-A (File Number 001-_____), dated ___________,
2022, providing for the registration pursuant to Section 12(b) under the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange
Act</B>&rdquo;), of the Common Stock. The registration of the Common Stock under the Exchange Act has become effective on or prior to
the date hereof. The Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Common
Stock under the Exchange Act, nor has the Company received any notification that the Commission is contemplating terminating such registration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.2.
<U>Stock Exchange Listing</U>. </I>The Shares and the shares of Common Stock underlying the Representative&rsquo;s Warrants have been
approved for listing on The Nasdaq Capital Market (the &ldquo;<B>Exchange</B>&rdquo;), and the Company has taken no action designed to,
or likely to have the effect of, delisting of the Shares or the shares of Common Stock underlying the Representative&rsquo;s Warrants
from the Exchange, nor has the Company received any written notification that the Exchange is contemplating terminating such listing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.3.
<U>No Stop Orders, etc</U>. </I>Neither the Commission nor, to the Company&rsquo;s knowledge, any state regulatory authority has issued
any written order preventing or suspending the use of the Registration Statement, any Preliminary Prospectus or the Prospectus or has
instituted or, to the Company&rsquo;s knowledge, threatened to institute, any proceedings with respect to such an order. The Company
has complied with each request (if any) from the Commission for additional information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.4.
<U>Disclosures in Registration Statement</U>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.1.
<U>Compliance with Securities Act and 10b-5 Representation</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Each of the Registration Statement and any post-effective amendment thereto, at the time it became effective, complied in all material
respects with the requirements of the Securities Act and the Securities Act Regulations. Each Preliminary Prospectus, including the prospectus
filed as part of the Registration Statement as originally filed or as part of any amendment or supplement thereto, and the Prospectus,
at the time each was filed with the Commission, complied in all material respects with the requirements of the Securities Act and the
Securities Act Regulations. Each Preliminary Prospectus delivered to the Underwriters for use in connection with this Offering and the
Prospectus was or will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except
to the extent permitted by Regulation S-T.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Neither the Registration Statement nor any amendment thereto, at its effective time, as of the Applicable Time, at the Closing Date,
contained, contains, or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material fact required
to be stated therein or necessary to make the statements therein not misleading; <I>provided, however</I>, that this representation and
warranty shall not apply to statements made in reliance upon and in conformity with written information furnished to the Company in writing
with respect to the Underwriters by the Representative expressly for use in the Registration Statement, the Pricing Prospectus or the
Prospectus or any amendment thereof or supplement thereto. The parties acknowledge and agree that such information provided by or on
behalf of any Underwriter consists solely of the information in the table set forth in the second paragraph of the &ldquo;Underwriting&rdquo;
section and the disclosure contained in the &ldquo;Underwriting&rdquo; subsections &ldquo;- Discounts and Commissions,&rdquo; &ldquo;Representative&rsquo;s
Warrants,&rdquo; and &ldquo;Price Stabilization, Short Positions and Penalty Bids&rdquo; of the Prospectus (the &ldquo;<B>Underwriters&rsquo;
Information</B>&rdquo;)The Pricing Disclosure Package, as of the Applicable Time, at the Closing Date, did not, does not and will not
include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in
the light of the circumstances under which they were made, not misleading; and each Issuer Limited Use Free Writing Prospectus hereto
does not conflict with the information contained in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or
the Prospectus, and each such Issuer Limited Use Free Writing Prospectus, as supplemented by and taken together with the Pricing Prospectus
as of the Applicable Time, did not include an untrue statement of a material fact or omit to state a material fact necessary in order
to make the statements therein, in light of the circumstances under which they were made, not misleading; <I>provided</I>, <I>however</I>,
that this representation and warranty shall not apply to the Underwriters&rsquo; Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
Neither the Prospectus nor any amendment or supplement thereto (including any prospectus wrapper), as of its issue date, at the time
of any filing with the Commission pursuant to Rule 424(b), at the Closing Date, included, includes or will include an untrue statement
of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading; <I>provided</I>, <I>however</I>, that this representation and
warranty shall not apply to the Underwriters&rsquo; Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.2.
<U>Disclosure of Agreements</U>. The agreements and documents described in the Registration Statement, the Pricing Disclosure Package
and the Prospectus conform in all material respects to the descriptions thereof contained therein and there are no agreements or other
documents required by the Securities Act and the Securities Act Regulations to be described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus or to be filed with the Commission as exhibits to the Registration Statement, that have not been
so described or filed. Each agreement or other instrument (however characterized or described) to which the Company is a party or by
which it is or may be bound or affected and (i) that is referred to in the Registration Statement, the Pricing Disclosure Package and
the Prospectus, or (ii) is material to the Company&rsquo;s business, has been duly authorized and validly executed by the Company, is
in full force and effect in all material respects and is enforceable against the Company and, to the Company&rsquo;s knowledge, the other
parties thereto, in accordance with its terms, except (x) as such enforceability may be limited by bankruptcy, insolvency, reorganization
or similar laws affecting creditors&rsquo; rights generally, (y) as enforceability of any indemnification or contribution provision may
be limited under the federal and state securities laws, and (z) that the remedy of specific performance and injunctive and other forms
of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefor
may be brought. Except as disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, none of such agreements
or instruments has been assigned by the Company, and neither the Company nor, to the Company&rsquo;s knowledge, any other party is in
default thereunder and, to the Company&rsquo;s knowledge, no event has occurred that, with the lapse of time or the giving of notice,
or both, would constitute a default thereunder, except for any default or event which would not reasonably be expected to result in a
Material Adverse Change (as defined below). To the Company&rsquo;s knowledge, performance by the Company of the material provisions of
such agreements or instruments will not result in a violation of any existing applicable law, rule, regulation, judgment, order or decree
of any governmental agency or court, domestic or foreign, having jurisdiction over the Company or any of its assets or businesses (each,
a &ldquo;<B>Governmental Entity</B>&rdquo;), including, without limitation, those relating to environmental laws and regulations, except
for any violation which would not reasonably be expected to result in a Material Adverse Change (as defined below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.3.
<U>Prior Securities Transactions</U>. During the past three (3) years from the date of this Agreement, no securities of the Company have
been sold by the Company or by or on behalf of, or for the benefit of, any person or persons controlling, controlled by or under common
control with the Company, except as disclosed in the Registration Statement, the Pricing Disclosure Package and any Preliminary Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.4.
<U>Regulations</U>. The disclosures in the Registration Statement, the Pricing Disclosure Package and the Prospectus concerning the effects
of federal, state, local and all foreign regulation on the Offering and regulations applicable to the Company&rsquo;s business as currently
contemplated are correct in all material respects and no other such regulations are required to be disclosed in the Registration Statement,
the Pricing Disclosure Package and the Prospectus which are not so disclosed. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.5.
<U>Changes after Dates in Registration Statement</U>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5.1.
<U>No Material Adverse Change</U>. Since the respective dates as of which information is given in the Registration Statement, the Pricing
Disclosure Package and the Prospectus, except as otherwise specifically stated therein: (i) there has been no material adverse change
in the financial position or results of operations of the Company or its Subsidiaries taken as a whole, nor, to the Company&rsquo;s knowledge,
any change or development that, singularly or in the aggregate, would involve a material adverse change in or affecting the condition
(financial or otherwise), results of operations, business, or assets of the Company or its Subsidiaries taken as a whole (a &ldquo;<B>Material
Adverse Change</B>&rdquo;); (ii) there have been no material transactions entered into by the Company or its Subsidiaries, other than
as contemplated pursuant to this Agreement; and (iii) no officer or director of the Company has resigned from any position with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5.2.
<U>Recent Securities Transactions, etc</U>. Subsequent to the respective dates as of which information is given in the Registration Statement,
the Pricing Disclosure Package and the Prospectus, and except as may otherwise be indicated or contemplated herein or disclosed in the
Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company has not: (i) issued any securities or incurred
any liability or obligation, direct or contingent, for borrowed money; or (ii) declared or paid any dividend or made any other distribution
on or in respect to its capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.6.
<U>Independent Accountants</U></I>. To the knowledge of the Company, BF Borgers CPA PC (&ldquo;<B>Auditor</B>&rdquo;), whose report is
filed with the Commission as part of the Registration Statement, the Pricing Disclosure Package and the Prospectus, is an independent
registered public accounting firm as required by the Securities Act and the Securities Act Regulations and the Public Company Accounting
Oversight Board. The Auditor has not, during the periods covered by the financial statements included in the Registration Statement,
the Pricing Disclosure Package and the Prospectus, provided to the Company any non-audit services, as such term is used in Section 10A(g)
of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.7.
<U>Financial Statements, etc</U>.</I> The financial statements, including the notes thereto and supporting schedules, if any, included
in the Registration Statement, the Pricing Disclosure Package and the Prospectus, fairly present in all material respects the financial
position and the results of operations of the Company at the dates and for the periods to which they apply; and such financial statements
have been prepared in conformity with U.S. generally accepted accounting principles (&ldquo;<B>GAAP</B>&rdquo;), consistently applied
throughout the periods involved (provided that unaudited interim financial statements are subject to year-end audit adjustments that
are not expected to be material in the aggregate and do not contain all footnotes required by GAAP); and any supporting schedules included
in the Registration Statement present fairly in all material respects the information required to be stated therein. Except as included
therein, no historical or pro forma financial statements are required to be included in the Registration Statement, the Pricing Disclosure
Package or the Prospectus under the Securities Act or the Securities Act Regulations. The pro forma and pro forma as adjusted financial
information and the related notes, if any, included in the Registration Statement, the Pricing Disclosure Package and the Prospectus
have been properly compiled and prepared in all material respects in accordance with the applicable requirements of the Securities Act
and the Securities Act Regulations and present fairly in all material respects the information shown therein, and the assumptions used
in the preparation thereof are reasonable and the adjustments used therein are appropriate to give effect to the transactions and circumstances
referred to therein. All disclosures contained in the Registration Statement, the Pricing Disclosure Package or the Prospectus regarding
&ldquo;non-GAAP financial measures&rdquo; (as such term is defined by the rules and regulations of the Commission), if any, comply with
Regulation G of the Exchange Act and Item 10 of Regulation S-K of the Securities Act, to the extent applicable. Each of the Registration
Statement, the Pricing Disclosure Package and the Prospectus discloses all material off-balance sheet transactions, arrangements, obligations
(including contingent obligations), and other relationships of the Company with unconsolidated entities or other persons that may have
a material current or future effect on the Company&rsquo;s financial condition, changes in financial condition, results of operations,
liquidity, capital expenditures, capital resources, or significant components of revenues or expenses. Except as disclosed in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, (a) neither the Company nor any of its subsidiaries listed in Exhibit 21.1
to the Registration Statement (each, a &ldquo;<B>Subsidiary</B>&rdquo; and, collectively, the &ldquo;<B>Subsidiaries</B>&rdquo;), has
incurred any material liabilities or obligations, direct or contingent, or entered into any material transactions other than in the ordinary
course of business, (b) the Company has not declared or paid any dividends or made any distribution of any kind with respect to its Common
Stock or preferred stock (c) there has not been any change in the capital of the Company or any of its Subsidiaries, or, other than in
the course of business, any grants under any stock compensation plan, and (d) there has not been any Material Adverse Change in the Company&rsquo;s
long-term or short-term debt. The Company represents that it has no direct or indirect subsidiaries other than those listed in Exhibit
21.1 to the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.8.
<U>Authorized Capital; Options, etc</U></I>. The Company had, at the date or dates indicated in the Registration Statement, the Pricing
Disclosure Package and the Prospectus, the duly authorized, issued and outstanding capitalization as set forth therein. Based on the
assumptions stated in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company will have on the Closing
Date the adjusted capitalization set forth therein. Except as set forth in, or contemplated by, the Registration Statement, the Pricing
Disclosure Package and the Prospectus, on the Effective Date, as of the Applicable Time and on the Closing Date and any Option Closing
Date, there will be no options, warrants, or other rights to purchase or otherwise acquire any authorized, but unissued Common Stock
or any security convertible or exercisable into Common Stock, or any contracts or commitments to issue or sell Common Stock or any such
options, warrants, rights or convertible securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.9.
<U>Valid Issuance of Securities, etc</U></I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.9.1.
<U>Outstanding Securities</U>. All issued and outstanding securities of the Company issued prior to the transactions contemplated by
this Agreement have been duly authorized and validly issued and are fully paid and non-assessable; the holders thereof have no rights
of rescission with respect thereto, and are not subject to personal liability by reason of being such holders; and none of such securities
were issued in violation of the preemptive rights of any holders of any security of the Company or similar contractual rights granted
by the Company. The Common Stock, preferred stock, and any other securities outstanding or to be outstanding upon consummation of the
Offering conform in all material respects to all statements relating thereto contained in the Registration Statement, the Pricing Disclosure
Package and the Prospectus. The offers and sales of the outstanding Common Stock were at all relevant times either registered under the
Securities Act and the applicable state securities or &ldquo;blue sky&rdquo; laws or, based in part on the representations and warranties
of the purchasers of such shares, exempt from such registration requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.9.2. <U>Securities Sold Pursuant
to this Agreement</U>. The Units and Representative&rsquo;s Warrants have been duly authorized for issuance and sale and, when
issued and paid for, will be validly issued, fully paid and non-assessable; the holders thereof are not and will not be subject to personal
liability by reason of being such holders; the Units and Representative&rsquo;s Warrants are not and will not be subject to the
preemptive rights of any holders of any security of the Company or similar contractual rights granted by the Company; and all corporate
action required to be taken for the authorization, issuance and sale of the Units and Representative&rsquo;s Warrants has been
duly and validly taken; the Common Stock issuable upon exercise of the Representative&rsquo;s Warrants have been duly authorized and
reserved for issuance by all necessary corporate action on the part of the Company and when issued in accordance with such Representative&rsquo;s
Warrants, as the case may be, such Common Stock will be validly issued, fully paid and non-assessable. The Units and the Representative&rsquo;s
Warrants conform in all material respects to all statements with respect thereto contained in the Registration Statement, the Pricing
Disclosure Package and the Prospectus.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.10.
<U>Registration Rights of Third Parties</U></I>. Except as set forth in the Registration Statement, the Pricing Disclosure Package and
the Prospectus, no holders of any securities of the Company or any rights exercisable for or convertible or exchangeable into securities
of the Company have the right to require the Company to register any such securities of the Company under the Securities Act or to include
any such securities in a registration statement to be filed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.11.
<U>Validity and Binding Effect of Agreements</U></I>. This Agreement and the Representative&rsquo;s Warrants have been duly and validly
authorized by the Company, and, when executed and delivered, will constitute, the valid and binding agreements of the Company, enforceable
against the Company in accordance with their respective terms, except: (i) as such enforceability may be limited by bankruptcy, insolvency,
reorganization or similar laws affecting creditors&rsquo; rights generally; (ii) as enforceability of any indemnification or contribution
provision may be limited under the federal and state securities laws; and (iii) that the remedy of specific performance and injunctive
and other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding
therefor may be brought.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.12.
<U>No Conflicts, etc</U>.</I> The execution, delivery and performance by the Company of this Agreement and all ancillary documents, the
consummation by the Company of the transactions herein and therein contemplated and the compliance by the Company with the terms hereof
and thereof do not and will not, with or without the giving of notice or the lapse of time or both: (i) result in a material breach of,
or conflict with any of the terms and provisions of, or constitute a material default under, or result in the creation, modification,
termination or imposition of any lien, charge or encumbrance upon any property or assets of the Company pursuant to the terms of any
agreement or instrument to which the Company is a party; (ii) result in any violation of the provisions of the Company&rsquo;s Certificate
of Incorporation (as the same may be amended or restated from time to time, the &ldquo;<B>Charter</B>&rdquo;) or the by-laws of the Company;
or (iii) violate any existing applicable law, rule, regulation, judgment, order or decree of any Governmental Entity as of the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.13.
<U>No Defaults; Violations</U>.</I> No material default exists in the due performance and observance of any term, covenant or condition
of any material license, contract, indenture, mortgage, deed of trust, note, loan or credit agreement, or any other agreement or instrument
evidencing an obligation for borrowed money, or any other material agreement or instrument to which the Company is a party or by which
the Company may be bound or to which any of the properties or assets of the Company is subject. The Company is not (i) in violation of
any term or provision of its Charter or by-laws, or (ii) in violation of any franchise, license, permit, applicable law, rule, regulation,
judgment or decree of any Governmental Entity, except in the cases of clause (ii) for such violations which would not reasonably be expected
to cause a Material Adverse Change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.14.
<U>Corporate Power; Licenses; Consents</U>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.14.1.
<U>Conduct of Business</U>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the
Company has all requisite corporate power and authority, and has all necessary authorizations, approvals, orders, licenses, certificates
and permits of and from all governmental regulatory officials and bodies that it needs as of the date hereof to conduct its business
purpose as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, except for the absence of which
would not reasonably be expected to result in a Material Adverse Change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.14.2.
<U>Transactions Contemplated Herein</U>. The Company has all corporate power and authority to enter into this Agreement and to carry
out the provisions and conditions hereof, and all consents, authorizations, approvals and orders required in connection therewith have
been obtained. No consent, authorization or order of, and no filing with, any court, government agency, the Exchange or other body is
required for the valid issuance, sale and delivery of the Units and the consummation of the transactions and agreements contemplated
by this Agreement and the delivery of the Representative&rsquo;s Warrants and as contemplated by the Registration Statement, the Pricing
Disclosure Package and the Prospectus, except with respect to applicable Securities Act Regulations, state securities laws and the rules
and regulations of the Financial Industry Regulatory Authority, Inc. (&ldquo;<B>FINRA</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.15.
<U>Director &amp; Officers Questionnaires</U>.</I> To the Company&rsquo;s knowledge, all information contained in the questionnaires
(the &ldquo;<B>Questionnaires</B>&rdquo;) completed by each of the Company&rsquo;s directors and officers immediately prior to the Offering
(the &ldquo;<B>Insiders</B>&rdquo;) as supplemented by all information concerning the Company&rsquo;s directors, officers and principal
shareholders as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as well as in the Lock-Up
Agreement (as defined in <U>Section 2.24</U> below), provided to the Underwriters, is true and correct in all material respects and the
Company has not become aware of any information which would cause the information disclosed in the Questionnaires to become materially
inaccurate and incorrect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.16.
<U>Litigation; Governmental Proceedings</U>.</I> There is no action, suit, proceeding, inquiry, arbitration, investigation, litigation
or governmental proceeding pending or, to the Company&rsquo;s knowledge, threatened against, or involving the Company or, to the Company&rsquo;s
knowledge, any executive officer or director that is required to be disclosed in the Registration Statement, the Pricing Disclosure Package
and the Prospectus which has not been disclosed<I>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.17.
<U>Good Standing</U>. </I>The Company has been duly organized and is validly existing as a corporation and is in good standing under
the laws of the State of Delaware as of the date hereof, and is duly qualified to do business and is in good standing in each other jurisdiction
in which its ownership or lease of property or the conduct of business requires such qualification, except where the failure to qualify,
singularly or in the aggregate, would not have or reasonably be expected to result in a Material Adverse Change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.18.
<U>Insurance</U>.</I> The Company carries or is entitled to the benefits of insurance, (including, without limitation, as to directors
and officers insurance coverage), with, to the Company&rsquo;s knowledge, reputable insurers, in such amounts and covering such risks
which the Company believes are adequate, and all such insurance is in full force and effect. The Company has no reason to believe that
it will not be able (i) to renew its existing insurance coverage as and when such policies expire or (ii) to obtain comparable coverage
from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not result
in a Material Adverse Change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.19.
<U>Transactions Affecting Disclosure to FINRA</U>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.19.1.
<U>Finder&rsquo;s Fees</U>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there
are no claims, payments, arrangements, agreements or understandings relating to the payment of a finder&rsquo;s, consulting or origination
fee by the Company or any Insider with respect to the sale of the Units hereunder or any other arrangements, agreements or understandings
of the Company or, to the Company&rsquo;s knowledge, any of its shareholders that may affect the Underwriters&rsquo; compensation, as
determined by FINRA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.19.2.
<U>Payments within Six (6) Months</U>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus,
the Company has not made any direct or indirect payments (in cash, securities or otherwise) to: (i) any person, as a finder&rsquo;s fee,
consulting fee or otherwise, in consideration of such person raising capital for the Company or introducing to the Company persons who
raised or provided capital to the Company; (ii) any FINRA member; or (iii) any person or entity that has any direct or indirect affiliation
or association with any FINRA member, within the six (6) months immediately prior to the original filing of the Registration Statement,
other than the payment to the Underwriters as provided hereunder in connection with the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.19.3.
<U>Use of Proceeds</U>. None of the net proceeds of the Offering will be paid by the Company to any participating FINRA member or its
affiliates, except as specifically authorized herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.19.4.
<U>FINRA Affiliation</U>. To the Company&rsquo;s knowledge, and except as may otherwise be disclosed in FINRA questionnaires provided
to the Representative&rsquo;s Counsel, there is no (i) officer or director of the Company, (ii) beneficial owner of 5% or more of any
class of the Company&rsquo;s securities or (iii) beneficial owner of the Company&rsquo;s unregistered equity securities which were acquired
during the 180-day period immediately preceding the filing of the Registration Statement that is an affiliate or associated person of
a FINRA member participating in the Offering (as determined in accordance with the rules and regulations of FINRA).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.19.5.
<U>Information</U>. To the Company&rsquo;s knowledge, all information provided by the Company in its FINRA questionnaire to Representative&rsquo;s
Counsel specifically for use by Representative&rsquo;s Counsel in connection with its Public Offering System filings (and related disclosure)
with FINRA is true, correct and complete in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.20.
<U>Foreign Corrupt Practices Act</U>.</I> None of the Company and its Subsidiaries or, to the Company&rsquo;s knowledge, any director,
officer, agent, employee or affiliate of the Company and its Subsidiaries or any other person acting on behalf of the Company and its
Subsidiaries, has, directly or indirectly, given or agreed to give any money, gift or similar benefit (other than legal price concessions
to customers in the ordinary course of business) to any customer, supplier, employee or agent of a customer or supplier, or official
or employee of any governmental agency or instrumentality of any government (domestic or foreign) or any political party or candidate
for office (domestic or foreign) or other person who was, is, or may be in a position to help or hinder the business of the Company (or
assist it in connection with any actual or proposed transaction) that (i) might subject the Company to any damage or penalty in any civil,
criminal or governmental litigation or proceeding, (ii) if not given in the past, might have had a Material Adverse Change or (iii) if
not continued in the future, might adversely affect the assets, business, operations or prospects of the Company. The Company has taken
reasonable steps to ensure that its accounting controls and procedures are sufficient to cause the Company to comply in all material
respects with the Foreign Corrupt Practices Act of 1977, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.21.
<U>Compliance with OFAC</U>.</I> None of the Company and its Subsidiaries or, to the Company&rsquo;s knowledge, any director, officer,
agent, employee or affiliate of the Company and its Subsidiaries or any other person acting on behalf of the Company and its Subsidiaries,
is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury
(&ldquo;<B>OFAC</B>&rdquo;), and the Company will not, directly or indirectly, use the proceeds of the Offering hereunder, or lend, contribute
or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing
the activities of any person currently subject to any U.S. sanctions administered by OFAC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.22.
<U>Money Laundering Laws</U>. </I>The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance
with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as
amended, the money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations
or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the &ldquo;<B>Money Laundering Laws</B>&rdquo;);
and no action, suit or proceeding by or before any Governmental Entity involving the Company with respect to the Money Laundering Laws
is pending or, to the best knowledge of the Company, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.23.
<U>Officers&rsquo; Certificate</U>.</I> Any certificate signed by any duly authorized officer of the Company and delivered to you or
to Representative&rsquo;s Counsel shall be deemed a representation and warranty by the Company to the Underwriters as to the matters
covered thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.24.
<U>Lock-Up Agreements</U></I><U>.</U> The Company has caused each of its officers, directors and owners of 1% or more of the Company&rsquo;s
outstanding Common Stock (or securities convertible or exercisable into Common Stock) (collectively, the &ldquo;<B>Lock-Up Parties</B>&rdquo;)
to deliver to the Representative an executed Lock-Up Agreement, in forms substantially similar to those attached hereto as <U>Exhibit
B-1</U> for officers and directors and <U>Exhibit B-2</U> for non-insider stockholders (together, the &ldquo;<B>Lock-Up Agreements</B>&rdquo;),
prior to the execution of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.25.
<U>Subsidiaries</U></I>. All Subsidiaries of the Company are duly organized and in good standing under the laws of the place of organization
or incorporation, and each Subsidiary is in good standing in each jurisdiction in which its ownership or lease of property or the conduct
of business requires such qualification, except where the failure to qualify would not have a Material Adverse Change. The Company&rsquo;s
ownership and control of each Subsidiary is as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.26.
<U>Related Party Transactions</U>.</I> There are no business relationships or related party transactions involving the Company or any
other person required to be described in the Registration Statement, the Pricing Disclosure Package and the Prospectus that have not
been described as required by the Securities Act Regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.27.
<U>Board of Directors</U>. </I>The Board of Directors of the Company is comprised of the persons set forth under the heading of the Pricing
Prospectus and the Prospectus captioned &ldquo;Management.&rdquo; The qualifications of the persons serving as board members and the
overall composition of the board comply with the Exchange Act, the Exchange Act Regulations, the Sarbanes-Oxley Act of 2002 and the rules
promulgated thereunder (the &ldquo;<B>Sarbanes-Oxley Act</B>&rdquo;) applicable to the Company and the listing rules of the Exchange.
At least one member of the Audit Committee of the Board of Directors of the Company qualifies as an &ldquo;audit committee financial
expert,&rdquo; as such term is defined under Regulation S-K and the listing rules of the Exchange. In addition, at least a majority of
the persons serving on the Board of Directors qualify as &ldquo;independent,&rdquo; as defined under the listing rules of the Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.28.
<U>Sarbanes-Oxley Compliance</U>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.28.1.
<U>Disclosure Controls</U>. Except as disclosed in the Registration Statement, Pricing Disclosure Package and the Prospectus, the Company
has developed and currently maintains disclosure controls and procedures that will comply with Rule 13a-15 or 15d-15 under the Exchange
Act Regulations, and such controls and procedures are effective to ensure that all material information concerning the Company will be
made known on a timely basis to the individuals responsible for the preparation of the Company&rsquo;s Exchange Act filings and other
public disclosure documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.28.2.
<U>Compliance</U>. The Company is, or at the Applicable Time and on the Closing Date or the Option Closing Date will be, in material
compliance with the provisions of the Sarbanes-Oxley Act applicable to it, and has implemented or will implement such programs and has
taken reasonable steps to ensure the Company&rsquo;s future compliance (not later than the relevant statutory and regulatory deadlines
therefor) with all of the material provisions of the Sarbanes-Oxley Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.29.
</I><U>Accounting Controls</U>. Except as disclosed in the Registration Statement, Pricing Disclosure Package and the Prospectus, the
Company maintains systems of &ldquo;internal control over financial reporting&rdquo; (as defined under Rules 13a-15 and 15d-15 under
the Exchange Act Regulations) that comply in all material respects with the requirements of the Exchange Act and have been designed by,
or under the supervision of, its respective principal executive and principal financial officers, or persons performing similar functions,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with GAAP, including, but not limited to, internal accounting controls sufficient to provide reasonable assurance
that (i) transactions are executed in accordance with management&rsquo;s general or specific authorizations; (ii) transactions are recorded
as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii) access
to assets is permitted only in accordance with management&rsquo;s general or specific authorization; and (iv) the recorded accountability
for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.
Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any
material weaknesses in its internal control over financial reporting, and, if applicable, with respect to such remedial actions disclosed
in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company represents that it has taken all remedial
actions set forth in such disclosure. The Company&rsquo;s auditors and the Audit Committee of the Board of Directors of the Company have
been advised of: (i) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial
reporting which are known to the Company&rsquo;s management and that have adversely affected or are reasonably likely to adversely affect
the Company&rsquo; ability to record, process, summarize and report financial information; and (ii) any fraud known to the Company&rsquo;s
management, whether or not material, that involves management or other employees who have a significant role in the Company&rsquo;s internal
controls over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.30.
<U>No Investment Company Status</U></I>. The Company is not and, after giving effect to the Offering and the application of the proceeds
thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not be, required to register
as an &ldquo;investment company,&rdquo; as defined in the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.31.
<U>No Labor Disputes</U>.</I> No labor dispute with the employees of the Company or any of its Subsidiaries exists or, to the knowledge
of the Company, is imminent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.32.
<U>Intellectual Property Rights</U></I>. The Company and each of its Subsidiaries owns or possesses or has valid rights to use all patents,
patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, copyrights, licenses,
inventions, trade secrets and similar rights (&ldquo;<B>Intellectual Property Rights</B>&rdquo;) necessary for the conduct of the business
of the Company and its Subsidiaries as currently carried on and as described in the Registration Statement, the Pricing Disclosure Package
and the Prospectus. To the knowledge of the Company, no action or use by the Company or any of its Subsidiaries necessary for the conduct
of its business as currently carried on and as described in the Registration Statement and the Prospectus will involve or give rise to
any infringement of, or license or similar fees for, any Intellectual Property Rights of others. Neither the Company nor any of its Subsidiaries
has received any written notice alleging any such infringement, fee or conflict with asserted Intellectual Property Rights of others.
Except as would not reasonably be expected to result, individually or in the aggregate, in a Material Adverse Change (A) to the knowledge
of the Company, there is no infringement, misappropriation or violation by third parties of any of the Intellectual Property Rights owned
by the Company; (B) there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others challenging
the rights of the Company in or to any such Intellectual Property Rights, and the Company is unaware of any facts which would form a
reasonable basis for any such claim, that would, individually or in the aggregate, together with any other claims in this <U>Section
2.32</U>, reasonably be expected to result in a Material Adverse Change; (C) the Intellectual Property Rights owned by the Company and,
to the knowledge of the Company, the Intellectual Property Rights licensed to the Company have not been adjudged by a court of competent
jurisdiction invalid or unenforceable, in whole or in part, and there is no pending or, to the Company&rsquo;s knowledge, threatened
action, suit, proceeding or claim by others challenging the validity or scope of any such Intellectual Property Rights, and the Company
is unaware of any facts which would form a reasonable basis for any such claim that would, individually or in the aggregate, together
with any other claims in this <U>Section 2.32</U>, reasonably be expected to result in a Material Adverse Change; (D) there is no pending
or, to the Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others that the Company infringes, misappropriates
or otherwise violates any Intellectual Property Rights or other proprietary rights of others, the Company has not received any written
notice of such claim and the Company is unaware of any other facts which would form a reasonable basis for any such claim that would,
individually or in the aggregate, together with any other claims in this <U>Section 2.32</U>, reasonably be expected to result in a Material
Adverse Change; and (E) to the Company&rsquo;s knowledge, no employee of the Company is in or has ever been in violation in any material
respect of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement,
non-solicitation agreement, nondisclosure agreement or any restrictive covenant to or with a former employer where the basis of such
violation relates to such employee&rsquo;s employment with the Company, or actions undertaken by the employee while employed with the
Company and could reasonably be expected to result, individually or in the aggregate, in a Material Adverse Change. To the Company&rsquo;s
knowledge, all material technical information developed by and belonging to the Company which has not been patented has been kept confidential.
The Company is not a party to or bound by any options, licenses or agreements with respect to the Intellectual Property Rights of any
other person or entity that are required to be set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus
and are not described therein. The Registration Statement, the Pricing Disclosure Package and the Prospectus contain in all material
respects the same description of the matters set forth in the preceding sentence. None of the technology employed by the Company has
been obtained or is being used by the Company in violation of any contractual obligation binding on the Company or, to the Company&rsquo;s
knowledge, any of its officers, directors or employees, or otherwise in violation of the rights of any persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.33.
<U>Taxes</U></I>. Each of the Company and its Subsidiaries has filed all returns (as hereinafter defined) required to be filed with taxing
authorities prior to the date hereof or has duly obtained extensions of time for the filing thereof, except in any case in which the
failure so to file would not reasonably be expected to cause a Material Adverse Change. Each of the Company and its Subsidiaries has
paid all taxes (as hereinafter defined) shown as due on such returns that were filed and has paid all taxes imposed on or assessed against
the Company or such respective Subsidiary, except for any such taxes that are currently being contested in good faith or as would not
reasonably be expected to cause a Material Adverse Change. The provisions for taxes payable, if any, shown on the financial statements
filed with or as part of the Registration Statement are sufficient for all accrued and unpaid taxes, whether or not disputed, and for
all periods to and including the dates of such consolidated financial statements. Except as disclosed in writing to the Underwriters,
(i) no issues have been raised (and are currently pending) by any taxing authority in connection with any of the returns or taxes asserted
as due from the Company or its Subsidiaries, and (ii) no waivers of statutes of limitation with respect to the returns or collection
of taxes have been given by or requested from the Company or its Subsidiaries. The term &ldquo;taxes&rdquo; means all federal, state,
local, foreign and other net income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise, profits, license, lease,
service, service use, withholding, payroll, employment, excise, severance, stamp, occupation, premium, property, windfall profits, customs,
duties or other taxes, fees, assessments or charges of any kind whatever, together with any interest and any penalties, additions to
tax or additional amounts with respect thereto. The term &ldquo;returns&rdquo; means all returns, declarations, reports, statements and
other documents required to be filed in respect to taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.34.
<U>ERISA Compliance</U>.</I> The Company is not subject to the Employee Retirement Income Security Act of 1974, as amended, or the regulations
and published interpretations thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.35.
<U>Compliance with Laws</U></I>. Except as otherwise disclosed in the Registration Statement, Pricing Disclosure Package and Prospectus
and as could not, individually or in the aggregate, be expected to result in a Material Adverse Change, each of the Company and each
Subsidiary, the Company: (A) is and at all times has been in compliance with all statutes, rules, or regulations applicable to the services
provided by the Company (&ldquo;<B>Applicable Laws</B>&rdquo;), except as could not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Change; (B) has not received any warning letter, untitled letter or other correspondence or notice
from any other governmental authority alleging or asserting noncompliance with any Applicable Laws or any licenses, certificates, approvals,
clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (&ldquo;<B>Authorizations</B>&rdquo;);
(C) possesses all material Authorizations and such material Authorizations are valid and in full force and effect and are not in material
violation of any term of any such Authorizations; (D) has not received written notice of any claim, action, suit, proceeding, hearing,
enforcement, investigation, arbitration or other action from any governmental authority or third party alleging that any product operation
or activity is in violation of any Applicable Laws or Authorizations and has no knowledge that any such governmental authority or third
party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding that if brought would result
in a Material Adverse Change; (E) has not received written notice that any Governmental Entity has taken, is taking or intends to take
action to limit, suspend, modify or revoke any Authorizations and has no knowledge that any such Governmental Entity is considering such
action ; (F) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims,
submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents,
forms, notices, applications, records, claims, submissions and supplements or amendments were complete and correct in all material respects
on the date filed (or were corrected or supplemented by a subsequent submission); and (G) has not, either voluntarily or involuntarily,
initiated, conducted, or issued or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety
alert, post-sale warning, or other notice or action relating to the alleged lack of safety of any product or any alleged product defect
or violation and, to the Company&rsquo;s knowledge, no third party has initiated, conducted or intends to initiate any such notice or
action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.36.
<U>Ineligible Issuer</U>.</I> At the time of filing the Registration Statement and any post-effective amendment thereto, at the time
of effectiveness of the Registration Statement and any amendment thereto, at the earliest time thereafter that the Company or another
offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) of the Securities Act Regulations) of the Units
and at the date hereof, the Company was not and is not an &ldquo;ineligible issuer,&rdquo; as defined in Rule 405, without taking
account of any determination by the Commission pursuant to Rule 405 that it is not necessary that the Company be considered an ineligible
issuer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.37.
<U>Real Property</U>.</I> Except as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company
and its Subsidiaries have good and marketable title in fee simple to, or have valid rights to lease or otherwise use, all items of real
or personal property which are material to the business of the Company and its Subsidiaries taken as a whole, in each case free and clear
of all liens, encumbrances, security interests, claims and defects that do not, singly or in the aggregate, materially affect the value
of such property and do not interfere with the use made and proposed to be made of such property by the Company or its Subsidiaries;
and all of the leases and subleases material to the business of the Company and its Subsidiaries, considered as one enterprise, and under
which the Company or any of its Subsidiaries holds properties described in the Registration Statement, the Pricing Disclosure Package
and the Prospectus, are in full force and effect, and neither the Company nor any Subsidiary has received any written notice of any material
claim of any sort that has been asserted by anyone adverse to the rights of the Company or any Subsidiary under any of the leases or
subleases mentioned above, or affecting or questioning the rights of the Company or such Subsidiary to the continued possession of the
leased or subleased premises under any such lease or sublease, which would result in a Material Adverse Change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.38.
<U>Contracts Affecting Capital</U></I>. There are no transactions, arrangements or other relationships between and/or among the Company,
any of its affiliates (as such term is defined in Rule 405 of the Securities Act Regulations) and any unconsolidated entity, including,
but not limited to, any structured finance, special purpose or limited purpose entity that could reasonably be expected to materially
affect the Company&rsquo;s or its Subsidiaries&rsquo; liquidity or the availability of or requirements for their capital resources required
to be described or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus which have
not been described or incorporated by reference as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.39.
<U>Loans to Directors or Officers</U>.</I> There are no outstanding loans, advances (except normal advances for business expenses in
the ordinary course of business) or guarantees or indebtedness by the Company or its Subsidiaries to or for the benefit of any of the
officers or directors of the Company, its Subsidiaries or any of their respective family members, except as disclosed in the Registration
Statement, the Pricing Disclosure Package and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.40.
<U>Industry Data; Forward-looking Statements</U>.</I> The statistical and market-related data included in each of the Registration Statement,
the Pricing Disclosure Package and the Prospectus are based on or derived from sources that the Company reasonably and in good faith
believes are reliable and accurate or represent the Company&rsquo;s good faith estimates that are made on the basis of data derived from
such sources. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act)
contained in the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.41.
<U>Testing-the-Waters Communications</U></I>. The Company has not (i) alone engaged in any Testing-the-Waters Communications and (ii)
authorized anyone to engage in Testing-the-Waters Communications. The Company confirms that the Representative has been authorized to
act on its behalf in undertaking Testing-the-Waters Communications. The Company has not distributed any Written Testing-the-Waters Communications
other than those listed on <U>Schedule 2-C</U> hereto. &ldquo;Written Testing-the-Waters Communication&rdquo; means any Testing-the-Waters
Communication that is a written communication within the meaning of Rule 405 under the Securities Act; &ldquo;Testing-the-Waters Communication&rdquo;
means any oral or written communication with potential investors undertaken in reliance on Section 5(d) of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.42.
<U>Emerging Growth Company</U>. </I>The Company has been and is an &ldquo;emerging growth company,&rdquo; as defined in Section 2(a)
of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.43.
<U>Electronic Road Show</U>.</I> The Company has made available a Bona Fide Electronic Road Show in compliance with Rule 433(d)(8)(ii)
of the Securities Act Regulations such that no filing of any &ldquo;road show&rdquo; (as defined in Rule 433(h) of the Securities Act
Regulations) is required in connection with the Offering. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.44.
<U>Margin Securities</U>.</I> The Company owns no &ldquo;margin securities&rdquo; as that term is defined in Regulation U of the Board
of Governors of the Federal Reserve System (the &ldquo;<B>Federal Reserve Board</B>&rdquo;), and none of the proceeds of Offering will
be used, directly or indirectly, for the purpose of purchasing or carrying any margin security, for the purpose of reducing or retiring
any indebtedness which was originally incurred to purchase or carry any margin security or for any other purpose which might cause any
of the Common Stock to be considered a &ldquo;purpose credit&rdquo; within the meanings of Regulation T, U or X of the Federal Reserve
Board<I>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.45.
<U>Dividends and Distributions</U></I>. Except as disclosed in the Pricing Disclosure Package, Registration Statement and the Prospectus,
no Subsidiary of the Company is currently prohibited or restricted, directly or indirectly, from paying any dividends to the Company,
from making any other distribution on such Subsidiary&rsquo;s capital stock, from repaying to the Company any loans or advances to such
Subsidiary from the Company or from transferring any of such Subsidiary&rsquo;s property or assets to the Company or any other Subsidiary
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.46.
<U>Lending Relationships</U></I>. Except as disclosed in the Pricing Disclosure Package, Registration Statement and the Prospectus, the
Company (i) does not have any material lending or other relationship with any bank or lending affiliate of the Underwriters and (ii)
does not intend to use any of the proceeds from the sale of the Securities hereunder to repay any outstanding debt owed to any affiliate
of the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.47.
</I><U>Regulatory Compliance</U>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus,
the Company (A) has not received any unresolved FDA Form 483, notice of observations, warning letter, untitled letter or other written
correspondence from the U.S. Food and Drug Administration (&ldquo;<B>FDA</B>&rdquo;), or any other court or arbitrator or federal, state,
local or foreign governmental or regulatory authority, alleging or asserting noncompliance with the Federal Food, Drug and Cosmetic Act
(21 U.S.C. &sect; 301 et seq.); (B) possesses all material licenses, certificates, registrations, approvals, clearances, authorizations,
permits and supplements or amendments thereto, and has made all declarations and filings with, the appropriate federal, state, local
or foreign governmental or regulatory authorities (including, without limitation, state or other food and drug regulatory authorities)
that are necessary for the ownership or lease of its properties or the conduct of its business as described in the Registration Statement,
the Pricing Disclosure Package and the Prospectus, and such Authorizations are valid and in full force and effect and the Company is
not in material violation of any term of any such Authorizations; (C) has not received written notice of any ongoing claim, action, suit,
proceeding, hearing, enforcement, investigation, arbitration or other action from any Governmental Entity or third party alleging that
any product, operation or activity is in material violation of any FDA regulation or Authorizations and has no knowledge that any such
Governmental Entity or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding;
(D) has not received written notice that any Governmental Entity has taken, is taking or intends to take action to suspend, revoke or
restrict any Authorizations and has no knowledge that any such Governmental Entity is considering such action; (E) has filed, obtained,
maintained or submitted all material reports, schedules, statements, filings, registrations, documents, forms, notices, applications,
records, claims, submissions and supplements or amendments thereto as required by any FDA regulation or Authorizations and that all such
reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and correct
on the date filed (or were corrected or supplemented by a subsequent submission); (F) has not, either voluntarily or involuntarily, initiated,
conducted, or issued or caused to be initiated, conducted or issued, any recall, or market withdrawal or other notice or action relating
to any alleged product defect or violation and, to the Company&rsquo;s knowledge, no third party has initiated or conducted any such
notice or action; (G) is not party to any corporate integrity agreement, deferred prosecution agreement, monitoring agreement, consent
decree, settlement order, or similar agreements, or have any reporting obligations pursuant to any such agreement, plan or correction
or other remedial measure entered into with any Governmental Entity; and (H) has not been convicted of any criminal offense relating
to the delivery of any item or service reimbursable under a federal or state food and drug program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.48.
</I><U>Clinical Trials</U>. The clinical trials conducted by or on behalf of or sponsored by the Company or in which the Company or its
product candidates have participated have been and, if still pending, are being conducted (i) in material compliance with all statutes,
rules, regulations and guidance applicable thereto and (ii) in all material respects in accordance with medical and scientific research
procedures that the Company reasonably believes are appropriate. The Company has not received any notices or other correspondence from
the FDA or any other Governmental Entity requiring the termination, suspension or material modification of any clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<U>Covenants of the Company</U>. The Company covenants and agrees as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.1.
<U>Amendments to Registration Statement</U>.</I> The Company shall deliver to the Representative, prior to filing, any amendment or supplement
to the Registration Statement or Prospectus proposed to be filed after the Effective Date and not file any such amendment or supplement
to which the Representative shall reasonably object in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.2.
<U>Federal Securities Laws</U>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.1.
<U>Compliance</U>. The Company, subject to <U>Section 3.2.2</U>, shall comply with the requirements of Rule 430A of the Securities Act
Regulations, and will notify the Representative promptly, and confirm the notice in writing, (i) when any post-effective amendment to
the Registration Statement shall become effective or any amendment or supplement to the Prospectus shall have been filed; (ii) of the
receipt of any comments from the Commission; (iii) of any request by the Commission for any amendment to the Registration Statement or
any amendment or supplement to the Prospectus or for additional information; (iv) of the issuance by the Commission of any stop order
suspending the effectiveness of the Registration Statement or any post-effective amendment or of any order preventing or suspending the
use of any Preliminary Prospectus or the Prospectus, or of the suspension of the qualification of the Units and the Representative&rsquo;s
Warrants for offering or sale in any jurisdiction, or of the initiation or threatening of any proceedings for any of such purposes or
of any examination pursuant to Section 8(d) or 8(e) of the Securities Act concerning the Registration Statement and (v) if the Company
becomes the subject of a proceeding under Section 8A of the Securities Act in connection with the Offering of the Units and Representative&rsquo;s
Warrants. The Company shall effect all filings required under Rule 424(b) of the Securities Act Regulations, in the manner and within
the time period required by Rule 424(b) (without reliance on Rule 424(b)(8)), and shall take such steps as it deems necessary to ascertain
promptly whether the form of prospectus transmitted for filing under Rule 424(b) was received for filing by the Commission and, in the
event that it was not, it will promptly file such prospectus. The Company shall use its reasonable best efforts to prevent the issuance
of any stop order, prevention or suspension and, if any such order is issued, to obtain the lifting thereof at the earliest possible
moment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.2.
<U>Continued Compliance</U>. The Company shall comply with the Securities Act, the Securities Act Regulations, the Exchange Act and the
Exchange Act Regulations so as to permit the completion of the distribution of the Units as contemplated in this Agreement and
in the Registration Statement, the Pricing Disclosure Package and the Prospectus. If at any time when a prospectus relating to the Units
is (or, but for the exception afforded by Rule 172 of the Securities Act Regulations (&ldquo;<B>Rule 172</B>&rdquo;), would be) required
by the Securities Act to be delivered in connection with sales of the Units, any event shall occur or condition shall exist as
a result of which it is necessary, in the opinion of counsel for the Underwriters or for the Company, to (i) amend the Registration Statement
in order that the Registration Statement will not include an untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary to make the statements therein not misleading; (ii) amend or supplement the Pricing Disclosure Package
or the Prospectus in order that the Pricing Disclosure Package or the Prospectus, as the case may be, will not include any untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein not misleading in the light of
the circumstances existing at the time it is delivered to a purchaser or (iii) amend the Registration Statement or amend or supplement
the Pricing Disclosure Package or the Prospectus, as the case may be, in order to comply with the requirements of the Securities Act
or the Securities Act Regulations, the Company will promptly (A) give the Representative notice of such event; (B) prepare any amendment
or supplement as may be necessary to correct such statement or omission or to make the Registration Statement, the Pricing Disclosure
Package or the Prospectus comply with such requirements and, a reasonable amount of time prior to any proposed filing or use, furnish
the Representative with copies of any such amendment or supplement and (C) file with the Commission any such amendment or supplement;
<I>provided </I>that the Company shall not file or use any such amendment or supplement to which the Representative or Representative&rsquo;s
Counsel shall reasonably object. The Company will furnish to the Underwriters such number of copies of such amendment or supplement as
the Underwriters may reasonably request. The Company has given the Representative notice of any filings made pursuant to the Exchange
Act or the Exchange Act Regulations within 48 hours prior to the Applicable Time. The Company shall give the Representative notice of
its intention to make any such filing from the Applicable Time until the Closing Date and the exercise in full or expiration of the Over-allotment
Option specified in Section 1.2 hereof and will furnish the Representative with copies of the related document(s) a reasonable amount
of time prior to such proposed filing, as the case may be, and will not file or use any such document to which the Representative or
counsel for the Underwriters shall reasonably object.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.3.
<U>Exchange Act Registration</U>. Until three years after the date of this Agreement, the Company shall use its commercially reasonable
efforts to maintain the registration of the Common Stock under the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.4.
<U>Free Writing Prospectuses</U>. The Company agrees that, unless it obtains the prior consent of the Representative, it shall not make
any offer relating to the Units that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a &ldquo;free
writing prospectus,&rdquo; or a portion thereof, required to be filed by the Company with the Commission or retained by the Company under
Rule 433; <I>provided</I> that the Representative shall be deemed to have consented to each Issuer General Use Free Writing Prospectus
set forth in <U>Schedule 2-B</U>. The Company represents that it has treated or agrees that it will treat each such free writing prospectus
consented to, or deemed consented to, by the Underwriters as an &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433,
and that it has complied and will comply with the applicable requirements of Rule 433 with respect thereto, including timely filing with
the Commission where required, legending and record keeping. If at any time following issuance of an Issuer Free Writing Prospectus there
occurred or occurs an event or development as a result of which such Issuer Free Writing Prospectus conflicted or would conflict with
the information contained in the Registration Statement or included or would include an untrue statement of a material fact or omitted
or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing
at that subsequent time, not misleading, the Company will promptly notify the Underwriters and will promptly amend or supplement, at
its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.5.
<U>Testing-the-Waters Communications</U>. If at any time following the distribution of any Written Testing-the-Waters Communication there
occurred or occurs an event or development as a result of which such Written Testing-the-Waters Communication included or would include
an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances existing at that subsequent time, not misleading, the Company shall promptly notify the Representative
and shall promptly amend or supplement, at its own expense, such Written Testing-the-Waters Communication to eliminate or correct such
untrue statement or omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.3.
<U>Delivery to the Underwriters of Registration Statements</U></I>. The Company has delivered or made available or shall deliver or make
available to the Representative and Representative&rsquo;s Counsel, without charge, signed copies of the Registration Statement as originally
filed and each amendment thereto (including exhibits filed therewith) and signed copies of all consents and certificates of experts,
and upon request will also deliver to the Underwriters, without charge, a conformed copy of the Registration Statement as originally
filed and each amendment thereto (without exhibits) for each of the Underwriters. The copies of the Registration Statement and each amendment
thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission pursuant
to EDGAR, except to the extent permitted by Regulation S-T.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.4.
<U>Delivery to the Underwriters of Prospectuses</U>.</I> The Company has delivered or made available or will deliver or make available
to each Underwriter, without charge, as many copies of each Preliminary Prospectus as such Underwriter reasonably requested, and the
Company hereby consents to the use of such copies for purposes permitted by the Securities Act. The Company will furnish to each Underwriter,
without charge, during the period when a prospectus relating to the Units is (or, but for the exception afforded by Rule 172,
would be) required to be delivered under the Securities Act, such number of copies of the Prospectus (as amended or supplemented) as
such Underwriter may reasonably request. The Prospectus and any amendments or supplements thereto furnished to the Underwriters will
be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted
by Regulation S-T.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.5.
<U>Effectiveness and Events Requiring Notice to the Representative</U>.</I> The Company shall use its commercially reasonable efforts
to cause the Registration Statement covering the issuance of the shares of Common Stock underlying the Representative&rsquo;s Warrants
to remain effective with a current prospectus for at least nine (9) months after the Applicable Time, and shall notify the Representative
immediately and confirm the notice in writing: (i) of the cessation of the effectiveness of the Registration Statement and any amendment
thereto; (ii) of the issuance by the Commission of any stop order or of the initiation, or the threatening, of any proceeding for that
purpose; (iii) of the issuance by any state securities commission of any proceedings for the suspension of the qualification of the shares
underlying the Representative&rsquo;s Warrants for offering or sale in any jurisdiction or of the initiation, or the threatening, of
any proceeding for that purpose; (iv) of the mailing and delivery to the Commission for filing of any amendment or supplement to the
Registration Statement or Prospectus; (v) of the receipt of any comments or request for any additional information from the Commission;
and (vi) of the happening of any event during the period described in this <U>Section 3.5</U> that, in the judgment of the Company, makes
any statement of a material fact made in the Registration Statement, the Pricing Disclosure Package or the Prospectus untrue or that
requires the making of any changes in (a) the Registration Statement in order to make the statements therein not misleading, or (b) in
the Pricing Disclosure Package or the Prospectus in order to make the statements therein, in light of the circumstances under which they
were made, not misleading. If the Commission or any state securities commission shall enter a stop order or suspend such qualification
at any time, the Company shall make every reasonable effort to obtain promptly the lifting of such order.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.6.
<U>Review of Financial Statements.</U></I> For a period of three (3) years after the date of this Agreement, the Company, at its expense,
shall cause its regularly engaged independent registered public accounting firm to review (but not audit) the Company&rsquo;s financial
statements for each of the three fiscal quarters immediately preceding the announcement of any quarterly financial information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.7.
<U>Listing</U>.</I> The Company shall use its commercially reasonable efforts to maintain the listing of the Units and the shares
of Common Stock underlying the Representative&rsquo;s Warrant on the Exchange for at least three (3) years from the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.8.
<U>Financial Public Relations Firm</U></I>. As of the Effective Date, or promptly thereafter, the Company shall have retained a financial
public relations firm reasonably acceptable to the Representative and the Company, which shall initially be [&#9679;], which firm shall
be experienced in assisting issuers in initial public offerings of securities and in their relations with their security holders, and
shall retain such firm or another firm reasonably acceptable to the Representative for a period of not less than two (2) years after
the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.9.
<U>Reports to the Representative</U>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9.1.
<U>Periodic Reports, etc</U>. For a period of three (3) years after the date of this Agreement, the Company shall furnish or make available
to the Representative copies of such financial statements and other periodic and special reports as the Company from time to time furnishes
generally to holders of any class of its securities and also furnish or make available to the Representative: (i) a copy of each periodic
report the Company shall be required to file with the Commission under the Exchange Act and the Exchange Act Regulations; (ii) a copy
of every press release and every news item and article with respect to the Company or its affairs which was released by the Company;
(iii) a copy of each Form 8-K prepared and filed by the Company; (iv) a copy of each registration statement filed by the Company under
the Securities Act; and (v) such additional documents and information with respect to the Company and the affairs of any future subsidiaries
of the Company as the Representative may from time to time reasonably request; <I>provided</I> the Representative shall sign, if requested
by the Company, a Regulation FD compliant confidentiality agreement which is reasonably acceptable to the Representative and Representative&rsquo;s
Counsel in connection with the Representative&rsquo;s receipt of such information. Documents filed with the Commission pursuant to its
EDGAR system shall be deemed to have been delivered to the Representative pursuant to this <U>Section 3.9.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9.2.
<U>Transfer Agent; Transfer Sheets</U>. For a period of three (3) years after the date of this Agreement, the Company shall retain a
transfer agent and registrar acceptable to the Representative (the &ldquo;<B>Transfer Agent</B>&rdquo;) and shall furnish to the Representative
at the Company&rsquo;s sole cost and expense such transfer sheets of the Company&rsquo;s securities as the Representative may reasonably
request, including the daily and monthly consolidated transfer sheets of the Transfer Agent and DTC. Vstock Transfer, LLC is acceptable
to the Representative to act as Transfer Agent for the Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9.3.
<U>Trading Reports</U>. For a period of six (6) months after the date hereof, during such time as the Shares are listed on the Exchange,
the Company shall provide to the Representative, at the Company&rsquo;s expense, such reports published by the Exchange relating to price
trading of the Shares, as the Representative shall reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.10.
<U>Payment of Expenses</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.10.1.
<U>General Expenses Related to the Offering</U>. The Company hereby agrees to pay on each of the Closing Date and the Option Closing
Date, if any, to the extent not paid at the Closing Date, all expenses incident to the performance of the obligations of the Company
under this Agreement, including, but not limited to: (a) all filing fees and communication expenses relating to the registration of the
Units to be sold in the Offering (including the Over-allotment Option) with the Commission; (b) all Public Filing System filing
fees associated with the review of the Offering by FINRA; (c) all fees, expenses and disbursements relating to the registration, qualification
or exemption of the Units under the securities laws of such foreign jurisdictions as the Representative may reasonably designate;
(d) all fees, expenses and disbursements relating to background checks of the Company&rsquo;s officers and directors and other due diligence
expenses; (e) the costs associated with receiving commemorative mementos and lucite tombstones; (f) fees and expenses of the Representative&rsquo;s
Counsel; (g) the Underwriters&rsquo; due diligence expenses; and (h) the Underwriters&rsquo; &ldquo;road show&rdquo; expenses for the
Offering, with all of the Underwriters&rsquo; actual out-of-pocket expenses under subsections 3.10.1(d)-(h) not to exceed $255,000, of
which $_____ has previously been paid. The Representative may deduct from the net proceeds of the Offering payable to the Company on
the Closing Date, or the Option Closing Date, if any, the expenses set forth herein to be paid by the Company to the Underwriters; <I>provided</I>,
<I>however</I>, that in the event that the Offering is terminated, the Company agrees to reimburse the Underwriters pursuant to <U>Section
8.3</U> hereof. Notwithstanding the foregoing, any advance received by the Representative will be reimbursed to the Company to the extent
not actually incurred in compliance with FINRA Rule 5110(g)(4)(A).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.10.2.
<U>Non-accountable Expenses</U>. The Company further agrees that, in addition to the expenses payable pursuant to <U>Section 3.10.1</U>,
on the Closing Date it shall pay to the Representative, by deduction from the net proceeds of the Offering contemplated herein, a non-accountable
expense allowance equal to one percent (1.0%) of the gross proceeds received by the Company from the sale of the Firm Units. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.11.
<U>Application of Net Proceeds</U>. </I>The Company shall apply the net proceeds from the Offering received by it in a manner consistent
with the application thereof described under the caption &ldquo;Use of Proceeds&rdquo; in the Registration Statement, the Pricing Disclosure
Package and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.12.
<U>Delivery of Earnings Statements to Security Holders</U></I>. The Company will timely file such reports pursuant to the Exchange Act
as are necessary in order to make generally available to its security holders as soon as practicable, an earnings statement (which need
not be certified by independent registered public accounting firm unless required by the Securities Act or the Securities Act Regulations,
but which shall satisfy the provisions of Rule 158(a) under Section 11(a) of the Securities Act) covering a period of at least twelve
(12) consecutive months beginning after the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.13.
<U>Stabilization</U>.</I> Neither the Company nor, to its knowledge, any of its employees, directors or shareholders has taken or shall
take, directly or indirectly, any action designed to or that has constituted or that might reasonably be expected to cause or result
in, under Regulation M of the Exchange Act, or otherwise, stabilization or manipulation of the price of any security of the Company to
facilitate the sale or resale of the Units. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.14.
<U>Internal Controls</U></I>. Except to the extent disclosed in the Registration Statement, Pricing Disclosure Package and Prospectus,
the Company shall maintain a system of internal accounting controls sufficient to provide reasonable assurances that: (i) transactions
are executed in accordance with management&rsquo;s general or specific authorization; (ii) transactions are recorded as necessary in
order to permit preparation of financial statements in accordance with GAAP and to maintain accountability for assets; (iii) access to
assets is permitted only in accordance with management&rsquo;s general or specific authorization; and (iv) the recorded accountability
for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.15.
<U>Accountants</U></I>. As of the date of this Agreement, the Company has retained an independent registered public accounting firm reasonably
acceptable to the Representative, and the Company shall continue to retain a nationally recognized independent registered public accounting
firm for a period of at least three (3) years after the date of this Agreement. The Representative acknowledges that the Auditor is acceptable
to the Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.16.
<U>FINRA</U></I>. For a period of ninety (90) days from the later of the Closing Date or the Option Closing Date, the Company shall advise
the Representative (who shall make an appropriate filing with FINRA) if it is or becomes aware that (i) any officer or director of the
Company, (ii) any beneficial owner of 5% or more of any class of the Company&rsquo;s securities or (iii) any beneficial owner of the
Company&rsquo;s unregistered equity securities which were acquired during the 180 days immediately preceding the filing of the original
Registration Statement is or becomes an affiliate or associated person of a FINRA member participating in the Offering (as determined
in accordance with the rules and regulations of FINRA).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.17.
<U>No Fiduciary Duties</U></I>. The Company acknowledges and agrees that the Underwriters&rsquo; responsibility to the Company is solely
contractual in nature and that none of the Underwriters or their affiliates or any selling agent shall be deemed to be acting in a fiduciary
capacity, or otherwise owes any fiduciary duty to the Company or any of its affiliates in connection with the Offering and the other
transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.18.
<U>Company Lock-Up</U></I>. The Company, on behalf of itself and any successor entity, agrees that, without the prior written consent
of the Representative, it will not, for a period of six (6) months after the date of this Agreement (the &ldquo;<U>Lock-Up Period</U>&rdquo;),
(i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant or
amend the terms of any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares
of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the
Company; (ii) file or cause to be filed any registration statement with the Commission relating to the offering of any shares of capital
stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company (other
than pursuant to a registration statement on Form S-8 for employee benefit plans); or (iii) enter into any swap or other arrangement
that transfers to another, in whole or in part, any of the economic consequences of ownership of capital stock of the Company, whether
any such transaction described in clause (i), (ii) or (iii) above is to be settled by delivery of shares of capital stock of the Company
or such other securities, in cash or otherwise. The restrictions contained in this section shall not apply to (i) the Units, the Shares
comprising the Units, the Representative&rsquo;s Warrants and shares underlying the Representative&rsquo;s Warrants to be sold
hereunder; (ii) the issuance by the Company of Common Stock upon the exercise of an outstanding option or warrant or the conversion of
a security outstanding on the date hereof or disclosed in the Registration Statement and the Pricing Disclosure Package; and (iii) the
issuance of Common Stock pursuant to the Company&rsquo;s existing stock option, equity incentive or bonus plans as disclosed in the Registration
Statement and the Pricing Disclosure Package. The Company agrees not to accelerate the vesting of any option or warrant or the lapse
of any repurchase right prior to the expiration of the Lock-Up Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.19.
<U>Release of D&amp;O Lock-up Period</U></I>. If the Representative, in its sole discretion, agrees to release or waive the restrictions
set forth in the Lock-Up Agreements described in <U>Section 2.24</U> hereof for an officer or director of the Company and provides the
Company with notice of the impending release or waiver at least three (3) Business Days before the effective date of the release or waiver,
the Company agrees to announce the impending release or waiver by a press release through a major news service at least two (2) Business
Days before the effective date of the release or waiver.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.20.
<U>Blue Sky Qualifications</U>.</I> The Company shall use its reasonable best efforts, in cooperation with the Underwriters, if necessary,
to qualify the Units for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic
or foreign) as the Representative may designate and to maintain such qualifications in effect so long as required to complete the distribution
of the Units; <I>provided</I>, <I>however</I>, that the Company shall not be obligated to file any general consent to service of
process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to
subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.21.
<U>Reporting Requirements</U>.</I> The Company, during the period when a prospectus relating to the Units is (or, but for the
exception afforded by Rule 172, would be) required to be delivered under the Securities Act, will file all documents required to be filed
with the Commission pursuant to the Exchange Act within the time periods required by the Exchange Act and Exchange Act Regulations. Additionally,
the Company shall report the use of proceeds from the issuance of the Units as may be required under Rule 463 under the Securities
Act Regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<U>Conditions of Underwriters&rsquo; Obligations</U>. The obligations of the Underwriters to purchase and pay for the Units, as
provided herein, shall be subject to (i) the continuing accuracy of the representations and warranties of the Company as of the date
hereof and as of each of the Closing Date and the Option Closing Date, if any; (ii) the accuracy of the statements of officers of the
Company made pursuant to the provisions hereof; (iii) the performance by the Company of its obligations hereunder; and (iv) the following
conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>4.1.
<U>Regulatory Matters</U>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.1.
<U>Effectiveness of Registration Statement; Rule 430A Information</U>. The Registration Statement has become effective not later than
5:00 p.m., Eastern time, on the date of this Agreement or such later date and time as shall be consented to in writing by you, and, at
each of the Closing Date and any Option Closing Date, no stop order suspending the effectiveness of the Registration Statement or any
post-effective amendment thereto has been issued under the Securities Act, no order preventing or suspending the use of any Preliminary
Prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or, to
the Company&rsquo;s knowledge, contemplated by the Commission. The Company has complied with each request (if any) from the Commission
for additional information. The Prospectus containing the Rule 430A Information shall have been filed with the Commission in the manner
and within the time frame required by Rule 424(b) (without reliance on Rule 424(b)(8)) or a post-effective amendment providing such information
shall have been filed with, and declared effective by, the Commission in accordance with the requirements of Rule 430A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.2.
<U>FINRA Clearance</U>. On or before the date of this Agreement, the Representative shall have received clearance from FINRA as to the
amount of compensation allowable or payable to the Underwriters as described in the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.3.
<U>Exchange Share Market Clearance</U>. On the Closing Date, the  Shares shall have been approved for listing on the Exchange, subject
only to official notice of issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>4.2.
<U>Company Counsel Matters</U>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.1.
<U>Closing Date Opinions of Counsels</U>. On the Closing Date, the Representative shall have received the favorable opinion of Michelman
&amp; Robinson LLP, counsel for the Company, in form and substance satisfactory to Representative&rsquo;s Counsel addressed to the Representative
and stating that such opinions may be relied upon by Representative&rsquo;s Counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.2.
<U>Opinion of Company&rsquo;s Intellectual Property Counsel</U>. On the Closing Date, the Representative shall have received the favorable
opinion of Morgan Lewis &amp; Bockius, LLP, intellectual property counsel for the Company, in form and substance satisfactory to Representative&rsquo;s
Counsel addressed to the Representative and stating that such opinions may be relied upon by Representative&rsquo;s Counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.3.
<U>Reliance</U>. In rendering such opinions, such counsel may rely: (i) as to matters involving the application of laws other than the
laws of the United States and jurisdictions in which they are admitted, to the extent such counsel deems proper and to the extent specified
in such opinion, if at all, upon an opinion or opinions (in form and substance reasonably satisfactory to the Representative) of other
counsel reasonably acceptable to the Representative, familiar with the applicable laws; and (ii) as to matters of fact, to the extent
they deem proper, on certificates or other written statements of officers of the Company and officers of departments of various jurisdictions
having custody of documents respecting the corporate existence or good standing of the Company, <I>provided </I>that copies of any such
statements or certificates shall be delivered to Representative&rsquo;s Counsel if requested.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>4.3.
<U>Comfort Letters</U>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.1.
<U>Cold Comfort Letter</U>. At the time this Agreement is executed you shall have received a cold comfort letter containing statements
and information of the type customarily included in accountants&rsquo; comfort letters with respect to the financial statements and certain
financial information contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus, addressed to the Representative
and in form and substance satisfactory in all respects to you and to the Auditor, dated as of the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.2.
<U>Bring-down Comfort Letter</U>. At each of the Closing Date and Option Closing Date, if any, the Representative shall have received
from the Auditor a letter, dated as of the Closing Date or the Option Closing Date, as applicable, to the effect that the Auditor reaffirms
the statements made in the letter furnished pursuant to <U>Section 4.3.1</U>, except that the specified date referred to shall be a date
not more than three (3) Business Days prior to the Closing Date or the Option Closing Date, as applicable. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>4.4.
<U>Officers&rsquo; Certificates</U>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.1.
<U>Officers&rsquo; Certificate</U>. The Company shall have furnished to the Representative a certificate, dated the Closing Date and
any Option Closing Date (if such date is other than the Closing Date), of its Chief Executive Officer, its President and its Chief Financial
Officer stating that (i) such officers have carefully examined the Registration Statement, the Pricing Disclosure Package, any Issuer
Free Writing Prospectus and the Prospectus and, in their opinion, the Registration Statement and each amendment thereto, as of the Applicable
Time and as of the Closing Date (or any Option Closing Date if such date is other than the Closing Date) did not include any untrue statement
of a material fact and did not omit to state a material fact required to be stated therein or necessary to make the statements therein
not misleading, and the Pricing Disclosure Package, as of the Applicable Time and as of the Closing Date (or any Option Closing Date
if such date is other than the Closing Date), any Issuer Free Writing Prospectus as of its date and as of the Closing Date (or any Option
Closing Date if such date is other than the Closing Date), the Prospectus and each amendment or supplement thereto, as of the respective
date thereof and as of the Closing Date, did not include any untrue statement of a material fact and did not omit to state a material
fact necessary in order to make the statements therein, in the light of the circumstances in which they were made, not misleading, (ii)
since the effective date of the Registration Statement, no event has occurred which should have been set forth in a supplement or amendment
to the Registration Statement, the Pricing Disclosure Package or the Prospectus, (iii) to the best of their knowledge after reasonable
investigation, as of the Closing Date (or any Option Closing Date if such date is other than the Closing Date), the representations and
warranties of the Company in this Agreement are true and correct in all material respects (except for those representations and warranties
qualified as to materiality, which shall be true and correct in all respects and except for those representations and warranties which
refer to facts existing at a specific date, which shall be true and correct as of such date) and the Company has complied with all agreements
and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date (or any Option Closing
Date if such date is other than the Closing Date), and (iv) there has not been, subsequent to the date of the most recent audited financial
statements included or incorporated by reference in the Pricing Disclosure Package, a Material Adverse Change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.2.
<U>Secretary&rsquo;s Certificate</U>. At each of the Closing Date and the Option Closing Date, if any, the Representative shall have
received a certificate of the Company signed by the Secretary of the Company, dated the Closing Date or the Option Closing Date, as the
case may be, respectively, certifying: (i) that each of the Charter and Bylaws is true and complete, has not been modified and is in
full force and effect; (ii) that the resolutions of the Company&rsquo;s Board of Directors (and any pricing committee thereof) relating
to the Offering are in full force and effect and have not been modified; and (iii) as to the incumbency of the officers of the Company.
The documents referred to in such certificate shall be attached to such certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>4.5.
<U>No Material Changes</U></I>. Prior to and on each of the Closing Date and the Option Closing Date, if any: (i) there shall have been
no Material Adverse Change in the condition or prospects or the business activities, financial or otherwise, of the Company from the
latest dates as of which such condition is set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus;
(ii) no action, suit or proceeding, at law or in equity, shall have been pending or threatened against the Company or any Insider before
or by any court or federal or state commission, board or other administrative agency wherein an unfavorable decision, ruling or finding
may reasonably be expected to cause a Material Adverse Change, except as set forth in the Registration Statement, the Pricing Disclosure
Package and the Prospectus; (iii) no stop order shall have been issued under the Securities Act and no proceedings therefor shall have
been initiated or threatened by the Commission; and (iv) the Registration Statement, the Pricing Disclosure Package and the Prospectus
and any amendments or supplements thereto shall contain all material statements which are required to be stated therein in accordance
with the Securities Act and the Securities Act Regulations and shall conform in all material respects to the requirements of the Securities
Act and the Securities Act Regulations, and neither the Registration Statement, the Pricing Disclosure Package nor the Prospectus nor
any amendment or supplement thereto shall contain any untrue statement of a material fact or omit to state any material fact required
to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>4.6.
<U>Delivery of Agreements</U>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6.1.
<U>Lock-Up Agreements</U>. On or before the date of this Agreement, the Company shall have delivered to the Representative executed copies
of the Lock-Up Agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6.2.
<U>Representative&rsquo;s Warrant</U>. On the Closing date, the Company shall have delivered to the Representative an executed copy of
the Representative&rsquo;s Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>4.7.
<U>Additional Documents</U></I>. At the Closing Date and at each Option Closing Date, if any, Representative&rsquo;s Counsel shall have
been furnished with such documents and opinions as they may require for the purpose of enabling Representative&rsquo;s Counsel to deliver
an opinion to the Underwriters, or in order to evidence the accuracy of any of the representations or warranties, or the fulfillment
of any of the conditions, herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the
Units and the Representative&rsquo;s Warrants as herein contemplated shall be satisfactory in form and substance to the Representative
and Representative&rsquo;s Counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<U>Indemnification</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>5.1.
<U>Indemnification of the Underwriters</U>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1.1.
<U>General</U>. Subject to the conditions set forth below, the Company agrees to indemnify and hold harmless each Underwriter, its affiliates
and each of its and their respective directors, officers, members, employees, representatives, partners, shareholders, affiliates, counsel,
and agents and each person, if any, who controls any such Underwriter within the meaning of Section 15 of the Securities Act or Section
20 of the Exchange Act (collectively, the &ldquo;<B>Underwriter Indemnified Parties</B>&rdquo; and each, an &ldquo;<B>Underwriter Indemnified
Party</B>&rdquo;), against any and all loss, liability, claim, damage and expense whatsoever (including but not limited to any and all
legal or other expenses reasonably incurred in investigating, preparing or defending against any litigation, commenced or threatened,
or any claim whatsoever, whether arising out of any action between any of the Underwriter Indemnified Parties and the Company or between
any of the Underwriter Indemnified Parties and any third party, or otherwise) to which they or any of them may become subject under the
Securities Act, the Exchange Act or any other statute or at common law or otherwise or under the laws of foreign countries (a &ldquo;<B>Claim</B>&rdquo;),
arising out of or based upon any untrue statement or alleged untrue statement of a material fact contained, or the omission or alleged
omission therefrom of a material fact required to be stated therein or necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading, in (A) the Registration Statement, the Pricing Disclosure Package, any Preliminary
Prospectus, the Prospectus, or in any Issuer Free Writing Prospectus or in any Written Testing-the-Waters Communication (as from time
to time each may be amended and supplemented); (B) any materials or information provided to investors by, or with the approval of, the
Company in connection with the marketing of the Offering, including any &ldquo;road show&rdquo; or investor presentations made to investors
by the Company (whether in person or electronically); or (C) any application or other document or written communication (in this <U>Section
5</U>, collectively called &ldquo;application&rdquo;) executed by the Company or based upon written information furnished by the Company
in any jurisdiction in order to qualify the Units and Representative&rsquo;s Warrants under the securities laws thereof or filed
with the Commission, any state securities commission or agency, the Exchange or any other national securities exchange; <I>unless</I>,
with respect to each subsection (A) through (C), such statement or omission was made in reliance upon, and in conformity with, the Underwriters&rsquo;
Information. With respect to any untrue statement or omission or alleged untrue statement or omission made in the Registration Statement,
Pricing Disclosure Package or Prospectus, the indemnity agreement contained in this <U>Section 5.1.1</U> shall not inure to the benefit
of any Underwriter Indemnified Party to the extent that any loss, liability, claim, damage or expense of such Underwriter Indemnified
Party results from the fact that a copy of the Prospectus was not given or sent to the person asserting any such loss, liability, claim
or damage at or prior to the written confirmation of sale of the Units to such person as required by the Securities Act and the
Securities Act Regulations, and if the untrue statement or omission has been corrected in the Prospectus, unless such failure to deliver
the Prospectus was a result of non-compliance by the Company with its obligations under <U>Section 3.3</U> hereof. The Company also agrees
that it will reimburse each Underwriter Indemnified Party for all reasonable fees and expenses (including but not limited to any and
all legal or other expenses reasonably incurred in investigating, preparing or defending against any litigation, commenced or threatened,
or any claim whatsoever, whether arising out of any action between any of the Underwriter Indemnified Parties and the Company or between
any of the Underwriter Indemnified Parties and any third party, or otherwise) (collectively, the &ldquo;<B>Expenses</B>&rdquo;), and
further agrees wherever and whenever possible to advance payment of Expenses as they are incurred by an Underwriter Indemnified Party
in investigating, preparing, pursuing or defending any Claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1.2.
<U>Procedure</U>. If any action is brought against an Underwriter Indemnified Party in respect of which indemnity may be sought against
the Company pursuant to <U>Section 5.1.1</U>, such Underwriter Indemnified Party shall promptly notify the Company in writing of the
institution of such action and the Company shall assume the defense of such action, including the employment and fees of counsel (subject
to the approval of such Underwriter Indemnified Party (which approval shall not be unreasonably withheld)) and payment of actual expenses
if an Underwriter Indemnified Party requests that the Company do so. Such Underwriter Indemnified Party shall have the right to employ
its or their own counsel in any such case, and the fees and expenses of such counsel shall be at the expense of the Company and shall
be advanced by the Company; <I>provided</I>, <I>however</I>, that the Company shall not be obligated to bear the reasonable fees and
expenses of more than one firm of attorneys selected by the Underwriter Indemnified Party (in addition to local counsel). Notwithstanding
anything to the contrary contained herein, and provided that the Company has timely honored its obligations under <U>Section 5</U>, the
Underwriter Indemnified Party shall not enter into any settlement without the prior written consent (which shall not be unreasonably
withheld) of the terms of any settlement by the Company. The Company shall not be liable for any settlement of any action effected without
its prior written consent (which shall not be unreasonably delayed or withheld). In addition, the Company shall not, without the prior
written consent of the Underwriters (which consent shall not be unreasonably withheld), settle, compromise or consent to the entry of
any judgment in or otherwise seek to terminate any pending or threatened action in respect of which advancement, reimbursement, indemnification
or contribution may be sought hereunder (whether or not such Underwriter Indemnified Party is a party thereto) unless such settlement,
compromise, consent or termination (i) includes an unconditional release of each Underwriter Indemnified Party, acceptable to such Underwriter
Indemnified Party, from all liabilities, expenses and claims arising out of such action for which indemnification or contribution may
be sought and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of any
Underwriter Indemnified Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>5.2.
<U>Indemnification of the Company</U></I>. Each Underwriter, severally and not jointly, agrees to indemnify and hold harmless the Company,
its directors, its officers who signed the Registration Statement and persons who control the Company within the meaning of Section 15
of the Securities Act or Section 20 of the Exchange Act against any and all loss, liability, claim, damage and expense described in the
foregoing indemnity from the Company to the several Underwriters, as incurred, but only with respect to such losses, liabilities, claims,
damages and expenses (or actions in respect thereof) which arise out of or are based upon untrue statements or omissions, or alleged
untrue statements or omissions made in the Registration Statement, any Preliminary Prospectus, the Pricing Disclosure Package or Prospectus
or any amendment or supplement thereto or in any application, in reliance upon, and in conformity with, the Underwriters&rsquo; Information.
In case any action shall be brought against the Company or any other person so indemnified based on any Preliminary Prospectus, the Registration
Statement, the Pricing Disclosure Package or Prospectus or any amendment or supplement thereto or any application, and in respect of
which indemnity may be sought against any Underwriter, such Underwriter shall have the rights and duties given to the Company, and the
Company and each other person so indemnified shall have the rights and duties given to the several Underwriters by the provisions of
<U>Section 5.1.2</U>. The Company agrees promptly to notify the Representative of the commencement of any litigation or proceedings against
the Company or any of its officers, directors or any person, if any, who controls the Company within the meaning of Section 15 of the
Securities Act or Section 20 of the Exchange Act, in connection with the issuance and sale of the Units or in connection with
the Registration Statement, the Pricing Disclosure Package, the Prospectus, or any Issuer Free Writing Prospectus or any Written Testing-the-Waters
Communication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>5.3.
<U>Contribution</U>.</I> If the indemnification provided for in this Section 5 shall for any reason be unavailable to or insufficient
to hold harmless an indemnified party under Section 5.1 or Section 5.2 in respect of any liabilities and Expenses referred to therein,
then each indemnifying party shall, in lieu of indemnifying such indemnified party, contribute to the amount paid or payable by such
indemnified party as a result of such liabilities and Expenses, (i) in such proportion as shall be appropriate to reflect the relative
benefits received by the Company, on the one hand, and each of the Underwriters, on the other hand, from the Offering, or (ii) if the
allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only
the relative benefits referred to in clause (i) above but also the relative fault of the Company, on the one hand, and the Underwriters,
on the other hand, in connection with the matters as to which such liabilities or Expenses relate, as well as any other relevant equitable
considerations. The relative benefits received by the Company, on the one hand, and the Underwriters, on the other, with respect to such
Offering shall be deemed to be in the same proportion as the total net proceeds actually received by the Company from the Offering of
the Units purchased under this Agreement (before deducting expenses) received by the Company bear to the total underwriting discounts
and commissions actually received by the Underwriters in connection with the Offering, in each case as set forth in the table on the
cover page of the Prospectus. The relative fault of the Company, on the one hand, and the Underwriters, on the other, shall be determined
by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission
to state a material fact relates to information supplied by the Company, on the one hand, or the Underwriters, on the other, and the
parties&rsquo; relative intent, knowledge, access to information and opportunity to correct or prevent such untrue statement, omission,
act or failure to act; <I>provided</I> that the parties hereto agree that the written information furnished to the Company through the
Representative by or on behalf of any Underwriter for use in any Preliminary Prospectus, any Registration Statement or the Prospectus,
or in any amendment or supplement thereto, consists solely of the Underwriters&rsquo; Information. The Company and the Underwriters agree
that it would not be just and equitable if contributions pursuant to this subsection (d) were determined by pro rata allocation (even
if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take into account
the equitable considerations referred to above in this subsection (d). Notwithstanding the above, no person guilty of fraudulent misrepresentation
within the meaning of Section 11(f) of the Securities Act shall be entitled to contribution from a party who was not guilty of such fraudulent
misrepresentation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>5.4.
</I><U>Limitation</U>. The Company also agrees that no Underwriter Indemnified Party shall have any liability (whether direct or indirect,
in contract or tort or otherwise) to the Company for or in connection with advice or services rendered or to be rendered by any Underwriter
Indemnified Party pursuant to this Agreement, the transactions contemplated thereby or any Underwriter Indemnified Party&rsquo;s actions
or inactions in connection with any such advice, services or transactions, except to the extent that a court of competent jurisdiction
has made a finding that liabilities (and related Expenses) of the Company have resulted from such Underwriter Indemnified Party&rsquo;s
fraud, bad faith, gross negligence or willful misconduct in connection with any such advice, actions, inactions or services or such Underwriter
Indemnified Party&rsquo;s breach of this Agreement or any obligations of confidentiality owed to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>5.5.
</I><U>Survival and Third-Party Beneficiaries</U>. The advancement, reimbursement, indemnity and contribution obligations set forth
in this Section 5 shall remain in full force and effect regardless of any termination of, or the completion of any Underwriter Indemnified
Party&rsquo;s services under or in connection with, this Agreement. Each Underwriter Indemnified Party is an intended third-party beneficiary
of this Section 5, and has the right to enforce the provisions of Section 5, as if he/she/it was a party to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<U>Default by an Underwriter</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>6.1. <U>Default Not Exceeding
10% of Firm Units or Option Units. </U> </I> If any Underwriter or Underwriters shall default in its or their obligations
to purchase the Firm Units or the Option Units, if the Over-allotment Options is exercised hereunder, and if the number of the
Firm Units or Option Units with respect to which such default relates does not exceed in the aggregate 10% of the number
of Firm Units or Option Units that all Underwriters have agreed to purchase hereunder, then such Firm Units or Option
Units to which the default relates shall be purchased by the non-defaulting Underwriters in proportion to their respective commitments
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>6.2. <U>Default Exceeding
10% of Firm Units or Option Units. </U></I>  In the event that the default addressed in <U>Section 6.1</U> relates
to more than 10% of the Firm Units or Option Units, you may in your discretion arrange for yourself or for another party or parties
to purchase such Firm Units or Option Units to which such default relates on the terms contained herein. If, within one
(1) Business Day after such default relating to more than 10% of the Firm Units or Option Units, you do not arrange for the purchase
of such Firm Units or Option Units, then the Company shall be entitled to a further period of one (1) Business Day within which
to procure another party or parties satisfactory to you to purchase said Firm Units or Option Units on such terms. In the
event that neither you nor the Company arrange for the purchase of the Firm Units or Option Units to which a default relates
as provided in this <U>Section 6</U>, this Agreement will automatically be terminated by you or the Company without liability on the
part of the Company (except as provided in <U>Section 5</U> and <U>Section 8.3</U> hereof) or the several Underwriters (except as provided
in <U>Section 5</U> hereof); <I>provided</I>, <I>however</I>, that if such default occurs with respect to the Option Units, this Agreement
will not terminate as to the Firm Units; and <I>provided, further</I>, that nothing herein shall relieve a defaulting Underwriter of
its liability, if any, to the other Underwriters and to the Company for damages occasioned by its default hereunder.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>6.3.
<U>Postponement of Closing Date</U></I>. In the event that the Firm Units or Option Units to which the default relates
are to be purchased by the non-defaulting Underwriters, or are to be purchased by another party or parties as aforesaid, you or the Company
shall have the right to postpone the Closing Date or Option Closing Date for a reasonable period, but not in any event exceeding five
(5) Business Days, in order to effect whatever changes may thereby be made necessary in the Registration Statement, the Pricing Disclosure
Package or the Prospectus or in any other documents and arrangements, and the Company agrees to file promptly any amendment to the Registration
Statement, the Pricing Disclosure Package or the Prospectus that in the opinion of counsel for the Underwriter may thereby be made necessary.
The term &ldquo;Underwriter&rdquo; as used in this Agreement shall include any party substituted under this <U>Section 6 </U>with like
effect as if it had originally been a party to this Agreement with respect to such Firm Units or Option Units. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<U>Additional Covenants</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>7.1.
<U>Right of First Refusal</U></I>. During the period ending two (2) years after the Closing Date, if and only if the closing of the purchase
of the Firm Units hereunder actually occurs, the Company grants the Representative the right of first refusal to act as financial
advisor or to act as joint financial advisor, on at least equal economic terms on any public or private financing (debt or equity), merger,
business combination, recapitalization or sale of some or all of the equity or assets of the Company (collectively, &ldquo;<U>Future
Services</U>&rdquo;). In the event the Company notifies Representative of its intention to pursue an activity that would enable Representative
to exercise its right of first refusal to provide Future Services, Representative shall notify the Company of its election to provide
such Future Services, including notification of the compensation and other terms to which Representative shall be entitled, within thirty
(30) days of written notice by the Company. In the event the Company engages Representative to provide such Future Services, Representative
will be compensated consistent with the compensation in this Agreement, unless mutually agreed otherwise by the Company and Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<U>Effective Date of this Agreement and Termination Thereof</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>8.1.
<U>Effective Date</U></I>. This Agreement shall become effective when both the Company and the Representative have executed the same
and delivered counterparts of such signatures to the other party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>8.2.
<U>Termination</U>.</I> The Representative shall have the right to terminate this Agreement at any time prior to any Closing Date, (i)
if any domestic or international event or act or occurrence has materially disrupted, or in your opinion will in the immediate future
materially disrupt, general securities markets in the United States; or (ii) if trading on the New York Share Exchange or the Nasdaq
Stock Market LLC shall have been suspended or materially limited, or minimum or maximum prices for trading shall have been fixed, or
maximum ranges for prices for securities shall have been required by FINRA or by order of the Commission or any other government authority
having jurisdiction; or (iii) if the United States shall have become involved in a new war or an increase in major hostilities; or (iv)
if a banking moratorium has been declared by a New York State or federal authority; or (v) if a moratorium on foreign exchange trading
has been declared which materially adversely impacts the United States securities markets; or (vi) if the Company shall have sustained
a material loss by fire, flood, accident, hurricane, earthquake, theft, sabotage or other calamity or malicious act which, whether or
not such loss shall have been insured, will, in your opinion, make it inadvisable to proceed with the delivery of the Firm Units;
or (vii) if the Company is in material breach of any of its representations, warranties or covenants hereunder; or (viii) if the
Representative shall have become aware after the date hereof of such a Material Adverse Change, or such adverse material change in general
market conditions as in the Representative&rsquo;s judgment would make it impracticable to proceed with the offering, sale and/or delivery
of the Units or to enforce contracts made by the Underwriters for the sale of the Units. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>8.3.
<U>Expenses</U>.</I> Notwithstanding anything to the contrary in this Agreement, except in the case of a default by the Underwriters,
pursuant to <U>Section 6.2</U> above, in the event that this Agreement shall not be carried out for any reason whatsoever, within the
time specified herein or any extensions thereof pursuant to the terms herein, the Company shall be obligated to pay to the Underwriters
their actual and accountable out-of-pocket expenses related to the transactions contemplated herein then due and payable up to the amounts
set forth in <U>Section 3.10.1</U> and upon demand the Company shall pay such amount thereof to the Representative on behalf of the Underwriters;
<I>provided</I>, <I>however</I>, that such expense cap in no way limits or impairs the indemnification and contribution provisions of
this Agreement. Notwithstanding the foregoing, any advance received by the Representative will be reimbursed to the Company to the extent
not actually incurred in compliance with FINRA Rule 5110(g)(4)(A).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>8.4.
<U>Indemnification</U></I>. Notwithstanding any contrary provision contained in this Agreement, any election hereunder or any termination
of this Agreement, and whether or not this Agreement is otherwise carried out, the provisions of <U>Section 5</U> shall remain in full
force and effect and shall not be in any way affected by, such election or termination or failure to carry out the terms of this Agreement
or any part hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>8.5.
<U>Representations, Warranties, Agreements to Survive</U></I>. All representations, warranties and agreements contained in this Agreement
or in certificates of officers of the Company submitted pursuant hereto, shall remain operative and in full force and effect regardless
of (i) any investigation made by or on behalf of any Underwriter or its Affiliates or selling agents, any person controlling any Underwriter,
its officers or directors or any person controlling the Company or (ii) delivery of and payment for the Units. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>9.1.
<U>Notices</U>. </I>All communications hereunder, except as herein otherwise specifically provided, shall be in writing and shall be
mailed (registered or certified mail, return receipt requested), emailed, personally delivered, or sent by facsimile transmission
and confirmed and shall be deemed given when so delivered or faxed and confirmed or if mailed, two (2) days after such mailing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Representative:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Boustead
Securities, LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6
Venture, Suite 265</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Irvine,
California 92618</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Mr. Keith Moore, CEO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax
No.: (949) ___-____</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
<U>keith@boustead1828.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>With
a copy (which shall not constitute notice) to:</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Olshan
Frome Wolosky LLP</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1325
Avenue of the Americas, 15<SUP>th</SUP> Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York 10019</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Spencer G. Feldman, Esq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax
No.: (212) 451-2222</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
sfeldman@olshanlaw.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shuttle
Pharmaceuticals Holdings, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
Research Court, Suite 450</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rockville,
Maryland 20850</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Anatoly Dritschilo, M.D., Chief Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax
No. (___) ___-____</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
dritscha@georgetown.edu</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>With
a copy (which shall not constitute notice) to</I>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Michelman
&amp; Robinson LLP</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">800
Third Avenue, 24<SUP>th</SUP> Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York 10020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Megan J. Penick, Esq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax
No.: (212) 730-7725</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
mpenick@mrllp.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>9.2.
<U>Headings</U>.</I> The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit
or affect the meaning or interpretation of any of the terms or provisions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>9.3.
<U>Amendment</U>.</I> This Agreement may only be amended by a written instrument executed by each of the parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>9.4.
<U>Entire Agreement</U>.</I> This Agreement (together with the other agreements and documents being delivered pursuant to or in connection
with this Agreement) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof and thereof, and
supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof. Notwithstanding
anything to the contrary set forth herein, it is understood and agreed by the parties hereto that all other terms and conditions of that
certain engagement letter between the Company and Representative dated as of November 10, 2021 shall remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>9.5.
<U>Binding Effect</U>.</I> This Agreement shall inure solely to the benefit of and shall be binding upon the Representative, the Underwriters,
the Company and the controlling persons, directors and officers referred to in <U>Section 5</U> hereof, and their respective successors,
legal representatives, heirs and assigns, and no other person shall have or be construed to have any legal or equitable right, remedy
or claim under or in respect of or by virtue of this Agreement or any provisions herein contained. The term &ldquo;successors and assigns&rdquo;
shall not include a purchaser, in its capacity as such, of securities from any of the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>9.6.
<U>Governing Law; Consent to Jurisdiction; Trial by Jury</U>.</I> This Agreement shall be governed by and construed and enforced in accordance
with the laws of the State of California, without giving effect to conflict of laws principles thereof. The Company hereby agrees that
any action, proceeding or claim against it arising out of, or relating in any way to this Agreement shall be brought and enforced in
the Los Angeles, California, or in the United States District Court located in Los Angeles, California, and irrevocably submits to such
jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that
such courts represent an inconvenient forum. Any such process or summons to be served upon the Company may be served by transmitting
a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in
<U>Section 9.1</U> hereof. Such mailing shall be deemed personal service and shall be legal and binding upon the Company in any action,
proceeding or claim. The Company agrees that the prevailing party(ies) in any such action shall be entitled to recover from the other
party(ies) all of its reasonable attorneys&rsquo; fees and expenses relating to such action or proceeding and/or incurred in connection
with the preparation therefor. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its shareholders
and affiliates) and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all
right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>9.7.
<U>Execution in Counterparts</U>.</I> This Agreement may be executed in one or more counterparts, and by the different parties hereto
in separate counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one and the
same agreement, and shall become effective when one or more counterparts has been signed by each of the parties hereto and delivered
to each of the other parties hereto. Delivery of a signed counterpart of this Agreement by facsimile or email/pdf transmission shall
constitute valid and sufficient delivery thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>9.8.
<U>Waiver, etc</U></I>. The failure of any of the parties hereto to at any time enforce any of the provisions of this Agreement shall
not be deemed or construed to be a waiver of any such provision, nor to in any way effect the validity of this Agreement or any provision
hereof or the right of any of the parties hereto to thereafter enforce each and every provision of this Agreement. No waiver of any breach,
non-compliance or non-fulfillment of any of the provisions of this Agreement shall be effective unless set forth in a written instrument
executed by the party or parties against whom or which enforcement of such waiver is sought; and no waiver of any such breach, non-compliance
or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance or non-fulfillment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
Page Follows]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the foregoing correctly sets forth the understanding between the Underwriters and the Company, please so indicate in the space provided
below for that purpose, whereupon this letter shall constitute a binding agreement between us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SHUTTLE PHARMACEUTICALS HOLDINGS, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anatoly Dritschilo, M.D.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confirmed
as of the date first written above mentioned, on behalf of itself and as Representative of the several Underwriters named on <U>Schedule
1</U> hereto:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BOUSTEAD SECURITIES, LLC</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keith Moore</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SCHEDULE
1</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underwriter</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 63%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
    Number of</B> F<B>irm Units </B> t<B>o be Purchased</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Boustead Securities, LLC</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TOTAL</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SCHEDULE
2-A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pricing
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
of Firm Units: 1,660,000 </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
Offering Price per Firm Unit: $_____</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting
Discount per Firm Unit: $____</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Accountable
Expense Allowance per Firm Unit: $____</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SCHEDULE
2-B</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issuer
General Use Free Writing Prospectuses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SCHEDULE
2-C</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Written
Testing-the-Waters Communications</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXHIBIT
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
of Representative&rsquo;s Warrant</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXHIBIT
B</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forms
of Lock-Up Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 37; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>ex4-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
4.2</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Form
of Note</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIS
NOTE HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES
HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;),
AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SHUTTLE
PHARMACEUTICALS HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10%
PROMISORRY NOTE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issuance
    Date: ____________ __, 2022</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Original
    Principal Amount: $_____________</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
    No. __</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, <B>Shuttle Pharmaceuticals Holdings, Inc.</B>, a Delaware corporation (&ldquo;Shuttle Pharma&rdquo; or the &ldquo;<U>Maker</U>&rdquo;),
hereby promises to pay to the order of _________________________ (the &ldquo;<U>Subscriber</U>&rdquo;), or its registered assigns (together
with the Subscriber, the &ldquo;<U>Holder</U>&rdquo;), the amount set out above as the Original Principal Amount, as reduced pursuant
to the terms hereof pursuant to redemption, conversion or otherwise (the &ldquo;<U>Principal</U>&rdquo;), when due, whether upon the
Maturity Date (as defined below), acceleration, redemption or otherwise (in each case in accordance with the terms hereof) and to pay
interest (&ldquo;<U>Interest</U>&rdquo;) on any outstanding Principal at the applicable Interest Rate from the date set out above as
the Issuance Date (the &ldquo;<U>Issuance Date</U>&rdquo;) until the same becomes due and payable, upon the Maturity Date in accordance
with the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Original Principal Amount is _________________________ Dollars ($__________). For purposes hereof, the term &ldquo;<U>Outstanding Balance</U>&rdquo;
means the Original Principal Amount, , plus any accrued but unpaid interest, collection and enforcements costs, and any other fees or
charges incurred under this Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Note is being issued pursuant to the terms of a subscription agreement dated as of ____ __, 2022 between the Maker and the Subscriber
and exhibits thereto (collectively, the &ldquo;<U>Transaction Documents</U>&rdquo;). Unless otherwise defined herein, all capitalized
terms, when used in this Note, shall have the same meaning as they are defined in the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
GENERAL TERMS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Payment of Principal</U>. Unless previously converted into shares of the common stock, $0.00001par value, of Shuttle Pharma or the
common stock of any successor in interest to the Maker (each the &ldquo;<U>Common Stock</U>&rdquo;) as contemplated hereby, this Note,
together with all accrued interest hereon at the Interest Rate, shall be due and payable on the earlier of the Company&rsquo;s completion
of its IPO (as defined below) or July 31, 2023 (the &ldquo;<U>Maturity Date</U>&rdquo;). In the event that within 12 months of the Issuance
Date, the Maker shall not have consummated an initial public offering of its Common Stock and the listing or trading of its Common Stock
on a &ldquo;<U>Qualified Securities Market</U>&rdquo;, as defined below (the &ldquo;<U>IPO</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Interest</U>. Interest shall accrue from the Issuance Date on the Original Principal Amount or other outstanding Principal at an annual
rate of ten percent (10%) (the &ldquo;<U>Interest Rate</U>&rdquo;) and all accrued interest shall be fully paid on the Maturity Date
(or sooner as provided herein) to the Holder or its assignee in whose name this Note is registered on the records of the Maker regarding
registration and transfers of Notes in cash.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
EVENTS OF DEFAULT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whenever
used herein, an &ldquo;<U>Event of Default</U>&rdquo; means the occurrence and continuation of any one of the following events, whatever
the reason, and whether it shall be voluntary or involuntary, or effected by operation of law or pursuant to any judgment, decree or
order of any court, or any order, rule or regulation of any administrative or governmental body:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Maker&rsquo;s failure to pay to the Holder any amount of Principal, Interest, or other amounts when and as due under this Note; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
A material breach by Shuttle Pharma of any material representation, warranty or covenant contained in the Transaction Documents or a
material breach by Shuttle Pharma of any material representation, warranty or covenant contained in the Purchase Agreement, that, if
capable of cure, is not cured within 30 days from the date such breach has occurred; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Maker or any subsidiary of the Maker shall commence, or there shall be commenced against the Maker or any subsidiary of the Maker
under any applicable bankruptcy or insolvency laws as now or hereafter in effect or any successor thereto, or the Maker or any subsidiary
of the Maker commences any other proceeding under any reorganization, arrangement, adjustment of debt, relief of debtors, dissolution,
insolvency or liquidation or similar law of any jurisdiction whether now or hereafter in effect relating to the Maker or any subsidiary
of the Maker or there is commenced against the Maker or any subsidiary of the Maker any such bankruptcy, insolvency or other proceeding
which remains undismissed for a period of ninety-one (91) days; or the Maker or any subsidiary of the Maker is adjudicated insolvent
or bankrupt; or any order of relief or other order approving any such case or proceeding is entered; or the Maker or any subsidiary of
the Maker suffers any appointment of any custodian, private or court appointed receiver or the like for it or any substantial part of
its property which continues undischarged or unstayed for a period of ninety-one (91) days; or the Maker or any subsidiary of the Maker
makes a general assignment for the benefit of creditors; or the Maker or any subsidiary of the Maker shall fail to pay, or shall state
that it is unable to pay, or shall be unable to pay, its debts generally as they become due; or the Maker or any subsidiary of the Maker
shall call a meeting of its creditors with a view to arranging a composition, adjustment or restructuring of its debts; or the Maker
or any subsidiary of the Maker shall by any act or failure to act expressly indicate its consent to, approval of or acquiescence in any
of the foregoing; or any corporate or other action is taken by the Maker or any subsidiary of the Maker for the purpose of effecting
any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
PREPAYMENT. This Note may be prepaid by Shuttle Pharma without penalty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
REISSUANCE OF THIS NOTE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
receipt by the Maker of evidence reasonably satisfactory to the Maker of the loss, theft, destruction or mutilation of this Note, and,
in the case of loss, theft or destruction, of any indemnification undertaking by the Holder to the Maker in customary form and, in the
case of mutilation, upon surrender and cancellation of this Note, the Maker shall execute and deliver to the Holder a new Note representing
the outstanding Principal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
NOTICES. Any notices, consents, waivers or other communications required or permitted to be given under the terms shall be handled according
to the Notice clause in the Subscription Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
addresses for such communications shall be:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Maker:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Anatoly Dritschilo, CEO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuttle
Pharmaceuticals Holdings, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
Research Court, Suite 450</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rockville,
MD 20850</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
[&nbsp;&nbsp;&nbsp;&nbsp; ]@shuttlepharma.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Holder:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
APPLICABLE LAW AND VENUE. This Note shall be governed by and construed in accordance with the laws of the State of New York, without
giving effect to conflicts of laws thereof. Any action brought by either party against the other concerning the transactions
contemplated by this Agreement shall be brought only in the state courts of New York or in the federal courts located in New York
County, in the State of New York. Both parties and the individuals signing this Agreement agree to submit to the jurisdiction of
such courts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
WAIVER. Any waiver by the Holder of a breach of any provision of this Note shall not operate as or be construed to be a waiver of any
other breach of such provision or of any breach of any other provision of this Note. The failure of the Holder to insist upon strict
adherence to any term of this Note on one or more occasions shall not be considered a waiver or deprive that party of the right thereafter
to insist upon strict adherence to that term or any other term of this Note. Any waiver must be in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
MISCELLANEOUS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Lawful Money; Costs of Collection</U>. All amounts payable hereunder are payable in lawful money of the United States. Shuttle Pharma
agrees to pay all costs of collection when incurred, including reasonable attorneys&rsquo; fees and costs, whether or not a suit or action
is instituted to enforce this Note, including but not limited to court costs, appraisal fees, the cost of searching records, obtaining
title reports and title insurance and trustee&rsquo;s fees, to the extent permitted by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>No Offset; Holder in Due Course</U>. All payments under this Note made by or on behalf of Shuttle Pharma shall be made without setoff
or counterclaim and free and clear of, and without deduction or withholding for or on account of, any federal, state, or local taxes.
Shuttle Pharma waives any right of offset it now has or may hereafter have against Agent or Holder and its successors and assigns as
to this Note (but retains any such rights as to any other prior or future transaction between these parties), and agrees to make the
payments called for hereunder in accordance with the terms hereof. The holder hereof and all successors thereof shall have all the rights
of a holder in due course as provided in the Delaware Uniform Commercial Code and other laws of the State of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Waivers</U>. Shuttle Pharma and any endorsers, guarantors or sureties hereof severally waive presentment and demand for payment, notice
of intent to accelerate maturity, protest or notice of protest or non-payment, bringing of suit and diligence in taking any action to
collect any sums owing hereunder or in proceeding against any of the rights and properties securing payment hereunder; expressly agree
that this Note, or any payment hereunder, may be extended from time to time; and consent to the acceptance of further security or the
release of any security for this Note, all without in any way affecting the liability of Shuttle Pharma and any endorsers or guarantors
hereof. No extension of time for the payment of this Note, or any installment hereof, made by agreement by the holder hereof with any
person now or hereafter liable for the payment of this Note, shall affect the original liability under this Note of Shuttle Pharma, even
if Shuttle Pharma (or any entity comprising Shuttle Pharma) is not a party to such agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Usury Protection</U>. The parties hereto intend to conform strictly to the applicable usury laws. In no event, regardless of any provisions
contained therein or in any other document executed or delivered in connection herewith, shall the holder hereof ever be deemed to have
contracted for or be entitled to receive, collect or apply as interest on this Note, any amount in excess of the maximum amount permitted
by applicable law (the &ldquo;<U>Maximum Rate</U>&rdquo;). In no event, whether by reason of demand for payment, prepayment, acceleration
of the maturity hereof or otherwise, shall the interest contracted for, charged or received by the holder hereunder or otherwise exceed
the Maximum Rate. If for any circumstance whatsoever interest would otherwise be payable to the holder in excess of the maximum lawful
amount, the interest payable to the holder shall be reduced automatically to the Maximum Rate and any payment received in excess of such
amount shall be applied to the outstanding principal balance of the Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Entire Agreement</U>. This Note, the other Transaction Documents, and all other documents and instruments contemplated hereby and
thereby together constitute the entire agreement between and among the parties pertaining to the subject matter hereof. No supplement,
modification or amendment of this Note shall be binding unless executed in writing by the parties. No waiver shall be binding unless
executed in writing by the party making the waiver. No provision of this Note shall be interpreted for or against the drafting party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Commercial Purpose.</U> Shuttle Pharma agrees that no funds advanced under this Note shall be used for personal, family or household
purposes, and that all funds advanced hereunder shall be used solely for business, commercial, investment or other similar purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Successors and Assigns</U>. All the terms and provisions of this Note shall be binding upon and inure to the benefit of the parties
to this Note and their respective successors and assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>Assignment</U>. Shuttle Pharma may not, voluntarily or involuntarily, directly or indirectly, by operation of law or otherwise, sell,
transfer, assign, hypothecate, pledge or in any way alienate this Note or any right or interest in this Note (each a &ldquo;<U>Transfer</U>&rdquo;)
without Holder&rsquo;s prior written consent, which Holder may withhold in its sole and absolute discretion. Any consent by Holder to
any Transfer shall not constitute consent to any other Transfer. Holder may freely Transfer its interest, rights, or title in or to this
Note or the other Transaction Documents in Holder&rsquo;s sole and absolute discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Construction.</U> Whenever used in this Note, the terms &ldquo;including,&rdquo; &ldquo;include,&rdquo; &ldquo;includes&rdquo; and
the like are not intended as terms of limitation, and, hence, shall be deemed to be followed by &ldquo;without limitation.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Severability</U>. If any provision of this Note, as applied to any party or to any circumstance, shall be found by a court of competent
jurisdiction to be void, invalid or unenforceable, the same shall in no way affect any other provision of this Note, the application
of any such provision in any other circumstance, or the validity or enforceability of this Note, and any provision which is found to
be void, invalid or unenforceable shall be curtailed and limited only to the extent necessary to bring such provision within the requirements
of the law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Survival of Terms</U>. The terms and provisions of this Note shall survive the Maturity Date until full payment of all amounts due
hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>Preferential Payment</U>. If at any time any payment made pursuant to this Note is deemed to have been a voidable preference, fraudulent
conveyance or other similar conveyance or preferential payment under any bankruptcy, insolvency or other debtor relief or similar law,
then the obligation to make such payment shall survive any cancellation or satisfaction of this Note or return of this Note to Shuttle
Pharma and shall not be discharged or satisfied with any such payment or cancellation. Such payment shall instead remain a valid and
binding obligation enforceable in accordance with the terms of this Note and shall be immediately due and payable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>Relief From Stay</U>. As an additional inducement to and material consideration for Holder agreeing to execute this this Note and
the other Transaction Documents, Shuttle Pharma agrees that in the event a Bankruptcy or Judicial Action (as hereinafter defined in this
<U>Section 8(n)</U>) is commenced which subjects Holder to any stay in the exercise of Holder&rsquo;s rights and remedies under this
Note or the other Transaction Documents, including, but not limited to, the automatic stay imposed by Section 362 of the United States
Bankruptcy Code (individually and collectively, &ldquo;<U>Stay</U>&rdquo;), then Shuttle Pharma irrevocably consents and agrees that
such Stay shall automatically be lifted and released against Holder, and Holder shall thereafter be entitled to exercise all of its rights
and remedies against Shuttle Pharma that is or could be subject any Stay under this Note or the other Transaction Documents. Nothing
contained herein shall limit or prevent Holder from exercising all of its rights and remedies against Shuttle Pharma that is not the
subject any Stay under this Note or the other Transaction Documents. Shuttle Pharma acknowledges that it is knowingly, voluntarily, and
intentionally waiving its rights to any Stay and agrees that the benefits provided to Shuttle Pharma under the terms of this Note are
valuable consideration for such waiver. As used in this <U>Section 8(n)</U>, the term &ldquo;<U>Bankruptcy or Judicial Action</U>&rdquo;
shall mean any voluntary or involuntary case filed by or against a Shuttle Pharma under the United States Bankruptcy Code, or any voluntary
or involuntary petition in composition, readjustment, liquidation, or dissolution, or any state and federal bankruptcy law action filed
by or against a Shuttle Pharma, any action where a Shuttle Pharma is adjudicated as bankrupt or insolvent, any action for dissolution
of a Shuttle Pharma, or any action in furtherance of any of the foregoing, or any other action, case, or proceeding that has the effect
of staying (or in which a stay is being obtained against) the enforcement by Holder of its rights and remedies under the this Note or
the other Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
to enforce the terms of the Transaction Documents, Shuttle Pharma shall not take any action and shall not fail to take any action which
such action or omission will or might tend to interfere with, delay, enjoin or otherwise prohibit the commencement, continuation or completion
of efforts by Holder to enforce its remedies under this Note or the other Transaction Documents, or applicable law. Without limiting
the generality of the foregoing and except to enforce the terms of the Transaction Documents, each Shuttle Pharma waives its, his, or
her rights, if any, to seek or obtain a stay, injunction or other form of order prohibiting in any way any act necessary or appropriate
for the commencement or completion of Holder&rsquo;s enforcement of its remedies under the this Note or the other Transaction Documents,
or applicable law (without limiting the generality of the foregoing, such waiver extends to such rights which may exist under any statute
or rule relating to bankruptcy cases, including, without limitation, 11 U.S.C. &sect; 105, 11 U.S.C. &sect; 301, 11 U.S.C. &sect; 302,
11 U.S.C. &sect; 303, 11 U.S.C. &sect; 304, 11 U.S.C. &sect; 362, 11 U.S.C. &sect; 348, 11 U.S.C. &sect; 706, 28 U.S.C. &sect; 157, 28
U.S.C. &sect; 158, Federal Rule of bankruptcy Procedure (&ldquo;FRBP&rdquo;) 3007, FRBP 3008, FRBP 3012, FRBP 8005, FRBP 9023, FRBP 9024,
or FRBP 9029).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
AMENDMENT AND WAIVER OF RIGHTS. This Note may be amended and the observance of any term hereof may be waived (either generally or in
a particular instance either retroactively or prospectively) only by a written instrument executed by the Maker and the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
WAIVER OF RIGHT TO TRIAL BY JURY.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EACH
PARTY TO THIS NOTE HEREBY EXPRESSLY WAIVES ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION (1) ARISING UNDER
THIS NOTE, THE OTHER TRANSACTION DOCUMENTS, OR ANY OTHER INSTRUMENT, DOCUMENT, OR AGREEMENT EXECUTED OR DELIVERED IN CONNECTION THEREWITH,
OR (2) IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO OR ANY OF THEM WITH RESPECT TO THIS NOTE
OR ANY OTHER INSTRUMENT, DOCUMENT, OR AGREEMENT EXECUTED OR DELIVERED IN CONNECTION HEREWITH, OR THE TRANSACTIONS RELATED HERETO OR THERETO,
IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER SOUNDING IN CONTRACT OR TORT OR OTHERWISE; AND EACH PARTY HEREBY
AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY. THE PARTIES
HERETO HEREBY AGREE THAT THE PROVISIONS CONTAINED HEREIN HAVE BEEN FAIRLY NEGOTIATED ON AN ARM&rsquo;S-LENGTH BASIS, WITH BOTH SIDES
AGREEING TO THE SAME KNOWINGLY AND BEING AFFORDED THE OPPORTUNITY TO HAVE THEIR RESPECTIVE LEGAL COUNSEL CONSENT TO THE MATTERS CONTAINED
HEREIN. ANY PARTY TO THIS NOTE MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS SECTION WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT
OF THE PARTIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY AND THE AGREEMENTS CONTAINED HEREIN REGARDING THE APPLICATION OF
JUDICIAL REFERENCE IN THE EVENT OF THE INVALIDITY OF SUCH JURY TRIAL WAIVER.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, each of the Maker has caused this Note to be duly executed by a duly authorized officer as of the date set forth above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuttle Pharmaceuticals Holdings, Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Anatoly Dritschilo</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
No. [ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>4
<FILENAME>ex4-3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
</B></FONT><B><FONT STYLE="text-transform: uppercase">4.3</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>Form
of Warrant</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">NEITHER THIS SECURITY NOR THE SECURITIES
FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF
ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;),
AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH
SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED
IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">Warrant No. _____</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">Issue Date: _________2022</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">THIS COMMON STOCK PURCHASE WARRANT
(the &ldquo;<B><I>Warrant</I></B>&rdquo;) certifies that, for value received, <B>[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ]</B> or any registered assigns (the &ldquo;<B><I>Holder</I></B>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time following
the Issue Date (the &ldquo;<B><I>Initial Exercise Date</I></B>&rdquo;) and on or prior to the close of business on <B>____________, 2027<FONT STYLE="line-height: 107%"><SUP>1</SUP></FONT></B>
(the &ldquo;<B><I>Termination Date</I></B>&rdquo;) but not thereafter, to subscribe for and purchase from <B>Shuttle Pharmaceuticals Holdings,
Inc</B>.<B>, </B>a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), up to [ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] shares of Common Stock (the &ldquo;<B><I>Warrant
Shares</I></B>&rdquo;). The purchase price of one share of Common Stock under this Warrant shall be the lower of $2.50 per share or 50%
of the per share purchase price of the Company&rsquo;s initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><U>Section 1</U>.
<U>Definitions</U>. For the purposes hereof, in addition to the terms defined elsewhere in this Warrant, (a) capitalized terms not otherwise
defined herein shall have the meanings set forth in the Subscription Agreement entered into by the Company and the Holder of even day
herewith and (b) the following terms shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Business
Day</I></B>&rdquo; means any day except any Saturday, any Sunday, any day which shall be a federal legal holiday in the United States
or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Common
Stock</I></B>&rdquo; means the shares of common stock, $0.00001 par value per share, of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 41.95pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Common
Stock Equivalents</I></B>&rdquo; means any securities of the Company which would entitle the holder thereof to acquire at any time Common
Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible
into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive Common Stock.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt; line-height: 107%"><SUP>1</SUP></FONT>
Five years from the Issue Date</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Exercise
Period</I></B>&rdquo; shall have the meaning as that term is defined in Section 2(a) below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 41.95pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Person</I></B>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 41.95pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Securities
Act</I></B>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Trading
Day</I></B>&rdquo; means a day on which the New York Stock Exchange is open for business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Trading
Market</I></B>&rdquo; means the following markets or exchanges on which the Common Stock may be listed or quoted for trading on the date
in question: the NYSE MKT, LLC, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York
Stock Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 41.95pt; text-align: justify; text-indent: 38.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Transfer
Agent</I></B>&rdquo; means VStock Transfer LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 41.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Exercise of
Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or
after the Initial Exercise Date and on or before the Termination Date (the &ldquo;<B><I>Exercise Period</I></B>&rdquo;) by delivery to
the Company (or such other office or agency of the Company as it may designate by notice in writing to the registered Holder at the address
of the Holder appearing on the books of the Company) of a duly executed notice of exercise (&ldquo;<B><I>Notice of Exercise</I></B>&rdquo;)
form attached hereto as Exhibit A(i); and, within three (3) Trading Days of the date said Notice of Exercise is delivered to the Company,
the Company shall have received payment of the aggregate Exercise Price of the shares thereby purchased by wire transfer or cashier&rsquo;s
check drawn on a United States bank. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender
this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised
in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date
the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the
total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing
the number of Warrant Shares purchased and the date of such purchases. In the event of any dispute or discrepancy, the records of the
Company shall be controlling and determinative in the absence of manifest error.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Exercise Price</U>.
The exercise price per share of the Common Stock under this Warrant shall be $1.00.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Mechanics of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in">i. <U>Delivery
of Warrant Shares Upon Exercise</U>. Certificates for shares purchased hereunder shall be transmitted by the Company&rsquo;s transfer
agent (the &ldquo;<B><I>Transfer Agent</I></B>&rdquo;) to the Holder by crediting the account of the Holder&rsquo;s prime broker with
the Depository Trust Company through its Deposit Withdrawal Agent Commission (&ldquo;<B><I>DWAC</I></B>&rdquo;) system if the Company
is then a participant in such system and either (A) there is an effective registration statement for its initial public offering registering
the Warrants Shares, in which case the Holder will simultaneously exercise this Warrant upon the effectiveness of such registration statement,
(B) there is a registration statement permitting the resale of the Warrant Shares by the Holder or (C) the shares are eligible for resale
without volume or manner-of-sale limitations pursuant to Rule 144, and otherwise by physical delivery of certificates to the address specified
by the Holder in the Notice of Exercise within four (4) Trading Days from the delivery to the Company of the Notice of Exercise Form,
surrender of this Warrant (if required) and payment of the aggregate Exercise Price as set forth above (the &ldquo;<B><I>Warrant Share
Delivery Date</I></B>&rdquo;). This Warrant shall be deemed to have been exercised on the date the Exercise Price is received by the Company.
The Warrant Shares shall be deemed to have been issued, and Holder or any other person so designated to be named therein shall be deemed
to have become a holder of record of such shares for all purposes, as of the date the Warrant has been exercised by payment to the Company
of the Exercise Price and all taxes required to be paid by the Holder, if any, pursuant to Section 2(d)(vi) prior to the issuance of such
shares, have been paid. .</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in">ii. <U>Delivery of
Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon
surrender of this Warrant certificate, at the time of delivery of the certificate or certificates representing Warrant Shares, deliver
to Holder a new Warrant evidencing the rights of Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new
Warrant shall in all other respects be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in">iii. <U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder a certificate or the certificates representing
the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such
exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in">iv. <U>No Fractional
Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As
to any fraction of a share which Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election,
either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or
round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in">v. <U>Charges, Taxes
and Expenses</U>. Issuance of certificates for Warrant Shares shall be made without charge to the Holder for any issue or transfer tax
or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall be paid by the Company,
and such certificates shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that in the event certificates for Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant
when surrendered for exercise shall be accompanied by the assignment form (&ldquo;<B><I>Assignment Form</I></B>&rdquo;) attached hereto
as Exhibit A(ii) duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse
it for any transfer tax incidental thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 39pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in">vi. <U>Closing of
Books</U>. The Company will not close its shareholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><U>Section 3</U>.
<U>Certain Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="margin-left: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in"><FONT STYLE="letter-spacing: -0.05pt">a)
</FONT><U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise make a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any Warrant Shares issued by the Company upon exercise of
this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of
reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by reclassification of shares of
the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of
which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such
event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event and the number
of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of shareholders entitled to receive such dividend or distribution and shall become effective immediately after the effective
date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="letter-spacing: -0.05pt">b)
</FONT><U>Calculations</U>. All calculations under this Section 4 shall be made to the nearest cent or the nearest 1/100th of a share,
as the case may be. For purposes of this Section 4, the number of shares of Common Stock deemed to be issued and outstanding as of a given
date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 36.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="letter-spacing: -0.05pt">c)
</FONT> <U>Notice to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 36.5pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 1in">i. <U>Adjustment to Exercise Price</U>.
Whenever the Exercise Price is adjusted pursuant to any provision of this <U>Section 4</U>, the Company shall promptly mail to the Holder
a notice setting forth the Exercise Price after such adjustment and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 1in">ii. <U>Notice to Allow Exercise by Holder</U>.
If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare
a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders
of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the
approval of any shareholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation
or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, of any compulsory
share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary
or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be
mailed to the Holder at its last address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior
to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the
purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders
of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y)
the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close,
and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common
Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange;
provided that the failure to mail such notice or any defect therein or in the mailing thereof shall not affect the validity of the corporate
action required to be specified in such notice. The Holder is entitled to exercise this Warrant during the period commencing on the date
of such notice to the effective date of the event triggering such notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><U>Section 4</U>. <U>Transfer of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.05pt; line-height: 107%">a)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><U>Transferability</U>. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. The Warrant, if properly assigned, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.05pt; line-height: 107%">b)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><U>Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 5(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Initial Exercise Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="letter-spacing: -0.05pt">c)
</FONT><U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose
(the &ldquo;<B><I>Warrant Register</I></B>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and
treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to
the Holder, and for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><U>Section 5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="letter-spacing: -0.05pt">c)
</FONT><U>No Rights as Shareholder Until Exercise</U>. This Warrant does not entitle the Holder to any voting rights or other rights as
a shareholder of the Company prior to the exercise hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="letter-spacing: -0.05pt">d)
</FONT><U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="letter-spacing: -0.05pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="letter-spacing: -0.05pt">e)
</FONT><U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding
Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 22pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="letter-spacing: -0.05pt">f) </FONT><U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 1in">The Company covenants that, during the
period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock one hundred (100%) of the number of shares
to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. In case such amount of
Common Stock is insufficient at any time, the Company shall call and hold a special meeting to increase the number of authorized shares
of common stock. Management of the Company shall recommend to shareholders to vote in favor of increasing the number of authorized shares
of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 1in">The Company further covenants that
its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of executing stock certificates
to execute and issue the necessary certificates for the Warrant Shares upon the exercise of the purchase rights under this Warrant. The
Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without
violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed.
The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant
will, upon exercise of the purchase rights represented by this Warrant, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 1in">Except and to the extent as waived
or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its amended and restated certificate
of incorporation, as amended, or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of
securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but
will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 1in">Before taking any action which would
result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall
obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies
having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="letter-spacing: -0.05pt">g)
</FONT><U>Jurisdiction</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be determined in accordance with the provisions of the laws of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="letter-spacing: -0.05pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="letter-spacing: -0.05pt">h)
</FONT><U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,
will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="letter-spacing: -0.05pt">i)
</FONT><U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder
shall operate as a waiver of such right or otherwise prejudice Holder&rsquo;s rights, powers or remedies, notwithstanding the fact that
all rights hereunder terminate on the Termination Date. If the Company willfully and knowingly fails to comply with any provision of this
Warrant, which results in any material damages to the Holder, the Company shall pay to Holder such amounts as shall be sufficient to cover
any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred
by Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="letter-spacing: -0.05pt">j)
</FONT><U>Notices</U>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company
shall be delivered in accordance with the addresses provided by the Holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="letter-spacing: -0.05pt">k)
</FONT><U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability of Holder
for the purchase price of any Common Stock or as a shareholder of the Company, whether such liability is asserted by the Company or by
creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="letter-spacing: -0.05pt">l)
</FONT><U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 22pt; text-indent: 0.5in"><FONT STYLE="letter-spacing: -0.05pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="letter-spacing: -0.05pt">m)
</FONT><U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors of the Company and the successors and permitted assigns of Holder. The
provisions of this Warrant are intended to be for the benefit of all Holders from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="letter-spacing: -0.05pt">n)
</FONT><U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company
and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="letter-spacing: -0.05pt">o)
</FONT><U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and
valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision
shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="letter-spacing: -0.05pt">p)
</FONT><U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[Signature Page Follows.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">IN WITNESS WHEREOF, the Company has caused this Warrant to be
executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><B>SHUTTLE PHARMACEUTICALS HOLDINGS, INC.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">Anatoly Dritschilo</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">Chief Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>EXHIBIT A(i)</U></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">TO:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">(1) The undersigned hereby elects to purchase_________
Warrant Shares of the Company pursuant to the terms of the attached Warrant and tenders herewith payment of the exercise price in full,
together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">(2) Please issue a certificate or certificates
representing said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-bottom: 0pt">____________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The Warrant Shares shall be delivered to the following DWAC
Account Number or by physical delivery of a certificate to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-bottom: 0pt">____________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-bottom: 0pt">____________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-bottom: 0pt">____________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">(3) <U>Accredited Investor</U>. The undersigned
is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">[SIGNATURE OF HOLDER]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Name of Investing Entity:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">____________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>Signature of Authorized Signatory of Investing Entity</I>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">____________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Name of Authorized Signatory:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">____________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Title of Authorized Signatory:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">____________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">____________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>EXHIBIT A(ii)</U></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ASSIGNMENT FORM</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 1in; font: 10pt Times New Roman, Times, Serif; text-align: center">(To assign
the foregoing warrant, execute this form and supply required information. Do not use this form to exercise the warrant.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">FOR VALUE RECEIVED, [_____] all of or [_____] shares
of the foregoing Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">______________________________________________________whose address is</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">______________________________________________________________________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">_________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">Dated:____________________<U>&nbsp;</U>,
    _____</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">Holder&rsquo;s
Signature:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">_______________________</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">Holder&rsquo;s
Address:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">_______________________</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">_______________________</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Signature Guaranteed:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">NOTE: The signature to this Assignment Form must correspond
with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever, and must be guaranteed
by a bank or trust company. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper
evidence of authority to assign the foregoing Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>5
<FILENAME>ex4-4.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.4</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMMON
STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SHUTTLE
PHARMACEUTICALS HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    Shares: _______</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
    Exercise Date: [___], 2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue
    Date: August [___], 2022</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
COMMON STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the
&ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set
forth, at any time on or after the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York
City time) on ______________<SUP>1 </SUP>(the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase
from Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject
to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under
this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain
Securities Purchase Agreement (the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated August [___], 2022, by and among the Company and the
purchasers signatory thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time
or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF
copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto as <U>Annex A</U> (the &ldquo;<U>Notice
of Exercise</U>&rdquo;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement
Period (as defined in Section 2(c)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise
Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States
bank. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization)
of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically
surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has
been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading
Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases
of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant
Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall
maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection
to any Notice of Exercise within one (1) Business Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this
Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated
on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1
</SUP>Insert the date that is the five year anniversary of the Issue Date, provided that, if such date is not a Trading Day, insert the
immediately following Trading Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Exercise Price</U>. The exercise price per share of Common Stock under this Warrant shall be <B>$0.01</B>, subject to adjustment hereunder
(the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Mechanics of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by
the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant
in such system and there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant
Shares by Holder. Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder
of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant
Shares, provided that payment of the aggregate Exercise Price is received within the earlier of (i) two (2) Trading Days and (ii) the
number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for
any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the number of Trading Days comprising the Standard
Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;),
the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to
such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing
to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share
Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent
that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard
Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary
Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;)
(based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading
Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable,
(c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported
on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price
per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined
by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and
reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of
a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in
all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
<U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section
2(c)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No Fractional Shares or Scrip</U>. No fractional
shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which
the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment
in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole
share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.
<U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax
or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form annexed hereto as <U>Annex B</U> duly executed by the Holder and
the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.
The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository
Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of
the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.
<U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not affect any exercise of this Warrant, and a Holder shall not have the
right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other
Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(d), beneficial ownership
shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being
acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d)
of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(d) applies, the determination of whether this Warrant is exercisable (in relation to
other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable
shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution
Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status
as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder. For purposes of this Section 2(d), in determining the number of outstanding shares of Common Stock, a Holder may rely on
the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed
with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by
the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of
a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then
outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date
as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo;
shall be 4.99% (or 9.99% at the election of the Purchaser) of the number of shares of the Common Stock outstanding immediately after
giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company,
may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(d), provided that the Beneficial Ownership
Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance
of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(d) shall continue to
apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered
to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with
the terms of this Section 2(d) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended
Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to
such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the
Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which
the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Reserved</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had
held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that, to
the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership
of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held
in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend,
spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent
(or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such
Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result
in the Holder exceeding the Beneficial Ownership Limitation). To the extent that this Warrant has not been partially or completely exercised
at the time of such Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the
Holder has exercised this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender
or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding
Common Stock or 50% or more of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one
or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share
exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v)
the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business
combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another
Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding shares of Common Stock or 50% or
more of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, at the time
of such Fundamental Transactoin, the Holder&rsquo;s Warrant shall automatically be deemed exercised and such Holder will recieve the
number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and
any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction
by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction
(without regard to any limitation in Section 2(d) on the exercise of this Warrant). For purposes of any such exercise, the determination
of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration
issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price
among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.
If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then
the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such
Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor
Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable at any time concurrently with, or within 30 days after, the
consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction),
purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of
the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; <U>provided</U>, <U>however</U>,
that, if the Fundamental Transaction is not within the Company&rsquo;s control, including not approved by the Company&rsquo;s Board of
Directors, the Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration
(and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to
the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form
of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative
forms of consideration in connection with the Fundamental Transaction; <U>provided</U>, <U>further</U>, that if holders of Common Stock
of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed
to have received common stock of the Successor Entity (which Entity may be the Company following such Fundamental Transaction) in such
Fundamental Transaction. &ldquo;<U>Black Scholes Value</U>&rdquo; means the value of this Warrant based on the Black-Scholes Option Pricing
Model obtained from the &ldquo;OV&rdquo; function on Bloomberg determined as of the day of consummation of the applicable Fundamental
Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal
to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date,
(B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg (determined
utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable contemplated
Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price
per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction
and (ii) the highest VWAP during the period beginning on the Trading Day immediately preceding the public announcement of the applicable
contemplated Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and ending on the Trading
Day of the Holder&rsquo;s request pursuant to this Section 3(e) and (D) a remaining option time equal to the time between the date of
the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date and (E) a zero cost of borrow.
The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within
the later of (i) five Business Days of the Holder&rsquo;s election and (ii) the date of consummation of the Fundamental Transaction.
The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor
Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents
in accordance with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to
the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of
the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor
Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without
regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies
the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock
pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such
exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity),
and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the
other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Notice to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to
be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such
notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
<U>Voluntary Adjustment By Company</U>. Subject to the rules and regulations of the Trading Market, the Company may at any time during
the term of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board
of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Transferability</U>. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable,
in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written
assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient
to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall
execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not
so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the
Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of
this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
&ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(c)(i), except as expressly
set forth in Section 3. In no event shall the Company be required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Authorized Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Jurisdiction</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined
in accordance with the provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, will
have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant,
which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover
any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred
by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
<U>Notices</U>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall
be delivered in accordance with the notice provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)
<U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and
the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)
<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)
<U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>SHUTTLE PHARMACEUTICALS
    HOLDINGS, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anatoly Dritschilo</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANNEX
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:
SHUTTLE PHARMACEUTICALS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of lawful money of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ______________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: ________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: __________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ___________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
______________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANNEX
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">ASSIGNMENT
FORM</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.15in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.15in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.15in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.15in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 39%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone
    Number:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _______________ __, ______</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature: <U>___________________________</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address: <U>____________________________</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>6
<FILENAME>ex5-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex5-1_001.jpg" ALT="" STYLE="height: 107px; width: 670px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>New
    York Office</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">800
    Third Avenue, 24<SUP>th</SUP> Floor</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    York, NY 10022</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0.75pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>P
    </B>212.730.7700 <B>F</B> 212.730.7725 www.mrllp.com</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 3.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
18,</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuttle
Pharmaceuticals Holdings, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
Research Court, Suite 450</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rockville,
MD 20850</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Re:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shuttle
    Pharmaceuticals Holdings, Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Registration
    Statement on Form S-1/A</U></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have acted as counsel to Shuttle
Pharmaceuticals Holdings, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), in connection with the Registration Statement
on Form S-1 (Registration No. 333-265429), as amended (the &ldquo;<U>Registration Statement</U>&rdquo;), filed with the Securities and
Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) for purposes of registering for sale under the Securities Act of 1933, as amended
(the &ldquo;<U>Act</U>&rdquo;), of: (i) up to 1,660,000 units, with each unit consisting of one share of common stock, par value $0.0001
per share (the &ldquo;Common Stock&rdquo;), and one warrant to purchase one share of Common Stock at an exercise price of $0.01 per share
(the Common Stock and the warrants together, the &ldquo;<U>Shares</U>&rdquo;), of the Company, which includes 249,000 units are
subject to the underwriter&rsquo;s over-allotment option (the &ldquo;Over-allotment Option&rdquo;), as described in the Registration
Statement, (ii) up to 232,500 shares (the &ldquo;<U>Underwriter Shares</U>&rdquo;) of Common Stock underlying the underwriter&rsquo;s
warrants issuable in connection with the sale of the Shares, including any shares issuable in the event of the underwriter&rsquo;s exercise
of the Over-allotment Option, and (iii) the resale of an aggregate of 913,334 shares (the &ldquo;Resale Shares&rdquo;) of Common
Stock which are being sold by certain selling stockholders.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
opinion letter is furnished in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Act and cannot be relied
on for any other purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this opinion letter, we have examined the Registration Statement and originals, or copies certified or otherwise identified
to our satisfaction, of (i) the Certificate of Incorporation of the Company, as amended to date (the &ldquo;<U>Certificate of Incorporation</U>&rdquo;),
(ii) the By-Laws of the Company, as amended to date (the &ldquo;<U>Bylaws</U>&rdquo;), (iii) certain resolutions of the Company&rsquo;s
board of directors (the &ldquo;<U>Board of Directors</U>&rdquo;) relating to the Registration Statement, and (iv) such other documents,
records and other instruments as we have deemed appropriate for purposes of the opinions set forth herein. &nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of the documents submitted
to us as originals, the conformity with the originals of all documents submitted to us as certified, facsimile or photostatic copies,
the authenticity of the originals of all documents submitted to us as copies and the persons identified as officers are actually serving
as such and that any certificates representing the securities will be properly executed by one or more such persons. With respect to
matters of fact relevant to our opinions as set forth below, we have relied upon certificates of officers of the Company, representations
made by the Company in documents examined by us, and representations of officers of the Company. We have also obtained and relied upon
such certificates and assurances from public officials as we have deemed necessary for the purposes of our opinions set forth below.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Los
Angeles |  Orange County | San Francisco | Dallas | Houston | Chicago | New York</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shuttle Pharmaceuticals Holdings, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> August 18, 2022</P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">Page 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the foregoing, we are of the opinion that (i) the Shares and the Underwriter Shares, when issued and sold by the Company, and delivered
against payment in accordance with the manner described in the Registration Statement, will be validly issued, fully paid and non-assessable
and (ii) the Resale Shares, are validly issued, fully paid and non-assessable; provided, however, with respect to the 943,334
shares to be sold by certain of the Selling Stockholders that will be issued upon the conversion of convertible notes or exercise of
warrants prior to such sale, such shares will be validly issued, fully-paid and nonassessable upon such conversion of convertible notes
or exercise of warrants pursuant to which such shares are to be issued prior to the completion of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not express any opinion herein concerning any law other than the General Corporation Law of the State of Delaware. We hereby consent
to the use of this opinion as Exhibit 5.1 to the Registration Statement and to the reference to us under the caption &ldquo;Legal Matters&rdquo;
in the Prospectus and to the references to us in the Registration Statement. In giving such consents, we do not hereby admit that we
are acting within the category of persons whose consent is required under Section 7 of the Act or the rules or regulations of the Commission
thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 3.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 3.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Michelman &amp; Robinson, LLP</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MICHELMAN
&amp; ROBINSON, LLP </B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 3.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 3.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 3.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 3.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 3.5in"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 3.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.32
<SEQUENCE>7
<FILENAME>ex10-32.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.32</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMENDMENT
NO. 1 TO 7.5% PROMISSORY NOTE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ORIGINALLY
DATED JUNE 21, 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
on June 21, 2021, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the &ldquo;<U>Obligor</U>&rdquo;), issued a $120,000
promissory note (the &ldquo;<U>Note</U>&rdquo;), in favor of Joy Dritschilo (the &ldquo;<U>Payee</U>&rdquo;), bearing interest at the
rate of 7.5% per annum; the Note was originally due June 30, 2022 (the &ldquo;<U>Maturity Date</U>&rdquo;); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Obligor and the Payee, now wish to amend the terms of the Note to extend the Maturity Date by 12 months to June 30, 2023 (the &ldquo;<U>New
Maturity Date</U>&rdquo;), to provide additional time for the Company to repay the Note and for the accrual of interest on the principal
amount of the Note during such extension.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE</B>, in consideration of the mutual promises set forth herein and for other good and valuable consideration the sufficiency
of which is hereby acknowledged, the Obligor and the Payee hereby agree that the unpaid principal balance of the Note shall be due and
payable on the New Maturity Date, along with any accrued interest through that date. All other terms and conditions of the Note shall
remain unchanged.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, this Amendment has been duly executed by the Obligor and acknowledged by the Payee as of the 29<SUP>th</SUP> day
of July 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SHUTTLE
    PHARMACEUTICALS, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Anatoly Dritschilo</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anatoly
    Dritschilo</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Acknowledged
    and Agreed</B>:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Joy Dritschilo</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joy
    Dritschilo</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33
<SEQUENCE>8
<FILENAME>ex10-33.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.33</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMENDMENT
NO. 2 7.5% PROMISSORY NOTE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ORIGINALLY
DATED DECEMBER 1, 2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
on December 1, 2020, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the &ldquo;<U>Obligor</U>&rdquo;), issued a $424,035.65
unsecured promissory note (the &ldquo;<U>Note</U>&rdquo;), in favor of Joy Dritschilo (the &ldquo;<U>Payee</U>&rdquo;), bearing interest
at the rate of 7.5% per annum; the Note was originally due December 31, 2021, and was amended to extend the maturity date to June 30,
2022 (the &ldquo;<U>Maturity Date</U>&rdquo;); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Obligor and the Payee wish to further amend the terms of the Note to extend the Maturity Date by 12 months to June 30, 2023 (the
&ldquo;<U>New Maturity Date</U>&rdquo;) to provide additional time for the Company to repay the Note and for the accrual of interest
on the principal amount of the Note during such extension.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE</B>, in consideration of the mutual promises set forth herein and for other good and valuable consideration the sufficiency
of which is hereby acknowledged, the Obligor and the Payee hereby agree that the unpaid principal balance of the Note shall be due and
payable on the New Maturity Date, along with any accrued interest through that date. All other terms and conditions of the Note shall
remain unchanged.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, this Amendment has been duly executed by the Obligor and acknowledged by the Payee as of the 29<SUP>th</SUP> day
of July 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SHUTTLE
    PHARMACEUTICALS, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Anatoly Dritscholo</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anatoly
    Dritschilo</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Acknowledged
    and Agreed</B>:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Joy Dritschilo</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joy
    Dritschilo</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.34
<SEQUENCE>9
<FILENAME>ex10-34.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 10.34</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMENDMENT
NO. 2 TO 7.5% PROMISSORY NOTE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ORIGINALLY
DATED DECEMBER 1, 2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
on December 1, 2020, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the &ldquo;<U>Obligor</U>&rdquo;), issued a $138,448.20
unsecured promissory note (the &ldquo;<U>Note</U>&rdquo;), in favor of Anatoly Dritschilo (the &ldquo;<U>Payee</U>&rdquo;), bearing interest
at the rate of 7.5% per annum; the Note was originally due December 31, 2021, as amended to June 30, 2022 (the &ldquo;<U>Maturity Date</U>&rdquo;);
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Obligor and the Payee, now wish to amend the terms of the Note to extend the Maturity Date by 12 months to June 30, 2023 (the &ldquo;<U>New
Maturity Date</U>&rdquo;), to provide additional time for the Company to repay the Note and for the accrual of interest on the principal
amount of the Note during such extension.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE</B>, in consideration of the mutual promises set forth herein and for other good and valuable consideration the sufficiency
of which is hereby acknowledged, the Obligor and the Payee hereby agree that the unpaid principal balance of the Note shall be due and
payable on the New Maturity Date, along with any accrued interest through that date. All other terms and conditions of the Note shall
remain unchanged.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, this Amendment has been duly executed by the Obligor and acknowledged by the Payee as of the 29<SUP>th</SUP> day
of July 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SHUTTLE
    PHARMACEUTICALS, INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Anatoly Dritschilo</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anatoly
    Dritschilo</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Acknowledged
    and Agreed</B>:</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Anatoly Dritschilo</I></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anatoly
    Dritschilo</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>10
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors of</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuttle
Pharmaceuticals Holdings, Inc. Limited</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the inclusion in the Amendment No. 3 to the Form S-1 Registration Statement of Shuttle Pharmaceuticals Holdings, Inc. (File
No. 333-265429) of our report dated June 3, 2022 (except for the effects on the financial statements of the restatement described in
Note 9, as to which the date is June 23, 2022), relating to our audit of the balance sheets as of December 31, 2021 and 2020, and statements
of operations, stockholders&rsquo; equity and cash flows for the years ended December 31, 2021 and 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also consent to the reference to us under the caption &ldquo;Experts&rdquo; in the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>/s/
BF Borgers CPA PC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certified
Public Accountants</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lakewood,
Colorado</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">August 18, 2022</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>11
<FILENAME>ex107.htm
<DESCRIPTION>CALCULATION OF FILING FEE TABLES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
107</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Calculation
of Filing Fee Tables</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>S-1</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Form
Type)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Shuttle
Pharmaceuticals Holdings, Inc. </U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in its Charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Table
1: Newly Registered Securities</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">Security<BR> Type</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">Security<BR> Class<BR> Title</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">Fee<BR> Calculation<BR> or Carry<BR> Forward<BR> Rule</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">Amount<BR> Registered</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">Proposed<BR> Maximum<BR> Offering<BR> Price Per<BR>
    Share</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">Proposed<BR> Maximum<BR> Offering<BR> Price Per<BR>
    Share</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">Fee<BR> Rate</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">Amount of<BR> Registration<BR> Fee</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="26" STYLE="font-weight: bold; text-align: center">Newly Registered Securities</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 10%; text-align: left">Fees to Be Paid</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 10%">Equity</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: left">Units, each consisting of one share of common stock, par value $0.00001 per share, and
    one Warrant</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">457</TD><TD STYLE="width: 1%; text-align: left">(o)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,660,000</FONT></TD><TD STYLE="width: 1%; text-align: left">(1)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">6.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">9,960,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$92.70
                                            per $1,000,000</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">923.29</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fees to Be Paid</TD><TD>&nbsp;</TD>
    <TD>Equity</TD><TD>&nbsp;</TD>
    <TD>Shares of common stock, par value $0.00001 per share, included in the Units</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">457</TD><TD STYLE="text-align: left">(i)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Fees to Be Paid</TD><TD>&nbsp;</TD>
    <TD>Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Warrants included in the Units</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">457</TD><TD STYLE="text-align: left">(i)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fees to Be Paid</TD><TD>&nbsp;</TD>
    <TD>Equity</TD><TD>&nbsp;</TD>
    <TD>Shares of common stock, par value $0.00001 per share, underlying the Warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">457</TD><TD STYLE="text-align: left">(o)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,660,000</FONT></TD><TD STYLE="text-align: left">(1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9,960,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$92.70
                                            per $1,000,000</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">923.29</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Fees to be Paid</TD><TD>&nbsp;</TD>
    <TD>Equity</TD><TD>&nbsp;</TD>
    <TD>Shares of common stock, par value $0.00001 per share, registered for resale</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">457</TD><TD STYLE="text-align: left">(a)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">196,967</FONT></TD><TD STYLE="text-align: left">(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,181,802</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$92.70
                                            per $1,000,000</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">109.55</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fees to be Paid</TD><TD>&nbsp;</TD>
    <TD>Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Resale Warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">457</TD><TD STYLE="text-align: left">(g)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Fees to be Paid</TD><TD>&nbsp;</TD>
    <TD>Equity</TD><TD>&nbsp;</TD>
    <TD>Shares of common stock, par value $0.00001 per share, underlying the Resale Warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">457</TD><TD STYLE="text-align: left">(g)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">196,967</FONT></TD><TD STYLE="text-align: left">(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,181,802</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$92.70
                                            per $1,000,000</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">109.55</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fees to be Paid</TD><TD>&nbsp;</TD>
    <TD>Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Resale Warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">457</TD><TD STYLE="text-align: left">(g)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Fees to be Paid</TD><TD>&nbsp;</TD>
    <TD>Equity</TD><TD>&nbsp;</TD>
    <TD>Shares of common stock, par value $.00001 per share, underlying the Resale Warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">457</TD><TD STYLE="text-align: left">(g)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">520,000</FONT> </TD><TD STYLE="text-align: left">(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> 3,120,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$92.70
                                            per $1,000,000</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> 289.24 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fees to be Paid</TD><TD>&nbsp;</TD>
    <TD>Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Underwriter&rsquo;s Warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">457</TD><TD STYLE="text-align: left">(g)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Fees to be Paid</TD><TD>&nbsp;</TD>
    <TD>Equity</TD><TD>&nbsp;</TD>
    <TD>Shares of common stock, par value $0.00001 per share, underlying the Underwriter&rsquo;s Warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">457</TD><TD STYLE="text-align: left">(g)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">232,400</FONT></TD><TD STYLE="text-align: left">(5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,394,400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$92.70
                                            per $1,000,000</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">129.26</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="11" STYLE="text-align: center">Total Offering Amounts</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> 26,798,004 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> 2,484.18 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="11" STYLE="text-align: center">Total Fees Previously Paid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,710.96</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="11" STYLE="text-align: center">Total Fee Offset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="11" STYLE="text-align: center">Net Fee Due</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> 773.22 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
    to a primary offering at $6.00 per unit for 1,660,000 units with each unit consisting of (i) one share of common stock and (ii) one
    warrant to purchase one share of common stock. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    additional registration fee is payable pursuant to Rule 457(i) under the Securities Act.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
                                            to a resale offering at a presumed offering price of $6.00 per share consisting of (i) 196,967
                                            shares of common stock and warrants to purchase 196,967 shares of common stock, and (ii)
                                            warrants to purchase 520,000 shares of common stock, with 520,000 shares of
                                            common stock underlying the warrants.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            additional registration fee is payable pursuant to Rule 457(g) under the Securities Act.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Registrant has agreed to issue, at the closing of this offering, shares of common stock to the representative of the underwriters
    a number of shares of common stock equal to seven percent (7%) of the aggregate number of units sold in the primary offering.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ex5-1_001.jpg
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #*!.T# 2(  A$! Q$!_\0
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M^@YJ?_@7)_C6511R1[+[@NS5_P"$G\0?]!S4_P#P+D_QH_X2?Q!_T'-3_P#
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MON"[-7_A)_$'_0<U/_P+D_QH_P"$G\0?]!S4_P#P+D_QK*HHY(]E]P79J_\
M"3^(/^@YJ?\ X%R?XT?\)/X@_P"@YJ?_ (%R?XUE44<D>R^X+LU?^$G\0?\
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M  D_B#_H.:G_ .!<G^-95%')'LON"[-7_A)_$'_0<U/_ ,"Y/\:/^$G\0?\
M0<U/_P "Y/\ &LJBCDCV7W!=FK_PD_B#_H.:G_X%R?XT?\)/X@_Z#FI_^!<G
M^-95%')'LON"[-7_ (2?Q!_T'-3_ / N3_&C_A)_$'_0<U/_ ,"Y/\:RJ*.2
M/9?<%V:O_"3^(/\ H.:G_P"!<G^-'_"3^(/^@YJ?_@7)_C6511R1[+[@NS5_
MX2?Q!_T'-3_\"Y/\:/\ A)_$'_0<U/\ \"Y/\:RJ*.2/9?<%V:O_  D_B#_H
M.:G_ .!<G^-'_"3^(/\ H.:G_P"!<G^-95%')'LON"[-7_A)_$'_ $'-3_\
M N3_ !H_X2?Q!_T'-3_\"Y/\:RJ*.2/9?<%V:O\ PD_B#_H.:G_X%R?XT?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#FMD=-1116AF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "H;N%KBSFA20QM(A4.!G:2,
M9J:B@#C? _@&T\$_;6ANY;F6[*[WD &-N>./J:V/%/A^#Q/X>N]*N#M$R_*W
M]UQRI_.MJBJ<Y.7,]P,_1M*MM$TFVTVT7;;V\81,]3[GW-<[XN\ 6_BG6M-U
M0WLMK/8_<V*#NPP89S]*[*BB,Y1?,GJ T#" $Y..M5K--C/[U;[4Q$VDUFU=
MIE)V31D>*M C\4>'KG2)IVACGVY=1DC# _TJIX+\)0^#=$;3(;E[A6F:7>X
M/.../I72T5IS2Y>7H2<_XN\):?XPT<V%]N0JV^*5#\T;>OO]*A\&^%7\(Z4=
M.74)+JV#EHED0 IGJ,CM7344<\N7EOH%D%%%%2 F :3 IU)D&@ P**,BC(I
M+BD(!ZT9&,YXHR*8!@4<4<4;AZT &!1@49%'% !11D49% !1BC(]:6@!,"C
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS0]NDCBU!!S'$>0I/?!)'T JM- *W@Q;F7PY8:A=ZA=7<UW:QR.)BN%)&3M
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M:CU-?23<-I-FUTQ:X:!#*3UW$ G]:NT@&*6H>X!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
? %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>formdrs_007.jpg
<TEXT>
begin 644 formdrs_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #G 8P# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'^E>RV\RW%NDJ]&&:^+I0EAZD\+/>.WH]O\ (]*HU-*JNOYDM%%%=!D%%%%
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M3K3_ (\X?]P?RI+PA;.8G^X?Y4D$B16UNCL%9E  /<XKPSI,CP__ ,?NI?\
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M1KXR1FVE/[V/CZBM>O#I555@IHWG!PE9A1116A(4444 %%%% !1110 4444
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MX?8^=I]Z+FPT2TN(X+BY,<LO"(S\M]*/K&;7M>/W#^J9?O9_><G_ &0/^?\
M_P#'#0-%0# U #_@!KI+G_A&K.X>WN=02*9/O(\F"*A-UX3'_,5B_P"_M4J^
M<=.7[F2\+EWG]Y@'1\=+\?\ ?)IG]B@G_C[3_O@UU]Q::%:>3]HNO+,V/+W/
M][Z5:?0].BC,DCLB 9+,^ *GZWFR_E^X?U++WT?WG#C0P?\ E\C_ .^32_V$
M,?\ '[%_WR:Z(W7A19?*.J0[\XQYM:<&CZ7<QB2"3S4/\229%5+%9O'5\OW,
M2P67O:_WG,6D,.GP2)$QDEE&&<C''H*ZK0+:2"S9Y 09#D ^E1RIHFCRQBYE
MBBD<_)YK=?I6T""H(Z$<5ST\/6E5^LXEWET[(Z>>E"G[&BK(6BJ=OJEC=W4E
MM!<QR31_?13ROUJY7:TUN8II[!15"^UO3--8+>7T$+'L[<T6>M:9J'%I?02G
MT5QG\J?)*U[:!S*]KE^BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%%
M !7D%M!=3>/-?%KI%MJ)#\K.V G/45Z_6/IWANQTS5;K4H#+]HNO]:6?(/X5
MTX>LJ2E?JOU,:M-S:\CC$\*ZOJ&OV%XVEV>DQ6S[F:!\E_:F>*9+V+XG:<^G
MP1S7(@^1)&V@_C7IU9$_ARQN->@UF3S?M<*[4PWRX^E:0Q?O7FM+-??\R94-
M+1[IG(>*;[Q7)X9ODO=)LXK8Q_O'2?) ]A6_X.N([3P%87$S!8XX-S$]@*W-
M3TZ#5M/FL;G=Y,HVOM.#BJ#^&+%_#ZZ)NG6S4;<+)AB/0FI=:$J2@U;6^G:W
MJ-4Y*?,G?0\JU2\CU][[6Y)YX[Y) ;&-8V("*?7'>O4/"'B!/$6AQ7!.+A/D
MF3N&%:]K8V]G:QVT42B.-0JC':LW2_"^GZ/J%Q>69F1[@DR)O^0GZ556O3JP
MY;6MM_E_744*4X2O??<\\T>.9_&&O^3H\.HXEY$C ;>>V:?IMN?$GC&!K>QM
M](?3GS-&IP[_ (>E>A:9X;L=*U&ZOK8R^==',NY\@TVY\+Z?<ZY'K'[V*\08
MW1/M!^H[UH\7"[MVLG\K;7L0J$K+U.5^)EFNH7FAVC$@33E"1VR*S(_$6K:?
MI\OA(QNVK"3R()?^F9_B_*O0M4\/V>KW-I<7)EWVK[XMK8P?>IVTBR?5$U)H
M%-VB>6).^*B&)@J<825[?G?3_@E2HR<W).U_R//?A]IW]D^-=8L=Y<Q1*"Q[
MG/-6_'.KV^H:O;>'WF=+12)+QXU+''9>*ZZR\.6-AK%UJD)E^TW0Q(2^0?PI
MVF>'K'2KBZN(0[RW+[Y'E;<2:)8F#J^U>KLOO!4I*'(MK_@</X!UV/3M6N/#
MTDK-;,Y:S=U*Y'IS4WBDQWOQ!T_3]6D*:68]RJ3A'?T-=;JWA?3M8O+:[N%D
M2>W.8WB;:15G4]"T_6+98+^W695^ZQ^\/<&AXBG[3VB6K6OD^Z#V4^3D[?U8
MJ77AWPZ]B4FL;18-OWL 8'UJ'4$LH_ ]VFGE#:K;,(RAR,8JNOP_T4$;VO)8
MQ_RSDN&*_E6V='LO[)?3(XO*M60ILCXP#Z5DYQ37O-ZW_K4M1;OHD>9>$[35
M)/#<#VVA:9=1\XEG?#GZUZ1I-C;VMJDBVD%O<O&/-6( <UB1_#C184"137Z(
M.BK<L!6MHOAJST*:66VEN7,BA2)I2^/IFM,36IU+N+_!_P"?Z$4J<H637]?<
M<K\,W1;G7HV8!_M9.TGG'-2>,W1_&GAI%8,PF)(!Y%;=]X&T6]O7O-DT$\AR
M[6\I3<??%2:9X,TC2[U;V*.66Y7[LD\A<K],U3KTO:.K=WMM;RMN"ISY>3^M
M[D^KZ)IEQ:WES-8PR3F)B9&7)R <5R/PVT73;_PRTMU90S2>>XW.N3BO0YX5
MN()(7SMD4J<=<&J&AZ#9^'[)K2Q\P1%B^';/)K&-=JC*%W>Z+E33FI6TU./^
M(B+'J7AQ%&%6Y  '8<4OQ$F=M2T6RN97BTN:7%PRG /L375ZQX<L=;N+6:[\
MW?;-OCV/C!JY?Z99ZI:&UO8$FB/\+"KAB(QY/*_XDRI-\WG8SX_#OA[["(UL
M+0V^WK@=/K4VBPZ38:8T>EM$+6)FW%&R >^362/A]HH. ]Z(_P#GF+EMOY5K
M+X=TZ+29-,MHC;V\@PPB;!/XUG.46K<[?]>I<5)._*D>7ZY?6OBK4=0NKBXF
MC2V798!(V(+#^+BNY\!>(_[=T413G%[:_NY5/4^AK?TW2K32K"*RMHP(HAA=
MW)_$U1MO"VG6>N3:O;^;'<3??"OA&_"MJE>E4@X6M;;^O/\ ,SA2G&7-??<Y
M?P@0/B%XFR0.1_.O02Z?WAS[UR]QX T>YOY[UI+Q)YVW.T<Y7)_"I+3P/IME
M>0W45Q?,\3;E$EPS*?J#45I4JCYN9[+IV7J534X*UOQ.7N] U2#Q9J%]9Q:?
MJHE;F.X?YH_;%-L[R&P\7V$>J^';>SNY25BDMGR,GU%=;?\ @G1[^\>[99X9
MY#EWAF*%C[T_3?!NCZ9=K=QQ22W"_=DGD+E?IFM?K--PM+5VMV_6WX$>QDGI
MW_KI^IT%%%%>>=04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
%10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>forms-1_009.jpg
<TEXT>
begin 644 forms-1_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 7$#Q # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BC-&: "BDS1F@!:*3-&: %H
MI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!
M:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H
M 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&
M: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS
M1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI
M,T9H 6BDS1F@!:*,T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH_X6OI__ $#KK_OI:/JM;^4/KE#^8]"HKSW_ (6OI_\ T#KK_OI:/^%KZ?\
M] ZZ_P"^EH^JUOY0^N4/YCT*BO/?^%KZ?_T#KK_OI:/^%KZ?_P! ZZ_[Z6CZ
MK6_E#ZY0_F/0J*\]_P"%KZ?_ - ZZ_[Z6C_A:^G_ /0.NO\ OI:/JM;^4/KE
M#^8]"HKSW_A:^G_] ZZ_[Z6C_A:^G_\ 0.NO^^EH^JUOY0^N4/YCT*BO/?\
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M/^%KZ?\ ] ZZ_P"^EH^JUOY0^N4/YCT*BO/?^%KZ?_T#KK_OI:/^%KZ?_P!
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M_P! ZZ_[Z6CZK6_E#ZY0_F/0J*\]_P"%KZ?_ - ZZ_[Z6C_A:^G_ /0.NO\
MOI:/JM;^4/KE#^8]"HKSW_A:^G_] ZZ_[Z6C_A:^G_\ 0.NO^^EH^JUOY0^N
M4/YCT*BO/?\ A:^G_P#0.NO^^EH_X6OI_P#T#KK_ +Z6CZK6_E#ZY0_F/0J*
M\]_X6OI__0.NO^^EH_X6OI__ $#KK_OI:/JM;^4/KE#^8]"HKSW_ (6OI_\
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M4)1W1K&<9?"[EFBDW"C-26+1110 4444 %%%% !1110 4444 %%%% !1110
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M6C_A:^G_ /0.NO\ OI:/JM;^4/KE#^8]"HKSW_A:^G_] ZZ_[Z6C_A:^G_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_'_QH_L[QO\ W-9_[^/_ (U[?11]=?\ *@_L^/\ .SQ#^SO&_P#<UG_OX_\
MC1_9WC?^YK/_ '\?_&O;Z*/KK_E0?V?'^=GB']G>-_[FL_\ ?Q_\:/[.\;_W
M-9_[^/\ XU[?11]=?\J#^SX_SL\0_L[QO_<UG_OX_P#C1_9WC?\ N:S_ -_'
M_P :]OHH^NO^5!_9\?YV>(?V=XW_ +FL_P#?Q_\ &C^SO&_]S6?^_C_XU[?1
M1]=?\J#^SX_SL\0_L[QO_<UG_OX_^-']G>-_[FL_]_'_ ,:]OHH^NO\ E0?V
M?'^=GB']G>-_[FL_]_'_ ,:/[.\;_P!S6?\ OX_^->WT4?77_*@_L^/\[/$/
M[.\;_P!S6?\ OX_^-']G>-_[FL_]_'_QKV^BCZZ_Y4']GQ_G9XA_9WC?^YK/
M_?Q_\:/[.\;_ -S6?^_C_P"->WT4?77_ "H/[/C_ #L\0_L[QO\ W-9_[^/_
M (T?V=XW_N:S_P!_'_QKV^BCZZ_Y4']GQ_G9XA_9WC?^YK/_ '\?_&C^SO&_
M]S6?^_C_ .->WT4?77_*@_L^/\[/$/[.\;_W-9_[^/\ XT?V=XW_ +FL_P#?
MQ_\ &O;Z*/KK_E0?V?'^=GB']G>-_P"YK/\ W\?_ !H_L[QO_<UG_OX_^->W
MT4?77_*@_L^/\[/$/[.\;_W-9_[^/_C1_9WC?^YK/_?Q_P#&O;Z*/KK_ )4'
M]GQ_G9XA_9WC?^YK/_?Q_P#&C^SO&_\ <UG_ +^/_C7M]%'UU_RH/[/C_.SQ
M#^SO&_\ <UG_ +^/_C1_9WC?^YK/_?Q_\:]OHH^NO^5!_9\?YV>(?V=XW_N:
MS_W\?_&C^SO&_P#<UG_OX_\ C7M]%'UU_P J#^SX_P [/$/[.\;_ -S6?^_C
M_P"-']G>-_[FL_\ ?Q_\:]OHH^NO^5!_9\?YV>(?V=XW_N:S_P!_'_QH_L[Q
MO_<UG_OX_P#C7M]%'UU_RH/[/C_.SQ#^SO&_]S6?^_C_ .-']G>-_P"YK/\
MW\?_ !KV^BCZZ_Y4']GQ_G9XA_9WC?\ N:S_ -_'_P :/[.\;_W-9_[^/_C7
MM]%'UU_RH/[/C_.SQ#^SO&_]S6?^_C_XT?V=XW_N:S_W\?\ QKV^BCZZ_P"5
M!_9\?YV>(?V=XW_N:S_W\?\ QH_L[QO_ '-9_P"_C_XU[?11]=?\J#^SX_SL
M\0_L[QO_ '-9_P"_C_XT?V=XW_N:S_W\?_&O;Z*/KK_E0?V?'^=GB']G>-_[
MFL_]_'_QH_L[QO\ W-9_[^/_ (U[?11]=?\ *@_L^/\ .SQ#^SO&_P#<UG_O
MX_\ C1_9WC?^YK/_ '\?_&O;Z*/KK_E0?V?'^=GB']G>-_[FL_\ ?Q_\:/[.
M\;_W-9_[^/\ XU[?11]=?\J#^SX_SL\0_L[QO_<UG_OX_P#C1_9WC?\ N:S_
M -_'_P :]OHH^NO^5!_9\?YV>(?V=XW_ +FL_P#?Q_\ &C^SO&_]S6?^_C_X
MU[?11]=?\J#^SX_SL\0_L[QO_<UG_OX_^-']G>-_[FL_]_'_ ,:]OHH^NO\
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M\,=?G ,QM;8'J'DW$?\ ?((_6MJW^$HR#<ZOD=UC@_J3_2O2Z*B6,K/K8N.
MH1Z7.%B^%6BJ09;N^<CL'4 _^.U;3X:>'5&#%<-[F8_TKKZ*S>(JO[3-EA:*
M^RCD?^%;>'/^>$__ '^-'_"MO#G_ #PG_P"_QKKJ*7MZO\S']6H_RK[CD?\
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M?\\)_P#O\:ZZBCV]7^9A]6H_RK[CD?\ A6WAS_GA/_W^-'_"MO#G_/"?_O\
M&NNHH]O5_F8?5J/\J^XY'_A6WAS_ )X3_P#?XT?\*V\.?\\)_P#O\:ZZBCV]
M7^9A]6H_RK[CD?\ A6WAS_GA/_W^-'_"MO#G_/"?_O\ &NNHH]O5_F8?5J/\
MJ^XY'_A6WAS_ )X3_P#?XT?\*V\.?\\)_P#O\:ZZBCV]7^9A]6H_RK[CD?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_GA/_P!_C1_PK;PY_P \)_\ O\:ZZBCV]7^9A]6H_P J^XY'_A6WAS_GA/\
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MF'U:C_*ON.1_X5MX<_YX3_\ ?XT?\*V\.?\ /"?_ +_&NNHH]O5_F8?5J/\
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MPY_SPG_[_&NNHH]O5_F8?5J/\J^XY'_A6WAS_GA/_P!_C1_PK;PY_P \)_\
MO\:ZZBCV]7^9A]6H_P J^XY'_A6WAS_GA/\ ]_C1_P *V\.?\\)_^_QKKJ*/
M;U?YF'U:C_*ON.1_X5MX<_YX3_\ ?XT?\*V\.?\ /"?_ +_&NNHH]O5_F8?5
MJ/\ *ON.1_X5MX<_YX3_ /?XT?\ "MO#G_/"?_O\:ZZBCV]7^9A]6H_RK[CD
M?^%;>'/^>$__ '^-'_"MO#G_ #PG_P"_QKKJ*/;U?YF'U:C_ "K[CD?^%;>'
M/^>$_P#W^-'_  K;PY_SPG_[_&NNHH]O5_F8?5J/\J^XY'_A6WAS_GA/_P!_
MC2-\-?#C+@17"GU$Q_K77T4>WJ_S,/JU'^5?<<-+\*]$<DQW-]'[;U('_CM9
M]Q\)8CS;:LZ^TD(;]01_*O2:*I8JLOM$/!T']D\?NOA;K<))MY[2X7MARK?D
M1C]:RSI/B_0,&.#4;=0?^6#%E_':2*]THK58V>TDF8O+Z>\&T>+V/Q'U^R;9
M<-%=*#@B6/##\1C]<UU6F_%'3+C:M_!-:-CE@/,3].?TKL+_ $73-47%[8P3
MG^\Z#</H>HKD=3^%NEW +:?<36C]E;]XGZ\_K5>TPU3XHV]"?98NE\$N9>?]
M?J=?8ZK9:E%YEE=PSKW\MP<?4=JM[O<5XEJ'@OQ'H$OVB&-Y%3I/9L21^ PP
M_*KFC_$C5;%A'J"+>Q#@D_+(/Q'!_$?C2EA+J]*5T5''<KY:T7%GL>:*Y[1/
M%VE:X%6VF"3GK!*=K_AZ_A6^'SVKDE%Q=I*QVQG&:O%W0ZBBBI*"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH ***KWU]:Z;:/=7DZ0PIU=S^GN?:A*^B$VDKLL5@Z]XOTGP
M^"EQ-YMSCB"+EOQ[#\:X+Q+\2;J]+VNC[K6WY!G/^L?Z?W1^OTJKX?\ A]J>
MLL+K4&>SMF.XLXS+)] >GU/Y&NV&%45SUG9=C@GC)3ER8=7??H0ZOXZUW7YO
MLUJ7MHG.%@MLEV]BPY/X8^E6]&^&>J7^V749%LHCSM/S2'\.@_$_A7I>C>'=
M+T&$)8VRJ^,-*W+M]3_3I6K1+%J*Y:*L@A@G)\U>7,_P.>TCP3H6C[6BM!/,
M/^6MQ\[9]0.@_ 5T/2BBN24Y2=Y.YW0A&"M%6"BBBI*"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HZT44 <]JW@
MK0M8W-+9K#,W_+6W^1L^I'0_B*X#6OAGJEANETZ07T0YVCY9!^'0_@?PKV"B
MMZ>)J4]GH<U7"4JNZL_(\1TGQKK>@S?9[DO<1H<-!<Y#K[ GD?CGZ5Z3H7C#
M2M<4)#,8KCO!+PWX>OX5H:SX=TO78BE]:JSXPLJ\.OT/].E>7^(/A[J>C,UU
MI[->6RG<"@Q*GU Z_4?D*Z+T*^_NR.:V(PVWO1_'^OO/8@X)IP->0^'?B+=V
M3);ZJ6N;?H)NLB_7^]_/ZUZA8:E;:C:QW-K/'+$_1E/^<&N:K0G2?O'70Q%.
MLKQ?R+]%-#9[TZL3<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK \2>+=/\
M#<.)F\V[892W0_,?<^@]ZJ,7)VBM29SC!<TG9&U<W,%G;O<7,J10H,L[G %>
M;^(OB<<O;:$G'0W4B_\ H*G^9_*N6O-1U[QOJBPJKS'.8[>/B.(>O_US7?>'
M/AQ8Z:$N=4VWET.?+_Y9(?I_%^/'M7:J-*@KU=7V//=>MB'RT5:/<X72_#.O
M^+;K[7)YGEN?FN[DG!'MW/X<?2O1M$^'VC:1MEFC^VW _CG *@^R]/SR:ZL
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M=&7^1]#6@#FN-IK1G>FFKH6BBBD,**** "BBB@ HHHH **** "BBB@ HHHH
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ME@8)\U1\S\R&UL[:Q@6"U@C@B7HD:A1^E3445R;G:E;8**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(2%!)(
M'))H S]<UFVT'2I;ZY/RH,(@ZNQZ**\:L;34O'7B=FE<[I#OFDQ\L,?H/Y ?
M_7-6?&&OS>*=>2VL@TEM&_E6T:_\M&)P6_'M[?C7J'A3P[%X<TA+<!6N9,/<
M2#^)O0>PZ#\^]>@K8:GS/XG^!YDKXNKRKX(_B:>G:?;:58165I&(X8AA1Z^Y
M]2:M445P-MN[/2225D%%%%(84444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/2GU@=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8CAB7"CU]2?<U:HHK@;;=V>DDDK(****0PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X;X@>$?[5MFU6QC_
M --A7]XBC_6H/ZC]?RKN:*NG4E3ES1,ZM*-6#A(\=\"^)GM+B/2KF0>0[_N6
M;^!B?N_0_P _K7JT$Q8-R*\K^(?A?^R;\:I9H1:7+?.J](Y/\#U^N?:N@\&>
M(O[3TYHI^;J' <_WAV:NK$PC.*K0V>YQX2I*$GAZFZV]#O@<TZJL,H;;QVJR
MIR*XCT!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N&^)'B+
M^SM,&E6[XN;M3YA'58NA_/I^!KL[JYBLK2:ZG;;%"A=V] !FO#XUN_&_C'G*
MFYDRW.?*B'^ _,_6NK"TU*7/+9'%C:KC%4X?%+0ZKX9>&^NNW2>J6H/Y,_\
M0?C[5Z945M;Q6EK%;0($BB0(BCL!P*EK*M5=2;DS>A15&"@@HHHK(V"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% %74;"WU33Y[*Z3=#,NUAZ>A'N.
MM>&LEYX/\3O%)G? VUL<"2,]Q]1S]:]\KA?B5X?%_I:ZK G^D6@_>8ZM%W_(
M\_0FNO"U$I<DMF<6-HN454A\43;TV^CN8X98YMR.@93ZC%;,3AESG/->4^ -
M8;>VFR$$J"\6?3N/Z_B:],M928AP.M85J;IS<6=%"JJM-31H44U3FG5F:A11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK7C(('TKA/1)**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %;4+*+
M4=/N+.8?NYXVC;VR.M>%:/)+HWB58)QM993!*/?./Y@5[]7C'Q)TXV/BIKA
M0EW&LH(_O#@_R!_&NW!M2YJ3ZH\_'IQ4:RWBST:PFR[_ "]O6MJ%LJO':N,\
M/7_VRRCN-YR\:D^Q[_K76VK@I'SVKC::=F=Z::NB[12#I2TAA1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5X=XLE?6O'EQ!&V=TZVL?MC"_SS7MTTBQ0O(WW44L?
MH*\2\%QMJGCNUFD&3YKW#^Q )_GBNW!^[S3[(\_'^]R4^[/;88D@@CAC&$C4
M*H] !@4^BBN(] **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH 9+$D\+Q2#*.I5AZ@\5X'I0?2O%
M4<#M\T5P8']SG;_.O?Z\-\<6[:=XWO'08W.LZ?4@$_KFNW!^]S0[H\_'^[R5
M%T9Z5ITQQ)R.U=!"V0O/:N0TN8/&[ <-@BNIM6R$X_A_I7$>@71TI:1>E+0
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MF/7M1^UK;1Q&(>1''M)+9^XHST'6B'OJZ"7N[GLM%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MIN0GG [KT].:^KHY$FB22-@Z. RL#D$'H:IQTNA)ZV9\G_'O_DJ5U_U[0_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *:Z+)&R,,JP(/TIU% 'S]I >Q\1I"QPR.T3?7D?SKU73).8/F[?TKS'
M6X_L?CF\ XQ?%Q]"V?ZUZ)IC_-!QV_I7;C=7&7='GY?I&<.S.LMVRAY[U:JA
M:-F-OK5X5Q'H"T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 <?\2F"^#Y03RTT8'YY
MK.^$Z_\ $HU!L<F<#/\ P&KWQ._Y%/\ [>$_D:J_"G_D7[S_ *^C_P"@+7:O
M]T?J>?+_ 'U>AWM%%%<1Z 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%>,^+/CY_PB_BG4-$_X1K[3]CD\OSOM^S?P#G;Y9QU]:5U>P[=3V:BO
MG_\ X::_ZE'_ ,J7_P!JH_X::_ZE'_RI?_:J8CZ HKQ"Q_:4T>1!_:'A^^MW
MW8(MYDF 'KD[.?;]:]4\,^+M$\7V!O-%ODN$4XD3!5XSZ,IY'\C3LQ7-NBBB
MD,**** "BBB@ HHHH **** "BBB@ HHKC_B-XY_X0#P_!JO]G?;_ #;A8/*\
M_P K&58YSM;^[TQWI-V&DWHCL**\1T#]H7^W/$.G:5_PB_D?;+A(/-_M#=LW
M,!G'EC/7IFO;JJSM<F^M@HHHI#"BBB@ HHHH **** "BBB@ HHK,USQ!I/AK
M3GO]8OHK2W7^*0\L?11U8^PH;L"5S3HJO8WD6H:?;7L&[R;B)94W#!VL,C/Y
MU8IM6=F).ZN@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KS_XKKG1K!L<"X(S_ ,!/^%>@5P7Q6_Y%^S_Z^A_Z U;X
M;^-$YL9_ EZ'.>$F']E,/1S7H6GGYHO]S^E>=>$C_P 2Q_\ KH:]"TX_-%S_
M  ?TI8C^++U*PW\&/H;D?W?QJ6HHC\GXU+6)N%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!A>,6">$-4)_YX$?GQ7$?";_D(:E_UR3^9KM/&_\
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M\CAK?_7_ #_^C&KW;]G3PU:IHM]XCFA5KN6<V\#L,E$4 MCTR3C\*\)\5?\
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MBBB@ HHHH ***^;?VD_^1FT7_KS;_P!#J6[->8TKW/I*BOES]G7_ )*)=?\
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MHBLRR/[IO]ZM,5Q'H"T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=\"7^K:IX)TJ_P!;:-K^Y@$KF--@(/*DCUVXSC'TKE/B3\8;#P1*=,L84O\
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ML4H::XLY(T!*$#)( KZ@IU%S02]?S(IOEFWZ?D? BM+:W 8926)\\C!5@?\
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M[9(ID*.AR>"#R*I?"_E^I#^-?/\ 0\X_:5_Y >A?]?,G_H(KR[X,?\E9T/\
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M1117">B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8D# P>/^!5]3'I0    , =!0>E5.5U8E*SN?!VM?\AW4/^OF3_T(U]7? _\
MY)-I/^]-_P"C6KY1UK_D.ZA_U\R?^A&OJ[X'_P#))M)_WIO_ $:U.E_!?R'5
M_B?-_J;'CC5O!FDVEH_C*.R>!W86_P!JLC<@-CG "MCBL'PQXF^$]_XAM+;P
MY;Z2NK.6\@P:0T+@[23AS&,<9[URW[2O_(#T+_KYD_\ 017EWP8_Y*SH?^]+
M_P"BGI4?>DUZ_D%32-S[#KB]4^+7@C1=3N--U#6_)N[9RDL?V29MK>F0A!_
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M(KN(:=.&"G#(?+/#*>5/U%?/OAOX(^,/$FF1Z@D=G86\HW1?;I61G7L0JJQ
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M@@?9*YB>/:<9_C [5\T_'O\ Y*E=?]>T/_H-<KH^NZ\^A2>$='$A34KD/)'
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MN)_A4_0\_"?QZOJ==8G]TW^]6JM9%B?W3?[U:R]:XCT!]%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% '@6J_\CO??]A*3_P!&&O0--_X^#_N?U%>?
MZK_R.]]_V$I/_1AKT#3?^/@_[G]17;C?L>G^1YV7_P#+SU_S.IL?]3%]?ZUI
M+WK-L?\ 4Q?7^M:2]ZXCT1U%%% !1110 4444 %%%% !1110 4444 >9?%O_
M )@__;;_ -DKH_AU_P B59_[TG_H9KG/BW_S!_\ MM_[)71_#K_D2K/_ 'I/
M_0S7=/\ W2/K_F>=3_WV?I_D=51117">B%%%% !1110 4444 %%%% !1110
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M"_E^IZY^S9ID(TS6]5* SM,ENKXY"@;B/Q)'Y"O=J\8_9O\ ^1-U7_K_ /\
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MU9\8?%6VCM/BAX@BB4*OVG?@#NRAC^I->O?LUD_V!KHR<"ZCX_X":\H^+_\
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M$84^OJSXM^*'_)3O$/\ U^-_2O;_ -G#_D1=1_["+?\ HM*\0^*'_)3O$/\
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M0 4444 %%%% !1110 4444 %%%% !1110!XI\2/^1RN/^N<?_H-=+I?WK?\
MW?Z5S7Q(_P"1RN/^N<?_ *#72Z7]ZW_W?Z5VXG^%3]#S\)_'J^IUEC_JF_WJ
MUUZUD6/^J;_>K77K7$>@/HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XSXG?\BG_V
M\)_(U5^%/_(OWG_7T?\ T!:M?$[_ )%/_MX3^1JK\*?^1?O/^OH_^@+7:O\
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MO^^0]'^IZA1117$>@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X%JO_([WW_82
MD_\ 1AKT#3?^/@_[G]17G^J_\CO??]A*3_T8:] TW_CX/^Y_45VXW['I_D>=
ME_\ R\]?\SJ;'_4Q?7^M:2]ZS;'_ %,7U_K6DO>N(]$=1110 4444 %%%% !
M1110 4444 %%%% 'F7Q;_P"8/_VV_P#9*Z/X=?\ (E6?^])_Z&:YSXM_\P?_
M +;?^R5T?PZ_Y$JS_P!Z3_T,UW3_ -TCZ_YGG4_]]GZ?Y'54445PGHA1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q;OPAX9O[J2ZO/#ND7-Q(<
MR3364;NY]22N36U10!0TS0])T59%TK2[*P64@R"UMTB#D=,[0,U?HHH ****
M "L>]\)>&]2NY+N^\/:3=7,F-\T]E&[M@8&6(R>!6Q10!0TS0])T59%TK2[*
MP64@R"UMTB#D=,[0,U?HHH **** .6UCX;^#M>=Y-0\/6;RN06DB4PNQ]V0@
MG\ZKZ9\*O VD2^9:^&[0OD,#<%I\$>GF%L?A78T4+38'KN(JJBA54*H&  ,
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M SG =2&Q^-;]%%@N<;IOPH\"Z5*9+;PW:,Q(.;@M/@CT\PMC\*[$    8 Z
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MJDBDM&SZ(^'_ ,1(?B!/J\EI9/;6=D\:1-*V7DW DD@<#ITY^M=O7A'[-/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 >*?$C_D<KC_KG'_Z#72Z7]ZW_
M -W^E<U\2/\ D<KC_KG'_P"@UTNE_>M_]W^E=N)_A4_0\_"?QZOJ=98_ZIO]
MZM=>M9%C_JF_WJUUZUQ'H#Z*** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .,^)W_(I_
M]O"?R-5?A3_R+]Y_U]'_ - 6K7Q._P"13_[>$_D:J_"G_D7[S_KZ/_H"UVK_
M '1^IY[_ -]7H=[1117$>@%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<%\5O^1?L_P#KZ'_H
M#5WM<%\5O^1?L_\ KZ'_ * U;X;^-$YL9_ EZ'+^%/\ D&/_ -=#7H.G?>B_
MW/Z5Y]X4_P"08_\ UT->@Z=]Z+_<_I2Q'\67J5A?X,?0W(/N?C5BJ\'W/QJQ
M6)N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S_ (W_ .1.U/\
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M*O'GB'QE=-+JVH2-#G*6L9*PI]%_J<GWKJ_COXBEUCXA3:>&/V;2T$$:]MY
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MY#_6OF[P7_R/6@?]A&W_ /1BU](_M ?\DQ?_ *_(?ZU\W>"_^1ZT#_L(V_\
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M>A<%:$O5?J?07[.O_)/;O_L(R?\ H"5QGQM^*7]J32^%=$G_ -"C;;>SH?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "N"^*W_ "+]G_U]#_T!J[VN"^*W_(OV?_7T
M/_0&K?#?QHG-C/X$O0Y?PI_R#'_ZZ&O0=.^]%_N?TKS[PI_R#'_ZZ&O0=.^]
M%_N?TI8C^++U*PO\&/H;D'W/QJQ5>#[GXU8K$W"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH Y_QO_R)VI_]<Q_Z$*X_X2?\?&J_[L7\VKL/&_\
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M7X_E_D13UJ?@?%-M;RW=U%;0+NEE<1HN0,L3@#)XKN_^%)?$/_H7O_)VW_\
MCE<&K2VMP&&4EB?/(P58'_&OLWP#X]TOQMH4$\%Q$NH*@%U:%AOC?')QW4]0
M::2<;H3;4K,^;O\ A27Q#_Z%[_R=M_\ XY1_PI+XA_\ 0O?^3MO_ /'*]_\
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M7O6;8_ZF+Z_UK27O7$>B.HHHH **** "BBB@ HHHH **** "BBB@#S+XM_\
M,'_[;?\ LE='\.O^1*L_]Z3_ -#-<Y\6_P#F#_\ ;;_V2NC^'7_(E6?^])_Z
M&:[I_P"Z1]?\SSJ?^^S]/\CJJ***X3T0HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH \4^)'_(Y7'_ %SC_P#0:Z72_O6_^[_2N:^)'_(Y7'_7./\
M]!KI=+^];_[O]*[<3_"I^AY^$_CU?4ZRQ_U3?[U:Z]:R+'_5-_O5KKUKB/0'
MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 <9\3O\ D4_^WA/Y&JOPI_Y%^\_Z^C_Z
M M6OB=_R*?\ V\)_(U5^%/\ R+]Y_P!?1_\ 0%KM7^Z/U//?^^KT.]HHHKB/
M0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X+
MXK?\B_9_]?0_] :N]K@OBM_R+]G_ -?0_P#0&K?#?QHG-C/X$O0Y?PI_R#'_
M .NAKT'3OO1?[G]*\^\*?\@Q_P#KH:]!T[[T7^Y_2EB/XLO4K"_P8^AN0?<_
M&K%5X/N?C5BL3<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G_&
M_P#R)VI_]<Q_Z$*X_P"$G_'QJO\ NQ?S:NP\;_\ (G:G_P!<Q_Z$*X_X2?\
M'QJO^[%_-J[:?^[3]?\ (\^K_OD/1_J>H4445Q'H!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!XI\2/^1RN/^N<?_H-=+I?WK?\ W?Z5S7Q(_P"1RN/^N<?_ *#72Z7]
MZW_W?Z5VXG^%3]#S\)_'J^IUEC_JF_WJUUZUD6/^J;_>K77K7$>@/HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH XSXG?\BG_V\)_(U5^%/_(OWG_7T?\ T!:M?$[_
M )%/_MX3^1JK\*?^1?O/^OH_^@+7:O\ ='ZGGO\ WU>AWM%%%<1Z 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5P7Q6_Y%^S_ .OH?^@-7>UP7Q6_Y%^S_P"OH?\ H#5OAOXT
M3FQG\"7H<OX4_P"08_\ UT->@Z=]Z+_<_I7GWA3_ )!C_P#70UZ#IWWHO]S^
ME+$?Q9>I6%_@Q]#<@^Y^-6*KP?<_&K%8FX4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% '/\ C?\ Y$[4_P#KF/\ T(5Q_P )/^/C5?\ =B_FU=AX
MW_Y$[4_^N8_]"%<?\)/^/C5?]V+^;5VT_P#=I^O^1Y]7_?(>C_4]0HHHKB/0
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU_R//J_[Y#T?ZGJ%%%%<1Z 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '@6J_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'BGQ(_Y'*X_ZYQ_
M^@UTNE_>M_\ =_I7-?$C_D<KC_KG'_Z#72Z7]ZW_ -W^E=N)_A4_0\_"?QZO
MJ=98_P"J;_>K77K618_ZIO\ >K77K7$>@/HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH XSXG?\BG_ -O"?R-5?A3_ ,B_>?\ 7T?_ $!:M?$[_D4_^WA/Y&JOPI_Y
M%^\_Z^C_ .@+7:O]T?J>>_\ ?5Z'>T445Q'H!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7!?
M%;_D7[/_ *^A_P"@-7>UP7Q6_P"1?L_^OH?^@-6^&_C1.;&?P)>AR_A3_D&/
M_P!=#7H.G?>B_P!S^E>?>%/^08__ %T->@Z=]Z+_ '/Z4L1_%EZE87^#'T-R
M#[GXU8JO!]S\:L5B;A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M<_XW_P"1.U/_ *YC_P!"%<?\)/\ CXU7_=B_FU=AXW_Y$[4_^N8_]"%<?\)/
M^/C5?]V+^;5VT_\ =I^O^1Y]7_?(>C_4]0HHHKB/0"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_#K_ )$JS_WI/_0S7.?%O_F#_P#;;_V2NC^'7_(E6?\ O2?^AFNZ?^Z1]?\
M,\ZG_OL_3_(ZJBBBN$]$**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#$4?\ "S/"'_07_P#):7_XBCV-3^5_<'/'N=917)_\+,\(?]!?_P EI?\
MXBC_ (69X0_Z"_\ Y+2__$4>QJ?RO[@YX]SK**Y/_A9GA#_H+_\ DM+_ /$4
M?\+,\(?]!?\ \EI?_B*/8U/Y7]P<\>YUE%<G_P +,\(?]!?_ ,EI?_B*/^%F
M>$/^@O\ ^2TO_P 11[&I_*_N#GCW.LHKD_\ A9GA#_H+_P#DM+_\11_PLSPA
M_P!!?_R6E_\ B*/8U/Y7]P<\>YUE%<G_ ,+,\(?]!?\ \EI?_B*/^%F>$/\
MH+_^2TO_ ,11[&I_*_N#GCW(/B=_R*?_ &\)_(U5^%/_ "+]Y_U]'_T!:R?'
M7C;P]K/A[[+8:AYTWG*VWR9%X&<\E0*@^'WC+0-#T>Y@U&_\F5[@NJ^3(V1M
M S\JGT-=:A+ZLXVUN<+?^V*72QZU17)_\+,\(?\ 07_\EI?_ (BC_A9GA#_H
M+_\ DM+_ /$5R>QJ?RO[CNYX]SK**Y/_ (69X0_Z"_\ Y+2__$4?\+,\(?\
M07_\EI?_ (BCV-3^5_<'/'N=917)_P#"S/"'_07_ /):7_XBC_A9GA#_ *"_
M_DM+_P#$4>QJ?RO[@YX]SK**Y/\ X69X0_Z"_P#Y+2__ !%'_"S/"'_07_\
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M_P"(H_X69X0_Z"__ )+2_P#Q%'L:G\K^X.>/<ZRBN3_X69X0_P"@O_Y+2_\
MQ%'_  LSPA_T%_\ R6E_^(H]C4_E?W!SQ[G645R?_"S/"'_07_\ ):7_ .(H
M_P"%F>$/^@O_ .2TO_Q%'L:G\K^X.>/<ZRBN3_X69X0_Z"__ )+2_P#Q%'_"
MS/"'_07_ /):7_XBCV-3^5_<'/'N=917)_\ "S/"'_07_P#):7_XBC_A9GA#
M_H+_ /DM+_\ $4>QJ?RO[@YX]SK**Y/_ (69X0_Z"_\ Y+2__$4?\+,\(?\
M07_\EI?_ (BCV-3^5_<'/'N=917)_P#"S/"'_07_ /):7_XBC_A9GA#_ *"_
M_DM+_P#$4>QJ?RO[@YX]SK**Y/\ X69X0_Z"_P#Y+2__ !%'_"S/"'_07_\
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M_P"(H_X69X0_Z"__ )+2_P#Q%'L:G\K^X.>/<ZRBN3_X69X0_P"@O_Y+2_\
MQ%'_  LSPA_T%_\ R6E_^(H]C4_E?W!SQ[G645R?_"S/"'_07_\ ):7_ .(H
M_P"%F>$/^@O_ .2TO_Q%'L:G\K^X.>/<ZRBN3_X69X0_Z"__ )+2_P#Q%'_"
MS/"'_07_ /):7_XBCV-3^5_<'/'N=917)_\ "S/"'_07_P#):7_XBC_A9GA#
M_H+_ /DM+_\ $4>QJ?RO[@YX]SK**Y/_ (69X0_Z"_\ Y+2__$4?\+,\(?\
M07_\EI?_ (BCV-3^5_<'/'N=917)_P#"S/"'_07_ /):7_XBC_A9GA#_ *"_
M_DM+_P#$4>QJ?RO[@YX]SK**Y/\ X69X0_Z"_P#Y+2__ !%'_"S/"'_07_\
M):7_ .(H]C4_E?W!SQ[G645R?_"S/"'_ $%__):7_P"(H_X69X0_Z"__ )+2
M_P#Q%'L:G\K^X.>/<ZRBN3_X69X0_P"@O_Y+2_\ Q%'_  LSPA_T%_\ R6E_
M^(H]C4_E?W!SQ[G645R?_"S/"'_07_\ ):7_ .(H_P"%F>$/^@O_ .2TO_Q%
M'L:G\K^X.>/<ZRBN3_X69X0_Z"__ )+2_P#Q%'_"S/"'_07_ /):7_XBCV-3
M^5_<'/'N=917)_\ "S/"'_07_P#):7_XBC_A9GA#_H+_ /DM+_\ $4>QJ?RO
M[@YX]SK**Y/_ (69X0_Z"_\ Y+2__$4?\+,\(?\ 07_\EI?_ (BCV-3^5_<'
M/'N=917)_P#"S/"'_07_ /):7_XBC_A9GA#_ *"__DM+_P#$4>QJ?RO[@YX]
MSK**Y/\ X69X0_Z"_P#Y+2__ !%'_"S/"'_07_\ ):7_ .(H]C4_E?W!SQ[G
M645R?_"S/"'_ $%__):7_P"(H_X69X0_Z"__ )+2_P#Q%'L:G\K^X.>/<ZRN
M"^*W_(OV?_7T/_0&K1_X69X0_P"@O_Y+2_\ Q%<C\0?&6@:YH]M!IU_YTJ7
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M_P"2TO\ \11_PLSPA_T%_P#R6E_^(H]C4_E?W!SQ[G645R?_  LSPA_T%_\
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M_P"(H]C4_E?W!SQ[G645R?\ PLSPA_T%_P#R6E_^(H_X69X0_P"@O_Y+2_\
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M_P"2TO\ \11_PLSPA_T%_P#R6E_^(H]C4_E?W!SQ[G645R?_  LSPA_T%_\
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M_P"(H]C4_E?W!SQ[G645R?\ PLSPA_T%_P#R6E_^(H_X69X0_P"@O_Y+2_\
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M_P"2TO\ \11_PLSPA_T%_P#R6E_^(H]C4_E?W!SQ[G645R?_  LSPA_T%_\
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M_H+_ /DM+_\ $4>QJ?RO[@YX]SK**Y/_ (69X0_Z"_\ Y+2__$4?\+,\(?\
M07_\EI?_ (BCV-3^5_<'/'N=917)_P#"S/"'_07_ /):7_XBC_A9GA#_ *"_
M_DM+_P#$4>QJ?RO[@YX]SK**Y/\ X69X0_Z"_P#Y+2__ !%'_"S/"'_07_\
M):7_ .(H]C4_E?W!SQ[G645R?_"S/"'_ $%__):7_P"(H_X69X0_Z"__ )+2
M_P#Q%'L:G\K^X.>/<Y[XM_\ ,'_[;?\ LE='\.O^1*L_]Z3_ -#-<'\1/%>B
MZ[_9O]FWOG^3YOF?NG7&=F/O >AK;\%^.O#>D^%[:SOM1\JX1G+)Y$C8RQ(Y
M"D=*[)PE]6C&VM_\S@IZ8N4NEO\ (]+HKD_^%F>$/^@O_P"2TO\ \11_PLSP
MA_T%_P#R6E_^(KC]C4_E?W'?SQ[G645R?_"S/"'_ $%__):7_P"(H_X69X0_
MZ"__ )+2_P#Q%'L:G\K^X.>/<ZRBN3_X69X0_P"@O_Y+2_\ Q%'_  LSPA_T
M%_\ R6E_^(H]C4_E?W!SQ[G645R?_"S/"'_07_\ ):7_ .(H_P"%F>$/^@O_
M .2TO_Q%'L:G\K^X.>/<ZRBN3_X69X0_Z"__ )+2_P#Q%'_"S/"'_07_ /):
M7_XBCV-3^5_<'/'N=917)_\ "S/"'_07_P#):7_XBC_A9GA#_H+_ /DM+_\
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MO_Y+2_\ Q%'_  LSPA_T%_\ R6E_^(H]C4_E?W!SQ[G645R?_"S/"'_07_\
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M7_XBCV-3^5_<'/'N=917)_\ "S/"'_07_P#):7_XBC_A9GA#_H+_ /DM+_\
M$4>QJ?RO[@YX]SK**Y/_ (69X0_Z"_\ Y+2__$4?\+,\(?\ 07_\EI?_ (BC
MV-3^5_<'/'N=917)_P#"S/"'_07_ /):7_XBC_A9GA#_ *"__DM+_P#$4>QJ
M?RO[@YX]SK**Y/\ X69X0_Z"_P#Y+2__ !%'_"S/"'_07_\ ):7_ .(H]C4_
ME?W!SQ[G645R?_"S/"'_ $%__):7_P"(H_X69X0_Z"__ )+2_P#Q%'L:G\K^
MX.>/<ZRBN3_X69X0_P"@O_Y+2_\ Q%'_  LSPA_T%_\ R6E_^(H]C4_E?W!S
MQ[G645R?_"S/"'_07_\ ):7_ .(H_P"%F>$/^@O_ .2TO_Q%'L:G\K^X.>/<
MZRBN3_X69X0_Z"__ )+2_P#Q%'_"S/"'_07_ /):7_XBCV-3^5_<'/'N=917
M)_\ "S/"'_07_P#):7_XBC_A9GA#_H+_ /DM+_\ $4>QJ?RO[@YX]SK**Y/_
M (69X0_Z"_\ Y+2__$4?\+,\(?\ 07_\EI?_ (BCV-3^5_<'/'N=917)_P#"
MS/"'_07_ /):7_XBC_A9GA#_ *"__DM+_P#$4>QJ?RO[@YX]SK**Y/\ X69X
M0_Z"_P#Y+2__ !%'_"S/"'_07_\ ):7_ .(H]C4_E?W!SQ[G645R?_"S/"'_
M $%__):7_P"(H_X69X0_Z"__ )+2_P#Q%'L:G\K^X.>/<ZRBN3_X69X0_P"@
MO_Y+2_\ Q%'_  LSPA_T%_\ R6E_^(H]C4_E?W!SQ[G645R?_"S/"'_07_\
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M7_XBCV-3^5_<'/'N=917)_\ "S/"'_07_P#):7_XBC_A9GA#_H+_ /DM+_\
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M_P#R6E_^(H_X69X0_P"@O_Y+2_\ Q%'L:G\K^X.>/<ZRBN3_ .%F>$/^@O\
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M_P"/53HHYY!RHN?;_P#IG_X]1]O_ .F?_CU4Z*.>0<J+GV__ *9_^/4?;_\
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M_P"/53HHYY!RHN?;_P#IG_X]1]O_ .F?_CU4Z*.>0<J+GV__ *9_^/4?;_\
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M_P"/53HHYY!RHN?;_P#IG_X]1]O_ .F?_CU4Z*.>0<J+GV__ *9_^/4?;_\
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M_P"/53HHYY!RHN?;_P#IG_X]1]O_ .F?_CU4Z*.>0<J+GV__ *9_^/4?;_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4UK_P ?*?C_
M "J&IK7_ (^4_'^5..XGL?0/P<_Y%&[_ .O]_P#T7'7H5>>_!S_D4;O_ *_W
M_P#1<=>A5YN(_BR.NE\""BBBL30**** "BBB@ HHHH **** "BBB@ KY(NO^
M/9_P_G7UO7R1=?\ 'L_X?SKOP6TCFQ&Z,VBBBN@R"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "IK7_CY3\?Y5#4UK_P ?*?C_ "IQW$]CZ!^#G_(HW?\ U_O_
M .BXZ]"KSWX.?\BC=_\ 7^__ *+CKT*O-Q'\61UTO@04445B:!1110 4444
M%%%% !1110 4444 %?)%U_Q[/^'\Z^MZ^2+K_CV?\/YUWX+:1S8C=&;11170
M9!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !4UK_Q\I^/\JAJ:U_X^4_'^5..X
MGL?0/P<_Y%&[_P"O]_\ T7'7H5>>_!S_ )%&[_Z_W_\ 1<=>A5YN(_BR.NE\
M""BBBL30**** "BBB@ HHHH **** "BBB@ KY(NO^/9_P_G7UO7R1=?\>S_A
M_.N_!;2.;$;HS:***Z#(**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBO7+#X'_;M.MKO_A(MGGQ))M^
MQ9V[@#C/F<]:F<U!7D-)R=D>1T5[+_PH;_J9?_)'_P"V4?\ "AO^IE_\D?\
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M]KQ&LGF^5Y?7MC)_G1[2/-R7U#E?+S=#GZ***LD**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(NO^/9_P_G7?@MI'-B-T9M%%%=!D%%%% !1110 4444 %%%% !1110 4444
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M]QY%[:SVTHY\N:,HWY&OK+4]6TS0+#[3J%U#:6R_*"QQ^"@<D^PK!_M#P?\
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M*\XKHIS4XW1E.#B[,****LD**** "BBB@ HHHH **** "BBB@ HHHH ****
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M*\/KZT\3_P#(J:Q_UY3?^@&ODNN?#3E)OF?8VK12BFD%%%%=1@%%;(\)>)2
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M&JZE[K8UJ4U"P4445L9A1110 4444 %%%% !15K3+%]3U6TL(W5'N9DA5FZ
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MM%%%=!D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7USH/\ R+NF?]>D7_H KY&KZYT'_D7=,_Z](O\
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M_ 6IJX&Z"/[0A]"G/\LC\:\-^&O_ "4/1_\ KJW_ * U>]>/[F.T\!:U)(0
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M[IG_ %Z1?^@"OD:OKG0?^1=TS_KTB_\ 0!6V*T@O7]#&C\?R_4^;/B'_ ,E
MUK_KX_H*^A_!MDFG^#-'MD7 %JC'_>8;C^I-?/'Q#_Y*!K7_ %\?T%?1OA:X
M6Z\)Z1.I!#V<1X_W1FLZG^[Q^7Y%K^,_G^AX3\7=7GU#QO/9LY^SV*K'&F>
M2H9C]<G]!7(:-J<^C:S::C;L5EMY5<8.,CN/H1D?C72_%2TDM/B%J)=2%GV2
MH3W!4#^8/Y5R-M!)=745O$I:25PB*.Y)P!73ATO9Q,ZWQNY]A1N)(DD7HP!'
MXU\J^-?^1WUO_K]E_P#0C7U1;Q^3;11?W$"_D*^5_&O_ ".^M_\ 7[+_ .A&
MN7#?Q';M^IO4O[+7R/H/X;_\D]T;_KB?_0C7C_QD_P"1_D_Z]H_ZU[!\-_\
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M6U6NM_\ @'31_A_?^;/ /^%4^-?^@+_Y-0__ !==G\/_ (6:MI7B"VUC63%
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M !H_+\F2_'3_ ) >E?\ 7RW_ *#7 _#/PK%XH\3A;M-]C:+YTR]GY^5?Q/Z
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MNM.>"#;N6&1RQR0. 4 [^M=K\"?^09K/_7:/^1J*DXRIRY7_ %H4HM3C?O\
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MO3[.0DQS7$<9!/0,P!_G7UTJA%"J  !@ 5M47L:?*NMS.+]I.[Z(Y3Q/\1=
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M6/\ KRF_] -3B*:@[+8K#S<I*_='RIIW_(3M/^NR?^A"OL#M7Q_IW_(3M/\
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M:I_U]R_^AFC"M\S0ZWPIGT?\-_\ DGNC?]<3_P"A&O'_ (R?\C_)_P!>T?\
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ME=2Z"K02LT%%%%=)B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.;D[GTY+(D,3RRL$C12S,3@ #J:\[\4?"72O$M^VIV-\UA-.=\A2,2QR$_Q
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M"<Q2N 0GT4C:![8Q64:-6W*WH:2G!OFMJ?2?C7_D1];_ .O*7_T$U\T>&/\
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M8(H=7O\ [3'$Q=!Y*)@XQ_"HHG1DZJGTT'":C!Q?F8=?6'A#_D3-$_Z\8?\
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M_)DOQT_Y >E?]?+?^@U0^!VBV\G]H:U(H:>-A;Q$C[F1EB/<Y _/UJ_\=/\
MD!Z5_P!?+?\ H-8OP5\26UC>7>AW4BQF[826[,<!G P5^I&,?2E2O["5O/\
M0*MO:1OY?J>@_$'QJ_@S2H)8+5;BZN7*1!R0BX&23CD]N./K7D,OQ/\ &&LW
M\-O'?B!9I%016L2KDDXX)RW?UKWCQ#X<TWQ/IIL=3A,D>=R,IPR-ZJ:YS2_
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M?_U\Q_\ H0KTSXK?$"WU.)O#^D2B6W# W4Z'*N1T13W /)/M7F>C?\AS3_\
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MS%H+B-9(R1@X(R*^6O&-C)IWC'5[:48873L/=6.X'\B*K"^[5=_ZU%62=/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=_\ 7^__ *+CKT*O-Q'\61UTO@04445B:!1110 4444 %%%% !1110 4444
M%?)%U_Q[/^'\Z^MZ^2+K_CV?\/YUWX+:1S8C=&;111709!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !72_#ZZM[+QWI5Q=3Q00)(2\DKA54;3U)X%
M<U10!]1:UXK\.2Z%J$<>OZ4[O;2*JK>1DDE3@ 9KY=HHK&E15-MI[FDZCDD@
MHHHK8S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU*\LU<@N+>=HPQ'K@C-4:*+*UA7+U_K6JZI&B:AJ=[=HARJW$[2!3ZC).*I
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M%A\8?"5W"&N+FXLGQRDT#-@_5 U?.=%.=&,]6*,W'8^D+KXN^#K>(O%?S7+
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MC+^SO[.@NXOLWF;_ +0BKG=MQC:Q]#2_#WXD-X35M/OXI+C3';>/+^_"QZD
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %36O\
MQ\I^/\JAJ:U_X^4_'^5..XGL?0/P<_Y%&[_Z_P!__1<=>A5Y[\'/^11N_P#K
M_?\ ]%QUZ%7FXC^+(ZZ7P(****Q- HHHH **** "BBB@ HHHH **** "ODBZ
M_P"/9_P_G7UO7R1=?\>S_A_.N_!;2.;$;HS:***Z#(**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HKV[X4^ K)M$;6=9L(+I[L?Z/%<
M1!U2,?Q8(QD_RQZUYW\0[S3KGQA=PZ59VMK9VI\A1;0K&'9?O,=HYYR/H!6?
MM4ZG(BU!\G,<K16MX<\.7_BC5X].T^/+GYGD;[L:]V8^E?0'AOX8^'= @C,E
MI'?W@P6GN5#<_P"RIX7^?O14JQI[BC!RV/FFBOL>.-(D"1HJ(.BJ, 5D:QX4
MT+7HF34=,MY6;/[T(%D'T8<C\ZP^M>1K['S/D^BNW^('P^G\'W"7%N[W&ES-
MM21A\T;?W6Q^A[UR%@JOJ%LK*&4RJ"",@C(KIIR4U>)C-.%[E>BOK#_A$?#7
M_0NZ3_X!1_\ Q-?+>K(D>LWT<:JJ+<2!548  8\"LZ=95'9(N=-Q5RG17T9X
M \-:#>>!=)N+K1--GG>(EY);5&9CN/4D9->5_%>PL].\;O;V-I!:PBWC/EP1
MA%R<Y.!Q0JR=3V=A*'N<YP]%%%;$!1110 445[M\)= T;4O!7GWVD6%U-]ID
M7S)[9'; QQDC-3.?)'F'%7DD>$T5Z=\9M*T[2]5TM-/L+6T5X'++;PK&&.[J
M< 9KS&E3GSQYD.<>5V"BBBK)"BBB@ HHHH **** "BO8/@QHVEZII^K-J.FV
M=XR2QA#<0+(5!!Z9!Q4GQFT72M+T?3'T_3+*T=[A@S6\"QEAMZ' &:QE649J
M%BXPYHN7K^!XW17I?P??1[S5;K1]5TRPNGF3S;=[BW1V!7[R@L,\CG'L:7XM
M>"8=#O8]8TV!(K"Y.R2*-<+%)CL!P 0/S!JI55&:@^H1@Y1;70\SHHHK0@**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ J:U_P"/E/Q_E4-36O\ Q\I^/\J<=Q/8^@?@Y_R*-W_U_O\ ^BXZ
M]"KSWX.?\BC=_P#7^_\ Z+CKT*O-Q'\61UTO@04445B:!1110 4444 %%%%
M!1110 4444 %?)%U_P >S_A_.OK>ODBZ_P"/9_P_G7?@MI'-B-T9M%%%=!D%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6SX5T1O$7B:QTQ<
M[)I!YA'9!RQ_(&L:O5_@9IPEUK4]18?\>\"Q+]7.3^B_K2E+EBY=@M=V/5?%
M&I)X9\'7UY JQ_9K?9 H' ;[J#\R*^5&9G8LQ)8G))[FO>_C=?-!X4M+13C[
M3=#=[A03_/%>" 98#U-<V$C>\N[_ *_,WKNR43Z.^%'AV+1?!\%VR#[7J $\
MC8YVG[B_3'/U)K.^*GCVY\.)%I.E.([^=/,DFQDQ)T&/<X//;%>B6,"VUA;P
M(,+%$J >@  KYN^*=PUQ\1-3R<B,I&OL B_U)K*/[VMKMJ4O<I76_P#F<K/?
M7=U<BYN+J>:X!SYLDA9O7J>:]6^%/C^_?58] U:Y>YAG!%M+*Q9T8#.TD\D$
M9QGI7D5%=LH*4>5G.FT[GTSXTUCPO=>'M0TO4=8LD:2$X02AW5@,J=HR>N#7
MS?IW_(3M/^NR?^A"JU6=._Y"=I_UV3_T(5-"E[-[[V"M4YX/YGV!VKY#UG_D
M.:A_U\R?^A&OKSM7R'K/_(<U#_KYD_\ 0C7+A?C?I^IT5O@^?Z'H?AOP7X\U
M+P]9WFE^)OLMC*A,4/V^=-@R>-JK@<YZ5Q_C+2M8T?7VM-<O_MUZ(U8S><\O
MRGH-S@&OH#X;_P#)/=&_ZXG_ -"->/\ QD_Y'^3_ *]H_P"M:*H_;<OJ9J*]
MES>AE>$_A_JOC&TN+C3[BRB2!PC"X=E))&>,*:DUOX;Z_HFI6&GE8+VZOMWE
M):,S8VXSG<HP.>O2O0_@7_R ]5_Z^5_]!KO/$VM:=X8TR76[V/<\2^5'M WN
M6/W >V2 3]/:BI6E"I9;#ITU*-^IY7I_P+OYK97U#6H+:4C)CB@,H'L266LG
MQ)\']:T2TDO+*>/4K>,%G$:%)% [[<G(^AS[5K6OQSU$ZHINM*M!IY8 I&6\
MU1Z[B<'OQ@5[9#*EQ!'-&=T<BAE/J",BHG4K0U948TY:(^.:]#\&>$_&6LZ#
M]KT+Q!]AL_-9?)^V31?,,9.$!'I7/>.].BTGQOJUI NV)9MZ*!@ , V![<U[
M+\&/^1#_ .WN3^2UO.I^ZYUY&2C:IROS/)/'>A>(="O+2/Q#JO\ :$LD;-$W
MVB278H/(RX&/PKDZ]9^.O_(8TC_KW?\ ]"%4?@[X6AUC6YM6O(Q);V&WRT89
M#2GH?P S]2*5*I^ZYY>8ZD;3Y5Y%3P[\(M?UNW6ZNVCTVW<97SP3(P]=@Z?B
M0?:NBD^ SA"8_$:L_8-98'Y[S7H_C#Q7:>$-%-_<(99&;RX85.#(_P!>P]37
ME]A\<M2_M$?VAI=H;$M@B#<)%&>N22&('L,^U91J5JEW$MPA!>\<=XJ\ :WX
M3_>WD2369.%N8"2F>P/=3]>/<UR]?6U]+I.HZ2\-[-;FSNH,D2N &1AUY_G7
MRUJ-A;6?B">Q2]BDM$GV+=1MYBE,\-\O7CGBM*%5S?++<FI!)<T37\*^ =;\
M6YELXTAM%.&N9R0F>X&!EC]/S%=U'\!G* R>(U5^X6RR/SWBNYT?Q=X+L-'M
M[6QUJQCMK>$;$9]C8 ]#@[CZ=<UYUJ'QRU8WS_V;IMBEH#A!<!V<C/4D, /I
MC\ZEU*LY-05AJ,%&\B/5?@AJ]K \FFZC;WS+SY;H86;Z<D9^I%>9W5K/974E
MM=0O#/$VUXW&"I]Q7U#X)\4CQ?X>74C;?9Y!(T4D8;< 1CD'TP17E/QPL(X/
M$MC>(@5KFW(<C^(J<9/X$#\*5.K-5.28Y0BX<T3<^!/_ "#-9_Z[1_R-2_'3
M_D!Z5_U\M_Z#47P)_P"09K/_ %VC_D:E^.G_ " ]*_Z^6_\ 0:FK_O"^04OX
M3^9X[H6JRZ)KMEJ</W[>4/CU'<?B,BOJ'7M*M_$_ABYL6PT=U#F-O1L95A^.
M#7R=7U%\.[XZAX!T>8G++#Y1_P" $K_2M,5&\%+L31E:9\PSP26MQ+;S*4EB
M<HZGL0<$5'78_%'3AIWC_4 H 2XVW"X_VAS^H-<=6U.7/!2(G'EDT%%%%62%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=_\ A),[5)Q]AZ_^1*)U(P^)A&+D[(\=HH/!KTKPE\(-0URTCO\ 5+DZ?:R
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M[>RMU#37$BQ1@G +,<#G\:V/%?A'4O".HBUOU5HY 3#/'G9(/;T/J*ZSX8^
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M^/6+_<'\J\</PIOO$GBS6-1U"<V-A)>2F/"YDE&X\@=A[GKZ=Z\ZC)1J-O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MWO!_AO\ X2OQ#%I7VO[+YB,WF^7OQM&>F1_.O1_^%#?]3+_Y(_\ VRN5^$'_
M "4*U_ZXR_\ H)KZ!U>__LK1KW4/*\W[- \WE[MN[:"<9P<=*Y<14E!KE9K1
M@IWN>4?\*&_ZF7_R1_\ ME13? >=5_<>(8W;T>T*C]'-2_\ "^?^I:_\GO\
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M2B/S-N[;GOC(S^=>G7?P-^RV<]Q_PD6[RHV?;]BQG SC_65P7@/_ )'S1/\
MK[3^=?3>K?\ ('OO^O>3_P!!-5BJDH)<K[D4(J<FI>1\A5ZY8? _[=IUM=_\
M)%L\^))-OV+.W< <9\SGK7D=>N6'QP^PZ=;6G_".[_(B2/=]MQNV@#./+XZ5
MM5Y[>YN1"W-[VQYMXBTC^P/$%[I7G^?]FDV>;LV[N,YQDX_.LRM/Q%J_]O\
MB"]U7R/(^TR;_*W[MO&,9P,_E6950YN5<VX2MS/EV"BBM.V\-Z[>P+/::+J,
M\3=)(K5V4_B!5-VW),RBI;BVN+.8PW,$L$J]4E0JP_ U%0!ZAX;^#_\ PD/A
MZSU7^W?L_P!I0MY7V3?MY(Z[QGIZ5Q_C+PS_ ,(EK[:7]L^UXC63S?*\OKVQ
MD_SKL/#?Q@_X1[P]9Z5_87VC[,A7S?M>S=R3TV''7UKC_&7B;_A+=?;5/L?V
M3,:Q^5YOF=.^<#^58KVGM-?AU-%R<GF<_115FSTZ]U&0QV-G<73CJL$3.?R
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M85WA;S%7^*XR@ DX R37M]K\#],ETZU>XU&]BNS$IG4;&4/CD#CH#]:XC0M
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MZ?QH\[^-\87Q?9N.K62Y_!VKS*O0_C/=+<>.A$IS]GM8T/L22W\F%>>48?\
MA+^NK*K?']WY!1116QD%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&-R(QY2NTH!ZL6!QGVQ7O-U;K=VDUL[,JRQM&2AP0",<>]><_P#"C_#/_/\
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M*^::]4^&/Q'M-!L_[$UEFCM-Y:"X"Y$>>2K <XSSGWKMK0;IVB<L)6FFS?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGTYH^N:9K]G]JTN\CNH0<$ID%3Z$'D'ZBO*/C'X.M+6VC\0Z?!' QD$=TB#
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MX\J<D;#_ +O0'\*WI0M.\):$SE[MI(R:***ZSG"BBB@ HHHH **** "BBB@
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M9_V!POZ 5C445T1BHQ45T,Y2YFV%%%%4(**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH 4$J01P1S7UIX<U:+7/#MAJ,+!A/"I;'9NC#\""*^2J[
MGP!\1)_"$K6ES&]QI<K;FC4_-$W]Y<_J*RK4^>-EN5"7+*Y-\4?"-]I/B:\U
M..V=].NW,PF1<JC'[RMZ<_SJ+X;>"'\3:TD^H64C:/$K-([;D65N@56&">>3
MCT]Z]KL/'_A3481+%KMG%D9*W$@A8?@^*34/B#X4TZ$R2ZY9RX&0MM()F/X)
MFN>-6<8\EM3:4(RES7.*\:_#?PEH?A:^U.)+JWEA7,06?(9SPJD,#QDCWXZT
M_P"!:1#0]5D 'FFY4,>^T+Q_,UP7Q ^($WC&YC@@B>WTR [HXV/S.W]YL<?0
M=N:@^'_C1_!VLM)*C2V%R EQ&O48Z,/<9/YUI&G-TFI/5DSE%25NAZM\8HM:
MD\,0G3//-J)#]L6'.2F.,XYV]<_A7CGA+PKJ?B76+:.TMI3;B4&:XVD)&H()
M^;IG':OH>S\=^%;ZW6:+7K!%(^[/,L3#_@+8-8/B?XL:#HUJZ:;.FI7Q!"+"
M<QJ?5GZ8]AD_3K65*<Z?NJ.I=2,:F[T._ P,5\C:\"/$6IACDB[ER<8_C->\
MZ/\ %KPS+HUF^J:H(;\Q+]H06TI ?'.,*1C/O7B7C&;3;GQ9J%UI-R+BRN)3
M,CA&7EN2,, >I-50A*%1W7]7%4DI0T/HCX>SK<> -%=3D"W"'ZJ2#_*O+OC5
MH=ZGB&+64@=[*6!8VE4$A'!/#>F01BHOAG\1[?PY;MH^L;Q8%R\4ZJ6\HGJ"
M!R5/7CG/UX]>7QIX7:'S1XATS;C.#=(&_P"^<YJ9QE3J\Z7],*;4H<K/&/A/
MX5U"_P#$]KK#V\D>GVA,GG.I D;! "^O)R?I7O\ <_\ 'K-_N-_*O,/%'Q@T
MZ*:.QT.0R[I5$]X4(1$S\VT=6.,\XQZ9K>G^*G@M[>15UG+,A 'V6;T_W*FO
M[2HKV*I<L)6N>">&='@U_P 16NEW%[]C6X8JLWE[_FQP,9'4\?C7K-S\#M,2
MPN3;ZE>R7?EGR Y14WXXW?+G&?I7B*2/%*LL;LCJVY64X((Z$5[CX1^,6GW-
MK%:>(B;6Z4!?M*J6CD]SCE3^GTKJK*I:\&8TW'F]X\G2^\3>$;PVJW.H:;*C
M$F'>R*>>NWHP_,5[S\--4\1ZKH$LWB*-PXDVP221>6\BXY)&!W[XYK93QEX8
MD0.OB'2@#_>NXU/Y$YK*UCXG^%=(A9AJ4=[, =L5I^\+$?[0^4?B:YYU)35N
M74TC!1=T]#EOCK)"-(TF,X\\SNR^NT+S^I6KGP3U>.Z\+W&F%AYUG.6"_P"P
M_(/Y[J\A\6^*KWQ=K37]T!&BC9#"IR(U]/<^IJ'PSXCO?"VM1:E9$%E^62-O
MNR(>JG_/6MH47[)P>[(G-<ZDNAZU\8_"5]JJ6FLZ? ]PUNABGBC7<VW.0P Z
MX).?K7E/A?PS>^)M<@L((9?+\P"XE"\1)GDD] <9Q[U[SH?Q2\+ZQ;H9;Y+"
MX(&^&Z.S!]F^Z1^/X"M>?QKX7MXC(_B#3"H[1W*.?R4DUC"I.DN5HN<8U-4S
M@[_X(Z+%;SS1:U>6Z(A;?,J.$ &23@+D?E7B4JHLSK$Y>,,0KE=I8=CCM7J/
MQ#^*4>MV<FCZ%YBV<G$]RPVF4?W5'4+ZYY/3Z^5UO0]I:\R*O)M$****W,CZ
MYT'_ )%W3/\ KTB_] %>/>/_ (?^*-;\:7^H:=IGG6LNS9)]HB7.$4'AF!Z@
MUV>D?$_P=:Z-8V\VL;98K>-'7[-,<$* 1PE7/^%K>"O^@U_Y*S?_ !%<%IQJ
M.27?\SHBXNFHM]$>06WPC\8SS!)-/BME_P">DMS&5'_?))_2O9? ?@F'P9I4
MD1F%Q>7#!IY0,#CHJ^PR?S_"J[_%?P6J%AK!8@?=%K-D_FM<OXA^-UJD+P^'
M[.268\"XN1M1?<+G)_'%5*5::Y; HTXN]R7XT^)X[?2XO#UO(#/<$2W '\,8
M.0#]2,_A[UXMIW_(3M/^NR?^A"DOKZZU.]EO;V=Y[B9MSR.>2:2SD6*^MY'.
M$2568^@!KIH4_9I(QKSYT[=C["[5\AZS_P AS4/^OF3_ -"-?17_  M;P5_T
M&O\ R5F_^(KYRU.:.XU6\FB;=').[J<8R"Q(KFPT)*;;73]3:K).&CZ_H>F?
M!SQA]AOF\.WL@%O<MNMF8_=D[K]&_F/>O<Z^.8I9(94EB=DD1@RLIP5(Z$5]
M >'OBYX>GT.U;6K_ .S:B%VS)Y$C L.-P*J1@]:O$4F_>B12G;W697QV_P"0
M9H__ %VD_P#017/_  6T'[=XCGU>5,Q6*80G_GHW'Z+N_,5)\6/%^A>)K'38
M](OOM+PRNT@\ITP"!C[RBMSX?>,O!OACPE;65QJP2\D)FN!]FE.'/;(3!P !
M^%*GS1HM6UU*J6E46NAZ#XK\11>%O#UQJLL7G>5M5(M^W>Q. ,X./7IVKS7_
M (7S_P!2U_Y/?_:ZQ_BOXXTWQ*EA8Z/<F>UB+2ROY;("_0## '@9_.O,J*-!
M.-YH*E2SM$]E_P"%\_\ 4M?^3W_VNO3O#.O0^)O#]KJL">6)E.Z/=NV,#@KG
M SS[5\F5ZC\*?'>F^'+6^T[6KLP6S,)H&\MG ;HP^4$]@?P-54H1Y&XK4F-6
M7,K[#/C1H'V'Q%#J\28AODPY'02+Q^HQ^1KS&O;_ !_XR\&^*/"5S90:N&NT
M(EMP;:8?..V2N.1D<^M>(56'YN3EDM@K6;N@KV'PU\'](UG0[/4I-;N95N4$
MF(8U3;ZKSNY!R,_I7CU=[\/OB/+X2+6-[$]QI<C;L*?GA/<KG@@]Q^/UTJ*3
MC[FYG%I/78A\9^#M2\#:VT^F-?#3RH,-XC'<O3(9E P<_3/%;_PU\5>,]2\0
MVMJT]S?Z9DK</.NX(N.OF$9STXSSFO3[#Q_X4U&$21:[9QY&=MQ((2/P?%27
M7CGPK:1&27Q!I[* 3B*=9#Q[+DUR^UER\LHW9NX1;O%V-+6I(8M#OY+G'D+;
MR&3/3;M.:^7/"9"^,-%). +Z'_T,5V_Q#^**^(+5](T99([!B/.G<;6F']T#
MLOZGV[^:VMS)9W<-S"<2PR+(A]"#D5IA:;C>4NI->2:Y4?84@+1L!U((KY#N
M+"\BFNP]K,/L[E9CY9Q&<X^;T_&OH[0/B5X:UJPCEEU*WL;C:/-ANI!'M/?!
M; 8?2LOXB>+/#5WX,U&PBUFSGN)HP(D@D$N6!!'W<XZ=ZPIN5*3T-7RU(I7.
M;^ __'QKG^Y#_-ZZ'XUDCP/$ 2 ;U,^_RM7"_"7Q3HWAF;56UB\^S"=8A'^Z
M=]V"V?N@XZBMGXH^-_#OB+PM%9:5J/VBX6Z20IY,B?*%8$Y90.XK6M&3K)I=
MB*,DHN_G^1X]7N7P+2(:'JL@ \TW*ACWVA>/YFO#:Z[X?^-'\':RTDJ-+87(
M"7$:]1CHP]QD_G714BY0:1A%VDF>K?&*+6I/#$)TSSS:B0_;%ASDICC..=O7
M/X5XYX2\*ZGXEUBVCM+:4VXE!FN-I"1J""?FZ9QVKZ'L_'?A6^MUFBUZP12/
MNSS+$P_X"V#6#XG^+&@Z-:NFFSIJ5\00BPG,:GU9^F/89/TZUR4ISI^ZHZG1
M4C&IN]#OP,#%?(VO CQ%J88Y(NY<G&/XS7O.C_%KPS+HUF^J:H(;\Q+]H06T
MI ?'.,*1C/O7B7C&;3;GQ9J%UI-R+BRN)3,CA&7EN2,, >I-50A*%1W7]7%4
MDI0T/HCX?_\ (@Z+_P!>P_F:\;^,G_(_R?\ 7M'_ %KN_!_Q&\*:5X0TNQO=
M5\JY@@"2)]GE;:?J%(KS3XEZWIWB#Q>]]I=QY]L8$0/L9.1G/# &B,9>WO;3
M45U[&WH9'A+_ )'+1/\ K^A_]#%?5LO^I?\ W37R9X=NX+#Q+I=W<OL@@NXI
M)'P3M4,"3@<GBOH*3XJ^"VC8#6N2"/\ CUF_^(IXN+E%67<5!I2=_(^>=-OS
MI>O6M^H)-M<K+@=]K9Q7UK!-#>6D<\3!X9D#JPY#*1D5\>N09&(Z$FO3_AU\
M4$T*U31];\QK%3^XN%!8PC^Z1U*_3D?3II7IN<%;="C/EJ-]&<IXU\(W_A?6
M[A)+=_L+R%K>< E&4G(&?4=Q79_!_P '7O\ ; \07UO)!;0H1;^8I!D9AC('
MH 3S[UZFGC7PN\'G#Q!IH7&<-<H&_P"^2<_I7%ZW\8=,36+*RTN4FT^T)]LO
M6C.T1@_,$&,GZX^F>M91J5''DMKW*E&%^>^AWGB?_D5-8_Z\IO\ T U\EU]#
MZ[\3?"%YX?U*UM]7WS36LD<:_9IAEBI &2F.M?/%/#1<7*Z[#K23BK!2CJ*2
M@=178MT<Y]B6W_'K%_N#^5>$_%GP;?6FOSZ[:6\DUC=8>5HU)\IP.=WH#C.:
M]%A^*G@M((U;6<$* ?\ 19O3_<K$\+_%_3+B62QUN3R&61EAO-IV2)GY=W=3
MC'/3Z5YT(U(S<DCIYHN"39YW\.?"%]X@\1V=T8'73K:59I9V7Y6VG(4'N21C
MVKZ*U34(=*TJZO[A@L5O$TC'Z"LR?QOX6M[<S/X@TTH!G$=PKM_WRI)_2O&_
MB+\2O^$F3^R]*$D6F*V9'<8:<CIQV7OBG/GKM*UD$%&GJV<CX?F:X\9Z7,YR
M\FH1.Q]S(#7U>WW3]*^1]"N8;/Q#IMU</LAANHI)&P3A0P).!STKZ&/Q5\%$
M'_B=?^2LW_Q%:8J#<4HKN12E[S;/FZZ)-W,2229&R3]:T_"FJ+HOBK3-1<XC
MAG4R'T0\-^A-9<[![B1E.06)!_&HZZH[(SJ:R=N[_,^P+RWBU+39[9FS%<PM
M&6'HPQG]:^5=?\-ZGX;U*2RU"VD0AB(Y-IV2CL5/>O0_ 'Q7BTJQATC7Q(;>
M(;8;M 6*+V5AU('8C\J]3@\:^%[B,2)X@TT*>TERB'\F(-<24Z,G971MS*I&
MSW/*O!OPB36M -]K4E[8SRO^XC4*,)ZL&&>><=*Y_P"(7@BP\&36B6VJ27,E
MP"?(DC 9%'\18'N> ,=C7KNO?%+PSHUNY@O4U"YP=D-J=P)]W^Z!^/X&OG_Q
M!KU[XDUF?4[YLRR'"J/NHHZ*/85I3E4G.[T0I*$8VW9[O\'4B7X?P,@ 9YY2
M^.YSCG\ *Y[XW1:TT5B\'GG2 I\X1YVB3/!?';&,9]ZY7X:>/T\)W$MCJ(=M
M,N&WEE&3"_3=CN",9^E>UP>-?"]Q"LJ>(--"D9 DN51OR8@BHJQE&KSVN.E)
M.'*>'?#/PKJ>J^*+#45MI8["UE$SW#*0K;3PJD]3D=NE?0VH G3;H*<$PO@X
MSV->=^+OB_I>FV[V^@NM]>L,>: ?*C]\_P 1]AQ[]JUX_BMX,EMU\[5MC.@W
MH;68X)'(X2IK>TJQO8=/EIRW/ ?#'_(V:/\ ]?L/_H8KZT[5\H6LVGZ=XUMY
MX;D/IT%^DBS!&YB#@YP1GIVQ7OA^*W@K'_(:_P#)6;_XBM,2G*,6EW(I6C)I
ML\>M/'.HV'Q&?7;R=Y@)6AF0=/)SC:!VQU'N*^A[FWLM=T9X9-L]E>0XR#PR
M,."#7R5>R)-?W$J'*/*S*?4$FO6_AK\2M,TKP^=+U^\,'V9L6TAC=]R'^'Y0
M>A_0CTIU:7-35EJAQJ6J/LV>9>)-"N/#>OW6EW ),+_(^,;T/W6'U%>F>&O@
M_I&LZ'9ZE)K=S*MR@DQ#&J;?5>=W(.1G]*I?%+7?"/BBRM[W2]3634[<[-GV
M>5?,C/;)4#@\_G61\/OB/+X2+6-[$]QI<C;L*?GA/<KG@@]Q^/UI.I*GII)$
MR48SOT(?&?@[4O VMM/IC7PT\J##>(QW+TR&90,'/TSQ6_\ #7Q5XSU+Q#:V
MK3W-_IF2MP\Z[@BXZ^81G/3C/.:]/L/'_A3481)%KMG'D9VW$@A(_!\5)=>.
M?"MI$9)?$&GLH!.(IUD/'LN367M9<O+*-V6X1;O%V-+6I(8M#OY+G'D+;R&3
M/3;M.:^1*]/^(?Q17Q!:OI&C+)'8,1YT[C:TP_N@=E_4^W?S"M,-3E&\GU%6
MDG9(****Z3 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#N_A!_R4*U_ZXR_^@FO>/%$TMOX4U>:
M&1XI8[.5D=&*LI"G!!'0UX/\(/\ DH5K_P!<9?\ T$U[KXN_Y$W6O^O*;_T
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M_P#0A7DU:X;^&OG^8JWQ_<%%%%;F0Y/]8OU%?8L?^K3Z"OCI/]8OU%?8L?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "IK7_CY3\?Y5#4UK_P ?*?C_ "IQW$]CZ!^#G_(HW?\
MU_O_ .BXZ]"KSWX.?\BC=_\ 7^__ *+CKT*O-Q'\61UTO@04445B:!1110 4
M444 %%%% !1110 4444 %?)%U_Q[/^'\Z^MZ^2+K_CV?\/YUWX+:1S8C=&;1
M11709!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 =KX&
M^(MUX,BN;<VGVZTF(=83-Y>Q^Y!VGJ.H]A61XO\ $,'BC7GU6'3_ +"\J*)4
M\[S-S#C=G:.V/RK!HJ>2/-S]1J32Y>@44450@HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ['P+XX@\%-=R_V
M1]MN+@*OF&X\O8H[ ;#U/\A6?XR\6W7C'6?MT\?D1(@2&W#[A&._.!DD]\?R
MKGJ*GDBY<W4:DTN5!1115""BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>H^RP_\ Q%<BLSK<"=2!(&W@@  '.>G2HZ*J,8QU2$VVK,[+_A:WC7_H-?\
MDK#_ /$5R$TTEQ/)-*VZ21B['&,DG)IE%)0BM4@<F]V:.CZ]JOA^Z-SI5]+:
MR'AMAR&^JG@_B*[>'XV>*(HPKV^F3'^^\+@_HX'Z5YO11*$9;H%)K8[O4_B]
MXLU&)HX[BWLE;J;6+!Q]6)(_"N&DD>:5I979Y')9F8Y+$]233:*(PC'9 Y-[
ML****H04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4UK_Q\
MI^/\JAJ:U_X^4_'^5..XGL?0/P<_Y%&[_P"O]_\ T7'7H5>>_!S_ )%&[_Z_
MW_\ 1<=>A5YN(_BR.NE\""BBBL30**** "BBB@ HHHH **** "BBB@ KY(NO
M^/9_P_G7UO7R1=?\>S_A_.N_!;2.;$;HS:***Z#(**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=^"VD<V(W1FT445T&04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5-:_\ 'RGX
M_P JAJ:U_P"/E/Q_E3CN)['T#\'/^11N_P#K_?\ ]%QUZ%7GOP<_Y%&[_P"O
M]_\ T7'7H5>;B/XLCKI? @HHHK$T"BBB@ HHHH **** "BBB@ HHHH *^2+K
M_CV?\/YU];U\]?\ "L_%_P#T"/\ R9B_^+KMP<HI2YG8YZZ;M9'G=%>B?\*S
M\7_] C_R9B_^+H_X5GXO_P"@1_Y,Q?\ Q==?-3_F1C:78\[HKT3_ (5GXO\
M^@1_Y,Q?_%T?\*S\7_\ 0(_\F8O_ (NCFI_S(+2['G=%>B?\*S\7_P#0(_\
M)F+_ .+H_P"%9^+_ /H$?^3,7_Q='-3_ )D%I=CSNBO1/^%9^+_^@1_Y,Q?_
M !='_"L_%_\ T"/_ "9B_P#BZ.:G_,@M+L>=T5Z)_P *S\7_ /0(_P#)F+_X
MNC_A6?B__H$?^3,7_P 71S4_YD%I=CSNBO1/^%9^+_\ H$?^3,7_ ,71_P *
MS\7_ /0(_P#)F+_XNCFI_P R"TNQYW17HG_"L_%__0(_\F8O_BZ/^%9^+_\
MH$?^3,7_ ,71S4_YD%I=CSNBO1/^%9^+_P#H$?\ DS%_\71_PK/Q?_T"/_)F
M+_XNCFI_S(+2['G=%>B?\*S\7_\ 0(_\F8O_ (NC_A6?B_\ Z!'_ ),Q?_%T
M<U/^9!:78\[HKT3_ (5GXO\ ^@1_Y,Q?_%T?\*S\7_\ 0(_\F8O_ (NCFI_S
M(+2['G=%>B?\*S\7_P#0(_\ )F+_ .+H_P"%9^+_ /H$?^3,7_Q='-3_ )D%
MI=CSNBNWU/P3XAT:T^U7^G^3#N"[O.C;D]. Q--TGP;K^N6[SZ=8>=$C[&;S
MHUP<9Q\S#U%.T;<W-H3S>]RVU.*HKT3_ (5GXO\ ^@1_Y,Q?_%T?\*S\7_\
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M7_\ 0(_\F8O_ (NC_A6?B_\ Z!'_ ),Q?_%T<U/^9!:78\[HKT3_ (5GXO\
M^@1_Y,Q?_%T?\*S\7_\ 0(_\F8O_ (NCFI_S(+2['G=%>B?\*S\7_P#0(_\
M)F+_ .+H_P"%9^+_ /H$?^3,7_Q='-3_ )D%I=CSNBO1/^%9^+_^@1_Y,Q?_
M !='_"L_%_\ T"/_ "9B_P#BZ.:G_,@M+L>=T5Z)_P *S\7_ /0(_P#)F+_X
MNC_A6?B__H$?^3,7_P 71S4_YD%I=CSNBO1/^%9^+_\ H$?^3,7_ ,71_P *
MS\7_ /0(_P#)F+_XNCFI_P R"TNQYW17HG_"L_%__0(_\F8O_BZ/^%9^+_\
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M9^+_ /H$?^3,7_Q='-3_ )D%I=CSNBO1/^%9^+_^@1_Y,Q?_ !='_"L_%_\
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MPK/Q?_T"/_)F+_XNCFI_S(+2['G=%>B?\*S\7_\ 0(_\F8O_ (NC_A6?B_\
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M7_\ 0(_\F8O_ (NC_A6?B_\ Z!'_ ),Q?_%T<U/^9!:78\[HKT3_ (5GXO\
M^@1_Y,Q?_%T?\*S\7_\ 0(_\F8O_ (NCFI_S(+2['G=%>B?\*S\7_P#0(_\
M)F+_ .+H_P"%9^+_ /H$?^3,7_Q='-3_ )D%I=CSNBO1/^%9^+_^@1_Y,Q?_
M !='_"L_%_\ T"/_ "9B_P#BZ.:G_,@M+L>=T5Z)_P *S\7_ /0(_P#)F+_X
MNC_A6?B__H$?^3,7_P 71S4_YD%I=CSNBO1/^%9^+_\ H$?^3,7_ ,71_P *
MS\7_ /0(_P#)F+_XNCFI_P R"TNQYW17HG_"L_%__0(_\F8O_BZ/^%9^+_\
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M *!'_DS%_P#%T?\ "L_%_P#T"/\ R9B_^+I<U/\ F15I=CSNBO1/^%9^+_\
MH$?^3,7_ ,71_P *S\7_ /0(_P#)F+_XNCFI_P R"TNQYW17HG_"L_%__0(_
M\F8O_BZ/^%9^+_\ H$?^3,7_ ,71S4_YD%I=CSNBO1/^%9^+_P#H$?\ DS%_
M\71_PK/Q?_T"/_)F+_XNCFI_S(+2['G=%>B?\*S\7_\ 0(_\F8O_ (NC_A6?
MB_\ Z!'_ ),Q?_%T<U/^9!:78\[HKT3_ (5GXO\ ^@1_Y,Q?_%T?\*S\7_\
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MS\7_ /0(_P#)F+_XNC_A6?B__H$?^3,7_P 71S4_YD%I=CSNBO1/^%9^+_\
MH$?^3,7_ ,71_P *S\7_ /0(_P#)F+_XNCFI_P R"TNQYW17HG_"L_%__0(_
M\F8O_BZ/^%9^+_\ H$?^3,7_ ,71S4_YD%I=CSNBO1/^%9^+_P#H$?\ DS%_
M\71_PK/Q?_T"/_)F+_XNCFI_S(+2['G=%>B?\*S\7_\ 0(_\F8O_ (NC_A6?
MB_\ Z!'_ ),Q?_%T<U/^9!:78\[HKT3_ (5GXO\ ^@1_Y,Q?_%T?\*S\7_\
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M7_\ 0(_\F8O_ (NC_A6?B_\ Z!'_ ),Q?_%T<U/^9!:78\[HKT3_ (5GXO\
M^@1_Y,Q?_%T?\*S\7_\ 0(_\F8O_ (NCFI_S(+2['G=%>B?\*S\7_P#0(_\
M)F+_ .+H_P"%9^+_ /H$?^3,7_Q='-3_ )D%I=CSNBO1/^%9^+_^@1_Y,Q?_
M !='_"L_%_\ T"/_ "9B_P#BZ.:G_,@M+L>=T5Z)_P *S\7_ /0(_P#)F+_X
MNC_A6?B__H$?^3,7_P 71S4_YD%I=CSNBO1/^%9^+_\ H$?^3,7_ ,71_P *
MS\7_ /0(_P#)F+_XNCFI_P R"TNQYW17HG_"L_%__0(_\F8O_BZ/^%9^+_\
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M9^+_ /H$?^3,7_Q='-3_ )D%I=CSNBO1/^%9^+_^@1_Y,Q?_ !='_"L_%_\
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MPK/Q?_T"/_)F+_XNCFI_S(+2['G=%>B?\*S\7_\ 0(_\F8O_ (NC_A6?B_\
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M7_\ 0(_\F8O_ (NC_A6?B_\ Z!'_ ),Q?_%T<U/^9!:78\[HKT3_ (5GXO\
M^@1_Y,Q?_%T?\*S\7_\ 0(_\F8O_ (NCFI_S(+2['G=%>B?\*S\7_P#0(_\
M)F+_ .+H_P"%9^+_ /H$?^3,7_Q='-3_ )D%I=CSNBO1/^%9^+_^@1_Y,Q?_
M !='_"L_%_\ T"/_ "9B_P#BZ.:G_,@M+L>=T5Z)_P *S\7_ /0(_P#)F+_X
MNC_A6?B__H$?^3,7_P 71S4_YD%I=CSNBO1/^%9^+_\ H$?^3,7_ ,71_P *
MS\7_ /0(_P#)F+_XNCFI_P R"TNQYW17HG_"L_%__0(_\F8O_BZ/^%9^+_\
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M9^+_ /H$?^3,7_Q='-3_ )D%I=CSNBO1/^%9^+_^@1_Y,Q?_ !='_"L_%_\
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M ,F8O_BZ.:G_ #(+2['G=%>B?\*S\7_] C_R9B_^+H_X5GXO_P"@1_Y,Q?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW8OYM78>-_\ D3M3_P"N8_\ 0A7'_"3_ (^-5_W8OYM7;3_W:?K_ )'GU?\
M?(>C_4]0HHHKB/0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \"U7_D=[[_ +"4
MG_HPUZ!IO_'P?]S^HKS_ %7_ )'>^_["4G_HPUZ!IO\ Q\'_ '/ZBNW&_8]/
M\CSLO_Y>>O\ F=38_P"IB^O]:TE[UFV/^IB^O]:TE[UQ'HCJ*** "BBB@ HH
MHH **** "BBB@ HHHH \R^+?_,'_ .VW_LE='\.O^1*L_P#>D_\ 0S7.?%O_
M )@__;;_ -DKH_AU_P B59_[TG_H9KNG_ND?7_,\ZG_OL_3_ ".JHHHKA/1"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q3XD?\ (Y7'_7./_P!!
MKI=+^];_ .[_ $KFOB1_R.5Q_P!<X_\ T&NETO[UO_N_TKMQ/\*GZ'GX3^/5
M]3K+'_5-_O5KKUK(L?\ 5-_O5KKUKB/0'T444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 <9\3O^13_[>$_D:J_"G_D7[S_KZ/\ Z M6OB=_R*?_ &\)_(U5^%/_ "+]
MY_U]'_T!:[5_NC]3SW_OJ]#O:***XCT HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'BGQ(_Y'*X_ZYQ_^@UTNE_>M_P#=_I7-?$C_ )'*X_ZYQ_\ H-=+I?WK?_=_
MI7;B?X5/T//PG\>KZG66/^J;_>K77K618_ZIO]ZM=>M<1Z ^BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#C/B=_R*?_;PG\C57X4_\B_>?]?1_P#0%JU\3O\ D4_^
MWA/Y&JOPI_Y%^\_Z^C_Z M=J_P!T?J>>_P#?5Z'>T445Q'H!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !7!?%;_D7[/\ Z^A_Z U=[7!?%;_D7[/_ *^A_P"@-6^&_C1.;&?P
M)>AR_A3_ )!C_P#70UZ#IWWHO]S^E>?>%/\ D&/_ -=#7H.G?>B_W/Z4L1_%
MEZE87^#'T-R#[GXU8JO!]S\:L5B;A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 <_P"-_P#D3M3_ .N8_P#0A7'_  D_X^-5_P!V+^;5V'C?_D3M
M3_ZYC_T(5Q_PD_X^-5_W8OYM7;3_ -VGZ_Y'GU?]\AZ/]3U"BBBN(] ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK_OD/1_J>H4445Q'H!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 >*?$C_D<KC_KG'_Z#72Z
M7]ZW_P!W^E<U\2/^1RN/^N<?_H-=+I?WK?\ W?Z5VXG^%3]#S\)_'J^IUEC_
M *IO]ZM=>M9%C_JF_P!ZM=>M<1Z ^BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUQ'HCJ*** "BBB@ HHHH **** "BBB@ HHHH \R^+?\ S!_^VW_LE='\.O\
MD2K/_>D_]#-<Y\6_^8/_ -MO_9*Z/X=?\B59_P"])_Z&:[I_[I'U_P SSJ?^
M^S]/\CJJ***X3T0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M .?\;_\ (G:G_P!<Q_Z$*X_X2?\ 'QJO^[%_-J[#QO\ \B=J?_7,?^A"N/\
MA)_Q\:K_ +L7\VKMI_[M/U_R//J_[Y#T?ZGJ%%%%<1Z 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% '@6J_\CO??]A*3_P!&&O0--_X^#_N?U%>?ZK_R.]]_V$I/
M_1AKT#3?^/@_[G]17;C?L>G^1YV7_P#+SU_S.IL?]3%]?ZUI+WK-L?\ 4Q?7
M^M:2]ZXCT1U%%% !1110 4444 %%%% !1110 4444 >9?%O_ )@__;;_ -DK
MH_AU_P B59_[TG_H9KG/BW_S!_\ MM_[)71_#K_D2K/_ 'I/_0S7=/\ W2/K
M_F>=3_WV?I_D=51117">B%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% 'BGQ(_Y'*X_P"N<?\ Z#72Z7]ZW_W?Z5S7Q(_Y'*X_ZYQ_^@UTNE_>M_\
M=_I7;B?X5/T//PG\>KZG66/^J;_>K77K618_ZIO]ZM=>M<1Z ^BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#C/B=_R*?_ &\)_(U5^%/_ "+]Y_U]'_T!:M?$[_D4
M_P#MX3^1JK\*?^1?O/\ KZ/_ * M=J_W1^IY[_WU>AWM%%%<1Z 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5P7Q6_P"1?L_^OH?^@-7>UP7Q6_Y%^S_Z^A_Z U;X;^-$YL9_
M EZ'+^%/^08__70UZ#IWWHO]S^E>?>%/^08__70UZ#IWWHO]S^E+$?Q9>I6%
M_@Q]#<@^Y^-6*KP?<_&K%8FX4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% '/^-_^1.U/_KF/_0A7'_"3_CXU7_=B_FU=AXW_ .1.U/\ ZYC_ -"%
M<?\ "3_CXU7_ '8OYM7;3_W:?K_D>?5_WR'H_P!3U"BBBN(] **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#Q3XD?\CE<?\ 7./_ -!KI=+^];_[O]*YKXD?\CE<?]<X_P#T&NET
MO[UO_N_TKMQ/\*GZ'GX3^/5]3K+'_5-_O5KKUK(L?]4W^]6NO6N(] ?1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!QGQ._P"13_[>$_D:J_"G_D7[S_KZ/_H"U:^)
MW_(I_P#;PG\C57X4_P#(OWG_ %]'_P! 6NU?[H_4\]_[ZO0[VBBBN(] ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 4444 %%%% 'BGQ(_P"1RN/^N<?_ *#72Z7]ZW_W?Z5S7Q(_Y'*X_P"N<?\
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M_O\ Z&C[5#_?_0UFT4>T8<J-+[5#_?\ T-'VJ'^_^AK-HH]HPY4:7VJ'^_\
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M_P#0T?:H?[_Z&LVBCVC#E1I?:H?[_P"AH^U0_P!_]#6;11[1ARHTOM4/]_\
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MO_H:S:*/:,.5&E]JA_O_ *&C[5#_ '_T-9M%'M&'*C2^U0_W_P!#1]JA_O\
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M5#_?_0UFT4>T8<J-+[5#_?\ T-'VJ'^_^AK-HH]HPY4:7VJ'^_\ H:/M4/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** +]E_J3_O?T%?75?(ME_J3_O?T%?75<V,VC\S6ANPHHHKA.D**** "BBB
M@ HHHH *^2+K_CV?\/YU];U\D77_ ![/^'\Z[\%M(YL1NC-HHHKH,@HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"_9?ZD_[W]!7UU7R+9?
MZD_[W]!7UU7-C-H_,UH;L****X3I"BBB@ HHHH **** "ODBZ_X]G_#^=?6]
M?)%U_P >S_A_.N_!;2.;$;HS:***Z#(**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH OV7^I/^]_05]=5\BV7^I/^]_05]=5S8S:/S-:&["B
MBBN$Z0HHHH **** "BBB@ KY(NO^/9_P_G7UO7R1=?\ 'L_X?SKOP6TCFQ&Z
M,VBBBN@R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +]E_
MJ3_O?T%?75?(ME_J3_O?T%?75<V,VC\S6ANPHHHKA.D**** "BBB@ HHHH *
M^2+K_CV?\/YU];U\D77_ ![/^'\Z[\%M(YL1NC-HHHKH,@HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP*5"HY1;D^I56"BU8SZ*L7EA>:=-Y5[:3VTO79/&4/Y$57K=.YB=OX$^'O\
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MT?GO-2-\>-KE?^$;Z''_ !_?_:ZVO#GQDTK6;^&ROK*73Y9GV(YD$D>3T!;
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M_P#C=>KZI\0O"VC:C-I]_JGDW4) D3R)6QD9ZJI'0U4_X6MX*_Z#7_DK-_\
M$5S*K6:NE^!LZ<%HSP'Q/X9O?"FK?V;?RP23>6LFZ!B5P<^H!SQZ5C5V?Q.U
MW3?$/BT7VE7/VBV^S(F_8R?,"<C# 'O7&5U4W)P3EN8S24K+8****LD****
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M'_7N_P#Z$*Q=:U3V=OZL:1A>'/\ UN>34445L9A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 7[+_4G_ 'OZ"OKJOD6R_P!2?][^@KZZKFQF
MT?F:T-V%%%%<)TA1110 4444 %%%% !7R1=?\>S_ (?SKZWKY(NO^/9_P_G7
M?@MI'-B-T9M%%%=!D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %>V_ G_ )!FL_\ 7:/^1KQ*
MO;?@3_R#-9_Z[1_R-9UOX<OZZH<?CCZ_YG3?%'0=3\1>%HK+2K;[1<+=)(4\
MQ4^4*P)RQ [BO'O^%4^-?^@+_P"34/\ \77T+K>O:9X=L5O=5N?L]NSB,/Y;
M/\Q!(&%!/8US_P#PM;P5_P!!K_R5F_\ B*XZ4YQ5HJYU5(Q=N8\M\._#3Q?8
M>)=+N[G2-D$%W%)(_P!IB.U0P). V3Q7T)7)VGQ+\(7]Y!:6VK[YYY%CC3[-
M*-S$X R5P.:ZRE6G.27,K"A&*O9GR'K/_(<U#_KYD_\ 0C7TG\-_^2>Z-_UQ
M/_H1KYLUG_D.:A_U\R?^A&OI/X;_ /)/=&_ZXG_T(UO5_@+Y?D9+^,_G^9Y5
M\;O^1RM/^O)?_0WKS2O2_C=_R.5I_P!>2_\ H;UYI6F'_A+^NK"O\?W?D=Y\
M(M4EL/'=O;*Y$-ZCQ2+V) +*?S'ZFOH#6+)-2T6^LI!E)X'C/X@BOFSX<*S?
M$+1@IP?.)_#:<U]/L<(2?2N?&+9^1>'=FSXX(*D@]1Q5W1M,EUG6;/38/]9<
MRK&#Z9/)_ 9-5;@@W,I'0N?YUZE\$M!^TZQ=ZW*G[NU3RHC_ +;=?R7_ -"K
ML<N6/,S&4?>Y5WL>UVMO!INGPVT0$=O;Q!%'9548_D*\P^'GC9M9\>Z[;3/F
M&]8S6V3T"?* /JN#_P !KI?B?K@T3P1>;6Q/=_Z-'@_WA\Q_[Y!KYYT#57T/
M7['4X\DVTRN0/XE[C\1D5QT*?M.9OT_7_(VJRY(I+^K'T1\3-!_M[P7=K&FZ
MXM/])BQURO4?BN?TKYFK[$AFBNK:.:,AXI4#*>Q4C(KY<\;Z$?#OBZ^L N(=
M_F0?]<VY'Y=/PIX:5I.#_KN.JN:*DC8^$>GK?>/[5W *VL;SX/J!M'ZL#^%?
M0.MWQTS0=0OAUM[=Y1]0I(KP[X),H\:W /5K%P/^^TKV/QK&TO@C6T7.392]
M/]TTL7\27E^H8=?F?*LLCS2O+(Q>1V+,Q.22>IIM%%=QS;G4^'?B!KGA?2IM
M/TUX%BED,F^2/>R$C'RY..P/2L[6_%6N>(@BZMJ,MRB,65" J@^NU0!6/14\
MD;\UM1\SM8]V^!MFL?AO4;S'SS77EY]E4?U8U<^+EKJ>KZ?I>B:5;R7$]S.T
MC(G]U!U)/ &6')I_P7V_\((V,9^UR9_):[C4]2LM'L)M0OYD@MX5R\C?R'<Y
M/:N*M*U:_:QT45>GZW/"E^"GBD1"47.FJXY"><^X'Z[,?K7.>)(O%VC736VO
M7.I*T@(!EN6=)5Z<-D@CVKVK2OBUX8U75%L$>ZMV=MD<MQ&%1SVP03C/N!71
M^)/#UGXFT2?3;Q 0XS')CF-^S"J=:I%KG6@E3@_A9\FT5/?6<NGW]Q9SC$T$
MC1N/<'!J"NU--71SM-.S"OH_X0_\D\L_^NLO_H9KYPKZ/^$/_)/+/_KK+_Z&
M:QQ'\-_(NE\:.0^._P#Q\Z'_ +DW\TJ#X%?\AC5_^O=/_0JG^.__ !\Z'_N3
M?S2H/@5_R&-7_P"O=/\ T*LJ?^[OY_F75_BKY'J?B;PO:>*4L8+\DVMM<>>\
M8X\S"D!<]ASS]*HKXX\&:5<QZ/%JMG 8_D6.)#Y2>VX#:/SIGQ-U&;3? &I2
MV[E)) L(8'! 9@#^F:^9*SH4_:)IO1&E27+9K<^P+RSM-4LGMKN"*YMI1\R.
MH96%?,/CCP\OACQ7=Z='N-N")("W78W('X<C\*]^^'%R]U\/M'DD;<PA*9SG
MA6*C] *\I^-J@>-+9AU:R3/_ 'T].E>%;D]12?/2YCJ/@7_R ]5_Z^5_]!KO
M=?\ #VF:X]G-JRJ]M8NTWER8V,<8RV>PZXK@O@7_ ,@/5?\ KY7_ -!J_P#&
MG4IK/P?#:PN4%Y<!),'J@!;'Y@4JUW6LM] HV]GKYG0VGC[PC-?IIEMK%MYH
M(1%"LJ'L K8VG\#6MK>A:?XATV2QU&W2:)@=I(^9#_>4]C7R/7UOX?G:Z\-Z
M7<.VYY+2)V;U)0<TZU%0BI)BIU7*5CY7UO2I=$UN\TR8AGMI3'N'\0'0_B,&
MO>/@Q_R(?_;W)_):\H^*2!/B-JN.YC/_ )#6O5_@Q_R(?_;W)_):UG)RP]WY
M$6Y:UEY_D<C\=?\ D,:1_P!>[_\ H0JQ\!_^/C7/]R'^;U7^.O\ R&-(_P"O
M=_\ T(58^ __ !\:Y_N0_P WJ:?^[OY_F54_BKY'JNM:#8>((+>#4HO.@AF$
M_ED_*Q ( ;U'/2LH^/O!]G>KI@UFTC=?D"HI\M<=MX&P=/6J'Q6U>;2? MQ]
MG=DENI%MPRG! .2WZ C\:^;:SH4O:)W>A=2?+;N?7.J:3IOB'36M+^"*YMI5
MR,\X]"I['W%?,_C3PO+X2\13:>S&2 CS+>0]70],^XY!^E>P?!?5IK_PG/9S
MR%S93[(\GD(PR!^>ZLKXZV:'3](O<?.DKQ9]01G_ -EIPO2J\G1B=JE.XOP)
M_P"09K/_ %VC_D:E^.G_ " ]*_Z^6_\ 0:B^!/\ R#-9_P"NT?\ (U+\=/\
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M;1$M'$SDJA/H.U5J[*-+V:9C4GSV"O:/@=K4 M]0T21PLYD^TQ _Q# 5L?3
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M@R#3XH8IKBW2*$".%K=LC X7Y<C/XX]Z\UU#XO\ BRZOGEM+R.S@)^2!($<
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MT?9_M+E?-V;]N 3TR,]/6O2KOX&_9;.>X_X2+=Y4;/M^Q8S@9Q_K*XOX:_\
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MS)?]:_\ O&FUUJ,;;$3;YF%%%%40?1>D?$_P=:Z-8V\VL;98K>-'7[-,<$*
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M>"*^E-6_Y ]]_P!>\G_H)I8W9>C%AOB?R/D*O9O@.YV:XG& 83_Z'7C->R?
M?KKO_;#_ -GKJJ_PY?UV,(?$C:^-_P#R)UI_U^K_ .@/4/P-51X6U!P/F-X0
M3[!%_P 34WQO_P"1.M/^OU?_ $!ZP_@9J\:OJ>CNP#OMN(AZX^5O_9:YJ:O0
ME_78Z*CM./\ 7<]%\6>#=/\ &-O;0:A/=Q);N77[.ZKDD8YRIKEO^%'^&?\
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M $!ZXSX(?\CG=_\ 7B__ *&E9T/X,OG^A=;XH_UU/2OBO(4^'.I8_B,2]?\
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MJBS.L3EXPQ"N5VEAV..U,KK@N6*1C-WDV%%%%42%%%% !1110 4444 %%%%
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MQPGVOD;5]E\Q(XI)I5BB1GD<X55&23Z 5U-K\-/&-Y")8M#F52,XED2(_DS
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MS7M0L_"?PVM+O4F5+47,I^;&YSGD1H.N!Z?G4WA7X@Z)XNN);:P-Q%<QKO\
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MDL3T '<U[?\ %KP-;7&G2^(]/A$=U!\UTJ# E3NV/[P[GT^E>1>&/^1KT?\
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MO(M4)94\B-L$G)Y92:YNBDTFK,$[;&QKWBG6?$S0-K%Y]I, (C_=(FW.,_=
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MR0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5'4+ZYY/3Z^5T5G'#13N]2W6=M HHHKH,@HHHH **** "BBB@ HHHH ****
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M1[)?F32ES.3\W^1\X6-Y+I]_;WL!Q+!(LJ'W!R*^M=*U"'5](M-0AP8KF)9
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MDO2LA(&,_,K;@>1]X_A6U:GS2O%ZF5*7*FK:'2:E\#=.D)?2]6N;9LY"SH)
M/8$;2.W//XUQGB[PEXXT:WFGU"^NM1L<8DFCN7D4+_M*W('X8]Z['3/CGI\K
M*FJ:3/;Y(!D@D$@^I!P1^M>J1O#=VJR(5DAF0,.,AE(_PK-SJT_B-$J<MCX[
MKZP\(?\ (F:)_P!>,/\ Z *^;/&>F0Z/XQU2PMQM@BG/EJ/X5/S ?AG%?2?A
M#_D3-$_Z\8?_ $ 5I7ES4E)=?\B*<>6HT> _%3_DHVJ?]L__ $6M<;79?%3_
M )*-JG_;/_T6M<;6M#^''T)K?Q'_ %V"NO\ A?(L?Q&TDMT+2+^)C85R%7='
MU%])UJRU% 2UM.DN >N#G'XUK:^ADSZWN4\VUFC_ +R%?S%?'LB&.1D88*D@
MBOL"RO(-0L8+RV</!.@D1AW!&:^>/B9X+N] UZYU"&!FTNZD,B2J,B-F/*MZ
M<]/:N##OEFT^IUU%S0NCA*FM[.YNS(+:WFF\M=[^6A;:OJ<=!R.:B +$  DG
M@ 5] ?"3P?<Z!I<^I:C"8KR] "1MPT<8Y&1V)/./85V5)J$6SFBN9V/GZK%D
M+LWL2V'GFZ9L1B#.\D]ACFO:_C-;Z)9Z#'+_ &?:C5;J8+',J!9-HY8DCKV'
M/K6?\#M%MY/[0UJ10T\;"WB)'W,C+$>YR!^?K41K*4'-K8N5/EDH]S.LOA;X
MSUVVB76M4:VMTRR0W,[3,A/<*#@?GFNITCX)Z+921RZA?W5[(ASM4")#]0,G
MT_BK>^(/C5_!FE02P6JW%U<N4B#DA%P,DG')[<<?6O(9?B?XPUF_AMX[\0+-
M(J"*UB5<DG'!.6[^M8TW5J?#HBYJ$%[VI]'=*^1_$'_(R:I_U]R_^AFOK<=!
MFOD?7CN\1:F<$9NY3@]?OFIPOQOT_4JM\"]?T/I3X?\ _(@Z+_U[#^9KR7XV
M7<DOC*WMB^8X+1=JYZ%B2?Z?E7K7P_\ ^1!T7_KV'\S7C?QD_P"1_D_Z]H_Z
MT1_WC[Q+^#]QSW@>8P>.=$=6VG[9&N?8G!_G7U/, 89 >A4_RKY2\)?\CEHG
M_7]#_P"ABOJV7_4O_NFJQOPKYBP_Q/Y'REX9LUOO&.EVC+E)+R-6'J-PS^E?
M5LT@B@DD/1%+?D*^4_#5VMAXRTNZ<X2.]C+'T&X9_2OJR5!+$Z'HRD?G1B[\
MJMYCI6]I*_\ 6K/D"]NI+V^GNIF+2S2-(Q/<DY-7M$\2:OX<EFETF\:V>=-D
MA"*V1_P(''UZU3U"SET_4;FSG4K+!*T; ^H.*U/"WA/4?%VH2V>G-"CQ1&5W
MF8JH&0,9 /)S74N7E\K?@8ROS:[W(]5\5Z_K<(AU+5;FXA_YY,^$/N5& 3]:
M^BOA[9I9> M&CC &^W$IQW+_ #'^=>$Z_P##CQ%X;TYM0O8;=K5" \D4X.W)
M '!P3DGMFO>/A_=1WG@+1I(SD+;+&?JORG]17/6<72]SN:03YUS' ?$[P=XK
M\3>*%GT_3S/8PP+'$WVB-1GDMPS ]3^E8/ACX>^-=%\3Z;J)TDQI!<*TC"YA
M.$SANC_W2:ZSQ]\1_$/A+Q*UA;65@]JT2R1/-$Y9@>#R' Z@]JP=-^+WC'6-
M1AL+#2M*GNICB.,1N,G&>IDP.!WI4G44%RI6_P"''54')\Q[9>VR7EA<6L@!
M2:-HV![@C%?*OAV,Q>,=*C;JE_$I_"05ZO>>,?BA8PO+/X5L]B?>,<#R8]_E
MD/'O7E/A^5I_&>ES, &DU")B!TR9 :>&@XR;%7DG"W];'UA7RGXRU6;6?%VI
MW<SEOW[1Q\\*BDA0/P%?59Z&OCZ]?S+^X?&-TK''XFLL*O?;\C2M\'S(2Q;&
M23@8&:2BBN\Y0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@"_9?ZD_[W]!7UU7R+9?ZD_[W]!7U
MU7-C-H_,UH;L****X3I"BBB@ HHHH **** "ODBZ_P"/9_P_G7UO7R1=?\>S
M_A_.N_!;2.;$;HS:***Z#(**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** /J3X?_P#(@Z+_ ->P_F:\6^+Y
M_P"+A77_ %QB_P#0:YFW\3:_:6Z6]MKFI0PQC"1QW<BJH]  <"J-W>W6H7+7
M-[<S7,[8W2S2%V..!DGFL(T6JO/?N:^T7L^0^D/A;J7]I> -/RP+VP:W;VVG
MC_QW;5'XQ:E]A\#/;*V'O)TB_ ?,?_0?UKP6QUW5],A:'3]5OK2)FW%+>X>-
M2?7 (YXI+_6=4U1474-2O+Q4.4%Q.T@4^V2<5,L/>IS7TO<<*O+&QW/P3_Y'
M>;_KR?\ ]"2O4/BK_P DYU3_ +9_^C%KYQLM1O=,G,]A>7%I,5VF2"5HVQZ9
M!Z<5:N_$>N7]LUM>:SJ-Q ^-T4UT[JV.>03BJJT7.2DGM;\Q4ZB@9E=?\--<
M_L/QO9.YQ!='[-+]&(P?P;%<DD;R$B-&<@%CM&< =3]*Z+P5X6O/$_B"V@BA
MD^R)(&N)MIVHHY(SZGH![UL[6UV,7?H?4M>&_&_6C/K%EHT;GR[:/SI0#QO;
MIGZ ?^/5[=-+';6\DTK!(HD+,QZ  9)KY,\0:M)KGB"^U.0DFXF9ESV7^$?@
M,"N##QYJE^QV5':'J9M>W_"/QQ;R:?'X<U&=8[B$XM'<X$BD_<R>X/0>GTKQ
M"BNZ<%./*SE3:=T?4WB?P/HGBT(VHPNMP@VI<0-MD ].A!'U!I?"W@G1O",4
M@TV.1II>))YFW.P[#@  ?0"OG[3_ (A>+-,A$5MK=QL P!*%EP/^!@T:A\0O
M%FJ0&&ZUNX\MA@B(+%D>^P"N7V%1+E3T-O:Q;NUJ>@?%_P ;P26Q\-Z=,)&9
M@;R1#D* >$SZYY/TQZURGP@_Y*%:_P#7&7_T$UPE3V=]=Z?<"XLKJ>VG ($D
M,A1@#UY'-;PI*$'%=3.I-S=SZ=^(/_(@:U_U['^E?+\$TEM<1SPN4EC8.C#J
M"#D&M&X\3:_=V[V]SKFI30R##QR7<C*P]""<&LJE1I.G?7<=2:FD?3?@?QU8
M>+=.C4RQQ:HB_OK8G!)'5E]5_E4?B+X8>'/$=ZU[/'/:W+G,DEJX7>?<$$9]
M\9KYJCD>&19(G9)%.593@@^H-=3:?$KQA90B*+7)F4#&9D24_FZDUG+#M2YH
M.PXU=+2/H/P[X5T;PG:/%IEOY>_F6:1MSOCU/I[# KROXK?$"WU.)O#^D2B6
MW# W4Z'*N1T13W /)/M7!ZOXT\2:[$8M1U>XEB/WHU(C1OJJ@ U@TX4'S<TW
M<;JI*T4=E\*_^2CZ5_VU_P#1;5[UXU_Y$?6_^O*7_P!!-?+-I>7-A<I<V=Q-
M;SIG;+"Y1ER,'!'(XJ_/XH\07,#P3Z[J<L,BE7CDNY&5@>H()Y%56HNHTT]O
M\R:510,JOI;X5?\ ).-+_P"VO_HQJ^::T[3Q'KEA;);6>LZC;P)G;%#=.BKD
MY. #CK5U8<\.5$PERRN=Q\;O^1RM/^O)?_0WK&^%?_)1]*_[:_\ HMJY:^U&
M^U.837][<7<H7:'N)6D8#TR3TYIEI>7-A<I<V=Q-;SIG;+"Y1ER,'!'(XHIP
MY(<OK^HZDN:5SZJ\7?\ (FZU_P!>4W_H!KYW^'OB"'PWXPM+VY.+9P89F_NJ
MW?\  X-9LWBGQ#<0O#-KVJ2Q2*5='O)&5@>H()Y%9-11H\ET];E5*G,DET/L
M&:&TU33WAE6.XM+B/!'574C^6*XBU^#WA.TOS=O'=31@[A!--F->_8 D?4FO
M$]'\:^(] @\C3=6GAA'2)@LB+]%8$#\*?JWCKQ-KEL;?4-7GD@88:- L:L/0
MA ,_C6:P\XOW65[6+7O(^EM&UG3-7BN%TN9)8;27[.QC'R@@ X7U'/:O%OC=
M8R0^*[2\(_=7%J%4_P"TK'(_(BO/[#6M5TM'33]3O+17.76WG:,,?4X(S1?Z
MSJFJ*BZAJ5Y>*AR@N)VD"GVR3BJCAW&:DF)U4XM-'M'P,_Y%O4O^OO\ ]D%5
M_CM_R#-'_P"NTG_H(K@_AY9>(]2UNWM=)N]0M[ 3+)=O!,\<848SG!P21P!U
MKJOCGJ44M_I>FH^9(4>:0 ]-V N?^^34U(_OXOO^B'3E[DE_6IY'111768$M
MK_Q]P_\ 71?YU]AK]T?2OC@$J002".016Q_PEWB7_H8M6_\  V3_ .*K*M3=
M1)(JG+E;9]-W'AC0+NX>>YT/3)II#N>22TC9F/J21DU'_P (CX9_Z%W2?_ *
M/_XFOFC_ (2[Q-_T,6K?^!LG_P 51_PEWB;_ *&+5O\ P-D_^*K#ZM/^;\S7
MVL>Q]+GPCX:Q_P B[I/_ (!1_P#Q-?,]EJ']A^+XK^-/EM+S?L7CY0W('X<4
MO_"7>)?^ABU;_P #9/\ XJL=F9V+,Q9F.22<DFM:5*4)-MW(J34HV2/K[3M1
MM-6T^&^LIEFMYE#(Z]_\#[5QNH?"+POJ&JM?LEW#O;>\$,H6-CG)X()&?8BO
M"-&\3:UX>9CI6HSVP8Y9%.4)]2IR">/2M*_^(OBW4[<P7.MS^6PP1$J1$CZH
M :S^KRC*\&6JJ:M)'T'HNH:)!?R>&]'6-180AI$BY6/)QM)[MU)_6N-^./\
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M)["<7[C-O:QDK21[UXM\5V/A/1I+RY=3.01;P9^:5NPQZ>I[5\Q-JMU)K?\
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MC:06L(MXSY<$81<G.3@<5[1\-_\ DGNC?]<3_P"A&O'_ (R?\C_)_P!>T?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7@/P\^'TGBZZ:[NV>'2H&P[+]Z5O[J^GN?\ (]X T+P9H?\ R[Z=I\/X9/\
M-F/XDUR8J46E'J;44[W6QRD/PBT2/Q9)JS,S6>X2QV./E5\Y.3W7T7^G%:?C
M_P :6GA7198UE5M3G0K;P@\KGC>?0#]:ZNWN(;RUCN+>59895#HZ'(93T(-?
M.OQ#\(:GI?B_EYKN+4I?]&GD8LS,3C83ZC(_#%8P3J24)O\ KL:MJ"<XG"DD
MG)ZT5W.I?"3Q;IZEUM8+N-02S6\XX'T;:?TKANAKOC.,OA9RN+6X44450CZ
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M9BT9V[D;/]Y<CTZ]N:>(D^=1;LB:*7*WU-NVU?1=9+06NH:??8Y:.*9)<?4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,/$6B:?X"L;:]UG3[:=6EW1372(PR[$9!.:QQ"O3=O(NG\:.0^.3$^*=/7/
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M'C_F!_\ ;;_V2O-/"7_(Y:)_U_0_^ABIPO\ #^\K$;_(^K9?]2_^Z:^.Y?\
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MN./5E _S[5ZG\3_^2=:O_N)_Z,6E\%>#[#P18?9_M*S7UVW[R9@%+D D*H]
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M?T/_ *&*O#?PX_UW%7^)_P!=$?5LO^I?_=-?)>D:5+K?B&UTR$[7N9Q'N/\
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M=3ZP\(?\B9HG_7C#_P"@"O ?BI_R4;5/^V?_ *+6O?O"'_(F:)_UXP_^@"O
M?BI_R4;5/^V?_HM:BG_O#^?YE/\ @_<;/P0_Y'.[_P"O%_\ T-*],^*O_).=
M4_[9_P#HQ:\S^"'_ ".=W_UXO_Z&E>F?%7_DG.J?]L__ $8M&)_B1^7YAA]G
M_70^:****[3F"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@"_9?ZD_[W]!7UU7R+9?ZD_[W]!7
MUU7-C-H_,UH;L****X3I"BBB@ HHHH **** "ODBZ_X]G_#^=?6]?)%U_P >
MS_A_.N_!;2.;$;HS:***Z#(**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Z7P%XB_X1GQ;
M:7LC$6SGR;C_ '&[_@<'\*YJBC?1@?2?Q1T3^WO \\D'SRVA%U%MYW #YO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 7[+_4G_ 'OZ"OKJOD6R_P!2?][^@KZZKFQFT?F:T-V%%%%<)TA1110 4444
M %%%% !7R1=?\>S_ (?SKZWKY(NO^/9_P_G7?@MI'-B-T9M%%%=!D%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 7[+_4G_ 'OZ"OKJOD6R
M_P!2?][^@KZZKFQFT?F:T-V%%%%<)TA1110 4444 %%%% !7R1=?\>S_ (?S
MKZWKY(NO^/9_P_G7?@MI'-B-T9M%%%=!D%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 7[+_4G_ 'OZ"OKJOD6R_P!2?][^@KZZKFQFT?F:
MT-V%%%%<)TA1110 4444 %%%% !7R1=?\>S_ (?SKZWKY(NO^/9_P_G7?@MI
M'-B-T9M%%%=!D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 7[+_4G_ 'OZ"OKJOD6R_P!2?][^@KZZKFQFT?F:T-V%%%%<)TA1110 4444
M %%%% !7R1=?\>S_ (?SKZWKY(NO^/9_P_G7?@MI'-B-T9M%%%=!D%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 7[+_4G_ 'OZ"OKJOD6R
M_P!2?][^@KZZKFQFT?F:T-V%%%%<)TA1110 4444 %%%% !7R1=?\>S_ (?S
MKZWKY(NO^/9_P_G7?@MI'-B-T9M%%%=!D%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:/LL/]S]31[-AS(S:*TOLL/]S]31]EA_N?J:/9L.9&;16E]EA_N?J:/LL/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1161XEUI- T*XO6(\P#9"I_B<]/\ 'Z"G&+D[(F4E
M%.3V1YE\2-9_M+Q"+*)MT-D"G'>0_>_H/P-3Z+9?9H+>/;\V,M]37,Z1;O?Z
MBT\Q+;3YCL>=S$_X\UWFGP@R0\]OZ5V8IJ$8T8]#AP47.4J\NNWH;&G0_N6^
M3^+^E=+"F&Z=JRK"$"%N3]ZMM%P:XCT!X'%+0.E% !1110 4444 %%%% !11
M10 4444 %%%%  :X/XGZ8;G0XKY%R]K)\W'\#<']=M=Y5/4[*/4-.NK.4?)-
M&R'VR.M:4I\DU(RK4_:4W#N<;\+-4%QH]QIKGY[:3>@_V&_^N#^==]7AWA*^
MD\.>,XXKGY%+M:SCTR<?HP!KW&ML9#EJ76SU,,#4YJ7*]UH%%%%<IV!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (:JWMK%
M=VTT$Z!XI$*LI[@BK=-89!H \)O+>^\%>*%>%FS$V^%STDC/8_AD&O:=&U:W
MUO2X;^U/R2#E3U1NZGW%8WB_PXNOZ9Y:[1=1 M"Y]?0^QKSGPAXCF\*ZQ);7
MBN+21]EQ&>L;#C<!ZCOZC\*]"2^LT^9?$OQ/,B_JE7E?P2_ ]NHIL<B2QK)&
MP=' 964Y!![TZO//3"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6WVLW[L#BM&-<*O%<QUCP.*6BB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ J.>>*V@>:>18XD&YG<X"CU)K.USQ#IWA^U\Z^FPQ'R1+R[_0?U
MZ5Y!XA\5ZEXIN1#@QVN[]W;1G.?=O4UT4</*IKLNYRXC%0HZ;R[&OXQ\>R:K
MOT_2F:.R/#R]&F]O9?U/Z5B:/H;,RSW*#IE8V_F:LZ3H8A_>W"EY1T '"_\
MUZZFTL@9%S$_3WK6K7C"/LZ.W<QHX:=27M:^_1=B.UM'*KPOWJZ*RLW#/D+T
MIMG8H(U_=M][WK;@MU4GY2*XCT!UO"55,@<"K8&!2(H '%/H **** "BBB@
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDLL<$3RRNJ1H"S,QP
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO2M^VBVQ@;0.:KVD"J4Z_=K110%Q7,=8\"EHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ I",TM% %:6+<&YZUSFO^&;/6D5;CY9
M%7"2J/F7_$>U=61GM43Q G[H-.,G%W1,HQDN62NCPN^T?5_"]XMU#(ZJC?)<
MPD@?0^GT/'UKM/#OQ.BEV6VN((WZ"YC7Y3_O+V^H_(5UUU8K)$5:!&!/((&#
M7":YX#2:22;3U%N_7RR?D/T]*[57IUERUEKW//>&JT'S4'IV9Z?!<0W4"3V\
MJ2Q.,JZ-D$?6I*\#@NM?\(W>8WFMB3DJ?FCD_#H?YUW>B_%&SG"Q:O ;:3H9
MH@60_4=1^M14PDTN:&J-:6.A)\M3W7YGH-%5[._M-1@$UG<Q3QG^*-@V/KZ5
M8KD:MN=B:>J"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !15>\O[33X#->7,4$8_BD8 5PVM?%&S@#
M1:1 ;F3H)I050?AU/Z5I3I3J?"C*K7ITE>;.]GN(;6!Y[B5(HD&6=VP /K7G
MOB+XG11![;0T\Q^AN9!\H_W5[_4_D:X6]U+6?$UUNN9I;C!X3HB?0=!_.KUC
MX<" 27 \QA_"#\H_QKK5&E1UJN[['$Z];$:459=V9BPZAKEVUS<2O(SG+32G
M/Y?X5TNFZ3#:*HC/S-U<CDUJ6]@V[:(5P!P.*UK33VQ'F!>OMZUA6Q,JFFR[
M'10PD*7O;R[E2TLB0W[S]*W[2R(9#O\ X?2I;:RVAOW*C\!6I%"%Q\@'%<YU
M$<,&U -W?TJVJX[T*H Z"G4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -90>U4;JUCFA:-X@
MZMP5(R"*T*8RY% 'CWBKP5+8227>F1.]M]YX@"3'[CU'\JO>$?B(]H([#6G:
M2#HER>63V;U'OU^O;TF: -N^;M7 >)? T-UFZT\K%<G):,C"/_@?\^]=M.O&
MI'V=;[SSJF&G2E[7#_-?U_78])AFBN(4FAD62-QE70Y!'L:?7A6B^)-8\(WC
M6Y5C$&_>6LW3ZCT/N/UKUG0/%>F>(HA]EEV7 'S6\G#CZ>H]Q65;#2IZK5=S
M>ABX5?=>DNQN4445SG4%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M51]1J^7WA_:-#S^X]CHKQS_A:.O_ //*Q_[]-_\ %4?\+1U__GE8_P#?IO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)3\Y^[Z4^ULF$9^5.M:T<.UCP.E<AVC8(0J)R>*M 8H5< 4Z@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH ,"F,@(Z4^B@"!H5)^[59[2,@?N_YUH4A7- &-+81G=^Y/ZU3ETU,C
M_1S^M=$4]Z8T63UH Y.33%V_\>[=?>JSZ8"3_HS?D:Z]K8$?>_2HS9@Y^<_E
M0!Q;Z-$WWK('ZK41T2#_ )\%_P"^*[8V0/\ &?RIAL1S^\/Y4^9]Q<J['%'1
M8?\ GP7_ +XI/[%@_P"?%?\ OBNS-@/^>A_*F_8!_P ]#^5/FEW%RQ[''?V+
M#_SXK_WQ1_8L/_/BO_?%=C]@'_/0_E1]@'_/0_E1S2[ARQ[''?V+#_SXK_WQ
M1_8L/_/BO_?%=C]@'_/0_E1]@'_/0_E1S2[ARQ[''?V+#_SXK_WQ1_8L/_/B
MO_?%=C]@'_/0_E1]@'_/0_E1S2[ARQ[''?V+#_SXK_WQ1_8L/_/BO_?%=C]@
M'_/0_E1]@'_/0_E1S2[ARQ[''?V+#_SXK_WQ1_8L/_/BO_?%=C]@'_/0_E1]
M@'_/0_E1S2[ARQ[''?V+#_SXK_WQ1_8L/_/BO_?%=C]@'_/0_E1]@'_/0_E1
MS2[ARQ[''?V+#_SXK_WQ1_8L/_/BO_?%=C]@'_/0_E1]@'_/0_E1S2[ARQ['
M'?V+#_SXK_WQ1_8L/_/BO_?%=C]@'_/0_E1]@'_/0_E1S2[ARQ[''?V+#_SX
MK_WQ1_8L/_/BO_?%=C]@'_/0_E1]@'_/0_E1S2[ARQ[''?V+#_SXK_WQ1_8L
M/_/BO_?%=C]@'_/0_E1]@'_/0_E1S2[ARQ[''?V+#_SXK_WQ1_8L/_/BO_?%
M=C]@'_/0_E1]@'_/0_E1S2[ARQ[''?V+#_SXK_WQ1_8L/_/BO_?%=C]@'_/0
M_E1]@'_/0_E1S2[ARQ[''?V+#_SXK_WQ1_8L/_/BO_?%=C]@'_/0_E1]@'_/
M0_E1S2[ARQ[''?V+#_SXK_WQ1_8L/_/BO_?%=C]@'_/0_E1]@'_/0_E1S2[A
MRQ[''?V+#_SXK_WQ1_8L/_/BO_?%=C]@'_/0_E1]@'_/0_E1S2[ARQ[''?V+
M#_SXK_WQ1_8L/_/BO_?%=C]@'_/0_E1]@'_/0_E1S2[ARQ[''?V+#_SXK_WQ
M1_8L/_/BO_?%=C]@'_/0_E1]@'_/0_E1S2[ARQ[''?V+#_SXK_WQ1_8L/_/B
MO_?%=C]@'_/0_E1]@'_/0_E1S2[ARQ[''?V+#_SXK_WQ1_8L/_/BO_?%=C]@
M'_/0_E1]@'_/0_E1S2[ARQ[''?V+#_SXK_WQ1_8L/_/BO_?%=C]@'_/0_E1]
M@'_/0_E1S2[ARQ[''?V+#_SXK_WQ1_8L/_/BO_?%=C]@'_/0_E1]@'_/0_E1
MS2[ARQ[''?V+#_SXK_WQ1_8L/_/BO_?%=C]@'_/0_E1]@'_/0_E1S2[ARQ['
M'?V+#_SXK_WQ1_8L/_/BO_?%=C]@'_/0_E1]@'_/0_E1S2[ARQ[''?V+#_SX
MK_WQ1_8L/_/BO_?%=C]@'_/0_E1]@'_/0_E1S2[ARQ[''?V+#_SXK_WQ1_8L
M/_/BO_?%=C]@'_/0_E1]@'_/0_E1S2[ARQ[''?V+#_SXK_WQ1_8L/_/BO_?%
M=C]@'_/0_E1]@'_/0_E1S2[ARQ[''?V+#_SXK_WQ1_8L/_/BO_?%=C]@'_/0
M_E1]@'_/0_E1S2[ARQ[''?V+#_SXK_WQ1_8L/_/BO_?%=C]@'_/0_E1]@'_/
M0_E1S2[ARQ[''?V+#_SXK_WQ1_8L/_/BO_?%=C]@'_/0_E1]@'_/0_E1S2[A
MRQ[''?V+#_SXK_WQ1_8L/_/BO_?%=C]@'_/0_E1]@'_/0_E1S2[ARQ[''?V+
M#_SXK_WQ1_8L/_/BO_?%=C]@'_/0_E1]@'_/0_E1S2[ARQ[''?V+#_SXK_WQ
M1_8L/_/BO_?%=C]@'_/0_E1]@'_/0_E1S2[ARQ[''?V+#_SXK_WQ1_8L/_/B
MO_?%=C]@'_/0_E1]@'_/0_E1S2[ARQ[''?V+#_SXK_WQ1_8L/_/BO_?%=C]@
M'_/0_E1]@'_/0_E1S2[ARQ[''?V+#_SXK_WQ1_8L/_/BO_?%=C]@'_/0_E1]
M@'_/0_E1S2[ARQ[''?V+#_SXK_WQ1_8L/_/BO_?%=C]@'_/0_E1]@'_/0_E1
MS2[ARQ[''?V+#_SXK_WQ1_8L/_/BO_?%=C]@'_/0_E1]@'_/0_E1S2[ARQ['
M'?V+#_SXK_WQ1_8L/_/BO_?%=C]@'_/0_E1]@'_/0_E1S2[ARQ[''?V+#_SX
MK_WQ1_8L/_/BO_?%=C]@'_/0_E1]@'_/0_E1S2[ARQ[''?V+#_SXK_WQ1_8L
M/_/BO_?%=C]@'_/0_E1]@'_/0_E1S2[ARQ[''?V+#_SXK_WQ1_8L/_/BO_?%
M=C]@'_/0_E1]@'_/0_E1S2[ARQ['(KI$:XVV8'T6I1IIQ_Q[M^1KJQ8#_GH?
MRIPL1C_6'\J3;8TDMCE1IO\ T[M^1J5-,Z?Z.WZUU LA_?/Y4\68X^<_E2&<
MY'I@P?\ 1V_6KL6FID?Z.>GO6TMJ!_$?RJ980#]Z@#*BT^, ?N#U]ZN)9QC/
M[K^=71'CO3PN* *Z6Z#'R5*(P!TJ3%% "8%+110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY^!]9Q'_ #Z/<_[7TW_H(VG_ '^7_&C^U]-_Z"-I_P!_E_QKPS_A&-1](O\
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MQJ/I%_WU_P#6H^KT/^?@?6<1_P ^CW/^U]-_Z"-I_P!_E_QH_M?3?^@C:?\
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M-_Z"-I_W^7_&C^U]-_Z"-I_W^7_&O#/^$8U'TB_[Z_\ K4?\(QJ/I%_WU_\
M6H^KT/\ GX'UG$?\^CW/^U]-_P"@C:?]_E_QH_M?3?\ H(VG_?Y?\:\,_P"$
M8U'TB_[Z_P#K4?\ ",:CZ1?]]?\ UJ/J]#_GX'UG$?\ /H]S_M?3?^@C:?\
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M,L8'\(J0 #M0 U4P.M/HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIIC)]* .8.FQ8^^_Z4PZ9%S\[_I74>4?:D\D^U '*G38O[[_ *4TZ=%_??\
M2NJ,!]J;Y#?[- '+?V=%_??]*/[-B_OO^E=3]G;_ &:/L[?[- '+?V;%_??]
M*/[-B_OO^E=3]G;_ &:/L[?[- '+?V;%_??]*/[-B_OO^E=3]G;_ &:/L[?[
M- '+?V;%_??]*/[-B_OO^E=3]G;_ &:/L[?[- '+?V;%_??]*/[-B_OO^E=3
M]G;_ &:/L[?[- '+?V;%_??]*/[-B_OO^E=3]G;_ &:/L[?[- '+?V;%_??]
M*/[-B_OO^E=3]G;_ &:/L[?[- '+?V;%_??]*/[-B_OO^E=3]G;_ &:/L[?[
M- '+?V;%_??]*/[-B_OO^E=3]G;_ &:/L[?[- '+?V;%_??]*/[-B_OO^E=3
M]G;_ &:/L[?[- '+?V;%_??]*/[-B_OO^E=3]G;_ &:/L[?[- '+?V;%_??]
M*/[-B_OO^E=3]G;_ &:/L[?[- '+?V;%_??]*/[-B_OO^E=3]G;_ &:/L[?[
M- '+?V;%_??]*/[-B_OO^E=3]G;_ &:/L[?[- '+?V;%_??]*/[-B_OO^E=3
M]G;_ &:/L[?[- '+?V;%_??]*/[-B_OO^E=3]G;_ &:/L[?[- '+?V;%_??]
M*/[-B_OO^E=3]G;_ &:/L[?[- '+?V;%_??]*/[-B_OO^E=3]G;_ &:/L[?[
M- '+?V;%_??]*/[-B_OO^E=3]G;_ &:/L[?[- '+?V;%_??]*/[-B_OO^E=3
M]G;_ &:/L[?[- '+?V;%_??]*/[-B_OO^E=3]G;_ &:/L[?[- '+?V;%_??]
M*/[-B_OO^E=3]G;_ &:/L[?[- '+?V;%_??]*/[-B_OO^E=3]G;_ &:/L[?[
M- '+?V;%_??]*/[-B_OO^E=3]G;_ &:/L[?[- '+?V;%_??]*/[-B_OO^E=3
M]G;_ &:/L[?[- '+?V;%_??]*/[-B_OO^E=3]G;_ &:/L[?[- '+?V;%_??]
M*/[-B_OO^E=3]G;_ &:/L[?[- '+?V;%_??]*/[-B_OO^E=3]G;_ &:/L[?[
M- '+?V;%_??]*/[-B_OO^E=3]G;_ &:/L[?[- '+?V;%_??]*/[-B_OO^E=3
M]G;_ &:/L[?[- '+?V;%_??]*/[-B_OO^E=3]G;_ &:/L[?[- '+?V;%_??]
M*/[-B_OO^E=3]G;_ &:/L[?[- '+?V;%_??]*/[-B_OO^E=3]G;_ &:/L[?[
M- '+?V;%_??]*/[-B_OO^E=3]G;_ &:/L[?[- '+?V;%_??]*/[-B_OO^E=3
M]G;_ &:/L[?[- '+?V;%_??]*/[-B_OO^E=3]G;_ &:/L[?[- '+?V;%_??]
M*/[-B_OO^E=3]G;_ &:/L[?[- '+?V;%_??]*/[-B_OO^E=3]G;_ &:/L[?[
M- '+?V;%_??]*/[-B_OO^E=3]G;_ &:/L[?[- '+?V;%_??]*/[-B_OO^E=3
M]G;_ &:/L[?[- '+?V;%_??]*/[-B_OO^E=3]G;_ &:/L[?[- '+?V;%_??]
M*/[.B_OO^E=3]G;_ &:/L[?[- '+C3HL_??]*<--B_OO^E=,(&_V:<(3[4 <
MT--B_OO^E2+IL61\[_I71^4?:E$1]J ,)-/CV_?>K<=C&&^\W2M01D>E/"X]
M* *,=J@ ^9JG6!1W-6,4M $80#N:>!@4M% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% "$>U1O&"#\HJ6B@"C);*Q_P!6#Q6=<:>&0#R%([C K>*BHGB!
M'4T >>:KX,L[LR.EL8)/[T1 'Y=*Y*]\&:G;$F%5G7M@A6_(_P"->S36J$-R
MU4)K",L/F;I713Q56&SOZG+5P=&IJU9^1Y/:>)_$N@L(OM=PJ@_ZJX7>/PW=
M!]*Z:P^+$Z[5U#34?U>!RO\ XZ<_SKH+C2X)(RKY92>0V"/Y5A7GA/2I68^2
M4..L9V_ITK;ZQ1G_ !(?<8?5L13_ (4_O.@L_B3X=N@OFS36K'C$T1/ZKD5N
M6WB'1KP@6^J6;L?X1,N?RSFO*+GP;$/]1=NOLZ@_RQ69-X6O8R=DD+CZD'^5
M+V6&E\,K#]MBX?%"_H>]JZNNY6##U!S2U\]C2=5M7W11NI_O1R ?R-2BY\1P
M?=NM27']R9_Z&CZI%[37]?,/KLU\5-_U\CW^BO O[5\4?\_^L?\ ?Z7_ !H_
MM7Q1_P _^L?]_I?\:/J7]]?U\Q?VA_T[?]?(]]HKP+^U?%'_ #_ZQ_W^E_QH
M_M7Q1_S_ .L?]_I?\:/J7]]?U\P_M#_IV_Z^1[[17@7]J^*/^?\ UC_O]+_C
M1_:OBC_G_P!8_P"_TO\ C1]2_OK^OF']H?\ 3M_U\CWVBO O[5\4?\_^L?\
M?Z7_ !H_M7Q1_P _^L?]_I?\:/J7]]?U\P_M#_IV_P"OD>^T5X%_:OBC_G_U
MC_O]+_C1_:OBC_G_ -8_[_2_XT?4O[Z_KYA_:'_3M_U\CWVBO O[5\4?\_\
MK'_?Z7_&C^U?%'_/_K'_ '^E_P :/J7]]?U\P_M#_IV_Z^1[[17@7]J^*/\
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M7]]?U\P_M#_IV_Z^1[[17@7]J^*/^?\ UC_O]+_C1_:OBC_G_P!8_P"_TO\
MC1]2_OK^OF']H?\ 3M_U\CWVBO O[5\4?\_^L?\ ?Z7_ !H_M7Q1_P _^L?]
M_I?\:/J7]]?U\P_M#_IV_P"OD>^T5X%_:OBC_G_UC_O]+_C1_:OBC_G_ -8_
M[_2_XT?4O[Z_KYA_:'_3M_U\CWVBO O[5\4?\_\ K'_?Z7_&C^U?%'_/_K'_
M '^E_P :/J7]]?U\P_M#_IV_Z^1[[17@7]J^*/\ G_UC_O\ 2_XT?VKXH_Y_
M]8_[_2_XT?4O[Z_KYA_:'_3M_P!?(]]HKP+^U?%'_/\ ZQ_W^E_QH_M7Q1_S
M_P"L?]_I?\:/J7]]?U\P_M#_ *=O^OD>^T5X%_:OBC_G_P!8_P"_TO\ C1_:
MOBC_ )_]8_[_ $O^-'U+^^OZ^8?VA_T[?]?(]]HKP+^U?%'_ #_ZQ_W^E_QH
M_M7Q1_S_ .L?]_I?\:/J7]]?U\P_M#_IV_Z^1[[17@7]J^*/^?\ UC_O]+_C
M1_:OBC_G_P!8_P"_TO\ C1]2_OK^OF']H?\ 3M_U\CWVBO O[5\4?\_^L?\
M?Z7_ !H_M7Q1_P _^L?]_I?\:/J7]]?U\P_M#_IV_P"OD>^T5X%_:OBC_G_U
MC_O]+_C1_:OBC_G_ -8_[_2_XT?4O[Z_KYA_:'_3M_U\CWVBO O[5\4?\_\
MK'_?Z7_&C^U?%'_/_K'_ '^E_P :/J7]]?U\P_M#_IV_Z^1[[17@7]J^*/\
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M7]]?U\P_M#_IV_Z^1[[17@7]J^*/^?\ UC_O]+_C1_:OBC_G_P!8_P"_TO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ P*,"BB@!,"C:/2EHH 3:/2C:/2EHH 3:/2C:/2EHH 3:/2C:/2EHH
M 3:/2C:/2EHH 3:/2C:/2EHH 3:/2C:/2EHH 3:/2C:/2EHH 3:/2C:/2EHH
M 3:/2C:/2EHH 3:/2C:/2EHH 3:/2C:/2EHH 3:/2C:/2EHH 3:/2C:/2EHH
M 3:/2C:/2EHH 3:/2C:/2EHH 3:/2C:/2EHH 3:/2C:/2EHH 3:/2C:/2EHH
M 3:/2C:/2EHH 3:/2C:/2EHH 3:/2C:/2EHH 3:/2C:/2EHH 3:/2C:/2EHH
M 3:/2C:/2EHH 3:/2C:/2EHH 3:/2C:/2EHH 3:/2C:/2EHH 3:/2C:/2EHH
M 3:/2C:/2EHH 3:/2C:/2EHH 3:/2C:/2EHH 3:/2C:/2EHH 3:/2C:/2EHH
M 3:/2C:/2EHH 3:/2C:/2EHH 3:/2C:/2EHH 3:/2C:/2EHH 3:/2C:/2EHH
M 3:/2C:/2EHH 3:/2C:/2EHH 3:/2C:/2EHH 3:/2C:/2EHH 3:*,"EHH ,"
MC%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 (1FF%"?2I** *SPL1VJO):N2>5Z5H8%(4![4 8LEC(<<I5273Y<-
MRG7U/^%=$T2G^&HVMT.?D/ZT <R^G2Y^\GYG_"H3ILW]Z/\ ,_X5U)M8_P#G
MF?S-,^QQ_P#/,_F: .6.FS<_-'^9_P *8=-F_O1_F?\ "NJ-E'_SR/YFFFRC
M_P">1_,T <M_9TO]Y/S/^%)_9LO]Z/\ ,_X5U'V&/_GD?S-'V&/_ )Y'\S0!
MR_\ 9LO]Z/\ ,_X4?V;+_>C_ #/^%=1]AC_YY'\S1]AC_P">1_,T <O_ &;+
M_>C_ #/^%']FR_WH_P S_A74?88_^>1_,T?88_\ GD?S- '+_P!FR_WH_P S
M_A1_9LO]Z/\ ,_X5U'V&/_GD?S-'V&/_ )Y'\S0!R_\ 9LO]Z/\ ,_X4?V;+
M_>C_ #/^%=1]AC_YY'\S1]AC_P">1_,T <O_ &;+_>C_ #/^%']FR_WH_P S
M_A74?88_^>1_,T?88_\ GD?S- '+_P!FR_WH_P S_A1_9LO]Z/\ ,_X5U'V&
M/_GD?S-'V&/_ )Y'\S0!R_\ 9LO]Z/\ ,_X4?V;+_>C_ #/^%=1]AC_YY'\S
M1]AC_P">1_,T <O_ &;+_>C_ #/^%']FR_WH_P S_A74?88_^>1_,T?88_\
MGD?S- '+_P!FR_WH_P S_A1_9LO]Z/\ ,_X5U'V&/_GD?S-'V&/_ )Y'\S0!
MR_\ 9LO]Z/\ ,_X4?V;+_>C_ #/^%=1]AC_YY'\S1]AC_P">1_,T <O_ &;+
M_>C_ #/^%']FR_WH_P S_A74?88_^>1_,T?88_\ GD?S- '+_P!FR_WH_P S
M_A1_9LO]Z/\ ,_X5U'V&/_GD?S-'V&/_ )Y'\S0!R_\ 9LO]Z/\ ,_X4?V;+
M_>C_ #/^%=1]AC_YY'\S1]AC_P">1_,T <O_ &;+_>C_ #/^%']FR_WH_P S
M_A74?88_^>1_,T?88_\ GD?S- '+_P!FR_WH_P S_A1_9LO]Z/\ ,_X5U'V&
M/_GD?S-'V&/_ )Y'\S0!R_\ 9LO]Z/\ ,_X4?V;+_>C_ #/^%=1]AC_YY'\S
M1]AC_P">1_,T <O_ &;+_>C_ #/^%']FR_WH_P S_A74?88_^>1_,T?88_\
MGD?S- '+_P!FR_WH_P S_A1_9LO]Z/\ ,_X5U'V&/_GD?S-'V&/_ )Y'\S0!
MR_\ 9LO]Z/\ ,_X4?V;+_>C_ #/^%=1]AC_YY'\S1]AC_P">1_,T <O_ &;+
M_>C_ #/^%']FR_WH_P S_A74?88_^>1_,T?88_\ GD?S- '+_P!FR_WH_P S
M_A1_9LO]Z/\ ,_X5U'V&/_GD?S-'V&/_ )Y'\S0!R_\ 9LO]Z/\ ,_X4?V;+
M_>C_ #/^%=1]AC_YY'\S1]AC_P">1_,T <O_ &;+_>C_ #/^%']FR_WH_P S
M_A74?88_^>1_,T?88_\ GD?S- '+_P!FR_WH_P S_A1_9LO]Z/\ ,_X5U'V&
M/_GD?S-'V&/_ )Y'\S0!R_\ 9LO]Z/\ ,_X4?V;+_>C_ #/^%=1]AC_YY'\S
M1]AC_P">1_,T <O_ &;+_>C_ #/^%']FR_WH_P S_A74?88_^>1_,T?88_\
MGD?S- '+_P!FR_WH_P S_A1_9LO]Z/\ ,_X5U'V&/_GD?S-'V&/_ )Y'\S0!
MR_\ 9LO]Z/\ ,_X4?V;+_>C_ #/^%=1]AC_YY'\S1]AC_P">1_,T <O_ &;+
M_>C_ #/^%']FR_WH_P S_A74?88_^>1_,T?88_\ GD?S- '+_P!FR_WH_P S
M_A1_9LO]Z/\ ,_X5U'V&/_GD?S-'V&/_ )Y'\S0!R_\ 9LO]Z/\ ,_X4?V;+
M_>C_ #/^%=1]AC_YY'\S1]AC_P">1_,T <O_ &;+_>C_ #/^%']FR_WH_P S
M_A74?88_^>1_,T?88_\ GD?S- '+_P!FR_WH_P S_A1_9LO]Z/\ ,_X5U'V&
M/_GD?S-'V&/_ )Y'\S0!R_\ 9LO]Z/\ ,_X4?V;+_>C_ #/^%=1]AC_YY'\S
M1]AC_P">1_,T <O_ &;+_>C_ #/^%']FR_WH_P S_A74?88_^>1_,T?88_\
MGD?S- '+_P!FR_WH_P S_A1_9LO]Z/\ ,_X5U'V&/_GD?S-'V&/_ )Y'\S0!
MR_\ 9LO]Z/\ ,_X4?V;+_>C_ #/^%=1]AC_YY'\S1]AC_P">1_,T <O_ &;+
M_>C_ #/^%']FR_WH_P S_A74?88_^>1_,T?88_\ GD?S- '+_P!FR_WH_P S
M_A1_9LO]Z/\ ,_X5U'V&/_GD?S-'V&/_ )Y'\S0!R_\ 9LO]Z/\ ,_X4?V;+
M_>C_ #/^%=1]AC_YY'\S1]AC_P">1_,T <O_ &;+_>C_ #/^%']FR_WH_P S
M_A74?88_^>1_,T?88_\ GD?S- '+_P!FR_WH_P S_A1_9LO]Z/\ ,_X5U'V&
M/_GD?S-'V&/_ )Y'\S0!R_\ 9LO]Z/\ ,_X4O]G2_P!Y/S/^%=/]AC_YY'\S
M1]BC_P">1_,T <R--F_O1_F?\*D&FS?WH_S/^%=(+*/C]T?S-/%G'_SR/YF@
M#FUTV;/WH_S/^%3)ITO'S)^9_P *Z 6D?_/,_F:<+6,?\LS^9H QX["09Y3\
MZMQV<@V\ITK16!!_ ?UJ01J,<4 5$MF ZKUJ=8CGM4VT#M2X% # A&.E/Q2T
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %&*** #%)B
MEHH 3%)M]Z=10 W;[T;?>G44 -V^]&WWIU% #=OO1M]Z=10 W;[T;?>G44 -
MV^]&WWIU% #=OO1M]Z=10 W;[T;?>G44 -V^]&WWIU% #=OO1M]Z=10 W;[T
M;?>G44 -V^]&WWIU% #=OO1M]Z=10 W;[T;?>G44 -V^]&WWIU% #=OO1M]Z
M=10 W;[T;?>G44 -V^]&WWIU% #=OO1M]Z=10 W;[T;?>G44 -V^]&WWIU%
M#=OO1M]Z=10 W;[T;?>G44 -V^]&WWIU% #=OO1M]Z=10 W;[T;?>G44 -V^
M]&WWIU% #=OO1M]Z=10 W;[T;?>G44 -V^]&WWIU% #=OO1M]Z=10 W;[T;?
M>G44 -V^]&WWIU% #=OO1M]Z=10 W;[T;?>G44 -V^]&WWIU% #=OO1M]Z=1
M0 W;[T;?>G44 -V^]&WWIU% #=OO1M]Z=10 W;[T;?>G44 -V^]&WWIU% #=
MOO1M]Z=10 W;[T;?>G44 -V^]&WWIU% #=OO2XI:* $Q2XHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
1** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>formdrs_008.jpg
<TEXT>
begin 644 formdrs_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" *D!9@# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXZ\0WT<O@K7M0?2WN+BOV7_:V_X(]^-_^"C7[=P^)G[=.O?"[QQ^P_\ !_\
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MQ7$-3)XXN$'34H8[+,1ERP]2;KX?$YRX8C$TH9BJF,,+XL?M4?\ !1/]O?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3_@FY^T#^R-_P2Y_X+\?M<?M?:CX"MOVH/\ @H#\,_C-\5O&OPY^%^JWFO\
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MRLSZ2=%7:B\/^U-_P1+_ &7_ -J+]I$?M51?&#]L+]FKXM:_X,T3X<?&*_\
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MOC+QM?:!93W-O#?>(8/#[Z'8S3PQ7>H0O(BM^2O_  5T_P"#A+X/_L3? _\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTK_U)?\ Y<?_ -X:/^&E?^I+_P#+C_\ O#1_JSG?_0%_Y<87_P"7!_;F5_\
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M\J)]I3_Y^4__  9#_P"3/]!JBO\ /C/_  <0_P#!SB.O_!'SP^/K_P $_?\
M@H&/_>V4T_\ !Q'_ ,'-PZ_\$?\ PZ/K_P $_O\ @H$/_>VT_J^(_P"@>O\
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MDSV]!M)5Z#;=DE6HMMV;LDJS;=DW9)NR;M9-K_0GHK_/I/\ P<,?\'/(Z_\
M!'711]?^"?'_  4&'_O:Z:?^#AO_ (.=AU_X(\:&/K_P3Y_X*"C_ -[76?L:
MW_/FM_X*J_\ RHKVE/\ Y^0_\#A_\F?Z#%%?Y\I_X.'?^#G0=?\ @CUH(^O_
M  3[_P""@G_S[*:?^#B#_@YQ'7_@CYX?'U_X)^?\% __ )]E/V%?_GQ7_P#!
M%;_Y2'M*?_/RG_X,I_\ R9_H.45_GQ?\1$?_  <WCK_P1^\/#_O']_P4"_\
MGVTT_P#!Q+_P<V#K_P $@/#@^O\ P3__ ."@(_\ >VT_J^(_Z!\1_P""*_\
M\I%[6E_S]I?^#*?_ ,L/]!^BO\]X_P#!Q1_P<U#K_P $@O#0^O[ /_!0 ?\
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M/H__ "X_T+J*_P ]'_B(Z_X.6?\ I$EX-_\ $"_V^?\ Y^-'_$1S_P '+/\
MTB1\&_\ B!?[?/\ \_&CZEC?^@/&?^$F+_\ F4/K&'_Y_P!#_P 'T?\ Y<?Z
M%U%?YZ7_ !$<_P#!RT>G_!)'P=_X@5^WS_\ /QH_XB./^#EL]/\ @DAX._\
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M_P""?/\ P4%'_O:ZR]C6_P"?-;_P55_^5%^TI_\ /R'_ ('#_P"3/]!BBO\
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M_P"#ES_I$?X/_P#$"?V^O_GXT?4\9_T"8O\ \),5_P#,P>WH?\_Z'_@ZC_\
M+3_0LHK_ #TO^(CC_@Y;'7_@DAX.'_=A7[?7_P _&C_B(Y_X.6O^D2/@[_Q
MK]OG_P"?C3^IXS_H#QG_ (28K_YE#V]#_G_0_P#!U'_Y<?Z%M%?YZ/\ Q$=?
M\'+/_2)+P;_X@7^WS_\ /QH_XB.O^#EG_I$EX-_\0+_;Y_\ GXT?4L;_ - >
M,_\ "3%__,HOK&'_ .@BA_X/H?\ RX_T+J*_ST?^(CK_ (.6?^D27@W_ ,0+
M_;Y_^?C1_P 1'/\ P<L_](D?!O\ X@7^WS_\_&CZEC?^@/&?^$F+_P#F4?UC
M#_\ /^A_X/H__+C_ $+J*_STO^(CC_@Y:_Z1(^#O_$"OV^?_ )^-+_Q$;_\
M!RW_ -(D/!__ (@5^WU_\_&CZEC/^@/&?^$F*_\ F4/K&'_Y_P!#_P 'T?\
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M?W^45_ '_P /]/\ @Z:_Z0K_ /G.3_@HI_\ /DH_X?Z?\'37_2%?_P YR?\
M!13_ .?)0!_?Y17\ ?\ P_T_X.FO^D*__G.3_@HI_P#/DH_X?Z?\'37_ $A7
M_P#.<G_!13_Y\E ']_E%?P!_\/\ 3_@Z:_Z0K_\ G.3_ (**?_/DH_X?Z?\
M!TU_TA7_ /.<G_!13_Y\E ']_E%?P!_\/]/^#IK_ *0K_P#G.3_@HI_\^2C_
M (?Z?\'37_2%?_SG)_P44_\ GR4 ?W^45_ '_P /]/\ @Z:_Z0K_ /G.3_@H
MI_\ /DH_X?Z?\'37_2%?_P YR?\ !13_ .?)0!_?Y17\ ?\ P_T_X.FO^D*_
M_G.3_@HI_P#/DH_X?Z?\'37_ $A7_P#.<G_!13_Y\E ']_E%?P!_\/\ 3_@Z
M:_Z0K_\ G.3_ (**?_/DH_X?Z?\ !TU_TA7_ /.<G_!13_Y\E ']_E%?P!_\
M/]/^#IK_ *0K_P#G.3_@HI_\^2C_ (?Z?\'37_2%?_SG)_P44_\ GR4 ?W^4
M5_ '_P /]/\ @Z:_Z0K_ /G.3_@HI_\ /DH_X?Z?\'37_2%?_P YR?\ !13_
M .?)0!_?Y17\ ?\ P_T_X.FO^D*__G.3_@HI_P#/DH_X?Z?\'37_ $A7_P#.
M<G_!13_Y\E ']_E%?P!_\/\ 3_@Z:_Z0K_\ G.3_ (**?_/DH_X?Z?\ !TU_
MTA7_ /.<G_!13_Y\E ']_E%?P!_\/]/^#IK_ *0K_P#G.3_@HI_\^2C_ (?Z
M?\'37_2%?_SG)_P44_\ GR4 ?W^45\ ?\$N/C[^U/^U!^PG\#/CI^VM\%?\
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M*U[_ .G;1*^S:_+>+?\ D<U/^P7"?^FZI]YP]_R+8?\ 7_$?^EP"BBBOF3W
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M_3^HJ;L/J?Y+4*=3]/ZBINP^I_DM8O=E+=>LOT-S]G'_ )"7[0W_ &6W3_\
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M/9^OZ&-3=>GZF?)V_'^E49>_^\?ZU>D[?C_2J,O?_>/]:ZJ>T?7]3">Z]/\
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M'"'!=/-\MHX6OB7G$,)[/&0J3H^SKNHYNU*K1FIKV4>5\]M[Q=U;^CG_ (?
M?L'?]%4UG_PW7Q _^9NC_A\!^P=_T536?_#=?$#_ .9NOXI?M!]1^8_PKZ;_
M &?/V0/VD?VJ+;Q/>? ;X</X[M?!L^EVOB2?_A+/ WAB/3KC6H[V7380WC+Q
M+X>^VO<1Z=>.1I_VKR%B4W/D^=#YG[5COHY^&V5X2MC\SXCSW+\#AU!U\9CL
MRRC"X6BJE2%*FZM>O@(4J?/5J0IPYI+FJ3C!7E)(_*L+XW\<8[$4<'@LDRC%
MXO$2<*&&PV#S"OB*TXPG5E&E1I8R52I*-.E4J-0BVH4YS=HPDU_5_P#\/@/V
M#O\ HJFL_P#ANOB!_P#,W1_P^ _8._Z*IK/_ (;KX@?_ #-U_*]\<?V%OVM_
MV;_#2>,OC)\&-<\*^$VN(+2;Q'9:UX1\8:-87%W(T-K'J^H>"-?\26VB_:IP
M+>V?5Y+*.>XD@MXF>:X@23Y&^T'U'YC_  K++?H]>%^<X=XS)^*<XS7"*I.B
M\3EN;Y+CJ"JP47.E*KAL'5A&I!2BY4Y.$U&49<KC*,GOC_&;Q RJM'#YGPYE
MV75YTXU84<=EV:82K.E)RC&I"%?%4W.FY1E%3ASQYHN+<9)Q/[6O^'P'[!W_
M $536?\ PW7Q _\ F;H_X? ?L'?]%4UG_P -U\0/_F;K^*7[0?4?F/\ "C[0
M?4?F/\*]#_B63@3_ *&W$_\ X59=_P#.XX?^(\\7?]"S(?\ P1C?_FX_M:_X
M? ?L'?\ 15-9_P##=?$#_P"9NC_A\!^P=_T536?_  W7Q _^9NOY5_@#^R!\
M3OVC?AM\<?BGX*\0_#K1?#?P!\._\)-XTA\9^(M0T74KVP_LC7=:\O04M- U
M73Y)OLGAZ^0RZYJ.@Z>+A[>+[=AIG@^3!<[@&# @@$$$8((R"..XKS\-]'CP
MRQF.S++,+Q'G]?,,G>#CFF#IXW+W7P#S##O%X%8B#RJ*A]:PT95J+C.JI0BV
MW"2<#LJ^-/'E# X+,JV19/3R_,:F,I8'%RPV,5#%5<OJTZ..A1DLQ;E+"U:M
M.G64J=/EE./*ZB?,O[6_^'P'[!W_ $536?\ PW7Q _\ F;H_X? ?L'?]%4UG
M_P -U\0/_F;K^4SXI?LF?$CX2?L^?!?]I+Q)KW@6\\#?'6[FLO"&DZ+JFNW'
MBRQG@LM2OW'B"PO_  SIND6J^1I5U@Z9KNKG?Y88*&9E^6/M!]1^8_PIY=]'
MCPRS:GB:N6<1\08ZG@\?C<JQ<\/C<OFL/F.758T,=@JO-E5-QQ&%K3A3K0Y9
M)2E%QJ5(M3:QGC5QW@'A5C<CR;#/&X'"9GA%5PV,C]8R_'0J5,'BZ5LQGS4,
M1"C5E2D^235.7-3@U9_VM?\ #X#]@[_HJFL_^&Z^('_S-T?\/@/V#O\ HJFL
M_P#ANOB!_P#,W7\4OV@^H_,?X4?:#ZC\Q_A7?_Q+)P)_T-N)_P#PJR[_ .=Q
MR?\ $>>+O^A9D/\ X(QO_P W']K7_#X#]@[_ **IK/\ X;KX@?\ S-T?\/@/
MV#O^BJ:S_P"&Z^('_P S=?Q2_:#ZC\Q_A1]H/J/S'^%'_$LG G_0VXG_ /"K
M+O\ YW!_Q'GB[_H69#_X(QO_ ,W']K7_  ^ _8._Z*IK/_ANOB!_\S='_#X#
M]@[_ **IK/\ X;KX@?\ S-U_(3^S]\%O%W[2'Q?\&?!7P+J'AS3/%7CF[U"T
MTF^\6:A=Z;X?MWTS1M1URY?4+S3M,UB_C0V6F7*PI::9>SS7+0P1PDR9&1\9
M_AAXA^!GQ5\=_"#Q7J7AW5?$OP]U^Y\.:W?^%=3DU;0)]0M8XI)3IU]<66GW
M4D:"94EBO+"QO;6X66UO;.VNH9H4\]_1X\,HYK#(WQ'Q LWJ9?/-H9<\;E_U
MJ>6T\5'!3QL8?V5RNA#%RCAY2]KS*I)+V7*^<[(^-''D\OJYM'(LGEEM#&4<
MOK8U8;&?5Z>.Q-"KB:&%G+^T5)5JN'H5JL$J;BX4YWJ1:47_ &&_\/@/V#O^
MBJ:S_P"&Z^('_P S='_#X#]@[_HJFL_^&Z^('_S-U_*7\*OV3OB/\7O@)\<O
MVBO#FO>!=.\#_L_V8OO&FG:_J>NVOB:_@_LZ34R?#=EI_AC5-*O&6WC=2NIZ
MUH^91L4LIWU;\8_L@_$WP/\ LM?#S]KC6?$/PZ?X<?$WQ&WACP[H5GXBU!_'
M::@MQXDMB][H]SH%KI#0AO"^I221:9X@U/4+>!H)[FQAB%TUKP5? [P@H8VK
MEU;C#.*6.H9MEN15L)/,, JU/.,XP=7,,JRZ<?[&:6*S#!4*V)PL>=TZE.E/
M]_":]F^RAXL^).)P]'%X?AC+*V&Q&7YMFM"M#"8ITZN79%7IX;.<9!O-(MT,
MMKUJ5+%2<8SA*<>2E6BW-?U4_P##X#]@[_HJFL_^&Z^('_S-T?\ #X#]@[_H
MJFL_^&Z^('_S-U_%+]H/J/S'^%'V@^H_,?X5[_\ Q+)P)_T-N)__  JR[_YW
M'C_\1YXN_P"A9D/_ ((QO_S<?VM?\/@/V#O^BJ:S_P"&Z^('_P S='_#X#]@
M[_HJFL_^&Z^('_S-U_%+]H/J/S'^%'V@^H_,?X4?\2R<"?\ 0VXG_P#"K+O_
M )W!_P 1YXN_Z%F0_P#@C&__ #<?VM?\/@/V#O\ HJFL_P#ANOB!_P#,W1_P
M^ _8._Z*IK/_ (;KX@?_ #-U_%+]H/J/S'^%'V@^H_,?X4?\2R<"?]#;B?\
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M9.!/^AMQ/_X59=_\[CRO^(\\7?\ 0LR'_P $8W_YN/[6O^'P'[!W_15-9_\
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MY_X;X_9D_P"AVU#_ ,)7Q/\ A_S"O_U>](/V^/V9  /^$VU#@8_Y%7Q/Z?\
M8*K\:-"_93^(FO\ [*/CK]L.VU_P+:_##X?>-+#P+K6CWVIZ[%XWN=8U&_\
M"FFVTVF:;#X9N-!GL&NO&.E*TMSXEL[D+'>D6C&*%;CYNTBPU;7]4T[0]"TV
M_P!:UO6+ZUTS2='TFSGU'5-4U*]F2VLM/T[3[.*:[O;V[N)(X+6UMH99YYI$
MBBC=V53P83PTX*Q];-,-@\_Q^)KY+C/J&;4J=?!\^78WZI0Q_P!7Q:GA*2I5
M/J6)H8J_-.G[&HI^VM&HJ75B/$7BW"X?+\9B<EP%'"YM0JXG+:]2CB52QU"A
MBZF!K5</)8R3G&EC*-3#3O&G)58./(U*$ZG]%/\ PWQ^S)_T.VH?^$IXF_\
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M[?O[,6 /^$WU#@?]"IXH_P#E2:_F\^T'U'YC_"C[0?4?F/\ "O3?@[PX[_\
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M\SQ52IBL7B,9**A5Q.)K8J2@VE"I6K5*\N1M\R2G4ERW;:2BFVU=_M9^Q/\
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MXS^)/#OB.PE\,^ ]<^ ^LZC=^$M#T7XC:5JWBOQ)'?WFL>%+W3K"XN(7\?\
M&?[,7[2EU_P;_P#_  46^#-K^SU\<;GXP>-_V\/C_P",/!?PI@^$WCV;XD^+
M_"6L_MO>&O%FC^*/"_@6/0&\4:_X=U7PM!/XETW6])TN[TR^\/PRZS:W4NG1
MO<K^@'_!0B[^./[-G_!0[_@G-^W'X8_9%_::_:N^$?P]_9^_:"_9[^(OAO\
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M]IUSQ7\(O /Q"4Z-X.U9=5U?22S:C;:5J>H)#/>3?;G[-'_!7_XF_!_X7?L
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M/BKKWAG7LZOK_B35-?T_[7HVG068&E:K9"VQ]HLQ;W;-.WTQX8_86_93UO\
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M^R[++_P4&^!OQWUCQO:_LO?MD?%GXN>+O"7Q;\(>$/$FH:EX/3Q1XFU]]/\
M%&I^!Y=''C=;'4M'_P"$<U>TBB\,7VK:?J.C0Z?JGAQ[?4;J;3>2&,\4Z&0N
M6 Q_%V*S'._"C(\]S6>,>)K8K!Y_'CFC@L\I9-#%8>%'+<ZI<(+%*CE^'C0J
MU%"&+>'GC7#$U?5J8;P]KYSB:>.P7#>&RS)O%!95ED<'&A2I8S(<1P?CL31J
M9E5PM:>)S')Y\4K 5,7BW*K3PRJU<+2J4,&OJU/=\.?!_P#9._;1_8>_:!_:
M-^!W[/GBO]D/XL?LT17GB'Q)X!O?BYXF^,?AKQ5X1LM(N?$2W1USQ4L=]'<:
MCH5AK(@2STW1'TG6M(%M<C5M/N1>-]!>)/@O_P $O/V9/V1?V1/VDOVEOA5\
M4/%NM_&3P%X;TMO!'PSU_P <ZEJ/Q%\<>)M TGQ!J?BJ[@E^('A73M MO"6G
MVVH7AMM,\3^%M+FM=2N(5T;Q!J,>EVD'QAKG[8G['7[,?[&'QV_99_8Y^+GC
MO]J+XN_M26\_A[QE\4=0^"_C;X,> O /@RYLKC0=1BETCXBVEGK5QJT/AK4-
M8M],ATLZY!>ZKK!U"ZO]'@L8M.DYW]N/]K7X!?&']CS_ ()Z? 7X<>-+OQ'\
M4_@;H=K'\4/#S>#/'&D6WA9[3X;6_AQE/B77?#FF>%M::358Y8(_^$<UO5\H
MAF<I$R._37K<9YGC*.69-FG'U#@[&>)7#N5X'.*]3.<-GT,CQO"./I\5598K
M&TO[4H913SJEA7@,5F4/9X3&UJU3!2@U0<.:C0X9P>$>-SC <&3XIP_!/&./
MQ6782&55LGEC,+GV6U.$(2H82H\#4S:>!GCO:X?"2^L8G T*5+&*?/6C4^S?
M"G[*7P#\&_L6?!3]I3P]^Q)\5/V[M0^+^LW^I?$.T\ _&/Q%X*USX%>#Y+W5
M(F71O"7A"[OKOQCK/A<00Z/J.C:C!=EM<L-1N]<\2>'],"6Y_"_Q3JOA[4/%
M_C*Y\'>'O%'A;P:_B_Q,O@W0/&DED_B_2_"::S>+X=L_$_\ 9UW?V*Z];Z4+
M6'54M;V[A6]2<1W,Z@2O^J_[%O[1W[$?[*NJ?"WXK2?\% OVB/A!JFGZ8NI?
M'']E5O@I\4?'7@_XH^*(]*2"\M]'UKP?HE[\,K73KZZAMX]#U?6=/O\ QCI^
MGQFR?Q#H+S372?F?^T)\=M*_:1^/_P :OCIX?\)ZAX'\+_$OXBZUXB\+^&=8
M2UBUBRT-TM;.UO-7@LR;6VU779+2;7]3M8);I+6_U2YMQ?7PB^V3_>\"XO/L
M)XA<1Y5C<?Q1GV6SPV98FAFN;1SC!X/+'A\SP&$P>35\!C\/')\5BI4*%?$9
M?G'#U:V*P57$SS.DYXNC]6^5XKHY/C.!\IS/#9?P[DN8_7<OC5P&6?V77KYC
M]>P^=8[%YAAJ^'KO.<!A\+/$8;!X[*LWI3P]"I2P%++JD?JDYXK[V_9QB^ >
MJ^'/AIH^E?\ !+[]K+]LS5=2OK&T^-OQ>T;QE\1O#/@?X?27FN26L[> -*^$
M6DZI'XIAT_12;V;3?%VH^&;^:]LVM5U*.&X-S#]>:O\ L!_L[>!_^"MGPT_9
M9N]$UCQ1\$OB#\+M0^*'_"':QXF\0VM]8+)X<^(\,6CMXCT.]T/Q$UG8^(/!
M2:G9R?VI]N:WF2QU&YNT28W'*:M^WM^R-XT_9G_9%^'EU^V]^TS^PWJO[/FB
MV5G\2OA/\!OAM\4[C6?CE-I.D:982QZ;\2/AO FBZ5'JFJV>HZO8R>*/$,]E
M=3Z_?GQ-X4>\BLM1M]3Q?_P4>_8^\8_\%=?@G^U5H?Q0U>7X%> ?V;W\'>-/
M&-_\,OBM87F@>*+FS^,4BZ//X8N_!,7BK6+B,^*="CGO/#>B:UIAEO28KZ2.
MVNI(/@\;GW'E3B_.J."P_%V P]:CXJ8#$86KBN(LQI<N&X<QM?A/&X6K4PM/
M(L#/$YAA88GA^'#\OKE"%:&#QV(KXAT83^EP>3<)QX0P53%UN',5B(8/P^Q^
M&K4\/DF"Q$,;/BW*Z/$6!KM8BIG>/J4<IQF(HY[/-(PR[$4Z;KX'#PA0Q%:G
MU/P*^ __  3N_:!_:N_:4_8,\*?L[_%S1?$GPCTGQ\=/_:;USXL:\\T_C3PE
MXHL/#_B'PYHOP^MKH>'+?0?#5[J]K'X:U778?$>H>(=-L;U==BM+X6]_>?+_
M .R+^S/\ ]$_9K_:M_;,_:L\,:_\3/ _[.FLZQ\/]$^$_ASQ+JG@\>,?'FDR
MZ;83V]UKVD7FFZW;&]U[7_#>A:,;>]MK>VFO=0O-0M=3%O!9B/\ 8;_;?_9G
M^$__  4=_:H_:B^(/Q OO#OP,^(WB/\ :#OO!WC)_ 7Q&U.ZU:T\9_$K1==\
M,SMX/T7PEJ7CBQ75-+LI[E4U#PW:S6>U8M0BLYFV5G_LF_MJ_LIS_L^_MC?L
MI_M1>)_%?P]^#?[0OQ'\9_$[P'\7]&\!^+/&KZ!J>K:]::AI+ZQX+\/Z)JGB
MZ&2*Y\.^$O$&DPIHDD<TL>K:?K$^A.+:ZEY)8KQ-PF38S#X/'\9UY9IX;>&W
M$&98JO/&XG,<'FV)XDPE'C:GD=7%4D\%FM/AZK7C/*\&X5:7U6%6&%ABO:UJ
M_JU<-X>U\]H2Q.#X7I8/+/$SBC)\%2PT<+2PV+R2/"N)Q.0SS-8:?^VY54XE
M6&<L?B%4I1]K4P\:ZPJ6'I?6OB_QA\"?'G_!#7X]^-/@%\./&'P;T+Q!\9_A
MW=^,/A+XP\3W/C=_A[X\C^)GP7M-5T+P[XTOK6UO_%/A6;2H-$U?2-7U%3J4
MG]IW$-_%874$NEV/Y3?L._&[P7^S[^U9\&?B]\0[&ZO?!?A#Q+<R:^;2U.H7
M6FV>L:'JN@#7X+%%DFO)/#DVJQ:\+6UCDOI_[.,=C')>- C?77Q(_:[_ ."?
M_AC_ ()D_&/]C7X ?%GXA^.O'^L_$WX?ZQI?B3Q?\'OB3X-L_C+K5OXZ^''B
M'Q-XN\*6=SHFHZ7X$\*:5H/A]M+L=(\<ZUH&O2SZ%<N;74);ZTO]4_-/X)1_
M!&_^)&B6?[0^O^.?"WPGN+?64\1>(?AQIMEK'BK2+K^Q;\Z!>VVE7MEJ2ZA8
MQZ^--_M>SMK*6_GTLW<=BT-TT4\?WWASA*<J/C$\3A^)JN2YUGGM,)5S3#9A
M'/LVR:MP)@\OJU\.L9&CC\3B:D88FA@W4DL9ST\%1Q,HXM58OXCCJM-8/PNH
M0JY!2S;+,'F<<90RFM@)Y5EF83XSHXW#1KK!RK8*A249X7$XMTXRPK2S"K1C
M.E":7[>_M<_\$Z-9_:9\5?&_]OG]A;]K34OC$GQ1T[4)?&/A;P?\1=6T;QAI
MGADZ&FG:[\.?#^M>']5B%[I$>GV/V8_"KQCI_AR\M;..YT:1-5OEM]/F_.K]
MF63X-VOPYAL;'_@G=^TW^WY\88]6NX=<T_P5XU\9>!_ACX.\'PQ6*:3>Q:U\
M*]$\3>+KGQ--*TPOK+7M)BTMXYHY+6^C91&?I;]G#]K3_@G1_P $X)_C/\5_
M@1^T?\2OVO\ XQ^/?!$W@7P;\,-$_9R^*7P4T:"5]6@U/3;SQWK_ ,0[*TT?
M48K"]@MO,URPG2]T[2_^$@&F>';^ZU6WMXY/@/\ MM_LZ1?\$ZO /[+GCK]K
MSXS_ + ?Q@\,?$"\\8>,OB5\'/AG\3?&.I?%.RU#7]=\07^CZ7XC^%,,WB'P
M^U_::KI>DW-WJ.N^&;BSN/#VGVP&M^'6N;"3X+ 8W/.'\CSO),AR_/LVX;RJ
MKP9@<IXDI93G'!^>8?!5\;FLLQRW-99;@5GV=Y7P]AY8:>(K9;A*>-K3Q\L-
M1Q-2,*U2?V.,P^4YYFN3YOGN,R?*^(,?7XJQ&8Y++,LOXHR3&3P^2X*& S7"
M8?%8V.591F6<XVBL%@J./Q7U2,</3Q>)H4(4Z=$]2_:A_8B_9]^&_P"U-_P3
MYL/"?@;QEX,^&O[6^L^&W\9_!7QKK?B9==\(>7K_ ( 'B#PO/J-_<P^,=(N3
MIOCE-&U6VN];DUG2]4TV[>VO;=Y$$&_^UE\ _P#@G5X2^.-W^P9\#?AU\3_^
M&MOB'XZ^%<&B^.I-0\7:Q\+_ ()Z1XZ\3>$+B]\.ZC<ZW\0+)]:FA^&MSK/B
MFU^T^'O&D\LURUK=>*M*O9-.TZQ\^_:7_P""@O[(OQ:^/W_!+;Q)\-?C!\1/
M''AK]F75&NOC%XJ^)O@;XF6_C[2M(M-<^#RP>)/&-_K'A6!?&WB;6[+PCK>L
MZS-X/N?$UY=WL<\DD8NKRV@G^3OVC/VUOAYXB_X*?^)_VQ_V?]7N/'W@/P_X
MZ^#/B'0-1N]!\5>"?^$H3P-X$\':1XETD:=XPT30?$5C!<W&FZMHANKS1XHW
M5FNK>.ZM'B>;LX<J>(>>XS@K"8S-.+\!1PV'\4JU2LZN:8&&,K</\2X;&<#8
M//*^.H.K6P^,P];"T&\ROC\RR:G6PV)KUH/,9G)G=+@W)\#Q?CL-@.&<=C99
M7X8_5\/*GE6+5+&9O@<SRKC.OE>%P-2&%CC,-1IUL;.CEW)@,)F\L%CJ5&G!
M9>CVK]K[7?\ @G!^RM\8?'G[']M^R3\;OB;XC^&_@:SM/%W[2_A_XSZA:^+=
M,^)>N^$K;Q)X>MK#X7:K>:7\/-?TY%U/1W\07P?1([%;B]M]-\/ZJ]K%+<I%
M\'_V9_V0?V%_@O\ M7?M)_ WQ7^U%\5/VE]>MK+X:_!/2OBEKWPA\-^'?#\N
MGZCK7]J:QXJ\.6[ZXMU!H>FG4;ZZ:RUBSDN]6T71;;2[5$O==ES/VO?BC_P2
MA^/'Q>^(G[5MW^TO\</#?C+XA^%-*U3Q'^S'X?\ V=?'%SXYU'XD:#X5MO#6
MEPZ=\5M1TRZ^$^E6MY;Z5H2:K;'4=;TXR0WUW9^)(!>1VUC/9?M;?L9_M1?L
M0_ K]G+]KSXK^.OV7_B7^SE?Q7/@/XG6/PA\;_&CPAXCT"6PU#1(-%NM ^'E
MI>:W!?0^';VWTZ]M]2.B06]WH>FZM8ZUJ$=Y?:'"\'CN*WPGDL:N;>(JS;_6
M'AO_ (BFZ]+-_K679=/&<0K-'PS46'YO9^VAED<PCPU*I&.3O!2I055UVS&8
M3AO_ %GQ;HY;P2\D_L7/O^(?JG/ ^QQN:1R;()9:N)(.LJ]G4GFLL-+/HPIO
M.E7BY?551B>K_&_]D']FK5-!_8&_:=^"7ACQ1X*^#7[57Q9^'/PZ\;_!?Q1X
MFU;7+KPSJ7B'6)/[3TK3/%4FH7&O&-(=#\5Z!J%RVMW,SS6EAJFD7-F+B2*+
MZ&\:? C_ ()L?#W_ (**>%OV#6_9:^)GB_5/BSHUOKUUX^?XQ>-M)\(?!5M2
M\):E>>%]$\,Z5;:^VO>,AKEQX=O]1US4?%NN7<FB:CJEG%I]MJ>DB73M/^(/
MC7^W_P#LY>(]4_8)_9M_9QU+QQJW[,?[('Q@\"_$KQ_\:O&_@[6/#5UX\U;1
M-7<RW_AGPC=:=;^+O[,LK+7/%NNZC'?:#IFHW-[?V6F:?I%RMB+F\ZSXA_MS
M_LP^-/\ @L7X-_:O\-?$2\U#X >$=,\":?KWCV7P#\1]-:UN-!\'^*],U<P>
M%-5\(V/C?4([&^U*U@+6'AJY^TEFEL1<PKYAPHUO$#-:V3X:6-XYPV0U*7C)
M5RRO[?-L%FN*RG+*&&QW <,ZKP4,9'&U<;#$T\O6.E3S3%X.%#"U95H5*M*O
M5:GPCEV#S+$O!\(U^(*67^%T<SH0HY;B\KP^>8[-\5@^*I930O+"3A2RBKA*
MN91P<:F7T,5*IB/9ITN>A[_\'/V<_P#@GGXX_;(^+W_!.6W^"?QDUWQAX%\+
M>*YV_:K\0_$S4]-N+;Q_IBZ=JEQX1T#X=: -.\)RZ5X?T#5X)K'Q-KUKJ;ZO
MJ6G7MC>Z&L$]IJ4GYL_ _3OA#X1\2?%SP?XH_8]_:#_;K^,'A+QUJW@[P?\
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MM^G_ ,51]H'M^G_Q5'M?/\%_D'LO[J-O[1[-^='VCV;\ZQ/M ]OT_P#BJ/M
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M[.W[2^A:OXH_9Q^/GP6_: \,Z!JJZ%KOB+X)?%/P-\5M"T36VM(;]=&U?5_
MFNZ]I^FZJUC<V]ZNGWEQ#=FTGAN!#Y,J.RA^\]K[/]Y[#^-[/]Y['6"_?>SY
M_8ZU::_?>RUJ4UO4IJI4TZ:INHG35;^"YIP5;6:_=.:@JNM.HOW3JZTZBWIU
M%#VFBBB@04444 %%%% !7RW^TK_S)?\ W,?_ +@:^I*^6_VE?^9+_P"YC_\
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M=DB,[_!5?BAX(/Q;2 :4-=,S?#@:X?&*Q#1&76#(=&"?V41J&[[(1-7XP_\
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M3KG_ ,#-%_\ ES1_PPA^T5_T)US_ .!FB_\ RYH_XB#P3_T5W#?_ (>LO_\
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M_H3KG_P,T7_Y<T?\1!X)_P"BNX;_ /#UE_\ \T!_J;Q1_P!$WGG_ (:<;_\
M*#Y*^T^_Z_\ V5)]I!QD@XZ<]/I\U?6W_#"'[17_ $)US_X&:+_\N:/^&$/V
MBO\ H3KG_P #-%_^7-'_ !$'@G_HKN&__#UE_P#\T!_J;Q1_T3>>?^&G&_\
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M[3_Y/IA_9.^+HZZ-.,?]>O\ \G4UQMPF]N)<B^6:X+_Y<+_5/B+_ *$&;_\
MAMQ?_P I/GG[2!T('X__ &5+]I]_U_\ LJ^@C^RE\61UTB;CC_EV_I>U&?V5
MOBL.NDS#\(.W_;Y37&G"KVXCR3Y9I@__ )<+_53B'_H0YO\ ^&W%?_*CP W
M/4@XZ9YQ_P"/4OVKW_7_ .RKWL_LM_%,==+F_P"^8?\ Y,IC?LO_ !07KIDP
M_P" 1'^5W37&?"W3B+)=>V9X3_Y<'^JO$'7(LV_\-V*_^5'@QN0>I!QTR?\
M[*E^T^_Z_P#V5>Z?\,Q_$T?\PZ;_ +]Q_P#R53#^S/\ $H9SI\W'_3)._P#V
M\T_]<>&/^BAR;_PY83_Y:+_5;B#_ *$>:_\ ANQ7_P J/#OM(Z9X],__ &5'
MVGW_ %_^RKW _LT_$D9S83#'7]TO_P DTG_#-7Q(_P"?&7_OTG_R33_UPX9_
MZ*#)_P#PXX7;_P &A_JOG_\ T(\U_P##=BO_ )4>'_:0.A QTYZ?^/4OVKW_
M %_^RKV__AFOXC_\^,O_ 'Z7M_V\_P#Z^U'_  S7\1_^?&7_ +]+]?\ GY_S
MTZT_];^&O^A_D_\ X<<+_P#+1?ZL9]_T),U_\-^)_P#E1X?]H&<\9]>,_GNI
M?M(/4Y_'_P"RKV__ (9J^(__ #XR_P#?I?\ Y)H_X9J^)'_/C+_WZ3_Y)H_U
MOX:_Z'^3_P#AQPO_ ,M#_5C/O^A)FO\ X;\3_P#*CQ#[3[_K_P#94?:??]?_
M +*O</\ AFGXD_\ /A-_WZ7_ .2:4?LS_$H]-/FZ9_U2],X_Y^:7^N'#/_10
M9/\ ^''"_P#RT/\ 5?/_ /H1YK_X;\3_ /*CPW[2#R2,CH?3_P >I?M/O^O_
M -E7N8_9E^)9Z:?-_P!^T_\ DJI;#]E[XH:IJ5YI%AIDT^HV&EZ5K-W;A(HS
M#INMWVNZ=I=UYLMW'"XNKWPSKD BCD>>(V+//%%%/:O.I<9<+Q4I2XAR6,8K
MFDY9EA$DDXIN3=6R5Y15WUDEU0UPOG[:BLCS5MNR2R[%-MM-V2]E=MJ,G9:V
M3?1G@_VGW_7_ .RH^T^_Z_\ V5?2)_8^^- ZZ!/Q_P!-+$_RU&F']D+XRCKH
M,_\ WW9?_+"LO]>>$?\ HI\A_P##M@O_ )>7_JEQ)_T3^<?^&S%__*3YQ^TC
MIGCTS_\ 94GVD8QD8],\?ENKZ,/[(OQC'70K@?4VG_R?33^R3\8!UT2;_OJT
M_P#D^G_KOPE_T4V1?^'7!?\ RX/]4^(_^A!G'_ALQ?\ \I/G;[2/7IP.>@]/
MO4GV@9SD9]>_Y[J^AS^R9\7AUT6?_P E?_DZF']E#XMCKH\P[?\ +M_\G4_]
M=N$WMQ+D;_[JF#_^7"_U4XB_Z$.;_P#AMQ?_ ,I/GS[5[_K_ /94?:O?]?\
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MS5\1_P#GQE_[]+_\DTU_V;?B*@R]G(HZ9,: <D <_:?4BC_7#AK_ **#)_\
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MY5$OM?+\BEL_\/ZLGCZC\/\ T)JYFY_Y*Q^SE_V5CQ+_ .L]_'2NFCZC\/\
MT)JYFY_Y*Q^SE_V5CQ+_ .L]_'2H7P8G_L!S+_U69@14VI_]A67_ /JPP!]L
M3]OP_K65+T_!OY"M6?M^']:RI>GX-_(5^=4]W\OU/L'L9TO?_=/]:SY>_P#N
MG^M:$O?_ '3_ %K/E[_[I_K7?3V^[_TDP?7Y_J9LO\7X?TK/E_B_#^E:$O\
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M=8.M5^>/_!,'X=_M ?LR_P#!?7Q?\$OC-\-_^"9OP/\ $/C/_@F[J_B/Q?\
M"[_@EIX4\=?#_P""NWP_\:_#Q\(:W\2/ _C:VTFZTSXM+'?ZS&;Z#2(8+SPA
M>:1(DDLLT\I_H9T[_@DG_P $X=)_9+UG]AG3_P!DKX8VW[+?B+48M=UOX9*/
M$3RZEXI@T^RTNW\<7/CN77G^)+?$.WL--L;:W^(:^,5\;P);1M%KZ29<V_V5
M_P#@E+_P3W_8D\5>'/'/[+'[,O@_X/>,/"W@/Q1\--,\2:%KGCK4]8N_"/C/
M6O#FO^);;Q)>^)?%>MS>,M:U+4?"/AS_ (J[Q>VN>+[/3]*@T:PUVUT9Y["7
M3!RI8;'8[$5*E?$QK87-\)"K4BN;$4,QX*APY@Z%3#.LHX599CZ7.L55Q6;X
MC%Y5_9^&A1RZ>4QA4YL5^_P,,-&A1IMTZ#<%))4,7A^*\+GLL:JZHR==XK!T
MIP6%H87*Z>%S&6*Q57%YB\QJ2C\R?\$"_P#E'M'_ -G7_MR_^M<?&"E_X+X?
M\F VG_9W7["__K6OPCK]._@%^SQ\'OV7_AZ/A5\"_"'_  @_@(>+/'/C@:#_
M ,)!XH\3?\51\2?%VL>._&NJ?VIXPUOQ!K/_ !.O%>OZMJOV+^T?[.T[[7]A
MTFTL--@MK.$^/G[/'P>_:?\ A^GPN^.?A#_A./ B>+_ OCQ="_X2#Q1X:QXK
M^&OBW2/'7@G5?[3\'ZWX?U@_V+XJT'2M4^PG4#INH_9?L.K6=_IT]S9S.5:+
MQV38E*7L\NQG V(KJRYY0X9GX>RQZI*]I2JKA/,?JBDX*;K8/VKH^TK>PJNO
M:QSY1T>:1XXCA[_8?$L./8X'VUK\OLGQ3E_UKDY^14<7[+VWLZ/MOQU_X..]
M=^*6F_\ !/;P[X=^'5U\-K'0?B5^U9^S-\,OC!>?&?6_&?AWX+'X6>,/B#;6
M.H:5\:=7^'LMGXSLO@[XC\4KX4\-_%!_#VIZ7J,O@O5M8M8;IOM#6\_P]^R9
M_P $V_V\/@W^W[^Q?^T!X_\ !?\ P07_ &0?!?AF3XE>'];T;_@FWHGQV^#?
MQ2_:8\ >*_ACK4]UX#NO"OC+PO:>#/B_8Z1?Z;H7Q"AN)[BWUK0(_#LOBB+5
MKJWT]K&Y_J;^)?PR^'GQE\ ^*_A9\6/!7AGXB_#?QSHUWX>\8>"/&.CV6O\
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M_MG]F/PEX?\ AIX6\/?#/_A-OB+IW]GZ%\']1\/:M\.;'_A,])\76/Q!N_\
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M?_T#;'_P7:=_C1_PRYX/_P"@;8_^"[3O\:^MJ*^9/</DG_AESP?_ - VQ_\
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M'_\ 0-L?_!=IW^-'_#+G@_\ Z!MC_P""[3O\:^MJ* /DG_AESP?_ - VQ_\
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M .N/IINC?1?YFH&ZC_/\2UTQP]%_86W9&;J3_F?WOND?-'_#/OA?_GQL^_\
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M@66,?\^%ASU__55*7]F[PIS_ ,2^RZ9Q]@L.V?3'IUKZQE[_ .Z?ZUGR]_\
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M_H35S-S_ ,E8_9R_[*QXE_\ 6>_CI731]1^'_H35S-S_ ,E8_9R_[*QXE_\
M6>_CI4+X,3_V YE_ZK,P(J;4_P#L*R__ -6& /MB?M^']:RI>GX-_(5JS]OP
M_K65+T_!OY"OSJGN_E^I]@]C.E[_ .Z?ZUGR]_\ =/\ 6M"7O_NG^M9\O?\
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M*_!C]."BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\*R_R#>.O^"@'PQ_9[_:G_9;U+]A#_@KK^V+^VOXG\=_M+^&_AO^TO\ !_\
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M?_":_P#(,^$__(M_]$B_Y)A_R3S_ *B?_)6/^JGT?\(5XD_Z*[\0_P#DH?\
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M -0S_DD__5,*/^$*\2?]%=^(?_)//^$*_P"09\)_^1D_Z*[_ ,DP_P"2A_\
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MM,^$\_\ PKC^Q/*_M/\ X0O_ (2'X8:]]N_X3#RW_P"$B_X6'_PGOV7SY?\
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M^U+'X=P_\)Q_:OF?8/\ A*/[%\ Z1]D_X1K>O]B?\(7_ ,(AY_DQ_P#"1_\
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MO_X2KR/-D_L#^P\1>7G:OX;UF]/B/[-X_P#%ND?VV='_ +,_LZR\"2_\(?\
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M=:^THZ7]G?3FO[O-.]M_92Y;\]*_7THZ_@W\C7'V/AK6K3^P_/\ B%XOU/\
MLG^T_M_VZR\ Q_\ "3_;]_V7^W/[-\#Z?]G_ +%W+_9G_"-?\(]YOEI_;/\
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MBZN(+2W:'58KEKNXNE*G2][_ &FF^E_8XG:T]=87UY8NV_[R-]85+"J5;/\
MV>:]R]O:X=Z^YII*UUS3UV_=2M\=*_=1]1^'_H35S-S_ ,E8_9R_[*QXE_\
M6>_CI5&/PMKF1_Q<CQH/^*C&N<6/P[_Y!FX_\4=SX"/_ !3G_3U_R-W_ %--
M89\/:O#\5/V?HY/'7BJ[:Y^.NN:O#-<6?@A9=/T^#X'?&2_E\+V8M/!UK"^A
M7EK9W.B7-Q?Q7WB9=,U;4);3Q%:ZS'I6KZ9G[.DJ>)MB8/\ V',=/8XE?\RW
M,-;N%M-^[M9:M$SJ5+4KX>:_VK :^UH/;,,#;12OJ[+RO=Z)GZ!3]OP_K65+
MT_!OY"N>OO"FO3:-XBTN/XF>-[2^US7)]6TSQ';V'PX;6?!UA-=6EQ'X9\.0
M77P_N?#UUH=K#:SV,%QXNT+Q3XD:UU&\>Y\07-\FGWECEZSX5UV_'BG[)\2O
M&NB?\) -%_LD:78?#J7_ (0;^R1%]O\ ^$6_MKP!JYN_^$FV-_;G_":GQA]G
M\Z3_ (1O_A'\1>5^=TJ5%MIXJFES15W0Q3T_=7E90O9>TJOE^)_5YV5ZN'Y_
MKY5*J5UAIMV;LJV&6MJMHW<[7?)35_A7MX7=J5?EZ27O_NG^M9\O?_=/]:YO
M6/"VN7__  E/V7XD>--$_M]=%_LG^S+'X=R_\(1_96S[?_PB_P#;/@+5_M?_
M  DNQO[;_P"$T_X2_P CSI/^$<_X1_$7E-N=!U5Y_%DR^-?$T4?B*PM[72+6
M.T\&F#P)/!IT]E+J/A1I?"4MS>7MY<RIJ]S'XXN/&6GKJ-O#%:6%KI+7&ES]
MU.G2Y4_K,+^Y>/LL1=7C1YE?DL^3VE2[6DOJ\^2_M</S8NI4O)>PG:\]?:T+
M.WMK.W-=<W)3M?5>WAS6]G7Y=27^+\/Z5GR_Q?A_2N=E\,:W\W_%Q?&1_P"*
M-'AC_CQ^'W_(;X_XN+QX$'_%9?\ 3C_R3[_J1*H2^&-;^;_BXGC$_P#%'#PQ
M_P >/P__ .0WQ_Q<3CP*/^*Q_P"G'_DG_P#U(M=D*=+_ *":?3_ESB?Y?\!S
M.I5_Z!Y]/^7N'[K^\=!-U/U'\JSI>_\ O'^M9EIH>J66H6-Y<^,O$FKV]IX<
MM-#N-)U&U\(1:?JFJ6\J2R^,KZ32?"FEZI'XDO8T:VNK73-2T[P@D,KM9>%+
M2X$=Q'AV7AK6;'_A'/M7Q!\7ZS_8;:S_ &I_:5EX"B_X3+^T_,^Q?\))_9'@
MC2OLO_"/;U_L?_A$/^$4\_RD_M_^W,R>9VPIT^5_[1!VNU^ZK^\[5'97CH[P
MIQO*RO7@_AIUG'#GJ:?N)J[L_P!Y0T5Z:N[2U5ISE9:VHR7Q5**EOR]_]X_U
MK-D[?C_2L.R\-ZS8_P#".?:OB!XNUC^PVUC^T_[2LO <7_"8_P!I^9]B_P"$
MC_LCP3I7V7_A'MZ_V/\ \(C_ ,(KY_E)_;_]N9D\S.L?#FL67_"-_:?'WBW6
M/[$_MC^T_P"T;/P)%_PF']I;_L?_  D7]D^"M+^R_P#"/[U_LC_A$O\ A%_.
M\I/[>_MO,GF=D:=)/3$0E92M:EB%S652UN:*MS<D+<UK>VCS6]G6Y>?VE1[T
M)J^]ZM!\M^2][2UY>>=^6]_92Y;\]+FW)>GX-_(55;J?J?YUSLOAW6,?\C[X
ML_Y&MO$7_'GX&_Y ^!_Q07_(E_\ (I_]/G_(\_\ 4Z55;P[K&6_XKWQ8/^*K
M/B'_ (\_ W_((_Z$3GP7_P BK_T^?\CO_P!3E79"G3Y5_M$/_!5?O_A.=SJ7
M?[B>[_Y>T.[_ +QTS]1]/ZFHG^Z?P_F*Y=_#FL9_Y'[Q;_R-'_"0?\>?@7C2
M<G_BAO\ D2O^16':[.?&OKXP-1:EX<UB\'B V_C[Q;I7]L?V5_9PL+/P)(/"
MO]GE/M?]@?VIX*U(W']N;6_M3_A*#XD\GS'_ +%_L?$>SHA3IVM]8@EI=^RQ
M%EK36RC=Z2E/3I3E'XITTTZE2TG[";?;VM"[]V;W<K+6,8Z]:D9?#"HUTQZ?
MBO\ ,4M<CJ'AO6;O^WOL_C_Q;I?]KG2O[/\ L%EX$D_X1;[ 8_M?]@_VGX*U
M'[1_;>UO[4_X2?\ X2/RO,?^Q?[(Q'L+[PUK-W_;OV?X@>+M+_M?^S/[/^PV
M7@*3_A%_L&S[7_87]I^"-1^T?VWM;^T_^$F_X2+RO,?^QO[(Q'LM4Z3M?$05
M[7O2Q#M?DO>T=>7FE>V_LY<M^>G?!SJ*]J$W:]K5:"O;GM:\M.;EC:^WM(\U
MN2I;K1T_%OYFGKT/^?X6KEKS0=5NKR[NH/&OB;38+G1;G28=.LK3P;)9V%_-
M,\D?B:T?4?"5_J#ZW:HP@@M[Z^O?#;1(AN?#]Q,7F> >&=:(/_%P_& _XIO^
MP^++P!SJF&_XK+GP,?\ BI#T^RC'A#GCPIG!H5.FTKXB";2NO98AV=E=74;.
MSTNM':ZTL/GJ*32H3:5TFJE!76MG9RNKK6SU5[/5,[5>@^@_E4Z]/R_]!6N'
M'AC6\#_BXGC$?\4T-#_X\?A__P A/'_(X\^!?^1D_P"G7_D4?^I5J]%X>U=9
M-"D/CKQ4Z:1;2P:A ]GX)$7BF66RBMDO=>*>#DFM[FWF1M0A3PQ-X<LVNYI$
MN+2>P$5E%,J=*TO]H@]'_P NL1T4FMX]6E%=G--^[&;352I9_N)K3_G[0ZSB
MF])=$Y2?5J#2]Z4$^SCZ+]?ZUW'[/7_)UWA'_LWKX[_^K(_9FKQ/3O"VN6O]
MA>?\2/&FI?V4=2^W?;;'X=Q_\)+]N+_9?[;_ +.\!6'D?V-N']F_\(Y_8'F^
M6G]L?VKE]_H/[-/AW5[+]J?X:0W/CSQ7K$FD_ OX_P![?W6HV?@>*?Q/;3>.
M?@!9QZ1KBZ3X-TNVM].M+C5+'5;>7PU;^'M6:_\ #>BQW6J7.ES^(M-U[RLX
MITEDN>6Q,)?\(V962HXE7M2HV^*"2YN6"5]O:QYM(5;=&#J5'CLKOAYQ_P"%
M/+KMU<.[7J3NO=DV[<T]M'[*5OCI7_6RBO/+7P5XDM] \*:/-\7?B'?:CX=\
M16VM:OXKNM,^$Z:_X\TV"]O[J7PAXKMK+X86?A>S\.WD%Y;Z;<W/@?PWX,\6
M+9:5826GB>UU&35+_4C_ (0KQ)_T5WXA_P#)0_\ A-?^09\)_P#D6_\ HD7_
M "3#_DGG_43_ .2L?]5/K\*]CA[R7UVE92G%/ZMC?>C&<XQFE[.Z52,8U(QE
M:<(U(PJ)5(5$OTOVM:R_V2I=QBVO;X7W7*,92@WSV;A*4H.4;QDX.4&X2@WZ
M'17GG_"%>)/^BN_$/_DH?_":_P#(,^$__(M_]$B_Y)A_R3S_ *B?_)6/^JGT
M77@KQ)<:!XKT>'XN_$.QU'Q%XBN=:TCQ7:Z9\)WU_P !Z;/>V%U%X0\*6U[\
M,+SPO>>';."SN--MKGQQX;\9^+&LM5OY+OQ/=:C'I=_II['#WBOKM*SE"+?U
M;&^[&4X1E-KV=VJ<92J2C&\YQIRA33J3IIGM:UG_ +)4NHR:7M\+[SC&4HP3
MY[)SE&,%*5HQ<U*;4(S:]#HKSS6?!7B35/\ A-/L/Q=^(?AS_A*?^$=_L/\
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MEH37>BW6=_PA7B3_ **[\0_^2>?\(5_R#/A/_P C)_T5W_DF'_)0_P#J&?\
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M2JUGRWPE2-^6]Z^%?+?V7-?EF[\GM*E^6_-["?)?VM#F]#HKSS1O!7B32_\
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M_5IV=JN'Y_0Z***Y3H"OEO\ :5_YDO\ [F/_ -P-?4E?+?[2O_,E_P#<Q_\
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MV;7Y;Q;_ ,CFI_V"X3_TW5/O.'O^1;#_ *_XC_TN 4445\R>X%%%% !1110
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MNI^H_E7SK^SC_P A+]H;_LMNG_\ K/\ \":^BINI^H_E7R&>_P#(YQ?KA?\
MU79:>UE'_(NP_P#BQ7_J?CS.E[_[Q_K6?+W_ -X_UK0E[_[Q_K6?+W_WC_6N
M2ENO5?D=<M_Z\C/E[_[Q_K5&7^+\/Z5>E[_[Q_K5&7^+\/Z5UPZ>D?SB83^+
MY(SY?XOP_I6?+_%^']*T)?XOP_I6?+_%^']*[*73U_4QG_7X&?+_ !?A_2L^
M7^+\/Z5H2_Q?A_2L^7^+\/Z5VPW?I^J,)[+U_1F?+_%^']*SY?XOP_I6A+_%
M^']*SY?XOP_I773V_P"WO\C"6W]>12?K^)_DM0MT;Z+_ #-3/U_$_P EJ%NC
M?1?YFNR.Z^7YHQ(J@/7\%_D*GJ ]?P7^0K5;+T7Y$/9>C&]S]!_-J3^#_@/]
M*7N?H/YM2?P?\!_I3,NWS_,=3EZ_E_Z$M-IR]?R_]"6A[/T?Y,%_G^3)JG7H
M/H/Y5!4Z]!]!_*HE]KY?D4MG_A_5D\?4?A_Z$U<S<_\ )6/V<O\ LK'B7_UG
MOXZ5TT?4?A_Z$U<S<_\ )6/V<O\ LK'B7_UGOXZ5"^#$_P#8#F7_ *K,P(J;
M4_\ L*R__P!6& /MB?M^']:RI>GX-_(5JS]OP_K65+T_!OY"OSJGN_E^I]@]
MC.E[_P"Z?ZUGR]_]T_UK0E[_ .Z?ZUGR]_\ =/\ 6N^GM]W_ *28/K\_U,V7
M^+\/Z5GR_P 7X?TK0E_B_#^E9\O\7X?TKKI_Y?\ I)S/_+\T9TW4_4?RK.E[
M_P"\?ZUHS=3]1_*LZ7O_ +Q_K7?#X?FS SY>_P#O'^M9LG;\?Z5I2]_]X_UK
M-D[?C_2NR&\?3]#G?7Y_J9TO3\&_D*JMU/U/\ZM2]/P;^0JJW4_4_P Z[(?"
MOG^9SO=^K_-D+]1]/ZFHG^Z?P_F*E?J/I_4U$_W3^'\Q6\?A?]=$+O\ UT1
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M _\ !^8?_/ 7_$4_$'_HI,3_ .",#_\ ,9^]_P#P_I_:%_Z)+\'/_ ;QS_\
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MC_B"WA;_ -$C@/\ P?F'_P \!?\ $4_$'_HI,3_X(P/_ ,QG[W_\/Z?VA?\
MHDOP<_\  ;QS_P#-I1_P_I_:%_Z)+\'/_ ;QS_\ -I7X(?:??_/_ 'S1]I]_
M\_\ ?-'_ !!;PM_Z)' ?^#\P_P#G@'_$4_$'_HI,3_X(P/\ \QG[W_\ #^G]
MH7_HDOP<_P# ;QS_ /-I1_P_I_:%_P"B2_!S_P !O'/_ ,VE?@A]I]_\_P#?
M-'VGW_S_ -\T?\06\+?^B1P'_@_,/_G@'_$4_$'_ **3$_\ @C __,9^]_\
MP_I_:%_Z)+\'/_ ;QS_\VE'_  _I_:%_Z)+\'/\ P&\<_P#S:5^"'VGW_P _
M]\TTWB X+J#TP6&<^F,4?\06\+?^B1P'_A1F'_SP'_Q%+Q!_Z*/%?^",#_\
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MD$9 R".*\Y;_ (+*_&QA@_#7X7]^EOXN[_\ <V5^,'VGW_S_ -\T?:??_/\
MWS711\(/#7#J4:/"V"IJ33DHU\?JTK)ZXZ6RTT,ZGB9QY5:=3B'$R:5DW0P2
MLF[O;"+J?LLW_!8SXU-G/PW^&'7/_'OXN_\ FKJ!O^"PGQH88_X5S\,AU_Y=
M_%O?_N:J_'#[3[_Y_P"^:/M/O_G_ +YKH7A5X>QVX;PB_P"X^-_^:S)^(W&[
MWS[$/_N#A/\ YE/V';_@K[\9GZ_#OX:?A;^+/7/_ $-1J%O^"NOQC;/_ !;S
MX:C/7_1_%?;'_4T^U?C]]I]_\_\ ?-'VGW_S_P!\U2\+N %MP[A?_!^,]?\
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M=T.OJOU,7^B*#]!]?Z&J$O?_ 'C_ %J^_0?7^AJA+W_WC_6NF'Z/\SG*,O\
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M<VXQ_5ZBOC7]BC]L;_AM/X>>)OB%_P ,K_ME?LF?\(UXPF\(?\(/^VO\#_\
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M^!?_ "-FK_\ 8K7?_IXT2OY3/^"JLA3]K[QC@@9T/P9U]O!V@?XU_5G\"_\
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M *2<S_R_-&=-U/U'\JSI>_\ O'^M:,W4_4?RK.E[_P"\?ZUWP^'YLP,^7O\
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M**_!C]./Q8^)7_*?_P#98_[1C?M/?^K_ /@E7X?? SX8^,O OPT_;._X*4_
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MBEBE57CDBD^-_P 2UDCD1@5='4E75@592000371?\$V/^"-_@7_@FO\ $_\
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M4,%@\+B(8&.&5?"TOPJ^$GQX_;5_X)$7/[.7[*_[<7A_P#^T/^Q)KWC+X?\
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M*K7JN,80]G3I%%%%<YN%?+?[2O\ S)?_ ',?_N!KZDKY;_:5_P"9+_[F/_W
MU[W#/_([P7_<Q_ZBUCR<\_Y%>*_[@_\ I^F?+=%%%?K1^>A1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >S_  +_ .1LU?\
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MO#OC5.ZX:S1/NJ>'3^]8Y/\ $_.-A;-,EPT$#7$8VQSM#&9D7GY4E,9=1R>
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M^S;V717LNB%_Q#OC9JSX;S1J][<E"UWN[?7K7?5VOYGYU?:/\X_^QH^T^_\
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MT+%BD$21*6/5BL:*"Q[DC)HF-O<J$N(89T!#!)HDE4,.C!71@".QQD5^C?\
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M4LLDE\@7AYQM&[CPYFL6]W&%"+?KRX]7^=S\YTECB01QHD:*,*B(J(!Z!50
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M_/\ WS1]I]_\_P#?-?:+_L.^.D&3>Q_A;:Q_70!ZU"?V(_'"XS>)S_T[:O\
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M_>/]:SY>_P#O'^M<E+=>J_(ZY;_UY&?+W_WC_6J,O\7X?TJ]+W_WC_6J,O\
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M)38]O^7"Q]O]BO?YNA^@_G6=+_%^']*[H4X;<J^Y?S)=CGG*2>C:T[O_ #/
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M#<QP H6-52)$1=;X ?L^:)\/]#L(+6P%L(4!_P"7F-Y)&339'GG*WACDFD>
MEV$:K@"-%2)$C'UO%!';QK%&-JJ% &6/&7/5BQXR>IKSN)N*<5Q1B]IX?*L/
M-O!8)NSFU=+%XM1;C/$3C\$+RAAH2Y*;=1U:LO2X;X9PO#F&^Q7S.O"*Q>+4
M4U!:2>%PS:O&A"2]^5HSQ$X\\[05*E&"*".WC\N-%10J\*H4=3T  XXI&ZC_
M #_$M3MT;Z+_ #-0-U'^?XEKPH?HOT/H'_7WHAI%Z#Z#^5+2+T'T'\JT,7NQ
M:4=?P;^1I*4=?P;^1H>S F7H/H/Y587H/H/Y577H/H/Y587H/H/Y5$OM?+\A
MK:7H6%Z#Z#^5;WPG_P"2S?$+_LB'P*_]69^U)6"O0?0?RK>^$_\ R6;XA?\
M9$/@5_ZLS]J2O.S'_D7X_P#[!*G_ *D9<;4/][P7_873_P#4?''T;+W_ -T_
MUK/E[_[I_K6A+W_W3_6L^7O_ +I_K7Q-/;YO\CZ>6W]>11D[?C_2L^3M^/\
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MG^_99_V-,O\ _3E8_4&BBBOP8_3@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *^6_P!I7_F2_P#N8_\ W U]
M25\6_M?V7CV\_P"%>?\ "$>)?"'A[R_^$M_M/_A*O!&L^,OMF_\ X1G[%]@_
MLCX@^!/[.^S[;O[5]H_M7[9Y]OY7V'[++]L^AX5@IY]@8NI3I)_6??JN481M
MA:[]YPIU9*]K*U.6K5[*[7CY_)PRG%R4)U&O8>Y347-WQ%):*4Z<=-W><=$[
M7>C\)HKR+^Q?CU_T4GX1?^&2\9?_ $0-']B_'K_HI/PB_P##)>,O_H@:_8_J
ML/\ H.P'_@W$_P#SO/S7ZS/_ * \9_X+P_\ \VGKM%>1?V+\>O\ HI/PB_\
M#)>,O_H@:/[%^/7_ $4GX1?^&2\9?_1 T?58?]!V _\ !N)_^=X?69_] >,_
M\%X?_P";3UVBO(O[%^/7_12?A%_X9+QE_P#1 T?V+\>O^BD_"+_PR7C+_P"B
M!H^JP_Z#L!_X-Q/_ ,[P^LS_ .@/&?\ @O#_ /S:>NT5Y%_8OQZ_Z*3\(O\
MPR7C+_Z(&C^Q?CU_T4GX1?\ ADO&7_T0-'U6'_0=@/\ P;B?_G>'UF?_ $!X
MS_P7A_\ YM/7:*\B_L7X]?\ 12?A%_X9+QE_]$#1_8OQZ_Z*3\(O_#)>,O\
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MX/\ ^>I]#45\\_\ "-?M7_\ 1:?V>?\ Q&'XD_\ T75'_"-?M7_]%I_9Y_\
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MB3_]%U1_PC7[5_\ T6G]GG_Q&'XD_P#T75']G4O^AQDW_A1C_P#YR!]>J?\
M0LS3_P $X/\ ^>I]#45\\_\ "-?M7_\ 1:?V>?\ Q&'XD_\ T75'_"-?M7_]
M%I_9Y_\ $8?B3_\ 1=4?V=2_Z'&3?^%&/_\ G('UZI_T+,T_\$X/_P">I]#4
M5\\_\(U^U?\ ]%I_9Y_\1A^)/_T75'_"-?M7_P#1:?V>?_$8?B3_ /1=4?V=
M2_Z'&3?^%&/_ /G('UZI_P!"S-/_  3@_P#YZGT-17SS_P (U^U?_P!%I_9Y
M_P#$8?B3_P#1=4?\(U^U?_T6G]GG_P 1A^)/_P!%U1_9U+_H<9-_X48__P"<
M@?7JG_0LS3_P3@__ )ZGT-17SS_PC7[5_P#T6G]GG_Q&'XD__1=4?\(U^U?_
M -%I_9Y_\1A^)/\ ]%U1_9U+_H<9-_X48_\ ^<@?7JG_ $+,T_\ !.#_ /GJ
M?0U%?//_  C7[5__ $6G]GG_ ,1A^)/_ -%U1_PC7[5__1:?V>?_ !&'XD__
M $75']G4O^AQDW_A1C__ )R!]>J?]"S-/_!.#_\ GJ?0U%?//_"-?M7_ /1:
M?V>?_$8?B3_]%U1_PC7[5_\ T6G]GG_Q&'XD_P#T75']G4O^AQDW_A1C_P#Y
MR!]>J?\ 0LS3_P $X/\ ^>I]#45\\_\ "-?M7_\ 1:?V>?\ Q&'XD_\ T75'
M_"-?M7_]%I_9Y_\ $8?B3_\ 1=4?V=2_Z'&3?^%&/_\ G('UZI_T+,T_\$X/
M_P">I[=XA_Y &N?]@?4__2*>OE*7I^#?R%=5KOAO]JL:)K)E^,_[/CQ#2M0,
MJ1_LR_$>*1XQ:3%UCE;]K:98W9<A9&BE5&(8QN 5/S1)H/[1^.?BM\$CPW3]
MG[QV/_?F#7T628"E&EB+9KE,KU8?#7QK2_=/>^3P_)^IY68XRHYTO^$[,E[D
MOBHX1?;7;,Y?H>L2]_\ >/\ 6LR7I^#?R%>3R:#^T9SGXJ?!0_,>GP!\=#U_
MZN4-9\FA?M$8Y^*7P7/#=/@)XY'_ +\B:^EI8*G?_D999M'_ )?8ONO^I6CR
MIXN?_0!F&_\ SZPO_P \3U:;H?H/YUG2_P 7X?TKRJ70_P!H7G/Q0^#)X'3X
M#^-QW_[..-4)=#_:#^;/Q/\ @V>G3X$^-AZ?]7%FNV&#I_\ 0QRW_P '8O\
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MZ&J$O?\ WC_6O*7T/]H3'/Q/^#77_HA/C<>O_5QAJE)HG[0/.?B=\'#\QZ?
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M/=?]2XPGBIV7^PX[?_GUANS_ .H\],E_B_#^E9\O\7X?TKS671OCM\V?B/\
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M:RI>GX-_(5Y/-H/[1W&?BM\$CTZ?L_\ CL>OK^TN:S9-"_:+QS\5/@J>&Z?
M+QT/_?E#7YW3P5.[_P"%++.G_+[&>?\ U*CZ]XN=O^1?F'_@K"__ #R/69>_
M^Z?ZUGR]_P#=/]:\GDT+]HCG/Q2^"Y^4]/@)XX'K_P!7(FJ,FA_M#<Y^*'P9
M/RGI\!_&X]?^KCC7=3P=.W_(QRWI_P OL7_+_P!BPP>+GK_L&8=?^76&\_\
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MZ"M>+#P[\=B!CXK?#@<#C_A2^N<<>_QFJ1?#?QXQQ\6?AP.!_P T6UOT'/\
MR67KV]/:E+"4K2_X4,!M_-C/_F :Q52S_P!AQVS^SA>__8<>W1]%^O\ 6NX_
M9Z_Y.N\(_P#9O7QW_P#5D?LS5\OIX:^/9VX^+GPY'/\ T1363W]_C+^-=S\
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M,?\ _.0/KU3_ *%F:?\ @G!__/4^AJ*^>?\ A&OVK_\ HM/[//\ XC#\2?\
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M@:]SAG_D=X+_ +F/_46L>7GG_(KQ7_<'_P!/TSY;HHHK]:/ST**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#WO\ 9V_Y';5/
M^Q6O?_3MHE?9M?&7[.W_ ".VJ?\ 8K7O_IVT2OLVORWBW_D<U/\ L%PG_INJ
M?></?\BV'_7_ !'_ *7 ****^9/<"BBB@ HHHH **** "BBB@ HHHH ****
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M]?Q/\EJ%NC?1?YFIGZ_B?Y+4+=&^B_S-=D=U\OS1B15 >OX+_(5/4!Z_@O\
M(5JMEZ+\B'LO1C>Y^@_FU)_!_P !_I2]S]!_-J3^#_@/]*9EV^?YCJ<O7\O_
M $):;3EZ_E_Z$M#V?H_R8+_/\F35.O0?0?RJ"IUZ#Z#^51+[7R_(I;/_  _J
MR>/J/P_]":N9N?\ DK'[.7_96/$O_K/?QTKIH^H_#_T)JYFY_P"2L?LY?]E8
M\2_^L]_'2H7P8G_L!S+_ -5F8$5-J?\ V%9?_P"K# 'VQ/V_#^M94O3\&_D*
MU9^WX?UK*EZ?@W\A7YU3W?R_4^P>QG2]_P#=/]:SY>_^Z?ZUH2]_]T_UK/E[
M_P"Z?ZUWT]ON_P#23!]?G^IFR_Q?A_2L^7^+\/Z5H2_Q?A_2L^7^+\/Z5UT_
M\O\ TDYG_E^:,Z;J?J/Y5G2]_P#>/]:T9NI^H_E6=+W_ -X_UKOA\/S9@9\O
M?_>/]:S9.WX_TK2E[_[Q_K6;)V_'^E=D-X^GZ'.^OS_4SI>GX-_(55;J?J?Y
MU:EZ?@W\A55NI^I_G79#X5\_S.=[OU?YLA?J/I_4U$_W3^'\Q4K]1]/ZFHG^
MZ?P_F*WC\+_KHA=_ZZ(@/3\5_F*6D/3\5_F*6K,!!T_%OYFGKT/^?X6I@Z?B
MW\S3UZ'_ #_"U UO]_Y$J]!]!_*IUZ?E_P"@K4"]!]!_*IUZ?E_Z"M3+:7HA
MK9^C_,LQ]%^O]:[C]GK_ ).N\(_]F]?'?_U9'[,U</'T7Z_UKN/V>O\ DZ[P
MC_V;U\=__5D?LS5Y6;_\B7._^Q-F/_IO#'1A/]^RS_L:9?\ ^G*Q^H-%%%?@
MQ^G!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5\M_M*_\R7_ -S'_P"X&OJ2OEO]I7_F2_\ N8__ ' U[W#/
M_([P7_<Q_P"HM8\G//\ D5XK_N#_ .GZ9\MT445^M'YZ%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110![W^SM_P CMJG_ &*U
M[_Z=M$K[-KXR_9V_Y';5/^Q6O?\ T[:)7V;7Y;Q;_P CFI_V"X3_ --U3[SA
M[_D6P_Z_XC_TN 4445\R>X%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 8_B'_D :Y_V!]3_P#2
M*>OE*7I^#?R%?5OB'_D :Y_V!]3_ /2*>OE*7I^#?R%?29'_  <1_P!?8?\
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M@DH2E**<X>SE>:<'.,[*-2I&$N:"47STXTZEEK#VOLY-SISE(HHHK,L****
M"OEO]I7_ )DO_N8__<#7U)7RW^TK_P R7_W,?_N!KWN&?^1W@O\ N8_]1:QY
M.>?\BO%?]P?_ $_3/ENBBBOUH_/0HHHH **** "BBB@ HHHH **** "BBB@
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MPV/^R3_T<]^SY_X>;X<?_-+1_P -C_LD_P#1SW[/G_AYOAQ_\TM?/?V'G?\
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M/F__ ,Z@_M;*?^AKE?\ X<\M_P#GB?2-%?-W_#8_[)/_ $<]^SY_X>;X<?\
MS2T?\-C_ +)/_1SW[/G_ (>;X<?_ #2T?V'G?_0ESK_PSYO_ /.H/[6RG_H:
MY7_X<\M_^>)](T5\W?\ #8_[)/\ T<]^SY_X>;X<?_-+1_PV/^R3_P!'/?L^
M?^'F^''_ ,TM']AYW_T)<Z_\,^;_ /SJ#^ULI_Z&N5_^'/+?_GB?2-%?-W_#
M8_[)/_1SW[/G_AYOAQ_\TM'_  V/^R3_ -'/?L^?^'F^''_S2T?V'G?_ $)<
MZ_\ #/F__P Z@_M;*?\ H:Y7_P"'/+?_ )XGTC17S=_PV/\ LD_]'/?L^?\
MAYOAQ_\ -+1_PV/^R3_T<]^SY_X>;X<?_-+1_8>=_P#0ESK_ ,,^;_\ SJ#^
MULI_Z&N5_P#ASRW_ .>)](T5\W?\-C_LD_\ 1SW[/G_AYOAQ_P#-+1_PV/\
MLD_]'/?L^?\ AYOAQ_\ -+1_8>=_]"7.O_#/F_\ \Z@_M;*?^AKE?_ASRW_Y
MXGTC17S=_P -C_LD_P#1SW[/G_AYOAQ_\TM'_#8_[)/_ $<]^SY_X>;X<?\
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M1_VO^HQ7;3R_'_\ 0!C]E_S XWR_Z@CGEC\!=_[=@=_^@W!?_-AZRW1OHO\
M,U W4?Y_B6O)F_:#^!//_%YOA9R!C_BX/A'L3_U&*B/[0/P*R/\ B\OPL_\
M#@^$O53_ -!?V_SS73# 8_\ Z <=M_T!8WR_Z@S-X_ _]!V!_P#"W!]U_P!1
MAZQ7G'Q$O);70Y9(V*E=F".O5^Q(%9/_  T!\"_^BR_"S_PX'A/_ .6_?_\
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MN#I8[ UHU\/7AS1E%KFC+3FIU(W;IU:;?+.$K-/5<T91E*PO0?0?RK>^$_\
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M]#<_9Q_Y"7[0W_9;=/\ _6?_ ($U]%3=3]1_*OG7]G'_ )"7[0W_ &6W3_\
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M:7HAK9^C_,LQ]%^O]:[C]GK_ ).N\(_]F]?'?_U9'[,U</'T7Z_UKN/V>O\
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M='UJ(WUQ'<*FI:K+IZS6L0O]+U6R>XL9N'_8^_9)_P""F'P=^)NL>)?VO/\
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M?VK]IZV_:/\ ^$&_X0/_ (6FGVC9]G_X0W_A)O\ A,H-V_\ X2+_ (1]=O\
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MC%*G2<<YG1JYO4IT::A2HXG,ZN'HU<?BJ,*>(Q-2"E.<>:<*A1114""BBB@
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M6:F%5147B84/8>TE059JBZJ7(JK5)M5&J;^0/MLO_/:7_OY)1]ME_P">TO\
MW\DKGVF,;M'('1T<HZ.A1D925974@,K*00P(!4@@C(K]WOVQ_P!C?]FOX4?&
MK_@FYX.\!_#J30M ^/VM^$K'XL67_"8>.=3;Q7;:GXI^%FEWH%UK/B34;O0W
MGM/$NLQL_AN?1O+-V'@$,EO;/#GGG%V5Y!F&09=C*.)J5N(ZN<4<#/#4J%2C
M">29%C^(,3]9E.K3E!5<%E]>GAG3C54\1*E&I[.G)U8F6<.X_-<'GN-H3ITJ
M?#V#PF-QU/$5:U.K.GB\WP>30A0@J<DZM/%8VG*K"LZ/)1A5:;JP5)_B#]ME
M_P">TO\ W\DH^VR_\]I?^_DE?>7_  5)^"/PI_9Q_:TUSX8?!OPNW@[P39^"
M/!.L0:*=;\1>(A'J.L6-S+J$ZZCXIU76]783O$C^3+J$L,3;A D2$(/3OV%?
MV<O@A\7_ -DC]O3XJ?$KP0?%'C7X)?#N37OAOJQ\2^+=%7P]JB^"/'NL"Y_L
M[P_KFE:9JQ_M'1=-N##KUEJML1;"(0"&:YCF\N?B+D-/@;"^($L/C_[%Q=#+
ML1"@L/AGF,(9GG%#)**J4?;^P4J6+Q$9UE'$R2H0G.FZD^6G+U5P-F[XTCP(
ML1@_[7EC9X"-?ZQB/[/=:&52S?F]K['VZIRPT>2+>&YO;-1<5"]1?E_]ME_Y
M[2_]_)*/MLO_ #VE_P"_DE?IA_P2._9U^"_[4'Q^\?>"?CAX.?QMX9T3X-ZW
MXLTW3!XA\4>&A;:]:>*_!VEV]]]M\):UH.H3F*RU:_B6VGNY+)C-YDMM)+'"
M\?>?\$^O@+^S;X^^ G[<GQL^-/P6D^,5S^SOH:^*O!OA+_A8_CGX?K=V^F>'
M/'>OW/A\:UX0U2T:"369- L+(ZMJ>FZZ; *MQ!92$SQ7&'$7B9D'#.(XCPV.
MPF95JW#&4\-YSC8X/"X6K]8PW%&;3R7+J>"=3$4O:8B&-C%8F%5480IU(2I5
M*SYHQ>0\"9SQ%1R.O@:^#IPS_B/,.&,&L3B:])T\PRW)I9Y7J8EQI5(T\+/!
MPG&E5A*I-UHN-2G3I_O#\D_MLO\ SVE_[^24?;9?^>TO_?R2OUL_9=\#?L)?
M\%*XO'GP>^&/[/\ \0/V'?VH/#'A#4O&W@G2[GXL^)/C1\-_'FF:=<)8RK<:
M_P"+[:'4)&LKR_TP:YI=EI'AN_LK2\MM3TG4-=ALM7LU\$_X)^_LK:-\;OVM
M[KX9_&K2)1\/?A%I?CSQ7\;--FU#4=&6WTSP,)=&N-+N=8TBZL-0L%;Q5=:;
M!=S65_:77V"&_>WN(F3S$JAXE9 \%Q+BLQPN99%B.$\HGGN<9;G&%PU#&PRA
M4L34I8["RP^*Q6#QE"O5PM7!PE1Q*=+'.&%Q,*,YPE-8G@;-Z=3)%@<3@<YP
M_$&:T\CR_%Y5B<16H_VO4J8:*P&(I5\/AL70K>RQ=+%PYJ%2%?"*K6H3G[*=
M-?!WVV7_ )[2_P#?R2C[;+_SVE_[^25^H?\ P4O_ &:O@1\,_#/[,_[0O[*_
MAJ[\.? C]H'X=P:K964VN>(O$?V77I+6S\16,US>^*-;\1:E:7FK>'];A@FT
MS^TY+:VN_#^H"&..03YT+;]G[]F+]C?]C'X>?M;_ +7_ ,._&_Q]^(/Q[OH;
M+X(_LZ^%_%VI_#W2;RSU+2[W6=(U/Q1XN\.G^W-.@FT&TC\1ZAK$,MQ;Z3:Z
MGI&E+X:U?49IR.>7BIPS#AG+^)I8?-$LUSJIPW@<CC@:53B"MQ#1QV)P%;)O
MJ,*[I0Q="KA*M6O.>*CAJ&%Y,14K*G)7Z9>'>?1XAK\/1K8"<\+E$>(,1FRQ
MTXY+2R-X2.,>:RQLZ2D\*HR>'CRT95:N+B\/0A5FXM_E9]ME_P">TO\ W\DH
M^VR_\]I?^_DE?6-IJG[.7[9WQ)^!WP?_ &9?V9/B=^RS\8/''C,>'O&6A^(_
MB+<_%[X2V^@:@]I#::YH'BW7+BV\:W^I:/;0ZAK6N6=SH6C645DMQ!:O>.L#
MP_2/[2/BS_@G5^R%\8M9_9>@_8N^)_[3VJ?#F*QT'XK_ !\O/VA?$WPVU>Q\
M7:CI%CJ5[;^"O N@VLGA#Q&^@PZC S1ZF_AVUM]52XT>ZDU:.T>_N'B?$S+<
M-++,&^'.**V>YK3S?$T.&Z&6X&>;TL#DE2C1QV8XERS*&74\"ZV)P]#"5UCF
M\;7K1HX>DIQFU%#@3&8AYA7CGF0QRC+(Y4L5GM3'XV.6K%9RZ_U'+Z<?J/U^
MKF#AA<56KX:&$E]6PM"6*JU?8R@C\O?MLO\ SVE_[^24?;9?^>TO_?R2N>-[
M',3-'!+:1RDR1VLKK/+;(YW);RS+'&LTD*D1O*L:"1E+!%!P/VU^+?P*_96_
M80_9>_9C^*7Q5_9/^(?[9GC+]H73--\2>*=;L_B[XM^$O@/X8:??>'M%U\Z9
MI^J>#+5X+O4[B#7K:V\/Z-X@A>?Q--I/B#45\0Z):VD6F#VN)^-,KX5HY-+%
MX/,,;B^(,RIY1D^69=AL/4QN,Q]3"5<=*DWB<1A,)AXT<+1J3JU,1BH1YHJE
M35:K*,)>7D7"V/X@Q>:8;!XK!TJ.39=C,VS+'XK%5H8.AEV"Q$<-/%1]E1JX
MFO&K6J4U0IT<+*K.-2,Y4Z45-T_QK^VR_P#/:7_OY)1]ME_Y[2_]_)*]#UFT
M\)_'7XTW&A_LG_"KXL:;X>\8:MIVG_#WX8>+TL_$/Q$BO3H]BVM6<DNAW>J6
M]WIT&LIK%QI^H2WTK1>'((-1UB:T>.\6W]H^,O\ P3^_;'_9^\$R_$;XL_ _
M7?#?@FV, O\ Q!8Z[X*\6VND+<R006\VNQ>#/$OB&[T&WEN+F"V2ZUFWL;<W
M4J6OF_:#Y==T.*<CC3RG^T,;A,EQF=4:-7 Y3G6(P.79M4G6E[-8;ZE6Q3G+
M$PK?N)PHSK0=9QITJM64X0?/+AS-IU\RI9?A\1G-#*JE2.*S#)J6-Q^7JG3@
MZOUA8BGAH\M"5%3JIUJ=*:ITZLITHQI3F?*GVV7_ )[2_P#?R2C[;+_SVE_[
M^25^O?QI^&?PQT?_ ((V?LQ_%+2_AUX%T[XE^(_C%>Z7KOQ$LO"6A6OCG6=-
M77/C/$-/U3Q7!81Z]J%D(M(TN)+.\OYK9(]/LHTB"VL 3Y&\ ?\ !-_]N#XH
M> +'XG>"OV?O$^I>#-4L#JNE7U_K7@KPYJ>KZ881<0:AI/A?Q-XFT?Q5JEG?
M6[)/I=S8:+<0ZM#)'+ICW:21LWD9=X@</8NAGN)S#$83(,/D?%F;\(U*^<X[
M+L+1QF.RAX3GK86I4G1BZ>)ABXU*5"7/B*<:<W6LG&9WXO@W.*,>'OJ5+$YQ
M6XAX<PW$M'#9;AL;7KX7"8C%XS!^RQ$(1J-SI5<&^>M3Y</+VM.$7SIQ?Q[]
MME_Y[2_]_)*/MLO_ #VE_P"_DE=KX"^"GQ?^)_Q)/P>\!_#OQ7XA^)L5YJ-A
M>>#+?2I;76=*N='F:WU==<BU#[)%H,6DW"-!J=SK4UA:Z?-B*[FAD95/V+I'
M_!+S]LG3?BY\*?AQ\1_@IKWAVT^(WB2*Q_M+3_&/PSO[5=$TQ)=7\6R6WB&P
M\4ZQX<L]<TSPKI^LZS9:1J-S_:6H)I[FPTO46 @?VL=Q1PUEM2E2S#/,EP=:
MOA)X[#T,3F67T:^)P=.A5Q,L3AZ4\0IUZ#H4:E6%6DITZD(.5*=6*<EY-#(<
M\Q4,34PN4YOB:>#K+#8N=#!8VK'#8F56%!8:NXT;4<0ZU6E1]C4Y*JJU:=.<
M*<IQ3^!?MLO_ #VE_P"_DE'VV7_GM+_W\DK]9_VX?^";GB;]C_XJ>%/&GPP\
M"^)_B9^SI!KGPSTZ/5?B1XW^&L]]XJ\>ZYK=PESX NM.T:+PYK,6EZL+2UT_
M^T9/!9L8([^=YM0N$C.WD/VC/V:_VJ/VE_VH]9\%>"O^"?W@+]E3QGX7^$>@
M>*[OX(?#KXL_!/6]/O/"2Z_JVECXC3Z[H,_@/P9/J&KZC<0Z0^C:5IYUV"+3
M;>6_CNC(+@?*X'Q2X4S*.1XO!8K"RR?.,#GN.KYKC,?E66QR19#2PM7$T,VR
M_&8E9A1K2ABZ,ZGLU.&!I5L)7QLH4,=A:DOH\9X?<09=/-\+C:->GF.65LEH
MX; X;#9ACUG,L[Q=;!X>668["T%@YPC6H5J4957!8O$T,7@L)SXK!XB$?S'^
MVR_\]I?^_DE'VV7_ )[2_P#?R2O6/@?^S5\<_P!H_P 4>)/!GP9\!W7B_P 2
M>#]%N_$/B:PDUKPQX9BT;2;&^M]-N9[S4?%^M:!I:S)>W,4"6*7KW\V)Y(+6
M2*UN9(?1O@=^P?\ M=?M(>'+GQA\&_@OK?BOPK;7MSIP\17>N>#?".BWUY92
MF"]BT74?&OB/PY:Z^+.X5[>ZET274(;>YCEMYI$FBD1?K<9Q+P[E_P!9^OYU
MDN"^ITL%7Q?UO,<!A_JU',?;?V?5K^UK0]E3Q_U>O]3E*ZQ2HU7052-.<H_.
M4,ASO%.FL+E6:XAUL3B\'25#!XRJZF+P$83QV%@H4FY8C!1J0EBZ-E/#*</;
MJDY1B_F'[;+_ ,]I?^_DE'VV7_GM+_W\DK7^)/P[\>_!_P 9:Q\/?B=X4UKP
M3XTT"6*+5O#VNVAM;ZV\^%+BVF7!>"ZL[NVEBN;*^M)I[*]MI([BUN)H75SP
MWVD>I_[Y%>EA\9A,70HXK"UL/B<-B*<*U#$8>I1KT*]&I'FIU:-:BZE*K3G%
MWA.G4G&2U3T:7%B,'BL)7JX7%4<3AL30J2I5\/B(U:%>C5C;FIU:550J4YQN
MKQG!.S3U4HRET7VV7_GM+_W\DH^VR_\ /:7_ +^25SOVD>I_[Y%'VD>I_P"^
M16WM(=H_^ Q_^1,?9R[S_P# W_\ )'1?;9?^>TO_ '\DH^VR_P#/:7_OY)7.
M_:1ZG_OD4?:1ZG_OD4>TAVC_ . Q_P#D0]G+O/\ \#?_ ,D=%]ME_P">TO\
MW\DH^VR_\]I?^_DE<[]I'J?^^11]I'J?^^11[2':/_@,?_D0]G+O/_P-_P#R
M1T7VV7_GM+_W\DH^VR_\]I?^_DE<[]I'J?\ OD4?:1ZG_OD4>TAVC_X#'_Y$
M/9R[S_\  W_\D=%]ME_Y[2_]_)*/MLO_ #VE_P"_DE<[]I'J?^^11]I'J?\
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MC!\#/B;\0?$_BG_A0_PH^.3RZUX)N=3N[4MHOQ%L(KM%N++31IZKIOB;2K>
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M\4X\LX2OR3A.?12_Q?A_2L^7^+\/Z5_,[\9OC]_P4@_:)_X+2_'G]@+]G/\
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MQ5\1-#UYO&<<MQX9FTN+X<:#XLU2\L]6AC>2&_AT]K&%1_I5Q 2 3X^?M5?
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MD[<T>:<]/Q7^8I:0]/Q7^8I:V.<0=/Q;^9IZ]#_G^%J8.GXM_,T]>A_S_"U
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M*UC5M+O+WQ/XAG@L8+*!I)[B#\A/B3^S;^T5??L"_P#!R?X-L?@'\:;SQ?\
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MR>!Q52OSR6:3SC'XRI"E0AA*?]CX"FHPCB*6)A7_ %NHHHK$U"BBB@ HHHH
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M4=/N+:_L+AH!#>6=Q!=6[R02QNWY)_#S_@H__P %#OA!X1TKX?\ PO\ VO\
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MN)<NSM8ZCC,7F4Z.'PE*GA&\)E>'RFG2P^-HQQ53$8AXJK _7+XW?"C]FO\
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M#I%_K":O?6EN-/M;V6Y6X98WAR2M?M=\-/CS^UMXF_X*W?&;]E/QGHWA:_\
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MF:;?_#OX,^*M7TW2(+*+3[:RL_&?BKX=ZQXS3[)9PQQ6=T^O/>VC*)K>YCG
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M_P!\US_VGW_S_P!\T?:??_/_ 'S1[==_R_S#V/\ 5SH/M/O_ )_[YH^T^_\
MG_OFN?\ M/O_ )_[YH^T^_\ G_OFCVZ[_E_F'L?ZN=!]I]_\_P#?-'VGW_S_
M -\US_VGW_S_ -\T?:??_/\ WS1[==_R_P P]C_5SH/M/O\ Y_[YH^T^_P#G
M_OFN?^T^_P#G_OFC[3[_ .?^^:/;KO\ E_F'L?ZN=!]I]_\ /_?-'VGW_P _
M]\US_P!I]_\ /_?-'VGW_P _]\T>W7?\O\P]C_5SH/M/O_G_ +YH^T^_^?\
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MAL-8\?>-]8\3>-]4TVUNKF:6STR^\07%A99CCM+:&*&%(]SX#_L=_LX_LO\
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MDZ&H;]I@F[D2.02JDK?$B/XLB :>"IUW[3'9-:L\0@<\/\/_ -A/]H+]I?\
M8/\ ^"/WQ8^&7QR^'_PK_;E_9-^&>H?$?X/> ?CG;P:[X8^('@;5]1TR?1H]
M>T40ZMXHTV+3/#.C^"X+?Q!I^@:Q'I5G?FR:+1]2;3-8TO\ 88_\$1O^"5$/
MQ7/QHC_8K^%B^-!J U06'VOQHWPU6\^S+:AU^"C>*C\&4A" 3"S7P"+-;[_B
M9" :@3=5[Y^UC_P3^_8Z_;<T/PMX>_:?^!?AKXGV'@7ST\&W#:GXI\&ZYX8M
MKS[%]LT_1/$_P_U_PIXET_2;W^SK#[9I%MJR:7=_8K7[1:2^1'M]G$X?%8S$
M9MF?LJ6'S#,\=PQBZ.'PF.K8:EE,^&:6;QP^-P>/^IUG6QKJYM*A0IULM^K4
M<FH++*LJU9TZ]'R:=2CAJ>78*%6K5P. P_$U"K4Q.%IU7F5+B7^SH5\'B\#]
M:Y:>&5#+U*O4IX^5:KF4X8ZER4J4Z53\2?"'[:7Q#_;+_P"":_\ P6 \#_%O
MX*?#;X;?M(_L]>!OC=\,_C1J7P4F74/A_P#%+Q79?#?Q+IO_  EVCW327^HR
MWL4?A:ZTR>#4?$'B6==-LM)GBU*"*Y72--^C_P#@DU?_ !DN_P#@B=^S@G[,
M-[\';GXYP_#KQ-;^ T^--SXIF^%D6NV?Q7\1Q:G!XV7X?.WC!+2UL9+J-XM&
M O(-2DL4N%6%I ?U9^"'[*/[.?[-'PF?X%_ WX0>#OA]\*)[>ZM]2\'Z;8RZ
MA:>(1J.GQ:5J5SXLO]<GU36/%^HZIIT,=EJFJ^*-1U?4]3MT$=]=W SGQO\
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M+C1+2WTJ;Q;^Q#XH'B:2PACMCKAL!\6[:R;4O*51<O;6VB:/;0R2 NEOIEC
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M/&6JZS>>/M%\37$VMZM*_BS3O%-OXF$FH73IJRM*QKT:^ KU*F)>&?L:=#Q
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ML\3FM3.\=AYXS&8JM.C3P>#G"G*=7G<8RG64I).=DY)-I7:N?PM_\**^+_\
MT3_Q+_X*;[_XS1_PHKXO_P#1/_$O_@IOO_C-?W2?\,>Z+_SS/_?[4O\ &C_A
MCW1?^>9_[_:E_C6/_$RN=?\ 1+93_P"'/,__ )27_P 0,RO_ **',?\ PAP/
M_P O/X6_^%%?%_\ Z)_XE_\ !3??_&:/^%%?%_\ Z)_XE_\ !3??_&:_ND_X
M8]T7_GF?^_VI?XT?\,>Z+_SS/_?[4O\ &C_B97.O^B6RG_PYYG_\I#_B!F5_
M]%#F/_A#@?\ Y>?PM_\ "BOB_P#]$_\ $O\ X*;[_P",T?\ "BOB_P#]$_\
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M%%?%_P#Z)_XE_P#!3??_ !FC_A17Q?\ ^B?^)?\ P4WW_P 9K^Z3_ACW1?\
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M$O"C+%_S.\?_ .$>#_\ EQ_+C_PJWQ__ -"Y>?\ ?'_UZ3_A5WCX=?#MX/\
M@/\ ]>OZ@)?V8-)&<(?O?\]=0]^.36>W[,.E#/R]E_Y:ZAZG_#M6Z\7\Z>V0
MY=_X78[_ .5F;\+,K7_,ZQW_ (1X3_Y:?S'_ /"K_'O_ $+UW_WR/\:3_A6'
MCS_H7[K\A_\ %5_34_[,6E9;"G''_+6_X^8^_P#+-1']F+2L_=//_3:_]1]/
M7L/Z"M%XMYT_^9%EVW_0;CO_ )60_"[+%_S.L=_X283_ .6G\S7_  K#QY_T
M+]U^0_\ BJ/^%8>/!U\/W0_ ?_%5_3%_PS)I7]P]_P#EM?\ K]>__P"K-<9X
MR_9[TW2=+DN4C.4"\^9>GE@P_B.. .GISW%-^+><I.3R++]-?]]QO_R O^(7
MY8W;^V<=_P"$F$_^6G\S>J6=YHU[+I^HQ""[A"^;%N5BF]0P!*L1NP?F&<J<
M@X((K/\ M ]OT_\ BJ[?XSD6_P 2O%,&XXBU&6,<]D=E'4@]JM?"3X4^(OBK
MX@M=,TFTN)+0RK]IN520H(U=%D/F(KE(H]ZB:8*Q0ND4:R7$D43?L<<TI4\O
MAC\74IX:C]4I8NO4G/EI48SP]&O.\Y27NQ]JXJZ<I-12C*<E%_D[P%6>-G@L
M-3GB*OUJIAJ,()NI5E"O5HPM"+^*7LU)JZC&\FY1C%R6E\+/AGKWQ/U^UTO2
M[9C;/+B>Y8B*((GS2_OF.Q$C7F63YBI*Q1K)<211-_0G^S#^S'HO@;2+(_8H
M6D$2-<73Q6CRW$J2:;,@_=W,C)#&1+Y$.6$89V=I)Y999%_9@_9DTGP#HUH!
M9&.0+:O<W#0W-N]Q)'_:<).T@*D<8=1%#E@F2[-+-++-)^AEA916-O'#"NU5
M10!DG@*H[\D_*.37\_\ &'%^)XFKO#T'4H9+AYWHT'S0GC:D&^7%8J-[J/VL
M/AY75)-5*BE7E:C^X\*<*4.'Z'UG$*%;-ZU.U2JK3A@Z<DN;#X9NZYFO=KUU
M9U&G3IN-"/[V73=.M].MHH((T1415 50H&,XX!/8XZG\R:Z[X3_\EF^(7_9$
M/@5_ZLS]J2L%>@^@_E6]\)_^2S?$+_LB'P*_]69^U)7Y_F'_ "+\=_V"5/\
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MO^NB%W_KHB ]/Q7^8I:0]/Q7^8I:LP$'3\6_F:>O0_Y_A:F#I^+?S-/7H?\
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M%RK,<GG>,<)#!RQ.7U,NP\\51_LC&QI8>&)HK#5,-AH[GP?^,WQ6_:$\)_\
M!K1\8_C?J%WK7Q2\<>.?B_J'BSQ%J#1/J/BJYLOV2/BSI%CXNU%X56.34?%>
MDZ?8>(K^5%437FI32[5WX'PO^T;X _:7_P""C?[;W[>>K>//^"0_Q3_X*8>#
MOV:?VH-6^ OP/U"'_@K#X>_8?\'_ +-%GX \(>&;O3&\$_!2VUC1[V^\=>+9
M=;'Q+U+XJZ]<:]!K\>NZ-HMG:6,/ABYLW_KF\7_L)_ KQ1XL_8G\3:9;^(O
M&G_L":WK&K_ 3P-X!N=!TGP/#::K\*=5^#</AOQ/IFI>'-9U&]\.Z+X0U:4Z
M-:Z#K'AN^AU.UM+B\U&^M4GLKCY9_:@_X(V_ /\ :-^.'B']HSP;^T'^V_\
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M?XOP_I6A+_%^']*SY?XOP_I7;#=^GZHPGLO7]&9\O\7X?TK/E_B_#^E:$O\
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M/Z5GR_Q?A_2NNG_E_P"DG,_\OS1G3=3]1_*LZ7O_ +Q_K6C-U/U'\JSI>_\
MO'^M=\/A^;,#/E[_ .\?ZUFR=OQ_I6E+W_WC_6LV3M^/]*[(;Q]/T.=]?G^I
MG2]/P;^0JJW4_4_SJU+T_!OY"JK=3]3_ #KLA\*^?YG.]WZO\V0OU'T_J:B?
M[I_#^8J5^H^G]343_=/X?S%;Q^%_UT0N_P#71$!Z?BO\Q2TAZ?BO\Q2U9@(.
MGXM_,T]>A_S_  M3!T_%OYFGKT/^?X6H&M_O_(E7H/H/Y5.O3\O_ $%:@7H/
MH/Y5.O3\O_05J9;2]$-;/T?YEF/HOU_K4WPR\+ZWXL_:8\$Z=H/Q&\9?#&\A
M^!?QQO9->\#V/P]U#5KNVC\?_LXP/I%Q#\2? GQ"T)=.N);F&]FEM-%M=66Y
MT^T2#5(;-[^TO88^B_7^M=Q^SU_R==X1_P"S>OCO_P"K(_9FKSLRJSHY3G%6
MFXJ=/*,PE%SITJL;JEAU[U.O2KT9JS?NU*52.S<6U%QVH4XU<7EU.?,X3S/+
MXRY9U*<K>UK/2=*I2J0>BUA4A+=<UFT_KO\ X4M\2?\ H[K]H;_PFOV4/_H8
M:/\ A2WQ)_Z.Z_:&_P#":_90_P#H8:^AJ*_%?[8Q_P#/A?\ PU9+_P#.4_0?
M[,P?\N(_\.&:_P#ST/GG_A2WQ)_Z.Z_:&_\ ":_90_\ H8:/^%+?$G_H[K]H
M;_PFOV4/_H8:^AJ*/[8Q_P#/A?\ PU9+_P#.4/[,P?\ +B/_  X9K_\ /0^>
M?^%+?$G_ *.Z_:&_\)K]E#_Z&&C_ (4M\2?^CNOVAO\ PFOV4/\ Z&&OH:BC
M^V,?_/A?_#5DO_SE#^S,'_+B/_#AFO\ \]#YY_X4M\2?^CNOVAO_  FOV4/_
M *&&C_A2WQ)_Z.Z_:&_\)K]E#_Z&&OH:BC^V,?\ SX7_ ,-62_\ SE#^S,'_
M "XC_P .&:__ #T/GG_A2WQ)_P"CNOVAO_":_90_^AAH_P"%+?$G_H[K]H;_
M ,)K]E#_ .AAKZ&HH_MC'_SX7_PU9+_\Y0_LS!_RXC_PX9K_ //0^>?^%+?$
MG_H[K]H;_P )K]E#_P"AAH_X4M\2?^CNOVAO_":_90_^AAKZ&HH_MC'_ ,^%
M_P##5DO_ ,Y0_LS!_P N(_\ #AFO_P ]#YY_X4M\2?\ H[K]H;_PFOV4/_H8
M:/\ A2WQ)_Z.Z_:&_P#":_90_P#H8:^AJ*/[8Q_\^%_\-62__.4/[,P?\N(_
M\.&:_P#ST/GG_A2WQ)_Z.Z_:&_\ ":_90_\ H8:/^%+?$G_H[K]H;_PFOV4/
M_H8:^AJ*/[8Q_P#/A?\ PU9+_P#.4/[,P?\ +B/_  X9K_\ /0^>?^%+?$G_
M *.Z_:&_\)K]E#_Z&&C_ (4M\2?^CNOVAO\ PFOV4/\ Z&&OH:BC^V,?_/A?
M_#5DO_SE#^S,'_+B/_#AFO\ \]#YY_X4M\2?^CNOVAO_  FOV4/_ *&&C_A2
MWQ)_Z.Z_:&_\)K]E#_Z&&OH:BC^V,?\ SX7_ ,-62_\ SE#^S,'_ "XC_P .
M&:__ #T/GG_A2WQ)_P"CNOVAO_":_90_^AAH_P"%+?$G_H[K]H;_ ,)K]E#_
M .AAKZ&HH_MC'_SX7_PU9+_\Y0_LS!_RXC_PX9K_ //0^>?^%+?$G_H[K]H;
M_P )K]E#_P"AAH_X4M\2?^CNOVAO_":_90_^AAKZ&HH_MC'_ ,^%_P##5DO_
M ,Y0_LS!_P N(_\ #AFO_P ]#YY_X4M\2?\ H[K]H;_PFOV4/_H8:/\ A2WQ
M)_Z.Z_:&_P#":_90_P#H8:^AJ*/[8Q_\^%_\-62__.4/[,P?\N(_\.&:_P#S
MT.>\*:+J7AW0+#1]7\7^(O'FHV?VK[1XK\5VWA.SU_5?M%[<W4/V^V\#^&/!
MGA>/[#!/%IMK_9?AO3=]E9VTE[]LU%KN_NBNAHKSISE4G.I.SE.4IRY80IQY
MI-M\L*4*5."N](TZ=.$5I&$8I17;",81C"-^6$5&-Y3F[15E>=2=2<G9:RG.
M<F]92D[ME?+?[2O_ #)?_<Q_^X&OJ2OEO]I7_F2_^YC_ /<#7N<,_P#([P7_
M ',?^HM8\O//^17BO^X/_I^F?+=%%%?K1^>G\VG_  =,3O#_ ,$X?!V)FBBD
M_:E^%:W&)#'&\*>&/B+/MFY"M&DD4<V'RJO&DG#(I'9?\%6_V[/V)_B%_P $
MKOVF_A]\.OVR/V6O''Q!\0?!32]'T/P/X*_:&^$WB7QCK>H_VEX;^T:7I7AK
M0O%][K>I7OV>*Y\^QL[*:?R8Y_,BV))CC?\ @Z8@>;_@G#X.Q"TL4?[4OPK:
MXQ&9(TA?PQ\18-TW!58WDECAR^%9Y$CY9U![+_@JW^PG^Q/\/?\ @E=^TW\0
M?AU^QO\ LM>!_B#X?^"FEZQH?CCP5^SS\)O#7C'1-1_M+PW]HU32O$NA>$++
M6]-O?L\MSY]]9WL,_DR3^9+L>3/P6<_6O]6?$S_=_J'^L& ]O_O/U_G_ -1.
M&K_5_P#F"]E['DM[;W_:^UO^ZY#[? ^P^N>&]_:?6OJV?>QM['ZM_P EC5_W
MB_\ M%^;EM[+_EW_ 'K'Y5_\%+;2'7/^"%'_  1K\/ZH9[G1_$7CW]F'1M:L
M1=W5NFH:9<_![QA;2VDTEM-#.$\EBL3QRI+;L%DMY(I$1U^^OVZO^"2_P4_8
M0_99^)W[7W_!,S5OBK^Q[\=?V?\ P_%\7+\^!OC%\6O%OA#XI^&?!0EU#7_"
MGQ#\)?$7QGXRT[7-.CT.XU>[T^W:--.,ZRVFJZ?J.G7UY;M\"_\ !2V[AT/_
M ((4?\$:_$&J">VT?P[X]_9AUG6KX6EU<)I^F6WP>\87,MW-';0S3E/)4M$D
M<3RW#%8[>.61T1OOS]NC_@JQ\'/V_P#]EGXD_L>?\$QM/^)O[6_QS_:!TFP^
M$FJ7/A/X-_%?PEX$^%'A;QA))!XD\3_$?QA\2O!W@O2_#]E<^&]/UVRTFZ\R
M:U6[9[Z\N;:TTZX)]SB+V?UWQ%>77_UK7'E;^R?J-O[:4_\ 5WA%8-QY/WO]
MGK'NO]:^N?\ "5R?75COW;J)^%EWM>;A#ZZY+AO_ %6Q+S-XM2>467&?%3Q?
MM5-2HO&?4E2]BJ*>/<GA/JR=3D/>_P!J3_@IA=7?_!#.V_;'TZ2W\-_%O]H[
MX*>'_AYX)TC1+E/M,/QK^)XF\ ZS%X4B,LEU<2>&;^/Q5XGL+:/SM0@T[02\
MT0F@EV?"?_!(WX:Z[_P2S_X*:^,/^">_B[7+^Z\'?M2?LK?"3XW^!+G4[V5[
M:]^,'@[PFB_$:WTR&6*&"*2^U:U^*6((O,NH]'\.>'K>YFN##&R>1_M+?LL?
M$KQK\=/^"2?_  16^#WQ5L? ?B#]E/X-G]I?XO?%NV^'^F?$?PUX6^(VDV][
MJ.A^*Y_ 'B#5=)TKQ3:VWBG3=:M[+1=>OH[&^A^(&FOJD-Y"\]E)!_P5D_9S
M_;__ &(-=_9,_P""F'QE_;I_X;.UC]F7XY>%O#RV]G^RG\*/V=;WP?X(\87,
MUWKD=_JWP[\0ZK%XGT7Q5/I2>#)K#6],)TV7Q29].O[1KNZCN-)8RE0XBK<0
MNG'#Y5C>*\5PM4S&,Z"RK_5>&&?"F+GATJLL13PU+Q#S&><TJT\/3PGU+)<-
M-5W"BI05'#5JV08?(%.-;,X<.QXAC@K5?KRXAJ8O^W\GA5E7A"E[6?!63?V;
M5I2Q3Q?ML]KQJT(U)MS^Y/VXO'_Q+_;Q_P""N'PR_P""5>C?$[XA?"S]F3X<
M?">;XT?M10_"[Q+>^$/$_P 5VNM,CU>Q\!ZMXCT=K?5K+PE+8:MX3TJYL(+Q
M;>Z_X2;5[^XMI=1T_P /76G_ *C?LO\ _!*G]CK]BOXB6OQ#_98\-_$OX.9T
MS5]-\0^ ]*^-_P 6_%?PR\;-J]M#;'5/%G@SXB^+_&5A>:WIHM;.72=4TZ32
M[JREM(5W20&6&7\=_P!K.^\7_L:_\%2_@K_P6(\.?#KQC\5_V+/VA/V>M%\#
M?'/Q9\,/#>I^+==^%FCWWA:RNK#X@^(]&TI9[F+PO'H6E>#->_MEHUL6L]#U
M[2'E@UB;0X-4_8G]F#_@JK^QS^VG\0;/X??LK^)OB3\96-CJ]]XB\;Z3\$/B
MYX4^&W@8:18I>FR\7^-/B/X/\%Z9::KJ1GLK32=)TO\ M?4+VYO[9_L\=F+F
M[M],CI4:5*%+$0IPXKI9MQ91SFG-..;4JM'/,UHX>E6BW[99/3X?HY?' *=L
MI]FL2X7Q_/(QS:K.LJ=?#SJU.&:V3\,5LKJ15-Y;4]ME675L;4A*BN6695,^
MK8B>)=5_VJHO")\N7QY5XU_P7LEDB_X))_MC-%(\3-X2\$1,T;LC&.;XK^ X
MIHR5()26)WBD0_*\;LC JQ!^3O!G_!2+0/\ @G!_P2M_X)-^-?%OPOUOXH:!
M\9_#7P(^#NLMH.OSZ;K?@S2-1^'TFJWWBS2=$M_"_B:[\<ZEIUKI?D:=X+M7
MT*?69Y8[>'7+.01I+]8_\%[(I)?^"2?[8RQ1O*R^$O!$K+&C.PCA^*_@.6:0
MA02$BB1Y9'/RI&C.Q"J2/PB_;TMKE_\ @DC_ ,$#%2WG=C\8_P!EE0J12,VZ
M?X<7I@7 4G=,.8AC,@Y3<*Y*%;$4LUXEA0G[-XSB?P3RNI)TE6C]7S;'<197
MBU[.;C&3>'QU22M.$E*E']Y!.I([<6J2X=R.M4I>W^IX'Q=S&-*-25*4ZV6<
M/Y!F.&7M*<93C^^P4;/DJ)<S?LZBBX2_;3PE_P %<?'.D_M;?!+]F;]J3]A;
MXL_LG:'^U,;J']F?XE>-OB?\,_&MYXTOK*RM[B;2_B%X%\$7%\?A3K+WE[IF
MDQ:#<^+/$^O0:AJ^EKJVEZ5#<2RV_P"56F_&KXB?!/\ X.+_ /@H1JOPC_9X
M\?\ [3OQ/\3?LW^"/#?@KX7^!M:\*^#;2[U4>"O@!K9U'QQ\1O'&H:=X3^'?
M@VVM](EM[[Q-JAOY5U"\TW3=-T?5=1O[:T?Z6_X+<1WA_P""BG_!"Z:UCN3M
M_:GU>-I;=)> WCKX$--&7C' :U2=I4)P;=9BP,:N0W]E.VN%_P"#F7_@HK,T
M$RPG]E7P$PE:)Q&5ET7]F]8B'*A2)#!,(SG#F&4+DQOCHR_VV,S'))?6ZE#$
M8;,_%_)?K<(8>>)K8+*N$,AQ.'=2-6D\+'&SH9Q4PM7$4\)&$H4:>(A@XUI.
MVF(A3P.49[)4Z-:EC^&/#?.GA)NK&A2QF,\1,7@,11CRUUB9824\HH8FE0EB
M76BZE>D\3*#4H_;G[.O_  4C\"_MO? ']N'PI\7_ -G'Q)\)_BG^RYX:^(/@
MS]IS]F'Q;XVT_P 0I-I\WA3Q<+K1]'^(WAS3]*_M31/$]IX?\0:"^O6N@Z;)
M:7$4EWIT=_8R:=J-[^ W[9OQ!^!GQ+_X-LOACXU_9V_9YA_9=^%NH?M/:7'I
M?P>@^)7B7XP-HE_IGQ%\=V&KZC-\0_%]AIOB7Q'<:[>6KZF7U2U$NGI/'I-O
M)+9V-LY^M_V18+L_MP?\')T*PW!\SPG?;8A'+^\EF\(_%E[7$8'S231.S6^
M6DC<F/*L2?SA\1Z/JVM?\&M'P%TK2-.NM1U/5/VMX[+3;*WC)FO;N_\ C1\0
M=/L8(2VU-UU?S0V<3,RQFXD2,L&.*\#$8NMF.4K'2IPI8C'\'^#^;U?8864Y
M?VCB_%^678AQA!2Q6)PTY931Q.&RR=6M3I8BM66%BJ]>-0]+"4*&6YI2HJM/
MZM@.,.*\+">)KKDHX&/A9/-E*;;IX:%6C]>KT*N/5*C6JX/#TZ>(G[*E4@_W
M@M_^"TWB+X'WW[+_ /PT-^PA\;/@=^R/\?5\&_#_ .%?[4_C+Q[\/[C4[_Q!
M?:9IT&F:AXQ^!NB'4?$7P\\,:A9B;7K:Z\4^++3Q3/X=@FU2T\&W9M[VWM.T
M^/'Q5_9GT7_@N/\ LL_#75OV1;/Q[^U)XD_9F\6>(_A[^U%+\8/$NBMX*T*P
MTGXRW,/@F#X2C3KGP/KD^IP:)XBL(O&VIWUMJ^CQ>*Y%MDDM[0K+^8'_  4V
M_:6T7_@IG\)OV1?^";'[/?PY^,]I^UDGQG^%?B#X_?#+QI\)/'?A+7/V;/#_
M (*\+ZKX:\1ZUXTU[7=&TWPK<Z9:WOB.+4;+Q+X8UO7?#>HZ+9_:8]4AN=2T
MJUN_J+]H+2I[#_@YD_X)^6J)<W$%A^QGXLM?M;QNWFI8^'_VC+5YI) NS=O>
M$2MD!9)XU.#(@/U-*M+'YS@6\6J]&KX@\3Y=E6<4HX5ULQRK_B'W%F:_VCA*
M].BL+[3!9Y4JX"GCLOI4J&*HPJ9=6C7IX?,Z5;YZCA:.%R7&MTI8?$4O#C"Y
MCC\HG+$PAEV88?BWA++<)AL3SU55K0S'*)2Q-7 XN5249TX9C2Y(XW+W3\&_
M8"_;G_X*<^+O^"J7[;/@OQ'^RW\1_B#HMSXR^%.D?$GX#>)?VW?!5_X)_8;\
M,7NH6EAJ?BGP3'K4%WX/^(BRZ3-<ZU?Z#\)]+T"^U62V%I<R37LL<J_JW\6/
M^"J_Q$U;]H'XM_LT?L#?L4>,OV[OB'^SS+I5K\>];L?C9\-/@%\,O &JZM'J
M07PO8^.?'MOK:>*?&-C>:=)8ZAX?L=)M#%=6^L6]O>W-UH>H6R_G+\ /C9X
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M652<O8S;4:BDJ4K35.4_U3E[_P"\?ZUFO_\ $_\ LU:4A!&1T+9'T.:S7_\
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M]?Z&J$O?_>/]:OOT'U_H:H2]_P#>/]:Z8?H_S.<HR_Q?A_2J$G5OI_2K\O\
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MKVE_VAI=[;77V#6=+T[4[3S?(O;*VN$DA3^<[X8_\%*?&_[>_P#P32_X+!>
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M*4[1Y^2!1116984444 %?+?[2O\ S)?_ ',?_N!KZDKY;_:5_P"9+_[F/_W
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M /P=:;_\E5_G/_VG<_\ />3_ +Z/_P 31_:=S_SWD_[Z/_Q-'_$JS_Z+9?\
MAA?_ ,\P_P")@U_T2D__  [+_P"8#_1@_P"$Q\)_]#-X?_\ !UIO_P E4?\
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M=S_SWD_[Z/\ \31_:=S_ ,]Y/^^C_P#$T?\ $JS_ .BV7_AA?_SS#_B8-?\
M1*3_ /#LO_F _P!&#_A,?"?_ $,WA_\ \'6F_P#R51_PF/A/_H9O#_\ X.M-
M_P#DJO\ .?\ [3N?^>\G_?1_^)H_M.Y_Y[R?]]'_ .)H_P")5G_T6R_\,+_^
M>8?\3!K_ *)2?_AV7_S ?Z,'_"8^$_\ H9O#_P#X.M-_^2J/^$Q\)_\ 0S>'
M_P#P=:;_ /)5?YS_ /:=S_SWD_[Z/_Q-']IW/_/>3_OH_P#Q-'_$JS_Z+9?^
M&%__ #S#_B8-?]$I/_P[+_Y@/]&#_A,?"?\ T,WA_P#\'6F__)5'_"8^$_\
MH9O#_P#X.M-_^2J_SG_[3N?^>\G_ 'T?_B:/[3N?^>\G_?1_^)H_XE6?_1;+
M_P ,+_\ GF'_ !,&O^B4G_X=E_\ ,!_HP?\ "8^$_P#H9O#_ /X.M-_^2J/^
M$Q\)_P#0S>'_ /P=:;_\E5_G/_VG<_\ />3_ +Z/_P 31_:=S_SWD_[Z/_Q-
M'_$JS_Z+9?\ AA?_ ,\P_P")@U_T2D__  [+_P"8#_1@_P"$Q\)_]#-X?_\
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M\KPV2X7#\-5*&)RK,WDL,'G5:%3-:_U_+<WJ91FU..+PF&HTOK>!Q$\5V?\
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MJQN'PF)A]9K>UKTZ=3#TU&A.@Z?-1JTI/:\\?WO_ $&CSQ_>_P#0:Q?M/O\
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MMG/I%L/#^F:U(=122&5(D@NI8.&OO^"G7@W_ (*4?\$CO^"E6J+\-?%'P/\
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MEK">*)+R709+:>X3Q=H$=D+@31)J'E>7)^EAZ#ZG^0K^4_\ X*G>%?B5X_\
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M^'<FKYYB8U<-6B\52HXK"4H+!XN=-0G.<U5P]*="K0E_79'U'X?^A-7,W/\
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MCI/QGN_@)^SCX(^(O_!03XL?LQ?!?QQIWAWP_:?&CQUI/CN7X<_LXV/Q!O\
MR[6\MO!'B?XV:KH^KVOAV]U*1;?P_#XKODUNYWQQ2J\[!3[)X*^)_P -/B3X
M%TOXH_#KXA^!O'WPSUS2FUW1/B)X*\6Z!XI\"ZQHB1O*^L:7XNT+4+_0-0TI
M8HY)&U"TU":T6-'<S!5)'\K?_!5_X=?M6_M)_P#!93X+? 7X9?#K_@FM\7M
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M\._'7X7ZUX%^&=Y8B(W=G\0O%^F>*+KP_P""KFV,\ N8/$E_ILL!GA\U%\Q
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MB1Y)/ 'B%(XT9W=M&U<*B("S,Q.FX"JH))/0 FLT_LZ_& =?".JCZZ;J@_\
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M--\46WC3QYXCT>Z\/:,]W=>.?$7B)/$,=A%;^)8M8MGFBDF_;C_X*B?L*?\
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M:IX*\1^!)(KRTT.XTJ\\.'4I[+2;&8ZPFH0+=C\X/V1_V+?@]^VK_P %:?\
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M>!?"GA6R\&PVEJ9],\-Q>)K_ %&V_M34O$%W//.K_OA\+/\ @CA:_#/X#?\
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MZV__ (!V7_R91_PQYX;_ .?6W_\  .R_^3*^\J*^:/;/@W_ACSPW_P ^MO\
M^ =E_P#)E'_#'GAO_GUM_P#P#LO_ ),K[RHH ^#?^&//#?\ SZV__@'9?_)E
M'_#'GAO_ )];?_P#LO\ Y,K[RHH ^#?^&//#?_/K;_\ @'9?_)E'_#'GAO\
MY];?_P  [+_Y,K[RHH ^#?\ ACSPW_SZV_\ X!V7_P F4?\ #'GAO_GUM_\
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MUM__  #LO_DROO*B@#X-_P"&//#?_/K;_P#@'9?_ "91_P ,>>&_^?6W_P#
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MEP)J+6$&MW,G]:__  2^_8X^(G[%W[+6O_ OXOZQX$\3>(=:^/G[27Q/:Z\
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M]0@TF\UJ&RTB.UON<_9(_P"">7_!0S]F#PA_P48\70?M0_L]ZU^UA^U[\>?
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M;K4-CH?[4=GX@/QAU3XNZ;\/+N*_AEU?19O!=YXSFN-/N;>ST,PSV7U=?_\
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M8C$8W%XBU%_6Y8NOA,+_ &5B*6)P\*$<OQ61ULNPV"QN"K_I71116)04444
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MXZ5TT?4?A_Z$U<S<_P#)6/V<O^RL>)?_ %GOXZ5"^#$_]@.9?^JS,"*FU/\
M["LO_P#5A@#[8G[?A_6LJ7I^#?R%:L_;\/ZUE2]/P;^0K\ZI[OY?J?8/8SI>
M_P#NG^M9\O?_ '3_ %K0E[_[I_K6?+W_ -T_UKOI[?=_Z28/K\_U,V7^+\/Z
M5GR_Q?A_2M"7^+\/Z5GR_P 7X?TKKI_Y?^DG,_\ +\T9TW4_4?RK.E[_ .\?
MZUHS=3]1_*LZ7O\ [Q_K7?#X?FS SY>_^\?ZUFR=OQ_I6E+W_P!X_P!:S9.W
MX_TKLAO'T_0YWU^?ZF=+T_!OY"JK=3]3_.K4O3\&_D*JMU/U/\Z[(?"OG^9S
MO=^K_-D+]1]/ZFHG^Z?P_F*E?J/I_4U$_P!T_A_,5O'X7_71"[_UT1 >GXK_
M #%+2'I^*_S%+5F @Z?BW\S3UZ'_ #_"U,'3\6_F:>O0_P"?X6H&M_O_ ")5
MZ#Z#^53KT_+_ -!6H%Z#Z#^53KT_+_T%:F6TO1#6S]'^99CZ+]?ZUW'[/7_)
MUWA'_LWKX[_^K(_9FKAX^B_7^M=/\!]7TG3?VM_AS9:CJFG:?>>(/@7\>](T
M&TO;VVM;G6]6A\9?L\Z]-I>D03RQRZEJ,.A:)K6M2V5DDUS'I.D:IJ+Q"ST^
M[FB\O-8REDV=J,92?]BYD[1BY.T:.'E)VBI.T8QE*3M:,8RE)J,92CT85J.-
MRQR:BO[4RY7DU%7E5JQ2NVE=RE&*5[N4HQ2<I13_ %2HKSS1OB[\)_$?_"%_
M\(]\3_AYKW_"Q_\ A(O^%>?V-XU\-ZI_PGO_  A_F_\ "6_\(7]AU.?_ (2G
M_A%_(G_X2+^P_MW]B>3+_:?V7RWP:-\7?A/XC_X0O_A'OB?\/->_X6/_ ,)%
M_P *\_L;QKX;U3_A/?\ A#_-_P"$M_X0O[#J<_\ PE/_  B_D3_\)%_8?V[^
MQ/)E_M/[+Y;X_#Y8+&QYN;!8R/)S\_-@\7'D]G[?VG/S86/+[/ZMB?:<W+R?
M5L3S\GU?$>P_1EB\++EY<5A9<W+R\N)PTN;G]ER<O+B)<W/[>AR<O-S^WH<G
M-[>C[;T.BO//^%N_"?\ Z*?\//\ DH?_  J+_D=?#?\ R5C_ *)A_P A/_DH
M?_4E?\C)_P!0RC_A;OPG_P"BG_#S_DH?_"HO^1U\-_\ )6/^B8?\A/\ Y*'_
M -25_P C)_U#*/J6-_Z L9_X1XO_ .90^MX7_H*PO_A3AO\ YH/0Z*\\_P"%
MN_"?_HI_P\_Y*'_PJ+_D=?#?_)6/^B8?\A/_ )*'_P!25_R,G_4,HUGXN_"?
MPY_PFG_"0_$_X>:#_P *X_X1W_A8?]L^-?#>E_\ "!?\)AY7_")?\)I]NU.#
M_A%O^$H\^#_A'?[<^P_VWYT7]F?:O,3(L%C7)06"QCG*W+%8/%N4KU*-)<L5
MA7*5ZN)P])<L7>KB,/25ZF(H4ZX\7A4G)XK"J*O>3Q.&45:%6H[R>(45:G0K
MU'>2M3H5JCM"C6G2]#HKSS6?B[\)_#G_  FG_"0_$_X>:#_PKC_A'?\ A8?]
ML^-?#>E_\(%_PF'E?\(E_P )I]NU.#_A%O\ A*//@_X1W^W/L/\ ;?G1?V9]
MJ\Q,FL_%WX3^'/\ A-/^$A^)_P /-!_X5Q_PCO\ PL/^V?&OAO2_^$"_X3#R
MO^$2_P"$T^W:G!_PBW_"4>?!_P ([_;GV'^V_.B_LS[5YB9(X+&RY>7!8R7/
MR<G+@\7+G]I[#V?)RX67-[3ZSAO9\O-S_6<-R<_UC#^W'B\+'FYL5A8\O-S<
MV)PT>7D]KS\W-B(\O)["OS\W+R>PK\_+["M['T.BN-U?XC?#WP_JVJ:#KWCO
MP;HFNZ)X-O?B-K6BZOXHT33=6TCX>Z;<RV6H^.]4TZ]OH;S3_!NGWD,UI>^*
M+N&+1+6YAE@GOHY8W09W_"W?A/\ ]%/^'G_)//\ A;O_ ".OAO\ Y)/_ -%/
M_P"0G_R3S_J=?^1;_P"HG4QP>,E&,HX3%RC*,91E'"XJ491DE*,HRCAI1E&4
M91E&492C*,HRC*491DV\3AHMQEB<-&46XRC+$8>,HRBW&491E7C*,HRBXRC)
M*49)II--+T.BO//^%N_"?_HI_P //^2>?\+=_P"1U\-_\DG_ .BG_P#(3_Y)
MY_U.O_(M_P#43K1B^(WP]N+GP/90>._!LUY\3M.N]7^&UI%XHT22Y^(6DZ?I
M-OKU_JG@>!+YI?%FG66A7=IK5W>Z"FH6UMI-U;ZC-*EG-',P\'C(ZRPF+BK2
M=Y87%15H4ZM:;O+#)6A1H5JLWM"E1K59N%*C5J4A8G#/;$X9ZQ6F(P[UG.G3
M@M*[UG4JTJ<5O*I5I4XJ52K3A4[*BO/-&^+OPG\1_P#"%_\ "/?$_P"'FO?\
M+'_X2+_A7G]C>-?#>J?\)[_PA_F_\);_ ,(7]AU.?_A*?^$7\B?_ (2+^P_M
MW]B>3+_:?V7RWP:-\7?A/XC_ .$+_P"$>^)_P\U[_A8__"1?\*\_L;QKX;U3
M_A/?^$/\W_A+?^$+^PZG/_PE/_"+^1/_ ,)%_8?V[^Q/)E_M/[+Y;XJ6"QL>
M;FP6,CR<_/S8/%QY/9^W]IS\V%CR^S^K8GVG-R\GU;$\_)]7Q'L$L7A9<O+B
ML++FY>7EQ.&ES<_LN3EY<1+FY_;T.3EYN?V]#DYO;T?;>AT5YY:_%WX3WV@>
M%/%=E\3_ (>7GA?QYXBMO"'@?Q):^-?#=QH'C/Q9>7M_IMIX8\*:Q#J;Z=XB
M\176HZ5JEA;:+I%S>:E/>Z;?VL5LT]G<1QG_  MWX3_]%/\ AY_R4/\ X5%_
MR.OAO_DK'_1,/^0G_P E#_ZDK_D9/^H91]2QMY+ZEC+QE.$E]3Q=XSISG3J0
MDOJMXSIU*=2G4A)1G3J4ZE.<85*<X0/K>%LG]:PMI1C.+^LX:THSC&<)1?UB
MSC.$X3A)-QG"<)PE*$X3GZ'17GG_  MWX3_]%/\ AY_R4/\ X5%_R.OAO_DK
M'_1,/^0G_P E#_ZDK_D9/^H91=?%WX3V.@>*_%=[\3_AY9^%_ ?B*Y\(>./$
MEUXU\-V^@>#/%EG>V&FW?ACQ7K$VIIIWAWQ%:ZCJNEV%SHNKW-GJ4%[J5A:R
MVRSWEO'(?4L;>*^I8R\I0A%?4\7>4ZDX4Z<(KZK>4ZE2I3ITX14IU*E2G3A&
M=2I"$SZWA;-_6L+:,93D_K.&M&,(RG.4G]8LHPA"<YR;480A.<Y1A"<X>AT5
MYYK/Q=^$_AS_ (33_A(?B?\ #S0?^%<?\([_ ,+#_MGQKX;TO_A O^$P\K_A
M$O\ A-/MVIP?\(M_PE'GP?\ "._VY]A_MOSHO[,^U>8F36?B[\)_#G_":?\
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M^$M_X0O[#J<__"4_\(OY$_\ PD7]A_;O[$\F7^T_LOEO@T;XN_"?Q'_PA?\
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M %%%% !1110 4444 %%%% &/XA_Y &N?]@?4_P#TBGKY2EZ?@W\A7U;XA_Y
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M%[LI;KUE^AN?LX_\A+]H;_LMNG_^L_\ P)KZ*FZGZC^5?.O[./\ R$OVAO\
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M2GS14X0JXS"9?[RA7K1QN,K4JF'I8*A'%,JKEKUH4OWU*%3!1I58N+5:G7X
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^<_Q_\
M\K=__!+'_LRGXJ?^JO\ ^"B-?V\5_$-\0"!_P=W_ /!++V_8I^*F?_#7_P#!
M1#_&O[=]Z^OZ'_"OQ[/O^1SF7_85+_TW0/T?*?\ D6X+_KQ'_P!+JCJ*;O7U
M_0_X4;U]?T/^%>0>B.HIN]?7]#_A1O7U_0_X4 .HIN]?7]#_ (4;U]?T/^%
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M2E3=:&(=*4J4J4I%%%%<9U!1110 4444 %?+?[2O_,E_]S'_ .X&OJ2OEO\
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MJ/VC_P#HOGQD_P##G>-?_E[7IO\ P4=^$GPZ^ /[9'Q<^$_PHT ^%? 7A=/
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M!'[)'[+_ .T9^T9KO[86L:E^T-'I]G+8? RY^#-SIN@:M?:5J.O37<^E^.=
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MRTJES_AJC]H__HOGQD_\.=XU_P#E[1_PU1^T?_T7SXR?^'.\:_\ R]K]&_\
M@H1_P3>^"G[-/P&N/C)\ /B#\1?B _P_^+.F_"[XT6_C'5O"^HZ;X;N=4TJ
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MM!T/4/A]HVN:/;Z==OJ'AW5?%5GK]J\:PRZ:LT\$<NGMZ+J82BJU)UL?3=7
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M-V'U/\EK![LM;KUE^AN?LX_\A+]H;_LMNG_^L_\ P)KZ*FZGZC^5?.O[./\
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M_:!9(8(((D\/R^'YO#SK'%&NNOJ[*JV1'TK\'?VGOV:OVB)_%%K^S_\ M#?
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M^'/BF34EUSQ+X<DLQHVAO\,ETS6;]C.+RYKT'2OVL/V6M<\?>$/A3HG[2OP
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MR;V..K4<6\=2Q%66%5"IAFOUWHHHK(L**** "BBB@ KY;_:5_P"9+_[F/_W
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MYEAX5L=6A4HX/"XZ%7&X3!4,,\-!?JS_ ,%&M5U?X@_\$R/^";OQ=\<ZO?\
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MD^3\1YAF6-KYG6PZIXC$8Z.$KX>5-8^KBL76JRK4XUHSE5E-GP2\+^)_'/\
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M;]/_ (JOLKXL_P#!0OXF_%'P%\0?AWHOP0_8\^!&E?%>+[)\2]>_9Z_9]M?
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MUC_PVA^S>?\ A2'A^/Q(\^L:_P#:=,O]9U+XE?V3I]_<7O\ 9>G^'_"M[?\
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M3'XPW%[86FB:%I(CUO1?$'@1I;'4!>ZPNH:G;7EO].?LM_M4?MN?M:_MK_\
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M2+X:U.34M??7M1TNX\8&:W'AO0IKB[^R6L6JZYIG[:_L(7_QHU;X)'5?B_\
MM9_!C]MVUU'79+KX;?M&?!?P;X=\":;XW\#MI>EJK>*?#W@G7_$G@*#Q/9>(
M%UN&:3P;J0TIM._L^.>TMM1BO$/S#\??"?[6?P]_9F^"'PH^'G_!,;]C']K#
MX?7?@*;1OCK^R3X0^(?@?X(?#KP1XNN);&]L(?A+!\5?!%U\,]5^'^G7%[KQ
MU"'4]"T?Q ]_';:EI4*->3K#Y]_P17_8+^,_[%'@?]I;7_B]X6\(?!D?M)?&
MJ7XL>#_V7O ?BY_'OAG]GKP_-:74=OX//C&%SHVMZW%;WMGHFH3>'A<Z,++P
MQI36>I7<$D5O8_18"4GF_$,'2G'"U*F-Q5#$U)U?8X>:Q61PPV1X?#5Y2PLZ
M,?\ A6Q65YID,IPE@GB</G4ZDHX)GC8F,H99D;<X5,33CA,'B*5.,>?$1?\
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M4,;#(,5448QA413GA,1DV695B<1"C3Q^>Y_1Q-6\IO+56X9R-Y1G-2E%W5/
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MPE\4?&+7;[PW;W4$=W%HUO>O!HRV&AZ1=ZH]@U[7FRH9M0P>0X.AB,10AA.
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M'TV^\5>(;2P-I;PIJ-Y-'86-HWX>_LV_LH?\%._^"-/C#XY_#']CW]F?P/\
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M/X;_ &;?@MX0^/OQ,_:@\.^#/[/^.?QA\%^!OA[\1O''_"1>++O_ (2+P?\
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MOP]XP\$>,='LM?\ #7B/1+Y-ESIVK:3J,4]I=V\F%=1)&6BF2.>%HYXHY%^
MOV2O^"-?_!,G]ACXDZC\8?V7/V1_ 7PU^*-^VH&+QU=ZWX^^(7B/P_'JUO=V
M6J6W@G4/B?XO\:2> +'4;&_N]/OK#P/_ ,(]97>G3-I\]N]DJ0+^D^EZKIFN
M:9IVMZ)J-AK&C:Q86FJ:3J^EWEOJ&F:IIFH6\=W8:CIU_:236M]87MK-%<VE
MW;2RV]S;RQS0R/&ZL;].$98:O6JPC+#XF=.>$KSC&5'$2I+VE*IAZTN6G5Y4
MI5J,Z51)QC*O1DHPG7H5)FX8G#TZ4W#$87GABJ,).-?#\[5.I3Q%*-ZE%N25
M&I"I#FC/EHU8N;C0K0_+SX?_ /!%G_@ES\+?VH;S]LSP)^QU\.-"_:+N_$%W
MXMC\;#5/'6I:+I'BV^N(+NY\6>&/AEK'BW4/A3X1\5->P?;X_$GA;P1H^M6^
MH7&H7]O?17FIZC-=>O?M"?\ !-3]AG]JOXZ_!W]IC]H#]G7P?\1OCI\ [W2;
M[X6_$2_U'Q9H^K:))X?UE_$6@6NLV?AKQ#HNC>.-*T+7I9]8T71/'FF^)M'T
MG4;J\N]/L;>:\NGF^Y:*5.4J*R^-)NE'*9QJ97&FW366U(*T:F 4'%82<8^Z
MIT/9RY5&',X4Z4*-3_>RQTZG[R>9T98?,I3]Z684)WYZ.-D[O%4IN4G*G7=2
M#E*<G'GG4J5/E,?L1_LP"Y_:SO!\,O\ 2?VYK2"Q_:FD_P"$T^(7_%T;6V\
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MU#_P3J\%,I,?B?\ 9!^(.HN USR;+X<_MU3\%&$P&=%'^K(7 .X??%?U?_\
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MQY_T+.J?]^A_\<K^Y7_ABZS_ .>9_P"^M5_^/4?\,76?_/,_]]:K_P#'J/\
MB9;&?]$CA?\ P\5__G>'_$"\+_T4>(_\-E#_ .;#^&K_ (5YX\_Z%G5/^_0_
M^.4?\*\\>?\ 0LZI_P!^A_\ '*_N5_X8NL_^>9_[ZU7_ ./4?\,76?\ SS/_
M 'UJO_QZC_B9;&?]$CA?_#Q7_P#G>'_$"\+_ -%'B/\ PV4/_FP_AJ_X5YX\
M_P"A9U3_ +]#_P".4?\ "O/'G_0LZI_WZ'_QRO[E?^&+K/\ YYG_ +ZU7_X]
M1_PQ=9_\\S_WUJO_ ,>H_P")EL9_T2.%_P##Q7_^=X?\0+PO_11XC_PV4/\
MYL/X:O\ A7GCS_H6=4_[]#_XY1_PKSQY_P!"SJG_ 'Z'_P <K^Y7_ABZS_YY
MG_OK5?\ X]1_PQ=9_P#/,_\ ?6J__'J/^)EL9_T2.%_\/%?_ .=X?\0+PO\
MT4>(_P##90_^;#^&K_A7GCS_ *%G5/\ OT/_ (Y1_P *\\>?]"SJG_?H?_'*
M_N5_X8NL_P#GF?\ OK5?_CU'_#%UG_SS/_?6J_\ QZC_ (F6QG_1(X7_ ,/%
M?_YWA_Q O"_]%'B/_#90_P#FP_AJ_P"%>>//^A9U3_OT/_CE'_"O/'G_ $+.
MJ?\ ?H?_ !RO[E?^&+K/_GF?^^M5_P#CU'_#%UG_ ,\S_P!]:K_\>H_XF6QG
M_1(X7_P\5_\ YWA_Q O"_P#11XC_ ,-E#_YL/X:O^%>>//\ H6=4_P"_0_\
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M ./4?\,76?\ SS/_ 'UJO_QZC_B9;&?]$CA?_#Q7_P#G>'_$"\+_ -%'B/\
MPV4/_FP_AJ_X5YX\_P"A9U3_ +]#_P".4?\ "O/'G_0LZI_WZ'_QRO[E?^&+
MK/\ YYG_ +ZU7_X]1_PQ=9_\\S_WUJO_ ,>H_P")EL9_T2.%_P##Q7_^=X?\
M0+PO_11XC_PV4/\ YL/X:3\/?'@!)\,ZH !DDQ   =23YG %1GP'XV'7P]J
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MXK>/CCCY?\TQA_\ PZ5=-;?] 9#\(,(O^9_6_P##=27_ +MG\I?_  @WC/\
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M![&=+W_W3_6L^7O_ +I_K6A+W_W3_6L^7O\ [I_K7?3V^[_TDP?7Y_J9LO\
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M1KMI8=-TFW@MIM2\ITW]B/\ :>M_C)_P;Y^*YOAELT#]A_X'_%/P?^U#?_\
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M_P#3],^6Z***_6C\]"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBEA&K,B@*K.[LD42/+)'&WL_[&7[&$7AU-.U_P 2627&MS2VL[BX2!S:;;B
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M'3_H\'_S7[]J3_YR5'_$1+_P1T_Z/!_\U^_:D_\ G)4?VKEG_0QP/_A50_\
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M ."6/_9E/Q4_]5?_ ,%$:_MXK_/F^!?[9W[-?[<W_!U3_P $R_BU^RS\2/\
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M_$M=4/T_R,W_ %]Z(:1>@^@_E2TB]!]!_*K,7NQ:4=?P;^1I*4=?P;^1H>S
MF7H/H/Y587H/H/Y577H/H/Y587H/H/Y5$OM?+\AK:7H6%Z#Z#^5;WPG_ .2S
M?$+_ +(A\"O_ %9G[4E8*]!]!_*M[X3_ /)9OB%_V1#X%?\ JS/VI*\[,?\
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MW'[/7_)UWA'_ +-Z^.__ *LC]F:O*S?_ )$N=_\ 8FS'_P!-X8Z,)_OV6?\
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@H **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>formdrs_003.jpg
<TEXT>
begin 644 formdrs_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $M EP# 2(  A$! Q$!_\0
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M_P"Q\1[+7_H>G].__#TO]D'_ *&KQ?\ ^$#XD_\ D2C_ (>E_L@_]#5XO_\
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MC'#NM2]K*"J0D_Z)/^'I?[(/_0U>+_\ P@?$G_R)1_P]+_9!_P"AJ\7_ /A
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M^&/_ !,LH_\ F,_!2FNN]'0':65E#8SM)! ;!X.#S@\'&#7[V_\ #K7]FO\
MZ*;\8?S\.?\ S/4?\.M?V:_^BF_&'\_#G_S/4?\ $U/@PM?[>S33_JG\?_\
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M5*?/&53$?@I17[U_\.M?V:_^BF_&'\_#G_S/4?\ #K7]FO\ Z*;\8?S\.?\
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M+!@\9:8-;M-*CEUF/PWXGM+)=,U62RL[FYM?M%O)/:R0I/%7ZB_\.M?V:_\
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M(^+)-/U?X=>-O$%]=_&?XS^(=7\+:I#>:%>6VBPZ1'\/?#[>'/%-T-43X/\
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MW=I;0?2M<DH\LI1;3<6TVG=-K>SLKKSL<[7*VKIV=KK5?+^N@4444A!1110
M4444 %:)_P"00G_83?\ ])%K.K1/_((3_L)O_P"DBU=/_EY_UZJ?^XRH?;_P
M2_\ ;3XL\+_L;^'/"W[</Q0_;G@^+?Q>U/Q1\4OA#X?^#]]\%]3URUE^"7AK
M3_#Z>'8XO%?AGP^L(O+7Q9?#PW U]>2W#PL^HZH\4:-=.3Z3^U!\)_$?QS^
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M+4AXU^$^KW/PLN=2N_%NM1_#2]U3Q1%X/L/@_JQ\1:Q:+IOC%+(:])J3)?\
M@F;\7=+TKP+#X'\9?!WPSK>C:/K%QXRU5K#Q.UOXN\?W'Q._:(\8Z-XMU^VT
MO3].O?%$EEX>^,>C:)/-J=_;:A&++6M-LKB'2X].,O[544?6Z]E&\+)6MR+:
M]U>[;=N[;;ZMMML^L5&K7C;_  KO?=N_WW;ZMGP9^P?^S%\1OV8])^-]CX]O
M_#$EK\3O'_@CQKX9T'PMXGO/$]IX9&B?"7PEX!\407,X\"?#?P]92ZWX@\,3
M:]:VGA/PAI&E0Z;>V=M=0SZK:7E_>_>=%%83G*I.4Y6YI--V5EHDM%=VT2ZF
M4I.<G)VN][*RV2V]$C0D_P"05;?]A"Z_])K:L^M"3_D%6W_80NO_ $FMJSZ<
M_L?]>J7_ *3()?9_P1_)A1114$A1110 5^>?[9/[,7QH^-?Q5_9Z^(7P0U+P
M!X \3?#3786O?C5-XH\:>&/BIX"T3[1J]QJ^EVFA:/::IX+^,WP[\1VFHM:W
M7PR\866FFU\02/JT.MIIM_J*6WZ&45<)RIRYHVO9K575FFG=-I/1[.Z[IK0J
M$W!\T;7LUKJM5;O_ )KR/SU^(7[)7CR7QU\8?B+\*IO ?AS7/$_[1?PG^.'P
MP73-8U#X>ZSX1B\+? NY^#WC^6'7=,\&^*]!TSQ9XG;5]=GFEU/P=XRT;7]
MU/4H-1CTWQ'>V.N:5YI\6_\ @G7JWCG]G[X ? VR\1>"O%)^!_[,/[1?P;B\
M0?$.VU:Y:^^)/Q?^'&B>%?"GQ!T^-;75;BT_X1[Q%:ZMJ<^K2R_\)%I-K/9W
MNC/)JRNT7ZJT5?UBJN2TDN1WB[*]^50U=[OW5;=;O>Y?MZGNZKW7=:=;6[]C
M\5/'?_!,?XHZUX]\=ZQX,\5_";PQX%UOQ6^M>#_"4">(M.M/#>EW%GX2:]LD
MTG3=#.E6,]YK6C:YJ]U]@#)=7FK-?7$DE[>7TA3PO_P35^-7A^'4K*[\8?"7
M6IO$LFF:?IWBNZO?%P\0?L^MI'Q!\ ^.9OB5\'(6T-EN_'7B:R\*W/AK5+1;
M_P )&W?3/"=U/KVJ:$FK:"W[645:Q==;2CM;6">EK=7KIW_'6[^L5.\=K?"N
MUNY^<?[,7["&F?!R72[/X@>'?A#XL\.0_ [X9^%M:T33] -_:ZM\<O WQ1^+
MGC&Z^+%Y;ZOI%M!J&K-X:^(6E:+I7BN]#>*8+C3[FW!MK"TTUA^CK,S,S,2S
M,2S,2268G)))Y)).23R3245C.I.H^:;N_P .NRN][Z^B[*V<IRF[R=W_ %_7
MW=@HHHJ"0HHHH *Y;QS_ ,B5XL_[ &H?^BJZFN6\<_\ (E>+/^P!J'_HJM*/
M\:C_ -?J/_IVD53^.'^.'_I43[ 7H/H/Y4M(O0?0?RI:_1#Z8*",@CU&**:_
MW&_W6_D: /XS]=_X(2^#M1U_Q#J1_P""DO[.EHVJ>(O$&J-:2Z1HIELVU/6;
MZ_:SE)^*BDRVC7!MI240F2)R8XS\BY?_  X9\&_])+/V<?\ P3Z)_P#/5K^2
MOQQI6F-X[\?LVGV3$_$'Q[DFUA)/_%8:V.I3TXKF?[)TO_H'6/\ X"P?_$5_
M0T?H+^'TXQJ/B'-DZD8U&E@]$ZL(56E_PKK1.JTM%HEHMC[9>">022D\;B;R
M2D_W<MY)2?\ S%=Y,_KZ_P"'#/@W_I)9^SC_ ."?1/\ YZM=-H'_  1)L/"^
MG>+M*T'_ (*?_LZ:=8^.] M_#'BF./0?#SR:EH=KKNE>)H+)+E_BF;BQ*ZWH
M>EWAN+*2&X=;8V[2&WFFC?\ C?\ [)TO_H'6/_@+!_\ $4?V3I?_ $#K'_P%
M@_\ B*J/T%_#^#YH<1YQ&232E'".+2E&4)*ZSA.THSE%]XRDMFREX)Y G=8[
M%)ZJZIR3U33U6+ZIM/NFUU/[A?!7_!,CXA_#WPEX>\#^%/\ @JM^RU8^'/"T
M]E-HEM>?#7X?:M=VT>G>*;OQI96$VHZA\1IKN[TN#Q/?W^JM93NPN7O;FVNY
M+BT,,$-*^_X);>-=1D:XN/\ @J;^RLNH7$/AN#5-:MOAE\.K77_$7_"'Z]X3
M\2>%[CQ/KD/Q#&I>(+S1-4\#>%?L=UJ%Q(YLM)6RG$R7E^]U_$/_ &3I?_0.
ML?\ P%@_^(H_LG2_^@=8_P#@+!_\173_ ,21\%<D:?\ K;G_ "048PA[&?+"
M,(\L5%?VQ[JC'W5:S4?=ORMIZ?\ $&<FLH_VGCN6*2C&T[))622^MZ66BMLM
M+VT/[;;G_@E3XMO?'8^)5_\ \%3/V6]1\7R^#M8^'VJWFH?#OP'=:?XF\$:\
M]^^J>&?%FBO\21I?B+3)EU&>WA6]M_M%G:PZ?#:SQ?V=:O'Z/X'_ ."=GBSP
MCYFG:C_P4B_8W\5^#X_#GQ#TG2O &H_"GX96/@S1]<^(GAOQ)X<U;Q7:Z%8^
M.!8OJ%S!XFN%\1VKPK!XSTO3M$T#7Y)-.T3219?PE_V3I?\ T#K'_P !8/\
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M:C&<*$ISE6IXBE+%\V'YHTI5*M"K%\S7Q1E'1N+W7[C_ -GW?_/-/^_]O_\
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M 4 8 %*L.J((PDLB"'=Y06]C41;\A_+ G 3<"0VW&[)SG->2S>)O#5OXKL_
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M[_V__P =H_L^[_YYI_W_ +?_ ..UQ.!Z#\A1@>@_(4?\0\P7_0SQG_A/A?\
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M_A/A?_DP_P!7Z'_016_\ IG;?V?=_P#/-/\ O_;_ /QVC^S[O_GFG_?^W_\
MCM<3@>@_(48'H/R%'_$/,%_T,\9_X3X7_P"2#_5^A_T$5O\ P"F=M_9]W_SS
M3_O_ &__ ,=H_L^[_P">:?\ ?^W_ /CM<3@>@_(48'H/R%'_ !#S!?\ 0SQG
M_A/A?_D@_P!7Z'_016_\ IG;?V?=_P#/-/\ O_;_ /QVC^S[O_GFG_?^W_\
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MC ]!^0H_XAY@O^AGC/\ PGPO_P D'^K]#_H(K?\ @%,[;^S[O_GFG_?^W_\
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MPL^*_CJ^L/&MSX$\(ZA\1O'^K^,FU:?7]:O=>\*:UX?\(ZO;>&K+;:4O&O\
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M'@;QEH.;_P 0?M"_">[^*&JZ58?M&:\/V@/BWXVT'0_$WB+4;*[L'BT7X?\
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M8MIVKWG@VV\<?M/:C\8?B)K@\>Z1?>)O"OB+6?!5Q^S=X1?1==T:U\!Q^'/
MUM+KNE?#K7? OB+7$UOP]INHZM)9>'WFUBUN.:.-DW33P\_?M?EYFTOWEVDX
M*]G!;M73;6EKI2NXVB_>:7I=R7;5+EU>FCNM-_TS )( &22  .I).  .Y)X
M[FIFMYT4LT$RJ!DLT;A0,$Y)*@ 85CUZ GL:_#/2_B__ ,%!8/"4'B[7?$7Q
M#\275UX,^$7B/4?A_=_L_P#A33M,NM4^)WQU^-'PN\=^$I#IGA"#Q)#I7@KX
M7>'/ GB^"SCU!==T[4[X>)M=U2X\/Z]!I*> >!=>_;4\->,=.\<>'/AO\2/$
M7C'4]0LKFU\*>*?!GBO_ (0>;6-1F^%>K1:?9Z-?^1HW@^T.L6%UIUE?V+V
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M:(2.(G(+QAV$;D="R [6([$@XIE% $K33,XD:65G5=JNTC%PH!4*&)R%P2,
MXP2,8--,CLB1L[M&F=D98E$W?>V*3M7/? &>],HH D\Z;.?-DSECGS&SEE"L
M<YSEE 5CU*@ \ 4IFF((,LI# A@9&((.<@@G!!R<@]<GU-144 2M<3NVYII6
M;Y/F:1RW[LDQ\EB?W9)*?W"25P3474DGDDDD]R3R2?<GDT44 %%%% !1110
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M[_T!XK_P]\1?_1"'_$:?%/\ Z+7./_ L+_\ ,I^\3?\ !;GP:RE6_P""5?[
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M:KVEUJUH^FNUKRL=GKDX+'9BY)V<5C*K=U%S=K56G:*NVFTMFTW8^_?[1?\
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M?'2?_!9:_P#Q-']HO_SXZ3_X++7_ .)K/HH]A2_D7WS_ /E@?VQFW_0SQ_\
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M ,36?11["E_(OOG_ /+ _MC-O^AGC_\ PKK_ /R9H?VB_P#SXZ3_ ."RU_\
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MMM1N=.BMKB]N-3TQ5U3Q#9P*G-^"/V'_ /@G1XTA^*FOWWB3P3H6@^(_@O\
M#3Q+X'\.Q?M0Q#Q#\'OB/XT_9=O/B9J6CVJZSK6C/XHTE/BS);>#K*3Q'<>,
M-;BU>U;POJ'AG2T>\U:W_._Q'_P3EUFU^(FN^$/"OQ4\&7_AV+7X=!\*Z]X@
M\,>(M.U/6IM3^.NH?L_^&+35M$TJPU)=)N]4^(ED@N;F*:ZTK2M.NQJ<\P6V
MNUB^>/C5^S3)\']$U6\NM>TSQ+K/@3XU>+_@#\4+:QTUX-(T#XD>']!TWQ.+
M?PY?7L,%YKND3P2Z]H][JDMI;Q2ZSX7NK[3C<:+JVEW,E8;+Z==4</@N-<XC
M4JT\.J<8PG[M/FHRI6HU90I89REAU0M&7QSJT)QDZTU/+%YI5PTL1B\R\/,A
ME1P];%.K.4Z7O5>6O&M>O1C4K8Q06+^L)SBU[.%'$0E#V%*5/]0_^"D/PK_9
M@D^$%W\9?">D_"SPG\2HM'_8U\.?#S6?A=\:?"WB5?C+!J7P2@MOCM;^(O@=
MX9N;BW^&E]\,]:TC3'N];-IIMWKFL7UW<ZE<ZI<ZH4@_#&H8[>WB9GB@AB=A
MAGCBC1V!.2&9%#-SSR3SSUJ:OL<GRVIE6"6#GCJ^/4*DY4ZN(34J=*7*H4()
MU:\E3A:4DG5DN>I/V<:5+DHP^!X@S>GGF82Q]/+L-ECG1I0JT<*TXU:T.9SQ
M%1QH8:+J5+QA>-"+]G2I^UG7K>TKU"BBBO4/$"OZW?\ @WL_Y-4^,_\ V>+X
M+_\ 54V=?R15_6[_ ,&]?_)JGQG_ .SQ?!?_ *JFSK\^\3_^22K?]C?(/_5H
MC]2\&_\ DN:'_8BXF_\ 5.S^AB[DT!=0TV/49/#:ZS(TO]A)JCZ(NNNX7_2/
M^$>6_(U9W"_\?']C L%SYWRUYK\=]<^%F@_"KQ(_QKTY-8^&/B&[\+> O$ND
MR:3=:U%J4OQ&\6Z'X&\/6<EC9-'>1K+XFU_1S_:EK+!<Z$RKK<%Q;S:>DT?E
M7QC_ &*O@7\=OVD/V8/VK/B!:>,9OB[^R#=^*+WX,W&B>*GTCPQ;S^,$C36?
M^$K\.K87*>)$;RD-H#>6#6Y!7?)&[HW=_M+?"36OCC\'-<^'7AOQ%H?A77[K
MQ/\ #/Q;HVM^)M/U#5/#\.H_#7XE^$_B-;6.L66DW=AJ<ECK$GA<:/-)874=
MW;+??:8%E>(0O^#2=7DQ;E1II6DZ5FINLE36M2+2UNG&S>JM&^BD?T[%4N?#
M_O)ZM.LW%P5)^T?\.2<W)**C/G48M2;2B^6[\W\1?LM_L>6"ZQH'C#2-"374
MUBUU?Q7X@\5?&#Q@?B?JLWC70I?AI8:;XS^(6J^-E\?ZYX2\;>&=(G\!6'A#
M7M;N/"GB32-,GT.STFZ:UF5>0_X5Q_P3I6T'Q-@U;]GZQ\.6'C1[:_\ $.F_
M&#3M-^'NH^-9=;?XBZ;X?\66MCXR@\&>)9M UXR>./!GACQ%;:A8>#[C=KGA
MBPTRU#2CC_C)^QW\:OCAXVU;QMXC^)OP6\-W/CN'X!P?$C3?#W@CQUK"PK^S
MI\2O'/CWP@G@>\UCQ#:3V9\46WCFYTWQ+)XEMKIM+NM+MKW0$EAO;B*+YA^,
M'_!/KXL^!/"^G/\ !/3?"/Q8\07W[,FD_LM?\(I?^#_#FG_#S2(K+]G'4?@E
MK'Q'\1Z+K?C7PPWVKQ!>-I5YHVIZ0=:O/#&DQZSI.N:7K-KJL<T/GN=50;CE
MU-)):.F[N=KQ]V+;:3TEV;Y6]&=E-4Y.,9YA44I/5QD^2*M:5Y3Y$KZ\NEN6
M-VDY**_2ZR^&7[+/P[L--\'_ -G_  R\/Z?\8_AOX3^ .A>&O$/BBVDB^*7P
MT\(Z9K:>$?AWH&GZ]K4S>+;.PTOQEK1MO[)2[U._AUQ'N+RZD>Q9?"_$7P@_
MX)UZKX>:\\7>,/AKJ/A_PC=6W@/7->\0_M,>([A)KW0_%4?Q*T?P7\0?$5[\
M2S<^*Y?"OBW0!XO\,>'O%M[JB>&KO1[NZT:UM+2UOT'H4O[-WBRU\8_ OQMH
M/BCX?-?_  ^_9Y\-?L[>.-.\:^$;SQM8#1=$U+PMXCF\8?"XQ7^FVFD>/+?7
M/#TUE;77B&WGTN2Q;2KZXMA=Z-'97'QY\*O^"77B'P9\2M!^(7C'XJ^ ?%9T
M7P_H.A7.FP^"O%EZ->OO#?PA^/?PGL_%4\?BOQ)JFC>';W4(?C8FM-X8\):1
MI'A+PM!X?GT'PS9+;ZG]MCN3K2DHK 4;/1.4.:*3C&:;:MM-W:MTY4^9.\4_
M9)2G+'5H2M=J#?-*2E4@XIM:/V:C:3E;WVVN5)+ZRUKX(_L- SZ)J+?#/0M2
M^$OP\T*2>?2OC!?^%?%OPO\ A@FL>)_$FB:PVOZ+XUTWQ'X/\.:E?_$;Q2__
M  D?V^S37--\8W&DW-_>:5J=E:-?C^"G[%/CWQ/<6ME#\.O%GB'X@Z1:_$>W
M\):/\4=3U6SUC2GU3POJLGQ1\-^!-,\7RZ39-X@U?P+X6FU_X@:)H]M<>*KG
M0!!K.JZ@[ZHEQ\S^'_\ @G+XRT'X&:C\!D^,'@B]TB#Q)\,?B?X?\=+X,\3:
M?\2KCXE_#_4_A3K%WX9\6>)=,\30W47P;U*[^%\,%AH^@R0>+M.L]1T:1KSS
M?"5D-2^@_P!E/]D.3]F[Q7\0_&5]XLT;Q5JOQ'\)^%=&U!+#2=>2;1]4TGX@
M_%OXAZX;/Q#XKUOQ!XBU/0M0U'XI-;V4.H7L=VT^E76K7D,$NJBSM+I*K4J1
MC/ T81<KN3A=)1E)7TTO;1>;YG=*R)NG"$I0QU:<U=1BN>*ES*+;N[63DY-K
M=6M\4N9_;4LCS2232,7DE=Y)&. 6=V+.Q   )8D\ #G@ 4RCCIE<]=NY=Q Z
MD+G<5&1N8 A20"02,E>HK;*UEI9=+)67E96T[6//"BBB@ HHHH **** "BBB
M@ K4/_(#7_L,-_Z0)676H?\ D!K_ -AAO_2!*RJ_\NO^O]+_ -RFM+_E[_UX
MJ_G1.7BDT ZO<Q0/X</B1;6-KZ.!]$/BD:>2# U_'$?[?&FDE?LYNU%CG9Y/
M5,_-?[3OBW]F_P .:C^SMH?[0NKZOX8U/XF_'&S^&_P&\6Z%KGC7P;J6A_&/
M7?"?B"2PM4^(/@35M#U3P1%XHT.UU+PPE_J&I0Z+K.HZGIOAZ[!N=2LR(/#G
M[%OP.\*_ME?$?]O'2+;QBO[07Q4^%>A?!SQ;=77BJ2X\#OX*\.IH::<FE^#S
M8)'I^K[?#NEBXU(ZE<"0I<M';0O>7#/T'[0W[-WA?]I&Y^$^F>.Y;&[\">!_
M$?Q U+QAX2O+6:2?QIHWCOX3>+OAF-.TG4H+FWE\/:UH5[XFM?%FE:[$D]UI
M^H:+:W-@+:]B@NX.>JJSH55[&DINM+EC93A.#J*TYJ\?>FM9:WN_)EP=&-6D
M_:U>3V<7.27).%3V<^:$-9\T8SY8QDTE.+DG&*>GA&D?##_@GC\2-.M-,/AW
MX>:9<>(?%?C7PGI_A[Q-XJU;P-XS\3:[\(4\9_ WQS'9:7>>)[#Q'KFG26MO
MXNT;Q#> W%IXZPWB'6QJNJP6U[;^TZ3I_P"R'\)KC2?%VG^)?@]X)DBT+7_#
MFBZ[??$G2K6V?P]^T'XPG^*VK6=I/JGB-[2XL_BAXNM[KQ?I5X!)_:"V]P^@
MW,6DPR0K^=>C_P#!*+XD0Z9\/=$\3?M0:'\1U\'>-?"_B[7/&&O>"_$6F>,=
M4U/PK\>OB%\7;NXFL?"WBFP\+Z]XG\7:!X\@\/ZWK/CVTUM?"WB'3=3\0>$-
M&L;?Q9J%O#V$'_!-;XHQ:/$S?%WX1)XX\/\ @+X*_##X:^.M(\$_$SP]K/PX
MT'X,_"WQA\*K;Q?ITVG>-3;^(?$_BO2?%,>H^*O GBO2M:^%FN):-X=U#3&L
M([74%XU/$)2ME]-M?#)4TM4DY)\K:>KY4T[-IW^%V[)1PTFE_:-5P;DI)^T:
M2O96YXIM-+F:DDU&UDVTCZSO/@U^PM9+?Z;?)\)[*P^ O@SPA\//&_AF?XIS
M6OA[PAX+\-PZE8_#WP]\:/"P\71Z1K<'AM=>U6U\%O\ $RPU2^TNZU:Y@TR9
M;J=(Q=\'?L;?LBM:Z=XQ\"^$3J2:S#X3U+2OB#H'Q>^)6M:GK6A>%?#?_"(^
M%-,L?'EKXZN]2U#P/:>$%@\+CPS;:JWAC4= L-.TO4-/NHM,M%@^2(/^"9/C
M726OGTKX\Z?JT^C^)M5UWPCJ7BG3_B =6\3:?XN^-VE_&WQKHOC^71O%D.F^
M![B_U33_ .R]*\2_!?2M&U^QG%MKUK=Z3=1W%I<_=7[)'P(O/V9/V>? /P.U
M'Q+I/BJX\$7'C67^W](T[5-#TFX@\6^/?$WC6UM+33]?UC7=5MX]*B\1)HXD
MU#6]1NKUK+[7)<O+<L!M0BZE5JM@J5.')*7/[-*TE-14;MM:QBKVM>R:O%HR
MJRC"E>CCJU63G&+IWJ13CR.3EKO:HVDG=ZM-<R;=&[_8T_9IN[[6M5_X5H;'
M6M<UFX\02>(-&\8^.]#\0Z+J]WXE\6^,+NZ\':[I'B:RU3P.MWXB\?>.+^[M
M?"-UH]I<Q>+O$&G3P2:;J,UI6E#^R3^SC::;:Z1I?PLTK0-/T_7'\3:5#X9U
M?Q/X9DT7Q"WPRM/@V-9T*\T'6]/O=%U"'X9V%GX7MKC3;FV:VBMUU.';K+RZ
M@_T5QTRN1R5W+O Z;BF=P4G@,1M)! )((!7=["@[OV5)WT?N1?R>C[^NIR>V
MK:?O:FEK>_+HK*VO;;I][;X7X=?#7P3\)_#<GA/P#HIT71KG7O$/BO4OM&IZ
MMKNKZ[XL\6ZG-K/BGQ7XD\0Z]>ZEKOB+Q+XAU6>2]U?6]9U"\O[V7RQ)-Y<4
M2)W5%%:1C&$5&,5&*T48I))>21#;DW*3<FW=MN[;[MO?^O*Q1113$%%%% !1
M110!I2?\@>T_["5Y_P"DMG6;6E)_R![3_L)7G_I+9UFUE2VJ?]?JW_I:-*F]
M/_KQ1_\ 2)!1116IF%%%% !7S5XT_:R^$'@'XV:5\!=??QG)XMN_#\'B;Q'X
MAT;P;JNL_#[X::5J.GZMJOA^X^)WBNQ\Q/"</B.PT+5[G3M0EL;O2+**TC?7
M]1T9;ZP-Q]*U^>'[3W[$/B#]I'X[^ /B'+X\\(>"/!6@>%-<\(>)=7\->%M=
MT3]H)_"WB'2;S1_%7P^TCX@Z)KEEH/BKX=?$"SO)+;6] ^(FDZI;^%(9M5D\
M-6=Q>:I#=:;S8J5>--/#Q4I\Z33C?1W\]%?1NSLNVYOAXT95&J\G"GR3]Z.Z
MDE[NB3YM;VC[O,[)R2N>D/\ MW? */PNWBTI\3FTXW&I2VMK'\.=1DU/4O#&
MB^!9_B=KGQ"TN-+XZ=>^!]!\ 6MQXFUV[CU,>(M&AB.E:EX8M=?D@TF7TWPS
M^T7X+\5_%^Q^"FF^%_BC;^*-7^']_P#%30M?U'P4L/@'7?AY9:AI&E6OBO3_
M !1:ZS?26^G^(M1UNSL_"D6MZ7I%_P"(9X=3CL;,MI&I"U^&;G_@FYX@E\/6
MNFP^-/@[:+8:!I?@>V^'ME\.O$]A\$Y=)\/_  ON?A;X>^+ESX7M-=&LK^T-
MI-G=2>(HO$<-[_8DVH);Z7<S3QV]OK$/W)\$_@E=?"?X@_$OXAZWXSO?B%KG
MCC1O@7X.TO5]8M6@\0Z;X'^!_P /H/#-GINL7QGFMK_4_$_C/4/&?Q"U:YTZ
M"RLAJ7BAX?LTDMJ;B3CI5<QG.*G3Y8^ZY-PBKI*JVM].9QA%VUC=/R?17A@(
M1DZ-2=27OJ,6YK6])0;O3BK6=235]4K:-:]!:_M _ 34+Y])TGXW_"#6];6Z
MO]/BT'1OB7X*U+6[O5-,L+K4[S2+/3;?7&GGU2*RL;R8VF%8?9;D2-']FN#%
MY[X0_;"^!/CKQT_PW\.:_JUQXLCOY--DM[S2K;3]+^U0ZGX:TB5;77[G55T7
M5U%]XMT1;<:%>ZK-J5O+=7>D0ZA;6<T@^.+3_@F"EAX&M/"5E\1O!EGJ5IX$
M^"7@U/$-G\-S:W'F_";]H/XN?'/4]31H=12\C7Q9'\4AX>:%;KS;>\TN[U6]
MFO8=02UBXF#_ ()(WDUKIVE:I\=["/2H?L%M?2Z%X)OK'6([&"R\(:==2Z%<
MSZW+;Z?JJVWAFXETNYECDAM+J]MC(CI;2>9I[;':?N8KK:*>OE>3=GMKMY+H
M*E@;2OB)]DW#5?WK1C:2?\MT_,_4-OC[\!$T:R\1/\<_@VGA[4M:O?#>FZ\_
MQ.\&+H^H>(=,>V34]"L=1;61:W6K:<U[9-?V,,KSVD5[9W$ZI;W4$K^LLI4E
M6&"."#_G\CT(Y%?D_/\ \$VO$'B+4=>\3^,OB/\ "]/$^L_ /XC_  #M;#P;
M\*[S3?!.BZ?XA^ 6C? CP;XWT_2=4U:ZO4\6V=MIL_B#QJXF6._M6TCPIH%S
M;Z=HJ7ES^I6@:;)HWA_P]HLUS]MFT3P_H6B37NUD^VS:/I-GILM[Y;L[QB[D
MM6N CN[H)=KN[ L=L-5Q-1OV]%4ERIIIN_-=J2:;=NC75:W,*]/#P:]A6=;5
MIMQY4E9--:*^MT]%=V:25S5HHHKK.<**** "N:\:?\B?XH_[ E[_ .@"NEKF
MO&?/@_Q/C_H"7O\ Z *QQ'^[XC_KQ6_],U3;#?[SAO\ L)P__J10/MQ>@^@_
ME2T@Z#Z"EK\L6R]%^2/V-[OU?YL*1NA^A_E2TAZ''7!Q3$]GZ/\ )G^3-XW_
M .1X\=?]CUXU_P#4JU>N9K]FO%/_  0O_P""E.I>*O%>I6?PF^',EGJ?BOQ/
MJ=G(_P >OA/$\EIJ6O:C?6LC1/XB$D3/;W$3-%(%DC8E'57!48?_  XC_P""
MF/\ T2/X;_\ A_OA+_\ -'7]O4^->#U2I)\4\/IJE233S;!)IJE2337M-&FF
MFNC370_SEQ'A]QW+$8B4>#>)I1E7KRC)9+CFG&5>M)--4[--2336Z:9^0->T
M?!WX)ZQ\9$\>W6G:]8^'].^'6A>']>UVYG\.>-?%U_<P^)O%NE^"]+M=(\.^
M ?#WB77[Z?\ M?5[:6\E%C':V=@DUQ+,7"1/^BW_  XC_P""F/\ T2/X;_\
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M)(;O5O$MC'#<>%=2U?Q99_$#39)Y'\,ZWXFGAU.SL]5\2VGVS]#-,_X)G?\
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MC\Q0%UW7WK_,6BDR/4?F*,CU'YB@+KNOO7^8M%)D>H_,49'J/S% 77=?>O\
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M:YU#5/\ D=O&8XU34  !XIU<  "Y      KG_/N_^@AJG_@UU'_Y*K;\6_\
M(X^-?^QW\:?^I5J]8%?YJ56W5JMRDVZU9MN4KM^VK?WC^UH?!3T7\.GTC_SZ
MI?W23S[O_H(:I_X-=1_^2J//N_\ H(:I_P"#74?_ )*J.BL[ON__  *7_P D
M5\E]T?\ Y$D\^[_Z"&J?^#74?_DJCS[O_H(:I_X-=1_^2JFL;8WVH:9IXD$1
MU'5-,TT3%=XA.HW]O9"8H"I<0^?YIC#+OV;-RYW#]--?_P""6WQ6\/?%/QCX
M1NO&WA*X^'OA_P 4?&CPCX8\:1:QX1L?'GQ"U3X'^#)_%OBZ3PS\(-:\6Z9K
M5S8Z<(X8];NH]7F32-,F_M6,:A)Y&GS^G@,GS3-(5)Y?A*V*A2JTJ-65*2M2
MG6IU*M-U.:M!PIN%*=ZK3A&7)3=ZE2G"?%BLQP.!E".+Q%.A*I3J5::G%_O(
M4YPA/DY:<E*:E./[M-2<>::M"$YQ_,7S[O\ Z"&J?^#74?\ Y*H\^[_Z"&J?
M^#74?_DJOM6X_P""=O[6L6E^$M0L_ WA3Q%=^,KSX36.G^&_"7Q,\%^(_%FD
MO\<=#N/$7PPOO%GANSU)=2\)Z+XETFRO[M-8UZ*RL[*+3[R:^:"W@:8]=H'_
M  39^/&J>%OBQXFU'6OAK;)X!^&OAGXB^ HO#/CWPMX[TKXZIXJ\?Q_#BRT?
MX;>)_#VKR:+>RV?B=+SP_J4S2R3P>+5TSPJ++[=J]M,O3#AOB&<N59/F:?LW
M5O.A4IQY%0JXGFYYUHQUHT:DHQ3E)RY*/+'$5J&'K8RSK*(Q4GF6":<U!<M6
M$WS.K3H6Y84W+2K4@FVE%1YJO-*C3JUJ?Y^>?=_]!#5/_!KJ/_R51Y]W_P!!
M#5/_  :ZC_\ )5?=7B#_ ()J_MA>$/%+>%_&/@'POX.B@\)7?C34?&_B[XD>
M#_#7POT72+'Q5:>!KNTUOXA:Q?VGA_3-?@\8W]CX=_L.>;[9/J%Y;-:_:+20
M70Y[PE_P3^_:F\<^$AXU\,>#O"FJ:*OCS3_AS<Q6WQ)\%7.JV'B'5?'<7PTT
MZYU"PL=4O!:^';WQE-%IUIKKW!MKJSD36;9)M)=+QI?#O$,:CHRR7-HUH^UO
M2E@\3&JE0]E[9^SE*-1QI^WI<TE3</WB49S:J*E2SC*7!5%F6 =-^S2J+$47
M3;J^T]FN=1<+S]E4Y8N2E[CO&-X>T^-O/N_^@AJG_@UU'_Y*H\^[_P"@AJG_
M (-=1_\ DJO>?CI^S)\7_P!G'_A$G^*6F>%[>T\;R^,K/P]J?@_QSX7\>Z1-
MK'P[UY?#'COP[>ZGX6U#4+33_$7A/7)(K#6M)N)%GM99HN6RX3P*O-Q6&Q6"
MKSPV,H5\+B*7+[2A7C.G5ASPC4AS0E-M*4)1G%W:E%IIO6W91KT<32C7P]6E
M7HSYN2K2<9TY<LG"7+)15^647%JR::LTM+R>?=_]!#5/_!KJ/_R51Y]W_P!!
M#5/_  :ZC_\ )51T5SW?=_\ @4O_ )(U^2^Z/_R)ZU\'/CU\:OV?/&-IX_\
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M7O[2OO\ GO\ ^0;?_P",T?VE??\ /?\ \@V__P 9JC11]=QO_0;C/_"O%?\
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MI-)0]QJ/*FTW&[?O-+\><*MJR]JGSW]E[O+[/W;:R3;EKK>RMZGPWXZ_:/\
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MO4C-?948J*6N^U]M$FV^^HVBBBL#H"BBB@ J^?\ D%+_ -A.3_TCCJA5\_\
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MBFWHDVWHF?Y??B[4=/'C'QJ#?V8(\;^-,@W4 (_XJG5^Q>N?_M+3O^?^R_\
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M.P%+_:6G?\_]E_X%0?\ QROTW_XB(?$__2-;]@G_ ,)74/\ Y3T?\1$/B?\
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MV\UXT4DGBGQAJ412.U@A9OM#_A*;#_H"W'_@U_\ N.C_ (2FP_Z MQ_X-?\
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MX2FP_P"@+<?^#7_[CI_5\RYG+V]&[LF_:+IM_P P]M/3MV5C^R)VM]2GO?\
MC4K_ '_6+]7IMJ^Y\<VO[&MYHWP>\*?#_P +?%*S\.^-O#'[3NF?M8'QR?A]
M)K_A[4_B'8>);KQ#<:+=^#O$'C6_U^Y\.:FD\6F7FJZK\0M5\<.L)U5_$LFJ
M.DT/B>@?\$P['P1J>L^)_ 7QYU?1O&/B?PMXJ\$^)-7USX::!XBTF\\.?%'P
MK>:'\8)-.\.#7=,M=)UWQ+KETGBOP;>0W,VE^"VMD\-ZAH_BO1)[F.3],O\
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M_P"R\3_-0_\ !K_^4FGU3%_] T__  9A_P#Y<;E%8?\ PE-A_P! 6X_\&O\
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M%3^'4_Z]U/\ TW,Z,)_O6%_["L-_ZDX<_P ?NQ_X\[7_ *]X?_1:U:JK8_\
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MA/Q!9Q:->26&OVVH:>(KS3((;NTGE\1T?_@IW^SQX@MM2GT/PS\7];G\-?\
M">77CNTT/P]X0UV/X?Z!\-=.^'6M>+_%'B'6])\<W?AN_P!&T_1?BGX3U*&/
MPGK'B/5KPG6M-@TYM6T:YLC[U8_LS?LY^&?"^L^ &TJVA\._%7X->$/V:;W1
MM<\<WCS^,?AAX%TKQ3;^&?"FB2W>IPWVH:S::9XQ\07$VKZ(\VN7Z75O>7$C
MK:6[CR[3_P!CW]C[1;;XFZK>Z_>ZQ)X[T3QA\-/B=XI\7?'F;5+N>V\6^%_
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MN:1R^O\ [=FC^'-<^'#:Q\$?B_H/@7Q[\)/BM\7)?$GB2R\):7K-CHG@*_\
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MU2Y;))Z[N6MAE%%%0=(4444 %;#?\B['_P!AZ3_TV)6/6PW_ "+L?_8>D_\
M38E./VO\$O\ VPRK?\N?^PBE_P"YCY3T']KOX ^)OVJO'?[%.C>,KVZ_:0^&
MOPZTCXK^,O [^&M<M[#3/ NN)HTFFZM#XKFM5\/ZA/-'XAT=Y=-M+N2]MQ>K
MYL2^7)B']IC]I+2_V9[+X<^)/$FASZMX-\1ZU\1D\;7NG+<77B#P_P"&/AS\
M&?'GQ;O]1\,Z+ $3Q!K=Y_PA::1;:1<7-I',M^TD4XGCC5O>H/ _A&S\37WQ
M MO!?A2T\;:QI\&AZIX\MO#.B6_C+5M(L]AM=%U+Q9%8IK^H:5:&&,VVF7>H
MS65OY4?DP)Y:;?&/C_\ #OX&?%N?X7_#'XU6]_J-WX[U[X@^%_AIHNG:AK^E
MW&MZ[KGPB\:Z3XYL%O="7%NQ^%M[XNDCN-3FMK:UF6.ZLY?[4BLU-+D<H^[+
MELN97NV[/F:M:RO9I:V2UN1/VZI5;U*2J.I)TI6Y(1IN<?91GSMIR4;QG+12
M;T4=UX+J'_!1WX/:*FJKXA^%O[0^@WVF^)-3\#0:/>> _#=WJNO?$324^'-[
M=^ /#]MI/CB_COM?_L'XL>!?$B7<LUMX=73-2U"UFUJ+6M"U;2[;2\0?\%%/
M@#X4UKPMX:\3V'Q"\->(?$7C>?X7ZKI6MZ%H4-YX!^)2>-+WX>Q^$/%%C!XJ
MFOM;NQXJM$6\O_AY#XQT33-"U#2/$.JZM8:9JUE/)S/C[]EK]EW]I_X=>*;K
MP1XUU'PI=1?&[Q)K]_\ $+3?$^M:=JOA3XH:)XD^'_@#XF6T5CJFHZ--H^H:
MG8? S2_!^A7+F&VTV]M)?%OAR/4GGD-WU&H?L6?L=Z]-9^*IM6U>X'B#Q9X=
MGU?Q%;?'J\,7Q9^(_A+XC:K\3/#.I^.]<@U4Q_$#X@Z3X_U75M4BMENHI;EY
M5TN]T6YL=/TVTL=;4+:JHG?5>\W\.G2V^W73569Q\V9WM&>%E"R:J7@E+]ZD
M]+WO&":EHE>2Y7SJQRVE_P#!3'X&7'A'3?$U[X?^(DBWU_8>'[.X32?!_A33
M/%'B:/X4:/\ &OQ?9>$CXZ^(>D,UMX'^'GB#1-5UD:M?6\][JFKZ=X3\,/XE
M\2S_ &$=_P"#/VU?"OQ5^-_P8^&GPG\(^)/%/PZ^+-I\9C;_ !NO[(:1X.OM
M9^$?A3PKXBO/#O@V.6\.L7^II=^*8M)UMO$>B:%91W%CJ,>AWFIRZ7J0@Y*3
M]F_]AC1;K0?V?[#Q':>&/&%A)XM^+WA_3-#^,5Q9_$?P]IOA;X?^$/@S\1=6
M37WO[N[\/>&Y/ %KX7\+>,-/U06R74:_VO&+?5+.34[/U7P/^S9^S/X$^*W@
MKXF^!KXZ7XJM+7Q?>_#/PG9?%V]OO T4OQ(T#1-(\=^*/!'P\N-;NK'5=7\:
MZ-X5T>XUKQ%:C5I+RYTVYUBWE@N[W6;F\35&SM&I=J7+>]MEROIIN[ZK1WZ#
MB\P<HIUL*X*=)3<''F24I>UAN[OX(V:4GS*SB^:_F5S_ ,%+_P!EBR6_^WZK
MX[L[C2/#WAGQ+K%A)X,EFU#2[/Q'!\2)[FPN+6VU"9Y]=\('X6^(;?QMI%D;
MFYT.ZU/PI"/M7_"0V[1]?/\ MU?![2Y_'VD^*?#/Q6\&^+_A7X*\1>//B/X#
M\0>%-+/BCPEH_AW4/AO:/:WG]D>(]4T2_P!2UJR^+'@O7M!CTC6+^SN]'NM1
M-S>V>H:3=6 P_P#AD/\ 8?U'Q/K?BG_A$/#FN7WBZQ_:7NO$6N0>-;S5?"/V
M3XVS^%I/CXFKZI8ZR="T&>232-%;1H9;NSG\"J=5;PV=*-YJ#23:O^QC^RCX
MJ^RV.LZ_XJUSQ'XZLM9DUGQ')\?-6E^(?QM\.^(D\%WUWIWC#7;;55U7XC>%
M8[?X9^!9=(MK*%;*PL?"5FEK,;2351>EJ':HM->OX=M'O9ZI[)WKFS"[]["R
M6O+9J*=Y)1;O=W=TTE>/NR@WS2@T[P[^W]\'_%-_INBZ)X&^-5WXE\6W4EK\
M*O"K^$O#UIKOQE%EXW\<_#_6[SP EUXOCL(+'P[K_P .?%=QK%SXTOO"830;
M2SURS6\M-1M@W$V_[>NHV_P:_8]^,FJ?!7Q+JEG^TMX?^*OB?Q?X1\&/%?>+
M?AQHWPO^'/BOXAZA=6-CXCU#P_8ZB;2R\+S0:_:ZIJ=I=P,\EIHT6I:D]I;3
M^T3_ +$_[/;_ /"(W%CH7BW0=:^'UE=V7@#Q5X=\?>(](\6^"6OOB%XA^*%W
MJ7AO789WGL=7N/%?BSQ(LU\\4_G>'M9O/#4T,FELD:=)IW[*/P.TKP#\)OAC
M9^&]9'@[X(>$_'7@CX<V5QXN\07>H:7X>^)7@W6? /C.#4]9N;N74O$%[JGA
MCQ!JMK'J>K3W%[9WERNIP2B\BCD"O0TM&;UUN];<K6CNMY-/NK=K77)F;;O5
MH1]SW7!*W.ZJE[T7%MVI)QW47_B;:\;@_P""CO[,M_?^)+/1]6\1Z];:'I6N
MZAI>J:5;>&GM?&5[X6@\+7'B;0]#LKKQ5:ZYH=QH:^,=&6[U_P"(.D^#/!<P
M@U^>R\2W-KX<U2>'R1/^"J?P:N+^^\16VDZXWPET[PK;:Q/K5KHTVN^.9O$N
MD2_M&1_$#P?#HVD:P?#K/H$?[/U[/X?\1Z=K>N:+XH;5X[>R<QW=C?1^\G_@
MG[^R^MC?:7:^%O%NFZ1<C3[G3M'TOX@>(K+2?"_B+3KGPG?#QQX5T])6M]-\
M;WVH^!O#.J:IK5VNIVUYJ5G>7BZ9!)K6L_;\Y_\ @G1^RC<6.M6.H^$O&FL?
M\)'>Z_J>O7VL?$[QAJ&JZKJ7BE_BE-K]_=ZE+>"X:YU.Y^,_Q&NYF0I'%<:[
M";6.WATG2X;9WPZV51[+7TU>]K]O\MBV:-ZRPT4N=I1M:_,^1:IMI1M>]KZ7
M:DG?.U[_ (*'_!WPU8^*)M4^'OQV_MOX>&>[^*_@RQ\%:!J/BSX4>'!JG@C2
M=.\8^,;2U\8OI\_A[7;CXB^%;C25\,:EX@UEK";6;R^TJRC\.:S]F^]YHF@E
MDA?;OB=XWVG<NY&*MM; R,@X.!D<U^>'QZ_X)[^#?C%XDU36/#?C35?A?9_$
M*]MY/C?+HDGBB?Q1\1-+LK_X:75KH%KK-EXNTC2K'P\;7X6^'[2;PUKN@>(=
M%6^>ZUZWABO+K4;;4?T0GE,\\TY 4S2O*5'12[%B![#.*B?L[1<+W=^9.[MM
M9)M*_7:^F^IT8=XOGK+$*'LXN"HRBHIS5GS2:C)VO[MTTDI7459$5%%%9G4:
MLG_("L_^POJ'_I)8UE5JR?\ ("L_^POJ'_I)8UE54MU_@A_Z2S*EM5_["*__
M *7 ****DU"BBB@ HK(\0^(-#\)>']>\6>)]5LM!\,^%M%U3Q'XCUW4I?(T[
M1=!T2RGU+5]5OIMK&.TT^PMI[JX94=Q'$P1'<JA^8?#O[<G[-?BCP;IOCK2_
M%GBQ-)U/4_$&G-I5_P#"[XBV?C+1[?PM+I:Z_P")O$G@M_#C^(M"\#Z7;Z[X
M?U&Z\:7EB/#\>GZ_I$S7HEN)+>"E&4M5%M7M=*^MF[?<F_ZUSG5I4VE.I"#:
M<DI22;BFHMZ]+M+S>U[.WUK17E?BSXV_##P1XRT/P!XE\2M9>)M?LM(U.*&W
MTC5]2TG0])\1:Z/"WAC6?&?B'3[*XT7P5H_BOQ03X:\+ZEXEO=/MM=UU9-/L
M7D>*5D\_/[7'P0'@_P#X3XWWQ$_X1&?6K[0M'UA?@[\3IE\5SZ39:[JFMZIX
M,M+?PS->^*?"_A_1_#.O:WK_ (JTNWET+2=%TV34KJ]2":T-P*$WJHR:=K-)
M]79?>T_N^8I8BA!N,JM.+CS<R<DFN6*E*^]N6+3?9-==#Z4HKG8O&/@^;2_#
MVMKXM\+QZ/XML=+U/PKJ=UK^E6%GXDT_7+6WO='N]#EO[NV_M.+4[2\M)[(6
M@EDF2Y@"INE13YM\0OVC/@K\*].T[6?'/CNPTS0]7@NKC2M?TZVO?$NA:BEC
MHOBWQ%?)9:KX;@U6TN)[31? OBJ_N(HW)C72FMRQN[BVMY4DWHDV^UF5*I"*
M;E.$4DFVY12L]4[WV=U9[.ZL]5?VNBN3T+QWX1\1VFCWNF:]8(GB)]13P]:Z
MI<0Z-JFOKI,:S:A/HND:G+;:GJ=K:V[I=2SV=K*D5JZW$WE1DD;>F:SHNMQ7
M$VAZWHNN06ET]C=SZ)J^G:Q#:7L:1R265W+IMS=1VUXD4L4KVL[1W"Q2QR&,
M(ZL59]GIN4I1=K23OM9IWLKNVO9I^C3ZFC1110,**** "N>\7?\ (J^(O^P1
M>?\ HNNAKGO%W_(J^(O^P1>?^BZNG_$I_P#7R'_I<3#%?[KBO^P;$_\ J/7/
MT!HHHKZT_%5LO1?D@KSGXP_\DC^*7_9.?&__ *C.IUZ-7G/QA_Y)'\4O^R<^
M-_\ U&=3J*G\.I_U[J?^FYG3A/\ >L+_ -A6&_\ 4G#G^/W8_P#'G:_]>\/_
M *+6K55;'_CSM?\ KWA_]%K5JOYQ6R]%^2/]0I?%+_$_S8445]&? ?\ 9N\0
M?'G2_'FMZ5XGLO#>F?#_ %'X<:/J9?P;X_\ 'FJWVI?%+7M2\.^&UL-!^'FA
M:]JJ6%M?:7<2:WJUW!#9Z=;R6Q!GFG2*M:5*I6FJ=*+G.5[15DWRIR>[2T2;
M>IS8G%8?!T)XG%58T:%-P4ZDE)I.I.-."M",Y-RG*,4E%ZO6RNU\W>1!YOG>
M3#YV0?.\J/S<@;0?-V[\A?E'S=..G%>J_ WX5#XS?%OP1\+XKV#0[?QAJUT-
M:UD6L,[:9X?T'1M4\4^)]4BM',<5_J%EX<T/5;C3K2=TCN]02VMY98XY7=?H
MG0O^"?O[0^O3^+)(4^&UMH'@Z]^(FC:MXM'Q+\+:GH \2?#K0_&7B"3PT)-)
MO+R[@UGQA8^ O$0\'VUY;6[W4D$!U9-*6XB+]#X-_8L_;>^$_C+P]\0-$^&N
MG^'?$O@S5M.U#1I/$7C;P+IMEJGB6;4]1\-O\.(K;5]?L8O$GBK5;^VU7P?K
MO@&Q:XU&[2[N-.8&*\28]-/!8E3IRJ83$2I<\7-1IR;<(S2J)<NUTI).ZYM5
M&3=FO+Q.>Y9*AB:6&SK+:>+^KU(T)5<73BJ=>I0F\,Y*HE?EG*E4E%0FZ:<9
MU*<8IJ791_\ !-S7O$GPD^!OQ!\'Z]JB>//C!?YOO _BOP]8YT&Q^)/A'Q;X
MW_9:T.PO]!N+O5KWQE\8M)\&W'AK5([_ $VPT/P[XV\5>"-+CNFM]:9DI0_\
M$R?&']C^(-4UGXN?"WPII_@GQ'H^@>+M0\8:-K7ASPOI4>H>*5\#:Y?Z)X@U
M8VL/B2+PKX]CNO!VL7=II]EX5/B*QN-.D\76NH6U[:6?*S_ []L.W_:2^(O@
M#X=>*[KQ!\6;/P[\)_B!XU\1?#GXAW5KH%IHURGP^\7?"'3[KQ7JU];3)>^"
M->U?P#X>\#Z9?W$VI:)XDTK2(-)F$5JM]76Z'\&_^"DVF:'::?:^+_&O@SPG
MJ0\0_$2&3Q1\>/"GA#PW=2^'?%D%]XVU^ZU#Q!XJM[:6X\(_$KQ/'IWC>SO9
MG7P[\3]=O-$U:RA\1WNI0MW*EAFW?*\;)PYJ4G3F^1SIJ,)2;CHI.I>51*;C
M%R<(NZ37A3QN:0C!PXOR&$:WL\736)HQ]O'#8N=2O3IPC-J52E3PS5'"3GAX
MU*JI_6*L;2E3J;UC_P $S%O?#>F"3XI1Z%X[C^('B;P=XCT_Q5\.-?T+0O"N
MC:-XAT>TT[Q5':K;WVOZJFJ:#JC:Q)IEEY2F9]/N-'U'6M+N8[R?YE^,W[+S
M?"+P/=^*E\46_B6;1/'W@/PEJSV^D2:7I=_X?^+?P9TKXZ?"+Q3HMO>A=6L)
M[SPK=ZMIGBKP_JZ//H6NV,'V"\N[2Z9U]T\1?!K_ (*):#X0U'Q)JOBOXC0Z
M2S:WX]UW0+_XGVFE^+9_%=CI]W=>,TTGP1=ZVGB3Q;XC\/Z!H']I:Z/#.GWE
MM;:):036T7V>T4)\^^*=1^).IW.E? #XO?$3P=X/T_0_&.LZ_P",/%?B?7;K
MQ-+I.O\ @GPD/A[867CG4O#TGB'5+ZX\#>$O"2^ _AMX,T:P698M1@T^PBG?
M68KJ+/$0PJ@XQP&(PU24+4YUI6C*<FE!^]-13^U.3:VDG&,;-=678C-*E959
M<19;F>'IUY5,30P=-3J4Z$;RK1C[.C.M-1?[NC2A&3?/2E&I5JQE&7R_]DM,
M%?LEKM)R5^SP[2>>2NS!/)YQGD^IJ<         <  #  '8 < =A7VSXS_87
M^(?@C3_$S:AX^^&MQXDT'1]9\9:?X0-SXAT:^\0_#3P]KO@?PYKWQ#;7/$&C
MZ;X9\(Z?H6J>/]+CUSP]XRU/2/$FCIH_BK^T+2"70I8I\3Q)^R%JOA"[_:&T
MKQ!\7OAO#JW[-WAG0/%7BQM,TWQOK?A3Q18^,+#PM<>!K+P7XZLM"70KW5_'
M&I>+;+0_"MA?I9OJ-Q9:GJLC6^AVK7XXI8+%1^*C*-KWNZ:2Y8U)M/\ >:-0
MI5)-;I1OIS14_:AGF55E%T\=3JJ7+R\D<3-M5*N'H0DDL,VX2K8K#TE-7BYU
M.5-JG6E1^0J*!TZ8]O3VHKE/4"O[&O\ @W!_Y,^^/?\ V>AX(_\ 50Z=7\<M
M?V-?\&X/_)GWQ[_[/0\$?^JATZOH^%?^1Q#_ + LP_\ 41GY?XP_\D16_P"Q
M]PQ_ZN8G[$?&G]C#X?\ QR_::_97_:G\2>.?BEX?\9_LD7GBN]\#>$?"7B"Q
MT[X>^,I?%\4<5^GQ'T6XTVZN]:CLUB T[[#?:>T*O(DK2H[*?0OVG/A1XK^-
MGP9UKX>^!KO0++Q9<>+/A9XNT:3Q3+JMOX?N9_AM\4?!_P 19M,U.ZT33]6U
M6SBU>U\+SZ7'?6>F7[V4]W%=/:3112(> ^-%S^VY%^TO^RS!\!=/^#=S^R=/
M>>*_^&PKSQO+&OQ0LK)8XQX./PIC>[A=Y&<S'5C!;7;Y$0(1"YK._P""@NFZ
M_JW[)?Q#T_PW!JEQJ$WBGX+O=QZ3HWB?Q'*OAVW^-GP^N/%L^H^'O!=Q:>*M
M=\.6WAB+5KCQ3I.B75M>:AX<BU2V\^**221?T)<S=%.<7MRZI\BYWI)65M;N
MS;NGN?S3+V2ACW'#U(OWG6;4H?6)*A%J5.=YW2C:'-""2E%^ZVF>1_'7]E+]
MH?XU^/M>\9WEW\$?!?\ PL2#]G.+QMI@U_X@^([CPW%^SI\3O'WCC3CX1O6\
M$^'X_$+>-M,\;K:7$NLVN@KX8U'29##%KUM?+-:?'_Q=_8'^)GPL\#V.G_#_
M .&_@OXW0:I^S=I/P A^%&A^"[J7X?0_$6#]FC4_@WK/QD\40(EJ^DZW>:Z=
M-F\*>,)=-NIHM+N=;A\6:[X8G>QU%]G0/$/[8/P\LOBW9_L\VVNZKX"T;3_V
MK/BU\)K#PM\*/$>@_#GXDZU8R_ +3/ 7A[PWX5^+EMXK\>> ?"OAA]?^+NIZ
M=X!T_7O,^)GBOPSJ6N:"9M(G.D24_&W[4G[=VA:/HDWA6#QIK\.E^)9]5\&Z
MW+\)/$.N)\:_":?%+X=>';[PYK4EI\"O#5_KFO:%X6U3QQ?7-S%X4^ >@P^&
MK6/Q5%XA\1ZCH<UE)T151.T9TFHMJUU&]DVKVD[?"EOIM=ZL\RH\+4IMSH8R
M$ZM.,G-)U;*4H*2A>$;I^T;=XKFMS6^%'Z#7O[-OC63QG^SUXV@MOA9XI?X9
M?L^^%_@IXCT;XE6NK:Q;^ ]<TC4_!^NS_%KX5MIFFWL%WXX@N] FT*/[5=^%
M1=VL&B7<?B2.W@N=/N?B?X8_\$O?B%HGQ T7Q5\2?$GP=\4>'K+1]"M]<\+F
M'Q#XCTG7_%.@?![]H#X8'Q?:^&=4\(:!X3\.0ZE?_&'1=:L?#MGI=Y-X=T_0
M;^VN_$?BG6Y8-;GW?AWX^_:8\9_M!? O3?B'XP^+^K>$O /[2'B*+Q7X\\,^
M!;WPK\(?%^F^,/A)\;=-\.>!M1\/:M\)/!OC;P[;:!K6B>%5\0Z+XI'BO0?#
M&NZ_HEUH_P 7-7DU2U-IZ3X[^-O[0VBV_P =\^(/B=I7C73?C;:>!]+\%Z1\
M'?M/@+X5_ R\^).FZ+X1^-.E?$F+X;>+;K5/^$G\#2OJ7BV^M+'XM:EHSZA>
M:E9?#W36T!TCC]ZGRJ<+M+7UG9).^EG)N^EE:^K1NW@Y05>5#$<JF[1NWS.%
M#F<I4^1[JFH)6DI2OR^ZI(Y#1?\ @GK\6M,^".O?""^\8?";4_$%WJ_PL\;K
M\:1#X@C^)GB^^\":C\(M3U3X)>+K_4?"6LPVWP8NF^&5Q8:5>S'Q=,MM<>')
M;[P%C2M4M=4^A/V2/V/M5_9Y\;^//'GBC5O"?B35O&/@+PEX5TN6P34-6UKP
M@=-^(OQ>\?:]H&G>(]7T?1I/^$3<_$C3+&PM=$TKPSID]QH]W+%X4T'31I>E
MVOPYX!_:%_X*1ZS\/S\0KC2/&>L^-] O/A=X*TCX47WP0@\-^&?B#?\ BJQ_
M:$TSQ)XQ\02:OX6TCQG:2VU_X.^$NM_:+2^\,:1HLVK*-5TJUM/%*Z=:^H>-
M?CQ^UGIL7P3B^%'B;XB?$'P]KOA?5=2OO'/CCX+ZAX4U;Q=\<$\;>!+";X)>
M)/"FC_!*[O)O!6B>&M4\72:?J=G9_"UM:$-Y=K\3KI_!4_V]R562<74I6=V[
M-+9;76U^566SZ+22)IU,%2E&M##8OFA91YHREI)Q::C+1I2JRO)ZIQU=Y09^
MPM%?-W[)NI_%CQ!\%-&\4?&W6?$&I?$3Q+XE^(5]J6F^(/#6D>$F\*Z58?$#
MQ1H?A;PYI.B:7I.E2Q:1;^%M+T6[M[_6/[1U767NY-9DOW@OX(8OI&N5KE;5
MT[.UUL[=O(]J$N>$9\LH\\5+EE922=[*26B=DFUTO9ZIA1112*"BBB@ HHHH
M **** "MAO\ D78_^P])_P"FQ*QZV&_Y%V/_ +#TG_IL2G'[7^"7_MAE6_Y<
M_P#812_]S'Q;X9_8T^'_ (6_;6^)G[=5EXX^*5W\2?BE\)M ^#^L_#_4/$%G
M-\(M)T'P\F@):ZUX?\-+IZ7UGXDN!X<LS=7LVISP%[O4GAMXVO)#78?';]GB
MQ^/OBW]G:_UR.UO_  G\&_B?XG^('BK0)+_Q/I6H>(+/6?A;XO\  6F6NC:I
MX4O]*OK.\L=9\26>IW!N=1M;.XL;6X@?SY7C@?DO#5Q^VNW[:?Q*M?%=A\'D
M_8(3X4:#)\*=1TR6(_&Z;XRD:%_PD<'B6$733CPHKMXD^QM+9Q1!$THPS.SR
MBO+OV^M';6+[]DM=3%A'X$LOCKXPN/B'?>)/AS\2_BMX"T_1I?@9\1;319_'
M7@GX5ZMHGB+4=/D\33:7!HD]SJ4&FV?B.33II ]P(!6L>9U(+G5W"*C)-/E7
M)*T=HI2BO=:>S>K9RU/8QPV)?U>2@J]652G)3A[6:JP<ZJ_B2=.I*TXRBK2C
M%\L8Z(^-O&__  3O^(WAM]=\#>"M)NM8\$3_  <_:T\9^.=&L+*_/A;XB?$^
MX\4?&/6?V*_".E:WXFU==9UWQ[X'/QH\6V/C3^TV>T2WT+PI--X@"K8M6W<_
M\$U/BYXNL='\57.O?"[X9:AX@\ V_@S7O@=X&O->T;X7_#\WWP?^%/P\E^('
MAV]_X034=0N/BC'<> +N;Q/;Z/I/@VZN[:^LM/T3XDZ9J.E77B'5_#_!7C+]
MN3X0:)'#HNC?%#0-.U;P/\)-(UKQQKNA^,O%%P^M>!/@=XT7X7:?I.DZY\._
MBOK6GZ/\3?$/]EW'B3PXWAF/Q':%/#_PX\2>-?#?B"X_MF;WRS_:+_X*!2>+
M/$\/BSPUK?@ZUM?$5Q8?$_1O#7PWU3Q+)\$OA7#XT^&FFZ?\5OA;97'PP-EK
MVN7/@75O&OB=].U3Q_\ %N]U=EO&@\#:3>^![G2;OHO527+4I6M\3:YG9\KT
MN][W5M=$KZJ_E1C@I2DYX;%WORJ$;JG%27/%J2C%V2@XN]U=RE9\K:Z?QE_P
M3(\8:CX<\-V/AWQ;\.M(\2V=_P#'R_\ $OBX:3>Z9KOBZ+XE_M+> _VA/#-C
MJVLR^%_$%_JL.LZ5X*_X5]\0)]934HK:UUR?4K"R\5:?#<Z)J-S0?^";/BFP
MGUG7-2\1_#2^\1ZMJ/P5U/39]3B\2ZY=>$+/P1^T/\5OC'\1/"&A^*8M&\.:
MI8:#XL\,_$C_ (1*VE\(:9X&M9KK^VO)T#PUHTNG6D/@7P(U_P#;&_X2)O"'
MAWQ1\;M"\'^+OB9\2+^Z^,7B#X(6,/C_ %WPC+XA_;C\::#>W0\=>#[G2_#M
MIK>I^&?@J=/LFT&SLM.TK7M,T[1=*TJ'QE:0+[M^S;^U!^T-X]_:*_9Q\%?%
MGQ7K_AS7OB1+\58OB1\!&^%5CI7A31?"/@[X"_#_ ,8^"_&-MXY;05U?1_%V
MJ>-]>UJ3Q9X8N/%4]U:7MU_PC-UX>T&+PY$=2A^U2DE4@TDY/36RZ=>STO9)
M.]KFZ^HRE2<\+B(2J3C3B^9N"<KI2;M%::-R23DY7BY6;,&Q_P"":_Q=C7PL
MK^-OA-9^&OAYJ3WW@GX7W::YXHTB]T73]7^ &MP_#GXA?$&/P-X1\1?$#P1X
MNN/@UJ.EZI>^+O#NO>*_#7AW4_#^DWFK?$.+3;PS>A^#_P#@GAXNT3QUJGQ*
MNM>^%-OXDU#XE_ KXD:1;Z%H&KFU^%6C_#W]H_XM?&OQU\-/AOJ5SI<%]I?@
M^]\-_$NW\&>&Y+6#0X-1NX-8GUK1](T>\L].@\D\"_M#_M;?$_4O#-EX#^)G
MQ#\1Z1XE_:%UKX;_ !F\0VGP.\/6&G_ ?P_I/[8.I_##1+'X:Z_>>!QH7B>'
M5?@SI?B&?Q9XHU&3QS;:#)H5EXNO;G0;F9["\YOQ1\3_ -J?Q=K/P-3XA>,?
MC[X2T+P]\:_"'BO]HGQ'X0^ \PO/V;?&FE>+?BIX9MO O@>+3? ^H0_$?X<Z
MO\.FTS6M=UO4](^*FC6DJ>'_ !D^IQR^)+31[2DJK;O4IQO9/2SL[=+KJ];[
MZO5:/.53 TXQ<,)BY\O-*G[TG%R@IZ\_+)748.UM(MQC;F3:_=R4'<9-C(DK
M.\>00&4.0=IZ,%/RDJ2 00>:CK^?W3_C#_P4)\-ZQXI\0W7A?QGX9U+XB3:!
MXAU/7KCP1K\UCK'Q'\/_  #^%]G\+_!2>$H?AU\3U\/:)\1II==USQWX9\.Z
M9X1AE\<6VK>$_P#A/?!VJ6+Q3>OCXH_\%!HH-0\97/B/XC_:K;1_&GB]?AG;
M_ OPO/X?CUGPW^VSI/P?\/\ @&"7_A%!XKO_  ]J/P!U+5O%=Y;C6D\4>(+;
M3M.\<:=KFG6%I=_;<?8/3WZ>O][KVTOUZ_?8]#^T8:_[/B=&EI3OH]GJETM=
M6?7E<DFS]HZ*^)?V+?B-\8O&]C\5=&^,-_XG\6:EX.\1Z!!I?Q(OO"<O@_P1
MXL.LZ?J4^K:9X$T76/AS\,/&6C'PS/8VB>)_"GBK1O$S^$]2U6UTW2OB)XOL
MV>XMOMJLI1<).+LVNJU6R?Z_\!;';1JJM3A5BI14TVHS7+)6;BTU96=XO]&]
MPHHHJ30**** -63_ ) 5G_V%]0_])+&LJM63_D!6?_87U#_TDL:RJJ6Z_P $
M/_2694MJO_817_\ 2X!1114FH4444 <SXUT.;Q/X+\8>&;:#PU=7'B/PMK^@
MP6GC319O$?@R\DU?2[JP6S\7>'[:\T^YUOPQ=_:#;:]I5M?V5S>Z9+<P6]U#
M,Z./QV^'G_!,_P",.B^%8AXG\5?#)]?A\,?&#X9?#SP:_C3XJ^+/!O[+_A/X
MH^(_#/BFV\=? [Q9KFG-XJOO&/A?Q7X>NO%/AGPKK-KI.C^&$UBVT3P]XGTA
M=/O[G4_VOHJX5)0346K-INZOMZO^O2Z?/6PM&O.$ZL6Y03C&TK)<SNWI%N_;
M6R[7LU^>/QI_9:^(G[0_B_1M<O=5M_AIX>O++P?X ^)LUMXG\00>-_'7A/X(
M?&X?$;P'K>L:7INEW'AGQ?I_BV.QEU"PT"\O?!6H^#-1\2ZM=W.O^,-(NHM
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MO5_$6B>*=;%YX.OEFN[G5]=U*ZU?3[#^SM#NA.(;32M/B#*_SAND_P">T_\
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M1U7X->#KWP+X ,$L'P_WV=GIF@:A=&\L8B8-2U0Q:K< 7,28XC=)_P ]I_\
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M@!P%;*@< 5[5Y\__ #WG_P"_TO\ \71Y\_\ SWG_ ._TO_Q=']DQ_P"?\O\
MP7'_ .3#_7.K_P!"^E_X4U?_ )2>(MINJL=S:=J+$XR6L[HDX&!R8L\  #T
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M?_DP_P!<JO\ T+Z7_A35_P#E)XA_9>I_] W4/_ *Y_\ C5']EZG_ - W4/\
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M3YJDZG^\U=.=IV_@]+6OU/$/[+U/_H&ZA_X!7/\ \:H_LO4_^@;J'_@%<_\
MQJO;_/G_ .>\_P#W^E_^+H\^?_GO/_W^E_\ BZ7]DQ_Y_P O_!<?_DR_]<JO
M_0OI?^%-7_Y2>(?V7J?_ $#=0_\  *Y_^-4?V7J?_0-U#_P"N?\ XU7M_GS_
M //>?_O]+_\ %T>?/_SWG_[_ $O_ ,71_9,?^?\ +_P7'_Y,/]<JO_0OI?\
MA35_^4GB']EZG_T#=0_\ KG_ .-4?V7J?_0-U#_P"N?_ (U7M_GS_P#/>?\
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M"N?_ (U1_9>I_P#0-U#_ , KG_XU7M_GS_\ />?_ +_2_P#Q='GS_P#/>?\
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M%/PMI%Y-+9^#?&VNJVEP '#>)?V$_P!KCQ!?>$O&/A+PGJ/P_P!1\):)XO\
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MEM%C96-@$5$06%E:V(5(L>5&HM(80(XMJ^6@&V/ V 5-10!GC1]$6.UA70=
M$-C-<W%A"-#TD0V%Q>;_ +;<6$(L_+L;B]\R3[;/:K#+>;W^TO+O;,TMAIUQ
M!+:7&F:7<VDT)MY[.YTRPN+.:V,JSFVFM)K=[>6V-PJW)MY(VA-RJW)3SP)*
MM44 5S96!GDNVT[36NY[6*PGNVTZR:[N+""7SH-/N+IH#//I]O-^^@L9I'M(
M9@)8H4D 86*** "BBB@ HHHH *M'_CP7_K^;_P!)DJK5H_\ '@O_ %_-_P"D
MR4 ?-NB?M8_L\^)/VG?&_P"QEHGQ(LK_ /::^''P^TGXJ^-?A8NC>(XK[0_
M&N+I#Z7XA?7I])C\+7D=PFOZ,[V-AK5UJ5LFHVS7-I$&;;TGQ)^*O_" _$7]
MG/P,/#L.LGX[?$7QCX$&KR7OV6;P@?"OPI\7?$D:Q:6_V2X.HS:@?#']A/;B
MXT\PPZ@]W]HF$)M9>JL_A;\,=.^(FL?%[3_AQX%L?BUXBT.T\,>(/BC:>%=%
MM_B'KOAFP\@6/AW5_&,5FNO:AH=G]EM1;:7=7TEG"+6V"0@6\03EOBY\$O#_
M ,8KKX:ZKJ?BOXA>!_$?PC\7:MXV\">*OAMKNE:'KNEZWKO@_6_ FKK<_P!N
M>'_$VDZEIU]X:\0ZG:265YI4GESR0W<$L4\"-0!XSXD_;6_9K\->/Y/"7B*/
M7[:[T_XCS_!S3/B'-\,C-\/[SXE1:_X>TGQGX/\ #_CL@D7?@K5?$>FWOQ O
MOLMAH]@++7[^VU'6KKPUK*V<'A/]M#]E?Q]\-_'7Q/\ "45_KW@/X9^&;#XG
M^-[NW^$[!]!L;WQWXS\%P:G<:3-9),WBBVUKP/XH\0W$0B&K6GA6.W\6B<VV
MK6XEJ^(_^"?G[/7C*#QW8^,9?B=XHTGXA:9\1X=6T+5/'KQZ-H_BSXPZ#8^'
MOBI\5?"-KI>D:=)X;^*'CBTL1?7^O6L\FE:-KE_K6M>$] \/WVM:C)/Z1\.O
MV2?@5\*O"OQS\%>"_"][8^&OVC=3U+5/BIIUWK-W?IJ3ZK\/M-^&5S8:*\R@
M^'](C\,:8LEKIMB/(M]?U#6=? :_U2Y=@#YQ\>_\%&/@'::]X9\+_#7P1XB^
M/&O>//COKWP-\?Z'X1\"QW>KK+X'U3Q3X3U77##J%O'9>.U?Q1X9^Q>!(]7O
MK?2/$WAI=7\4Z7J]OINBLL^6_P#P5%_9\LO%NE:?::=KUW\*M0\'^)O&UW\4
M-'\.76FZ7X6MM,\#_!KQ?X:\,ZQX?U+^S;J\\9>.[_XU>'?#NG6.AQS6.F:V
M8M-UB[AO);V:Q]=^&7_!/?\ 9B^$&MZ)XB\">'O%NGZOX?U[X)>)-/N;WQIJ
M.I[M6_9_^&GB#X4> I[Q+F$_:5O?#?BC7-4\< E)/&?C*\_X2K59?MZ 'D8O
M^"8?[)</A^+PNFB^/WT6.SN+%[:Y\<O>M<V\GAGX>^&;+[1)>Z3<[I=%/PJ^
M'WB72)8UB,/BOPY%J%X+[3[W4=)NP#K_ !C^VYX*T_X/> OC)\./!_B[XHZ;
MXM_:2\(?LUZSX+T6QA'Q"\,^+];\2W_A?Q-8_P!A65YJ6F:GXB\)WUG%.UA!
MKX\.ZAIUTFJIXHCTL?;#P&@_\%*_@GK?B7QWI=OH7CW6=(\.67AS6/#?_"&>
M$M6\2^.=6\/)X'N_%WQ?U_QAX&9=.N/ UA\#M0LW\*^,8IM0U/4;C6Y(=/T>
MPU/4KBVLIO<KK]D/X6S_  I\.?".VUSXEZ+IOA7XLZ5\<]&\9>'?%ECH7CZW
M^*FC:U<Z]8^)1?Z=X>A\+PV:7MT\#^$K+PE9^#3I21:0N@IIXD@E\EOO^"?G
M[*GA6WGU.#6?'_PUO=4L#X6U7QG8?%O_ (1S7?$.BZSX9NO"_C/PQJVNZW;7
M$%]!\4K2XFUCQVZ11ZYJ'BF.W\3>']1\.ZG9V\T8!U:_M_\ [-MQ-;C3-5\<
MZ[IWB#5;SPY\+O$&B>!-1O/#OQX\7:9XE\/^#M7\&_!#5&NH1XU\3:5XH\4:
M/I%Y:7<&@V18ZIJ%IJ-WI&@:YJ&GL^'G[;'A/Q7\#?!GQD\1_#[XB:%JWQ$^
M,7Q;^#?@CX0>&_#=YXM^*VO^(?A5XT^(OA^^MH_"IDTN2WU>/PU\-=>\8>)-
M-EO1:Z%%;7.FV.H:U-_9S:A7/_!/7]FQ&L%TRS\?Z'I7A?5;SQ/\(?#^@^.I
M[3P[\ ?%^K>)_#GC;5/&WP/LVT^Y?PQXAU;Q1X6T;6+B?6+OQ1I:(=5TVPTV
MUT;Q#K=A?]C8?L<_"G2?A;X(^%FC>(?BSI"_#CXD>-OB[X+^)EEX]S\8=$^(
MOQ*U/QMJ?C[Q'%XSO-&N[6>3Q2?B-XRT^^LKC0I-/M]+U=;;3K:RDT[39[0
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M/[$'_1-=?_\ #C>._P#Y?5^D=% 'YN?\.F?V(/\ HFNO_P#AQO'?_P OJ/\
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M?^_'@K_YCZ]5HH \J_X5C=?]%#\:_P#?CP5_\Q]'_"L;K_HH?C7_ +\>"O\
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M8^O5:* /*O\ A6-U_P!%#\:_]^/!7_S'T?\ "L;K_HH?C7_OQX*_^8^O5:*
M/*O^%8W7_10_&O\ WX\%?_,?7D_Q*^#?B635O ?BK3(!\9+/P=JFLW.H?#7Q
MW=^&-)TW5&UG2O[-M-=TZ[A\-0:6VN>')0TME#KMO<6CVE]J#6DUEJ"VTS?5
MM% 'CGP+\$:UX!\"MI&NVVF:3=:AXE\4>)+;PMH=S)>Z'X*T[Q%K-SJECX/T
?>[>&U6>RT2&X$)DMK.SL3<O<BPM8;(0+7L=%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>formdrs_004.jpg
<TEXT>
begin 644 formdrs_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #) F\# 2(  A$! Q$!_\0
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M_05U3_P97O\ \?JC11RQ_EC_ . P_P#D YI?S2_\"G_\F7O[4U7_ *"NJ?\
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M"NJ?^#*]_P#C]4:*.6/\L?\ P&'_ ,@'-+^:7_@4_P#Y,O?VIJO_ $%=4_\
M!E>__'Z/[4U7_H*ZI_X,KW_X_5&BCEC_ "Q_\!A_\@'-+^:7_@4__DR]_:FJ
M_P#05U3_ ,&5[_\ 'Z/[4U7_ *"NJ?\ @RO?_C]4:*.6/\L?_ 8?_(!S2_FE
M_P"!3_\ DSLX]3U3_A"KMO[3U+</&.FH&_M"\WA#H&KL4#>=N"E@&*YP2 2,
M@5S7]J:K_P!!75/_  97O_Q^M>/_ )$F[_['/3/_ %'M7KFJPH1C?$>['_>J
MWV8_RX?^Z;UI2M0]Z7^[4OM2_FQ']XO?VIJO_05U3_P97O\ \?H_M35?^@KJ
MG_@RO?\ X_5&BM^6/\L?_ 8?_(&'-+^:7_@4_P#Y,O?VIJO_ $%=4_\ !E>_
M_'Z/[4U7_H*ZI_X,KW_X_5&BCEC_ "Q_\!A_\@'-+^:7_@4__DR]_:FJ_P#0
M5U3_ ,&5[_\ 'Z/[4U7_ *"NJ?\ @RO?_C]4:*.6/\L?_ 8?_(!S2_FE_P"!
M3_\ DR]_:FJ_]!75/_!E>_\ Q^C^U-5_Z"NJ?^#*]_\ C]4:*.6/\L?_  &'
M_P @'-+^:7_@4_\ Y,O?VIJO_05U3_P97O\ \?H_M35?^@KJG_@RO?\ X_5&
MBCEC_+'_ ,!A_P#(!S2_FE_X%/\ ^3+W]J:K_P!!75/_  97O_Q^C^U-5_Z"
MNJ?^#*]_^/U1HHY8_P L?_ 8?_(!S2_FE_X%/_Y,O?VIJO\ T%=4_P#!E>__
M !^C^U-5_P"@KJG_ (,KW_X_5&BCEC_+'_P&'_R <TOYI?\ @4__ ),O?VIJ
MO_05U3_P97O_ ,?H_M35?^@KJG_@RO?_ (_5&BCEC_+'_P !A_\ (!S2_FE_
MX%/_ .3+W]J:K_T%=4_\&5[_ /'Z/[4U7_H*ZI_X,KW_ ./U1HHY8_RQ_P#
M8?\ R <TOYI?^!3_ /DR]_:FJ_\ 05U3_P &5[_\?H_M35?^@KJG_@RO?_C]
M4:*.6/\ +'_P&'_R <TOYI?^!3_^3+W]J:K_ -!75/\ P97O_P ?H_M35?\
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MA7JVGVT4&H:-+;Z-H^O6.MZ[]N>Z@UJ^DDY'G=2;_P!GPL*T+I.;K581:?\
M9D&X_P"S2YG&KF+@]$N7#59)MW4>M9-3BOW^*E2GRMJ"I4IM-?VE)*2^LJRE
M2R]35FWS8FG&R5G+^X.#5=(NM.;6;36=&N]%2"XN7URTU?3;G1([:TW?:[F3
M68+J33([>TV/]KG>Z6*VV-Y[Q[3B&/7O#\NEMKL/B+P[/H,;2))K\&OZ/-H$
M3Q,JRI+K<5Z^E1/$SHLJ27:M&SHKA2R@_P ;>J_ WXM>$_V1/VQ?A-X#^&'Q
MH_X9$^$?_!9B35/C/\#_ (?Z;XTL]9U']ABS>]U#QUH'PWTV:.+5M9^&TH%M
M+J%CX>N[BTU=?L-R\E_%:WLH?\4?AI9^(OV>_P#@L)XH_8:^!_QA^'/_  3W
M\;_ SX-^&?A5\-==\ ?$?PIIGBO]H[1O$FB2?$/7OA%\)_&:W'C#1K&VT^2.
M+Q%<)I%JE[=^1-(S); 6Z>>5$KO!.ZH5*C@JE7GE*G#'2E*DOJUI8:$\$J56
MK*4*D)XBBE2DW:8LFI2>F,7*ZT*:FX4N2,9SP,8PJOZS>&)G#&NK3I1C.G*&
M'K-U8VO#^R:QU?1]5\_^R=9T;6/LD@ANSH^KZ=JHM)RN\079T^YN1:SE,.(9
MS'*4(<)M(-7Z^2OV)OV8O@;^RQ^S[\/_  E\#OA?HWPRL_%O@OX>^-?'RV$6
MHG6O%_Q U#P#X<@USQ1XNOM7N;O4K[Q%<S0M#?>=)#';S1RQ+:02^?N^M:]V
ME*I*E3E5C"%248RE"$I3C%R2ERJ4HPE*R:NW".M[*UCQ:L81J3C3E*<(RE&,
MIQC"4E%N-W&$IQC=IV2E+2UW=NQ1116AF%%%% !1110 4444 %%%% !73WO_
M ")_AS_L.^*__2;PQ7,5T][_ ,B?X<_[#OBO_P!)O#%85OCPO_82O_3&)-J/
MPXC_ +!W_P"GL.<Q1116YB%>$_M"W_[4&G>![.7]DGPA\"_&OQ/DU^S@N])_
M:#\7>,_!?@:+PR\%P;Z\M]5\"Z7JVLRZY'="TCM;.2WCLI()+F268211H_NU
M2P,J31.QPJR*S'!. &!/ Y/X5,X\\)0YYPYDUSTY*-2/G"3C-*79N$MWIVJ$
MN2<9.$)\KOR5$Y0EOI**E!M:[*<=EKW_ )Z/V6/^"P7QQ\5_"?2_VM?VU/"/
M[(O[.7[&5S\6?%_P#U#QSX/\4_'7Q7\5+?XM:!>7NEZ59P^$CX?\0:'#X2U/
M4M.O'NO$>I:C:0V.E0O>W7V-P(F^[O$7_!77_@GUX3\ ?#KXF>(?CAJ^F^&/
MBNOB2Y\#6[_!SXTS^+]1T;PCJ?\ 8NO>*]3\ 6O@";QMX9\$VVK"73K;QIXE
MT'2?#&I7=K>1:=JET;2X,?Y4^&?^"8O[6]O_ ,$VO@W^S/X@^&?ABY^)'AC_
M (*?Z1^TGXQ\*7/CSP+?:,?@?%\1]2\0ZEJ\NJMJ\N@:I-+HMTIE\+QW,^LW
M$<CVYTYY]]L/3_\ @J!_P3G_ &A?C+^VH_[5GPD^#]_^TQX6\??LUV_P%UWX
M<:)^UQKW[(6N?#WQ-X9OIIM \5ZYXCTRZLQ\1OAEK=EJ=S#K_@&TN8M1O+FS
MDQ-I82TN[SYJGB,ZH8125.=>:IX.4_K-&K4K>TQ"Q#Q$DJ*IWIX9T:,/8PHR
MG&6(YY3<59?13P^3UL5RNI"A!U,8H_5JU.%+V>'>'6'C>JZEJF(]K6G[:=:,
M)1H<L(<SN?J=\?/^"CW[%/[,_ASX7^*_BW\=-(M-%^-&@W'BSX6OX'\.>,OB
MOJ'C+P?:6D=[=>,],T7X8^'_ !9K"^#K>"6-9_%%U8V^B0W+&SDO5ND>)?D[
M]H#_ (+/_LW?!_X[_L+?"KPO>P?$+P-^V/IT?C>Y^+FD:5XYU72/"'PTUFYN
M] \#ZEH>D>'_  Q>W7B3Q'XL\86=[H]WIJS&?P1;Z5=W7B[2K"&]T^YKXB^/
M7_!.']N+2O#G[+'P0^#?@#PUXN_9Y\)?LA>(?@CX\\$?##]IW4_@$WP^^,?B
M'Q3JOB1/$.L?%SQ3I'B+X]?$CX$^&[G5[>ZL/ACH6N*?$EQI5Y!K=M9Z?=_8
MM3T/ '["7[<WP9\!_P#!%/QEX=^!WAOQ[\1_V M2^,GA;XT_"L_&WP+X34:#
M\1KJTTZT\::%XUN6U+0=6LHM,L/[6;2=--WKKF:UTR?3H)7N;BRNKC<XE.I3
MAAI4(P6#G[2.%K57?ZQ@EBX1;FU6@Z-:O*+BHU(QHU4HJ<6R:6"RF,*<Y8B-
M:4_K<>26*HTDU[#&O"SDE"]&:JT:$6I.5.4JU-\SA)(_2.3_ (+*_P#!,^V\
M;+\/=2_:G\-Z%XD3QIXK^'NI-XB\(_$/0/#OAWQ=X+EE@U[2_%?C#5?"=KX5
M\+*LL$ZZ7>Z[J]C9:]Y$S:+/?+&Q'JOPP_X*3_L/_&'X.?%;X^^!OC]X?F^%
M?P/N4L_BQKWB70_%G@;4O!5U<1QR:;!JGA3QGH6A^*WEUYIHK7PVEIHUPWB*
M_D6PT87EV?)K\8W_ ."8/[6<O[(%U\(I?A7X2;QUJO\ P65N/VQ=7T>7QUX"
MN+/4/@%+XGTF_3Q+?ZG-JATR]OETFVN;8^$)IWUWR \(TLM.8).M_:X_X)8?
MM-_M%>(_^"O%SH&F>&=$LOVE?B[^RM\7_P!G:;5/&NFZ=9?%#_A1GAW18?%7
MA'79M"O9==^'DVKW-IJ%CI&LZW;Z=Y.M+I^I>9#9*^HQTL=G2BYO!4ZC=-RC
M2CAZ].7/+#8RK"+G*M)?NZF&HTYKE3J2Q,(+DDZ?-+P63N2BL9.'[R,95'7H
M5(\L<1A*4Y*$:47^\IXBK4A[S4(X>4GSQY^7]6O#'_!3_P#89\8?!#XJ?M$Z
M'\;U;X6_!"?2(?BS=ZKX ^)7A[QCX&7Q!<P6F@WFM?#/7_"6F_$2/3-;N+A$
MTG58O#,NGZ@([E[6XD2UN&CXG1O^"OG_  3]\8:7\;KOX>?'6W\=:O\  ;X3
M^(?C+XI\.:=X+^(NF7^O>"?#T0$NJ>!)M4\'PQ^.]/GU":RL)=4\%Q>([;3D
MNFU*[3[#:73I^0,W_!*W]IKQ5^R1_P %!8M-_9BM?@U\;_VDO!/PF^'/P^^'
MGC']M?Q-^TY\0?%>F^!O%NE^(-9U/XB?%WQQKL'PWLM-M4AN$\$V6GP6&L:?
M9B\T[4KB59;=Y_TC\=_L6_&7Q-^W3^S%\7=%\+^']'^%/P^_X)J?%K]E3Q?X
MHCUSP_:2^&/B#XR\&7'AWP[H4&@VDK^(-1T&QO+ZZE74=&TR_P!)LXIKR5&6
M2<I<5'&9S.--_5J<6XT5+_9L1>4JV(Q=%SBIU*?LE1ITZ&(J0J0>D[-QA44H
MS/"91!U$L14E9U7#_:,/:*HT,)6]G+DA/VCK5*E>A3J0FM872G.G*,OH;_@F
MC^WMX7_X**_LRZ3\>=%T-?"'B%/$.N^'?&_@>WM/$S67@_5;74KN;0]+MO$/
MB+2M+M_%LMSX4?1M3U+6?#WVO14U.\NK"*2WFMI+.#] Z_+S_@D!\'_VD?V;
MOV*/ ?[-7[2_PFTGX9>)/@=?:[X7\+:IHWQ.\,_$FR^)'AG5]?UCQ2OBU(_#
M2&/P?Y-WK#Z2N@:C=7=_,ML-1=K<3FUB_4.O5P$J\\%A9XGF^L2H4W7YZ;HS
M57E_>*5-ZQ:DFG:T96YHI1E%+S,?&C#&XJ&&Y?J\:]14>2HJL?97]QQJ+22<
M6FKMN-^63<HR84445UG(=+'_ ,B3=_\ 8YZ9_P"H]J]<U72Q_P#(DW?_ &.>
MF?\ J/:O7-5A0WQ'_856_P#2<,;5MJ'_ &#4O_2L0%36T0GN((6)43311%@
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MZ&WXIW/BN3P1#X8_L%O#@\1$/XGB?3?[8&EG1%5?MC:@+$BX/E'Q"_X*X_\
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M9XJU7PUK^J^!_&'Q/\)>&+VX.BMIK3:QH7B)=.\2VD<5]J*Z8^BPQW[? ?\
MP3Y_X)F?M!?L[_$#]I?6_C9?:=XD\-?#'X'>._V1/^"?5N?$>FZO=6?P"\7>
M)?&WCR?4=6:*^N6T/6=3U#6_#_AW5/[>CTR^#:?+-#;KIBK-)XUXC_X)D_MG
M:-_P3$_8/\/_  ;TCP[X-_X*%_L;/X[\/:59S>,O"C:5+\//CJ/%/@?XO^%I
M?&D>J_\ "-26MSX.UW2_$1EM=6EN8I-(N;#2/.U*[,$Z6,S7EC7E@Y+EI5IS
MPL83<I*CB,)2E"-Y6>(JQ^MUL+>24J,::<)<[DF\)E=Y4(XN+YJM&$,3*<%&
M+K4,55A.2Y;JA2E]4I8FR=JTJEI1Y%%_K?XD_P""H?["_A+X*^%_VA-=^-_D
M?"OQS\0/%?PN\"ZK9?#_ .).L>(?''C7P-J=[H_B_3O!G@/2/"=]XY\46/A_
M4=/O(-1U[1?#]YH4(B$W]H-!)%(_F/BG_@IIX%\0>-?^"=O_  S7/X+^,GP=
M_;E^,/CSX8:AX_NV\4:-J_@^+P/X:O-7O3IN@W,6E7FG^);75+*?3-7T7Q=I
MD=Q8[ CV44D@D3Y,_:@_8._:G\!?"7_@G;\$/V1_!Q^)7P3_ &>_ GB7X?\
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M#>H>*/'^O0V^K:WXENM"9-7M]!\+^&X=2U2ZDL'68WQTR.3%K)<LGQ?\,/\
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M*[LM6:/]D?"7_HFMM_X,KK_X]1_9'PE_Z)K;?^#*Z_\ CU9U%7RU/^@O'_\
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M1_LCX2_]$UMO_!E=?_'J;-8_#*RL[ZZL/A[!:SQ6\>94U"X9C&]]9QM'\TK
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M-^'=;^"GBWXYZ1#>VVD2^ ;_ ,):1X$\3>)=4O\ 0O#NIW5UH]MJ _?OXJ_
M;_@D)\-OCW^SO^S!X\_9-_9SD^-/[3%WXM/PJ\':9\&O#NJ2S:5X)T:XUGQ%
MK?C*:(1#0/!EQ%;OI<,NHQ7=GX@U<#3EL;E+:YFM>;U3X&?\$;_#G@?XS^/_
M !7^QI\#O#.E_L\^/-9^'?Q=T37/V=K>^\4^&-<L[&/Q!I%SJWAO1+'7Y)?
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MGAKX[>*/B#J6NCXHZ/XZBTJUF\%Z-X?BM;C2-7U."'3K74;[5)[N.3ZY\8_
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M2CS\-<\X.=.5W/V/)[94Z<*49RA*E>,9SIRI<\'_ #__ ++'[*'[0>N^*_\
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ME@E420RQ.I*O%+$RR1.I*NC*RDJ0:*Z#$**** "BBB@ HHHH **** "BBB@
MJ"^_Y!>J?]>T'_IRL*GJ"^_Y!>J?]>T'_IRL*PQ7^[8C_KQ5_P#2&;8?_>*'
M_7ZG_P"E(GHJ]_9FI?\ /A>?^ TW_P 11_9FI?\ /A>?^ TW_P 16O/#^>'_
M (''_P"2,N67\D__  "?_P @4:*O?V9J7_/A>?\ @--_\11_9FI?\^%Y_P"
MTW_Q%'/#^>'_ (''_P"2#EE_)/\ \ G_ /(%&BKW]F:E_P ^%Y_X#3?_ !%'
M]F:E_P ^%Y_X#3?_ !%'/#^>'_@<?_D@Y9?R3_\  )__ "!1K,UL:PVAZZOA
MY[9/$+:)K"^'WO!FT373IUR-':Y Y,"ZB;8R?[(.>,UT/]F:E_SX7G_@--_\
M11_9FI?\^%Y_X#3?_$4<\/YX?^!Q_P#D@Y9?R3_\ G_\@?RW_LS:1\/]6TK_
M ()E>&/AQH-ZO_!333_VG+2'_@H)]M\/:F?CA/\ #&2+QO!^V1!^UEJVH6D,
M6N?"'Q1;7GANR\"P^.[S4O#>HWUW\.A\+H&NK6!8OT1_X(H?#7P7\.OV/_%Q
M\-?#O0/ ESJ_[77[8B:M%HGA33_"-]K&F:!^T#XVTCPG%?"WTZQFNK'2O#T%
MII7AN2YCGM=/T:.VM]- L8XXZ_8-K+5V78UI?E.!M,$Y7"_=&-N..WI36T[5
M'.7LKYC@#+6\Y.% "C)3H   .PKEIT*=.HJGM:;:BXI)0CT4>:_M)/GDE><O
MMRU?8Z*E6<XRA[.HE*2DVU4>TISM_#2Y8\W+37V(JWI_,?XW^&7[8W@;]O\
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MGH[-7L3[:IJO9U+6@E95%RJ$:2LKTVK-TN9JS5Y:IM7/P7_8?\=?#.X\,_\
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M_P !IO\ XBKYX?SP_P# X_\ R1'++^2?_@$__D"C15[^S-2_Y\+S_P !IO\
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MBKW]F:E_SX7G_@--_P#$4?V9J7_/A>?^ TW_ ,11SP_GA_X''_Y(.67\D_\
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M%H_RQ_\  8__ "(7?=_>_P#,L?:[O_G[NO\ P)F_^+H^UW?_ #]W7_@3-_\
M%U7HHM'^6/\ X#'_ .1"[[O[W_F6/M=W_P _=U_X$S?_ !='VN[_ .?NZ_\
M F;_ .+JO11:/\L?_ 8__(A=]W][_P RQ]KN_P#G[NO_  )F_P#BZ/M=W_S]
MW7_@3-_\75>BBT?Y8_\ @,?_ )$+ON_O?^98^UW?_/W=?^!,W_Q='VN[_P"?
MNZ_\"9O_ (NJ]%%H_P L?_ 8_P#R(7?=_>_\RQ]KN_\ G[NO_ F;_P"+H^UW
M?_/W=?\ @3-_\75>BBT?Y8_^ Q_^1"[[O[W_ )EC[7=_\_=U_P"!,W_Q='VN
M[_Y^[K_P)F_^+JO11:/\L?\ P&/_ ,B%WW?WO_,L?:[O_G[NO_ F;_XNC[7=
M_P#/W=?^!,W_ ,75>BBT?Y8_^ Q_^1"[[O[W_F6/M=W_ ,_=U_X$S?\ Q='V
MN[_Y^[K_ ,"9O_BZKT46C_+'_P !C_\ (A=]W][_ ,RQ]KN_^?NZ_P# F;_X
MNC[7=_\ /W=?^!,W_P 75>BBT?Y8_P#@,?\ Y$+ON_O?^98^UW?_ #]W7_@3
M-_\ %T?:[O\ Y^[K_P "9O\ XNJ]%%H_RQ_\!C_\B%WW?WO_ #+'VN[_ .?N
MZ_\  F;_ .+K4GNKH:/II%U<@F]U3)^T39($>FX!._) R< G R<8R:PZU;C_
M ) VF?\ 7[JO_HO3*B<8WI^['^(OLQ_DJ_W2XMVGJ_X;ZO\ GI^92^UW?_/W
M=?\ @3-_\71]KN_^?NZ_\"9O_BZKT5=H_P L?_ 8_P#R)%WW?WO_ #+'VN[_
M .?NZ_\  F;_ .+I1=WA( N[HDD #[3-U/3^.JU/C_UD?^^O_H0HM'^6/_@,
M?_D0;=MW][_^2/CGQ1_P48_8S\%>(_&/A3Q3^T=H^D:S\//$.H>%/'Q;PO\
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MS?\ Q='VN[_Y^[K_ ,"9O_BZKT46C_+'_P !C_\ (A=]W][_ ,SP[XH_M7?
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MW][_ ,RQ]KN_^?NZ_P# F;_XNC[7=_\ /W=?^!,W_P 75>BBT?Y8_P#@,?\
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MN_\ P"I_\K,N679?^!T__EAD45K_ -F6W_09T[\KS_Y%H_LRV_Z#.G?E>?\
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M4NVVVVWJVVWJS(HK7_LRV_Z#.G?E>?\ R+1_9EM_T&=._*\_^1:/:0[O_P
MJ?\ RL7++LO_  .G_P#+!J_\@*;_ +#-O_Z07595=2NGV_\ 8TJ?VK8;?[6M
MV\W_ $K8"+&Y&PC[-NW'.X<;=H.6!P#F_P!F6W_09T[\KS_Y%J(5(7J:O^)+
M[%3^6G_T[+G&7N:+^''[=/O4_P"GG]??;(HK7_LRV_Z#.G?E>?\ R+1_9EM_
MT&=._*\_^1:OVD.[_P# *G_RLCEEV7_@=/\ ^6&116O_ &9;?]!G3ORO/_D6
MC^S+;_H,Z=^5Y_\ (M'M(=W_ . 5/_E8<LNR_P# Z?\ \L,BBM?^S+;_ *#.
MG?E>?_(M']F6W_09T[\KS_Y%H]I#N_\ P"I_\K#EEV7_ ('3_P#EAD45K_V9
M;?\ 09T[\KS_ .1:/[,MO^@SIWY7G_R+1[2'=_\ @%3_ .5ARR[+_P #I_\
MRPR**U_[,MO^@SIWY7G_ ,BT?V9;?]!G3ORO/_D6CVD.[_\  *G_ ,K#EEV7
M_@=/_P"6&116O_9EM_T&=._*\_\ D6C^S+;_ *#.G?E>?_(M'M(=W_X!4_\
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M<RI!;6EE9PO<W=W<SR,L<-O;6\4D\\TC*D44;NQ"J37\V?[$WQF_:4U#7/\
M@FO\4+_QMXMU&?\ :QGUN3XY:U\5?VVO#?QJT#]H+3]=\">(O&WBP_"G]FKP
MKI&JV?P'\4?"'QM;65E9Z3X6T[X=Z)X%\-Z=J'@+Q_=7VO"&.7])O^"C-S\6
M/%^B^ /@+X>^"7Q_^(/[/WQ/B\6ZA^U-XV^ 6A^&_$7B9/ASX:T]9-/^!]G8
MZOXV\'7^FK\9M6N([7QEXHLIIET?X>:/X@TRU9-7\1V,UK<<3&5*=51DE%I)
M/JY<O+K%/1\RN[:*[7-HY3.@X5(TW*/O7;DG9*SDI+5J[]U\JO[S:6CNE]X_
M#'XH?#KXU> /"_Q5^$?C30?B)\-?&UA)JGA#QOX8N7O?#_B/38;RYTZ2^TF[
MDA@:YM5OK*[MA,(E1Y(',9>/:[>H7'_(&TS_ *_=5_\ 1>F5^2'_  1"\01Z
M[_P2[_94AM_!_BKP=9>'O"_B?P_86WB;1M/T6VU2QM/'_BR6VU'PG%I^JZK'
M=>&(8IUTJUN)?L$L=WIUY:+8K#;Q33?K?<?\@;3/^OW5?_1>F54)^TIX>II>
M;IR=KI7=.K>U];7O:^MK$RCR3KPUM!5(J]KM1J02;MI>R5[:7,JBBBMS(***
M* "BBB@ HHHH **** "BBB@ HHHH **** -5?^0%-_V&;?\ ](+JLJM5?^0%
M-_V&;?\ ](+JLJHAO4_Z^2_])IE2^Q_U[C^=0****LD**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *@OO^07JG_7M!
M_P"G*PJ>H+[_ )!>J?\ 7M!_Z<K"L,5_NV(_Z\5?_2&;8?\ WBA_U^I_^E(\
M^^*/AOXG^*?#UKI_PE^+]O\ !3Q-#JUO>7/BVY^%OASXNQW>D1VMY%<Z&/#'
MBC6M"T^U:[NIK.\&LQWCW5NM@UFEO)%?3/'^?6A_\$X?%/ACXES_ !I\-?&7
M]F#P]\8[F^U'5+CXL:'_ ,$L_P!EG2OB3/J>L12PZMJ,WC>Q\2P>))+_ %2&
M>>'4+MM1,]Y%-*EQ)(LC _J;114P].K+FGS7225I-)6ZI6=GYJS\R(U)P346
MDGO[J;?DV]6O)W7D?FIXA_8/^*WBUOB._BO]H_X">)W^,?\ PC__  M]O$/_
M  30_9LUEOBK_P (G''#X5_X6.VH^+[@^-O^$9AAAB\/_P#"2'4?['CBC33_
M +.L:@1_%']@KXH_'%_#$GQK_:*_9^^,$G@DY\&2?%'_ ()E_LT>/I/"1S <
M^&I/%/BW5'T/FVMC_P 2UK8#[/#@?NDV_I?14/!T7OSOO>;=^NMXV>K;U3U;
M>[N4JU16LXJVUH15M$M+6MHDM+:)+9)'YH?$S]@GXH?&J[BO_C+^T1^S[\6[
MZW\--X,M[SXF?\$ROV:/'5U;^#VU2#7&\*03^)O%NIR0>&SK=K;:P=$B9--.
MJ6\%_P#9OM,22C2M?V(_C19:?\+])LOVGO@A9Z5\#[N/4/@KIEI_P39_9RMM
M/^$&H112017WPPLX?&26_@.]C@EEA2Z\+QZ7.L4DB!]KL#^CM%'U*AO:=WN^
M?5^KY;OYMZZ[I-'MJEDKQLMER1LKIIV6RNFUHEHVMFT_RTD_X)Q^*Y?$OB'Q
MI+\9_P!F&3QEXN\4:7XX\5^+7_X):_LM-XG\3>-=#U9M?T3QAK^O'Q-_:FK^
M*-'UUWUG3->OKJ?5+'57?4+:ZCNV,IUKK]@+XDWWQ=@_:"O?V@OV>+SX]VUP
MEW;?&ZZ_X)C?LRW'Q<@NX[!]+CNH?B-+XK;Q='<IIDLFGI.FK"5;*1[4.(6*
M']-:^'?VV_CK\3?A4W[+WPL^#FH:)X5^(G[6?[2OASX":;\3/$N@6WBG1_A9
MH \*>*/B!XR\6V_AO49(M%U[Q?-X=\(W>B>!M*\0M+H,_B#4HKC4[+4(+0V<
ML3PN'A%R:F[6T4M7)M15O=W<I)<UU:[=]VW&K5DTE*-VFKN,;**BW)/?W5&+
MNK--)+E>B//Y_P!C#XP:;\0M=^.MY^U9\!=,^*NK>&KKPOXG^,U__P $Y?V:
MM/\ 'FI>#KJ"WMKWP]XA^(EWXWAUNZ\-7-O:6EO=:7J>KOID\5K;130NL,2K
MA_#/]@CQY\+_  _XKTGX,_M%?LV?#WPG\3K5U\;Z?\+O^"9W[+WACPY\1;"[
MMY[:1?$\/A3Q?9Z9XNL;JUN;F!O[2&H6T]O<31G?'*X/YM?\%!?B-^T'X]^'
M7[1?[&OQ+^+]IKEW\!?VO?\ @G=;S_%G2OA%\.;6#XT?"G]I7XD^%M1T7P;\
M4_AQ>6%WX&MM?\ :Q8W%SJ]CX=TZS\*_$'18M+T[Q)HKV-WJUO=?LE^UA\?-
M _8-_993Q+I6D:'>:SHJ^#O@_P#"G2(/"UMX5^'\GQ"\1/#X?T#7/%FC>"=,
MAT#X>?##1;M;OQEXU.D6%AH6@Z!97VFZ3#%YEE%6,:="3J2<*L(TX*4I2J+F
M4VY*4=(MW3BXMW]Y[W1H_:I4TI0E*I+EC&,(\KC%0<'=I*SY[Q7+[B3^%Z/R
M?3_V+_BOH%U\-K[2OVK_ -G[1+WX&6=WX7^#]Y8?\$ZOV9M-N?@S9>(4MH;[
MPU\.KB#QS#+\.X=>B2RAN=$\//I U6,6<;VLZF ''UC_ ()U>-_$'@C_ (57
MXA^.'[-.M?#C4_&.J^/!\-M;_P""7O[+NH>#-2^(-SNN]=\9Q^#[_P 4RZ/>
M^,9Q*]UK/B"+3Y=9D61I[ZZ*L7/P'_P2N\$_!SX]^"?^"LO[-.H?'R']HKQ!
M\0/VH=2\7>(OBU<W%]+KVL>)O%7P/^%OV;XW>%_MUE /"]MX7^*MG<7GPYM[
M P3>$CX9TNULXTBLQ++[#\ OV=_&'_!0[X=?\$^/V[O''Q8OO#/B[P?\*_#4
M7Q"\+):^-3!\8_$/A_7[OPIXTU/7[W3?&^B1>&;#6-'T2XU7PG/X*T[1=4_X
M2J]BU/QEJ?C'PS_Q394*=.I&#A2E+G3=O;)I1C4=.=_W=FXKDE:UFGRV]U)5
M)SA*:E44?9R2YO8K5NG[2#2O=<TG4BFW=/W[^](^VO!'[(O[1OPP7Q1!\,OV
MP?A9\-V\0ZS;:YXSC^'_ /P3P_9\\)R:KXDETR*RT_7/$L&@^.+-;S7FTBVM
MX;#4-8AEO)-/MH(XGDM(E4>.7W_!/GX\366NZ-?_ +8OP'L=%\=_$+3?'7B.
MRB_X)N?LOV[>(_B3HCRZCX=^,,EMJ.LSZ=KG[1*W5K9K>>-M3M-5*Z1ID;Z+
MI]A?6:WH]5_9I_8+D_9Y_:7^-W[0TGQ3N_&-M\8UOUT_P+<1>,X+;X;QIJS+
MHVGZ!J.J^.-;A\2:?<>%U@A\43^,].UO66\6+-J7@W4_"7AJ0>&%J6^HS?%[
M_@J9XA\'>*%^V>"?V-/V7/AK\2O _A>]BWZ7?_&#]I3Q?X[T._\ B2JR*4DU
MKP=X ^'<G@[P]?Q W&AKXN\4/;2Q7&I.4*N P]6,%7IUE^\<(0ABJT$U+F]Y
M^QG23O",G9V:<K74GS0Z\#FN,RZ5:6$GA&YPA4E/$9;@,5*,Z?*X^R6-PN*4
M)1J.DN91E&7LJ;E3E&,X8G@]3_8-_:4UQ/BE9ZU^V5\ KZ3X[2V/B7XWZ#/_
M ,$X/V<KS2_BQJNB);V&@67Q#TN_\275]XY\!7PM)G\1'QD^M^(I-5\X>'/$
M&D0 VD/ ^&O^":_COPY'K_@KP7^U%^R%IT+^$+KP1XI\!Z)_P3+_ &1[6VU?
MX?\ B'Q#=^)=;^'/Q!\*Z!KEK=77PRT/6M3GUSX?^%KJUM;.S\07 U'Q6WB"
M>9Y9J/[-?@.\^"?_  5Q_;2U'QS\9/B3\8KW6/V(_@E\5/$_C'XF76G,- TV
M;XT?&6>'PIX*\)^&=.L/#W@WP)X,\,:19:3H_A_0=.::^:QN-:U6;4M>U6_N
MI_A3]D'PQ=>"I/\ @EQ^T9KO@/1?!7@#XF?M(?%BVT7]KG1C;77[3G[6(_:"
MT_XE:E\+= _:S\,6]SO\+>#O'\4$>N&[7XA_&]K;5O#_ (02W\)_"NWN+FTT
M7D>78).#]EB5)U)QE?'XMN*A5A#FNJCBN:512=TH)MPM>2B>G_K'FMG%?V3R
M<D.6"R#)U%J5&;5))X/G<8TZ?LE:I*M[-1DJJE%US]*_$7_!/#]H/QA<?#NX
M\7_MB_!KQ3>?"'3+7PM\)M?\0_\ !-C]F+6O$_PN\.Z?;0_V=XA^'.I:GJ5S
M#X*^(]I=6MG;0WGAVUT[P;!H]K!';^&(KZ&.X5^F?\$]_P!H?1K?X;V^C?M<
M? +P];?![4K[Q!\(=,\-_P#!-+]F[2])^#&NRO;I*/@Y:IKC/\/],\<V\+GX
MJOHSVVM:]<RR_P!AZEHT#*D?K'[9/Q)_:/T;X_?L+? G]G[XD^%_A/9_M$^.
M?CMI?Q9\9:Y\/?#OQ'U[2_!_PO\ AGI7C*QF\!Z/XH8Z*GBDZI</9Q'4K>^T
MMK6]FO-1L+R'34@?XZU3]NO]H+0O#'C;X)>(_B;X;_X7E\*_VZO&?[*.K_%7
MX8? ;6OBI\6OC+X'\-?"VY^..EZI\%?V8_"V@>(_"-S\;7\+7>C>%_'T'B 6
M'PH\(V]MK'BU?(DEL+%:EE^7PG.+AC/=O[WUW%VE*$8/E3>)YM$X6D[V:2U:
M3:CQ+G,U%K^R&Y7D[Y%DO,E.=12FTLK45S5'4E)1BM9R?+&#5.G[3KG_  3Z
M_:!UOXJ:!\?/$G[6_P"SIX@^./A6ZL[[PI\6O%O_  32_9JU+Q[INK3B^M%\
M.6?CR[UX>,[3PAX=@OG;X<Z=H^NV7B:PU M_:NL:M;E[>;HM$_8V_:NT_P 2
M_$#Q?X7_ ."@?PV@\8?$&&T\(?%3Q]HW[ ?[."?$'Q[8:1H]OI=GJGQ-\2Z3
MXB2X\2?%+PE9@:)X6?7UF\-Z)X8>&PNO"\TCAQ^87BO]H+]J7]IG0_@_X%^)
M?COQM\(O'?P _P""T_[._P '%O\ 7OA9\%=,^(GB+PIXH^'^A_%/P'J'Q=\#
M^"]<\9_"K2/B!X"D\5W>DZCX>\)7_P#PC^HO9V<_B+2[;7;>XAA]7D_;\^-N
MB?$[Q;\ O!UM;^#_ !'\1/\ @I'^V3\-[[XE? _]E-/B[\0-#^#G[.GP^^''
MBB]U33_@[X'T#5+7XF?&+QIJWB.VT[Q!\1_&NC:Q#I>@K+J>KQ7#:=IHCS^I
M9?K/V>+2:3YOK^,4I2E!WCI73YN:\')O5/F32:M?^L.<Z)+)[QTM_862<L(Q
MG%Q=Y9;).,;1J*-I)2A%2C/WE4^R-+_X)Z_M":-8_#C2=&_:[^!/AW2/A#K-
MWX@^$NE>&_\ @FG^S7I>G?!G7/MSW9UKX-V2:RUMX!U?QVKR_P#"V]0TF."Z
MU^2YNCX>FT(R"02S?L$?M(+X7\?^$[G]L+]GQ_"7Q9\0W7C;XI>!]3_X)M?L
MY'X>_%3Q_P"(8AI^J67Q'\/2^)$@\;>%;MQ8SZ4NM/>>/KO6[>T;4?$VHPQP
MV3_-LO[:G[;FM67P&^%=IJI^&7CGQI_P41O_ -E34?C1\4OV;3X*\0_$O]G_
M %+X,>(_BCX?^)MK\!O&;:?_ ,*Z^*VEI;#2+S3[W2K'PG?^)_#MOJ0\-R>#
M=>DTZ;S7]H7XC_M(_%6V\+_!GQE\?&@\3_LS_P#!;K]DOX$V_P 6/#'PJ\ :
M1??$OPUX@N/!_P 0O!'B#QCX$>UN/!MEK_P^U/61FQT.RMO#7BJXTZRN]6TE
M'C5$;P67I7C2QS?+S1_VS%1O.2B^57KZ.TM&XN+22Y7&2@2N(<W;49+)N5NS
M3R/)Y+D3E%7M@%)P=G#2M&HHRE+VD:J]O']&/A!^QQ^U+\#O"5C\./AE^VY\
M-_ GPXT"6_;PSX/\"_\ !/']GKP9HL,FL7":EJVHZEH/A3Q5H'AV/5Y-3:YC
MM[C0],T^"737C.I0WFIF6];ZA\,_ S0= ^/7B']HWPIXMN+76OB3\.?#/@'X
MP:'I5EI,_A?XI:W\.9[N#P+\1)[BWN9)?#GC#P?#J'B3P](NDO<PZCHNI1Z'
MJK#^P-.DA_.N+]J;]IOX=?M0CPM^U'\0/&'[.?A"^_:9L_A;\.-!\3_LEV7B
MC]ECXX?"_P 4VEW!\+KGPA^UWX.N)-:\$_&KQQ'#9ZMJ&F_$+6= T'0?'-S/
MX'M/!NHZ<+7=[K^SE?7'PN_;W_;:_9?T9#!\,;GP)\#?VN_!7A^" 6^E?#[Q
M/\:-2\?>"/BQX:TB"%$MK#3_ !5XL^'EM\16TN!(HXM?\0>)]0BC_P")G-M]
M#"T\/2C&G2C54(U?9Q56M4J2BXJ;@U[2<YQBU&<$G)^ZDKSBY2?BX[$XG&UJ
MF*Q,J#K5*:G.6'PV&PU.HKP4VZ>%H8>A[24YJK4<*45*K.HU"C[E&E]4I^RY
M^S)'\2?^%RQ_LY_ I/BZ-5?71\4%^$W@5?'PUN2T;3Y-9'BL:'_;(U5[!WLW
MU 78NFMG>$RE&8'TRV\#^";/5_&&OVG@[PK;:[\0[>RM/B#K4/A_28]5\=VF
MF:=)H^FVOC*_6T%UXFM]/TB:;2K*#69;V*UTV62RA1+9VC/445WJ,5>T8J[N
M[1BKMZ-NT5=M-IO=IM-M.QP7;W<GI;64GHM4M9/1-)I;)I-)-7/"_AY^R[^S
M+\(M3TO6_A1^SK\#/AEK6AW6I7VB:QX ^%/@CPCJNCWFM:2-!UBYTK4-"T6Q
MN]/EU70P-&U%K26+[;I0^P7'F6O[JKGA7]F[]G7P+XRG^(W@CX!_!?P=\0KG
M5M1UZ?QWX6^&/@S0/&,NN:Q#>6VKZPWB32]&M=7&IZK;:CJ%OJ-ZMV+B]AOK
MN.Y>1;B4-[112Y(*R4())W248I)[724;)VTNK.VE[!S2U]Z6JL[RD[KL[R=U
MY.Z\CR;P=\ O@1\._&GB7XD_#_X)_"7P+\1/&;ZC)XO\>>#_ (=^$_#?C'Q1
M)K%\=4U=]>\1Z1I-IJVJ/JNIDZCJ37=U*;Z^)NKDRS$N?6&571T=0Z2(\<B,
M R/'(I22-U.0R2(S(Z,"K*Q5@02*6BFDEHDDM79))7>[LDE=]7:[ZMB;;U;;
M?=MMZ;*[;=ET5[+HD<]X4\(^$_ 7AW2_!_@7POX>\%^$M"AEM]$\+>$]&T_P
M]X=T:WGN9KR:#2M%TFWM-.T^&:\N;B[EBM;>))+FXFG93)*[-VUQ_P @;3/^
MOW5?_1>F5E5JW'_(&TS_ *_=5_\ 1>F5,]/9I:)5(V2T2]RKT1<?^7G_ %[E
M_P"ETS*HHHJR HHHH ^3_P!MW]H'Q5^R]^S;XO\ C-X)T'P=XC\4Z-XH^$_A
M71]-^(.H:QI?@J.?XF_%?P7\-'U;Q)>Z \6L1:9H,'BR76YEL9H9)OL @::*
M.1Y%\+T[]I?]I_2?C[X)_9O\52_L7^/?%_QJ^$7Q@\=_"[QG\#-:^+>L^&/A
M]XB^$5QX428_'KPMJ>NZOX@A^&_BU?%L&G:#XJ\*:UIMX/$VE7NA-:W,D\4\
M/M7[=/[/6O\ [4_[-7BGX(>&SX2-_P")O&WP6UR\M_'0E?PKJ'AWX?\ QF\!
M_$#Q7I.K01:9K(O%U;PUX9U73;6PN-.N++4+VZM[._:"SGGGC\L\$?L56O[.
M'[:%U\?/V3?!'P7^&OP6^/O@.+P3^UO\)](T'3?A^/\ A)?  EO/A!\8OA+9
M>%/"<]A_PD!2]U'P=\0O!,UWX9\-:QI;Z;XM@E;Q%87*ZAR5H5G6C*$IJFE"
M,N63^TYJ;4=G9.-Y-WC=22E9VV@Z?LVI).?[QJZ[*'(G*]XW?.TE%J;3C)QY
MDU'^R[\<OVROB]\8OCUX*^)^C_LB:-X(_9P^,3_!_P 9WGPXM_CN_C/Q;?3?
M#_0O&MEKGA(>+=:N?#VCVB3^([+3[RRUR*_F:&ROIK>X62:U"^Z_&O\ ;%_9
M]_9ZU;4=%^*?BCQ5I]YH'@]?B%XOE\)_";XL_$S2OA]X#>[N+&+QE\3-<^&W
M@GQ5HWPW\,W%Q9:@;;6?&U_H=E<6^F:I=Q2M::;>S0UOV>O@CXK^$WQ,_;'\
M9^([_0;S2_VA?VB+;XM^"X-'NKVXOM-\-P_#7PAX-:S\21W5A9PVFLG5/#][
M.MO83ZE:_89+:0W@F>2"/X>_X*"?L2_M0?M8:Y\9/#7A[Q!X-\4?!_XB_ :#
MP%\+/#/C7XZ_%;X2^#O@5\6;S2?'.B^,OBEXF^%/PI\*R2?M#:OXCTW7/#=E
MX>F\6?$3P_H_A"#2YX+OPIXCMHHXIQ>VI4/=4ZE1R>DWSM+WDOM)V?+'KISM
MZ+9_NIU5S.-.GRQORWBKM0YK-\VJ<I[[J%O7Z5M/V[?A_HOQ%_:6T'XE7.D>
M'O 7P<\7?L\>#_ACX@\)67BWQ]XR^,FK_'_X=3^.M(TGPWX$\)Z5KWB'Q3K[
M^43H>C>!M&U:\N]"BO=8O(([>QN9XNGO_P#@H%^R5I_AKX;^)S\3=5U&+XN>
M*_'W@'X?>&- ^%_Q7\2?$K7?B#\*X8KGXC?#V;X4Z#X)U'XD:)X]\&VDJWVN
M>#=>\+Z9XAM+!)KXZ>UI!-,GQ1I?[ 7[1O@_XCZ)\?O#6K?"+6_B7\-/'O[+
MOCSP1X!\0>+?%&G^$?&L/PT_9DO?V>/B]X;\3>-++P5>:CX.U&Y&JW&O_#?Q
M=8^%?$\.^Q6+7/#MLFHR16GI/P?_ &)/C1X?_:3^$G[4/Q$U?X96WBFX_:?_
M &H/VD_C/X*\(:MKNJ:'X._X7'\'?AU\&_A]X,^&>LZGX=TJX\:7FB:'\.K*
M_P#&_BO6--\%+JNK:IJ%QIFC06OEV87M,4FTJ=[R;5XMV3=UJII.WPI6T5I.
M^I7+0M?GVCLI6O)1U5G!O5I/FO:[<4E:Y]6WO[;/[-5OX$^&/Q%TWQSKOC+0
M?C+%XEN?AMI7PU^%_P 5/B?\0/$EIX*6X'CF]_X59\/_  9XC^)&D6/@2YMF
MTSQQ>ZYX7TVU\(ZU/9:)K\MAJU_9V<_T%X'\<>#_ (F>#?#/Q"^'_B32?%_@
MCQEH]IK_ (7\3:'=)>:5K.E7JDPW-K.N"K)(LMM=VLR17=C>P7-C>P07=M/#
M'^*%O_P3#^*?AT?"'QK?^&?A-\=_%7@76_VL]"\1_#'7OCW\;_@%H$G@;X]?
M'+5/C7X"\7^#_BW\*M&G\16?B_PK=-:Z#XP\&:_X0U;PUKECJTL^E:KI]_X<
MM+S4?UD_9G^$L/P,^!7P[^%D7A+X<>!'\,:7=&]\(_"-O&$OPZT/4]7U*\UC
M4[3PS=^/]8U[QCJ<'VV^FDO=8U[4WN]9U%[O5!9Z;%=I86^E*=>51JI34(*"
M:EK=R]U66KT?O/R22\WG4C24;PFY/F:M=?#[W2R>GNZ[2N]%HE[I111709!1
M110!JK_R IO^PS;_ /I!=5E5JK_R IO^PS;_ /I!=5E5$-ZG_7R7_I-,J7V/
M^O<?SJ!1115DA1110 4444 %%%% !1110 4444 ?//[5WQ[C_9B_9]^(GQN_
MX1A_&E[X1M]!LM"\*C5;70+76_%'C#Q/HW@SPM9ZKK]Z&MM"T(^(-?TZ37M8
MD24Z=H\=[=1Q2RQI&W'_  0^.'Q/U;XS?$W]F;]H#1OA9IWQM^&OPY^&WQ@F
MU'X*7WBZZ^'NL^ ?B?J/BC0--A-AX[>?Q5H?B30_$G@W7;&[CU"YDL]>TB32
M/$&E1VD%Y+9P^G_M%?#WQ)\6/@7\5/AMX0?P OB;QGX.U/0]'A^*GA*'QS\-
M[Z[N50C2_&WA>5D;4?#VJQI)IU]+:L-0TQ+D:KII^WV5N#\F?L3_ +&^H_ /
MXE?&7XU^)O GPW^$^O?$[P9\,OA=H/PK^&/Q&^('QGTOPOX+^&ESXEUMM7\0
M?&#XH:;HGC+QKXC\3>)O%^K-:6=UH]GIG@WPGIN@>&=+-RMK-=2X3]K[>GRI
M^SY7SZ^ZM[W763]SEV<=;7YG;6/L_93YK<]_=WYG\-K=HI<_-HTW:[C9<WZ-
M4445N9!1110 4444 %%%% !1110 4444 %07W_(+U3_KV@_].5A4]07W_(+U
M3_KV@_\ 3E85ABO]VQ'_ %XJ_P#I#-L/_O%#_K]3_P#2D3T5J_VC;?\ 0&TS
M_OK4O_EA1_:-M_T!M,_[ZU+_ .6%:<TO^?4O_ Z7^9GRQ_Y^1_\  *G^1E45
MJ_VC;?\ 0&TS_OK4O_EA1_:-M_T!M,_[ZU+_ .6%'-+_ )]2_P# Z7^8<L?^
M?D?_  "I_D95%:O]HVW_ $!M,_[ZU+_Y84?VC;?] ;3/^^M2_P#EA1S2_P"?
M4O\ P.E_F'+'_GY'_P  J?Y&57D'QP^ WPN_:,\#Q_#[XLZ#=ZSHEEXD\/>-
M?#VHZ+KFK>%/%_@KQSX1OAJ7A;QSX$\8^'[JQU_PCXO\/7F^33-<TB\@N84F
MN;:3S;:YGA?W3^T;;_H#:9_WUJ7_ ,L*/[1MO^@-IG_?6I?_ "PI-N2:E2;3
M5FG.DT_Q_II-:I,:23355)K5-1JIKYV_K\#XEB_8*_9D_P"$"UWX?:GX5\6^
M)K/Q?\8? OQ\\=>,?%WQ'\9>)/BI\0OBS\--<T;7_ GBGQY\3-2U.7Q5XF'A
MJ[\/:/9:=H][>_V-#HEBFC)8K8R31R?9D=U<PRM/!/-!*^[=)!(\+D.<L-T9
M4[2>2N<=..*O?VC;?] ;3/\ OK4O_EA1_:-M_P! ;3/^^M2_^6%**45:-"RL
MHV4J*32O9-=;7>]]V-^]K*JI:MZQJO5VN]5ULON78^/O&?[.USX;\ _M20?L
MT75CX#^+W[5WB>_\7^./'/C+Q%XGU?2]*\:^)_">A?#37/B-HNG+#K!L==\.
M> M$M+CPIX:T^VT_0+[Q-IFGR:G=6-O<7UT?8?@S\)?!WP%^$?PT^"?P^MIK
M7P3\*?!/AWP'X9CN2K7DVF>'-.@T^.^U!URLFHZE)%)J&H2@MYE[<SN6<G<?
M8/[1MO\ H#:9_P!]:E_\L*/[1MO^@-IG_?6I?_+"A+E=U1DG;E5ITDDG)S:2
M325Y.[MO9=$DAV:LZJ=WS.\*EVU%13;M=VBK)=%W>IE5\M^*?@'K2?M8?#O]
MJ3X?:KHUAJ,GPUU;X$?'3PWKDNH6UOXT^%HU>?QIX$U_0I=/L;Y6\>_#CQI+
MJ4.DVVJ"RTO5/"_C+Q):7.IVES9:6LGUS_:-M_T!M,_[ZU+_ .6%']HVW_0&
MTS_OK4O_ )84Y7E:]*6DE)>_2NG%W36OFT^Z;74225[5(ZIQ?N5-4U9K;T?D
MTGT/$M.^"'PTTKXW^*_VB[+0[E?BWXW^&GA;X0>)==FU?4;G3+_X?^#-=UWQ
M+X>T9?#4\\FAV\UMJ_B769KG4H;-;W4(+E+2\EEM[>*-?!_AS_P3]_9?^%7B
M[P1XK\(>&/&XL?A7XE\6^,_@W\,O$/Q3\=^*/@E\$_%OC=]5;Q#XC^$'PBUS
M6+OP=X$U21=>UV#2YM+L2GA^UUK4[;0H].AN2J_<O]HVW_0&TS_OK4O_ )84
M?VC;?] ;3/\ OK4O_EA4N,9--X>[C)R5Y47:4M6]]VTF][M)[I6:;5TJUKI1
M=E5UBDTD]-DFTMK)M7LVG^?7[77[&LW[5'QE_8T\<7WBO4O"OA+]FOQO\7_&
MGB*Y\(>-/&/P\^*9U#QQX TSPOX2U#X9^,O!HAO-$U72-7L9)=<EN]1L(+O0
MKJYL%6^6ZGM3NW/_  3Z_9<D\ > / &F^%_&WA9_AA\3/$/QI\&_$WP=\4O'
M/AKX[67Q?\91ZC!XX^)FH_&FPU9?'6O>,?'5IJU_8>,M4UG4KW^W]-F73KJ+
M[#!!!']T?VC;?] ;3/\ OK4O_EA1_:-M_P! ;3/^^M2_^6%2Z4'*<GA^9U/B
M<ITG=62LKO162V^\KGDE&*KV4/A48U5:[;OHM7>3WOH[6ZGY[Z5_P32_9(T'
MPMXK\+:'X:^)6DMXS^.?@O\ :;UWQC9?&GXD+\2V_:#\!Z;8Z3HWQ>T_XA2Z
MY-XDTSQIJ%EI\*>*=0L[N./Q1))=2ZK;RM=29ZO5?V!OV8]4TS7+-?"_C#1-
M9UK]H#Q#^U)!\0/"WQ+\:^&OBEX3^._B[2M-T+Q5XZ\!?$/2M4@\1^#'\1:+
MI5KI6LZ)H]U%H.HV+W<%UITJW<N?MW^T;;_H#:9_WUJ7_P L*/[1MO\ H#:9
M_P!]:E_\L*/9PV^K*S7+O1VUTW\W\VWN+FE_T$/>^U7?3R\EY:;'QCX9_86_
M9E\)6?PSM](\$ZU)J/PJ^.6N?M+Z)XKU?QOXIUKQQXI^//B71-8\.:_\3_BE
MXPU'4)M;^)_B/5-$UV]TV>3Q=<ZA:Q6D6FP6MM;PZ791PS>,OV(?V=?'-O\
M$I-7\.^+=.U+XK?'SP)^U!XD\3^%?B)XN\+^+]*^._PTM]!M/!7Q \#>)-)U
M&'4/ ]]H]IX;TNU-EX?>VTV\M_M\5W:RKJ-UO^R/[1MO^@-IG_?6I?\ RPH_
MM&V_Z VF?]]:E_\ +"G[.#7+]65G>ZO1ZKE?7JM&W>_6X<SO?V[OWM5OOS=O
MYM5T3V70^(F_8+_9XN?&.F>*]7/QC\0Z7I'Q+M/C)8?"OQ/\=OB?XE^!MO\
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M#:9_WUJ7_P L*.:7_/J7_@=+_,.6/_/R/_@%3_(RJ*U?[1MO^@-IG_?6I?\
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M6>&:.-DB:..:*1)$1HHV16"M&A!0%*S%B6.,GT554>@55"JJ@<*JJJJ %4
M"DKK6R]# **** "BBB@ HHHH **** "BBB@ J"^_Y!>J?]>T'_IRL*GJ"^_Y
M!>J?]>T'_IRL*PQ7^[8C_KQ5_P#2&;8?_>*'_7ZG_P"E(T/L5Y_SZ7/_ 'XE
M_P#B*/L5Y_SZ7/\ WXE_^(KQ:BO*_ME_] R_\&O_ .5GI?V2O^@A_P#@I?\
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M^_$O_P 11]BO/^?2Y_[\2_\ Q%>+44?VR_\ H&7_ (-?_P K#^R5_P!!#_\
M!2_^3/:?L5Y_SZ7/_?B7_P"(H^Q7G_/I<_\ ?B7_ .(KQ:BC^V7_ - R_P#!
MK_\ E8?V2O\ H(?_ (*7_P F>T_8KS_GTN?^_$O_ ,11]BO/^?2Y_P"_$O\
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ME_\ B*\6HH_ME_\ 0,O_  :__E8?V2O^@A_^"E_\F>T_8KS_ )]+G_OQ+_\
M$4?8KS_GTN?^_$O_ ,17BU%']LO_ *!E_P"#7_\ *P_LE?\ 00__  4O_DSV
MG[%>?\^ES_WXE_\ B*/L5Y_SZ7/_ 'XE_P#B*\6HH_ME_P#0,O\ P:__ )6'
M]DK_ *"'_P""E_\ )GM/V*\_Y]+G_OQ+_P#$5J3VEV='TT"UN<B]U3(\B7(!
MCTW!(V9P<'!Z'!QT->!5LW'_ "+^D?\ 83US_P!%:-4RSAMQ_P!G7NS4OXKU
MM&:M\&GQ7^14<J2YOW[UBU_#6GO0=_C_ +OXGJ'V*\_Y]+G_ +\2_P#Q%'V*
M\_Y]+G_OQ+_\17BU%5_;+_Z!E_X-?_RLG^R5_P!!#_\ !2_^3/:?L5Y_SZ7/
M_?B7_P"(H^Q7G_/I<_\ ?B7_ .(KQ:BC^V7_ - R_P#!K_\ E8?V2O\ H(?_
M (*7_P F>T_8KS_GTN?^_$O_ ,11]BO/^?2Y_P"_$O\ \17BU%']LO\ Z!E_
MX-?_ ,K#^R5_T$/_ ,%+_P"3/:?L5Y_SZ7/_ 'XE_P#B*/L5Y_SZ7/\ WXE_
M^(KQ:BC^V7_T#+_P:_\ Y6']DK_H(?\ X*7_ ,F>T_8KS_GTN?\ OQ+_ /$4
M?8KS_GTN?^_$O_Q%>+44?VR_^@9?^#7_ /*P_LE?]!#_ /!2_P#DSVG[%>?\
M^ES_ -^)?_B*/L5Y_P ^ES_WXE_^(KQ:BC^V7_T#+_P:_P#Y6']DK_H(?_@I
M?_)GM/V*\_Y]+G_OQ+_\11]BO/\ GTN?^_$O_P 17BU%']LO_H&7_@U__*P_
MLE?]!#_\%+_Y,]I^Q7G_ #Z7/_?B7_XBC[%>?\^ES_WXE_\ B*\6HH_ME_\
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M*_Z"'_X*7_R9[3]BO/\ GTN?^_$O_P 11]BO/^?2Y_[\2_\ Q%>+44?VR_\
MH&7_ (-?_P K#^R5_P!!#_\ !2_^3/:?L5Y_SZ7/_?B7_P"(H^Q7G_/I<_\
M?B7_ .(KQ:BC^V7_ - R_P#!K_\ E8?V2O\ H(?_ (*7_P F>T_8KS_GTN?^
M_$O_ ,11]BO/^?2Y_P"_$O\ \17BU%']LO\ Z!E_X-?_ ,K#^R5_T$/_ ,%+
M_P"3/:?L5Y_SZ7/_ 'XE_P#B*/L5Y_SZ7/\ WXE_^(KQ:BC^V7_T#+_P:_\
MY6']DK_H(?\ X*7_ ,F>T_8KS_GTN?\ OQ+_ /$4?8KS_GTN?^_$O_Q%>+44
M?VR_^@9?^#7_ /*P_LE?]!#_ /!2_P#DSVG[%>?\^ES_ -^)?_B*/L5Y_P ^
MES_WXE_^(KQ:BC^V7_T#+_P:_P#Y6']DK_H(?_@I?_)GM/V*\_Y]+G_OQ+_\
M14%]9WG]F:F/LESDVT& +>4D_P#$RL.F$].?H">@->.UT7A;_D,1_P#7O<?R
M2LJV;NI2JT_JZ7/3E"_M6[<RM>W(KVOM<TI98H5:<_;M\DXRM[-*_*[VOSNU
$_0__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>formdrs_005.jpg
<TEXT>
begin 644 formdrs_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #( FT# 2(  A$! Q$!_\0
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MM']8BKK31VTNK.VE[-I_1\)M_P!N875ZTL5?5Z_[.WKKKKKK?77?4Y?XH_\
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M7QJTNRO9]3BL&U*YT*VMM.\4PVQU)1%-I\=TEI)/!\M>$OC1^W!>_"?]E?\
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M%-?\)7"ZY:>*/#NB07^HQ>$+".)99/$4UC9ZGJ]SIEH-.THQS7DI;V3]H?\
MX+H_M!_ KX\>+_@98?L[_"WXB^(OV=$^&OAW]HO2/"6C?M+Z_K'Q&^(OB71]
M,U_QSI?[-6K>$O OB?P=X9\.^%K"^GCT:]^/FLZ+JFOO8SWEO93Q+]F/ZT^$
M/^";GP*\%6?[ ]CI7B7XGSP_\$Z+;Q1:_ ]K[6O#KOXCC\6Z?+INI'XF>1X7
M@366A@E9[+_A'U\,I%*%,BS(-E<C\:O^"5OP(^-'QK\<?&G_ (6M^U!\(C\8
MI_ ]U^T+\+_@9\:=4^&WPL_:(N_AV]N/"UY\5-&TNP?6YKVRL[2VTY[WPMX@
M\-7<EK$7\Y;J6:XD^?CE^<4,+&GAL2Z4XSPT535:E*"IQPE/ZQ.,JU*I[\\=
MSSJ.<YNI17+3C!2Y7[KQV55L1*IBJ'M8N.*;FZ56,W.6,J/#PDJ52'N0P#A3
MI*%."I5K.<I<O,O@/_@H-_P6M^*G[)OQ)O(/A=\-_P!G?Q;\+_#'A3X0>)]?
M\/\ CWQC\1M4_:(\01_$_3+'Q)="#P3\*;#6O#_P0L=&T/4K6QM+_P#:"O/"
M:ZQK:R/I4>I[QI,7,^+OVPOVX?!/_!3C]MCQ-I[_  J\0_ KX%?\$V%_:%\.
M_"CQ1XR^(@TW1? 5UI>F>.?#&KZ=HFC6EGI-Y\8-?\:6VFZ#X[N+J6'3;3P5
M/JK>&M6ANYH[)ON7]H'_ ((R_LS?M$>/OVA/&FN?%/\ :A^'^A_M2:?X5'QM
M^$_PM^+4'AKX5>-_%/@.PLK+P-X\UKP]=^'-6O\ 5O$'A&;3K'5=$TW5]7U#
MPE#JUO\ :YO#LWGW"2^B?%7_ ()<_!?XK_%K4/C)=_%G]H?P7XD\4?LOC]D7
MXEZ1X#\<:!H_A/XM_"2+POJ?A>RC^(>B7GA#4DU36-.348M=M'L)]-TC_A(M
M)TG4IM)E%J\$U5<+G=2K4DZSY(8JE6P\(8FG!*,%C*<MJ":@XU,+5]C4YUS0
MJQO)J,I33Q.34Z=**HKGEA:E+$3GAJDVY2>#J+_E_K-.GBJ2K4^3W9TI-).<
M(_G9\-_^"J__  4B^(?BS]E_P%9_LG_L@0^)_P!M_P#9BUC]HG]GJ6?XR?%6
MPTGP=I?A"Q-]XDOOC=YFA7UT;'6K;3]0NO"OACP+]KU:TCUGPW;ZQXDGDMM=
MEM\CQU_P7H\9:1^RC^Q[\1O#_P $_ NC_M"?M1>)/CCX=U;2?%R?%_QC\&?A
M^G[./BK_ (1'XA:T--^#'ASQK\8O$%OXCU::RB\(6&DZ5J#Z5!)=W_B2_DM+
M56F_5GP)_P $Y?@=\/?'/[(7Q T3Q)\3;G6OV*OV=]?_ &9OA3;ZEK/AZ;3M
M;\!>(]+?2;[5/'44'AFWN-3\4QVSE[:]T:YT+35GP\NE3*JH/(8_^"/_ .SE
MI?P7^"7PF\%?$[]H[X8^*/V<?B1\4_B?\%/VB?AI\1-(\(?M ^ M7^-'B"]\
M0_$;1M+\6:?X4&A3>&O$$UX-/GTV\\,7$@L+2T)N7O$DNI6\-GT:4U'&.=1T
MY).I5H.SM@)KD:PT%"I*2S"G&I+FC&#I7C\$HI8G))5(.>$C&"FFU3IUXIJ^
M/C::>(FY4XQ>73E"-I2FJS4KJ<9?(FB_\%@/VG?B9\/_ -A)?A+^RWX MOCC
M^U=\8OC)\ /%_@KXPZI\4?AYX.T#QK\+_".F>(K#Q_X/U/4M%L?&,7PNUNRU
MFS\730Z_X7U7Q,F@P7WA2U#>)X7U&/Y=_;1_X**?MZ^/OV%?VC-+M?#WPC^
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MWJX7,:=5UE[?EJ.G5J8%Q<(P?NU9TVG=GR7X,_X*V?M2CX7?ML?M8?$[X#?
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M'MHV&IP6,>N#^TZQ],_X(Z_LXZ?X;\9^&;OXI_M*>)X_B#^TE\(_VL?%VO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYDCAF>/,^,_[=O[%7[.>N1^&?CW^U7\#/A#XAG\&:3\1K31O'/CO3=)OM0\
MZ_J\.@:'XQTJ(>>NK^']6UB>*RT^_P!+>\2YW&Z0&QCEND'C*ZYKYMCERV4K
MXV/NW5U?]QI=?U?0%A<,[6RO!/F3<;8*3YDM&XVK:I/=JZ76Q]1?\*X^#WKX
MV_\  ZU_^1J/^%<?![U\;?\ @=:__(U?-WP\_;6_8\^+GQ0B^"?PJ_:A^!?Q
M(^+T_A:S\;V_PX\$_$30O$7BJY\(W^EZ=KEGKUM8:=<3)<V<NC:OIFJ-%!-)
M>P6-];SW-I"K-MI^"?VY?V,?B5\:=5_9P^'O[4WP.\:?'W1+S7-.U7X0>'/'
M6FZCXYM-1\,,R^(]._LN,B.ZU#0V24:E8V5Q<W5MY%SNBQ;7'E/ZWB':V:X]
M\TG"-L;%WFM7%?N-6NP?5<,K_P#"7@M(\S_V*6D7M)_OM(_WG9>>CM]._P#"
MN/@]Z^-O_ ZU_P#D:C_A7'P>]?&W_@=:_P#R-7S-X"_;?_8U^*GQCUW]GGX:
M?M1_ _QY\=?#$NNV^O?";PMX\TK5?&NG7'A><6OB2W.FPOY=Y<:'<'RM3@TZ
MXO);9ED+*5BD9?J.JCB<5--PS3,))-Q;CC$TFG9IVP[U3W0GAL)&REEN BVD
MTI81Q;3V:3KJZ?1[/N5?^%<?![U\;?\ @=:__(U'_"N/@]Z^-O\ P.M?_D:K
M5%5[;&?]#+,O_"O_ .]R?88/_H79?_X2_P#WP%C\//A%%?6,L!\9^?%>V<L'
MF7ML8_/CN8GA\P"W!,?FJF\ C*Y&:74/AY\(YM0U":X/C/[1-?WLUQY=[;"/
M[1+=2R3^6#;DB/S6?8"20N 35BR_X_;'_K]L_P#TIBIVH?\ (0U#_K_O?_2J
M6L_:XOVM_P"T<QO[*U_K6MO:WM?ZOM?6UM];]"_88/V=O[/P%O:7M]6TO[*U
M[>WWMI>^VENIE?\ "N/@]Z^-O_ ZU_\ D:C_ (5Q\'O7QM_X'6O_ ,C5:HK3
MVV,_Z&69?^%?_P![D>PP?_0NR_\ \)?_ +X*O_"N/@]Z^-O_  .M?_D:C_A7
M'P>]?&W_ ('6O_R-5JBCVV,_Z&69?^%?_P![A[#!_P#0NR__ ,)?_O@J_P#"
MN/@]Z^-O_ ZU_P#D:C_A7'P>]?&W_@=:_P#R-5JBCVV,_P"AEF7_ (5__>X>
MPP?_ $+LO_\ "7_[X*O_  KCX/>OC;_P.M?_ )&H_P"%<?![U\;?^!UK_P#(
MU6J*/;8S_H99E_X5_P#WN'L,'_T+LO\ _"7_ .^"K_PKCX/>OC;_ ,#K7_Y&
MH_X5Q\'O7QM_X'6O_P C5:HH]MC/^AEF7_A7_P#>X>PP?_0NR_\ \)?_ +X*
MO_"N/@]Z^-O_  .M?_D:C_A7'P>]?&W_ ('6O_R-5JBCVV,_Z&69?^%?_P![
MA[#!_P#0NR__ ,)?_O@J_P#"N/@]Z^-O_ ZU_P#D:C_A7'P>]?&W_@=:_P#R
M-5JBCVV,_P"AEF7_ (5__>X>PP?_ $+LO_\ "7_[X*O_  KCX/>OC;_P.M?_
M )&H_P"%<?![U\;?^!UK_P#(U6J*/;8S_H99E_X5_P#WN'L,'_T+LO\ _"7_
M .^"K_PKCX/>OC;_ ,#K7_Y&H_X5Q\'O7QM_X'6O_P C5:HH]MC/^AEF7_A7
M_P#>X>PP?_0NR_\ \)?_ +X*O_"N/@]Z^-O_  .M?_D:C_A7'P>]?&W_ ('6
MO_R-5JBCVV,_Z&69?^%?_P![A[#!_P#0NR__ ,)?_O@MP> /A0FBZE:H?&/V
M*>^TR:YW7EL9_/MX[];7RF%N (]LUQYP())\H@C!K*_X5Q\'O7QM_P"!UK_\
MC5OP?\@;4/\ K]T[_P!%WM959PJXQ.HUF.8J]1MVQ5KODIJ[_P!GU=K*^FB2
MMIK<Z&#:IWR_ .U-)7PU[+GJ:+]^K*]W;75O76RJ_P#"N/@]Z^-O_ ZU_P#D
M:C_A7'P>]?&W_@=:_P#R-5JBM/;8S_H99E_X5_\ WN1[#!_]"[+_ /PE_P#O
M@J_\*X^#WKXV_P# ZU_^1J/^%<?![U\;?^!UK_\ (U6J*/;8S_H99E_X5_\
MWN'L,'_T+LO_ /"7_P"^"K_PKCX/>OC;_P #K7_Y&H_X5Q\'O7QM_P"!UK_\
MC5:HH]MC/^AEF7_A7_\ >X>PP?\ T+LO_P#"7_[X*O\ PKCX/>OC;_P.M?\
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M]3^1+_@H#\;?A7\!OVF?^"ZOP;\7?#OX#_M"^+_VH_V>_ /B+P_\4?%GQ/\
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M6? WA/XZ>&/@I_P0B^(G[*]K\6;O5/ _BCP;+^U5J?B'Q%<:!X"\*#Q-J_\
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MPI_X*(?%'XS>#_@'JW@O]DRSA\;_ +5-EX[\7_ 3P!XC_:*T;1_[0^%'PO\
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MG[A_V9J/_/C=?]^)/_B:^5OVA?V%_@)^U3K?@GQ#\=/!/C_Q7J/PWU32M?\
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M&Z_[\2?_ !-'/#^>'_@<?_D@Y9?R3_\  )__ "!1HJ]_9FH_\^-U_P!^)/\
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MW=<DDO>?,U_#ORWV7-97=K7/SW_X)M_LF3_L??LX2>"-;TA- \;?$'XE^/\
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M&BKW]F:C_P ^-U_WXD_^)H_LS4?^?&Z_[\2?_$U7/#^>'_@<?_DB.67\D_\
MP"?_ ,@4:*O?V9J/_/C=?]^)/_B:/[,U'_GQNO\ OQ)_\31SP_GA_P"!Q_\
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MKO[SN^I9^VWG_/W<_P#?^7_XNC[;>?\ /W<_]_Y?_BZK45W6C_+'_P !C_\
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MJ*+1_EC_ . Q_P#D0N^[^]_YEG[;>?\ /W<_]_Y?_BZ/MMY_S]W/_?\ E_\
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M>$)_$GAB#QEI%I?^)O#-A/IDUY/X:N8M4DM;)[F6",M%(HG4QUS?CK_@H_\
M 3P'X=^&_C:33/VC_'/P[^+Z_#N'X9_$SX4?L^_$[XD?#SQCK/Q6O(],\"^$
MM+\4>'K":T'C/5M8ECT.X\,7*0:EI6ML=+U*.VND=%^*?'W[.O[7GC3XR?\
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MU6.32M#N;JZN]1TN[T2T636?)L9=K]I6Y^+W[57Q/^+/QJ_8QT'XP1-\,_\
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M^SS?_#[X._MQ?MM0>!?$VB?M'_L\_P#!0KXY?M1>$?%.MMXJL=<\8_ #X/\
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MVV\_Y^[G_O\ R_\ Q='VV\_Y^[G_ +_R_P#Q=5J*+1_EC_X#'_Y$+ON_O?\
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M?_+#+HK4^R:9_P!!N/\ \%NH_P#QNC[)IG_0;C_\%NH__&Z/:1[5/_!57_Y
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MNC[)IG_0;C_\%NH__&Z/:1[5/_!57_Y .27]W_P92_\ EA4LO^/VQ_Z_;/\
M]*8J=J'_ "$-0_Z_[W_TJEK1M+331>69768V87=J57^SM07<PN(R%W&/ W'
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MXRA+B[-'"<90E#GR51<91E%QY5P_%*/+)Q44HJ,5",%!4Z2I9?'8     9P
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M,,4:K'%#%&JQQ11JL<<:JB*JJ -7[)IG_0;C_P#!;J/_ ,;H^R:9_P!!N/\
M\%NH_P#QNGSPNWRSN[)OV52[2O97Y.EW;U#DE:UXV5[+VE.ROOI[3K97]#+H
MK4^R:9_T&X__  6ZC_\ &Z/LFF?]!N/_ ,%NH_\ QNG[2/:I_P""JO\ \@+D
ME_=_\&4O_E@L'_(&U#_K]T[_ -%WM95=-#:Z<-)OE&L1E#>6!:3^SK_Y2$O
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M:3[[)(ZE\Y)WD$%N23SGJ:C#, 0"0&QN ) ;!R,CH<'D9Z&M/[)IG_0;C_\
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M#_PEXVN[/PSKEQJK:E?P:GIMIJ-FWYN_&3]LZ7XG_P#!/?\ X)6^"?'GC/\
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M'_(0U#_K_O?_ $JEJ?\ EY_W#_\ <B*_Y=_]Q/\ W&RI1115$A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% &K!_P @;4/^OW3O_1=[656K
M!_R!M0_Z_=._]%WM953'>?\ U\?_ *13*EM#_KVO_2Z@44451(4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5-I_\
MQ_WG_7CIW_I3JU0U-I__ !_WG_7CIW_I3JU>9G'_ "+ZW^*C_P"G4>CE7^_T
M?\-7_P!-,9<?\?DG_8*\)?\ J(:'3*?<?\?DG_8*\)?^HAH=,K?+_P#<L+_U
MZ7_I50PQW^^8G_KZ_P#TFF%%%%=ARGS=\3OV?O$_Q$\;#QKHG[3_ .T#\()(
MM*M-)L] ^&.G_LZOI.G101[;R>PU3XD_ #XB^-;:369O]+U:U7Q8=*FN?GMM
M.M4_=UYI-^QOXON1?BZ_;?\ VM+H:M-;W.KBZ\/?L6W(UBYL_P#CSNM8$_[(
M$@U:ZLO^7*YU$7,]I_R[215]N45#IP;NT]=?CJ?DJB7X%*<DK)JR_NP_-P;^
M]L_#'XV?\$*?V:OBUXU^-/QN^+?[8_[?EOXC^,7@Q_#WQW\3:=\>_A?\.O#W
MC#X>:1H7]F7NB>,=+\+?!'P_X7M_!T/AZWGAUJQ%E9:3=6,FH2ZI',MY?/-]
M:?!O]CW2[#X8_#)_@9^WW^T[??"S3/AUX9\,?"KQ'X)F_8P\0:-=?##1]/@T
M_P -67A[QG:?LHW\^N^&?L=I$\$ZZO?6NHSK)?S2W-W++</XC_P7W\=>*OA_
M_P $E?VL;_PA=7^G7WBJS^%GPOUG5-.E$$^G^#?BK\8O GP_\;.TN0T<5_X7
M\0:IH[2(=T;ZDDC?NTDKQ>P_:9N?V9_^"J/AW]D[7OCKI?PI_8Y^'O\ P1U\
M-^/O GPX\6:YX2\)_#V#X@>!_%UOX=A\9:3?ZG;6$U]XFM/ NAW23VMGJT]M
M/:6E[<KI<EPLLM<<OJ]"NX^RC%25/VE7GG%\U:=7ENW42<5[*4I-N_,UU9U+
MV]6DG[1RY74Y*;C&24:4*5^5*FWS/VD8Q5K*,7JM$?HY;?LB>/K'3WTG3OV\
M?VQ]*TJ2&Z@.FZ18?L>:1IZ1WPE%YY-GIO[)%K;P/<F>:2:6"..62:1YV<S,
M7K\Y_ 7_  ;Q_LH?#/4?AU?^$?VGOV_K>V^$OQ4M/CA\._#6L_'+X=>*? _A
MKXNV$ES+9_$*'P/XF^"6K>%K_P 2V[7MZ([_ %72[YUCOKV(#R[RY67\OOV5
M?VO/^"A'[76G?\$7?AK8?MX?%KX9ZG^V';_\%"8_C=\5]#\/_#OQ%XJ\4Z!\
M*/BKXGTSP!J-A8^(/"D^AV_B3PYX9LM/TCPGJR64-OI4#?VA<V6HW,,:M6D_
M;2_X**^(?@W\&O@3I/[;?C_0_BI#_P %S/%O_!/F^_:7B\*>")O'WB[X+PZ+
MXAFLI?&VA3:'+X8UG5-.G2.[LUAL+)/.M;&&XEFAMR9<'B,-4Y7+#2G:,90<
MI-^])4)*,;U=/XL7?17BO5:JCB*?-&->G!MM348VT4J\.:5J.JO2J)6O*TO-
MH_IBA_9$\>6T5_;VW[=G[8%K;:K+=7&KVMKI/[&MM:ZQ<7T?DW]QK%K!^R)'
M;ZK<7\.(;^?4([F:]A ANGEC 40V/['7C'2I;:;2?VX?VM=(GLK6:QLI](\/
M_L6Z5/96%S,+BZL+.;3_ -D"VDM;"ZN0+FZL8&CM;FX GGADE >OYI?V^_VN
M_P#@IQ\$_P!K+XM_LD_ []J+XB?\(]^Q=^S?\-_B0GQH^*7QX_9,^ 6I?&+6
MO'DL?B'5_BU^T /C1X4LK#XL^!=&U:\L_AO'X$^#9\-RZ-IVBWD5S>O?ZU=7
M,7;_ +?G[</_  41M/$WPY\>^%_VG(O@O\/_  E^P-\&OCS\:O '[(WQ3_9B
MU_XD?#GXK>,M(&M>*_B#XM^"'Q@U/2/$7[1_P:U6\-C=>#=-^$7CC29!X%GO
MKF36XY[6Y@GIXNBO:IT:O-2E&,DYR2N_C3;JZ<DE):1:=N;1-M0L-6?L[5*5
MJL7*+Y5LDG&Z5)OWTXVUT;Y7K9/^ARR_8Q\4:9/!=:7^VO\ M6:5=6LUS<VM
MWI7A?]B?3+NUN;V.**^N;6ZL/V/;>XMKF^A@@AOKB"2.:\A@@BN7ECAC5;=G
M^R!XWTZ\O]1TS]N?]KS2]2U9VDU?4]+T7]C+3=3U>1IC<.^K:C8_LA07NJ.]
MP6N'>_GN&>X8SN3*2Y_F>_;=_P""HW[>_P 5?C9X,\+?LF_&"Y^%_P -?#O_
M  3N^#O[7UGXUTWXI_LX_LBZ?\1=<^)-A!<^(/B=\1=/_:@M/%4?B'X9>&M<
MM)?#MQ\(_AQKHU71VCUDIXBU**;[9%]8:_\ M=?M<?M0?'W]G3X >/OVZM"_
MX)MZ'>?\$O?!/[9?B;XK_""[^%%]H?QI^-OC"XDTK7?["\<^.)M6\(:Y\'O"
M-KI\/BJ/PWX0U.XU.;3]:<QZF)=EQ$_K5!NHHTIMPE",;U)1C)RM?WI55&*B
M[:MI25FG=J+7U>LE!RG37-&4I+D4I045?WHQHN3;Z*-VG>Z5FU^R_B+]FS59
M]1\/^"O&/_!1#]J*]U7Q7/?W'A7P;XM;]B74;_Q)=:!82WNJ7?A_PUKG[)EQ
M-JMQHFEO<75]=Z?932:=8//)-+# \A.Q=_L?>-+VSL;'4/VY?VN+[3=',,VD
MZ=?Z%^Q?>:9HK64/E6TND6%U^R#+9:0UG;KY5O)I\%LUM HCB9(U"C^?;XBO
MK/C?_@L5_P $F_C=KW_!0L>+M US]ACXK^,[GXY_"/2/!OA'X-^.(OA'<:Q:
M^.]*^'VAZ_'X@O[?PC\?9=(N_P#A8FC6VK:QXD?4+[5;?X?:CIV_2XK/R7]C
M;_@I;^V=\2?^"B?["HF_:@^*GQ9_9J_;C\?_ +2NEW?AKXCC]GGP=X*O?#7A
MNS\?W6G6?PL_9J\":[XW^-/P6T+P--I7AW3O"GC#XL^.)[SQO;&>^TS1K6WF
MF1TL72<^5T9:UHP3563ERR5-1J-<[WE5BMVDNK=DV\/5Y>:-2#M2E4DG344G
M%U>:$6Z2UY:4GJHN^C2Z?T6_#SX :;\5?#NF^/OA+_P4=_:$^(WA.?5]:FT3
MQM\.IOV%_%.@/XACNFT_Q+=:/XC\._LF7EBNO&]@>Q\07EA=KJ4MS";;4Y7D
MBV*_P]\!;#XJZGK[^%_^"D7[0_Q.UOX5^*;GP;XGFTBY_88\;ZS\-/&^FBWU
M*[\*:Q<0_LFZG?\ @SQ3I_GVFHSZ+<2:=JEHTUM>-;QN\<I_DU_8"_:*^.G[
M*/["_P"Q;\=/@I^W@-=N[[_@HNO[.&L?\$V$T7X;3^&/%'@SXE?%?7=/\50W
MVFV4#_%R]^(MU;ZT/&.G>+Q<+H^G6\F@+ING+<V'F7WM?C7]K']HK]D;X8_\
M%/S^R[</H/CGX\_\%^=?^ .I?$:SUOPAX3U7X?\ AGQ+\/?#FJ7&H^'_ !Q\
M0K/4/ASX"\1^*;W2;7PII7C?QU9W>@>'IM6EO9;>63!68XRFX1G*BUHY24:L
MY;TE.+A^\W<KQ:DE)1UWVN6%J*<HQJ1=I*$'*G&-_P!XX24KTDU:/O)PO&3O
M%,_IJ\??L]'PW'X8U3XK?\%&?VDM'BU+Q;HG@WP5JGQ(D_8>MUN_'?BZ^6W\
M-^%O"NH>*?V3.?%GB;4X$AT72-(F75=8U"%$LX9[F- 'WGP"<>.7\*ZC_P %
M)OVDS\3KGPW>ZC+H&H:I^PZWQ G\'1W\%EJ,]Q8W7[*9\1OX7_M.\MK:]CF0
MZ4]Y=0I/&TLZ;OY]M=^*G[5/Q\_X(W?\%;O"/[97C;0/'7B7]E;5M$\4_!GX
MBVOQV^!GQQ^+OA'Q;X*U/3?B1H_A?XG_ !#_ &=6T_P4/B!X1\6:%IJ>'M7T
MG1] O)?#FO?V3Y5S]D^U7/[3?"+]ASP/\;?'GP1_X*+^-?$>HV?Q[^)G[/GP
M9U+Q7X6N?AQ\+M0^'LVD^+O@KI5]XL\,>)_"^J>&'D\6Z]>^/=:@\<'XB^)+
MBY\?:1>>'=+\'Z7JEIX,^V:+/M3JJJX*E1OS4XU+2J5(-1YYPFG[[5U*,7'9
M24KV3B8S@Z:ESU%>,YT_<ITY)R4*=2%O<32<9OFNO=E%+5.YZ]X1_9TC\7H\
MW@#_ (*+_M&>*(_ ^LZOX;$W@N;]AC6%\%:_I5R^G:_H=I)H7[)TX\+ZG8WB
M2V&KV-F;":.Y26VNT\Q70=''^QIXJAE:>#]MK]JZWN&U'^V6N+?PS^Q3;W!U
MKY_^)T;B']CY)O[:Q)*/[7W_ -HXEE'VG$CAJW[$_P"P-\,OV%=.\<:5\,O%
MOB3Q19?$*71]8U]?%7ASP'IMS:^+X3?3^+=;\.WGA+0-%F\/>&?&VJW::\WP
MLT[R_A[X+UE+R[\$Z/I UC4HYONBNJ%-.*<X<L[:Q52I)+72SYU=6MVUNNAC
M*;4FH2YH]&Z=.+>BO=<CMK?U5GU9\3Q?L>^-(-5N=?M_VY/VN+;Q!>+*EYXA
MMM!_8OM_$-XLZJEPMYKL/[(*:M=+<(JI<"XO)!.BJDN]5 'VK$C1Q0QM)),T
M4,433R[/.G:*-4:>;RTCB\Z=E,LWE111>8[>5%%'M17T5I&$87Y5:]NLGMMO
M)[>5C-R<M[:>45^45^-PHHHJA%FR_P"/VQ_Z_;/_ -*8J=J'_(0U#_K_ +W_
M -*I:;9?\?MC_P!?MG_Z4Q4[4/\ D(:A_P!?][_Z52U/_+S_ +A_^Y$5_P N
M_P#N)_[C94HHHJB0HHHH **** /@/]OS]H_Q=^SII/[-8\,_%CX4_ K3/C+^
MT7IGPF\<?%_XQ^%;/Q?X1\">%+OP'XR\3OJ@TO4_&WP_TF/49]5\/:?8PW6I
M^(H;9(KF9%@EF>/;Y=^SU\?_ (]?M%>./CE\)?A;^U7\ /B[X;\ :%\+_%/A
M3]LSX4_ &S\2_#2/Q#XBN]?L?''P!UOP5I_QIOO!?B#QQHMGI^D^*1KWAOXF
MR7GAS2]373O$OAZVOKBQ,_V-\<_@1+\9?&'[,?BI/$MIH,7[._Q[M/C7=:==
M:,^K?\)?!:^!_%O@_P#X1N"47EK'H\[R>)X]1&J3PZC&JV+6_P!B+SK-%RGP
M8_9FO?@)^T#\<_B#\.O&.F:9\!OC[)I'CWQ!^S^?#MQ%!X*_:!MTDT_Q=\3_
M (<ZY::G!I6@:%\4])%A>?$+P<_AZ9=1\9Z:GBRSU&UN]1U2.YY9TZLJSES3
M5)\L;0GRM)P?,TG>-N>R;^/^5-7:V4J:I6M'VB4FFXIIR]HK)MJ]U#X5\#U4
MK/E/+/\ @G;\2_VEOCS\$= ^.OQY^+'PY\6VWC&^^)>@:?X%\!? E?AA%X=O
M_A]\6O&/P]AUE_%4OQ0\;WFN1ZOIWA-;ZXTF;1].CL[S49!#?316L8E] \9_
MMO?"_P"'?Q8\,_##QI\//C[H>E>+?C!X=^ ^A_&6^^&UA9?!C4/B?XIA<Z1H
MEEK>H>++/QUJ6E3ZE&_AQO&FD?#K4?!(\0JUE%XAFMT>]7N/V2O@)<?LP? /
MP?\ !*Z\56_C:?PKKGQ*UE_$EMI$NA6]^OQ ^*'C'XC1VZZ5/?ZE+;G2H_%:
M:/)(U[*+R2P>]1($N%MXOST^)'_!*_QK\1?CE)\6-2^,_P +=0%G^U]X#_:G
MT+QIXR^$OBKQQ^T)8>'/ OC ^*-)_9NT_P"(^O?$6X\.> O@_HT%]JVE:-:?
M"OPCX,NM2ACT-_&:>(9+74I=0)*O"E1C34I3<H^T<I1E9:.=W)ZK=)1?1*]G
M=M>QG4JN<E"%I.'+%J[U4$E%.WV6^;I>^IZ5\%?^"CUKJWPG\-ZG\2? ?Q"^
M)_QJUC4_VG?$FK?#K]F?X;1>*-4\+_!;X$_M >/_ (1V?Q'\2:/K7C'2(--T
MJ2U\+Z?IA6UUK4O$7BSQ-%JY\->&+F.">"T[_P 5?\%//V:?#USK+Z'I/QJ^
M*/AKPO\ !GX:?M$^,O'_ ,*_AI'XE\">#/@?\5;GQ!:^'_B/XCU?4_$GA^_B
MTO29?#&KGQ9HNF:/JGB_0X[:61?#E\EGJC:?Y?X"_P"">?QB^!%W9>,OV?OV
M@_AYHOQ0U'P1\?\ X5>.]3^)?PCU_P 6^"]9\!?&#]H/X@?M!>#M6\/:#H7C
MSPYK&C?$+X5:U\0M7T:&[OM;U/PGXPM)&EUC0(O)LXX+6B_\$PM,\&_";]IK
MX.>"_BS+;>&_CS^Q%\+/V._#VH:]X8?4-8\(W7P[LOC*NI_$O7S8:M86?B%O
M%.K?%^ZU4^&M,AT--)&FRV4.H30W,!MH_P!KM9+5):M0>RD]'S>\YM)3;2Y6
MURE6PU[W=F]DY+1N*>G([**;<;-\ROS6:L_=O'O_  4(_9U^'GC7Q+X5U6X\
M<ZMX<\ :MX&T'XI_&+PUX<TK4?@]\)];^)%CI6J>#]+\=:_=^)M-\5+<7VF>
M(?#.HZI-X3\$^*['PM8^)M$N_%=YHD%Q<26OW 1@D'''<$$'T((X((Y!'!%?
MDM>?\$QX]-^)OC7Q?X2E_9*US1_BIKOPP\8>,]=^/7[(7A+XW_&7P1XJ\%>"
M/!/@#Q?)\'/&?B+58M&M?#OCO1/ .BW5CX?^(.B^*K;P+KEWJ^I: ^Z[")^M
M)().,X[9.3@<#)^GMCTK>BZS=3VL4ES+DVVUNE9NZMRN[L^9R6R1E45-*'LV
MV[>]?OITY59WYM$VK<KWN)1116QF%%%% !1110!JP?\ (&U#_K]T[_T7>UE5
MJP?\@;4/^OW3O_1=[654QWG_ -?'_P"D4RI;0_Z]K_TNH%%%%42%%%% !111
M0 4444 %%%% "$A59F(545G=F(541%+.[L2%5$4%G9B%5068@ FOF3P+^U+X
M3^,'C6W\,_ _P;X[^*_A&QUB?2?&_P <=-TN/PS\#_!TEE-<6]_::?XS\4-8
MWOQ)U^)XH9+&P^'.@Z_X9U*WN&*^-K:\M+FP7Z<Z=*\*B_9K^#6G?%"V^,OA
M;PK)\/?B-]MEO/$.M_#;5=0\$:?\0EN9)I;^V^)_A/1)H/!WC]M3EF#WVO>(
M- N?&3K;6=M;^*+:RMDM3$^?W>1I+F]^_P 3C_=;O%.^]T[K:VMZCRVES)MV
M]VVR>OQ+1OI:SM?=-:'Q'9?MY_&3PW\1/^"B2_&GX&:1\,?A[^Q]^SIX0_:
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M[1?^ =E_\CUI>?\ +#_P-_\ RLBT/YI_^ +_ .6&516K_;6I?\]HO_ .R_\
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M &UJ7_/:+_P#LO\ Y'H_MK4CTEB)]!9V9/Y"WHO/^6'_ (&__E86A_-/_P
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M>$E1-"LYEB++YBKN&5S2OR_N^:U[>T=[=[<@[0WO.W?V:M_Z6)16K_;6I?\
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M9]4U=K.PBFN)2([>*2X62>3Y(E=N*3<TFVH)+5MS:27_ (+':'\T_P#P!?\
MRP913=5\>:;H-O87>O\ BOPKH%GJUS!9:3>:[JOAG1;/5[VYC6:VL])NM3FM
M;?5+NYA9)K>VL)+B:>)TEB1XW5C:F\7);ZI;:%<ZYHEMKU[:W-_8Z!<7&AP:
M]?6%F[1WE_8Z++LU2\L+.1'CN[VVM);6VDCD2>5&C<*<TMK4[Z*WM'N]E\'6
MSMW"T/YI_P#@"Z;_ &^G7MUL5Z*O0>)9[OS_ +)J.GWGV6ZN+&Z^R+I=T+6_
MM'\N[L+HV\<GV:^M)<Q7=E/Y=S:R@QSQ1N"M3_VUJ7_/:+_P#LO_ )'HO/\
MEA_X&_\ Y6%H?S3_ / %_P#+#*HK5_MK4O\ GM%_X!V7_P CT?VUJ7_/:+_P
M#LO_ )'IWG_+#_P-_P#RL5H?S3_\ 7_RPRJ*U?[:U+_GM%_X!V7_ ,CT?VUJ
M7_/:+_P#LO\ Y'HO/^6'_@;_ /E86A_-/_P!?_+#*HK5_MK4O^>T7_@'9?\
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MF5TY?_N6%_Z]+_TJH<V._P!\Q/\ U]?_ *33"BBBNPY0HHHH **** "BBB@
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M 7B#Q-+I5OJOB;31X%\/:EXG\?65MJUQHK61_6RO./BC\'?A+\;_  Y'X/\
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MH **** "BBB@ J;3_P#C_O/^O'3O_2G5JAJ;3_\ C_O/^O'3O_2G5J\S./\
MD7UO\5'_ -.H]'*O]_H_X:O_ *:9NZ]X4\1:3J$/_$KN=5MKK2]'B%QHL%S?
MFWN='T72M)N(;J+R(C$D\L$DUG*&;S8482)%(H0Y']EZY_T+7B;_ ,$EU117
MBT,UQ-"E"C&-&48*T7.$G*UVTFXSBG:[L[7[MGK5LLP]:K.K*56,IOFDHRBH
MWLDVE*$FKV5U>W9(/[+US_H6O$W_ ()+JC^R]<_Z%KQ-_P""2ZHHK7^V\7_S
M[P__ (!/_P"6F?\ 8^&_GK_^!P_^5A_9>N?]"UXF_P#!)=4?V7KG_0M>)O\
MP275%%']MXO_ )]X?_P"?_RT/['PW\]?_P #A_\ *P_LO7/^A:\3?^"2ZH_L
MO7/^A:\3?^"2ZHHH_MO%_P#/O#_^ 3_^6A_8^&_GK_\ @</_ )6']EZY_P!"
MUXF_\$EU1_9>N?\ 0M>)O_!)=444?VWB_P#GWA__  "?_P M#^Q\-_/7_P#
MX?\ RL/[+US_ *%KQ-_X)+JC^R]<_P"A:\3?^"2ZHHH_MO%_\^\/_P" 3_\
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M^]K?B5_[+US_ *%KQ-_X)+JC^R]<_P"A:\3?^"2ZHHI_VWB_^?>'_P# )_\
MRT7]CX;^>O\ ^!P_^5A_9>N?]"UXF_\ !)=4?V7KG_0M>)O_  275%%']MXO
M_GWA_P#P"?\ \M#^Q\-_/7_\#A_\K#^R]<_Z%KQ-_P""2ZH_LO7/^A:\3?\
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M_GK_ /@</_E8?V7KG_0M>)O_  275']EZY_T+7B;_P $EU111_;>+_Y]X?\
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MU_\ P.'_ ,K#^R]<_P"A:\3?^"2ZH_LO7/\ H6O$W_@DNJ**/[;Q?_/O#_\
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MM#^Q\-_/7_\  X?_ "L/[+US_H6O$W_@DNJ/[+US_H6O$W_@DNJ**/[;Q?\
MS[P__@$__EH?V/AOYZ__ ('#_P"5A_9>N?\ 0M>)O_!)=5TGAKP5X@U)KZ_F
MM?[(A/V:RMX-52YM[Z;[*UU-+<M;>01%;N;Q8X&,KO(8I69(U";RBN?$YEB,
M52=&I&E&$G%RY(R3?*[I7E.5E?71)Z6O:Z-\/E]##556A*I*<5)1YY1:7,K-
,V4(W=KK6ZUVOJ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>formdrs_006.jpg
<TEXT>
begin 644 formdrs_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &= D@# 2(  A$! Q$!_\0
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M.QSA8VZ*Y(1F(0$L0#YJE6=E%WNO=2O=JR>B2_E:?HT]FB"_]NO_ /G^N_\
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M#X^C2DI.-:2NU*DFYT)Q]^E5LX*2G-'3A<75PE12@_<=E./J]W;73H^GX/\
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M_A7'Q#_\(7Q7_,Z1CZ'I[U_,?]F9E_T+\=_X28G_ .4G@J$WM&7W/_(X^@G
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M 4444 %%%(3@$]^/Y_\ UZ3VMW:MZ[_H! Z!N_#;B1C[VTGKDD8P<?=#+U#
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M0Z/IFMZQX7\,:Y<2ZE.U_9VD2ZIK%C8Z2]Q"C/'+]NA5'8=<XQ@'#!N0.OS
M'_\ 6:\<^)'Q.\2>%?%'@[P%X%T30]3\8^+]#\:^+Y+_ ,7:SJFA^#/"?@WP
M!;V)\0:YJ\NBVUSJVJW.[4K6RL="TD1RN"^H7=Y%%;!)OSQ)MV2^?16[G-3L
MI)N,96V4KWUMM^OR/@BY_:[^*_@N/X>>'?#%EX@\=:4W@;X;:YX/N?CG\/?$
M^A_&_P#:GF\;?$B]\*:OHOA5?"\>GZ%X)\0^"_"\5KXCU+4?$&GRSZQ8366K
MZIIMA;3W5<YJ'[:'[7-II^K^(T^'WPPDT>Q\)^.OB!#X?;P1\1!XB?2/A[^T
M/8?!0>#I+I=62W;Q%XG\/ZH/%5OJ:69L])33YYX=.N[.83I]:6/[<OPHT[3?
M"P\>:[I-CXFUZ75CJ]O\/];M/'OAC0;2S\30^$U\1W6LF?3[R+3-2U.XLIH=
M.BTZZ\36,-Q)%J.D)'8W5]6_>?MJ?!32[;4]1U:X\<Z'963W/]AW>J>%FTVT
M\>RV7C2;X>W47@6XO]02TU6>'QC%]@E.I3:-;+;N-0^T-9YN4I.UTX-V>^C_
M #.KWM?]FB[^B_/]/S/DBZ_;V^*5AX^^*FDP>'/!?B?0_A_XT_:,\*7GA;PI
MX(^(&K^.?!GA_P"$7AVVUGP;\3?%%[IU_P#V1K^@^(=<N5\*7^@Z7)IEVMTR
M2V-W')!>1P<SX/\ VXOVH?'GAB)-#\$?#.#Q%:ZA^T1]N\2:EX,\8WGAG6]!
M^$'PD\,_$[PE+I6CZ+XAF@M;_P :W>M77A]'&MZEIEU)"MQIQFO4F@K[)\%?
MM+?L_:3INL7GPYT#Q<NF:I;:S\8/&DWA;P=*UM9Z[K/BG4O#>M7WB:YEU5+2
M/Q=K/BW1+VQ8V\MQI<\T']H'4+32,7KS0_MP_!>_TNTUFP7XD:M9M;2R:VND
M>"IM;;PK'9>/IOAPT'B&?2M2O[>V/_";)'H=HVDW&L12-<0:G#+_ &69)[=W
M[4HOS>_X#3:_Y@J<O-M)_P!+^F>-^ /VN_CAXM^*5C\-I_@S;ZCJ$'PDT?\
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M.OPOT?X7Z9:VBZMXC^)6N:U<:XOB;Q[XU^-1M]$\(_#"3QF+'0;C4=/\*?\
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M8K:VB2"%#+(\TK+'&%7?++(\LCD%GD=G8EB35B@QV;<8QBG_ "MW>O7I;<3
M!<C@R9\PC +AL%@Y !;<RAFSU89/4Y6BB@5DKM7UWO\ \.PH/W7_ -T_S%%!
M^Z_^Z?YBCJO\-7_TF(/;YK\T?6_P0_Y$E/\ L*ZG_P"C(J]AKQ[X(?\ (DI_
MV%=3_P#1D5>PU^Y9%_R)\N_[!:?Y,]6E_#A_A04445ZQH%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU^Y9%_R)\N_[!:?Y,]6E_#A_A04445ZQH%%%% !1110 4444 %%%% !1110
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MXI_MB^!?#WPIT+0O"_Q1U*:_\?\ BWQ!XOO_ !=\-'OX?$7A;Q'^T%=:;/\
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MQ#W.O^@C+/\ PIJ__,P?V1BOYZ/WR/[T,CU'YBC(]1^8K^"__A^A_P %(_\
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M0 6.%)8X7#<Y#8.&Q@8^8C(S^^OA/_@G=^S!XSU/0?CHUGXH\!_"#6/V)O\
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M[[W6SO=W)2LFM6F[V>JU[7V6NQ_6E_P0E_X*&_&#XP:]??L>?&":X\=0>"?
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M (;TOQKH.H:W\2]'>6_A35? ]A;7,L^NV$<VE:I;WDD2LUI<V%S;S;)H)8U
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M1[ZPN_$-A?Z+;-;HS2:C97\)1S93(@!Y[_PQ_P#$7_H:?AI_X4\__P JZ/\
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M^7/3^ZQ'XU]5?"G_ )$ZVZ?\?VH]  /^/I^P  _ "@#TBBBB@ HHHH ****
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MET[)[KSOZ6MT/I7]F[Q+/;ZSJWA2:0FUO[1]5LHL?)#=6Y$=RL9S\BR0E7=
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MY99X3<6T$=[J\DEU"/+9[NW@36Y/-M29$BDNH)&MP7C(E,L\>*M__P $X_\
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M#7Q+K/BCQ'XA=Y=:UJ_O\MO,,DQ%I&,_=BM8F6V"@G(PKL <%^,#"P,'@88
MD8&"#\P!'L3G'KS7TE'A.+C%8O$*HW=5*5!<KUWBY/=-:/2S6G='B5<_<FUA
MZ5EK932;MY_=]S-CXS:/%X0*^-?#]A>:[X&\0R_:H;^Q95AT2[E8M+INH%@U
MS;+-+N>&>6,)&0T$K*"I/SG)\2P,^7HP8'.7DN@ QQMW;%!16*';D9*J2@;;
MG/T]X:\9:KX7^U6T"6NIZ1J(>/4O#^J0_:M+ODD."6B8,(99D+>;+L\M\ NK
M5FZM\._@!XN=[V,>)OAQJ5PQ:>'2/+U301.3DM';,MPB(SDE$3R5VD?*N,#\
MAXF\)*U+&SQN3T9XK#U*E2<Z,9.#INI*4G3]U)>XY./3;2^AS3KRQ*YZ->&%
MFOCC52<7+[5KIQM>]MK:)76I\XCXERDA1H\&T_*%%X5R&P-N0N0#@#(S@*H
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M7ZGN=Q)]2PPY)[[EX8GJ.#Q2DMG))R0>23D@@*?P*@ ^H '05G]8G_+#[O\
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M"SBN[OSG0'YHNO\ @H'_ ,$Q- \(>"?%K^//AC9>$]>?QCXZ\*O8_!3Q!/\
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M-*$4E&$&FK='IU>[3UOOJ?-MRDW*3O*3;D[MW;U>K;ZA1115""BBB@ HHHH
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M.1N_)KXT?'/Q5\8M:E-Q<7&E^$K6>1-!\+V\TB0PVRN/(OM2\E@E]K$JY!#
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M6UJ63Q'XC^&%U9_##7/ \$$>H:7_ &+]E>[ETG7M3:@#]TOAS^R'\*/AM?>
M+OPHWC.>X^'_ ,0_$/Q+\,VU_KL5Y'<^*_%WPFA^"VH17:+IR?:K*3P;#$NG
MV[+;20:PIO&G*.MF?H+PKXAT+QSH\OB#P9K&G^*]$AU/6M%FUC0)FO\ 3EUG
MPYJ-QI/B'3&G0%4OM%U6UNM.U.W;:UO>6T\>"$S7CBZ-^TQX$\%?$/5-!^)?
MA3]H#XI3^,H/%'PRT_XD^#=$^#WA'3_#$6IV-Q/\-M0U'P$U\LDTVEPZBFF^
M,M2M'FM]9N;.35+=K))"?R6\7?\ !/K]M"_L?A##X2UKX9^&;[PMXHUGXIS:
MAHWQ(U73;OX>>.?%G[2>J_&+Q;X=L+VYTFZM]=LY_!%_:>%+;Q-X/T7PY<^(
M-1;4K#Q#J0T"*PA(!^]LEI=1+ODMYT3:S;VAD5=B!2SDLH&U5<.3_P \\R?<
M!:C[+=%7<6\Y2,%I7$3E(DV+())' V(C(P<,6^[R< J6_';P[^P[^T/\+&\%
M^,/AQK.B:MXPTS_A7_C7XI^'M5^+GC"TL/B]\0/!7[4OC'XF-;7&M:H^KV>C
M)>?!SQ%I_A.RUE[+[ #ID7ARZM!I%I!*/*-?_84_;NU[Q5\%_$UQXL^'>E:K
MX#\7^'_&T_B31_BSXEGU'0K>;]H7Q;\1/'_@RRO=:T^]U#5M-U7X>Z_8^&-)
MNO"^GZ#9ZI%;76B>,=0FL8M-MP ?O ]I=QD"2UN$9E9U5X9$+*H+$J&4;L1C
MSCC.V$J[;017 _$'XE_#SX2^&Y?&/Q0\;>'/ /A6*]M-,.N^)+XVUG/J>H,Z
MZ=IEC%;175[JFJ:@8I6L],TRTO+^>.*69;80Q22)^4G@C]D[XJ_#CXL?L@_"
M?0-9\66OA.7X<6?Q _;HU:QU;QIK'A3Q1XQ^#GB>Y\5?"^^T?Q[JM]+;W?BC
MXE^-]130/%FCVXMI[WP5X;LC>6J6'D@_<WQ[_P"&D_'7P-\*ZA\#?AWX"T+X
MZ:OK'A[4[ZS^*6JZ#/-\&;*[ANE\8>)? M_JVDZKX;U3XIZ-87+Z=X/O-0M/
M[*L[J^DU&_COH;-=+G /4;7X^_ J^\3^!?!=C\8_AO>^*_BAHMOXD^'&A6?B
MBQN;WQOH%W#<3V6KZ \)>SGM+^&SOGTY;FZM;G4?[/U%;&WN)+"[2&3PI\>/
M@?XZ\->-/&G@WXO_  Z\2^#_ (<?;C\0O%.F>)K)M!\$PZ;9/J5]>^)=1N3;
MPZ;I<&GQS7JZO(6TJZMH)Y+*]N1#(%_,&[_X)^?$^XT&Y^$?A3PKX!^&7PI^
M)%M^SQJ/B?Q;-\29/&WQ0^!NJ_ G0?&NE:IHOAJYM="LV^(MUXWO_$L/BJW\
M2:/?>'=/TK6-5\60WUG MQ:A^>\;_P#!.K]HWXY_#;Q;X3\9>+_A3\#[4_ K
MX6? RX^&'A#3Q\4_AU^T+9_!?PO\3[?PIKWQ6D%SX$O- \/:GXO\<:1KUEX;
MMY-6O((="$7BE=5@S8L ?N3X#?3/$^K>$+[3[VVU31-=_LW5]+U*PG6>PU72
M+V!-0T_4K&X3*7-G=VY@N[65<+- Z,.'%<YXNUJ;7O%OBJ]F9V6'7K_3;4.>
M(K33I!:P1JO\(VH6(Q]YB>N<\]^SAHGB3X7_  Z^!'A3QQK&E:]XK\ > ? '
MA#Q9KFB:>NDZ-J.K^'=!T_1-3NM,TX7%W]FL4EMI((6-W*&BA3(CD#K76>.=
M!D\/>+O$5NRD6^HZI<:W8O\ >66TU(^<9%(!RJR[U=ONANAZX .9@A>XFAMH
MS&7N)8HD\S(5999/+W2%<,8TB.0@.TL=SX7)K^;_ %#_ (+LM\0?VHO'7P>^
M#FM?L:_"3X3_  R^-B? V3QO^UO\1_B#X=\<_&;Q+INL+I7B]_ASIG@SPU<^
M%?"VC:>\5S!X?U;QOK$$&IWT<43,B2.\7](%O,UM-%.BJ9(98Y@K8*^8K+N1
M]IPZ-&JI( <2+F,X'S5_./\ $W_@@UXE\7:7\?/@!X._:F\+>$?V(_VEOVF-
M)_:@^(OPVU7X)VWB3X[^&?%MGJBZQJ?AGX;?%>75X['2_#^K7(:.*ZOK(W.G
MP%8UM+B%[^#44VDKO1 ?T:R>7YC^6Q\HL/*9V5F97^:/F-I$=FC*OF-W1E(=
M792&/&7OCVZ\.^*="_LB7%QI6L:=/J$L;'E/M<(GL("IY-Q#N6[/(9&(ZTW5
M;FQ\%>&=*TG2%>./3='TWPSX>CN9FNIX=.TC3K?2+.>>>3Y[FYMK*UACENI%
MWSS*TK<N:\^\#^'[OQ?XT\/:% LD\^HZS9O<. 23:P3";4KQWP5416\,PD8_
M*DA1,[G7/I8+#1J0J5JEHQBE[-NUI7NY6OV2ZKT.+$U[<M.'O-R]]+=)=]EU
M[]+;GTW\7=/BT[X@:T( L<-\EAJ:QKR-UY:()@1C"LT\32!<=&9@<5YO7H/Q
M5U2WU;QYKL]JRR6]K);Z7&XR0?[.A$#N",@C[1Y\8/JN>F#7GU?H66\_U#"1
MFFI1HQ3OOLGKUV:W_P SXS%V>*Q$HM-2J-W3OTMV7]=0HHHKM.<**** "BBB
M@ HHHH **** "BBB@ HHHI2?+3DTO>3@U+^6TM7WV["?1;)R2;\KG&?M2>*]
M0\%?LU^"-/T9S:R^/_'\MSJ\X8#[58:%%)<KI]UMY>TGE6W+KD[%@52""17Q
M7HNJP:Y8I>VX500L5S!@MY-RI)\LJ.2LBY:/_GHF6!P./MG]IWPU=>-?V7-.
MU334>>^^$GC)M1U:"(!WB\/:K');7EXT>,M'"+FUDD/\,:S,"?+./R_\+ZVV
MC:DDC,QL;AQ#>1(< *_*W7'#3VJDKA<LD(+-SQ6V28>CB,!C+)2Q5/,\34JV
M^.4*CIRHRU7\B35]X]-';]*R:O"GAJ$')1I.$;RZ72U^=[]-R;X_ZO\ M/6.
MA>%[;]E3X>_"GQYXVUGQ!-8Z_=?&3QAJ7A/PEX1\.+ITEP->4Z)97FI>(+VX
MOUCT]=,L_LHAM ]U+.B1L:^;?^"=?[9OC7]LKP)\9+OXC?#CPUX!\<? GXTZ
M]\%_$M_\/]?F\3_#+QMJFB12/>ZUX%UJXA5[JSMKJ!X[HQ336Y@O-.G@N)8[
MDHO>?MQ_ #XZ_M._!L?"GX%_M(_\,U+XDO;J'XA^*K+PQ<ZYKOBKP;?Z>(_^
M$6TG4].O['4/#4-S=-)-J5UIL]O<7MD38/,L$LRO7_8?_9M^*G[*OPTE^$?C
M/XB?"7QCX"T"WTJV^&NA?"CX0+\*H/#7EF\?Q!?^);@ZEJ5[XQUKQ%-+;W-Y
MK6K7,^HO=1S2S7$AD4+R58XMY@TE*-!1]YMQY7).VU^9.*6NFK=MCW;S55./
M\)PNI73C+TUTU=[]=-+*Y]JG/;G!SM(4JV,D!PW! .#CJ:_1']FK6I==^!?B
M30KIWE;P+XLA;3WE(+1V6L1QW36B$Y*(L\MZRIG"I)&@X7%?G<0I&&QC*GDD
M8PPY&.I[!>I[<U^CO[//AV;PM\![S5KZ-XKSXC^)5O[%& #/H^GJD-G<LAP1
M'.D4\T>-Q,4]NY&&./.XBY)8*BFDYRKQ5/O)PD^:RWTCS)MV6JMT,<2THPN[
M7D]?-O7R.U)))!X.<[<Y(!8 XQ]X*67<0#@$$]:BGL=/U.WN+#5K2+4M*OX'
MLM2TNYB:6TU33YSLN]/GA&))TNHV97A4?,L; L$,BGYQ^/GBO]J7P[XF^!MK
M^SE\+? /Q%\*^(OB%#IO[0.J^-?$Q\.ZAX ^&<OV-9/$/A&%;ZS.NZSNEO0=
M-,=VN;:-O)*L29/VR_$OB[P?^R?^TAXH^&VIZWI/CCP_\)_&&I^#-5\/02/X
MBLM>MK0+IEYI%O:0--'JAD"B!U@E-NQ\P0.H:O!4.>4)WY597CVLDK?A^ICR
MR[?U]Y\D^*/V._BS:?"OP'X$^'EMX8\.ZQ8^'/C[\,-7U71_$?A[3-*\*_#O
MXK?$.7Q9I$$6C:UX8U:#4]'L+.2VN]0M_"3:9XOLM4@MK*PNWTV626RW_#_[
M+OQB\(?$.ZUO2M(\(:]X$^'?_"T]5^'G@KQ9XMT6_P! ^(FM?%&]\(SWLM[-
M:^$3XH\-7D;^'=2\1"3QQJGB>RTGQI<:4-%E.E6<DUO\\:G\4_VS_P!D/X6:
MMX^\=ZM>ZU!\4]7^&^@_!KP1\4_$VJ_M'ZSX6URS\!:[XH\?:UK_ (T\*:7X
M,M_#VF>.+NVTK3_#7A?7=7:UT_41/'%<3ZG=6ND2\?<_\%!OVJ=%U#Q7XSO/
M#OA8:3XR\!_L>Z_X6\!ZUX'\6+I7P5L?BYX0U_4?B/\ $+5-9DN=(N?$>@Z-
MXLT9?!^K6FJWNGS:=J^K:.MW-IJ6K1WG:H5+)TY4FK7V2EU5WIO9N[O?7?>^
MJO9>B/U=_9G^&WB?X5?#6_\ #?BNWAL+C4_B)X[\:Z?I"Z_!XPU'0M&\7ZG%
MJ5MI?B;QE##9VWC#Q/'?F]NM3\06UF%F>]@LXC,+%;E_H @C.> , GC ).-I
M[AAP2".%(;H03^1>G?MP_M3ZE>^'=9?X2?#C2/#MIIO[(MQXRT2XTGQ_K.L:
MY=_M(^/=>\#ZY<>$/$5K-;:;8Z)X3TVQTSQF3J6G7EQ:6EXND:SY$9BU [W@
M/]JG]H/PG^P+X]^.OB:WTOXR_'#P3\7O'7@O5=*MO">O>&8O".E0?&J^\'0:
MEXR\-+/!?7%GX&\)O;>)+F31Y+*VO/#:Z7]INV?[=J-8RH57K&='F;46M-$[
M=U;16^>AERR[/^OR/U6 )SQTV[AP2I;:0& )(.'4\C!!X)(( 5;)&TG ))_A
MP,<Y.!@\X[\-D#!K\<[7_@H+\?\ [;^S)8WW@/X;'3?C'XJUGP[\4?&6F>&/
MB+K>@?"7P5I_Q.M?"/AWXW:BND?;K9/"?Q+BG_X131O#LNIM?:'XLECUN[UJ
M\\,6\UU7G&J_\%"_CWXX\$?$^'2/#WA759=/TWXLM/;?"?2?B1HWC?X/7GPJ
M_:%\/_#CPO<>,?%3->Z5JR?%KPW=W5U91>$]LMI+87:R/?:<;T6R>%K*_OTM
M%?X4NMM[6^7SV:;?))=/Q7^9^Z>,$@D+@A<L=@+' "#=CY\G;L.&+ J 6P"G
MX<]U[KUSDCY<J05< DJX*D JP'Y'>/?VW_VH?ACX:\??&3Q%\-?ASJOP@TK]
MHSXE?LO^"O#6BZ%XYM?B5_PF%M/?^$_@GXM\47VH7ZZ/?>%_'GQ(;0M!U-=*
MTM6M["_EU>WOQ&B-#],_M3_'3XM? KP;\$K>W@\"^'O$'Q&N]9\.?%'XE>(/
M#_C3Q!\.OAAXDTKX7:MXGCTVUT7PE.^O/=>-O&M@G@WP7>W]X;/3-0:WNKS[
M9/)':SPJ%9_;I*U]>6^JW5K7^:NO5:@H.^J:7<^V<'YNVW&=P:/KG:,2!#EB
M"%4@$\<8(RG8L>%4,Q8@@ +W)QP&ZH3A6R #N90?PE^$G[??[1L$?[*?PDGT
M.+Q5XC\=?#/X=V/Q&\3^// /CB'QG;>,OB5X+\;^(++QO_;#2:9IVI:5HVL:
M5HFE7UA'HDL45U<0:;JFK:-K,D%H]OX!_P#!03]J?4KO]F#P#XK\(>$_B%?^
M,_"/PSN?'?B^^\/>(?"/B#X@:_XU\3>)-*\=:?X5^T3VVFZ#XF^#,.DPV_B'
M2)M'N+'5M0(:X_X1^S-M=2N6%JK5U*;:V4%9W\]KJP.%MKL_<\@@[<9.6'&.
MJ[NH)# '8^"P ^1LD8Y"0,Y91M.ULL  > <$D!L%@#M+$<]@2/B_]H#XG^,[
MG]G5O%NJ>'_BA^SC=2?&3X2^%_$2W^L6%OXUT7X>ZA\5?#&C^*_$-MK?@F\\
M10:?HVL^&[N^9[JSE6ZTVR$\MTD+@BOF3Q9^U)\3_A'?>*K/X1:IJ'Q<^"5]
MXZMM*\ _&_XQOJ.NZ;H5_I_@&77_ !=X(A\1ZK<^$K[Q3I5]X@^PZ?H?B#5[
MRXDL[V34M-TI]8ND@M8Y^KU-^;WGOJMEMW%R2[,_6S!QNP2,-S@XRA(9<G +
M#&<#.1@C(()3C!;<NP9!?(QE<$C!^8C81)N"E/+(;=R!7YAZG^VG\8+#1?&?
MB!O!?@FU\7^'O#]M<6'[.W_"/^/=4^)$L,WA3P=KDWQ5?QI!&GAR7X=V=WXD
MUF?[%<66FSW6D^&Y;:/78]<::RL\RP_; _:9USPCJ.MZ'X0^%5Q<>%?"7Q!\
M97^M/HWBG6]&\?6W@_Q5\.?#^DZ1X>MO#.OZA!X=OM3B\9ZJ^I,NK>*2C: U
M[81W9EN8+.EAZC3:J05G;WDF^VFFVOZW#EEV9^I^#NV[6#$XVD$-QG.0<$8Q
M\PZJ,%@ 02<<#().,8(;(.3O^7<-@569G^ZH5@2'!6ORF\<?M0_'WP9\1EM]
M;\1_#[0I_!^@?''1Y]/N_!'Q&D\%?&+Q)X4UOX5ZGX,T3PIINE7MU?Z'X^\0
MZ7XJU3PSIFJ7.K:I8N]O>7MO8WH:YM[."']N+]HK5-1^)=A:?"#PGX<U+0DU
M.UT?PCXDAU:Z\2?#K4+7QQX;\):/-X\L-#U?[?K=EKMEK4VH.+73?#(A:.VN
M=.GU&S-Y=1)X>I=^_%[:QLEKMT_KRZG)+LS]8 "VW"M\W0;23@LJJ>,_*^]2
MC?=*G)( -+@@$D@*H)9BPPH52QS@D@@?PD!^1A2""?&?BKXP\/\ ASX.?$_6
M?%'Q/O?#D/@32]0TOX@_$/X::(]]XD\.:YHSQ1ZQ'X6\.30:_<6VOW4LJV6F
MZ28-4GL7U*UN1.2B35^:=Y\8/B''X,M]4;XY?$C1M(O?"WQ9\8? 2PT?7;OQ
MIXOO?BA9^+?#$'P\^ GQ5\76_A^=?'_B6U\+W4^I7_A34 ;%XM;U*VN-6U63
MP_'<1YNB^L]5\.EULFEIWO?HK7N^C.679G[)$$=1C@]>.0,JISP&?HH..>&V
MY&3'7U!P1Z?7WQ\Q7[X4@E1FOB;Q1XD\;:)\1_C];?$?XN>./"7P^_X4G\#_
M !7I]UX,\/1V4/PEU/7_ !9K^C^+=.\-ZAINE:_J5Q<RM:6]MXE\:RK?ZIH.
MCROJ]KIUC;:?!(OH7[(OBGQ1XN^!^GW_ (OUJ[\4:SIGC7QYX<M/%LMS>ZG8
M>*?#FB^(IU\-ZMX:U_4]/TK5_%GAG^RI8=.LO%6L:3IFKZVUC=W-Y -B22'L
MI))QGJ]7Y/KHU^O^8<LNS_KYGW)\)O\ D9YO^P7<?^CH:*/A/QXGG_[!=Q_Z
M.A]?ZT5X&.TQ$D]':/ZG'7_B/^NYY0P+22*#@F4C/H2F/R'!KY"^#?B;]L_5
MOVD?VEM"^.'PQ^%7A/\ 9:\/S:''^RGX^\(Z\NH?$+QY#)+!'X@/Q&TD:[J*
MZ0+. W!LUDTO0Y))(D00S!!<2?>4GPX\:%Y,:*2K-GF[LSDL-I'^N&1C';OS
M3/\ A6WC3H=%S\I7!NK(K@XW':9BH+$$G '+-ZUR&)^&_P#P4@L/VLO&W[47
M[)'PB_9KU;XJ6>E>+O@S^U/XB\86/@'X]^(?V:_#X\3^%(O ]O\ #_Q)XP^)
MFA^%/%WVB7PS=ZG>W&D>#[RP#^*HFN84^TK;S5\Z:_\ MR_M\?!WXV^ /V)]
M0D\,?%GX@:%\)$^&GQ1^,H^#7C6+5+OXW3?LS>)?B18_&7PQKJ:[9:1XHT"Z
M\?Z/I'A:!X?!NF>']0UNX^Q7VL6VO3_V:W]*H^''C=4,8TEQ&61V7[99?,R!
ME0L?.R0H9@J] &8$')S*OP_\>+$(1I<IB!!$9OK4Q_*ZRQC9]HVXBE7S4 P!
M(2YR<8 /Y;?V</\ @I]^W+JWB']EOX8>)/ 7@WXE6_B;X*?"+5O''CGQ!X&\
M5^#?&/Q;U[Q;\//%_B?XJ^*_#XEU6.WT;6/@CXJT"U\#^+_#*>%KJTUK6X-6
M^UW_ (8&I:-;*>*O^"@'_!1;7?@WX#\0:T_P\^$VH>*= _8$^/VN>-/!WP.^
M)CP^!_AW\=_COXF^&?Q<^%WB_2];\1:A?ZM#X<TC0M,\0^(];L%TG5M(\-ZK
M?:>]EID5[;:O#_4F? /CYE=&TV8JX=65;ZT0;9)%F< ),NWS)5#S%-IG/$N\
M<4?\*_\ '89B-*?YY'E8->6;AI),>:SAICN\U<JX/!4A<850 #\3?VXOVY_V
MF_V?_P!JWX)_!7X0?"'P=XL^'OQ \+>!?$\_BWQ?8ZY';?%37?%7Q/M/!?B3
MX=^!]>T_5K6V\$ZYX+\*2KXWBEN=)\4WLCWFEC4K&T\/07.I)\G^*_\ @K)^
MU!X4/[3E]K.B?"KPQH/PC^-GPD^&?P-^(OB/X.?&O3M ^/WPR\?_ +1Q^#WB
MWX]Z9%=7^FR3:-\-=.)\-ZEX-\-:A?ZMXB\4V,GBC3I8O#.IVM@?Z88OA]X\
M@7;%I<J G=D7MF2&*-&2N9B%WHS))@ R*Q5R5P!R/C?X 2_$K1['P[\0? .D
M^,=!TSQ'X:\8:;I&OM97UC8^*_!FK6NO>$O$-M$UPOEZKX<UJRL]5TFY!S:W
M]M#< %UY /YK=?\ ^"C?[:L-CKWQ.\+_  UTSQ=KGA?X#?'&S^&VM6O@_P"+
MVB_ OXYWGAC]LSX8?!GP/\9;?X62W\NK:18^*_ _BO6]?A@O+^Z\0V6G^';[
M4='OG\//<(_W?\$_VH_VM]2_;FU+]A7XP^'?A-JWB#X4^%=1^.WQ>^,_P[\*
M^)_#_@KQ)\!?&'AK2M,^#/\ P@^BZQXEUR]T#QWJ?Q<_X2_PYXF&K7=_!/X?
M\.VEY8VD%Q<RS+^RC^ _'\DAE?3IFD9Q(SF_M-[2*I1"S>>2RI&3&D?W A92
MI#'/F_A;]F#1_!'C#XB?$'PE\+/#V@^.OBY?Z5J?Q/\ %]DUNWB#QS=Z%:?8
M-#.NZE<WD\\EMHUEF#3-/MC;Z?:-)-<Q6HNKB>9P#\#OVG?VWOVG=+_;0\'?
M";29+GP/X"^$_P"V3X6T34?A1X,^&'Q/UOXG?&GX!6O[-_BKXCWWQ5USQQI;
MW/@[5_A'XJ\=(O@B#P+I^EVVJR:SH4,)UEM9N8;0?/'@_P#X*@_MT_&2+X;Z
MZEGX<^'?A;PS^V5\ /#_ (L\1Z+\$/&MGI_Q.^#_ ,7?@]\0_%C_  \\2Z/?
M>)?$DOA;[+\3?#NC?#;4-6BUB"^L_%&MZ7!XGM='N[*XL+G^K]/ /CZ.(PII
MLRQL0647]J 2"KACB<?,) 901C:[';@8%(W@#Q\_^LTZ:3Y#&=]]9D>46+&(
M#SL!"3E@H!9L,3O^:@#\%OV%_P#@H;^V#^T-H7Q&U?XA_LE/XLO-!N_AXB^"
MOA/=Z1X!\7?"[4?&%_XCMO%_@?XC0?%3QC'I6MW'PRM]'LKJ]U#3M0T[Q9J<
MEU>6MWX/LW.G;_8OVT/B_P#M1:?\9O#-M^S5X%^(7BSP?^RQX?T/XX_'ZW\*
M:SX;\/:9\0+CQ/>!+/X2:G;>)[VQU3QO8Z7\)=-\<^-KG0_ Z:GK%OXJO/ ;
M30B8K&_["3?#WQW< "?2Y9 &=_FOK3_6N5+3?Z__ %Q"(OF??(1<DD9IH^'7
MC<%"ND,AC.Y EW9(J-N#!T59@%?A5+CYF151B5 % 'X!:U_P4A^.^JWWQRO/
M@Y:_"SXE0>%O%'Q]\,>#_A_:?"WXH+XH^'?A/X>V^@3_  L^*WQ3\1)J\=AX
MBTOQV^NIX9UCP=H=EHVKV>K7-JVEWXETG7X8/HKX5?&3XK:7^U[XU\*_&7Q;
M<67@'P=9_&3P;=:U_9_B+P[\-/&/C2+X@?!S0/ ?B/3=)UK4-=L]$NM9N/$5
M_H7A;1['5KBP*3S-;&3[1=7*?JSX>^"VL>$H-6M?#'A"RT&VU[Q+K'C+6X-,
MELK:/5O%?B&[?4-=U_4%6?%QJ.K7TLMU=R-A&FD=D1 S Z%[\*_%6IVRV>I>
M&[?4+-)[2[CM;V73[F!+RPN8KNQN_*DE*-<65S#%<VDCJ3!<Q13Q[9(T( /R
M0_:Z^*":)^T]\%OA=X1^/'Q,^'/Q8U>3X?\ B&VL+K7=5\,_L[^#O!-IXS?^
MWYO%FCV6@W%K\8/B9\:8(9?A]X?\ ZE=W,7AZQNH?$D\WAO3[07=YX3\%?B%
M\?\ Q]X?^..F>%_CK\;;'QT/V3_'_C/XYWGB/0Y/$,W[/_[5>B_$;QA:Z5X#
M^%FA>+-'CT+PKJE_X!TI=-TOPSH\&KZ/:Z;9^'_&%G8S:G=QWEY^^ ^'7C<<
M#1N/F/-U8LP9R-SAVE9ED90 SJ59CAB=P!I6^'GCIU1'TJ1UC8LJM>VA4,0B
MAMIGVEPB(F\@L415)( % 'X@>-OBWX_TGQ-^PI=:5\7/C-+\5]7T']E&Y^)/
MP2N3XOL=+\>>"?'WAI;+XC^)?"WAN+PK)X+^(_BR76+@ZQ\:]8\=^)+34OAE
MH_AY;KPY#9ZC?1V]S^PLR1K-*%PZK/*,[C(K^4[K$X,@8G:I#(S9<M\[,20%
M[I?A[X[4%5TN158L2JWMFJ_.JB4*HF^03E$><(5\YE!EW]*B_P"%;>-?^@,>
MF/\ C[L^Y!_Y[=<B@#ACC(XZ#'8E@#N&YB"1SSA-B]3MW'=2$9&" >#GY0@)
M/4E8RBC:1^[V;6 X=G5F![K_ (5MXT_Z Q_\#+/_ ./T?\*V\:?] 8_^!EG_
M /'Z .'8[@V3G=P^X[BP=@&"L?F08.5 )"MO<#+FO;HO"9^(G@+2I+B=(]>T
MMKRSTV_D4@2P6\C1+:794%FA= HR2=K#?M)+9XAOAQXT53G16)(P,7=G]X?,
M"?WWW<CGH<=#FO?_ (>Z3J&C>&H;#4X#;74=Y>R-'OC?Y)9V>,[HWD4@J1D9
MSG/% 'Q;K.A:OX=N6LM;LIK"=7V!Y5Q;3<G;);W )C>)A@I\P?'WE4\5E9 7
M<2-C%@1G"@K]]G(R@ '.XL 1C.*_16ZL+*^C,-[:6]U$PP8[B&.92",'"R*P
M7(ZE0#WS7C_C[1? 7@[0+S7I/!^C7<PEAL[:T,;1175S>R+&L<B(?+VA/,EE
M)7[D;<C@C2E"52K3I0BIRJR4%%M*[?F]%ZLBI4C2ISJS=H07-)VN[;:+KOLC
M\X=036?'/B9].\/:=>ZQ-%(=/LK33X6N!&,D33RR)F&WB9E+&6608!'+#K])
M>'/#^G_ [1KZ>>ZM-2^*>O6;6>RV<3VGA'3[CRWEA#C.;R7'F2LIC:YD2-U
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MW"JZ)<HB($2X19,+,JAMH"-NC&P?55%/^TL1VB_.[U%[:?E_7R/E;_A7WC/
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M.;T_\"077?\ !_Y#Z*9EO?\ [Y_^O_G/TP9;_:_[Y_\ KT<WI_X$@NN_X/\
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M_-2_\#?_ ,B'S7WK_(GHJ'_@(_\ 'O\ &D_X"/\ Q[_'W'YT7?\ -2_\#?\
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MH[)EV+?+CYCNY)Y4\APT<3K* )%E59%D )(#(RE6498A6& >@&2:_$?]JO\
M;K_:!^%G[1OQ)^&#?%3X/_LI>&?"GA3P?K'P0U+XZ?!KQAXQ\#_M,:IX@T*V
MU+6TU'XMZ3/'H?PYTF#5Y!H:1):W%WIC[[V\<QH57Z'U?]HW]HOQ9^TO\#OV
M??!6O?"3P1<_&+]BCQ-\;)]?AL/^%K>$M"^*^F^(=#TRWU#0->L+VP;Q7\/C
M:WEZ]O;PBVEU#=#<B[B\N:)Y>#J633J:I/XY)7LGIIJEW7:V^A2Q&';:M>U]
M;)7:=KVM\]_T9^F4:I$5EBCBBE'RB2.VBCE (*D"5$#@;3M.&'''2@!0YD
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MQWPQ=E0H65XQ=E>3=E?JV?QROI8\065^%,H?IC,6NKMHHV6EMM#^O;_AI?\
M9Y_Z+5\,>G_0[^'??_I_Z<=?KZ4?\-+_ +//_1:OAC_X6_AWUQ_S_P#^3Q[U
M_(3Y47]Q?RH\J+^XOY4O^(,9?_T.\=_X(H?YC_XFQX@_Z)3*/_"W&?\ R)_7
MM_PTO^SS_P!%J^&/_A;^'?3/_/\ _P"1S[4?\-+_ +/'_1:_AC_X6_AWUQ_S
M_P#^3Q[U_(3Y47]Q?RH\J/\ N+^0H_X@QE__ $/,<O/V&'_S#_B;'B#_ *)3
M*?EC,9?_ -)/Z]A^TO\ L\'_ )K7\,?_  M_#OZ_Z?T]Z/\ AI?]GG_HM?PQ
M/T\;^'??_I__ ,\^G/\ (5L3^XO'3Y1D^V !^0ST]J/+08^11G) VCD $'''
M09Y/3/N:?_$%\NLW_;>8-+>2PU!Q7J^8']++/MX\*Y4U;2^)QZO/3W>90<%U
MU<DM--3^O7_AI?\ 9X_Z+7\,?_"W\.^W_3__ )X]>#_AI?\ 9X_Z+7\,?_"W
M\.^__3_[?S].?Y"A%'G:(T)QG&T$X)P#C&<$G _*D,<9_@4XXZ#C';CTI?\
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MA0?Z@_I8<0)M?ZJY,[.UXX[&27G=\N][G]>W_#2_[//_ $6KX8_^%OX=]_\
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M_7;./Y<)_P""'_\ )C_XEL\._P"?/_\ PZ+_ .9#^X+_ (B(/V ?^?;X\?\
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M6^X_N"_XB(/V O\ GU^/'_AL)/3_ +#/K^G/M1_Q$0?L _\ /M\>/_#82?\
MRY]/\/>OX?:*/]=LX_EPG_@A_P#R8?\ $MGAW_/G_P#X=%_\R']P7_$1!^P%
M_P ^OQX_\-A)_P#+FGP_\'#/_!/VYN;6WF_X7?8PSW5O!+>W?PNN6M+..>98
M6NKLP:I-*EI;A_.NGCCD=84<I%*^U3_#U2')X!P3P&'!7/!Y&2 5)5@%;<#C
M&,T?Z[9O]J.$MU_<M:>JG=?(3^C7X>--*>?WE[L?^%.G*TI:)M5,)R-1;4GS
M)JR>C=D?ZE?@'QYX.^)?A#P]\0? 'B31_%G@OQ7IEKJWAWQ)H=Y%?:5JNFW*
MEH+BVNHB00>4D@<+/;3I+;SHDT<D:]BDBD'#;L'K@^@/.1Z'/XU_G[?\$T_^
M"HGQ(_8*\6IX:UD:KX\_9J\2ZBD_C'X<K<^?J'A"XNFCCN_&?PY6X;RK34H5
M/G:SH"LEAXC2,,J6^J,+Q_[N?@]\7?AO\>?AQX6^+'PF\6:?XS\!>,=-CU/0
MM>TMP\4\1S'/;7<#!9K'5+&=)+34]/NHH;JRNXI8)X8W7%??9)GF&S?#4Y4V
M_K,5:O16C@UNUS/F<'T;NUHI:V;_ )1\2O#+.O#K-)TJU.6-R;$XBK'+<UI+
MEH5HQ7,L-5WC0QM*+3JTY\L*T5[6A>+<*?J@8'I_(_X5\E?M%::(=:\.:NJ'
M;>6=Q83''RL]G*+E<G^\T<NU2>,)V(./K$>V3[9 SQZ G/X8]/:O'?C=H<FM
M^";B>"(R7FB7-OJ<*("TC0JS17*J &8AX)'8J.6,8'/?ZS*J_P!7Q^'J;+GY
M))V6D[+77H[;VL?DV94Y5L#B(\J=H<R2DF[I]-&KVN?$J]!WX'\J6F[ER1D
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M714_6:SWG?U7:]GONKNWJ_DEAJ2:?+MMM_D/D=I)))&ZR.S\DD_,20"69F)
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MM>K!TU**5-R<>6I'?GC+F347HK2@GUV9*6!!QSP>Q]*^"O\ @I=_R:)\0?\
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M4?!7BS]J?X$>&O&&D:M)H.J^&-<^(&EZ;KFGZVDPMCI=UIUP5GBO4N2L4T+
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MB!)HWCD:_C@,+(Z3!)0$8?B5Q)4:?U#*VTK)JCBW=.]VVL5._-S)R>S]W71
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M>).W]N4':Z4ED.7J5NW.K3MV7-9+166C_F2_XAY?C9_T=5^S_P#^"OQEZ?\
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MBBBH6FVE][:?D:7?=A1113N^[^]DM)ZNS\V%%%%+K?KWZ_>/3R"BBB@!\?\
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M +>>DT445ZI\,%%%% !1110 4UE# @@,"""I *D'J"#P1CL?4TZBEHFY=?\
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MW?\ %_(\>$(4URPBHKLDE^@4444RPHHHH 3 ]!^5+110 8'I7&^//^1<NO\
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MAPNJOK7AWQ'KGBW6=$^'UE-X^\202>*=0OM=OOB7<> HH8Y6?4?"UCXC6_\
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M]Z')*UWN[)+5M^25V[=;*RZM!W\E=WT26VK=DO+77H2UQOCS_D7+K_KM;_\
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M*(_]9'_OK_Z$**PG"3:LK[]5W]3M@U9^?D^WH>KM\(O#K$M]JU49QQYT'O\
M],.O.,^O/2D_X5!X;!R+K50?7SX/?U@/J?S]:]6Q_M-^GICT_P GGK1C_:/Z
M?7T_STZ5\9[&E_S[C]Q^L_VGF/\ T&5?_ O^ >5?\*B\._\ /WJV<'GS[<'U
MQQ;X[X]/TI/^%0>'""#=ZISD$^=;C()Y&!!QD?S]:]6Q_M-^G^%&/]H_I_A[
M_P"<"CV%+^2*]$/^T\Q_Z#*O_@7_  #RK_A4/AW(8WFJ%@0=QE@)X&.OV?T
M'MC/4TG_  J'PZ"I^UZJ67<0QFM]Q)]3Y SCIV_G7JV/]IOT_P /;^?J:,?[
M3?I[^WO_ )P*7L*7\B?JD']IYC_T%U?O_P" >4?\*@\.?\_6J9( )$UOR0^\
M$_N.<$]^P/J*&^$?AS/_ !^ZJ"-Y!\Z$E3(,-_RPQ@Y/RC"@$C%>KX_VC^G^
M'M_G)H QW)SZ\T_84O\ GW'[A?VGF6ZQE5-:_%_P#R@_"+PV2"+C4V'0#SH
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M+:>(QVNED_9T59MM:^Z_D?N_@5*,<9Q"I22:PV 7K^^KRNOE)&?12;_]I/\
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M4H<0+'SG6K4O84:F*C.,:<K1JR<L0O=G3]^RO)75E*#YSU;^R-'_ .@1I?\
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M_87%I?:S;P'[=6#J?[47[;=KINI>(+?PMX5EL(/"WCKQS:^&D^#WC"35Y8_
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MI'#*EB\+4GF']DT?8<T)2H.,9T*:PN+I-QG^^YHINE+#U7.?.YSF]4N0^/\
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M$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MFV/'[P\$$#& "&#=B,YPH.3RJA3E1BC[,<D^:V20S$@$L1C!?)(;@!>F H
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MT8#^E=;7Z5EU_J6'OH_9Q_(_-LP_W[%?]?I_F%%%%=QQA1110 4444 %%%%
C!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>coverlogo.jpg
<TEXT>
begin 644 coverlogo.jpg
M_]C_X1'317AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
M    D(=I  0    !    I    -  +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P($-3-2!-86-I;G1O<V@ ,C Q,SHP.#HR,R Q.3HP-3HR.    Z !
M  ,    !  $  * "  0    !   ),J #  0    !   &80         & 0,
M P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @
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M 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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MD4N?^FQ]G^C9_A%9Q<WZOY6=D45-)P\;&&2[.]1WI.'TK6L_>;36YGJV?O\
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M=JZO!<-..$))300Z      "3    $     $       MP<FEN=$]U='!U=
M  4     0VQR4V5N=6T     0VQR4P    !21T)#     $EN=&5E;G5M
M $EN=&4     0VQR;0    !-<$)L8F]O; $    /<')I;G13:7AT965N0FET
M8F]O;      +<')I;G1E<DYA;65415A4     0   #A"24T$.P     !L@
M !     !       2<')I;G1/=71P=71/<'1I;VYS    $@    !#<'1N8F]O
M;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O
M;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0               !"
M;&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M  IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M         %-C;"!5;G1&(U!R8T!9        .$))30/M       0 2P    !
M  $!+     $  3A"24T$)@      #@             _@   .$))30/R
M   *  #_______\  #A"24T$#0      !    '@X0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          $X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300        "  (X0DE-
M! (       @          #A"24T$,       ! $! 0$X0DE-!"T       8
M 0    @X0DE-! @      !4    !   "0    D     !  ".MP  .$))300>
M       $     #A"24T$&@     #.P    8             !F$   DR
M P!3 %  -0    $                          0             ),@
M!F$                      0                         0     0
M     &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M!F$     4F=H=&QO;F<   DR    !G-L:6-E<U9L3',    !3V)J8P    $
M      5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L
M;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O
M1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M*       #     (_\        #A"24T$%       !     LX0DE-! P
M$+D    !    H    &\   '@  #0(   $)T &  !_]C_[0 ,061O8F5?0TT
M ?_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3
M$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+
M#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,
M# P,# P,# P,# P,# P,#/_  !$( &\ H ,!(@ "$0$#$0'_W0 $  K_Q $_
M   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M6TW9+_\ MIB\-LHZM]9,CJW6JZMXH!R\H D[&/=MKIK_ .)I'M_[KXUB[_\
MQI=:]#IS\1CH?FN^S-B1%519D9KMP_?N.+C?U/66M_BSZ;31]3:'%OOZ@;;K
MYUG<YU%?]G[/55[5-RDCBQY.9JSEF,6._P#-8?F_Q\GNJRB^''^Z.*7]Z?\
MZ"YW^*GJXR.EC">Z;,4F@B9.T[LG$<?[#LJG_P!!EWZ\5^JF8.A_7;)Z<P@4
MVW68M;2=!8QYLPO\Y[?LG_H2O:*[&VUML89:\!S3Y$2F9X<&?(!\F6N8Q_\
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MQ::20R3&@D1]>RN$=@YMGU=Z,]MK1CBIM[JGV"ESZ??0[U,>UOV=]7I6UO\
M\)5L?]#U/YNM.>@X!K:PORO8YSFO^V97J#>&->WU_M'K>E^B9^A]3TO\(M%)
M'W)_O2^U7".P0X>'C8.-7B8E8IHI&UC&\#O_ %G.<[W/>[Z;T9)),))-G4E*
MDDDDE/\ _]D .$))300A      !5     0$    / $$ 9 !O &( 90 @ %
M: !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H
M &\ <  @ $, 4P U     0 X0DE-#Z       /AM86YI25)&4@   .PX0DE-
M06Y$<P   ,P    0     0       &YU;&P    #     $%&4W1L;VYG
M      !&<DEN5FQ,<P    %/8FIC     0       &YU;&P    !     $9R
M241L;VYG*+O'2@    !&4W1S5FQ,<P    %/8FIC     0       &YU;&P
M   $     $9S241L;VYG          !!1G)M;&]N9P          1G-&<E9L
M3',    !;&]N9RB[QTH     3$-N=&QO;F<        X0DE-4F]L;     @
M         #A"24T/H0      '&UF<FD    "    $     $          0
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M24-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D
M!@ Q  !A8W-P35-&5     !)14,@<U)'0@               0  ]M8  0
M  #3+4A0("
M             !%C<')T   !4    #-D97-C   !A    &QW='!T   !\
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M0S8Q.38V+3(N,0
M                    6%E:(        /-1  $    !%LQ865H@
M             %A96B        !OH@  ./4   .06%E:(        &*9  "W
MA0  &-I865H@        )*    ^$  "VSV1E<V,         %DE%0R!H='1P
M.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC
M:
M  !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U
M<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U
M;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M    9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN
M($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W:6YG($-O
M;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M     '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B
M     $P)5@!0    5Q_G;65A<P         !
M H\    "<VEG(     !#4E0@8W5R=@        0     !0 *  \ %  9 !X
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M P,# P,# P,# P,# P,# P,# P,# P/_P  1" 9A"3(# 1$  A$! Q$!_]T
M! $G_\0!*@ !  (!! ,!              $)"@('" L#!08$ 0$  00# 0$
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M@D-3@R0T1(3D-45U5O#AHF-D9?'#Q"5&PN*%)PF5I29F_]H # ,!  (1 Q$
M/P#/X
M
M
M
M
M
M
M                           /_]#/X
M
M
M
M
M
M
M                                                       /_]'/
MX
M
M
M
M
M
M
M                       /_]+/X
M
M
M
M
M
M
M                                                   /_]//X
M
M
M
M
M
M
M
M                   /_]3/X
M
M
M
M
M
M
M                                               /_]7/X
M
M
M
M
M
M
M
M               /_];/X
M
M
M
M
M
M
M                                           /_]?/X
M
M
M
M
M
M
M
M           /_]#/X
M
M
M
M
M
M
M                                       /_]'/X
M
M
M
M
M
M
M
M       /_]+/X
M
M
M
M
M
M
M                                   /_]//X
M
M
M
M
M
M
M
M   /_]3/X
M
M
M
M
M
M
M                               /_]7/X
M
M
M
M
M
M
M                                                           /
M_];/X
M
M
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M*49>Y=:8'MFG%T9^HD@
M
M
M                                                           '
M_]?/X
M
M
M                            !Z3(<CLF*6FJOF0W&FM5KHV\T]75RMBB
M:J_>,1SNUSEX-3O4I,_G\CI61O:GJ=Z&7RV7BYW;MR2C"W!<92D\$EWG;8L7
M\U>AELM!W+EQ\L8Q592;X)+M97QNKUAW2Y236C;>D6W6Y]-44M7>[BS^399)
M?H-FM<3=/+Y4UT=(BZKQ0P2ZL^N7ELE>OZ!TKL>FNVI\KU&[3T+BDU+XO:]U
M*49T<+LN:W*/")D#LWH7F<["WJ&[I^AM3C7XO#[;6N'/+A%-<8X27><(JZJJ
MKI4^W76JJ;K7<=:ZY325M7Q75W+/4JYS45=5Y6JB>@P!US<&O;FS4\YN'.W\
M[.<W<?IKLYP4Y.KE&W*3MP>/O(Q26"P,E--T;2M'M1LZ9E[=E0BHIQA%2HN^
M5.9^RV>%55>U=?6?(X'TZM\2      :D<YOWKG-]2JGV#A<MV[JY;L5)=S2?
MSSG"Y<MXPDX^1T/EL@P[&\GIWPW>UTLLB_2BJXXF15=/,G%E1%-'HJO:O%.;
M5->U%+E]/^KO4?ICJ5G4-GZOFLO"U*+>7=^[+*W(IXVIV)2=M0DL'RQC)+W+
M3+>;QZ6[#WWEKEG<.FV)W9IJ.8C;A',6Y/\ OD+D4I<Z>*YFTWQ3/IMOMR]]
M=B:^.IP3**S.<<1(HY\6S"O1[**C:[6=MMY.1JNY4TC8U-=383T_]?3:FZ[;
MR/6O2OP?G?<V<YIL*9;&BCZ>R^:[58N=SF4:8I*ABCK_ *LV\]FW8W>F^H/5
M-/597K&>G7-*F+5F:Y8/NA!1;+>=B^IC ][K?##02SV+*XXT;7XI>VI1W>.>
M.+FJ'PTS]'.8BHY473L,NLKF=*U;(0UG;F<M:EI]WW&:R\E.S)^^BI)M<T7A
M)5P9;3+YJ[.Y/*9^Q<R>;MMJYE[R<+T.YRBZ.CXITQ.1QR*P
M
M
M
M                           __]#/X
M
M
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M\.
M
M
M                                       #_]'/X
M
M
M
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MI?03\/H9>V<NS*@M.
M
M
M                                                     ?_2S^
M
M
M
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MP1WKM+.;,UVYI.9?/;?GVKE'2=M\/[J/"2[&;\%U3R0
M
M
M
M                 /_3S^
M
M
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M54HOM35&GVIF#[C*+<9IQ:P:?%-<4_%=I^LYD
M
M
M
M          '_U,_@
M
M
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M:M9M._&N.,GY^/T]:+L1R[,D"V8
M
M
M                                                           !
M_]7/X
M
M
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MREVMQT\[T<ERI)]RDZOL+=S:H8A@
M
M
M
M'__6S^
M
M
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M<4Y<:'L#B<@
M
M
M                                          ?_U\_@
M
M
M
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MM&]YZL^:
M
M
M                                       #_]#/X
M
M
M
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M+?-7QY>7'M+&S-$LB
M
M
M                                                #__1S^
M
M
M
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M%&%*::JCSG$D
M
M
M                                          __TL_@
M
M
M
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MV4UYR?C5/VS7EK>G/1]:S>DNO^379V\>U1>#^:;WGK3Y8
M
M
M
M              !__]//X
M
M
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M
M
M
M                              __U,_@
M
M
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MH;@91E"3A)4:=&O%&%B::JN#/(<20
M
M
M                                                         ?_5
MS^
M
M
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MS@:Z]7T]:3JV:TI5IEKL[2;XM0DXI^RD;W'HCYX
M
M
M
M       /_];/X
M
M
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M>=)<'<BZ>VUB^_B6)F:)9$
M
M
M                                                  '_U\_@
M
M
M
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ML4W RC*$G&2HU@T85IJ24EP9K.)(
M
M
M                                                      !__]#/
MX
M
M
M            !LUOWG5'@&V&37:6YMM5RJK=56W'YE35S[[5P.CMT<::IQ61
M4.C.:OI^W<C?W%J_^9Y"#OWVE6EJVN:>';@GAVD?%\UG9QR&1^WWWZ.VJTK.
M6$57Q;12K2>UK"V6X2>=<:E75-QJ%TYZBMG7S)Y9%[W*JZ:KX:&AK=NXLQNW
M=&H;DS-R5QYS,7;L7)MOT<IOT2HZT2MJ."P1L1VQH]O0= RFE0MQMRM6H*:C
M_A*+G;?:^:N)^D\\?= !S$Z)\,;?,ZR'<#VA[(<1AGQ=E')"J-GK;C3MJ)JF
M%Z\%:V-[4U3OU0V=^I7T_OZ%LW-]0-0C%O7%".5:HY1L6;DTY2^AE*XIQ<>Y
M)]IA_P!=-R6M6W)#0<O6FFU5RN"=R<4\.]*+CCWU18!NIF5KP+ <GR:[7.*T
M4]!::UT5=+][%5K3.]F\.*NT,TN64VH0XR=%Y661<E"+N2X157Y$=3![X3J;
MN_4OU@9/57.X.N#MO9I\<2J8Y4@K/I*OFJW54<J:::J;-_5[VC>VQL6%[-P4
M;F<?I.RM/*6:W!G(YG-SO6I\T+E4O"C52K'CKVE]ZO@><)T'' -4';\0J.*"
M$(=HT_@^)*\!3L([."KK^0$&3HO;J*=Y/94A>[TZ_,,41V5)[/C(X$\!H3AW
M$4'Y(\ !XH@?:"1/@$\!Q"[@'4'*+HNWBEV,ZEMK\YGN#Z+'J+([:_(8VJY&
M5=,VL:D<4G*J?EN7M+;=6MM9?=&Q<[E)VO37H0;M+M4J5JC[>B9N[E<U'T+I
M*4DJ_L<:G;8;>Y;-U7=(='><?2"EJ<IQNF;:7?0<C74C(YJ-_'[U7(UO$U#;
MDV]E==T;4-K:G%.&8LWK$E)8*4H2@GC6C4J-/L>*+ZY'.7<EF;&H6)-3M3A.
MJ?;%IOAWTX%:OE/IU?2R.1\U')+13N:NJ+44<BTM0NO]S8XT*:IIN8T;5<UH
M^;MNU<RMVY:E"6$H\DVHU\L:27>FF;&-,SUG4].L:AEY*<+UN$DUP;<57YM4
M"A*X\%3 M33STZ.<QTT4D;7L=R/8Y[5:U[')V*BZ*BE5D=0S.D9_+ZQDJ.]D
M[MN_;3X.Y9G&Y!/P<HI/P*7/9*UJ62O:?>=(7X2MR:XI3BXMKQ2>!=1L'FMG
MSC;#&:ZSSRSLM=!2V&M69KFRMK[53,IYT?S*JJJZ([7OUU-[^SMR6MX[2TW=
M=J2G^$+$+LFL$KC5+J2QHE<4DL>"1KLU?39Z-JN9TFXFGE[DH*O'E3\U^S&C
M-Y3TA\\
M
M
M                                  __T<_@
M
M
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MA4$U[2!W?#@34ET&GS_P" /0*T'@0G#7TBM!7"A/PT(\!VA>TG&H87@,4&J
M>*((%< 2FOK\.X>)RX]@7N\%[Q3M%.T<!V$8#5 J"IXI>9$9(QSFNAEAJ6*U
M='<U-*V=NB^MIRBHR3A+%--8^*:_5.VQ-VKJN)>'MJGZIV9GXMIU=5?4!TOU
M..9)>(XZK&/8;%:+/-(Q)N2@I&TTLK$UU75&^!JCZS[4N[/W]F<A*CC=K=37
M#SY5I\TO/MW,VLSIJ5MU</-?E6'$Y:;W8?:\!W4RC%[0V5M"V2.]T['M<C8X
M[N]9Y(VR.X.7S5>JZ=FIH^];C9V;VYU=S>OSARY?6U',6VE2*FH1MW(+LJO1
MJ3^F,Y>B&N6=1VA#24_LF0;@_&,I-Q?MMKV#:PQ?+R@ Y[]$F=3)59+MHM K
M:2GA;E=/<&\(TDK)$H9J)$\4\GS%]9L_]2C=:U3I]G=KYS-.YF-,S+=FTW5V
M\I<A!Q:_8N]Z2GC4P^ZZZ+'3]U6M2R]KDMYNW64DL)74VFO*H*+?@6'F9Q9,
M
M
M
M                           __]+/X
M
M
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MY."HOB;AFFG1F%"::JC40
M
M
M                                               ?_]//X
M
M
M
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M/_1KLH)]Z3JG[31O6>S/C@
M
M
M                                               __]3/X
M
M
M
M  5=$55[N(!4?U9YS-ENZ\=KM%^CN&*8Q:%HJNVQM_.Z?*G3(LLG,J\7Q1H^
M-W#AJ:_O7@W_ )24-.Z6Y=269LRAGLPU@N2Y&2LPE]$IQ;E3LY3(;H!MS,W,
M_F=V7E%Y=1=BUVOTB:YY+NY:4KXG&DUYF4X /)34?UI<;18D23FR*ZT=B:Z-
MKGK&EQ?Y,DCD;Q1$9S<2Y'2+8^8ZB]2-(VK8ER1O9B$[DZ5Y;=E^EDZ=M7!1
M=:+SCQN_]PQVOM+.:KR\TN1PBN%97%R_,3;]@O2P##Z+ ,.Q[#K<YSZ''K;3
MVVF>_P"_?'3LY&N=Z5[S>1<=MR?HHJ$>Q+!)=R1@%"/)%1K4Q.OQG3K23;C9
MZFVXPG(7276Y551B^1V&&1&/='70IYE2^/7548UZ)KIW%ZN@&SUN[?\ 9C=?
M+#*Q]-5K!RBZI>4\_N;.+*Y'T;7VQTK6E*KB=>'$SRVHFJKJKGJJ]NLCED7Y
MU-H54\%V?J8%F[DY3N.;XLU+IP]:?*1Y#AY"10$!JA!(7@3@.U16JH.+'%0A
MBU0<!1# +\XXC C5-435-5[$54U7U(%6F"P"KQ&J(%Q()#[R5W#7CIX]X\"0
MJ:$-4("?8)[:$H<=>SAX_D <,0JZD,ANHUT70G@3BL#2YJ.TUX\KVO3^Y,=S
M-7Y4)5:X=N'MX!2<7S([$K\5@ZN*K<[I_NNS.:9/[9D>*>:RS6NHD;YB6Z"9
M6M;%'KJB(Q$[N)J^]8/:EC:G47,0R%ODR]]*Y7L<Y8RQ+V[?S?QO38UE5P\W
MV%VEI/4-A]MP;=W([-9+=/0V>LAHK[3ODYG0S5MT:^2XM@D<B<&N:WZ*=FIH
M_P#7,V1=V[U,M;L@HJQK]J5Q)<5>L.,;TI*F'.YQ:\C,U.@^X/PAMN[H5Q/F
MT^:HWVPN5<4OI>7YILL8B%]  <Z.BG.+E%>K]MY*D#+*ZEJ,DH5^BV5UQEFC
MBKTU7BNJ*SAZ#9-ZD>]\MF=M:AT_S=VN8REWXS8C)U;LW<+BC^PMM1P][S>)
MB=U[T">6UVQK]B%+68AR3:X>DCP;\9)ORT\"QXSG+!@
M
M
M
M        _]7/X
M
M
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M
M
M
M                        ?__6S^
M
M
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MNU<EZ-/_  ;;<'[,3D47&/.@
M
M
M                                               '_]?/X
M
M
M
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MQ6XI6IQ=FX^UW$ZPJN[D3H_8+.#8 8[
M
M
M                                                       '_]#/
MX
M
M
M        -ANI#.J#!MJLBEGN?U7=;[23V+'IFN<R9UYK8ECI?)<SBBM54<?
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MO'++3LI;;:J5E+2PQM1C6M:FKE1K>":KJJF#6+;;Q;Q?E9?W!)1BJ)))+P7
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MLY@
M
M
M                         __1S^
M
M
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MSG-PZM>UC/NMR]*N'!+LHNPO;H>C930-*M:5DZN-M8MXR;?'F?;B<KCY1]8
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MB^:O:8 [[T.YM[=F=T_D<+?I'.WA1.$_.7+V43;2IPI3L.3A>$\B
M
M
M
M              #_TL_@
M
M
M                         'ILBOUMQ>QW7(KO,E/;+-13U]=,O'RZ>G9S
MR.T.=N'I)J%5'Q?!)8MLXSER1<GV%%61WR3)\DR+)'5U17PWZ\UUSH9:E[I'
MLMU3.Y]OB8KNQJ0JS1$-)G7??4^HG535=P<KA:MW7EK46Z\L,M]A;78E.=MW
M$E]%V\3/#IEMV6VMG97)7&I7+J]-)I4QN>>D^]J,DO8/3EHCWX -^.F3"Z;.
MMXK=2W:VSU-DQRV+D?MD:JV&.]4U2J4%/*[14U16LE1#._U(-@VL_K>H]3,Q
M+'2_\DL0?;<S%JMRYXKT<W'#@S&WU@-Q7+=G*[5LTY;Z]-=?;YDJ1CX8I2\A
M;MD%WAQ^Q7>^5#'206FW5EPEC8J(^2.D@=.]C57AJJ-T0V.MJ*YGP1C(=5#[
M^'JZCZFNLO)J?'+M62XKCWF4-RLTTO-'2WJ"?E<G(G!%3138)ZK&RI:-MF]N
M;4K')FLQ<?H9OMLNO#PX%MMYZASWHY.W.L4D_)+MQ*1S*HM]X FN !. &OS$
M$L=H=!Q"D/@".'P4>()BIYZR>EMU(BNK+C4PV^C1$556JJWI# FC?X9R"5Q6
MX.[/W,55^18LYP59<[55'%KP7$[*;\7.]W'0=/6Q5%N]N!BD=-G^44T-0VIJ
M8TDAK(ZN%L\5;&QZ:<S&JWE=XJ:Q.O>_'O#=]W)Y24UE<JW'E;\R3X52\I=#
M9NF.UE?PG?49.Y]J=//A'M53*(+&GM@  #1)&R6.2*1.9DC'1O:O8YCV\KD7
MUHH!CX]9FT\^UN\5;74EN;;<0RU//QYK$T9+6M;SW/1$[^?F4KLO+FAROL.B
MXO.KWG _>#:W&-[=K\OVMR^B@K[+DELJ6K'*Q'.;711*ZA5CN[\\5#TNU=QY
M_:.XLMN#3Y.,[,E5=CBWYU5VX'S-5TZSJFGW,E=[55/M37"C[# UZ@]F,FZ>
M]Y,XVGRVG]GN>/76=]/RM<D3K;52.?;T8KNW1B<=%-KFUMQ9#=F@9?7=-GZ2
MW>@JONE3SE[99C,9>[EWZ._!VY0\UI\:KM]FJ-FT31-#[^)3D]@"PQ"_*35A
MCT'&O8. [OM$UP%"$[5X<$T"X#Q1'WS7=W!4\>U-":XU[A1(S!/Q4/K#EP/=
M[->F&Y23,M.7+37"@?,]OLRU<RI)Y<//IH[F[=# KUM=I/):WE=]*2Y<W%9?
MD7%.':_:+L;+SGI\B\E[Y.4Z^%6J>V98O6OA+\/W/LFY4DD#;7GL%)AK:>%J
MMECNM'(M5#/*U."^8LB(KC4KZY6P\[N_IEEMSZ=RJ6W+TKMU4\ZY:S"5N;YN
MZTH\Z3JG7L,@^BNXLMMO>[R5]2E^&8QL5KA"=MN4,/V3E2O@<8#5$L54S;>#
MH #E3T@Y<S'MSZFUW2^NH;3D5H2DH+9*]4I*F^QS*])43L21T?)&U=..B(9Z
M>H_OM934M4Z:WHX9W_+K,J8NY:MJ%V->R*M04O%F-7K ;>E-9/=-MX6U\7FN
MY-N49>+<G0M=-C)C.
M
M
M                                       #_]//X
M
M
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MPU3L4WE6[MF_;C?RTU.W<C&49+%.,DI)KV&8 4G&L;BI)-IKN:=&?0G(
M
M
M
M                 '__U,_@
M
M
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M.')+L\JDG5>)R\,@"WX
M
M
M                                       !_]7/X
M
M
M                                                 -O-V,KGPC;K
M+LHI%B]NM%FJJFA9,J<LM7HC(8T3AJJJO8A\C<&O:9M?0LYN/6I^CRN2LSNW
M)TKRJ,73VY<J]DJLCDLSJ6=M:?DX\]V].,(Q[VW^M5E($U545]35W*L;&VNN
M=747*X>4U&L?7UDGG54B(GYIRJIHEW-N#/;KW#G-R:C.5R]G+LKC<W5I2;<8
M>$8+"*X)8&PS0-)R^AZ-E]*RT5"-F"32[94\Z7E;Q;[3QGPSZX .971-A#KW
MEM^W)2:GEH,?BJ\1BII$5TS+B^5E14U$;>Q.18^5'>E=#:+ZENQLUM_8>?W;
MJ=J,9ZS?MRR[P<U8L0E!NO%1N.49)+!TJZT,.NN6OV=6W5:TS+2=-/A*$U[U
MSFTW1=KC2E?$YD=2&[6.[*;/9EGN37!ULH+;:ZED=6QR,DCJI87) YCE[%1>
M)F/R7;GV.PN:<O<KO?<685*T9T_77-OUD749U/[IY[D%UEO,4667JBL%=/)Y
MLK[3[2K8M7^K4VL]%=H979_3[)V<O%PN9N$;UU/LF^/ZA9G<N>N9O4)U>"\V
MGA%NAQ*U+JU/-UH1W</'B3@.S$D>" T^(<>(H",> [1KW<">&!/@$)7 A-]A
M9_[HGI-KNK'K'VWQ^KLOUQA-EOM'69&KF.?'"^GJ4D9S(GH15+&=?]Z0VEL>
M]:LRE',9E<L'%X\KP?SSTFW,B\WGH0BTI)J33[8_]L3MQ<'Q.TX+B&.8?8X$
MIK3CMHH;50PMX(R"D@;$U$3XM36'5MN4G5MMNO>W5EY5@J<#ZH        %/
M7O(=NJ:VWK$,_L]N?[5>IIZ/):YJ:M2"EC3V57N1.'<A4Y>YRMP[SJNJJP*Q
M].56N;Q5%1WQHNJ%;5-'242>^^Z:%S/;G&]_\8HJ:.NP9:I<[KO+5*JMI9EY
M*-JN;]\C>9.[@9$^K3OS\6MZO:>;<IQU>BM8^;;<>+?=6AYW<^G+.::\U#W5
MK#R\S,6:-Z21QRM[)&,D3U/;S)K\IL0FN63CW-HM+*/))Q?%-I^Q@:_414XN
MG80NO=VCM'%A/21VC !U('I\/MDU[2>PE>*:#B'P,EK\64ZMZ[9/K&_4LOV0
M.M6!YO;Y*:.F?(C::6XR/5=9&JO'M14,+/6XVEEEE<CO+*6W+-7;JLW9+LM*
ME*ES]D:A<O0GI]Q^:H\_CS</G(SG>O?#:*"/ ]W[+13U%7%=:2W9'<:1.='X
MM+#JSS$1.+.96J:TNN.R+/43I#K6W[.7CF=2A9=W3^9T5O,VWS<ZE[U\BGQJ
MG@FN!=;:.NW=K;QTW<$KSL92S=2S?+B[EB7FN#7:N9Q?@<+F/9(QDD;D?'(U
M'L>U=6O:Y-6N:J=RFD5J46XS3BU@TU1I]S78T;#K=R%ZW&]:?-&:337!I\&C
M40<SD!TQYO;L$W9M\US=5K3973IBT;(%5T:7*JE;);Y)8NS1.61%=W:F:'J5
M;US>F;]S6Q;UR,,IJF7G>7,Z4OY:CC&/[*ZKC5/V*,?NOF@6LQHUC<L$W=RT
MXVFEVPN5Q?TK7S2X8V>F*8
M
M
M                                          !__];/X
M
M
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M+ENV9.$UW2BZ-'VQ]4I@
M
M
M                                       ?_]?/X
M
M
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M)#^>)R)V(G'0U&9N_+-9N[F9MMSDW5^++UY:W.UEX6[N,DL7WG,\Z#O
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MR+0
M
M
M                       __]#/X
M
M
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M3?!3IVEH^L^W;FM[2EFLI!2OY.7I$^WT:5)QKW8UIX%U9M\,+@
M
M
M
M         ?_1S^
M
M
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M[2)Z!K69T6?^CS<4^^/&+]F-&;V'KCY(
M
M
M                                                 !__TL_@
M
M
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M<M:I;S$'"[)+C=BW2O\ <4+*C.PL$
M
M
M                                               ?_]//X
M
M
M                                                      .%?6;G
M=;9,2L^)VBMHTER6O?%?J57HM;%9X(5J8IF1HNJ-=,QC%U3L4QA];7?4-H])
M[^C6N>.;UN4<O9G!TY(QDKEYR[>25N,K;IVRIWETND&WIZ[O&UF)14K.27I;
MB:JG[V'LJ33]BI6;HB<$31$X(B=B(G8B&H])12C'@C-MNKJ"0>"JG6FIJBI;
M&LKX()961-^^FDCC5T<+?2Y41J>LJ]/R%[5M1RVDY9\MS-WK5B+I51E>N1M*
M32Q:BY<S\$4F?SEO3LC>U"ZJQL6YW&N%>2+E2OC2GLEPO2_@5)@NTUB\E:CV
MK)XHLHN4=1IST]9=*=CW4W_T;4:SXC>ULG:%C8&S].V58:DM.M>BE-*BG<JY
M7)I=BE-R:[:/$UWZSJ]W<&K9C7+RY99J;GR_0KA%>Q%),QY/QFCK3;LMTXR[
M3V^>.J_5!BELTC[?(U:RWW.=G*Q97-UY4:W1?C+_ '1/:&8WEU"REBQRN&2E
M&_<C+A*$7BO$\QK>=CDM,N2?NIKEBUV,ZW&/S>5%GD=-,Y-99I%5SY7:ZJY[
ME[5-K');@E;LI1A'"*7!+N18^]==Z[*Z_?-LU^D<3K\1KZ$#XBI'RA$$D,D$
MI @8@D4H06'>ZMVJI=Y^M'!<'JX8IF/M]1<86S-YFI4T\JK$YJ?FM4X&,WK<
MZIJ6D=')YC29N-V6;LPERX-PDUS+R4XGN]BO+VM2C>S*3C)7(X]_*J?-9VX^
MQ6,5.&;18#BU5S)-9,=H:%R/^^1(H_HHNOH-==4TFE2J3]FBJ7,A;C:CZ./!
M&[)!S            /SU42S4M3"G;-3S1)ZY(U8GV0#&0W?Q"JP'<S+,9K&>
M7-'=:VX\G%%6.MG65B\>Y=3Z%G&W4IYJDC;Z-?I(G^"M6-45>'*].5WS'8TJ
M>0X&&#[X/$EQ3KLW$;!$C;;76RR3T[VIHQ\LL+W2I\ILL]7?5+>I]+\G3"<)
M337D:+2[ERZRN?N6N+;4O896.7NX<,3S:IP' 5%$%' ,GY_6'5 @5!"=_H[!
MQQ&")^'Q@5[CFK[O+J'R/IFZL-K<YQZODML=?E-GM]\JXI%B?%;O/1KG([T<
M.TM%UPVCE]W]/\U;O-\^2C*];7?)'I-M9Z64S\7Q7N:?3.IVUZ3V7JAZ8HJC
M':BCN[LQPUGU=6U?+(V&[S4*-2H5R?>N1ZZZIH:M\CF'D<U"_?@INU).47VM
M<47<S>66>RD\I*7*KB:;794J*LDDS(*ZT5BHMRQ>Z5>,796KJQ;C:N5LRQ+W
MMY7-T4TA]<>G.>Z6]3-1VQG91E&<WFK+CVV,S.<X579*O,FO!&>/2O=EC>.R
M\MJ-F,H.Q7+34OH[*BFUWIIQHSW):4N*?3X5D4^)Y?C61QW*IM=/:;S055SJ
M*:18W/M#*AJW.&3N5KH4>BHI=_H+O6>P>K&D:XH\]N[<^*W(UHN3-?8>=]E+
M3GSX]QX#J=H'XQ[,S>4B^6=E>FBZ5^U>>TO&25/9+S;-=J&_6JWWFV3-J+?<
MZ6&LI)V\6R03LYV.33T&["<>27+5/N:X--537E1@?&7-&I[(XG(
M
M
M
M       '_]3/X
M
M
M            !I<Y&-<]>QK5<OJ:FJA8N@*7M_\ .+?N)NM?K_;65D5';6MQ
MB&.KU8Y);._V:X/9%V(UTS%5KN].)J:];S?-_='526W\O?C>R&BV86K7)P]+
M=2N7U+OG;N5@^Y8&8G0[;UO2]K2UBY"4;^>FW+F^@@^6'+X25)>)LX8KEZ0
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MJ+Q'D
M
M
M                      ?_U<_@
M
M
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MUH8V^L#M^<\OE=TVVE&TU8N+M?/]KI[-:ENZ<>*=BFQXQD
M
M
M
M  !__];/X
M
M
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MM(
M
M
M                 /_7S^
M
M
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MI^<C*_W1\C<*_P#L.8?@OGF)K&J\C>S3E0V3RQDZEF6^PUJ1A0@$#RC05P%
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M_J]MR[M_>M_,R:=K46[]NG9]'&G9RMJG?4Y_&2Y;(
M
M
M                                                        _]#/
MX
M
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M;8FFG1F(1)
M
M
M                        !__1S^
M
M
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M.?)]!.+Y;D/'EG5)]IKLUC1[^WM5OZ%F9*=S*RY7)<&NQ^RL3D*>H/G
M
M
M
M         __2S^
M
M
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M;3I^Q[3"BJY$FMM;(BHJ>15IP_A6*ALOA&7I(I^!;"Q%PS=N+^BA\UH[1O\
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M)
M
M
M              !__]//X
M
M
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M(QY50OS.;G)R9\3OMC]%D>U&;4=:W5D%@N-=$O#Z,U'2NG9V^K0[(^Z53K?
MQ=LDL<>98!G&*21),W+,8O\ CS8U1%U6N58DTU[_ *)]_3<Z]/U7*ZDG3XO=
MA<^I917;:O69V?HXM>V8 V_FV%3M3O!N1M.M//#+CE[JK/31R-T<]TS7)'Y:
MKVZKV*;<-K:[;U_;F3W%54OVU-T^:68S>5>0SL8M\W)+V:1:I4[.O\74LDN/
M^[_P2UU:.;6T=%;X:ACD^DQ74ZS(B_WHU9]7,W#/]2=6S=K&$KKI\[]0O!H:
M:TNU7BU7VW4OS+='U0              #BOUH_M<]PTTUUMK$_\ KVG;9^V)
M'&?N68\M*NE'2>'LM/\ XRWN*_BRF*B_?547M72U!4\NOL55 _7\SS/[?F+Q
M] KCAU5TR*P4I2K[2/E:\E^ LS7]C\\Q1-H<&J-S]S,#V_HV/DJ\CO-MA@BC
MXR2OCK63<K$[U^BO V6:MG;.G9+,9_,2Y(6HRDWW43I\TLIFKF8R]B=_*QYI
MI\J7TV#^8V=N/[L+96AVOZ>L6N<MJGM.17.PVJS72GFC\I?)LM-'2P/Y/X;D
M1VII_P!X:W?W%N;-ZIF'S-W)13_8J3I\PO;MC2,OH>B6LEEE12I<:[I257\U
MEE1YP^\4)=?]!+3]1M15MB\NFJ<6M?*]&Z-=4<JJ]VOCPXE9EY5BX'3<6-3'
MG][-TM0;_P#3Q4999;>^3,MKH:V^PRTJ(ZLN<.J\M$]-.9S41>":F2'JZ;QC
MM_<US3\[=Y+%]127?(MSOFS<L2R^=RT%+TDN2Y)\+<?HJ^0PU>2>%SX*N-T-
M73O6&K@>FCX:AG\4B>U>Q6KP5#8C":G!7(\)*J\AX22BI>8ZQ['WJO$GM4GC
MP./%CT=X\ Z C$4 ;J1V&]73CNA<]G-\=M<]H+K-::2SY;9ZF]S1.<Q)K7%4
M(D\,RM5/HJBGB.I.V\KNG9>>TW,6O37%:E*TNZY3!KQ/LZ'F[F5SL90=&VDN
M[%JM? [>_HQWBQ?JMZ7,3RB*FIZG'[W88K+4P1.58ZJD2C;"Y7:\?IM5=34G
M*SF])SLLM?3A?L2HTUBI(O9%V[]JF$DUCVIE<F38Y<L.S',<6N% ZVT]GR*N
M@Q^"1%1\V.Z-=056J]J*Y9&HO@TT[^M/T]T[I[U6OV=%A-9/4K:S<6_<*[<E
M)W;<'P?*TIM=G.9I=%-RYW<&T?0:I.+S&3F[5%[KT*2]'*2\<57P/4F.!> _
M307=^.W6SY*VJEI&8Y=**]U4D.O,ZAMT[:JOAY6JBKSPL>W3TEVNA6]I]/NJ
MVD;B4/20=WXO<BW1<F93L<S?=;<^=_2G@.IVWI;FV9F\A;ER3MKTT72OVKSV
MO+)1I[)>SA^46W-<7L666=SW6R_VVGN5$Z1BL>L-0SF1',7L5%U0W;W;:MSY
M4U)4337!II-->5-&!UN:N04UV_\ P/I#K.8
M
M
M                                              !__]3/X
M
M
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M8[I6Y)-M>'.Y+V#FR7O/&@
M
M
M                                 '__U<_@
M
M
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M
M
M
M           '_];/X
M
M
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M3M31.)W4[S@6Y^[!;IA6XZ]RY1 NG_2B%%F/=G?;::="T@Z#L
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MKS@
M
M
M             #__U\_@
M
M
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MX1G"BG3P\Y4786C&61:@
M
M
M                              '_T,_@
M
M
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MHK4T[?ONTJ*G46]>['33"-PO#\)H?YD:4%ZO/4J(<"T ZCF
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MUH;A+EN=J;MW%1KBC#&,HS7-%U3[3W!P)
M
M
M                                          /_T<_@
M
M
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MK2;=%VLUV;@T*WM7<.<VS9YG;RDDH2GQE"2K!M]KIQ9S2/>GR@
M
M
M                                                          #_
MTL_@
M
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M25(^R73IQ37Q-BAC@
M
M
M                          ?_T\_@
M
M
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MEXIH<X78WGRR5&0XN.*9:!T8]2,^\&*KC653Q+FN-1LIJNJ=+$Q;S$Q.%3#
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MIIJ4914L&L,&Z/N:H:]XPS-NMK.0=N[!N,XO!IIM-4?D-V3N.0
M
M
M                                                         /_4
MS^
M
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MIUC[7EX1MQ^EBJ(L=FKLK]^5QNN.'DXGAXG=CP.BK"=OR$U%!VA58[2._7O
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M59:P
M
M
M           '_]7/X
M
M
M       !5-UB9S^%&Y5)ART'ETNW\-/6P7%LZ21UU?>J7F56(S@GDL1T;FKQ
MU4U_>NYU!S%A:9TWTK-+T=^$\SGK4?=)QE&-BW<?T,XMW$NUQ3[#(;H%MNSF
ML[FMSYRT^;+.-O+S?N6Y1?/*/>XTY6^RIQ2->9E. #V6+8?^J3GN';>OI'UU
MJOUYI5RAD2*JTUBIU6J=+*]J+R:RLBT5>TR\]3/8%G='4V>Z-3MS65T.S*_9
MN*JA\=K&-J$G2DT[<KKY>])MX%@NO^Y;VG[<M;=R$XNYGYJ-^#HY?%DFY/\
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MVRJCK*&XTD-53542ZQS1R,14>U?7J;AYQ<94?@_8:JO;3,+DZH]J<20
M
M
M
M#__6S^
M
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M-GMN0<IQRMQJ,Y*CG&3<DZ<*8M)K# YFEP3XH
M
M
M                                          !__]?/X
M
M
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MS6\Q+#F?-3T3?:TJ2J^PN?-CIC4
M
M
M                                 ?_0S^
M
M
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M3D
M
M
M      #_T<_@
M
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M8<S;]L\G'Y"*LX<2!V#Q&B=O>'6@["? FO<.(3P%<0L">'>,:DX=I'?I\?Q
MC@-2/(*X!/1VD^ 5>PL\]S_"DO6A86:*J+9I57^]EH^N-[T/3S-5[</F'9&#
MGF\CX7U^H=MMM<U&[=84U.[&[4G_ %*TU4VO<+V?GLR(N>[]KYQ]X=AP   *
M5_>7HOZJ.W"I_J<N''T>TM*S+-)/O.F[Q*Z).#'JWAJUW;WZIJA4K'!G47;>
M[O8K=K[NJ]K[E"J_X@?-N_;&5$/<EA)P.8 *VO>.[@TUJV_LVW#XU\_,9G5R
M3I)R\D5J>LO*C4[=5:IW6%6=7P.%RO+@?$^[-QA&6K/\AN%!_)"7.CIK3621
MJBMI%A5)4A>J<=51-513EF))RIW'&VL*LM;*<[0  #P5,"5--44[ET;402P.
M7P26-8U7YP#&MZA\1CP#>G,<3@D:]E+/[>BM1&MTKW^>CN5/0I7V']C52GN)
M*1O'T)YS<\;WYM.*TC^6@S&&J6Y?2Y&/=1Q(L7,BZ(NBIPU..8BVJHY6B_8H
MCN.#/7U)ILU4Q]TDDB*G?]ZG8IV672XF<9^Y91) U&PP>"11Z]_Y1$0^C5LI
MC<?:6-LFZ&%Q::\]S;P\='L.NYC:9,:J2:,F>S)RVBV-3AI0TJ:>J%#YQ5'L
MP  >&H_E>?\ PF7_ (Q0#&*W955W0SI535?PCNJ>'#VUY767YA3S]T<?-X55
MNTFXCNY+#(OS/X%=DZ?'+/TWZQTW:>BEY#K^,\X[@9X[MURR\+Z?Y97M-O6V
M\-MZ?_)[?SBR6H?YP_\ MVL^5T355T/L=I0U)'E U^5>'Q $]W >0GLH0",1
MV^LCB ,!VXCUDX#RD.:US5:[BU4T5/%%[B5AB2L'5=AEB_BRG6A5[;;M2;&5
M]8VMNN4WZ..WQU=4C646.3L5)VQMF5$1&KR]A@QZU.RE8S=G=N1LOD<>6[/L
MYF^TN3M#4:TRLI4A2B7:Y)8_-,[CJYP2MS?:_P"M<<;1NN>.5<=\6N2*.:1U
MEI87R7&.*=J*O*L>KN"Z<#73UEV+D^HG374]OYBWZ2_"U*]E:*LHYBVN:/H^
MZ4TG;JL6I-%X=HZ]?VUN3*:M9GR0C<BKN-$[3=)<W>DGS4[U4JHCECGC9-$J
M.BE8V2-4XZL>G,U?D4T@NW>M2=G,Q<+MMN,XOC&<6XSB_&,DT_%&PBU>LYBW
M',9=\UNXE*+7!QDJQ?LIHUD/%4.9S&Z)-P*7'LNR/;"MDGJ*K+W.RNS*^9?*
MI8+>Q:>OIV0KP35[T7AVZ<3:]ZFN]);GZ5W=KS@XW-O7Y0<V\)V\R_26E%<:
M6XQY6J43X&%76O07H>]7J$IIPU."N6XI4:=OS;E?+)U^>6@&5Y:<
M
M
M                                                        '__2
MS^
M
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M*ZQSQR-UYVJGI-Q,XN$N5JG_ 'XHPNC)254>W.)(
M
M
M                                          !__]//X
M
M
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M)=IKQW1H$-I[FSFVK;<H9::Y9--5C<7I(I5X\JDHM^!S7+C'Q
M
M
M                                                    #__4S^
M
M
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M:,D9J<K6M_,M1/D30^<5!J  !X*K^5JC_")?\;4 Q>]R5UW(S]WY9,JO"?\
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M73L>V1C)&+JQ[6O:OBUR<S5^0V5M-.C[#&%8XFH@
M
M
M                                          __U<_@
M
M
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M+XI*32KY51^R;T'U3H
M
M
M                   !_];/X
M
M
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M/T-RVES/NHTU[1:69G%E0
M
M
M                      ?_U\_@
M
M
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M2ECJ:2LIW<\4K'-XJUWH75%-VS4DE*2IS)27D:JC Z,E+@ZTP]H]^02
M
M
M                                                       ?_]#/
MX
M
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MN*-RU7@^>KFHONBZ>2IS=,@3P(
M
M
M                         !__T<_@
M
M
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MKDC]' K<O'EMU?:4]QUD<T/=>)I8=U^S_3'0]B:?\Y-.K,^[.=K@6ME.=H
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M<AN.,J3TQ-M8^=;G))I>/,XOR5+M(WI(QDC>Q[&O3U.3F0VL/!T,1C60
M
M
M                                                       ?_]+/
MX
M
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MVN3\# ,OJZY#D#D['7FO7Y9U-NVCX:+D_P!QA\XL;GG7,SIWOY[/5E>4A/\
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M>/I[:]'?7L78RQ[>)KRW#HN9V[K>9T;-JD[,W1?L)8P?LQ:-^#VI\<
M
M
M                                                    '__3S^
M
M
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M
M
M                                                          /_
MU,_@
M
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MNP4_\']T5\<@H%]7\A-*2][H[;:HF6JG2=@     !5M[RQ?YS;>M\:JY^O\
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MMF<DT^*Q=/F%\<O>A?LQN0:E5+%=YLYU182W!]VZ^I]K2:+<!U7DE'!_T-)
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MW;O17&D;L(W(I^*4DGXFOF<)6KD[$\7;E*#\7"3B_FH^O.XX@
M
M
M                                             '__U<_@
M
M
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M)7$ESQ2]J7LG.TRW+0
M
M
M               '_];/X
M
M                                                           !
MM_NAFULV]P>^Y1=9)8Z:BI7Q1K#_ !5U54M6*F;'Z>94/F:WJ^4V]HF<W!J$
ME"QD;-R_<<N'+;5?FNB]DJ,GE;N?SMG(6%6=^<812[Y.A2)7W&XW>NK+K=ZR
M6X72XU,U96ULRZR5$TS^97NU]&B&B_?6Z\UOK>FJ;QSEM6IZCF+E[T:;E&U&
M3\VW%O%QBN'E-A&V-$M;;V_E-$M2Y_B]N,7*E'*7%R:[V?D/*GW00VDJL%CO
M1/@;:/&KIN5)42O=EKF4=#22-<UE-0VM[F-GC:[BBS*]>;^XH;?/59Z;3V!T
MOL9S5K'HM3U:4LS=;]VK$J?%[4_&VN=]J\Y4,'>J^Z([FW==>5FY9;*I6K:[
M.:->>2\).GM'"WWU'6-;^FWI[R%]/<K741I:;K#E%GFD5:OR*ZW/BMRMB1%X
M^:YCT,MMH;?S>Z-Q9;1<BN:Y=G'#O2DN;YE2T^HYF.5RTI3?*VG1OOH=57E6
M3W/-,FOV5WBLFKZR^72NKV3U#E=(RDJJEU130)KKP8QS6HGH-NVBZ5E-#TBQ
MI62@K<+4(KE7T5$I?-J6/SN8EF,Q*Y/C7'R]IZ#XOR3ZC*.O>0GJT^+B2QCP
M)[>'V2/ > &(P[ 1B/ ?#0G$$)P](P);78B?G)(H0NJ]G!2/*%Q'K^"]XJNT
M8$I]HA!#Y. )';W$\2*H"J(!!)?%^+C,7]\=QF3_ +2HSY:G4QU]92?_ /I*
MA^R7SC[FDI>DL-]EU?/.U+3L3U)]@UN%[20   #'TZU7.=OMD"(OWKU3C_<>
MXK,LU1G3=XG$F=-*>=55%_.9-%U_A%*E8M'47R]"\T<.RE++*]L<4*,DDD<N
MC6L9$KG.5?!$0^;=?V67E*F'N:E4.^]PAS/JFR-U/-[=9KYG=FME,Z)?,TI)
MI%AG5J^A4*J-(6N;O.J6,Z%A/7+B-#AW3IC./VIBI08VM)0TZN^^Y'.;S*NG
MBJ'3E_MN)V7/<'HO=B(GX,;E.3AK?:'A_P!)-&8]T(8*A:<=!S      *K?>
M8JJ6S;?3OJKK_C"G?E_MAUW$Z8%2C/O6KX)V)Q7B5SXG0<[_ '?<:/W>D>J(
MJL@JE153736/N*7,K!,[;7:;Y^\ULLLM!MG=Z2E3^1[E<65]4QG'R?(U8V5R
M=VNNAUV)4E3O.5Q85*G?OM'-73F1%3NU0KJ]YT'(?I'T_9/[2_Y.N7\SL*>_
M[@[+?$R-BB.\   _/5_RK4_Y'F_QM0@8M>9_^D'<7CI_X:7WC_\ >$I]*&$4
MF4LN-3BCUDO\OI&Z@'Z\&X8NJ]FO&3B>KV.E+>NFP[7=_6.C,-K+S?@8#;UU
MGJG?FJJH7U_GSC;5E<,I97="/SBQV:?^43\K'H.\Z.R@'# @<4&)RX!>SL#X
M$4KX$:\?BU% 2.PC$GMX:$D\<"/N'$>0=RDCL(7BGAQ^,8=J"X$_#U#Q&'8
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M=_$_S8XY$16I(QCT:O:G.WFT4W)QE&<5.#JGBGWI\#"!IIT?$UD@
M
M
M                                               '_]?/X
M
M
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MC*XHKA&:DN6N.#J8#=0=N+:V[<UI5MUMNEVW])<JTG7M5'4Y5EYCQ@
M
M
M                                                 /_0S^
M
M
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M1Z#D=7@1V?+W>'QAX!D]HXXD\7@3Q QXD:>/K)H1Y1IZB*#M"=O=J$2JA/R
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M75%:J:HJ*;3C$DU
M
M
M          '_T<_@
M
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M1N\>Q/D@
M
M
M '__TL_@
M
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MK-9?=66BV[WV*]1-XQ7F2?8ERKE\6RSXV"&.0
M
M
M                              !__]//X
M
M
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M?_*--X\B_P#'J;7+E?2,LYF?M\_+^H?L^R<#H[!\1"&(](KVCQ'W2?*!\/B
MH%[?1IV_:##H01X$$@$:\="222 !P )("*FJA8$T7:!Q((7T<1VDX5)T1!A7
M$,W&V?W(O^S^Z6#[D8Q6S6ZZXUD-NK?;*>589(Z2*='U&DB=GT4/.[LT'*[F
MVWF]&SBK"Y;E3"OG)/E^:?0T[-RRF9C>7O6FEWNM#M]O=Q]3>-=5O2IMKN!9
M;I+>:I,=MMOOU34*V57W!E(B2(LC>#N'!>'<:AM9TK-:#K%_2LW%PN69R5'@
MZ5=/F%\LO>CF+$;JQYD<9.I;!:G!-U[O+)[)!:<SJ)KUCE)3*UJ0PPP-CKJ?
MRF_>JUS'2+_<M35?ZY_3[\"[UR^^]+RW)E-4MJ.9N13H\[%M2E/L3G;]'&-*
M)N/"M3++H-N;XWI5[;6<O<UW+R<[,'V6:+"/A%\S?&E388PO,@CVEEO=UQN[
M6^^66MFM]QMM5#40U5.J),D37I[5"Q51?XK%S1KP[''KM@[SS/3S>6G[URD>
M:60N<\H_16VG&['RNVY)5KC0\[NS0;>Y]O9K0[CIZ>/FONFL8OZI*O@7CX1D
M]NS'%K+D-KJFU=+<:"GE\YJHJ+.D2-J6*J=[9$<UWI13>KD,]:U33\OJMA4M
MYJU;O154Z1NPC<BFUVJ,DGXFOB]8N96_<RMWW5J4H/RP;BW[:/JRJ.L
M
M
M                                               '_]3/X
M
M
M                           /QW"NI[705ERJW.;2T%+/65#FMYG-@IXU
MEE<C>_1J*<H1<YJ"PJZ8\#C.2A%S?!*I2!NAG\VY^X>39E3WFNNN,7"IC9AU
M/71)$MKLT2*US(&:NY6SNY7JFO:B&I/UMNHOX[=3[F@Y>VK=C;OI<BFGA=O*
M:=Z;7!TE&D)<:-F8G0W;$M&VL];O2YYZIR7H88PM<K4(I_LDZM=Z/A#%PO6
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M':%B.(["? <"",2"2:85)J.X=E14R!?Q<5O_ +]N.OX?Q)B>G^6#%;UGY?\
MV6TGX'L- QM0_=8_J':4)V)ZD^P:^B[)(   !C@=5+__ 'AMSDTUY;UIQ_N*
ME;EEYCQ[2GN>ZH<?YIFT\,U0Y/HQ1/E=IVJC&J]3O7'$X%Y?N_MLJO!MI'Y%
M52(]F?SP9!2-U171TZQK C53M3BWL/GW9.5Q]R*F'"IST.LY%>OO&'_^9GR]
M.VNA77U.U.VQ]M1PN>X/7>[E9IMUD+_S=PI%^2E0F]A.A,/<EC9TG(
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M*V<\3,0LN
M
M
M #__U<_@
M
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MB^]/%/V48,-.+<98-8/RKB?I.1
M
M
M                 !__UL_@
M
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M<5/_ 'X,?=W<T2)Z_/,4?6B:CI=E+C0]EM[[5"O^$7ZAVCZ=B>I/L& !=<D
M   QMNIQZ+U%;M-3M9D"(OI^@I6V*\E>\Z+GNC>3H,VVDS'>'\):ZVPW/%L=
MHIFRR2L62*"]QOYJ5-4X(Y--?$XYF6"B3;7:7RHB(B(G!$X(GH0I#N !7/[Q
MUR_J30MX:>TL7X^8[LNOLM3A<]R>W]WK'R[55C^]]53*O'A_*Z"_]L$%YJ+
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MMQKVM-.OE1RX+['@@
M
M
M       #_]?/X
M
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M4<N'M<MLM5_OU9CUW=6HD*/H;8YS**217]G,J)HOB5=U>DM*<>PZ(>;*A?\
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MT,/N)Y"
M
M                                                         #__
MT,_@
M
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M)^8G$ 4&*X#T#RCA@.STBE "&.P:KW)\1/'P">(XKQ[/AXAT';@!AVAA?AZ
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M#F=&O?WN588U^QRQ@WY8F^9<8\X
M
M
M                #__1S^
M
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MJ<S.NY6A5KP771?#5?L%6\#H+.O=@:_7.[VO;YUJ^S(4N9[#NM<"X$I3M
M.%/71M;19]LY<[^_SG7/!(*B]6RGAA65U3*]&T[XOHHJI]%RKP.RTZ33.$U5
M8<3CM[M;=2:IMF1;57)(*."R0TMTL[IIVMGJJFX<LM;2Q1/775BN551$[CMS
M,:2YN\XVI*G+VHM?*8[3XS<-W)@^4O[VV:M7_P"J4 QA[R[FR"_KW+=:M>SO
M69VI].-5%%*^)7M[SVMI*'HQW5;5S-B=76?V>CYW-:L\^KOSMB+V]O<=6U-?
MS67ZZ[,T/2DYW)9ZN82][:I'%_\ >5T].C?VKJN=OX1C9\Q]\JO!&#[1)I2P
MI_"+P_NRFZ?,I+,3BN_]0QXNXW9>4_1W_&4_:=/:.'P\2:C >H4?!#R!.'H"
MP"'!=?AQ [1Q&)' )Q^R1Y25B%^WP)8H.[084H,: 4? @?:#X$D:=Z)Q'D&(
M1>[P[?6/*. XKKPX=Q/ >0E.&B$8CM)^V.TGAQ-)%&<2?L^!/90FA'#311PQ
M[2#(X_%M^MEO3=U@VO:W(9ZFIL&ZE544-'3R5LD%%133HV))%8]R,UU75.'<
M8B^M3LGX]HMK>.2MI/*45Y]LJ\"X>S=14;CRDV^5I)+QQK[9V2^]& T&[>UM
M^QF>I=!!<+>VXTM53QLGD;4T3/;Z-T.J+VR,;Q;Q4P*E9LYRQ=R&95;.:MSL
MW$^VW=B[=Q>S"31<67-!J[;]W;:G'PG%\T7[$DF4@V.HK9:)U/=(74UUMU56
M6VX4TC71RQ24-4^FA?+&_BBR1M9)Q_-&D3K/L"/3+J1J6TLLKCREJ?-E;ER/
M+Z6Q))J4,$G"$G*TFNV&+K4STZ;[HGN[:.5U/-R@\VH\F8C%UY+D6TD^U.4>
M63K]$>X+7'NSE+TD9XW$=R'X[)2-EI\]\JDEK))WL;0U-NIG30N1CEY-',8K
M5X:JY4,ZO4JZCO3];SO335+U+&<C\8R<6W_G*:5RU;7!>D@YW985;B8X]>]L
M*YE\ONK*0K.#]%>:6')3S9R?@Z17E+839&8P
M
M
M                          __TL_@
M
M
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M/M.AOGG3N+_-O<.H< PK&\.MKN>CQ^U4UNAE5B,?*V%OW[T3O557B41WGV8
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M9-)_W22:\IN,?=*$
M
M
M    _]//X
M
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M;<<CJF7W+85(YRMN:2_OD%52?@XT7E+)3.DL"
M
M
M                         ?_4S^
M
M
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M\I:S^6^U7X1N0[?,FE*./D?MFO\ N6YV+LK%SW5N3C+RQ='\U'NSO.
M
M
M                                         /_5S^
M
M
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M3G899%H@
M
M                                                      ?_UL_@
M
M
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M0U,2^,<\:2,7Y%-R]8O&#JGP?>NQF#V/:?L
M
M
M                     /_7S^
M
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ME]#P@
M
M                                                 !__T,_@
M
M
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M<6T_*C#Y-22DN#/*<20
M
M
M  ?_T<_@
M
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M]A5OR]O%>)55Q.DM%]V*B_6.ZRKPUFMW#U*\HLQ[H[K7!ENQT':
M>BR7&[/EUCN6.7^C97VB[4SZ2NI9/O989$T<W7N7T@&.OU3=/&1[$Y'=:!(9
MJS"K[4RRXS>6-7RZ9L[U\FS2(B+HL;51.95XGM-C:M:TO=F1SU]^9;GYS\#Q
M74+1[NM;*U'2\NJW+MND/+B8@_OB^EEU/76WJ+PZT>;)53-LV604FJ,H:2F;
M]*Y3L:FGTE7BY5-G&U=;MRE"W=FE:S$4[2IQ<C$/I!KMRW:S&S=0;])E7)\S
MQ;DJI17D*#6*U[6O8Y'-<B.:J=BM5-45"X5"]+BXOEEQ7%$Z>D4\2&L1IKWZ
M<?@@Q[0D1W\?#MU'90FM51FKN7B3P"-/#3MUXZ:^GM&/:&L< B\?'0C%,C@/
MNACM"\?E%:X"N-21B\"/$=@X$\$/0.P> 543O!/@B2<!CP(4=I#&FI% E4>)
M*XCO&OH(?<Q5#7AX@5[ ..!!'!.(\">XG7O)X<2&?08CE5[P;*K!F&.5\MKO
M%@N=+74]= Y6S11PRI).C')QXM30^+N'0=,W1H6:T'6+7IK%^#3@^#E3S/:9
M]'3,_?T[-QS.7ERR7!]S[SM;/<?=9UGZN.D+%:JCF62MPZ@H[34R5$S75E3+
M'$C*B21CEYM$?V+H:A-S[:U'9FX\UM?6,,Q8G*5.ZW)U@O:+Z6<S9S=F.8L/
MFBU1O]DO=?-.1?79MQ)'06'>*U4\<46)+4P9>Z%-)Z^UU[/9:>25K457^0]W
M,WXBPO7OIM^5/IAG= R5N#U'+TS.5N2591=C[).U%^]]/&/HV\<'P/7[&W-^
M)V[,MKEQR=C&U=A%T4HW/-YFNWT=>9' Z-[98XI6+JR:*.5B^+)6)(Q?D4TI
MRC*W.5NXJ2@W&2[I1;C)>PTS8#"<;D(W8.L9I23\))-?,9IEACG8L4K4<QRL
M71>Q',>DD;O[JY$<GJ.W+9S.Z=F+>H:;<=K,6)*Y:G%T<9P?-%I^5+V#JS64
MRV?RUS)9R*G:NQ<9Q?!Q>#+>^F+<J?<+;FC;=9X/P@Q]WU3<*6-S5E92TB)!
M;JF5$XZRQ-:]5T[5-X72??VG]2M@:?N?(W7=N.U;M9IR7+)9N$(J_P RJZ<T
M^:4<<8M/ U\[JT#-[8W!F='S=OT:C.4K23JG9<GZ-I_2T3[F<CRXIY\
M
M
M                                      '_TL_@
M
M
M         J'ZR=R?U1-RZ;;6V5T=QPK#('5&5T:,^@W+X9FNM]+*YWWW*SS%
M735$5$U[C%?UNNJ<]A]/X[0T+-_%]9UJD;D57G6G2J[LXM>XE*2MI-M-Q<J5
M52Y?2#9JW=N^.>U/+N[ING+TO/6D?C47]CMR5?.P<FU1I-*M,#CDJJJJJ\55
M=5]:FII))41G&VVZOM(!![3'\=NV8Y'9,2L=*M;<;Y70P24['-21EJ21$N=6
MB.5/HL8NBK_#%Y^@?3:74_J7D-%S4)O3[%R-_.7(ITA:MOF47/A&4YJ/*JUD
ME*E<2W?4_=7XJ[5OWLO.,<W?3MV8OBW+"32[5%<>Q5+MK19L=VGP&&TV>)E%
M8<4L\C:.">=C$5E) KV1+-*J(BO<FB<>U3=/.;DJNF"IW<.!@HE&$?!'66?C
M O7/4=0^_P#7[;8U72TUAM5TN*YK8UK'5445UH9G4]!R<JJUOT6,=HBF>7JP
M;!CI^2N;OU&TXWII*TWPE&7%EL=TZD[]UPYJJ.,&O+BG\UF.^U$1$3N1$1/4
MB:(9>5Q;/#<>)*'%!#14]1/ FC'V!2I' >HBO<'0+Z26QY2>'W @Z&D8=I!/
M:%1D\<6. [1@ B $NTD>A>P5Q'@QJ&*@=N('S!KM #XXA$+WHJ#@.!*>@CM'
M:%)_5#!''$ E(@>G7Y>'QZCQ8\3G!T,='.0]6&Y-#[7%4T&V%@J8:W)+LZDF
M='=6P2HLEEIWJW1'/X:.0\YN/6LKI62N*[-1?*W+%>;'O/,;MW2MK92,,K#T
MVH7WR6;:Q:D_<RHL:8G8Q^[<Z!<9LMAQO*;WC\-HP;#Y(&85BOL24JUTU(S2
M"ZW%Z(GG(O:O-KKJ:VNKG4>_NS49:3I\G')6<'1_;)+WU5V,N1TEZ=W= R\M
MU;D?I]7SKYY.2PM1?O(I\*?J%]$<<<,;(HF,CCC:C&1QM1C&-:FB-:UO!$0L
MS2G O2VWQ-8           *<?>A+_/O;Q$715L=\5/4CM%*C+>Z=3KN>Y.?/
M1^BITW[5(O;^#K?YJD.F;K-OQ.:X')4XD@     %1GO0?Y:V;7LTK;WQ[?\
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M>UKV/:NK7,<G,US53N5.*&SEIQ;C+!K Q83354:B"0
M
M
M                       #_]//X
M
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MMZ-G=O:OF-'S]MVI69R4$\:VZ^9)/M3C3'OJ<C3V)\L
M
M
M                         __4S^
M
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MO'PU^T53.HM-]V3_ "SN@J\-9K>FGJ<\HLQ[NAWVW54+;3H.P
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M)>ZMS3E9H_?<L4U)]CH>Q,6B^1O=TW[BR;;;MVKSED2PYSY&/7ZHFFY:&UK
M]9;?7.C7@U7OD<U[]>Q$,[_4IZFVM-U3-]+M8S$;67SKGF<G%QQEFZ*-RWS5
M]_",%"-./-B8S=?MIRD\OO'(VI3FJ6,PT_-C;3;A.G@W+F?=0N5BD9-&R6)R
M/CD:U\;VKJUS')JUR+X*AL?::=&8UFL@
M
M
M             __5S^
M
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M&G9G1]2S.D9J#A/*W96_.P<E%T4E7LDN#X/L.2IZ(I0
M
M
M                       ?_];/X
M
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M@/0/ 8\"-"* )KWDKB'X$_*.P+O P[0/C%4"-%XKW+V#@.PGB@&*((!*^!.
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M["K-%3LT5-?DX>!5/@=1:M[LO33<I=./G4/'^[.*+,?;6=]NO*6RG0=@
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MQKV/:J*US'IS-<U4[45#8&TTZ,Q]-8
M
M
M         !__U\_@
M
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M4N2LMO#G]&W'G2[I4JO Y.GUC@
M
M
M     ?_0S^
M
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M$TTZ,Q]-8
M
M                                               /_]'/X
M
M
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M;#\MJX60SU%*^A<R--&_SN5*5':>*\NI\V<>65"JBZHW_.)(
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M3Q:2?::\=0TK-Z'J%_1\Y"4)9:<K:Y^,HQPC/^Z5'AWT.3YZ I
M
M
M                            ?__2S^
M
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M;G<*/.\%JYW):\;6AGM%.]WT6^U(CJAT2=VJ\5**_%J7-WG=;?86KG0=H
M             ,,K\:RQ%,SQ/%HW,:],;Q>2^(J]K'0UC='(OQF1/0K4([<U
M?*:G8PNYS,QR\GWQ:>'S"W>JOXWN;,9.Z_-MY7GC]-5</;, *)ZR1M?^:37Y
M5-E%R*C<<5V,MW*+BW'N/(IP(9&JIW:A/L"XD^ 8[0 UB-50BK&*   9"ZIW
M*.T($U!*($NT4!'D U%14>C[':3VBM &0/4/(3Y!KP^&H)K@$"P(6(^' -=H
M0'>0%XH#E7 (JZ?:4GL'#@0J<R*U>QS7-7U*FBD1P:9"K6IDW?BWW7P[I]W\
M79G-K]60X5DE71LQNR4<G)[?<JOEAG1[%X.Y5<J\4,*/6JV#*4[&^M,M2G.5
M89F2X0A'W+?M(N7L_4TX/)79=\L>^M*>UB=D)F^(V/=7 KIB]ZCDDLV46EC9
M6,=RR)'4Q)/"NJ=Z*J*85V[CC5P>$DT_))4?MH]W.$+D>6:37<_ HVJ;1>L7
MO5^Q#)*6:AO..72IHUIJC^+OM2O7ZIK'KPU\UB.7@G<::_62Z8V^F'4[-9+2
M[#M:3GV\QDG[SE;^RVH-XM69-)U;?G8LS;Z/[NN;IVG"UG[RN9[)TMW^^G][
MD_IHI^T"P9=4W@Z>=PI=L=WK16RR*RP9K[-C>1RS.3V.VQQS++17%R+V.<]Z
ML<[7L:AGAZE?5*SI>HYKI3J]R%K+YUSS>4D_=/,J$8SLUK11E",?1Q2JYN7>
M8S]>]H3G*QO/)1E.45&Q?BN"A6L;E.^K:D^Y(NA@FBJ88JB"1LL,S&RQ2,75
MKXWIS-<U?!4-CS33HS&H\I
M
M                                                           /
M_]//X
M
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MZ)F8RB\O<E&+DJ.<%[F:\&NWP.3Q[,^2
M
M
M        ?__4S^
M
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MDH\PO.4GQ9W6G@TRV8ISM*E_>?PO?'M'*FO)%<KHKUXZ)K$FFI49=^=0Z[O
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M1475%-E;3BW&6#1C%Q/*0
M
M                                                        ?__5
MS^
M
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MW^/=IV FBK1D=WR!H@D# $\2"#CQ!/!?R.\EHD?%\9'D 1"<0E4A./B@)P7
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MOFF!&\=YZSO745J&J2Y805+=J-5;MQ?<NV3[9.K[G0W5[?B.X\B1VIW+IZM
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M)TG!U6#36.*>'!OM*#5--RNLZ;?TG/*MG,P=N='1T?<UW.C]@MEZ3MUI=P,
MCM%ZJ:2/)L4D=9Y;>QR)5OL]!I2VNYRQ^$\;6NU1-.)O"Z9[_P!/ZG['R.\,
ME.,KMZ$5FXP34;.;I6]:2=72,J\K?%*IKYW#H.:VOK>8T+-0E%6)-6G+C<M)
MTA<[O.5&Z<#E4>Z/C@
M
M                                                    _];/X
M
M
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M$15+B<'LY]YOA;*&II<!L%T?>XI'M9/?**1EO5K45$5%C3CJNBZZG:LO-XO
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M::[FN*,38RC.*G!U3Q3/.<#D
M
M                                                         ?_7
MS^
M
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M4?J7YOL'+\N\>4
M
M                                               /_]#/X
M
M
M      /093D5%B6.7K)KBR>2@L=OJ;E6-IV+).M/2QK++Y;$[5T0Z<QFLGDK
M$\YJ%V-BQ:BY7+DVHPA"*K*4F\%%+%M\$<[=N[>FK5B+G.32C&*JY-\$EVM]
MA2%G&6U^=99>\JN$]1.MSK)'T#*IR.FHK6UR^Q4',G=&BN5$_AE-)O6GJ3F>
MJW4+.[JN1]'83]!EH?0Y>TY*%:>;S2;<G)>Z3C6M#/'IYM.&S]L6-.DU*_/[
M)=EWSFDZ=](K!+L=3Y4M4>Y !OATT[9,W4W2II[C!4.Q7 YHKU-6P+HUV543
MT=0V^1RHJ)Y:.YW)X.0V(^I5TLNY;TW5_58R@YPEE]/BUYMRU<POWO&+Y8Q@
MUVQD8K=>-WPSV9CLO)M3MV)*YF.]78XPAY8UJ_*CE=[P;JHQ_I0Z<=P=PKE6
M4RW"AQVXRTUM5Z+7U$"PK#+-2Q=ZMYDTU3M4V"Y+(9G5<]8TK)?;LU.-N#?!
M2EPKX&/4IPM0E=N^Y@JOR'49]3F_%_ZE-ZLRW4OUPN%PANUVJWX^VY2+)44-
MJ?([RJ;1?O>"]AMFZ8;(L=/]H9?0X1C&])*68<>$KO:RRNOZF]1STKB?FKS5
MY$_--A3W]#X(X_#M&% !X $>! ^'$G#L)(X(O:O'7U EC3^!W!4("?/\WQ$I
M(84P)[=>_P"=",2<5B1QT](JF1VDIQ_) H1Q]:>CM%!Y">/9PT^<8T'@!VD!
M.Q>WXR70Y<1Z/G(\"/ ?#4 A./H]8IW@D A51$U7AIQ5?0*-NBXCLH<B]@^F
MK-M^*M:ZB?#CN$4BJZJRJX1RR4MP5C^5]!:(X/I23<%15;JC.'-VH?)SFH79
M7/B6DI3OMM.;QMV6J/[)3%MIX16)Y_=>[] V-E5F=>YKE^23AE;;4;LTVUS5
MEYL8IKB\'BEBB[[9C L5V"Q>CQ_;&V-L5RA<LEPS:*67\,;S,K=.>INK7<\+
M4U7E93N8WT'D]1Z7[6U[7KNO[JM+5G.$(1RV;A"]E++C[J=NQ<4K?/<=)2<H
MMJE(T39C/K_7#?NN9):;E\Q^#[4;DYURLI6;DHR?FVY7(.,W&VJJ/G>=6LJM
M(^QD>^:>HJI7OFJJJ:2IJZF9RRU%542N626>IGDU?)(]RJYSWJJJJJJKJ7$@
ME;LV\M;2C:M14(0CA&$(JD80BO-C"*248Q22222H6A?GW)79U<YMRE)XRDVZ
MN4F\6V\6W5MXLT]R=Z?'K\A(?$<.[Y.WCWIQ '#L]''0!$:)Z>SAV^ &).GV
M4U]7B!0?#5/FTU!' :_-V]G<!CVA>"^@#R'MK Q9,AQQB)Q?DF/,1?[G>H&]
MQ\W6731,\^[+9C^!F?1T=<VLY&*[<SEU[=Z!V)>QU.M+M+@-.NNL6-VUBZ\5
MU2!-54TPN;GY[[3<?R>C\SN-UB     #&NZF8?+ZBMWW+_RW(T<BKP33D4KK
M#\W@4]SW1LS!JDT>J:ZRQJG>B?33Q.U^<TE_VP.-:1D_ H<S35^59DB:JY<H
MR9.WO^NIS<3MOS= TVO9E<M_ VS3]N.KUW4?',YG^&N&?9T-W:W7[I,V*O5I
MD\ZWW+ K5/3S>4^%TR,:M-(]T<FCD7GC<G'P-1.\\AF=+W9J.GYV/)=M9BZI
M*J=&Y.2Q6#P:9MFV;J&6U7:NGZADY<]JY8MN+:I5**CP?#%,Y7'F3TH  !3_
M .]#IG+7[8UB-U2FHKYQ\%730J,NZMQ.JYP/W9-,Z;W:MGE>O,KJ"B557T7I
MR'&*I<HSDVG"I5?"O\B1+P1/9HM.[3\Z0KNTIR[_ -WE9%HMHUNW*B)=JE[D
M>GY?RET^V4%YMW'4J8>X18&=1R-ANIFE2MV3SFG5J.1]M1='<47ED1Q*XA\#
M&]<WEJ*IO%$CJ96HG=]%VA].N"*7M"3Q4O/65#E93TD4M5,[17*R&FC6:9R,
M3BNC6JNB=H]%._*&6M*L[DX0795RDHI5\6T0[L+%N>8N.D;<)S;[E&+DW[2*
MX>C*>ANW6YB,JU,,5'=LKS=U'-4O; V;V^6=UOB;YNGTY>9J,8O%57334V/=
M:\CF+70*_DG!NY9L9%24?.H[:ASO#LC1U?"F)KCZ,9VQ=Z[Y?.1FE;O7\XXR
MEA7TCFX<>V551=^'$SR;3'Y-JML6FGE4%'&J:::*RG:U4T-9<?<KR(V4SPFU
MXL]@<CB   <:NKJV1W#I^W%E>C>:WV26M:Y>U$C>UKD;Z>*'9:^V(XS]RS'0
MHG(ZBI':HNM- [5=.^)%U/H8U*;L../5RJ_J'7K71$7(L5[>_P#GDI?[U94O
MRLV'_P"FS7\&6"]9=O\ )3>7?F<K_"%36O'CZO6IL?-=&"''CW^'VA@,!X=O
MBO%>WPT \@^+C\J^A>( 1/5]P!]A/V/AQ((1';Q^30GP&([/AQ^+4$^4<?#C
MZEX @^/SG L2W*Q^HQC-+/3WFU3JKF,F;RU-#.J:>T4%4S22%_9S+&Y.9$1'
M:HA1YW(V<]!1NUC*#4HRBZ2BUPHU1T[XOS9=J9Z3;&ZM;V?J7X3T.[Z.33C.
M+\Z%R+XQG!UBZ>]E3F@\8M,I6ZANE[+-CKI572W>9DFVU4Z6HMU^B8[VBQ0<
MZ)]7Y&COO9&\R(V5-&/3[W713H^.RRTH6=3:C*5$KBPA.7T-/>R\'Q[.#,Q-
MC[YTG?\ E)2R2]#G[5?2Y9XR:_PEJGNH<>9*KAAS4JCC U4<U'(NK53Z*IV+
MZCZ#33I+B>O\'Q0 )XD8C$+\7 DEL</C^8>)&#&N@%: ,>0=GBJ?*22_ :Z]
MP(!&) !(\1WC </'UCL 3M(""]O#3T_:):#H-15@:=_B.*'8!AV@+P[PWW"G
M<%XHNOJT]?B*XU'87*^Y/ZX;OTB]5.-VZ>>>IL>;W:V6ZW4U4[FL]HK'RM94
MUDK%^\YF<VJIH8V^LCT^_&C;'XP9)15_(IRFW[J4.Q+OH>QVKJ:RE]6FL)ND
MGVMMX?,.U,QB]8CO7MK0W%KZ'(,<RNSL96,CTEI)UEB1M3$FNO!':Z&N2W<G
M!\T<'P?M8EUVE)8K!E-.;8?==N\XR3!KW)3/K;75K6T/LKE=%]0W%[GVGZ2J
MOTD:UR.3NX&G_P!9[I5#IGU$N9C2K2MZ1J[G?RE'PE%KT]OE?G15N4HT;PES
M8<&9I='=X/<NVUD,Y-SSF1I"ZVN,']KDGP;:3JN*HJGSACB7</N-LL_EVKSN
MSYPQ6QV^E<RERGD8GM-7C:2>94PQ/[UCU?(UJ\-?29(>J_U1N].^I&7R&=E<
MGIVL-96Y;4J0C>NODLWW%^:N237/)+F<%2M$6@ZR;0CN+;4M2RL81S603N<[
M7G2M1\Z=M-8XJK2>%7P+N[+=J6^VBVWJBYEH[I14]?3*].5ZP5,22Q*YO<NB
MH;@+D%";BG5+M7!^)A?"2G%27:>S.!R
M
M
M  !__]'/X
M
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M5W9>C:2^+9QN]:Y52,4^-OMQB\7P]UP.>YD:6X
M
M
M         !__TL_@
M
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MNF7WA/4GTGX]68EM9D%F=BM97R7-;-D=FCO,5+62HB2NHI)GHL;'<J:L:FG
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MA5^QKP\0%2E62J?#[I! 1==>W[0X"G>1Z?AX]I)-.P>"\415^)0/ =GI^QQ
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M=LW$I6YQ:<9Q?"46L&FN#1@I2Y'S;L7"2XQ:HT^YKL?@?3D@
M
M
M                  __T\_@
M
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ME-MX1OMU<5V^=C)+@J8%EAF&6:
M
M                                                        /__4
MS^
M
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M!^;)=C1K^SV0S>E9V[IF?5+UB3A/NJNU>#XKP-RSZY2@
M
M
M            _]7/X
M
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M55N;BG3O/I*G>#=JL:UE5N9FU0QC>5&RWZK<B-_,HG@?-CLC9D'6&E95-_\
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MQ]_%1?<E4MC-BQC2
M
M                                            #__6S^
M
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M9Y4;]EQSS@
M
M                                    !__7S^
M
M                                                 #XG<+.;3MUB
M=WRN\/18+92R314J/:VHKJA$_.J2E8O%SWKHB-0H]1U+3=&T^]K&LWEE\IEH
M.Y=N2P4(Q3;;\72B7:\#ML9?,YN_#*Y.#N7;C48Q7%MX4*1K_D%URR]W/)+U
M6U5?7WBLGK?,K%19J:FGD62EH41$3E;#&K6<J)P5%[S2%U7Z@Y[J?OS/[NSG
MFV[MQPR]M-N-O+VWRVU&K=%-+TCIVS9GQL7:UC:.W+&E6\;G*IW94QE.2JZ_
M2UY?8/4%NSV  -^NF_;)^Y>X](^L]J@Q_$74M]JZN*))*:NN5//STUFE<Y%:
MG8V21J]K5T,W_4XZ1O7M;GU3UJ$99+3I3LY:W.+K<S$HK[/'L<;-4X2_PB:K
M@8Z]<MZ_%<M'9^0;5R]2=Z<7[F"?VMKOEVKZ%HY?]=75'B'23TZY[N7D-P;0
MNM=@KF4$5+)$RMBE?2N9%4TT"I^47331#9UD,AG-8U"SI>17-?S$U""?;)OM
M,69SA:BYS=(I>T=1GU>]1V4]5F_>7[OY3<JRZNKJJ6DL5573NFG6RME5:;S&
MKHU':(W5$0VN=*MC6.GVSK.C6E]EN?9;V%*76O.2?%KB6:W#JT]2S;D^$?-I
M]+5)^RL3C5]LN-VGGO(1P[N(?$-4)'%"G:"*L$<=?0 :NPGRD\".'!>_30GL
M'9@","*,>L4'E&FG'3M&*&(T''B*$$-$!./8<NT4''3B1CP)/T4=)67*MI;7
M;*2HN-TKI6045NHXG3UE7*]=&QP0,U<Y5]!UWKMG+67?S$E"$>+DZ*O=7O?8
MCLMVIW$Y+!156^Q)<6WV)%FW3?T02<]KS[>B.)7)R5MGP'D=JD3DYH791SJN
MC^]:=O*YJ_?:H?&O1S>MVE;CS9;*RQ;]S>DTU1?L8/&N',\*-8EE=]=9LCH4
MKVC;2IF<U%\D\RVI6(8-2=EKW<DZ<LJN/'"M"SJEHZ2WTE/0T%+3T-#21^32
M45'#%34M-$GY2""%&L8G>NB>L^S9LV[%M6;$5""X)*B_^/>^+[3%?.9S-ZAF
MIYW/W97KUS&4YR<I-^+;KY%P2P2/T:>'VM-/C.RC*?LH1]WX:J*,GP1/#X_%
M>_N(HR,:8#X^W7T]G>31BM%B3\GY)%&.TT\=%U1.SU_*31DL:+IKV<-/R!0C
MP[">/KT[^'8*,-T([U[%]/#AZ!1CLP"^&FB#E8?@./9^1V>L49-:<!IZ$[/#
MO^,48'K3TZ\=/D%&!QX\.WLX:\-.XB@)[UXZ\/#YA1]Q%!X=WA_  ([_ $]W
MKU^"BCH2G1#1.[U]Z:*G9H*/M02[3WJ93E21)"F59.V%&>6D3<BO*1I$J:+&
MD:3Z<O=IIIH?*>@:"Y^E>0RW,W6OQ>S6O?7DK7Q/J?AW75#T:SV9Y:4I\8NT
MIW4YZ4IV&53[@2Q7FW=/&\%XKVU*6S(MU::JLCYW2NCFBHL9@HJ^2G61533S
MVN1RI^61=>)@9ZV.<R68WSD<IE7'TF5RG)=4:54I7)3@I)=O(U3PH9T^JID\
M]8V5G<WFE+T>9S7-:<JT<8VXPDTWQ\].M.VI?48M&4(  !\EGL$E3A.64\*N
M26?'[M%&K55'(^2B>UJM5..NO@!Y#%TO%E2WWRZTM0M2ZM@K:A*A[ZRLYG.6
M=RIS(Z33O\#Z=JBB4LJ\SJ?+9:M=!B&4SVJ9]+<J?'[O44<Z.5SV3P4$DS5:
MLNO'Z/#TGH-JQR5S=6FV=1@KEBYF;,)Q?!QE-+&G95X^!\#=3SEO:NI7M.F[
M=^WEKTX27%2C"3JO'##Q*7)=P,[K4:ZKR_)G2N3672]7&+ED7B].6*1J)QU[
M$X&UJWL[:65;CE=,RL8KA_D]IX+ABX/L-5%S=^[LU%2S6IYN4FL:YBZL7QP4
MTCYZMK[C<IFSW.X5]SF:U&-GN-;55TK&(O!C9*I[U1J<=$1=#[.6RF4R5OT6
M2LPL0;KRVX1A%OOI!)5\>)\C,9O-YVYZ;.79WII4YKDY3=%V5DVZ>!^7T:>K
MC\IWT93OZ(COTT]7K[A0GQ)X?8[QB'X$<? 8$.G862="&Z,]KQO=K:6HN"QT
MN4QVF_6V@?(U//KJ&>.GJ/9V+Q54B:YSD:O9Q5##7UM-O5RVE;LR]EOT4IV;
M]Q+",'%R@YO@DY4BF^W S']4W<"CF]4VK?NT]+"%ZQ;;QE<4E&:@NUJ%9-+L
MQ-G^M"ZTU5GV/VB">.:6SX[$RMC:Y'.IJN6>36&5J?>NY.1WJ5#U?JJ:9?RF
MQ\WJ5V+C'-YERMNF$K:A!<R?:N9->5'EO6JU2SF]\9/3K,DY9/*J-Q+C&XYS
M;BUV/E<7Y&CAVOI^3^ 9/HQBP&B>'HU\?! %X$:)KV=OV@02B)JB^"Z]Z*CD
M75%1>W5.Y15DG,3 .O[K VRQRU8AB.^&646,62)*>U6>=]#60T=.BZI!'4U4
M+YE8B)HB.D71.":%J==Z)=,MPYN[G\_I=N-^\VYSMN4&Y/C+EC)1K7MIB^)=
M'0^M'4G;^4MY#(:G<=FTDH0FHS48KA&LHN5*=[P1RXV0]Z]UC5NXV!8Q77VV
MY5#?<GLUFJ8JR.K2LJ(;C7,I9/+6%[8T>B.U;JW37N+,[W]6;I[I.W-1W#E,
MSF[,\I8NWHPYK;MUMP<DGYG,TVJ/$O)LKUE>H.J[AT[;^;RV5O1S=^U9E/EF
MKE)S46U22C5)UX4,R&RU$]79[5553/+J:FW44]1'^8GEIFR2M^)RJA@:FI)2
MCP9G5).+<9<4>S)(   *A^NW=O>'!]R;;;<.RZYXQC\ENI9$^KW1HE54O:OF
ML?SM=\J%3EXPDWS]AUW&TL"OV\[N[K9%25-#?,\O=SHZUKF5E-/4N1E1&Y=7
M,DY$3@JE2K5M.K1U<TN\KXWVZE[]MCER8CB]AM%?+24L,UPJKVE7(Q994YF1
MTS:22-=$:J:JY5XZF4O1_H#H74#:L=S[@SE^TKTI*W"PX*D8NC<W.,L6T^%,
M#%SJ[U^US8&ZI[8T#)V+SLQB[L[ZFZRDN9*"A*.%&N-<38&X=9>Z]:QB4UOQ
M:U/9S:RT%-7*]Z+V<WM<LB<.[1"].2]5WIME)-W[F:S*=,+DH47U$8\2S&?]
M:#J1FTE9AELM3MMPGCY>:4N!QNRO*+UFE]K,DR"I]LNU?Y25,Z,9&BM@9R1-
M1D:(FC4X=A?3;V@:7M?2;6AZ-;]%EK->2-6Z5=7BVWBRQFOZ_JFY]6NZYK-S
MTN8OTYY42K3!8))8(^=T^7[/Q'VJGQPJ=G;ZA4> T^SI^2!C7 :)]CY^\59&
M(T33T_9%0-/C\!48C3Y?AWBI(1$^''7B*C&E J:\.WAZA4$: $Z:_9[NT5#8
MT3NX\.WL%14:?#XA45&@J.RHT3C\-15BI.G9\PJ14VNW:V>PC>G'6X]FE"CU
MIU<^U7NDB@2]V25_"1;=5R-54:Y-4=&[5O>B(O$HLUDHYA^DMR=NZJ-3CQ=.
MR7?'L:?9PQ/:;+WWKFQ\\\SIC5RS-4N6)M^BN+C5I-4DGBI*CJE6JP*4=]^G
M3-]B;G))<H77K"JB94MF6T,$WL443WZ4]/>7NU2"=4X<KE3F5-4314.G)Y^[
M<N2R>HQ]'?AV\+=U/AZ-OBU[Z-6U[)F)MC=6@[SR$<YHEREYJMS+S:]-!I*O
MFI*L*O"25*8<4S8!%YDU316KQ14XHJ>)]1JCHS[[)^P1X$#U"O<'X!>[T!X$
MU(1.XCB\2.+Q)3TIZ_M$X$X5 Q./ #LH .S >! P!*A^!+KVCN'O13O'K^(C
MRCRCTCRBKXFES4>G*Y.9-471?%%YD7Y3DFXNL0G).L71F7M^+7>\0DV]S"IV
M&S>[5,D4"2W&NN]QK5U?8&KI2VN@CE71SHU^]8U->PU\>L]T[_ &NV]XZ9:C
M:R6<:MN,%B[SQE.2\:\2[6U=5AFK'Q6;;G%55>"BL*5,\O># ;3O5M=5TE+2
MTE7<:FW,O.'UU8U6K;KJZ))J*MC=JG([E71?68B:[H>F;HT+.;8URWZ7)Y^U
M*S>@ZTE%IT3:H\)4>#3P/;Y/.9K3<[:U'(3]'?L24X37&+3XJM5PJBF=8JJD
MJ*VVU\;HKE:*^JM-SC5JM1E?0R>34^7KVL5?O7)P5.*&C?J#LC5^G&\,YL[7
M(I7\JTXM.JG9N5E:N+NYXXTXKM-@.TMR9/=F@6-:R3;4TXR35&KD,)KV'P?:
M2>-/2&].PNYE9MGN#;*SGC=9+[-!9;Y'5U2T]%1TM1)]&[/5RHU%@775>]%X
MF5/JH=5UL/?<=M:U?E;TC6*PDN,89O\ O%Q]D8R;<;L^Y1Q++=:-F_A[0OPY
MD;?-F\EB^^5GWZ\7'C%>++EJ:I@K*>&JI9HJBFJ(F303PO;)%-%(WF9)&]O!
M6JG%%0VRM-.C,.SSD
M
M                                           '_]#/X
M
M                                                       7AQ\
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MQ9:YR<FY2Q;-7=J0*85'9\@' #$@!(#^"*=Y)"ZKWZ$>(J$15\-/G.5:A+#
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M^"G A< N-"/BU7@O'[1-$,24XZK\/B(HD'5CAP\$7U=J=XH%4:<=4T\-%&%
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M+Q.:)D&6\
M
M                                  !__]'/X
M
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MFEC)^++)ZCF[F;S4KMQ\V/'O/D?3XGVOU2@\2-.SY?B' (D/$@?#UD4J2^
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M'P)X\!Z!3V2.P#AB01\?;\P9/8$7X*.P>).OQ#C@,1VIQ]?CJ!V49D5?B_\
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MR=J_%PG%TE%X.+7%-=Z/I3N(
M
M                                                /__2S^
M
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M9J4=U9""67S.%_\ 8W>$73NDN+^B99J9SEA0
M
M                                                           #
M_]//X
M
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M/!.Z_%8\JI3@VSE*J<SM555\5]*KVGUN.++.QBDJ(CD[N_X=H#Q1'(G:OP]
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M[UJ46TGCRM/M-?NN:+F]NZQF-#SM?29>;C5K"2XJ2[TTU[)O>>O/E
M
M
M                _]3/X
M
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MZ9Y\T]^NFO=\001).-#B-?X)%2:C37CZ0N \2$3157MU&(J3Z1PQ%,*@55"
MGRCAB2@G=J$^P>)I>]C$YGN1K>Q%<J)JO<B:]ZC@Z]B]I>+)47.7+%-OP53E
MYTZ=(>:[V5=/?K_%5XGMQ3U2LJKG.R6FO%U=#HYT5GI9$3FC=JB+*YR)Q^BJ
MGQ,WJ-[,)Y?1J2FVE*X_<1B^,H/WTUV+AXGD-W[]T#8]IPSK^,9UP;A8C1I-
M^Y],^,$\:\9*GN<2Z?;W;/"MK+!%C6#V&CLM"U62U;X&(M5<ZMC.3VVX5&B.
MEE5-=7+XG;D\C;R<,9.Y<:\ZY+W<_%OYR[#$+=6[]<WCJ#S^KW6TJJW:6%NU
M%NO+;CV*O'O/NN5WA\16U1Y<<BIW?!2:HG <J^'QBH? C05%.TGE5%3X(HJ0
ML!RJ*H)=I'*NGP]8J"53OX"H?&C'+Z-148#E45!'+\$^345))Y5\.[450:'*
MHJ1V5(1OV.Q?N"I*'(J]WR"I":J.5$7L05&#8Y4]'Y J.P<NOAQX"M":5'+X
M\$U^'8*D47:1R=^J^&G<B^HGF%!RZ_#O%:"B2[QR+WKP3U)J.9$478/+X?D)
MW>L<P\ C$73Q',R6.1>S1-?B',11]Y"L]7#15)YAY6/+X]G:.8GBJCD5=4[5
MT[2.8C@1Y:]GBJ\>!/,@.1?#N^)>\<R)I@.5?!$UT7L%1@1R<%',/*.7OTX?
M,*D> Y>&J>GC]CM)J<L$0C4X>OY?0*D4:)Y45>SMXD5%!RIQ[/N"H(1O FH[
M2>3M3T_,.84(Y/L?.*@GD]/P[R.8=F(Y?A]P5"'+]GA]M!48CDX_:^UJ*C$<
MGI)YAVU(Y>\5J%X$\G;XD5((Y?L]OVB:DD\OCP^V*C'N(Y?3KZ!48CE]'P[^
M(J,:$<O;V>CXQ4$\OJ^TO 5(Q')Z$3T?DCF#J0K..B^OTCF[@\.PCDXKH3S#
M@JT)1B<?'@GJ#;'EX$<O?KX]PJ'A@T$:G;KIJNG9P458\!R>GQ3YQS!--T(Y
M?5^1X@5Q'(OHX]_SZBJ';B1R+W^.GS"J))Y%]'W=/'48$#DU[$X_%W<1@B2.
M7^!ZQ@0.3T=GV.W0C!XHG$<GS_.OB*$5"M\41=%XBGB2.3C\2Z)\^H'@.7T)
MIVIH*,4'+IK\/1H11ACE^1>&GI)H1AP'(OAQ3M]) \".7AKIW\?2,2> 5J_)
MW?=&(P)Y5[-./#TI\0Q%5V$<GHT[].U!B1@SQ5%+3U<$U+64\-52U,4D-135
M$;98)X96*R6*6-W!6N:JHY.]%.J_E[.:LRR^9@KD)8.+Q3\I4Y3-YO(9F&=R
M%R5F];?-"<'247WIE6W4MT-MA]NSW9*D\MB)-5WS!%D<E/# UOG2UF.-:BZN
MUUYJ=4:B)]ZJKP/DJ]F="L?9G+,9:%:NG-<A'L2[91BO925$C*CI]U>R^X[]
MO0]V2A8S4^6-J_A&%R5.6EY^]E+CS8IR=9-<2L*>"IHZJIH*ZEGH;A22.AJZ
M&KC=!5TTC>"MFIY-'-^-#[UJ[:OVHWLO)3A)533JO_CWKBB\]RU.TZ254^#7
M!^1\&O(>+O[3G0Z^#'H([<1X F@=0.#'$@4[2 @JNTG D=O<0/B'E)J/NC$5
M[AJ14,T.:JZ*V1\4C7LD9)&JM>QT<B2,<QR=BHJ(2U"2<;BYHM--/@TT<X7'
M:DKD>*.P _%F/>:-W!PQ.F/=')?9[W842CQ*URHDBR4\+48RLDG5>9.=$1%U
M30UG^L)T[_$K=4M2R2<LIG6Y\U,(W)/W*["[^VM3^.9;T5QIN"6-<7ACA\PR
M?.K7:1F>8&_*+4KX<CPERWZ'V2%9*B]4%*SFJ;*_DXJR1J:\##_JKTZT[JGL
M7.[1SD(?&+D'+*7I*OQ?,13<+B^<UVEQ=L;CSFU-=RVN95NEF2])!.GI;;]U
M!^#*J*>9*F"*=K7,25O,L<B<LD3M='1RL7BUR=[5XH:0=2T[.:1J.8TG48.W
MF,M<E:N1:::G!T:QQ]DV!Z=GLOJF0LZCE)*5N]%3BTT\'V8=J[3S%$5AOAL#
MNG<]LL]MR^T.DQO(IX+/>;?-,D-%32U4G)!>WO=P:L*_Q1R]K=$,O_5$ZM1V
M;N][%UR[&WI>LMN,I?WK.I)6N7L^SX6Y-T45%.I8?K?LS\+:5'=&0@Y9G)I1
MG&*]W9;QD^W['C+"K=2Y&">*IABJ()8YX9HVRQ30R-EBD8].9KXY&*J.14[%
M13:>TTZ,Q)3354>4@D
M
M                                       __]7/X
M
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M,<#FH7[/ @
M
M                              '_UL_@
M
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M@[<XNDHR5)1:XIKL:/J#N(
M
M                                         !__U\_@
M
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M1:3K@8I=<-D2T_.K>&EVDLO>5,TT_<W:I0FHTHHR6$G6KD^!:B9Y&/X
M
M
M              /_T,_@
M
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MT3,MR5M_8YM4])!XJ2[Z5Y6UVIG) N2><
M
M                                                   /_]'/X
M
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M-22DFG5-22DFGXIIF%2=?#L]E8,]X02
M
M                                               #_]+/X
M
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M9@%G@
M
M                     ?_3S^
M
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MMSHW2<)8278S7]J6G9W1M2OZ/J4>7,9>7+-=G@UWQDL4^TW[/OE&
M
M
M       ?_]3/X
M
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MI*JQ1^\XD@
M
M                       __]7/X
M
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MI2P6!@WU/V/'9&OJ.1ARY#-UE82JU"F,X-]E'5Q3][0L2,D2W(
M
M
M   /_];/X
M
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MG\AG=)S][2M3MNUF+$G&<'Q5'@^[%4>'>;R'V2E
M
M                                                   /_]?/X
M
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M&].9KFN;P4VB--<3%/CP/T$
M
M                                  '_T,_@
M
M                              'CEECABDFE<C(HHWRR/<NC61QMYWN<
MO@B(JJ3%.345Q9#:2JRG3J4W9I=WL]@AL=PEK,+PF:>"UU%/(Z*@O-WEC6&X
M2S4ZZI*VG=S1M<O8YJ*AK^]<KK)>M<O2#;697)**N:IRU4E-23LV%<B^#C2<
MTN.,9539D%T-V)#/YE[WU:R^2R^7*<U'&=52=SE:]ZZQB^^C1L0:\N&",K
M:))&Q,5[D5416M1K457.>]R,8QJ)WJJHB%7D-.U#5\]9TK2;3O9K,SC;M06+
ME<FU&*\E6JOL57V%+G<[E=-RES/YV7)9LQ<ION257[+X+Q+7NG7:RW[,X'49
M7D]52,R"_4,5ROMS8KHZ:FM:I[504:,?KHL;'-\SCQ?KH;M.D/373.E&Q\OM
MC)0:OSY;V;E)J4YYJ4(QN)R22<8->CA1+S8KB\3 +=^Y\[N_7KVL9MIQQC:2
M5%&RFW!4JZ-K%^+9AQ_C#7O2*ERWS9G;^ZU<-PO4[;$RWPN;[9C45,CDDO;I
MFK]%M0UW#E1."=IGSZO72Z6N:@M;U-*-JWYTH/W37O>5]G L9N?6)YO,^ARZ
M^P6,5-^XN-<8T[6C"75TDCI)IGK+45$KYZF95U=/42JKI9GKWJY>*J; H0C;
MMQMVU2,%1+P7 \-<N.Y)RX+L7<N[R$CMQ.!YZ.CK+C64MNMU)45]PK9FP4M)
M2QNEEFE>NC6HUFJIJJ]JH=&;S>6R.6GG<[-6[5M5E)]B_5.[+Y>[F;BMVE5L
MN8Z//=@73(V6W<3J)H5MMHE=3U=MP&2=65TD37)-#65<K-/HO5$7R]/C+:ZS
MN/4->NQR6BMV,HL;EU_WZ+]Y#MB_$MMO'JII&U(7,CH;6:SV,5-+S;4^^2=5
M*GL%[=BQNPXK::6P8Q9Z*QV:AC;#34=OIVTT?EL;Y;%E;%HCG\J)JY4U7O.G
M*Y7+Y*/+EUB_?/&37<Y<6O Q7U75M3US-RSFJW7=N2Q=7YJ;XM+@O8/:)!PX
M(NGJ\"H<O$^:R4A3P5.'RCF'$T^2G9HI-2<$R/)3P7Y!7Q)4DG4UNB1=."\/
M1W(0FR927<:%A3P7Y":^)%5W$>3Z/F[AS,<T>X>2GP0<S%8OL(6%!5BL7V$>
M2@YF/-'DIZ1S,4B0L*>DGG9'+$CR4](YV.2(\GTK\@YR>2-34D2?P2',Y<B7
M TNCU^'V0I'%P1I\KTG+G(Y$1Y*?#4>D9/*/*34<YQ<1Y*:_#[!/.R>7RCRD
M^"$<[(Y5XD>2GP]6A/.Q0>4@YV*(>2U/DT'.Q@1Y#?%>_4<[9.!'D)X^/?XD
M^D8P'D)PXCTC)P(= G;KJ2KC(HF/(\%[O@@](,!Y&O?\-!Z0-1-*P:=G'Y2?
M25(Y4^TCRE](YT.2/>1Y'K0GTA/*N\CR%\/CXCTA'+XCR1SCEK@/)X?P=?6.
M9,<C[R/)[N/KT4<R'*^-1Y/#U?*.9#EQXCR$X]WY YD*#R?2OP\"*H4\2/)3
M7M7P)YA3#B/)U33BFGBG:*BF/$CR./;VIX=VG8.8>R3Y">*\/N=Q',21[.BI
MVD\[(P(2G^QZ1SL-=Q'D+X=NNHYA0CV==5]?Q$\Y%#3Y"^"CG.7+W#R%\%'.
M1RCR%](YQRGU> X1=-Q<ZPO;ZR3T-+><ZRW',-M%5=9*B"UTUSR>\0V2@J+E
M-213RLIV2SL=,Z*&1Z,15:QZZ-7Y^KZME]%TG-:QFE*5K*6;EZ:@DY.-J#G)
M13<4Y-1:2<DJTJTL3Z>C:1F=<UC*:+E)1C=SEZU8@YMJ"E=G&W%R<5)J*<DY
M-1DZ5HF\#<'J"Z?,YZ;-QJS;+/Y;167FEMEJN\%TQR6ZU-@NE!=J9)XJBU5E
MXHZ&:5L;TDIYG+3HC9HY&(KN75?C;/WEI.]]%CKNCJ<;4I3@XW%!7(2@Z-3C
M"<TFU22\YUC)/"I]K>NRM8V'KD] UIPE=C&$U.TYNW.,U5.$IPMR='6+?*DI
M1DL:5-D?*7T_(>JYT>2Y9#RE](YR.5D>6OI'..5A8M?$<R%)$>3KW?+QXCF2
M)7,AY7AV]Y',A20\GYR>9"DAY/H^Z.9$><>6EMU375-/14-+45M;63Q4M'24
MD,M155554R)%!34U/"BN?(]ZHQC&HJN541$53C<O6[4)7;LE&,4W)MT2256V
MW@DEBV^".5NW=O7(V;47*<FE&*3;;>"22Q;;P26+? Y"]2?2WN#TM9-C>)[B
M7'%+E=<GQB+*J3\$KA=[A34E%+<)K:M)<);M0T#FU#9('\S8FR,TT5'KV)XW
M9&_=&W]D;^HZ-"[;MV+KM/TT81;DHQE6*A<N>:U)4JT_ ]QOSI]K?3S/V--U
MRY9N7,Q:5Z/H93DHQ<I1Y9.=NWYR<75)27[(XY>3KQT7XNP]KS(\)CW')KJ;
MZ2-S>E'(,;Q_<6LQB[NRNSSWBTW?#JJ^W"R/2DK745;;9*R^6^W.]JA_.Y98
MF1N1L<L3E=J_1/"[%ZB:#U!R=_.:+"[;^+S4)PO*$9XQ4HR4;=RXN26*3;57
M&2I@7 Z@=-]P=.,[8R6N2M7?C,'.$[$KDK>$N647*Y:M/GC@VDG2,HNN)QD\
ME>/!=./<>[YHG@/8(\CM[>.@YD,>XCR%^7M[2>=$XCR5^7UCF1QQX&GR>Q%^
M[\Y/,D3B%B]2IK\. YD11K%(CRE\.[\C0GF0QJ/)]'V>WP'.A1CR?%!S(8G)
M7>?I/W*V(V]VCW'SJJQMEMWDM3KQCUDMU5>W9+986VNCNZTV56^YT%+%33I%
M6PHL4-1,K7H]KE3EX^&VSU"T+=NLZCHFDQN\^F3Y+DY*WZ*;YYPK:E&Y-RC6
M#QE&-51JM3WNZNG6X-G:)IFNZN[7H]4ASV[<7<]+;7)"=+T9VX*,J7(X1E.C
MJG2AQI\D]S5'@L>X>4G\$BI&/<1Y7Q$U00\KX?&*HDA8D\.P5(I7B1Y7H]'%
M-4)KXB@\I$XZ=Z]WIU%?$$>2B\5[?CX>!%2*FE:=-.&J?+J34FN)/LZ>'KXJ
M145-/D?PJ]_'BI)(6#C]Q".PA/ CR43N7AZ.*BH7$+"FFNB_(J"HP(\GT*GP
M[R:C CR4^"CF&!/DIZ?E(YB<.)"P+HNNO#T+Q',3AV&CR43LU^(8$8/B3Y*>
M#OR1@"/)3T^GXR10>2GI]';V]P(H/)1>''O[==./$C!$GUF!X%D6Y69XQ@&(
MT$MRR3+KU0V.T4D44\B+55\Z1>T5/LS)'L@A:KIZF7D5(XF/D=]%JGS]6U7)
M:'IE_6-1FH6,M"4YMM<(JM%5I.4O<Q5?.DTEBSZ.CZ1G=>U3+Z-ID'<OYF<;
M<$JO&3I5T3:C%5E)T\V*<G@C<7J(Z>,PZ:-R:G:_.[EC-WO]+:+5>I*S$JRZ
M5UG6EN\3I:6-E1>**@F61J-7G:M.B(O8YQ\;9F\-,WSHD=>TF%VW9E.<*7HQ
MC.L'1ND)W(T[O.KX(^WO?9>J;"UV6WM8N6KMZ,(7'*S*<H4FFUC.%N5>_P V
MGBS8M8$\/E7M/5GDE@/(3YO@N@P \A/3W:?%QX"J&%!Y">GO[A5'&B(]G3^&
M[^&G?V$U)HC3Y"=O'A]SB/9)H@L*=O'Y>((HN!I6G3M]7I)3%>PCR$]/R*2
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MJK];;HK^3_=2WQMZTWHVMSE.<HI*WE\[.L[EA))*,9)2E;CPC&-,3*_H9O\
M>M:<]FZQ<2SV0BO0IOS[N5CYL9MMUE*/FQ;XNM3VAB$9 D.:CVN8Y-6O:K7)
MXHJ:*2FXR4XNCBU)-<4TZIKQ31QG"%R$K5Q<T9)II\&G@T<\.C;>>HBJ';-9
M5=/:)X8'56 K/JL[K)2-5*RAFJ'K]-T3W-1NO%4U-Q/JU=7;_5K8DH:S<=S6
M=(DK6;FTH^EA)5R]U4PE*4(OTG*DHNB,$NINS;>QMR_%,JN7)9Q.YEE6M*?;
M(/NY9-<M6VT6+F09X$
M
M                            '__1S^
M
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M<YD\U=T_4K3L9FQ+EN6Y<8OL\J:Q3[4S?HKR
M
M                                             #__TL_@
M
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M+:9?DSZWGD]^3KL;65_Z'-_T>X>PZ>?V_P!#_P"89+^DVS,=-:!M2
M      !CO^^(CY]\-L5X\-J8T_\ *ZY&:'JTRIM7/K_U?_R;1@SZTRKN_3OY
M'_\ .NE17D^OYC([G1C'RHSE35";@@             4G>^;CY\9V#]%]W ^
M>WVDRD]61TSVL?N>7_;7C$KUK*?@_1:_X3,_M;)0I[.OJ^(RZYD88T1'LZ\?
M4.841EI^[Y;R='.Q[?"Q7W^G.Y*:[NLCKU+U5_\ F6_X&T;+NB/YK-(_<[G\
M/=.91;(NJ48>^DC5_P"QLT[OU8OG_!70RO\ 5@:7X<K_ .C_ /JS#WUKU7\
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M45/!=45/$V87(2MS<)=G_9/V3&6$E.*DNT]R<#D
M
M                                              #_T\_@
M
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M<90IYURW-]M'*J?<TNPM.,ACP@
M
M                                 /_4S^
M
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M23?+*,G1Q>*P, <SE<YI>H9C1-4CZ/-Y2;A=AW?0OQ4DJIK!G*0^N<
M
M
M#__5S^
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M/F%2:KN+G?<\-Y<CWW]-DP'NT_Y_NIC#ZRO^9:1]/F/VMHRS]57_ 'AK5/\
M!Y;]M>+TS$TS+/ELWPK&=QL3ON#YG;/KG%\EH7VV]VOVRX6_VVB>]LCH?;;5
M+!41ZJU%YHIFN])]#2M4S^B:C:U73+GHLQ8ES0GRQERR[^6:E%\>#31\W6-(
MT[7],O:/JUOTN6S$>2Y#FE'FCQIS0E&2X<8R3\3B5^]Q]&7]1O\ 7"W5_1PN
M+^6SJ=\I_P WRGP!;'\@?2;Y)_G.<_K _>X^C+^HW^N%NK^C@_+9U.^4_P";
MY3X ?D#Z3?)/\YSG]8'[W'T9?U&_UPMU?T<'Y;.IWRG_ #?*? #\@?2;Y)_G
M.<_K!^JD]W=T;T4OG0[,4KWJQ6:5>:[D5\6CE157R*Z\2,UX<'<NJ=R\5.NY
MUHZF78\LM4:7A8RT7[<;*?S3LM=".E%F7/#28M_LLQFI+VI7VO9I4^RW=VYP
M7:_I0W^Q;;S$['A]@CV7W;JOJVQ4$-%#/638#6QRUM8]B<\\[VL8UT\SG/5K
M6M5VC41/F;<UO5M?ZAZ/J&LYBYF;SSN37-<DY-)9B%(Q[(Q3;:C%)5;=,6?5
MW1H.B[<Z9ZWINA9:WE+"R&=?);BHIR>6N)RE3&4FDDY2;;22K1(Q+.5?#YC8
MG4UC\J'+Z/F%1RH<GH^85'*B.3T$\PY2.1/ 58Y6.1/ <S'*QRIX"K(Y32D;
M?#7XB>9DM>!/(WPX>''B.9BA'EIX=PYR&B/+33AIKZN(YV1AP2'EI]WTJ%)A
M)#RT[>'R<1S,FD>XT^7JO=I]PER(I$GR_%/AX#F"425C37L^52%(*,33Y?H0
MY<PHB/+7P3Q_('-W#E[0L:^'#P(YAR]M3\MQMENO%NJK->:""YVFNBD@JJ"K
M8DU-(R5O*]5A?JU5T\4.G,Y>QG;+L9E<T6J>,?&/<UV,J<CG<YI>;AG].N.U
M=MM-23I6G8^]/M115UI^Z[EBFNVZG3S%4RPS(ZMOV"N8V:::L3B^2S-;JD4:
M)K]'@GH._3-Q:AMJS#*Y]/-92&$9K&Y"';*Y)\:=N)E#L?JGI^Y''2=Q\N6S
M;KRW>%N3?"%%[YO!&P_NK^LO+>C'J/IL7R*:JLF-76[04UUM%9YU)4T.70U:
M,MWM"KHGE<_(KVZZ*AX[KKT_T[?NU8;FT:+OW[*K"5OA*W3SI-<73$OYHN=S
M&FWTI32QXRQBHT7#C1L[43IPWHL74+M307N.MM]RK'VZGH,D;;GM?2I5U5(D
MDC(T;V(YCD^/4UO7+=RQ=E:G52BVGV<'0NQ9NPOVHWX8QDBM+?39>MV2W7NR
M6YC7X#GCGWBQ^6Q[8+%70.\N:UN71&HLO.Y^O?RF#WKP;!MZKM_3^J&2MTS.
M2<,EF8V[:\^PTW',7YI<[=J48VXU\U*X_ O?ZOVX):-K^:VM=E_DV?K?@YR?
MF7EAZ.VGYJ4TW*7:W%&VQK0,P0 >QQ/,[]M7G-CW(QN:1/JQ5H\CM**J45WL
MM3(UM34U<;?OY*9B*L2JBZ(KE,O?5+ZUQZ?;F>QMQ75#1M:NQ7I+DI..3S#3
MI.$,8QC?E176L92Y.)8#KCL*>LY".[]'M.><R,'Z2W"*YLQ:P]U+BW:57%<*
M.1>?AV66/.<:L^5XY7T]RL]ZHXJRCK*9_/#*QZ?21KOX5VJ*;5;UFY8N>CNJ
MC_4>*^88FVKMN_;5VT^:+[4?3'4=@
M
M                                 /_6S^
M
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M]>U][0M=UHDWTTU)/_T_]*L%W^@WYU]*_P!9_H>8,G0P,-C8
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M7Q>[1N<9]E)RK*#5$DU'B6L&61:H
M
M                                '__7S^
M
M                       ;:[N9Q;MO<!ON27-*AT,=.ZBA92KRU#ZNN8Z&
MG;$O<NO'XCS6\MR9'9^T]1W1J-U6K61R]RZWVMQ7FJ*[9.35%VGT=(TZ_J^J
MY;2\M'FG?N1@EY7C7N5*E(\LT]1++4551/5U-1+)-/4U,BRU$\LCN9TDTB_?
M.7O4T4:QJVHZ_K&;U[5[CO9O.WIWKTWQG<N.LI4[*]QL/TW3\KI.G6-,R4>6
MU8A&$%W**/&?.*T &X.U.%+N)N%C>(R,KFT%PJEFNU;1,U]BM](U9Y5DE[&J
M]S6QIKVHY2_'J[]*)]5NH%G*YN"GIFG4S&=3ER\]N/N+471^=.;B_I8R+9=5
M-YK:.W91R\G'-YM.W9:5>5OW4WX)57E:+%^J'=6V]/>QUVJ+%-;J"\MM7U3B
MUMGY6I.YL'L[_*B3M5D>JZ^)NIV[H=W6M3RN@:;%1;Y(0BEYL;<*)12[(J*H
MEW& ^Y-=RVW=%S6O:B_,MQDY2;Q<Y)T?EYL68O=363W*LK+I5.<ZJN=5/<*E
M7*KOS^LD6HF1%7NYG+H;'-(TO*Z)IEG2\G%0A:BE1*GG47-\TU9:YK&<W!K&
M8UC/S<[EV<J-NKY:MQ^90\7$^@?*\I'Q?&*$>#';P(I@/ >LDGRA$X#P9"6
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M[7=&S>WM8S&BYY<MRQ-KRQK6#KVUC1OQ-Z3UI\H
M
M                                          __T,_@
M
M                                ' ?K:SBMHZ'&=OXJ1CZ&_P K[U5U
MWY>GDLKT=3P)_ABO7Y##OUU]<T_*]+,OH$KG+G,[GLO.$,?/M6>9WJ=GF\T*
MU?;A4O3T)T^_F=YO/*-;67L7.9_0SDDH>W1E>)JV,Q   #G%T+T]1)D6Y%5-
M U:6*FL,5!4+'Q;(Z*7VQC)._54;JG<;0/4DV]E<ITTSFZ;::OY_.WK-QU\V
M4<JU&VDNRBFZ]^%>!A]UXU&]F-Y0TZ;3MY>Q;E!4Q3N)N>/;5I>0X3>] W9?
ME&YEBVOA@2!F#,=<JB9->:J=<Z?E:UR]FC4<G VP^KWMVUF,YF]=S<?.L<JM
M/RTJ:Y?6=W/F,KD,EMW)2\S,\SO+R5I\XK$^QW>@RM;JZLPR2Y4HKAP":^)Q
M1*\1KW$CR$IIW_&!V#[8%2- $L#4FG=P7Q(!IU_(]9)%2=.'P[0B?!$)J,0D
MPGI[2$%X@GRBH^QW$ DD#X< $Z@$@     %N?NV>FK'L\L6Y&Y>X>/4-[QZ[
M455MOC5#=J*FK()5J&1UN4WJF@K8WM;+"BTE/254?%KUJ6HJ.:IC?URWUG=(
MS>1T+1;TK5ZW)9F[*$G%JE8VH-Q:JI>?*<'Q7HWP9E5ZO'3O(:YDM0W%K^7C
M>R]V+REF,XJ2=4I7KB4DZ2CYD+<UP?I$L4<"=_>G'<GIZRFKL>8VBIEL<E7*
MS',SHZ:9^.Y'1ZJZ"2FK$16Q5/(FL]'*Y)8UUX.C5DC[P;/WOH>]-/CF],NI
M74EZ2Q)KTEJ7:G'BXU]S->;)=SK%6.WST^W#L+4Y9+5K3=ER?HLQ%/T5V/8U
M+A&=/=6Y4E%]CC23V"/8'A@     "P/W:F(9/>^I>QY/::>J_!["K)DM9EE<
MUCTHF4]ZQZJL5IMTT_!OFS5<\4T46O,YL$CT32-RI9KKIJ60RFQ+N0S,EZ;-
M7+4;,??5A<A<G)+C2,(N+?!.:7OE6^_J[:5J6<ZBV=2RL7\7R=N]*_+WM+EJ
M=N$&^%93DI*/%J$G2D6UD:&$AL"/#43PTL$]542-AIZ:&2>>9ZZ,BAA8LDLC
MU[D:U%53E"$KDU;@JRDTDN]O!(X7)PM0=RXZ1BFV^Y+%LPWKM5QU]UN=="U[
M8:VX5M7$V1&I(V.HJ73,;(C55$<B*FJ(JIKWJ;.,M;E9R]NU+C&,4Z<*I)&I
M#-78W\S<O0X3E*2KQHVWB>O.XZ  <SO=[_MOMHO_ ._OZV%Z+7]9_P VNI?Z
MO_2K!=[H-^=?2O\ 6?Z'F#)I,#S8V ##BR3_ $Q7[_NU=/YND-FV1_S*S])#
M]JC4CJ'^?W_W2?[9GI2J*0      R'/==_M:Z[_VFY3_ *$VPPMZ_?VZA_);
M7[>Z9[^K5^;N?\LO?M+)8V61,@BLKWK/'IXPW_VSX[_2/D1?CU>?[:9K^17/
MX?+&.7K/?V!RG_,+7]&S1C^:)X)\AF35F"9'*GA]K[ JP.5OA\ZBK!RXZ$[_
M  XUU7;0UD\OE05]VO&/2(LBQLEER7&*ZQ4$3_'6IJ(%:WO<C2W'5S)SS_3O
M4K4%5PA"YPX*U=MW)/ZF,J^%2ZG1//QT[JAI-VXZ1G.Y:>-*N]9N6XKZN4:+
MOH90)@*;)0 8I_57L]==E]\<ZQ:LHYJ>S5UZN&18?5OC=Y%PQ6]ULE;:WT\W
M8]U.CG4DZIII-$]-$X&PSIYN;+[IVGE-0M24KL(1MWE7&-V$5&=5V<WNX_L9
M(UB]3MIYK9^],[IEZ#C9G<E=L2[)V;DG*%'VN-7;E^SC(XZ<GI/;<Q;\CD7T
M$\R Y%] YD!R+Z!S('M+)8KQDEXM>/V&WU-UO5[KZ2UVJVT;/-JJZX5TR4]+
M2P,[W/>Y&IJNG>JHA3YO.97(Y6YG<Y-6[5J+G.4L%&,55M^"159+)YK4<W:R
M&1MN[>O2C"$(JKE*3I&*\6V9:NR.W;=IMH]O-N?-AGJ,3Q:V6RXU-,U6T]5>
M/)]HO=73M5$5&35DD\C.;CHY-=5U4UR;KUM[CW)G=;HU',W9RBGQ4*TMI^*@
MHI]F&!M*V;H"VMM7(;?JI2RMF$)M<)7*5N27A*XY-=M'CB;IGGSTQC@^\OR"
M*]]4EYH(7^8N*8?B./3:+S(R:6C?DKF(O,Y."7%-4T;HNO#755S@Z$Y)Y7I_
M:O35/C%Z]<7D4E:_^7XFOKUBL_#.=2[UB#K\5L6+3\KB[W?_ .:N[R=I7_HO
M@OR%X\"Q0T7P7Y!@!H*($"B T%$!H1R@S/S5Z;>@ 8U/O'T1>K+.>"?YRX1_
M2C2&<_1!/\G64^GO_P -,UX>L%^='._N>7_@('!7E3P3Y"[=&648Y4]'R"C%
M".1!YP'(G@/.!'(A.)&)')Z?F%7W$CD]/S"K[@.1?$5&(Y%%09;?3=^UVV$_
M]B^UO](U":Y-\?VUUC^6YO\ A[AM+Z>_V!T/_E^3_HULWH/+GKR@[WLJ*N\V
MW&G]3!G]-5Q,P/5U:_%C/?RK_P"5;,'_ %H?[7:?_(__ )UTJKY5\#(.J,91
MRK\%'FBH5'>G[(\T5?8QHO@HP%:D:+X+\A-1@-%\/F%11&4=T(_M2]F?^XM[
M_INN)@%U<_.+JGT\/X&V;)^BGYKM(_<[G\/=.7!;@NF4M^]\37]CU_ML_P#Z
M9,HO5L_XU_JG_P!48A>M7_P'_7?_ *0I<T3P,HZLQ"HAHG@*LBA&@J1RCE%2
M:#E05%'WD<OH05(HQR^HFHHR.0<Q.)/+Z!4CSBXKW1*:9%OE_P!Q<$_FZZ&,
MWK(NN2TGZ?,?M;1EGZJU?C^M5_P>6_;7B[\Q2,R3C#UH)KTL[VI_^2JK^:X3
MWO2[\X.E?NZ_:R+<=7OS::S_ "=_MHF*ERJ;"JHUEU'*HJA4CE450J.7U# 5
M3(Y?0,",!R^CYA@3@.7T# 8$<J> HA1#EU[E^<40P&G 40(Y?7]HBB&/>-/3
M\PY(]J.7-<7"31'(B?P":4P6!Q?,\9.I"L\-/R>X<"'5#DX<>T8BCJ1R^GU]
MO$"H5O#['%0,2.7L%14<B_#B,>P.O8%;IZ_M#&I#=&0K5^':34-I$<JJI JF
M.1? FI+2(T]6OY)#?81AVD\J]R$U0=.P<O;PX]PJ10CE[O$5[24E0A4\?G0E
M3<75=A#BFG%]I:?[K[>N?$<\NNT]?46^CL.6/FO#:BK=Y<KKI$BLAIX)'<-7
M<R\-3$OUA-JK+YZSN;)PI"<:7Y=\^S$S4]6;>#SNFW]J9Z=;EJ3=B-?>+CA[
M1>1NAB=!FN"9'9*ZE2L\VTUU10QZ(JI<J>D?+;Y&)XI*C50Q.W1HDMS;9U';
M<'%2U#+7\O&4N$97K<K<9/Z64DZ^!EQIF=_!FIY;4L?\GNPN47%J$E)KV4J%
M'DL%12RRTM5%)!4TTLE//#,U62LEA>L;D>UW%.S4T.ZKHV>V[J>8T#4H.%_)
M7)69IJCK;?+6C^B24EX-&Q+3M0L:KD+.IY9UMWX*:]E8^TZHT% 5H .6_1SF
MOX.[A5V)>QR3PYM3^:D['(C*.KM3%>Z:1'+Q21CFM33P,[/4KZCW,GK><Z9Z
MG=?H<U#XSDXTK2];K\83?9%VU!Q7T5>\QNZ\[5A*Q9W;E(>?&7H[[KQC*GHW
M3OYJION+3S9"8Q@
M
M                 '__T<_@
M
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M?\\K)UA;BN7P.,"<?B+QU+#5"<>_Y.P@!=->!(0X=_?X=H'@0GPU(05&222
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M\$YDY=>"IKHNJ)19KKSL++I^A>8OT^@LTK]TE;\F)7Y/U<.H^::5^.6R]?\
M"7ZTQ_\ *A<\N'SSE5MK[J"Q4=12U^[&Y=9>V1N;)48[A-N2TTLJL1')%)D=
MU6:9\;EX/2.AA?R_>R-<J*VWNN^L3F[L)6=NY"-IOA<ORYVO%6X<L4UV5N25
M>*:P=S]N^J]DK,XW]TZC*\EB[67AR1?@[L^:33[:6X.G"2>*M'V\VSP/:C'*
M;$]O,8MF+6&F<LGLENB=YM54.3E?67*OJ%?454[D1$=/4ROD5$1O-HB(F/\
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M]*WNZ+?L_DM?F>[EUQ/<6XNM=1:;1B\-D6Y8O0+5R1OJ+Q6/R")JU-0C&+%
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MV':<
M
M      ?_TL_@
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MB;*NB]NY;Z8:1&Y%Q?HINC5,)7KDHO'L<6FGVIIK!G*\MV70
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M5(4D.P<JIX$\R%:$*U4X_%H*H$:+WHOR!,>+)75=.'9P&'$85J0J*B:Z+Q]
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MJJ/ENV83C5=CI)51KDUG+3R>KYK)W<)6KUV#\L9RB_FH^_/1GS0
M
M                                                    ?__3S^
M
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M5[9_^S[#/Z7*8WE=(OS3[7I\DZ;_ $.R:]]Y_P!L-6I_',U_#S-P2X9YH
M
M                                                          '_
MU,_@
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M-YF2:Q33O3::?:FC<0N >>
M
M                       !_]7/X
M
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M0"--.SXR*"E.!/BGP\1Q(IV$>H4)\@T0F@P) (_@@=I.O8$A@O9'=H/$$=W
M#LP'P_)( [21Q)U7L\.Q2".TA22?  )4&B]WS<2.!#P!))()":^C73O#.+X$
M>@$^!&GK(H1A4DG#B2.T#B%UU^&@(JP"57M)5 .(1$T])' <""0 %@3Z@"%^
M'B /613O(X\1]LGM))!(31>WM[@0^)'J[1Y!Y"=5TT(\13M(3X:DH(G3CVIK
MZ^!'B/$$@@ D  >0?< (T3L(&"'S^HD     :_9 J2"2.((Q" (G3O\ #O&
M=.TC5!4A41*JO @GAP'<OCW>HGM(=2/L D*&&2B]XXCLQ ! !*>'<0*#3M^+
MX(2/  $ 8#T@8<2>W3T=@H..)&O=W+\O CB1Q8)\A.)(! [0->.@[17&A(
MJ1Z!Q'$   GTZI]L=HKB 20H(9*+IQ'8.S$=OQ@>4<$[/G(01'K)'E'\$  #
M[( '$4'81P' +V:KV$I<SHB&TE5EB?N\>GBIW1W%7<.^T%'4X5AE4YCHZQKE
MGEOD2^91R4[>":)HJZZ*8P]?MYP<+>T=.N<RDE*]RO&,EV,R_P#5KV'<MSN;
MVU.VXRBW'+\RPE%\6J]Q?IGF76S \1O627&KI:.*VVZI?2>UR)''47!(');Z
M)JKVNEEY(VHG>IB7K.JY70=&S>O9Y-V,C9NYBXDZ-PLPE<DE7WS46EXF8>5R
MUS/9RUD;+I._.-N/=S3DHJOA5XE(%_OUQRJ^7?);QY2W6^UTMPKEA9R1K+)H
MQB(U=?O8VL;V]QHPWUO#-[_W?G]X9VL99^[*Y&#;?H[>$;<%7@E!)M*BYF\#
M8-M;0+.V= RVBVJ5LP2DTJ<TWC*3[W5TKW(]2>3/0  :Z:KV</L\#A.$[L?1
M6DY2E1)+BV^"7BSA<N0LVY7;CI&*;;[DB[W9J@FM>T&U5LJ&JVHMVVV#4$[5
M316S4F,4M/*U4]#FJ;_M&M*QI&4LK#DLVH^U"*-;F::>:N-<'*7SV;DGTCH
M
M
M!__6S^
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MGZM$?@+</\0O_4/]<GVF'\W_ ,1)]P?A?1?XY9^K0_ >OK_0+_U#"U,'YO\
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M[>'RCR$X]@))([P1VD@D@$#4 A=>/H(J0ZD]Y/:22"2$XCB0@ -./H HZCQ
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M1/1IH;B)<O,^3AV>0PL2:5&?N()
M
M                            !__7S^
M
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M7NY+KA*N.&&/86\SFTMT9"<H9O(7X\N+:MRE&G?S137S3]U5N7LM5/<^KS;
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MW]_(_!>8_P #+ZED_A*WQ]+'VT>!V,]+#OOH-L%[^-;9O[^<XZ/FY81L3?\
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MK#[)>#M7OJ3@_5@W][V[8^J/P2=!G47&FOU+2N[M$\U5^1$.<?6&V'[^W?\
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MGA0
M
M     #__T,_@
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M2BTC.GIUOS*[[T9YOE=O-Y=J&8MO@IM5YH/WT)+&J]RWRO%'Z"T)<
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MM:5:E*/!R<Y8^1RH_91[IMDM+$1K:&%$3L1>=W_'*>(O[_WYF7S7];U"3?\
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M^_X*S]WB0O6GMA_V-R5?_NY_W#DO7.Z,=LL]]YW"/R);^_P-G[M$C]FKM?\
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M%UDWBSD(496
M
M              '_T<_@
M
M       '$'J5Z<H-R*1,RQ"&&BSZSPO<V-G+!3Y'3::/HKBY$XN:W58G:<':
M%LNK?2O0NKVTI[;U:EK,6V[F4S*59V+R6%']!-^;<5:.+?;B>GVANO4-FZU#
M5\BZQIRW+?O;D.U-=ZXQ?8Z%6RMJ(IJBCKJ2HM]QH9I*:X6ZLC6&KHJF)W))
M'-$O%$5>+%[%:J*:9]Y[,W%T_P!QYC:NZ<N\OF\O)K'W-R'O;EN7"4)+&JX.
MJ? SIV[N+2]TZ5;U;2;BG;FL5[Z$NV,EV-/VT2>7/N@
M
M
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M-.9T57B6M'TSZ
M
M                  /_TL_@
M
M             XA=0?3#;]RYI,RQ*9EESR&-?/X-2WY,QK$CAIKMKV*Q$^A*
MB*J:EK.K'1W:'6'1/P=N"+LYRS%K+9RW]ML/%I-<+EMOC;D^4]9M#>>M;+U!
M9S2Y<UN37I;,O<7%X]S[I+%%:648S?\ ";Y6XWE5OEMEVM\C(I>=DB4-4LC>
M:.6W5KT1DS7(BJB,<JIWHAJ4ZH=(=Y])M7ED-RY=O+3;]!FX*MB]!.BES*OH
MY.J\RYR2>/*FDS,W9V^]#WGDU=R%Q0OQ2])9DZ3C+N2?NEXQKXGHRV![0
M
M
M
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M]*>#N3:4I-*O N%M]OHK514]NM]/'245)$V&GIX6HV.*-J:-:U$/4G8?L
M
M
M  !__]//X
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M^,Z+F5=7T+7+->6#\Y \9&49KF@TUX'HP<@
M
M
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MQJ-8U$:UK41&M:B:(B(G8B'TP:@
M
M                                 #__U,_@
M
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M."_@B[TNN+%5?^)*:7J<]"+CKR9J"_8WE]8=RZQ=5[>"S\)^6W_WGZ&](O6
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MM2G*;K)_]O!<$>345%41].<20
M
M                                 #__U<_@
M
M
M
M
M
M
M
M  __UL_@
M
M
M
M
M
M
M                              __U\_@
M
M
M
M
M
M
M                                                          __
MT,_@
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MA>A8M1HG.Y.,()MT592:2J\%CB\#83]G;T/_ +LGI4_MAMHOT8/5?DOZE_\
M3NI_>&:^"/B_CEM#Y5R?WU8^O'[.WH?_ '9/2I_;#;1?HP/R7]2_^G=3^\,U
M\$/QRVA\JY/[ZL?7C]G;T/\ [LGI4_MAMHOT8'Y+^I?_ $[J?WAFO@A^.6T/
ME7)_?5CZ\W@VTWHV=WGH;G<]GMV-M-V+;9:N&@O-PVTSO%L[H;375$/M$%%<
MZO%ZJJC@E?']-D<KFN5OTD14XGGM9VYN';EV%C<.0S&0G<3E".8L7;$I13HW
M%78Q<DG@VJJN!]33]6TK5H2N:5F;69C!TD[5R%Q1;Q2;@VDZ=C-RSXQ]
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MEM1LW+%Q<87(2A)>6,DFO:/69?,Y;-VU>RMR-V#X2A)27MIM'T!2'>
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M6[++YJ$K=R.#C*+C)/N::37LGK+5VU?@KMF2G%\'%II^1K ]B=)V
M
M                   '_]'/X
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M4U&364FR]^Z/O7*N63?HLS;5;EB37-%8+FB_?PJZ<R2:=%*,6TG806F/<
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M[=7;:AKJBZ4.WNY&<X/1W.KCCAJKC2XGD]58:>NJ88?H,DF93I(]K."*JHG
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MW&L2<L-3FNUJIAV;01HB*ZNK,8NLTMHN4JJCF^33S6MFBHO-JQ4?CCO#U/\
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MNSD\*T;<(QX)0E*4:TJZ5;["WPQ_+H@     'RF=X1B^YF#YEMOF]L^N\+W
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M\'!\RH\*X-.+4E1U2:YE%X'*H\,>D
M                                                   !_]+/X
M
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MGI/227NF8/\ 4W=,MT;HO7;,N;+9:MFS3@XQ?G37?Z259)\>7E785BEZBWH
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M_P#EPNN#^JGTJ?Z^-W?TC'Q/TP>FG\1U/[CE?ZZ?1_(+N_\ C.3^Z7_ZN/\
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M!-0AY[<K=J.I?4:WL_++3]-Y;FH7E5)XQM0?]\FNUO%0CV^ZEYJI+!NSW/\
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M^=+MG-XSF_II-T[E2/!(Y'GCS[X
M                                                 /_3S^
M                                                          #K
MTO?"?\)+U3?T5XG_ %M+(;:/5\_,YH?[E=_I%XP<ZI?V^U+Z>'\%;*TR\IX
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M_;[WC^Q_W#_IEQ\QA];;\UEO^79?^#OEX^AO]M9?R:[^VMF<$:T#+\
M^4SO_2/F7]"F1?Z$3%?I?^\\M^ZV_P!NBFSO^9WOI)?M6=6B;OC7, #L _<D
M?\&'TR_[<_\ O@\L-4OK*?GJUK_4_P"@94S9Z1?F\T__ !_])O%JQ8PN2
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M"<:\83C2<'VQDGVF?FCZKE-;TNQJV2=;68@IQ[U7C%_LHNL9+L::-U#X9](
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M-I]EJ*:47.=;X]*]E?BIH2S&=A3.YM*=VO&$>,+7ARIUG^S;56HQ+?#'\NB
M   #JT<[_P!.^9?T59#_ *+S&[_2_P#=F7_<K?[1&N7.?YY=^GE^V9\H5Q3F
M=;[@7_@\<<_]JVY_^B<!K"]:K\[=[^2Y;]JS,?HI_8:W^[7OGHNL,;R[8
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MF3];>>6M%HK.MUV]V.@K(&N2>[S1^R9_G=-YB(J)2PN^I**5BJUSYKBUR-?
MQ5\EZVO4CT5BQTUTN?G7.6_G6GP@L;%A_3/[--/%*-EJJDS[G0W:7I+ES=^=
MCA#FM9=-<9<+EQ>1?8XOM;N=J1EC&"!DN
M                                                         ?_4
MS^
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M[QSJBW3T[ITC<YL<Z2PJ[FC=IL8Z=[PRV_-F9#=.6HGF;:])%>\O0\R]#O\
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MQIE>;6[!)&JR%9W>?%G"VYT2<J:(LB-17:,35RHA:C/=&.JVG-QS&@9V5/\
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MXMMMXLW$/D%<
M                                    ?__5S^
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M  2__P#27^P$\U^A=_\ ]+__ (__ &X^O^D)_P"T?SK_ &8?_,V?_!+_ /\
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M?O7FW7%W;DIMXX^^[38GI>3AIVF9?3X*BL6K=M+N4(J/ZAN(?(*\
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M]G=1-!WE#T64D[.:BJRL3:YJ+BX/A<BN]><N,HQJBR L\>]
M
M           /_];/X
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MSIE_VY_][YEA8SUE/S*ZU_J?]/RI<CI%^</3_P#'_P!&O'8!FJ4S:
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MFEW8_%W[6':9!= ,Y"WJ>HZ>WC=M6KB7>K4I1?M>E7MF7B8!&4
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M>=,O^W/_ +WS+"QGK*?F5UK_ %/^GY4N1TB_.'I_^/\ Z->.P#-4IFT
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MTXS2[%+EJZ'/(M:>S
M                                       !_]?/X
M                                                 .O2]\)_PDO5
M-_17B?\ 6TLAMH]7S\SFA_N5W^D7C!SJE_;[4OIX?P5LK3+RG@#*M_%D_P#^
M-K__ !M__7Q@QZZ/_P"-?_Q#_P"A,D?5[_XO_JO_ -295A@R9(@
M    PJ/QCW]O!M9_8J8/_7=SDV0>I]^;3/?\SO?T7)&)/7K^U^6_D=O^'S!C
M^F5I9,O7_%Y/V^]X_L?]P_Z9<?,8?6V_-9;_ )=E_P"#OEX^AO\ ;67\FN_M
MK9G!&M R_      /E,[_ -(^9?T*9%_H1,5^E_[SRW[K;_;HIL[_ )G>^DE^
MU9U:)N^-<P .P#]R1_P8?3+_ +<_^^#RPU2^LI^>K6O]3_H&5,V>D7YO-/\
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M26$HM23::9G9INHY/5\A9U/(35RS?BIPDNU/O78UPDGBFFGBC< ^25P
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MKT$X8_L6Y_5&2/J_9J?_ -TR3]RO037@WZ6,O;2C[1E5F#)DB
M
M           #_]#/X
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MW!H61W)I%[1]1C6W>5*KW4)+&,X]THNC78^#JFT=<OU-=.NX?2GO9G.QNYU
MM-D>&71\%/<8H98[7E%@J?S^P9989)?XI17"F5D\2Z\S%5T,J-FBD8W;YLO=
M^D;ZVWE=S:+/FLYF-7%M<UN:PG:FEPG;E6+['A*-8R3>!^X="SVV]7O:/J$:
M7+3HGV3B_<SCWQDL5W8IXIHV%/4GQC(<]Q1[PYVR.X\721NO>O+VGW<OK'[:
MW:X3QMI<"W4N;FT\=I=-,K?+MV1.\NG<W5S8K@E.]K&-JJN4Q)]9_I)^,NCO
M?VA6ZY_(0_RB$5C?RT<>:BXW,OC+L<K3FFVX6XE\NC>^?P1G_P 6-2G3+9J7
MV*3>%N\\.7PC=P7A/E:2YI,S/37098      '6H]=O[>#K)_LJ^H;^N[>#<G
MTO\ S:;=_P"69#^BVC '>7]K]5_EF:_AYG%0]T>;.R#]V_\ M".D+^Q_VT_I
M:@-/76'\Z>X/Y=F/X1F>FPO[%:7_ ":U^U1S6+;GKC'!_&#>BY-Q=J,>ZOL'
MM,;\PV;@AQG=%E+$[VN][6W:XHVT7F1L2.61]AN=0O-HB:4E;42R/\ND8U,P
M?5.ZC?@C7;W3_4[E,OJ+=S+5>$,S&/GPQX*_;C]TMPBE6XV6%ZW[3^/Z;#=&
M3C]ERGF7J<969/S9>/HYOZF<FW2*,.0V&&*X +RO<5=%*=1?4K^K?FMH6JVG
MZ<:FVY&QE92.DMN3[K5"NGP>QH^3E;(VV.8Z^52,5W(^&CBF8L57QQE]9[J1
M^*&S?Q9TVYRY_6%*W@_.MY587I]Z])7T,:TJI7)1?-;+P]'-I?AW<'X7S<:Y
M;(-2Q6$[S^UQ\>3[8^YJ":I(SCS689@@ ZU'KM_;P=9/]E7U#?UW;P;D^E_Y
MM-N_\LR']%M& .\O[7ZK_+,U_#S.*A[H\V9P7XO'^T(O']D#N'_2UCYK1];;
M\Z=O^0Y?^$OF7W0S^Q<_Y3=_:6B]<Q@+R   &$W[_P ZN7;R=2UKZ=\4NZ5.
M =.E--2WV.DE5U)=-WL@B9-D\L[HUY95M%&E):HVO174]3]8,1?SQR&R3U5-
M@K;NS9[NSUOES>KM.%5C'*6VU;2[5Z6?-==,)P]$^Q&(_6S<_P"%=P1T++2K
M8R"I*G!WY>[\O)&D%]#+G7:4%&5)94L.VB]U)U_;[;<XMNUM=T^5M_P#-:*6
MY8O>Z_</:3$IKM;HJR2A;<(K)F5_M]P9!*^)[J>66D8V:)630J^&2-[K2:_U
MUZ4[7UB_H.MZM&UF\LU&Y"-C-75&32ERN=FQ<MN232DE)N,JQE22:7N=+Z:[
MVUG(6]3T[(N=B\JPD[MF',JM5Y;ER,J.F#:2:HU5-,W(_>2/>>?N9?UY^GS]
M-A\?])3HK\M?S//_ -5*_P#)%U#^3_W_ "WPP_>2/>>?N9?UY^GS]-@_24Z*
M_+7\SS_]5'Y(NH?R?^_Y;X8?O)'O//W,OZ\_3Y^FP?I*=%?EK^9Y_P#JH_)%
MU#^3_P!_RWPP_>2/>>?N9?UY^GS]-@_24Z*_+7\SS_\ 51^2+J'\G_O^6^&*
MS\SP[)]O,ORC LULU7CV887D%XQ7*+#7>7[99\@L%?):[O;:E87/8KX9XI(U
M=&]S5TU:YS515O-IVHY+5]/L:KIMQ7LOF;<+MJ<>$[<XJ4)*M'1Q:>*3[TF6
M^S>5S&1S5S)9N#MW;,I0G%\8RBVI)^1JG<?,E:=!DV?B[O6'^#.<YKT:9E=.
M2S[@^W;C;0^US?0ILVLUM;^&^+TG.JK_ #QM=/'<H8V\L;'4%2[19:GCA=ZW
M'3WX[IF6ZB:=#[)E.7+YNBXV9R^PW'^YW9.VWBVKL/>P,@^A>Z?B^<O;4S<O
M,OUNV*]ER*^R07TT$II<%R2[9&7:8!F3X  !AM_C '0_7;;[MT76'@EIDDP#
M>*IH[+N>RBA58,6W1H+>VEH;Q5,C1&Q4V04<".21$5/;J>I=*Y)*N%K]A_JI
M]2[6L:#+I[JERF:T].>6J\;N6E)N4%WRL3E2G^"G!15+<FL5>MNT)Y#4UNG)
MQ^P9IJ-ZG"%Y*BD^Y7(KZN,JNLE7'*,OBPYNILGO5N3T\;H8CO%M)DE3BN>X
M5<?K&S76G:R:)[9874EPMERHY=8ZFBK*>26EK*65%9+"][')HI\/<FW-'W;H
MF8V]K]E7\KF8\LXO!X-.,HM8QG"24H26,9)-'T=(U?/Z%J-K5=,N.W>LNL6O
M:::X.,DVI)X--HSG?=_^]RZ?^M&QV?%\ENMEV>ZA&QP45VVRR*[0TEMRJY*B
M,^L-K;W<7,;<H:A=7I;'.]OIUYV.CGAC963ZQ^JW0+=?3G-7,]DX3U#2<7',
MVX-RM1^AS,(U]&X\/2?:IX-.,F[<<Q=D]3]$W99AELQ*.5SV"=J4J*;[[,G[
MM/Z#W<<4TTE)VT%ABY@    /E,USO"=ML;N.8[AY=C6#8G:(G3W3)<NOEMQV
MQ6^)K5>KJNZ7:2*%FJ-71'/U73AJ5VFZ7J6LYR&GZ1E[F:OW'2-NU"5R<GX1
MBFW[139O.933\O+-9Z["S:CQG.2C%>5R:1C8^\-]_;AMJL.3;0=$E14Y+E5R
MIJNRW3?^JI:BW8WC,-1"M-5R[:6VM;'55]Q8KG)#=*F**E@>ULM.RN:]LD>8
M_23U6=1OYJSN#J4E9L0:G'(IJ5RXTZI9B2K&W;>%;47*<DW&;M--.P6^>M.4
MMV;FE[1;N79)Q>9::A"N#]$GC*7=-I17&*G6JQW>A_JYS'HOZD<*WUQYU;<[
M;1U;K-N1C451R.S?;R]5,:Y38)7S.1BU"I''6T$LJJV.M@IYGHYK'-=EQU,V
M#I_4;9V9VQF^6$Y+GR]QK[3?@GZ*:ICRXN$TL7;E.*HVFK%[/W/FMIZ_9UFQ
M644^6["OVRU)KGCY<%*+?":BWP.QLV_SS$]T<'Q+<?!+S39#AF<X]:<IQB]4
M:N\BY66]T3*^@J49(B/C<L;T22*1K7QN1S'M:]JHFH+5=+S^B:GF-'U2V[.9
MRMR5JY!\8S@W&2[GBL&JIJC3::,\,EG<MJ.3M9_)34[5Z,9PDN#C)53\,.*>
M*>#Q/KSYY5   '5HYW_IWS+^BK(?]%YC=_I?^[,O^Y6_VB-<N<_SR[]/+]LS
MY0KBG,ZWW O_  >..?\ M6W/_P!$X#6%ZU7YV[W\ERW[5F8_13^PUO\ =KWS
MT76&-Y=L       &UNY>]VT.S3L7;NON3AVWCLVO+<=Q!N6WVALKLDOKE8C;
M39DK7M\^=?,C_.X]5^DGBA]O1MM;@W$K[T+)WLW\6AZ2[Z*$I^CACYTZ)\L<
M'B^YGSM0U?2]*]&M2S$+'II<L.>2CSR^AC7B\5@;I'Q#Z(  !UV/O6MLZW:K
MWA/5)8ZNF?!%D>Y=QW,M\JH_R:RBW5IHMP_::>1_!Z)-<IH9%:NC98Y&<%8J
M)MSZ%:U;UWI-H>9MNKLY>.6DNU/*MY>C[L+::[XM/M,%>I.GSTW?&HV9*BN7
M7=7BKR5VJ]F33\4UV%>A=H\.7>^Y"Z\L0Z1]\,KVXW=O,>/[0[]08_;ZG**Z
M16VC",^Q^>>/&+W>)'(J4UNJXJVJH;A5<&Q.6EGG<VGIY'LQI]9;I;J&_MLV
M-8T"WZ74-+=R2M1]W>L7%'TD(?17(.$9VX\9+GC%.<TG=[I#O3*[8UB[D-4G
MR97.\J<W[FW<BWR2EW1DI.,GV>:Y>;%M9RM-4TU;34]91U$%71U<$532U5-+
M'/35--/&DL%13SQ*K7L>U4<Q[55%145%T-94X3MS=NXG&46TTU1IK!IIXII\
M49AQE&<5.#JGBFL4T^U'G.)(  !X*FIIJ*FJ*RLJ(*2CI():FJJJF6."FIJ:
M"-99ZBHGE5&L8QJ*Y[W*B(B*JKH<H0G<FK=M.4I-))*K;>"22Q;;X(B4HPBY
MS=$L6W@DEVLP8_?=]=^*=7&^^,;>;2WNGR'9W86DOEKM^34"J^VYIG^0U,+<
MOO\ ::E$1*FW4\5%14%OGT5DCHZFH@>^GJ8W+LW]6KI=G]@[7OZOKUMV=1U5
MPE*W+W5FQ;3]%"2][<DYSG<C@TG"$DIP:,.NKV\\MN?6;>1TR:GE<DI)37"Y
M<DUSRB^V*48QB^#I*46XR1229*%HR^K\7@VSJ<LZVLEW ?3*ZU[4;-Y3</;.
M5KF0Y!F%RHL4M5)JYKE1TU%-=9$5JM72)R:JBJU<6O6WUF&0Z;6=*3\_/YNU
M&G?;M1G=D_8FK2[?=+REZ.AFGRS.[KF>:\W+6)NO[*;C!+V8N?M&;>:US+H
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MENPQPJXMN%<%<49=AYO=NW;&ZM S&BWFHNY&L)/WER.,)=]%)4E3%Q<EVG7
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MMF4F80F1@
M                               /_]'/X
M                                         .O2]\)_PDO5-_17B?\
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M?_,>]<']2SI4_P!8^[OZ>1^A]TT_CVI_=LK_ %(?EZW?_%LG]SO_ -8/#/\
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MH9U;1VWEMIZ#8T7+OF<%6<_H[DL9R\E<(KBHJ*=:5.5QX0]*
M
M          #_TL_@
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MS^CO^S8N<EU>7DIW,L1K6S]S;>;_  ODKMJ*]_R\UO[I#FA_XJG%0]T>;
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M]&N:,\D]@]';&C7H:QN9QOYF%)0LQQMVY<5*3?VR:[%3DB\?/=''(N,0R^P
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M<DZHS\VQN70]P:?:EI.9A=E&W!SMJ2])#!+SX>ZC1X5:HWP;1RS/!GI@
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MI<*W)I>DO3H[ESRNBI%=D(I17%UE5OFL6W/6@
M
M'__3S^
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M11L1$:UJ(B-:B:(G!"WLI2G)RDZMXMOBWWL]2DHI1BJ)'D()      -E-_\
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MBDC[@^85@
M                                   !_]3/X
M
M
M
M
M
M
M
M   /_]7/X
M
M
M
M
M
M
M                               /_];/X
M
M
M
M
M
M
M                                                           /
M_]?/X
M
M
M
M
M
M
M                           /_]#/X
M
M
M
M
M
M
M                                                       /_]'/
MX
M
M
M
M
M
M
M                       /_]+/X
M
M
M
M
M
M
M                                                   /_]//X
M
M
M
M
M
M
M
M                   /_]3/X
M
M
M
M
M
M
M                                               /_]7/X
M
M
M
M
M
M
M
M               /_];/X
M
M
M
M
M
M
M                                           /_]?/X
M
M
M
M
M
M
M
M           /_]#/X
M
M
M
M
M
M
M                                       /_]'/X
M
M
M
M
M
M
M
M       /_]+/X
M
M
M
M
M
M
M                                   /_]//X
M
M
M
M
M
M
M
M   /_]3/X
M
M
M
M
M
M
M                               /_]7/X
M
M
M
M
M
M
M                                                           /
M_];/X
M
M
M
M
M
M
M                           /_]?/X
M
M
M
M
M
M
M                                                       /_]#/
MX
M
M
M
M
M
M
M                       /_]'/X
M
M
M
M
M
M
M                                                   /_]+/X
M
M
M
M
M
M
M
M                   /_]//X
M
M
M
M
M
M
F                                               /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_002.jpg
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" "/ /4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V:BBB@ HH
MHH **** "BBB@ HHHH **** $HHJ*YN%MH&E?HHI-I*[&E=V):*X?7/B!::)
M=I#>W(AD<;A&B;RJ]BWI71Z/K,>IPHRNK;UWHZ='7UJ%4T3::3V*<'KY&M12
M4M:$!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 AK"\07T4,;><VV"!#-,?8=JV9I!%&SL>%&:\A^*.O&'35T
M]&Q/?-YDH':,=!^)K/V;K58T5UW]"X^[%S9YOK&J2ZSJ]S?3'YIW+ >@[#\J
M]%^$VMG[/)92/EK9PZ _W#U_(UA>#OAU/XHT>\U"1VAC12MM_P!-'']*Q= O
MIO#'BJ)KE2GEOY,ZG^Z>#_C7M8N$*]&5*&\=OD<].3C)-]3Z;5MR@CH:6L_1
M[D7%FHW9*<9]1V-: KQJ<N:*9M)6=A:***L04444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !24M1R,$5F8\ 9-#=@,K7KM(HO
M+9MJ %Y&]%')KYT\0:J_B+Q%/=$X$T@2('^%.BBO2?B?XB-OI9M8GQ/?G!P?
MNQ#K^9JI\._#%G=^![V^NHE>2><*C$<J%(Z>G-=& M3A+$R6^B]!5M6J:Z'J
MNAZ=%I6AV=E"H5(8E7 ]<<UX?\6=.CLO%>^-0!,N3BO? Z(B!F R !GO7,ZA
MH%GJNM:E<7<2RLEKY2AAD $9)^O%%"M[.IS,4HW5C!^%_B+[?I,22MF6#$$F
M3U_NG\J]'6OG3PAJ@\/^,7MV?%K-(8')[<_*?P-?06GW'VBU5C]\<-]:RKT_
M8UFEM+5%Q?-!/L6Z*2EJ!!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 444E !63KEXL,!C9]JD%I&S]U!R:TY91$C.QP%&37DGQ1
M\2F"Q-C$^+B^Y?'5(AV_&HY'6FJ,>OY%1?*G-]#SOQ-K3Z_KMQ><B(G9"O\
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MC<N44E+68!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%)2$XH
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M8HI:* $P*,4M% "8HQ2T4 )BBEHH 3%&*6B@!,48I:* $Q1@4M% "8HQ2T4
=)12T4 )1BEHH 3%+110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image_003.jpg
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" #= D # 2(  A$! Q$!_\0
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M)X[:(K(MFJ20A58L-P1>,$'KQQ5]K&P6Z>X:VM1<%-K2F-=Y7I@GKB@#S?\
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M7T&4S:):NW4QC^57+G_CUE_W#_*L_P ,_P#( M/^N8I]"?M&K1112*"BBB@
MHHHH *BN?^/:7_</\JEJ*Y_X]I?]P_RH @TC_D#V7_7!/_015RJ>D?\ ('LO
M^N"?^@BKE#W%'9!1110,*2EHH 3%&*6B@!,48I:* $Q1BEHH **** "BBB@
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M"DD%V64N\GEX\LYX&PC /3%='X=TI-'T:"W"N)6'F3L[;G>5N79CW)-:=+0
M4444 97B?_D7+W_<'\Q5VR_X\X?]T52\3?\ (N7O^X/YBKME_P ></\ NBGT
M)^T6*S=._P"0CJ?_ %V7_P! 6M*L[3O^0CJ?_79?_0%H6S![HT:***104444
M )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F**6B@!,44M% !1110!%<_\ 'K+_
M +A_E6?X9_Y %I_US%:%S_QZR_[A_E6?X9_Y %I_US%/H3]HU:***104444
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MMS7?^>%E_P!\'_&N&8%&*N"K#JK#!'X4NU@NXJP7.,D<9]*/9P[!S2[G<_\
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M[CG'>AO%>GG[,)[BXO)(4A5YW@VERLY=CC_=/XT?\(7;6=OYT\DLK"VGWPR
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M_P *BUW_ )^++_OL_P"%0Q?"O69IIXUGM-T+!6RQZD ^GO7ME9VG?\A'4_\
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MRB>,_P#"HM=_Y[V7_?9_PH_X5%KO_/Q9?]]G_"O9J*/;S#V43QG_ (5%KO\
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MXUM"AS*]S.52SL?2M1W'_'M+_N'^5?-W]K:C_P _]W_W^;_&C^UM0_Y_[O\
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MW+CH>H]Q2W5]<WLC/=7$DK.VYMQZG& <?3BH**5AW$VCT%&T>E+13 3:/2C
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M_P#UJ/;P#V<CQBBO9_\ A4>@?\]+W_O[_P#6H_X5'H'_ #TO?^_O_P!:CV\
M]G(\8HKV?_A4>@?\]+W_ +^__6H_X5'H'_/2]_[^_P#UJ/;P#V<CQBBO9_\
MA4>@?\]+W_O[_P#6H_X5'H'_ #TO?^_O_P!:CV\ ]G(\8HKV?_A4>@?\]+W_
M +^__6H_X5'H'_/2]_[^_P#UJ/;P#V<CQBBO9_\ A4>@?\]+W_O[_P#6H_X5
M'H'_ #TO?^_O_P!:CV\ ]G(\8HKV?_A4>@?\]+W_ +^__6H_X5'H'_/2]_[^
M_P#UJ/;P#V<CQBBO9_\ A4>@?\]+W_O[_P#6H_X5'H'_ #TO?^_O_P!:CV\
M]G(\8HKU;6OAIH>G6T9@>[:>658T#29'/7MZ9J^GPDT$H"TE[DCG]Z/\*/;P
M#V;/&J*]G_X5'H'_ #TO?^_O_P!:JL7PMT-M2N+9WNP$1'3$O)!R#V]11[>
MO9R/(J*]G_X5'H'_ #TO?^_O_P!:C_A4>@?\]+W_ +^C_"CV\!^SD>,45[/_
M ,*CT#_GI>_]_?\ ZU'_  J/0/\ GI>_]_?_ *U'MX![.1XQ17L__"H] _YZ
M7O\ W]_^M1_PJ/0/^>E[_P!_?_K4>W@'LY'C%%>S_P#"H] _YZ7O_?W_ .M1
M_P *CT#_ )Z7O_?W_P"M1[> >SD>,45[/_PJ/0/^>E[_ -_?_K4?\*CT#_GI
M>_\ ?W_ZU'MX![.1XQ17L_\ PJ/0/^>E[_W]_P#K4?\ "H] _P">E[_W]_\
MK4>W@'LY'C%%>S_\*CT#_GI>_P#?W_ZU'_"H] _YZ7O_ ']_^M1[> >SD>,4
M5[/_ ,*CT#_GI>_]_?\ ZU'_  J/0/\ GI>_]_?_ *U'MX![.1XQ17L__"H]
M _YZ7O\ W]_^M1_PJ/0/^>E[_P!_?_K4>W@'LY'C%%>O:C\+M L=.N+GS+S,
M4989E[XX[>M&G_"G1+FQAEF>\$CJ"P$G&?RH]O$7LW>QY#17L_\ PJ/0/^>E
M[_W]_P#K4?\ "H] _P">E[_W]_\ K4>W@/V<CQ^Q_P"0A;?]=D_]"%?3(Z"N
M(B^$^A0RI(LEYN1@P_>CJ#GTKMQ6%:HIVL:4XN.XM%%%8F@4E+10!F7\<EG=
M#4+="X"[;B-1RR=F ]1^HJ]!/%<PK+"ZO&XR&4Y!J2LR?2I(9FN-,F%O(QR\
M9&8Y#ZD=C[BGN3JMC3I:QO[7O;;B\TN4G^_;L'!_ X-)_P )(O\ T#M0_P"_
M0_QHY6',C:HK%_X25/\ H'7_ /WZ'^-'_"2+_P! [4/^_0_QHY6',C:HK%_X
M21?^@=J'_?H?XT?\)(O_ $#M0_[]#_&CE8<R-JBL7_A)4_Z!U_\ ]^Q_C1_P
MDJ?] Z__ ._0_P :.5AS(VJ*Q?\ A)%_Z!VH?]^A_C1_PDJ?] Z__P"_0_QH
MY6',C:HK%_X21?\ H':A_P!^A_C1_P )(O\ T#M0_P"_0_QHY6',C:HK%_X2
M1?\ H':A_P!^A_C1_P )(O\ T#K_ /[]C_&CE8<R-FJ.J:I#I=MYDGS2-Q%$
MOWI&]!_C6>VK:K>?)8Z=Y(/_ "TN&SC_ ("/\:EL-!\NX-W?S-<W3#EG[>P'
M846MN%V]A=!L)8Q+>WN&NK@[VQV] /8#BMFD Q2TF-*P4AI:*!F3;O\ V7?&
MTEXMYV+6['H&/)3\^16K45U:Q7ENT,Z!XVZ@_P QZ&LWS;_2OEEC>^M1TD3_
M %JC_:'\7U'-/<G8UZ6LR/Q%IC_>NTB;NLN4(_ U)_;FF?\ /_;?]_!19CYE
MW+]%4/[<TS_G_MO^_@H_MS3/^?\ MO\ OX*+,.9=R_15#^W-,_Y_[;_OX*/[
M<TS_ )_[;_OX*+,.9=R_15#^W-,_Y_[;_OX*/[<TS_G_ +;_ +^"BS#F7<OT
M50_MS3/^?^V_[^"C^W-,_P"?^V_[^"BS#F7<OT50_MS3/^?^V_[^"C^W-,_Y
M_P"V_P"_@HLPYEW+]%4/[<TS_G_MO^_@H.NZ8!G[?;?]_!19AS+N7J1F"J2Q
M  Y)/:LF?Q/IL?RQ2M<OV2!2Q_/I5)H-1\0L!=)]DL,\P@Y:3_>/I["BW<7-
MV%M6.OZT+L _8K;*PY_C/=O\/:NCJ*WMH[6%8HE"JO85-0V-*PE9NJ9M)X=1
M0$K#E)@.\9ZG\" ?SK2I&7<"#@@\$&D@:N"NKJ&4@J1D$=Z6L<";0V.Q'GTX
MG(51E[?UP.Z_J*TK:\@O(A+;2I*A[J<TV@3)Z*3-+2&%%%% !1124 +1244
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MDV/_ #[1_P#?(J[10%BE_9%C_P ^T7_?(H_LBQ_Y]HO^^15VBBX6*7]D6/\
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D_(<5J6EA;V482WB5 /059HI-MC22$I:**0PHHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image_004.jpg
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" "/ /4# 2(  A$! Q$!_\0
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MX[L>@K7T[PR[XEO<J.HC'7\:Z"*V6&,)&@51T KZ562L>35Q*CI'5E70[5M
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M)><S$MZY(XKI*F<8Q=HLJ+;6H4445!04444 %%%% !1110 4444 )BC%+10
MF!1BEHH 3%&*6B@!,48I:* $Q1BEHH 3 HQ2T4 )BC I:* $Q1BEHH 3%&*6
;B@!,48I:* $Q2T44 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
